Clustering O 0 5.9336114645702764e-05
of O 0 2.764113276043645e-07
missense O 0 0.0002523976727388799
mutations O 0 8.801692456472665e-05
in O 0 4.3909824398724595e-07
the O 0 4.362223990028724e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 8.209229417843744e-05
in O 0 3.7014729059592355e-08
a O 0 6.358036586107119e-08
sporadic B-Disease 0 0.002455450128763914
T I-Disease 1 0.999988317489624
- I-Disease 1 0.7331181168556213
cell I-Disease 0 0.23738965392112732
leukaemia I-Disease 0 0.3857807219028473
. O 0 1.1179380408066208e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.8722972869873047
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.51105400098595e-09
is O 0 6.761430859647533e-10
a O 0 1.0383268467251128e-08
recessive B-Disease 0 0.05245935171842575
multi I-Disease 0 0.05106383189558983
- I-Disease 1 0.9999996423721313
system I-Disease 1 0.9999130964279175
disorder I-Disease 1 0.7327742576599121
caused O 0 1.3693170330952853e-07
by O 0 2.3754114231167023e-09
mutations O 0 3.245962432174565e-07
in O 0 2.721911362968399e-09
the O 0 7.283017744441622e-09
ATM O 0 9.041536941367667e-06
gene O 0 1.2685716228588717e-06
at O 0 1.849282256216611e-07
11q22 O 0 3.1570550618198467e-06
- O 0 3.7002416775067104e-06
q23 O 0 6.319653039099649e-06
( O 0 1.4660956537682068e-07
ref O 0 4.04481443183613e-06
. O 0 3.351279254104611e-09
3 O 0 2.719349367907853e-08
) O 0 2.135044496753835e-08
. O 0 5.3467992700007017e-08

The O 0 4.93848688165599e-07
risk O 0 7.257823426698451e-07
of O 0 5.985661744034587e-09
cancer B-Disease 0 2.7561475235415855e-06
, O 0 3.1605573713733293e-09
especially O 0 4.142891540936944e-08
lymphoid B-Disease 0 0.00010419861791888252
neoplasias I-Disease 0 7.53206477384083e-05
, O 0 5.122415824843074e-09
is O 0 2.255846620613511e-09
substantially O 0 2.190224819287323e-07
elevated O 0 1.4657562132924795e-06
in O 0 1.2291839368572255e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.451882028253749e-05
and O 0 1.3801614962005715e-08
has O 0 3.768411804827565e-09
long O 0 2.0901804731465745e-09
been O 0 1.4058366692992763e-09
associated O 0 1.274212557689225e-08
with O 0 8.897765724213968e-08
chromosomal O 1 1.0
instability O 1 0.9999974966049194
. O 0 1.366362880617089e-06

By O 0 4.3526750914679724e-07
analysing O 0 3.453095996519551e-05
tumour B-Disease 1 0.9999998807907104
DNA O 0 1.9559356587706134e-06
from O 0 2.762858031246651e-08
patients O 0 2.215171335251398e-08
with O 0 4.282314947090526e-09
sporadic B-Disease 0 0.029550911858677864
T I-Disease 1 0.9999914169311523
- I-Disease 0 0.447663277387619
cell I-Disease 0 0.14807270467281342
prolymphocytic I-Disease 1 0.73250812292099
leukaemia I-Disease 1 0.9982603192329407
( O 0 9.390760737915116e-07
T B-Disease 1 0.5489568710327148
- I-Disease 0 4.7947112761903554e-05
PLL I-Disease 0 2.8244956411072053e-05
) O 0 2.371395968481238e-09
, O 0 1.6413800874026663e-10
a O 0 5.649451462197419e-10
rare O 0 7.697257942140823e-09
clonal B-Disease 0 8.576142818128574e-07
malignancy I-Disease 0 1.0211475682808668e-06
with O 0 9.648867260736438e-10
similarities O 0 1.4221702926420221e-08
to O 0 4.002213671583377e-09
a O 0 4.424138211334139e-08
mature B-Disease 0 1.344817519566277e-06
T I-Disease 1 0.5270943641662598
- I-Disease 0 7.723811722826213e-05
cell I-Disease 0 5.174361285753548e-05
leukaemia I-Disease 0 2.8750211640726775e-05
seen O 0 8.515299043665436e-08
in O 0 2.1149329398895134e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
, O 0 3.87016596548051e-09
we O 0 4.142334530943259e-10
demonstrate O 0 9.838837522480048e-10
a O 0 8.067899681662993e-10
high O 0 5.634582134206312e-09
frequency O 0 7.875844687532663e-08
of O 0 7.411630198461694e-10
ATM O 0 2.7451134883449413e-05
mutations O 0 2.104757413690095e-06
in O 0 1.4823254446127976e-07
T B-Disease 0 0.190235435962677
- I-Disease 0 7.951149018481374e-05
PLL I-Disease 0 0.00016432687698397785
. O 0 4.1754648805181205e-07

In O 0 7.506630481657339e-07
marked O 0 2.499579352388537e-07
contrast O 0 3.9901120629792786e-08
to O 0 4.91332352581253e-09
the O 0 8.165060627618459e-09
ATM O 0 1.878274451883044e-05
mutation O 0 9.705250931801856e-07
pattern O 0 1.4222388244888862e-06
in O 0 1.9456757627267507e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 5.625387378138669e-10
the O 0 1.9224920266847079e-10
most O 0 1.188044385092013e-10
frequent O 0 5.013222281746721e-09
nucleotide O 0 1.9333896261741756e-08
changes O 0 4.857600544028173e-09
in O 0 1.3497640782844655e-09
this O 0 6.861207157982108e-09
leukaemia B-Disease 0 1.925683864101302e-05
were O 0 1.0101483205460227e-08
missense O 0 1.4697827282361686e-05
mutations O 0 1.2033587154292036e-05
. O 0 3.272129163178761e-07

These O 0 1.4255275004870782e-07
clustered O 0 8.45197178023227e-07
in O 0 7.578226934867871e-09
the O 0 3.105486090504428e-09
region O 0 5.1200421680164254e-09
corresponding O 0 7.715822647469395e-09
to O 0 8.185983002562125e-10
the O 0 4.412809229137338e-09
kinase O 0 1.487765302954358e-06
domain O 0 3.096716127970467e-08
, O 0 3.1181504600574783e-10
which O 0 4.825416177745012e-10
is O 0 1.843075275731465e-10
highly O 0 9.053248706258898e-10
conserved O 0 1.1079190009866124e-08
in O 0 5.017545934293821e-09
ATM O 0 3.670329533633776e-05
- O 0 4.247160916293069e-07
related O 0 1.0051321552850823e-08
proteins O 0 4.593665892116405e-09
in O 0 2.544097821299829e-09
mouse O 0 7.394262411253294e-07
, O 0 2.1451911358383313e-09
yeast O 0 4.6412793608396896e-07
and O 0 5.084356491380504e-09
Drosophila O 0 2.2643945385425468e-07
. O 0 4.069058334721376e-08

The O 0 2.780743670882657e-07
resulting O 0 7.175361247391265e-07
amino O 0 1.0369286655986798e-06
- O 0 2.3907364266051445e-06
acid O 0 5.065725190434023e-07
substitutions O 0 1.5248792806232814e-07
are O 0 9.176805981780944e-10
predicted O 0 2.955566458240355e-08
to O 0 9.926960364836646e-10
interfere O 0 2.55854217812157e-08
with O 0 1.4357642852402819e-09
ATP O 0 1.2102540836167464e-07
binding O 0 5.2330122457533434e-08
or O 0 1.3366016737847985e-08
substrate O 0 5.149209982846514e-07
recognition O 0 6.203163849249904e-08
. O 0 1.5350784110523819e-07

Two O 0 9.96479627701774e-08
of O 0 5.39666267229677e-09
seventeen O 0 1.3407411358912213e-07
mutated O 0 6.67082122163265e-06
T B-Disease 0 0.0006508090300485492
- I-Disease 0 5.32445801582071e-06
PLL I-Disease 0 1.5640984202036634e-05
samples O 0 4.336168757390624e-08
had O 0 4.643286644068212e-09
a O 0 6.578161348969047e-10
previously O 0 8.957103503348662e-09
reported O 0 8.316596904478502e-07
A B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999979734420776
T I-Disease 1 1.0
allele O 0 0.00015545138739980757
. O 0 3.168115938478877e-07

In O 0 2.6091396421179525e-07
contrast O 0 1.994041838315752e-07
, O 0 2.274970878346494e-09
no O 0 2.3179920205507187e-09
mutations O 0 1.526797177575645e-07
were O 0 2.21479856676865e-09
detected O 0 8.237096693619606e-08
in O 0 1.2231838875109702e-09
the O 0 2.1242709813407146e-09
p53 O 0 1.0649860371358955e-07
gene O 0 3.2605811384200933e-08
, O 0 1.7586546108283585e-10
suggesting O 0 4.287389998580693e-09
that O 0 7.064030471681804e-10
this O 0 3.990264119124731e-08
tumour B-Disease 1 1.0
suppressor O 0 9.306681749876589e-05
is O 0 3.3839862023654632e-09
not O 0 4.95804730604732e-10
frequently O 0 1.129014659539962e-08
altered O 0 1.6694482951606915e-07
in O 0 6.939027574759393e-09
this O 0 2.652588904084041e-08
leukaemia B-Disease 0 0.00013996401685290039
. O 0 1.0724343013635007e-07

Occasional O 0 0.00011510270996950567
missense O 0 0.001774351578205824
mutations O 0 0.00022304475714918226
in O 0 4.2920029841297946e-07
ATM O 0 8.244933997048065e-05
were O 0 2.4080982541363483e-08
also O 0 1.4511323254140507e-09
found O 0 2.428947265542547e-09
in O 0 3.7169307631756965e-08
tumour B-Disease 1 1.0
DNA O 0 2.263390683765465e-07
from O 0 5.478877795894732e-09
patients O 0 5.6286744154476764e-09
with O 0 2.5007409476529574e-09
B B-Disease 0 3.102278697042493e-06
- I-Disease 0 2.0767099613294704e-06
cell I-Disease 0 1.3607382243208122e-05
non I-Disease 0 1.873389237516676e-06
- I-Disease 1 0.9420186281204224
Hodgkins I-Disease 1 0.9999840259552002
lymphomas I-Disease 0 0.45820358395576477
( O 0 2.410888271242584e-07
B B-Disease 0 5.619298008241458e-06
- I-Disease 0 4.445167633093661e-06
NHL I-Disease 0 1.0540848052187357e-06
) O 0 1.5741860037721267e-09
and O 0 6.192294454976377e-10
a O 0 7.034642202086161e-09
B B-Disease 0 1.6616287439319422e-06
- I-Disease 0 1.4200215900928015e-06
NHL I-Disease 0 2.780679551506182e-06
cell O 0 7.86214877734892e-06
line O 0 7.58113746996969e-05
. O 0 3.0122512839625415e-07

The O 0 7.172857863224635e-08
evidence O 0 4.592868307895515e-09
of O 0 1.6847105654971273e-10
a O 0 6.40352326719551e-10
significant O 0 4.5211603905137565e-10
proportion O 0 1.046583930630618e-09
of O 0 3.468756115676541e-10
loss O 0 2.3184978203971696e-07
- O 0 8.883493478606397e-07
of O 0 4.809770359770482e-09
- O 0 3.522192855598405e-06
function O 0 8.880895308038816e-08
mutations O 0 3.0528872230206616e-07
and O 0 3.827133054912224e-10
a O 0 1.864584930899582e-09
complete O 0 3.214409627361192e-09
absence O 0 2.9880098395551613e-09
of O 0 6.02680544359302e-11
the O 0 9.765417363638562e-10
normal O 0 1.7801099261305353e-08
copy O 0 1.8576183435925486e-07
of O 0 1.7471234181609674e-10
ATM O 0 2.702699930523522e-07
in O 0 4.807557685282404e-10
the O 0 2.7002644564788625e-10
majority O 0 8.558179165341073e-10
of O 0 1.7182406608640122e-09
mutated O 0 0.0007468569092452526
tumours B-Disease 1 1.0
establishes O 0 2.210717639172799e-06
somatic O 0 2.3029099338600645e-06
inactivation O 0 2.2359386093739886e-06
of O 0 3.8206274255436767e-10
this O 0 5.338682274036444e-10
gene O 0 4.184960644693092e-08
in O 0 1.0716399989618708e-09
the O 0 2.447755109713512e-09
pathogenesis O 0 1.0283681461942251e-07
of O 0 1.195507692841602e-09
sporadic B-Disease 0 0.0005040758987888694
T I-Disease 1 0.9997033476829529
- I-Disease 0 0.001031431369483471
PLL I-Disease 0 4.804080163012259e-05
and O 0 4.421959687306298e-09
suggests O 0 3.3715905622955233e-09
that O 0 4.543359855002649e-10
ATM O 0 3.8731371887479327e-07
acts O 0 2.245082519891639e-08
as O 0 6.074984071346989e-09
a O 0 2.514551340482285e-07
tumour B-Disease 1 1.0
suppressor O 0 0.0006817815592512488
. O 0 5.300295242705033e-07

As O 0 3.6918277146469336e-07
constitutional O 0 1.223621381996054e-07
DNA O 0 1.5895449223535252e-07
was O 0 3.4606046028784476e-08
not O 0 2.0245889686965057e-10
available O 0 2.571416135577209e-10
, O 0 5.921983042833645e-11
a O 0 1.2944160188155251e-09
putative O 0 7.074263521644752e-07
hereditary O 0 0.0006794173386879265
predisposition O 0 9.090455932891928e-06
to O 0 4.0832009062796715e-07
T B-Disease 1 0.9611877799034119
- I-Disease 0 0.00010375879355706275
PLL I-Disease 0 2.8216902137501165e-05
will O 0 6.705746180557526e-09
require O 0 2.6369797456737842e-09
further O 0 1.1700723723251372e-09
investigation O 0 7.147111791283578e-09
. O 0 2.844812385660589e-09
. O 0 3.227207656664177e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.05926330387592316
kinase O 0 0.003741459921002388
is O 0 2.6213351489445813e-08
involved O 0 2.517313468786142e-09
in O 0 1.234021884677361e-09
the O 0 1.5662674490712902e-09
modulation O 0 4.660964592062555e-08
of O 0 1.7522226725130707e-10
the O 0 1.9619781355117993e-09
Ca2 O 0 7.863991982048901e-07
+ O 0 3.041330387532071e-07
homeostasis O 0 4.9094569476437755e-06
in O 0 2.9013321523052582e-08
skeletal O 0 0.0011887390865013003
muscle O 0 0.0005546720349229872
cells O 0 3.583953230190673e-06
. O 0 1.9397656103592453e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999480247497559
DM B-Disease 1 1.0
) O 0 3.4609288945830485e-07
, O 0 1.954575168383599e-09
the O 0 1.43314882183887e-09
most O 0 3.983342100610798e-09
prevalent O 0 5.7496825320413336e-05
muscular B-Disease 1 0.9992005228996277
disorder I-Disease 1 0.804512619972229
in O 0 1.5179944057308603e-06
adults O 0 4.863072717853356e-06
, O 0 4.529552288801142e-09
is O 0 1.6611186870463257e-09
caused O 0 4.352226667947434e-08
by O 0 9.363645858684322e-09
( O 0 4.023601007929756e-08
CTG O 0 4.144475497014355e-06
) O 0 1.3827383682496475e-08
n O 0 4.1200874534297327e-07
- O 0 4.893228151559015e-07
repeat O 0 2.8547671604428615e-07
expansion O 0 7.573631499724343e-09
in O 0 6.323104262406787e-10
a O 0 1.1976278857517286e-09
gene O 0 3.8189920559261736e-08
encoding O 0 4.5538968151959125e-08
a O 0 1.278355821199284e-08
protein O 0 7.113536071301496e-07
kinase O 0 5.681269249180332e-05
( O 0 7.763861731291399e-07
DM B-Disease 1 1.0
protein O 0 2.6026040359283797e-05
kinase O 0 5.5967586376937106e-05
; O 0 5.221975030167414e-08
DMPK O 0 3.605543952289736e-06
) O 0 3.3358462658839017e-09
and O 0 2.8442573296594276e-10
involves O 0 9.88575110660861e-10
changes O 0 1.0617283940916877e-08
in O 0 8.240754745258982e-09
cytoarchitecture O 0 5.818842964799842e-06
and O 0 3.966664507970563e-08
ion O 0 2.856938590412028e-05
homeostasis O 0 0.0010528243146836758
. O 0 6.156382141853101e-07

To O 0 1.584429440981694e-07
obtain O 0 4.807140285834066e-08
clues O 0 1.335075978659006e-07
to O 0 2.2694450763083296e-09
the O 0 6.213472514282614e-10
normal O 0 9.946999668386525e-09
biological O 0 5.542044156925385e-09
role O 0 1.0686068696585949e-09
of O 0 1.5580399470582762e-10
DMPK O 0 3.475949483799923e-07
in O 0 3.592834030285985e-09
cellular O 0 7.043290111141687e-07
ion O 0 1.5337349395849742e-05
homeostasis O 0 0.0008245570934377611
, O 0 1.538107308185488e-09
we O 0 4.089470428958464e-10
have O 0 2.2214310946289118e-10
compared O 0 2.694436673778e-09
the O 0 3.488809463547682e-09
resting O 0 9.748509199880573e-08
[ O 0 1.9573890952528927e-08
Ca2 O 0 2.9927858236078464e-07
+ O 0 1.567939733604362e-07
] O 0 6.317227274621473e-08
i O 0 1.5776857154037316e-08
, O 0 1.351463663201713e-10
the O 0 4.958860544412858e-10
amplitude O 0 1.9080642843505302e-08
and O 0 6.112336192742873e-10
shape O 0 1.724677112235895e-08
of O 0 8.169387388790028e-10
depolarization O 0 4.2910082242997305e-07
- O 0 2.8527388167276513e-06
induced O 0 2.933164751084405e-06
Ca2 O 0 2.1237065084278584e-06
+ O 0 2.5728863306540006e-07
transients O 0 4.0245879517897265e-07
, O 0 5.156821636376208e-10
and O 0 2.0083547325189244e-10
the O 0 1.987908171408037e-10
content O 0 4.342415316216375e-09
of O 0 2.2616961081745046e-10
ATP O 0 9.718397109281796e-08
- O 0 2.5716792606544914e-07
driven O 0 1.506812026264015e-07
ion O 0 6.891224302307819e-07
pumps O 0 6.352073000925884e-07
in O 0 9.11980535533985e-09
cultured O 0 8.152333066391293e-07
skeletal O 0 6.792352360207587e-05
muscle O 0 7.725044270046055e-06
cells O 0 4.045594437229738e-08
of O 0 6.383877315663256e-10
wild O 0 8.999713685398092e-08
- O 0 2.570797187217977e-05
type O 0 3.4455271816113964e-05
and O 0 4.2026382374160676e-08
DMPK O 0 5.1269042160129175e-05
[ O 0 4.877159653915442e-07
- O 0 1.4663050933449995e-05
/ O 0 0.00010832986299647018
- O 0 9.607337233319413e-06
] O 0 6.791849500586977e-07
knockout O 0 1.5595986042171717e-05
mice O 0 6.102881161496043e-05
. O 0 2.0800329991743638e-07

In O 0 1.4436992614719202e-06
vitro O 0 5.390025398810394e-05
- O 0 2.7518994102138095e-05
differentiated O 0 7.45655279388302e-06
DMPK O 0 0.0001456359022995457
[ O 0 2.1914377157372655e-06
- O 0 0.00010130868759006262
/ O 0 0.00021346521680243313
- O 0 4.722945959656499e-06
] O 0 2.8517030159491696e-07
myotubes O 0 5.475041007230175e-07
exhibit O 0 4.5464329190281205e-08
a O 0 1.163232621337329e-08
higher O 0 1.837251346614721e-07
resting O 0 2.765594899756252e-07
[ O 0 3.307818019493425e-08
Ca2 O 0 5.146544026501942e-07
+ O 0 2.0106034526179428e-07
] O 0 1.0907322689490684e-07
i O 0 3.0284386554058074e-08
than O 0 8.266473061624424e-10
do O 0 2.2687398626430877e-09
wild O 0 3.734077580475059e-08
- O 0 1.8672801161301322e-05
type O 0 2.402336940576788e-05
myotubes O 0 3.51960738953494e-06
because O 0 1.1968057656019937e-09
of O 0 5.972153327427066e-11
an O 0 2.6518071072345606e-10
altered O 0 3.669657360205747e-07
open O 0 9.480636720127222e-09
probability O 0 4.7056074592433106e-09
of O 0 1.405783045527187e-09
voltage O 0 1.1094563888036646e-05
- O 0 2.3632371721760137e-06
dependent O 0 3.033196946944372e-07
l O 0 4.871223609370645e-06
- O 0 4.0234138509731565e-07
type O 0 7.650685347471153e-07
Ca2 O 0 1.1051836281694705e-06
+ O 0 1.0487710255802085e-07
and O 0 5.251377110937483e-09
Na O 0 5.509542120307742e-07
+ O 0 2.541793548971327e-07
channels O 0 4.5226138922771497e-07
. O 0 1.393326130028072e-07

The O 0 3.943844717468892e-07
mutant O 0 2.193072759837378e-06
myotubes O 0 3.677684162539663e-06
exhibit O 0 1.2865505993886472e-07
smaller O 0 3.1940963651777565e-08
and O 0 4.829608268863694e-09
slower O 0 6.703190820189775e-07
Ca2 O 0 1.4291962315837736e-06
+ O 0 1.1594364224265519e-07
responses O 0 2.294678758119062e-08
upon O 0 2.9988234118150103e-09
triggering O 0 1.6115782841552573e-07
by O 0 2.8513200689417317e-09
acetylcholine O 0 1.0786789061967283e-05
or O 0 1.745091111615693e-07
high O 0 4.049942106121307e-07
external O 0 8.106096629489912e-07
K O 0 2.3918582883197814e-06
+ O 0 1.2124553450121311e-06
. O 0 2.2178309677656216e-07

In O 0 4.354024554231728e-07
addition O 0 1.7095917570486563e-08
, O 0 1.2096668111638564e-09
we O 0 3.1472133232846033e-10
observed O 0 1.8502614995696831e-09
that O 0 1.7636597737791249e-10
these O 0 8.206024193491146e-10
Ca2 O 0 3.639558485701855e-07
+ O 0 1.9098817460871942e-07
transients O 0 1.2702543017439893e-06
partially O 0 5.832771421410143e-07
result O 0 5.927153434726051e-09
from O 0 4.798725861121511e-10
an O 0 1.3462410353159981e-10
influx O 0 9.62038448903968e-10
of O 0 1.9345128277059587e-10
extracellular O 0 3.7744200653833104e-08
Ca2 O 0 2.741823266205756e-07
+ O 0 2.368499707472438e-08
through O 0 2.395069476079925e-09
the O 0 8.98501095747406e-09
l O 0 1.8772631165120401e-06
- O 0 5.41576639534469e-07
type O 0 1.3774784974884824e-06
Ca2 O 0 2.7425030566519126e-06
+ O 0 8.715053922969673e-07
channel O 0 6.948963346076198e-06
. O 0 3.126500587313785e-07

Neither O 0 8.508941391482949e-07
the O 0 2.857233916131463e-08
content O 0 2.9690705005691598e-08
nor O 0 5.934007951680087e-09
the O 0 6.559556231522379e-10
activity O 0 1.4704526485331826e-08
of O 0 1.2715581920730301e-09
Na O 0 5.890348120374256e-07
+ O 0 5.080171376903309e-07
/ O 0 1.7768147699825931e-06
K O 0 8.261325206149195e-07
+ O 0 4.7321884721895913e-07
ATPase O 0 4.353340955276508e-06
and O 0 2.353616146422155e-08
sarcoplasmic O 0 2.8952877983101644e-05
reticulum O 0 2.5856972570181824e-05
Ca2 O 0 9.888652130030096e-06
+ O 0 1.7898081523526344e-06
- O 0 2.861368102458073e-06
ATPase O 0 4.18842091676197e-06
are O 0 1.8862473805114632e-09
affected O 0 2.3257078041183377e-08
by O 0 1.3180598834594548e-08
DMPK O 0 3.428803393035196e-05
absence O 0 4.55977243518646e-07
. O 0 9.561123448520448e-08

In O 0 5.952045398771588e-07
conclusion O 0 6.93068358259552e-08
, O 0 1.9304040588252747e-09
our O 0 1.637606605875419e-09
data O 0 9.55415657699632e-09
suggest O 0 6.458023005251334e-09
that O 0 5.826761295679717e-10
DMPK O 0 9.842315193964168e-07
is O 0 3.5181160762398633e-10
involved O 0 2.1023624507954253e-10
in O 0 1.2090901613248661e-09
modulating O 0 2.238976435364748e-07
the O 0 2.3337762833364195e-09
initial O 0 3.9182967981332695e-09
events O 0 1.3782325281042063e-09
of O 0 7.996019957268174e-10
excitation O 0 1.8648012201083475e-06
- O 0 1.4353840015246533e-05
contraction O 0 9.764820788404904e-06
coupling O 0 1.5680878959756228e-06
in O 0 6.074198211081239e-08
skeletal O 0 0.00019595774938352406
muscle O 0 2.6894840630120598e-05
. O 0 2.4899000194977816e-08
. O 0 7.380602085049759e-08

Constitutional O 0 0.0001466035464545712
RB1 O 0 0.03541111946105957
- O 0 0.0002341766667086631
gene O 0 4.700757926912047e-05
mutations O 0 3.648417259682901e-05
in O 0 7.92273198158e-08
patients O 0 6.134532526402836e-08
with O 0 1.0521646665040407e-08
isolated O 0 6.381676485034404e-06
unilateral B-Disease 0 0.00025858316803351045
retinoblastoma I-Disease 0 0.16204756498336792
. O 0 2.5592069050617283e-06

In O 0 2.479417844369891e-07
most O 0 1.7574123489794147e-08
patients O 0 3.1184036686227046e-08
with O 0 1.8478386598630436e-09
isolated O 0 2.018369968936895e-06
unilateral B-Disease 0 2.2576770788873546e-05
retinoblastoma I-Disease 0 0.024169089272618294
, O 0 2.9868715500924736e-08
tumor B-Disease 0 1.5970343838489498e-06
development O 0 2.3590531750272703e-09
is O 0 6.801449958793171e-10
initiated O 0 1.270812166609403e-08
by O 0 1.9127601724733267e-09
somatic O 0 2.5283972604484006e-07
inactivation O 0 6.48983416340343e-07
of O 0 1.7187512524330373e-10
both O 0 1.2859949771737433e-09
alleles O 0 3.928753145032715e-08
of O 0 4.74077499479364e-10
the O 0 4.6726160718435494e-08
RB1 O 0 7.511278090532869e-05
gene O 0 3.1053925795276882e-06
. O 0 3.3542616506565537e-07

However O 0 2.398562060079712e-07
, O 0 2.1255028848088386e-09
some O 0 6.289493925670797e-11
of O 0 4.504957865081316e-11
these O 0 6.630551663278084e-10
patients O 0 6.467403501630997e-09
can O 0 4.33834212998363e-09
transmit O 0 3.537277734722011e-05
retinoblastoma B-Disease 0 0.00011500419350340962
predisposition O 0 3.3959161100938218e-06
to O 0 1.2372584734521297e-08
their O 0 3.586386299048172e-08
offspring O 0 1.0606221394482418e-06
. O 0 1.2047462405462284e-07

To O 0 1.2708198937616544e-07
determine O 0 1.879285171924039e-08
the O 0 7.065718232723839e-09
frequency O 0 1.1283600542810746e-06
and O 0 1.0492382518378918e-09
nature O 0 1.3980020474591015e-09
of O 0 3.5269107079294315e-10
constitutional O 0 6.287140053018447e-08
RB1 O 0 0.00011363525118213147
- O 0 1.987081759580178e-06
gene O 0 4.544371222436894e-06
mutations O 0 2.0329764538473682e-06
in O 0 2.7945832314912877e-08
patients O 0 4.748345361349493e-08
with O 0 3.001925152901208e-09
isolated O 0 1.1422488341850112e-06
unilateral B-Disease 0 1.397942742187297e-05
retinoblastoma I-Disease 0 0.00026654062094166875
, O 0 3.6645770862264726e-09
we O 0 5.386447954336404e-10
analyzed O 0 9.816759849456957e-09
DNA O 0 1.616507994128824e-08
from O 0 3.6697809235874956e-09
peripheral O 0 1.5056010624903138e-06
blood O 0 3.4983207797267823e-07
and O 0 2.951216382385269e-09
from O 0 2.2780376696118765e-08
tumor B-Disease 0 1.3068201042187866e-05
tissue O 0 5.909799256187398e-06
. O 0 1.4091882860611804e-07

The O 0 3.632927985108836e-07
analysis O 0 4.099096031495719e-07
of O 0 2.576411439747517e-08
tumors B-Disease 1 1.0
from O 0 6.696418353158151e-08
54 O 0 1.5142798304168537e-07
( O 0 4.33289226720035e-09
71 O 0 2.7992724582759365e-08
% O 0 7.818901082146112e-10
) O 0 2.0820585533432023e-10
of O 0 1.859093851086513e-10
76 O 0 1.9968982201135077e-07
informative O 0 3.243060007207532e-07
patients O 0 9.176429216495308e-08
showed O 0 1.07682271845988e-05
loss O 0 2.810132855302072e-07
of O 0 3.0671349904309864e-09
constitutional O 0 6.074836278457951e-07
heterozygosity O 0 4.957350392942317e-05
( O 0 6.358897621794313e-07
LOH O 0 0.0016562279779464006
) O 0 5.9362186277667206e-08
at O 0 3.764779137327423e-07
intragenic O 0 3.832599031738937e-05
loci O 0 1.0251666026306339e-05
. O 0 3.265959662712703e-07

Three O 0 1.4826589733729634e-07
of O 0 7.838181659280963e-09
13 O 0 1.76050974687314e-07
uninformative O 0 5.994923412799835e-05
patients O 0 2.1311848286131863e-06
had O 0 2.833645567079657e-07
constitutional O 0 5.820135697831574e-07
deletions O 0 2.643386324052699e-05
. O 0 6.786695507798868e-07

For O 0 3.309395992801001e-07
39 O 0 1.2052705642418005e-06
randomly O 0 4.4075460436943104e-07
selected O 0 5.690812940883916e-07
tumors B-Disease 1 1.0
, O 0 5.880167108784917e-08
SSCP O 0 4.2170653614448383e-05
, O 0 7.694190173879178e-09
hetero O 0 3.2705272587918444e-06
- O 0 8.367193231606507e-07
duplex O 0 6.324548849079292e-06
analysis O 0 2.13112638647317e-08
, O 0 2.691502576368521e-10
sequencing O 0 6.045347333838436e-09
, O 0 2.446185753957053e-10
and O 0 3.1875443951001614e-10
Southern O 0 5.283436355085769e-09
blot O 0 4.505619017436402e-06
analysis O 0 7.183575068125947e-09
were O 0 7.788967248956169e-10
used O 0 1.1509350139604635e-09
to O 0 2.4796760200729295e-09
identify O 0 2.2032766366919532e-07
mutations O 0 2.1146804556337884e-06
. O 0 1.409392638151985e-07

Mutations O 0 0.0016400025924667716
were O 0 5.597703420789912e-07
detected O 0 2.210717639172799e-06
in O 0 6.08795502898829e-08
21 O 0 5.7866081704105454e-08
( O 0 4.479634441167946e-09
91 O 0 3.58960932089758e-08
% O 0 6.475497360547422e-10
) O 0 2.842359403398831e-10
of O 0 7.886149511193707e-10
23 O 0 4.3260824895696715e-05
tumors B-Disease 1 1.0
with O 0 1.0681458206818206e-06
LOH O 1 0.9981334805488586
. O 0 8.094355052890023e-07

In O 0 1.0477268688191543e-06
6 O 0 2.765080751032656e-07
( O 0 1.3815652621929075e-08
38 O 0 1.2694385986833367e-08
% O 0 3.8702083204888993e-10
) O 0 2.298136542178142e-10
of O 0 4.4789061348637915e-10
16 O 0 1.6011754269129597e-05
tumors B-Disease 1 1.0
without O 0 9.304716286351322e-07
LOH O 0 0.007456792052835226
, O 0 1.4732255415594864e-09
one O 0 7.883637631600493e-10
mutation O 0 7.44555777032474e-08
was O 0 3.228322142945217e-08
detected O 0 7.169588656097403e-08
, O 0 3.542626469954513e-10
and O 0 2.7829738513673874e-10
in O 0 1.9428114672592756e-09
9 O 0 5.514389656013918e-08
( O 0 1.2371350610607124e-09
56 O 0 4.849648238547388e-09
% O 0 6.710371147633509e-11
) O 0 7.046667416243935e-11
of O 0 8.471094659068257e-11
the O 0 4.999846510145289e-07
tumors B-Disease 1 1.0
without O 0 4.3070963329228107e-07
LOH O 0 0.0025689073372632265
, O 0 1.0918927983993854e-09
both O 0 9.818252877380473e-10
mutations O 0 7.533539303494763e-08
were O 0 2.086237405052316e-09
found O 0 8.49420711546145e-09
. O 0 6.646511252483833e-08

Thus O 0 3.1598725058756827e-07
, O 0 4.178888346473286e-09
a O 0 1.0070333456013714e-09
total O 0 2.4570998014006307e-10
of O 0 1.061496446297383e-10
45 O 0 5.0579114230231426e-09
mutations O 0 3.6372814093965644e-08
were O 0 1.0514298320885018e-09
identified O 0 1.6530913526935365e-08
in O 0 2.393354350260779e-07
tumors B-Disease 1 1.0
of O 0 9.565716219128717e-09
36 O 0 4.30602057122087e-07
patients O 0 2.830277594512154e-07
. O 0 1.1863658500033125e-07

Thirty O 0 4.5431747821567114e-06
- O 0 1.5018440535641275e-06
nine O 0 5.7839129041781234e-09
of O 0 1.204587124492562e-10
the O 0 1.4070679066335856e-09
mutations O 0 1.8950549929286353e-07
- O 0 5.1114678711883244e-08
including O 0 7.958832481946843e-10
34 O 0 8.349654301298415e-09
small O 0 2.46693909744522e-09
mutations O 0 1.562938365395894e-07
, O 0 5.449182771677386e-10
2 O 0 2.4599144943238116e-09
large O 0 4.1581369458754125e-09
structural O 0 7.990856829565018e-07
alterations O 0 1.5697427215854987e-06
, O 0 1.2216776479334612e-09
and O 0 2.1376755920954338e-09
hypermethylation O 0 1.3324394785740878e-05
in O 0 1.631579920058357e-07
3 O 0 0.0006584397633560002
tumors O 1 1.0
- O 0 0.012892236933112144
were O 0 2.5397355329914717e-08
not O 0 2.96601104787797e-10
detected O 0 1.9700713949077908e-08
in O 0 7.897348330843101e-10
the O 0 1.1942404842812948e-09
corresponding O 0 1.7098200189025192e-08
peripheral O 0 7.580021588182717e-07
blood O 0 3.0544134688170743e-07
DNA O 0 1.2156230013715685e-06
. O 0 2.418939857307123e-07

In O 0 1.0743973462012946e-06
6 O 0 3.5539397913453286e-07
( O 0 1.6230050192689305e-08
17 O 0 1.0388003346406549e-08
% O 0 2.0906062991876695e-10
) O 0 5.532406477382068e-11
of O 0 1.5030717989694686e-11
the O 0 7.727468664953108e-10
36 O 0 7.932043466496452e-09
patients O 0 1.4480137089378786e-09
, O 0 8.560069320040498e-11
a O 0 1.990048792421817e-09
mutation O 0 1.532091857825435e-07
was O 0 6.526154550101637e-08
detected O 0 9.527772704132076e-08
in O 0 2.7820943326872793e-09
constitutional O 0 8.136051832252633e-09
DNA O 0 2.438046031727481e-08
, O 0 2.7536273261574706e-10
and O 0 2.0354304353098485e-10
1 O 0 5.317402074211941e-10
of O 0 4.016885435387252e-11
these O 0 2.9155916569933993e-10
mutations O 0 2.1826259910540102e-08
is O 0 1.1511056691171362e-10
known O 0 8.674863605229177e-10
to O 0 5.207338449331189e-10
be O 0 6.385922901586127e-10
associated O 0 2.0930450705947123e-09
with O 0 2.2989095072034615e-09
reduced O 0 7.534501378358982e-07
expressivity O 0 4.1942363168345764e-05
. O 0 3.3481703098914295e-07

The O 0 3.827793904065402e-08
presence O 0 1.0790612847699776e-08
of O 0 4.3885831080281434e-10
a O 0 3.768979794926963e-09
constitutional O 0 1.6767298660624874e-08
mutation O 0 2.8631811233026383e-07
was O 0 4.5532541292914175e-08
not O 0 1.4478802878858943e-10
associated O 0 4.91709895023007e-10
with O 0 1.2733511467466485e-10
an O 0 2.3453503028569855e-10
early O 0 1.6835803080539335e-06
age O 0 3.7518539386383054e-08
at O 0 5.7406346343213954e-08
treatment O 0 1.2932450488278846e-07
. O 0 7.12064931462919e-08

In O 0 6.803648489039915e-07
1 O 0 1.4956164307022846e-07
patient O 0 1.436294354562051e-07
, O 0 2.4566324530184147e-09
somatic O 0 5.322851848177379e-07
mosaicism O 0 6.101246071921196e-06
was O 0 6.40554489450551e-08
demonstrated O 0 3.806329473832193e-09
by O 0 3.523743796751688e-10
molecular O 0 5.38680033912442e-09
analysis O 0 9.649824272983665e-10
of O 0 1.1020649670623328e-10
DNA O 0 1.462670606855454e-08
and O 0 1.753948986049636e-09
RNA O 0 1.6898556509659102e-07
from O 0 2.0639122411125754e-08
peripheral O 0 2.116227005899418e-05
blood O 0 1.5595271179336123e-05
. O 0 4.437322047579073e-07

In O 0 1.1641235460047028e-06
2 O 0 2.6482067028155143e-07
patients O 0 3.7246877582219895e-08
without O 0 1.5702816824614274e-09
a O 0 8.924906147456113e-09
detectable O 0 4.399568751978222e-06
mutation O 0 4.0261582512357563e-07
in O 0 1.9505538517705645e-08
peripheral O 0 1.3963731362309773e-05
blood O 0 1.7723098153510364e-06
, O 0 5.101150613029404e-09
mosaicism O 0 1.1399308732507052e-06
was O 0 7.491583886576336e-08
suggested O 0 1.5847914980327005e-08
because O 0 6.251035800097782e-10
1 O 0 5.279273129765727e-10
of O 0 4.6252859181583617e-11
the O 0 4.163581035498964e-09
patients O 0 9.48975866776891e-08
showed O 0 0.00022451566474046558
multifocal O 1 0.999976396560669
tumors B-Disease 1 1.0
and O 0 7.810709234945534e-08
the O 0 2.8625126713421878e-09
other O 0 3.218739441646079e-10
later O 0 7.373085697537363e-09
developed O 0 2.0649242316039818e-08
bilateral B-Disease 0 7.622589492939369e-08
retinoblastoma I-Disease 0 2.687564119696617e-05
. O 0 2.2932486842819344e-07

In O 0 4.0210085217040614e-07
conclusion O 0 3.242849189177832e-08
, O 0 1.5442008782784455e-09
our O 0 1.053758746927258e-09
results O 0 4.9953161607163565e-09
emphasize O 0 5.086751908578435e-09
that O 0 6.110677935877717e-11
the O 0 2.582834779385479e-10
manifestation O 0 6.968338350787917e-09
and O 0 6.711372568801721e-10
transmissibility O 0 6.998163826210657e-08
of O 0 2.4793200825712347e-10
retinoblastoma B-Disease 0 9.864984207297312e-08
depend O 0 7.190726902805977e-10
on O 0 9.113805710114775e-09
the O 0 7.424506009989784e-10
nature O 0 1.928960324804052e-10
of O 0 2.0681848594827912e-11
the O 0 1.0921921700379755e-10
first O 0 5.931017343918654e-10
mutation O 0 4.963357280729497e-09
, O 0 5.866591934466925e-11
its O 0 1.040548869291058e-09
time O 0 1.5992381863227934e-09
in O 0 5.709311357016134e-10
development O 0 7.643281146885172e-11
, O 0 2.8820789504946376e-11
and O 0 6.309813088689609e-11
the O 0 1.0462401084376793e-10
number O 0 8.537468648706081e-11
and O 0 5.7144292769928384e-11
types O 0 1.3838609425054216e-10
of O 0 5.0703378995375914e-11
cells O 0 2.561675538359509e-09
that O 0 4.2804262911921853e-10
are O 0 3.698434614118895e-10
affected O 0 5.3610729189301765e-09
. O 0 2.4113326890784492e-09
. O 0 2.0915615905892082e-08

Hereditary B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999603033065796
of I-Disease 0 1.636077406885761e-08
the I-Disease 0 1.6666128033193672e-08
fifth I-Disease 0 3.147721017171534e-08
component I-Disease 0 1.2509954849804217e-08
of I-Disease 0 3.9082928560141283e-10
complement I-Disease 0 7.491395059844308e-09
in O 0 1.0903658420602369e-08
man O 0 4.408710481129674e-07
. O 0 1.2466369980757008e-07

I O 0 0.0002743455988820642
. O 0 5.4362967603083234e-06

Clinical O 0 5.090269405627623e-05
, O 0 1.324024623272635e-07
immunochemical O 0 7.756122613500338e-06
, O 0 6.393373386259782e-09
and O 0 3.0541287276975027e-09
family O 0 8.579385024631847e-08
studies O 0 5.5613188720826656e-08
. O 0 7.085993303235227e-08

The O 0 1.753629419454228e-07
first O 0 3.544387539022864e-08
recognized O 0 1.567702767601986e-08
human O 0 7.361590892429604e-09
kindred O 0 3.5478005884215236e-06
with O 0 2.2852580627841235e-07
hereditary B-Disease 1 0.9999992847442627
deficiency I-Disease 0 0.20794370770454407
of I-Disease 0 9.44648026468542e-10
the I-Disease 0 1.099609558963266e-08
fifth I-Disease 0 1.1464019422646743e-07
component I-Disease 0 1.083600764673065e-08
of I-Disease 0 7.575621241429076e-10
complement I-Disease 0 6.028837162830314e-08
( O 0 9.558206670590152e-08
C5 O 0 3.289158485131338e-05
) O 0 4.808357711993949e-09
is O 0 3.0975590981086043e-09
described O 0 1.7447482036914153e-07
. O 0 9.740759310261637e-08

The O 0 3.714975491675432e-07
proband O 0 6.479712737927912e-06
, O 0 2.3871431498179163e-09
a O 0 2.6329087798870887e-09
20 O 0 7.847949845540825e-09
- O 0 1.4181699725668295e-07
year O 0 1.1399658106370225e-08
- O 0 4.399789474973659e-07
old O 0 2.813876562868245e-07
black O 0 4.9547335123634184e-08
female O 0 3.319206598462188e-08
with O 0 2.551651618887263e-07
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999992847442627
erythematosus I-Disease 1 1.0
since O 0 0.00015431834617629647
age O 0 3.703584923187009e-07
11 O 0 1.864742493751237e-08
, O 0 2.131218757028819e-09
lacked O 0 6.029309247423953e-07
serum O 0 3.4181075534434058e-06
hemolytic O 0 2.6203457309748046e-05
complement O 0 8.510509275083677e-08
activity O 0 1.4016022475971113e-07
, O 0 2.371576934834252e-09
even O 0 4.1930361405206895e-09
during O 0 8.206266244314975e-08
remission O 0 1.6546440519960015e-06
. O 0 8.327408096420186e-08

C5 O 0 0.007820785976946354
was O 0 1.790730038919719e-06
undetectable O 0 4.131673449592199e-06
in O 0 1.9401053208412122e-08
her O 0 1.9140824036867343e-08
serum O 0 2.0586288940194208e-07
by O 0 2.1909334346759124e-09
both O 0 4.636578232464217e-09
immunodiffusion O 0 6.3190323089656886e-06
and O 0 7.341136409877436e-08
hemolytic O 0 0.0004018248582724482
assays O 0 9.449359640711918e-05
. O 0 1.7639999896346126e-06

Other O 0 3.3652575837095355e-08
complement O 0 4.809745135503363e-08
components O 0 2.7808649605276514e-08
were O 0 1.1419609702301159e-09
normal O 0 2.440484081489558e-08
during O 0 4.423935706654447e-08
remission O 0 1.9277747753676522e-07
of O 0 2.6350088777604697e-09
lupus O 0 6.813752861489775e-06
, O 0 2.9979312365924216e-09
but O 0 9.1033651727912e-09
C1 O 0 3.0290623271866934e-06
, O 0 2.4344017912625304e-09
C4 O 0 9.90604689832253e-07
, O 0 5.7259348373861485e-09
C2 O 0 1.4111493555901689e-06
, O 0 1.4317007579478513e-09
and O 0 5.338338660010322e-09
C3 O 0 2.110229615936987e-05
levels O 0 8.816152217150375e-07
fell O 0 0.0002953933144453913
during O 0 8.297876092910883e-07
exacerbations O 0 0.00011191743396921083
. O 0 6.161704391161038e-07

A O 0 2.3921388674352784e-06
younger O 0 2.1607654616673244e-06
half O 0 1.5989363078006136e-07
- O 0 2.139959360647481e-05
sister O 0 2.1043453671154566e-05
, O 0 1.3966001688459073e-09
who O 0 9.295026415223617e-10
had O 0 3.4621545630386663e-09
no O 0 2.4405524268189538e-09
underlying O 0 3.3814529842857155e-07
disease O 0 1.91586673281563e-06
, O 0 8.997920186715191e-10
was O 0 7.194300621904404e-08
also O 0 6.822238329817765e-10
found O 0 8.18236201016731e-10
to O 0 1.8209611596375908e-09
lack O 0 3.65203298713368e-08
immunochemically O 0 7.545579865109175e-05
detectable O 0 0.00021009892225265503
C5 O 0 0.00010394129640189931
. O 0 6.468059723374608e-07

By O 0 2.4768658022367163e-06
hemolytic O 0 0.061502598226070404
assay O 0 0.00041067018173635006
, O 0 6.633644034081954e-08
she O 0 2.6907043704227362e-08
exhibited O 0 2.627898822993302e-07
1 O 0 1.6466811914028767e-08
- O 0 5.230128508060261e-08
2 O 0 2.8812079388984557e-09
% O 0 1.2299279650296313e-10
of O 0 1.77450033833626e-11
the O 0 1.2229482981851447e-09
normal O 0 5.523442041521776e-07
serum O 0 1.8524112874729326e-06
C5 O 0 1.5056872371133068e-06
level O 0 1.5028906119596286e-08
and O 0 7.673843227529176e-10
normal O 0 9.388718247294037e-09
concentrations O 0 8.110951021933488e-09
of O 0 9.997431354991093e-11
other O 0 3.373454571242718e-10
complement O 0 2.6630724292431296e-08
components O 0 2.0697986258255696e-07
. O 0 5.979615735896004e-08

C5 O 0 0.0005440975655801594
levels O 0 4.808443350157177e-07
of O 0 7.788238942652015e-10
other O 0 2.1676468953124584e-10
family O 0 3.466112064032245e-09
members O 0 1.1602643845698424e-10
were O 0 3.1832186886404656e-10
either O 0 7.115850686467695e-10
normal O 0 3.426752215318629e-08
or O 0 5.2456412547030595e-09
approximately O 0 2.202085847002877e-09
half O 0 1.6230575994313767e-08
- O 0 4.5921441937935015e-07
normal O 0 9.14803166551792e-08
, O 0 4.6499315509151984e-10
consistent O 0 6.6434422407724014e-09
with O 0 2.9632192255490963e-09
autosomal O 0 0.00016880205657798797
codominant O 0 8.894837264961097e-06
inheritance O 0 7.943734203763597e-08
of O 0 4.4141879040893173e-10
the O 0 1.3067829485180482e-08
gene O 0 2.566285547800362e-05
determining O 0 7.044231460895389e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.4945370594432461e-06

Normal O 0 0.00045915055670775473
hemolytic O 1 0.9860408902168274
titers O 0 0.004026608541607857
were O 0 3.359787683621107e-07
restored O 0 6.071934421925107e-07
to O 0 4.140456422163652e-09
both O 0 9.466560868531815e-09
homozygous O 0 0.008449029177427292
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 1.6309251805068925e-05
C5D B-Disease 1 1.0
) O 0 3.8089460474566295e-08
sera O 0 2.6985429713022313e-07
by O 0 6.473755975733297e-10
addition O 0 4.811465115217572e-10
of O 0 2.367995799446021e-10
highly O 0 2.0451613735872343e-08
purified O 0 4.0707007542550855e-07
human O 0 1.0560877683474246e-07
C5 O 0 5.08669727423694e-05
. O 0 2.7455598683445714e-07

In O 0 1.2215160722917062e-06
specific O 0 9.427532745576173e-07
C5 O 0 0.00011340943456161767
titrations O 0 1.0283382835041266e-05
, O 0 4.962145805365026e-09
however O 0 2.648851138431496e-09
, O 0 2.6454013979382296e-10
it O 0 1.0158515140190616e-09
was O 0 2.09539479101295e-08
noted O 0 2.8049937372820466e-10
that O 0 2.0194276806329015e-11
when O 0 1.4017713378944308e-10
limited O 0 3.1505648090401905e-10
amounts O 0 4.0407938106667984e-10
of O 0 6.116371298325873e-10
C5 O 0 1.539243044135219e-06
were O 0 2.038329727227506e-09
assayed O 0 4.9441887028933706e-08
in O 0 3.505616907872877e-10
the O 0 2.014074462763915e-10
presence O 0 1.0303974340430955e-09
of O 0 2.747426453009183e-10
low O 0 1.007132155450563e-07
dilutions O 0 6.281063633650774e-07
of O 0 1.0017441320897547e-09
either O 0 1.586848838996957e-07
C5D B-Disease 1 1.0
serum O 0 2.1624434793920955e-06
, O 0 1.128678150941198e-09
curving O 0 7.584332450960574e-08
rather O 0 3.4825464734211664e-09
than O 0 6.095280391527069e-10
linear O 0 5.889862375596522e-09
dose O 0 7.56422821268643e-07
- O 0 3.2693873208700097e-07
response O 0 1.867354804119259e-08
plots O 0 6.316010825457852e-08
were O 0 5.452481577350454e-09
consistently O 0 2.3326158782310813e-08
obtained O 0 1.518312919834841e-09
, O 0 1.5910349426828674e-10
suggesting O 0 4.655755780902382e-09
some O 0 5.551943904613665e-10
inhibitory O 0 3.5891582683689194e-07
effect O 0 6.519113071590255e-07
. O 0 9.797777522635442e-08

Further O 0 9.572388535161735e-07
studies O 0 1.1314165249132202e-07
suggested O 0 1.058029326372889e-07
that O 0 4.649455043193029e-09
low O 0 2.5856522825051798e-06
dilutions O 0 5.9179586969548836e-05
of O 0 4.8017430032132324e-08
C5D B-Disease 1 1.0
serum O 0 3.3796613934100606e-06
contain O 0 2.988273450910128e-08
a O 0 9.095242781143043e-09
factor O 0 7.3600747718671755e-09
( O 0 2.1089943125218724e-09
or O 0 3.7434744193376446e-09
factors O 0 1.1866816418404369e-09
) O 0 5.391114776820416e-10
interfering O 0 1.3864012160524908e-08
at O 0 4.349552273907875e-09
some O 0 1.2281252403933962e-10
step O 0 1.1425317358870757e-09
in O 0 1.1390264287314267e-09
the O 0 1.2429042683947955e-08
hemolytic O 0 2.9581906346720643e-05
assay O 0 1.8405185073788743e-06
of O 0 5.959483573292346e-09
C5 O 0 1.5330198948504403e-05
, O 0 5.231330368893339e-10
rather O 0 6.830636611887542e-10
than O 0 3.214285226871283e-10
a O 0 4.490447569338585e-09
true O 0 7.172651805831265e-08
C5 O 0 1.959322253242135e-05
inhibitor O 0 1.6560411495447624e-06
or O 0 1.5567233901947475e-07
inactivator O 0 2.4642075004521757e-05
. O 0 3.1340800887846854e-07

Of O 0 1.8885637587118254e-07
clinical O 0 8.211212048081507e-07
interest O 0 1.275764560659809e-07
are O 0 3.2540561356597664e-09
( O 0 2.5460977770563886e-09
a O 0 3.1122342480927045e-09
) O 0 3.8588568451736194e-10
the O 0 1.0355417634499986e-09
documentation O 0 2.6679327191914126e-08
of O 0 1.29943824589418e-08
membranous O 1 0.9938074946403503
glomerulonephritis B-Disease 1 1.0
, O 0 8.055502803472336e-06
vasculitis B-Disease 1 1.0
, O 0 6.933432814548723e-07
and O 0 3.0132216124911793e-05
arthritis B-Disease 1 1.0
in O 0 3.242385560042749e-08
an O 0 3.0202575995730285e-09
individual O 0 8.186955113842487e-09
lacking O 0 2.7602775389823364e-06
C5 O 0 0.0006683538085781038
( O 0 9.354933716565483e-09
and O 0 9.045464377521739e-10
its O 0 6.426554399752149e-09
biologic O 0 2.8886799441352196e-07
functions O 0 1.1794074161741719e-08
) O 0 1.1773434449580122e-09
, O 0 3.763862832517617e-10
and O 0 1.1458838322653264e-09
( O 0 2.611283633768835e-09
b O 0 1.5392203067676746e-08
) O 0 2.8979002530959974e-10
a O 0 9.844693948934946e-10
remarkable O 0 1.0015267726259935e-08
propensity O 0 1.278762624679075e-06
to O 0 5.104190563542943e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 1.363315362823414e-07
the O 0 1.3625894190738563e-08
proband O 0 6.710168918289128e-07
, O 0 3.7754388504396275e-10
even O 0 4.957763088953016e-10
during O 0 4.36337010967236e-09
periods O 0 1.157332629730945e-08
of O 0 2.7391697243750457e-10
low O 0 3.767458110814914e-06
- O 0 9.452344329474727e-07
dose O 0 7.359459459621576e-07
or O 0 1.3255476716267367e-08
alternate O 0 2.7265684821031755e-08
- O 0 7.000606387919106e-07
day O 0 1.1349720097086902e-07
corticosteroid O 0 2.0239742298144847e-05
therapy O 0 3.431292498135008e-06
. O 0 1.1523176368655186e-07

Other O 0 4.78336943388058e-08
observations O 0 7.544942803860977e-08
indicate O 0 3.31799796526866e-08
that O 0 1.094833224080105e-09
the O 0 1.3691336064880488e-08
C5D B-Disease 1 1.0
state O 0 3.543587867582687e-09
is O 0 7.180009919949271e-10
compatible O 0 1.123952575454723e-08
with O 0 3.433015816067808e-10
normal O 0 5.391140689425811e-08
coagulation O 0 5.851514117694023e-08
function O 0 4.266823783183327e-09
and O 0 3.5257741171079715e-10
the O 0 7.09021785727515e-10
capacity O 0 1.260842541483953e-09
to O 0 6.995234946849394e-10
mount O 0 1.3468566351093614e-07
a O 0 2.4014389055082574e-07
neutrophilic O 0 0.000629352405667305
leukocytosis O 0 0.00047218395047821105
during O 0 9.076630703930277e-06
pyogenic B-Disease 0 0.34438323974609375
infection I-Disease 1 0.7371348142623901
. O 0 1.2519699055246747e-07
. O 0 2.6264856956004223e-07

Susceptibility O 0 0.40214434266090393
to O 0 0.014023522846400738
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.9267051219940186
twins O 0 0.018516764044761658
: O 0 2.235889251522849e-09
the O 0 4.2005907086029026e-10
role O 0 1.5375147821572455e-09
of O 0 1.816021083511643e-10
genes O 0 1.4819120153219956e-08
, O 0 3.0466291711661597e-09
HLA O 0 2.9247914312691137e-07
, O 0 5.356879384521562e-10
and O 0 3.1203400974177953e-10
the O 0 4.730065228386593e-09
environment O 0 2.1438019359720784e-07
. O 0 7.500676701965858e-08

OBJECTIVE O 0 1.3441047030937625e-06
To O 0 1.0484785484266013e-08
determine O 0 2.2668884547272228e-09
the O 0 4.791053109798327e-10
relative O 0 2.344725080760668e-09
effects O 0 6.1520832872474784e-09
of O 0 1.3542400534305443e-10
genetic O 0 1.2716776964794008e-08
and O 0 6.569334520811765e-10
environmental O 0 1.5143855058852296e-09
factors O 0 8.452312738604917e-10
in O 0 5.885740783639903e-09
susceptibility O 0 5.0009482947643846e-05
to O 0 0.023543423041701317
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0006533983978442848
AS B-Disease 1 0.9999971389770508
) O 0 1.0552722073953191e-07
. O 0 1.210787416994208e-07

METHODS O 0 2.4812852643663064e-05
Twins O 0 6.12224466749467e-05
with O 0 4.247516827149411e-08
AS B-Disease 1 0.9980942606925964
were O 0 1.2142623573296873e-09
identified O 0 1.22538357238966e-09
from O 0 2.6511193240708053e-10
the O 0 1.2409162586379807e-09
Royal O 0 1.834430918279395e-07
National O 0 2.27120882101417e-08
Hospital O 0 1.5320041484301328e-06
for O 0 1.395573434592734e-07
Rheumatic B-Disease 1 0.9999707937240601
Diseases I-Disease 0 0.002283424371853471
database O 0 8.60702039062744e-06
. O 0 9.55434870775207e-07

Clinical O 0 3.578672112780623e-05
and O 0 2.746238010331581e-07
radiographic O 0 1.5499312212341465e-05
examinations O 0 1.4516224382532528e-06
were O 0 5.813620251871043e-09
performed O 0 1.320757725409294e-08
to O 0 9.872072048722202e-10
establish O 0 4.600849834446308e-08
diagnoses O 0 5.683654308086261e-06
, O 0 3.1505362763084577e-09
and O 0 1.2390076165047503e-07
disease O 0 4.897104008705355e-05
severity O 0 3.6610272218240425e-05
was O 0 1.8501056047171005e-06
assessed O 0 2.1245556425242285e-08
using O 0 8.278500551739398e-09
a O 0 1.1282913270349582e-08
combination O 0 4.367835870766612e-08
of O 0 1.4319574415111447e-09
validated O 0 1.594877687693952e-07
scoring O 0 1.6033598626563617e-07
systems O 0 5.804974989587208e-06
. O 0 3.448843415299052e-07

HLA O 0 0.0024522636085748672
typing O 0 0.00010932808072539046
for O 0 3.628572073921532e-07
HLA O 0 3.374481821083464e-05
- O 0 3.2700097563065356e-06
B27 O 0 4.416324372868985e-06
, O 0 2.8322531875346613e-08
HLA O 0 4.35503488915856e-06
- O 0 2.6453241730450827e-07
B60 O 0 5.176630111236591e-07
, O 0 2.166531842817676e-09
and O 0 1.1791577492203942e-08
HLA O 0 2.5290504709118977e-05
- O 0 3.422348527237773e-05
DR1 O 1 0.995877742767334
was O 0 2.634232032505679e-07
performed O 0 6.1552283270316366e-09
by O 0 4.090570104864355e-10
polymerase O 0 3.2241902658824984e-07
chain O 0 5.95704307215783e-07
reaction O 0 3.836543527313552e-08
with O 0 2.2982868941312518e-09
sequence O 0 4.1226805080896156e-08
- O 0 1.897689969609928e-07
specific O 0 9.565078507023372e-09
primers O 0 1.952484126377385e-06
, O 0 1.21860099788762e-09
and O 0 1.6426681126446852e-09
zygosity O 0 5.681924335476651e-07
was O 0 3.4650827984705757e-08
assessed O 0 3.573126861056153e-08
using O 0 1.1645850150898696e-07
microsatellite O 0 1.4155786629999056e-05
markers O 0 6.7913915700046346e-06
. O 0 2.1233306313206413e-07

Genetic O 0 1.2361057997622993e-05
and O 0 1.9045483412583053e-08
environmental O 0 1.6375512501554113e-08
variance O 0 7.397779278051075e-09
components O 0 3.108575441501671e-08
were O 0 2.542729582444281e-09
assessed O 0 2.313107261286973e-09
with O 0 2.2375647168448864e-10
the O 0 4.598197822502925e-09
program O 0 1.2396205839593222e-08
Mx O 0 4.928813268634258e-07
, O 0 1.3187526071156697e-10
using O 0 1.0918345116905925e-09
data O 0 7.54846585238056e-09
from O 0 4.2938774758027876e-10
this O 0 9.922998533973271e-11
and O 0 2.171002544404388e-10
previous O 0 9.405423107011757e-09
studies O 0 8.887444669092304e-10
of O 0 3.834659256796158e-10
twins O 0 2.8002344265587453e-07
with O 0 6.804905083868107e-09
AS B-Disease 1 0.999998927116394
. O 0 1.9526129335645237e-07

RESULTS O 0 7.142615686461795e-06
Six O 0 1.3639318297009595e-07
of O 0 8.17338108305421e-09
8 O 0 4.474291301903577e-07
monozygotic O 0 3.7686659197788686e-05
( O 0 7.12980863681878e-07
MZ O 1 0.9997825026512146
) O 0 7.895638987065468e-08
twin O 0 0.002118084579706192
pairs O 0 2.704834969335934e-07
were O 0 8.510281901408234e-08
disease O 0 1.3711245401282213e-06
concordant O 0 6.243188863663818e-07
, O 0 2.444722202454841e-09
compared O 0 2.21133831246334e-08
with O 0 1.6516565892743529e-09
4 O 0 1.8905417675796343e-08
of O 0 4.820053800536073e-10
15 O 0 1.8203438756358992e-08
B27 O 0 1.1237316357437521e-06
- O 0 1.428441350981302e-06
positive O 0 2.8357513315313554e-07
dizygotic O 0 1.3452598068397492e-05
( O 0 1.6637075361813913e-07
DZ O 0 0.0005684556672349572
) O 0 2.8181995403997462e-08
twin O 0 5.666055130859604e-06
pairs O 0 5.38809743488855e-08
( O 0 7.466317342164075e-09
27 O 0 4.316166979378977e-08
% O 0 3.3938873933436753e-10
) O 0 2.3646648528163894e-10
and O 0 5.643463474314103e-10
4 O 0 8.836807730006058e-09
of O 0 1.0274242567831493e-09
32 O 0 8.879690653884609e-07
DZ O 1 0.7065341472625732
twin O 0 0.00021800310059916228
pairs O 0 9.141334089690645e-08
overall O 0 2.2385452780326887e-07
( O 0 7.249893574368116e-09
12 O 0 6.8073200409912715e-09
. O 0 2.3114433977955429e-10
5 O 0 6.051807943663334e-09
% O 0 1.1696617008283283e-09
) O 0 5.639463562800984e-09
. O 0 2.87081967087488e-08

Nonsignificant O 0 8.40821085148491e-05
increases O 0 6.394558340616641e-07
in O 0 7.487852116128124e-09
similarity O 0 4.98499863610391e-09
with O 0 4.650933804750679e-10
regard O 0 2.831193279817512e-09
to O 0 5.756618293162319e-09
age O 0 3.1019123269970805e-08
at O 0 8.841495855449466e-07
disease O 0 8.684457498020492e-06
onset O 0 1.419964883098146e-05
and O 0 4.2043919457057655e-09
all O 0 2.9435356929674583e-10
of O 0 1.4782348956021707e-10
the O 0 3.629810763072783e-08
disease O 0 4.6941631808294915e-06
severity O 0 9.197489703183237e-07
scores O 0 2.2007607469731738e-07
assessed O 0 8.289438824249373e-08
were O 0 5.50145440314509e-09
noted O 0 1.1004823718963053e-08
in O 0 4.841878009642642e-08
disease O 0 0.0012188291875645518
- O 0 0.005916720721870661
concordant O 1 0.5365726351737976
MZ O 1 0.9999978542327881
twins O 0 4.674602678278461e-05
compared O 0 2.961272400625603e-07
with O 0 5.8838917738057717e-08
concordant O 0 0.0010343041503801942
DZ O 1 0.9999295473098755
twins O 0 0.0005142177105881274
. O 0 5.531433089345228e-07

HLA O 0 0.01059784833341837
- O 0 2.4493021555827e-05
B27 O 0 1.3094024325255305e-05
and O 0 1.2694578721550442e-08
B60 O 0 1.6565608973451162e-07
were O 0 1.1988253723060893e-09
associated O 0 1.5346407478133983e-09
with O 0 1.9097262660139336e-10
the O 0 1.3673538745706537e-08
disease O 0 6.500512768070621e-07
in O 0 3.857475228130625e-09
probands O 0 1.8501339127396932e-06
, O 0 1.7419923836747842e-10
and O 0 1.3562512224396528e-10
the O 0 1.4354850641495887e-09
rate O 0 2.01716417791431e-07
of O 0 9.272077550193103e-10
disease O 0 4.6215447468966886e-07
concordance O 0 2.4585327196291473e-07
was O 0 4.403579723089024e-08
significantly O 0 8.581627497505906e-08
increased O 0 2.8255733752757806e-08
among O 0 7.97807775398951e-09
DZ O 0 0.00611716927960515
twin O 0 8.670370880281553e-05
pairs O 0 8.762376069171296e-08
in O 0 1.033220087265363e-08
which O 0 4.701498301784568e-09
the O 0 8.378977511824814e-09
co O 0 8.009151315491181e-07
- O 0 5.469756160891848e-06
twin O 0 0.00018903324962593615
was O 0 4.053565660910863e-08
positive O 0 1.4311029028490907e-09
for O 0 1.8253903943943328e-10
both O 0 1.172494101808752e-09
B27 O 0 7.729959179414436e-07
and O 0 6.097890548062423e-08
DR1 O 0 0.011421078816056252
. O 0 9.561375691191643e-07

Additive O 0 1.6765412510721944e-05
genetic O 0 2.068134563160129e-06
effects O 0 4.1574736542315804e-07
were O 0 3.707335327618466e-09
estimated O 0 5.974924999208042e-10
to O 0 4.513922569060469e-10
contribute O 0 7.17256365412311e-10
97 O 0 6.937307173160434e-09
% O 0 1.2835145446477014e-10
of O 0 2.278190656956891e-11
the O 0 5.917751844108921e-10
population O 0 1.7807678664993887e-09
variance O 0 5.018304705117771e-08
. O 0 6.520033224433064e-08

CONCLUSION O 0 2.894219051086111e-06
Susceptibility O 0 1.3200233297538944e-05
to O 0 1.5076774673161708e-07
AS B-Disease 1 0.999864935874939
is O 0 1.8119841183050767e-09
largely O 0 3.0414617491203444e-09
genetically O 0 1.26192354343857e-08
determined O 0 2.2328006110683418e-08
, O 0 1.9479495794172408e-10
and O 0 1.0699075653208823e-10
the O 0 4.645818174608962e-10
environmental O 0 8.781490534737202e-10
trigger O 0 2.935488510047435e-07
for O 0 7.903797616393149e-10
the O 0 1.0172717423984068e-07
disease O 0 1.901201540022157e-05
is O 0 4.104726780695955e-09
probably O 0 9.312442017517242e-08
ubiquitous O 0 2.2866931885801023e-06
. O 0 1.1267196953212988e-07

HLA O 0 0.004881910979747772
- O 0 2.319455234101042e-05
B27 O 0 4.488524155021878e-06
accounts O 0 3.125930803093979e-08
for O 0 3.4291286477028393e-10
a O 0 7.330034357266868e-10
minority O 0 2.5106148271447637e-09
of O 0 3.418547389610893e-11
the O 0 5.208450892801864e-10
overall O 0 2.7356794163324594e-08
genetic O 0 1.1360072704746926e-07
susceptibility O 0 3.293066015430668e-07
to O 0 5.0367255255423515e-08
AS B-Disease 1 0.9999984502792358
. O 0 2.8070232360732916e-07

Cell O 0 0.0008411919116042554
cycle O 0 0.00021758755610790104
- O 0 8.792275366431568e-06
dependent O 0 2.197845248019803e-07
colocalization O 0 2.2467288545158226e-06
of O 0 1.92274618449062e-09
BARD1 O 0 3.170617219439009e-06
and O 0 5.9264300134032055e-09
BRCA1 O 0 7.257200422827736e-07
proteins O 0 1.990755826852819e-08
in O 0 2.7593700657746467e-09
discrete O 0 3.568488438077111e-08
nuclear O 0 4.2561299551380216e-07
domains O 0 1.012057737170835e-06
. O 0 1.2772046886766475e-07

Germ O 0 0.15915918350219727
- O 0 0.06729209423065186
line O 0 3.398392800590955e-05
mutations O 0 3.07638129015686e-06
of O 0 1.7263744878093235e-09
the O 0 1.2640505531180679e-08
BRCA1 O 0 4.041163265355863e-06
gene O 0 2.803143956953136e-07
predispose O 0 1.350093441487843e-07
women O 0 6.34184982306607e-10
to O 0 8.791160577281687e-10
early O 0 2.5858644221443683e-06
- O 1 0.7491683959960938
onset O 1 0.9999991655349731
breast B-Disease 1 1.0
and I-Disease 1 0.9999985694885254
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.413279093753772e-08
compromising O 0 6.220711270543688e-07
the O 0 3.992286945475598e-09
genes O 0 8.486114211336826e-08
presumptive O 0 1.8163505046686623e-06
function O 0 1.0937609928873826e-08
as O 0 1.5127890051758186e-09
a O 0 1.8894098730015685e-08
tumor B-Disease 0 1.0064405614684802e-05
suppressor O 0 6.628700793953612e-05
. O 0 3.286299090632383e-07

Although O 0 2.922215287526342e-07
the O 0 2.2785027198324315e-08
biochemical O 0 2.3205991794839065e-07
properties O 0 3.444523599682725e-08
of O 0 2.4432773582105938e-09
BRCA1 O 0 3.857127921946812e-06
polypeptides O 0 4.413460317209683e-07
are O 0 4.784898033349805e-10
not O 0 6.754986014989584e-10
understood O 0 1.8851502581185287e-09
, O 0 1.0031393077314377e-10
their O 0 7.812937519169338e-10
expression O 0 1.0768942182437513e-08
pattern O 0 2.7028647764382185e-07
and O 0 9.838987402588373e-10
subcellular O 0 3.421351664201211e-07
localization O 0 1.694897804327411e-07
suggest O 0 1.753996592412932e-08
a O 0 4.886249183044811e-09
role O 0 5.970770100560685e-09
in O 0 1.4212102605881682e-08
cell O 0 6.4685309553169645e-06
- O 0 4.170099782641046e-05
cycle O 0 6.976864824537188e-06
regulation O 0 3.5610275972430827e-06
. O 0 1.3846496926817053e-07

When O 0 1.2995544693694683e-06
resting O 0 1.4834724879619898e-06
cells O 0 2.3868261678217095e-07
are O 0 1.5040483303252472e-09
induced O 0 9.231658282260469e-08
to O 0 3.0324718292007447e-09
proliferate O 0 2.0607188844223856e-07
, O 0 2.7755947540342163e-10
the O 0 6.146989584010498e-10
steady O 0 1.6079829379123112e-07
- O 0 1.3499011686235463e-08
state O 0 4.900835293142336e-10
levels O 0 3.643390034113736e-09
of O 0 1.5536509578861768e-10
BRCA1 O 0 9.622338126291652e-08
increase O 0 1.2083593015077554e-09
in O 0 2.3640527313517623e-09
late O 0 3.2173975341720507e-06
G1 O 0 4.844843033424695e-07
and O 0 6.447226086336855e-10
reach O 0 1.8768342435748764e-09
a O 0 4.815672749458599e-09
maximum O 0 2.7767624644070565e-08
during O 0 7.639677335191664e-08
S O 0 5.717272870242596e-06
phase O 0 2.2682786493533058e-07
. O 0 7.957140013559183e-08

Moreover O 0 1.1340949868099415e-06
, O 0 2.0949073586962186e-08
in O 0 1.2852796160700564e-08
S O 0 1.1881813861691626e-06
phase O 0 4.0174356286115653e-08
cells O 0 1.2001947879980435e-07
, O 0 5.885920639769893e-09
BRCA1 O 0 1.8455416466167662e-06
polypeptides O 0 2.817539268562541e-07
are O 0 9.512947096723678e-10
hyperphosphorylated O 0 7.650583029317204e-07
and O 0 1.6449569484322524e-09
accumulate O 0 9.010430801481562e-08
into O 0 6.876299973868072e-09
discrete O 0 1.2872060040081124e-07
subnuclear O 0 7.727556294412352e-06
foci O 0 5.875682745681843e-06
termed O 0 2.228152197858435e-06
" O 0 1.1325219873015158e-07
BRCA1 O 0 2.3234048057929613e-05
nuclear O 0 3.4735180634015705e-06
dots O 0 5.431033423519693e-05
. O 0 3.335161125050945e-07

" O 0 3.5929226669395575e-06
BRCA1 O 0 4.6305493015097454e-05
associates O 0 1.5351148476838716e-06
in O 0 1.733971899398057e-08
vivo O 0 2.844575703875307e-07
with O 0 1.1964474966319472e-09
a O 0 2.5276635895465915e-08
structurally O 0 1.5684297977713868e-05
related O 0 1.0888096113603751e-07
protein O 0 1.052953507496568e-06
termed O 0 7.358382390521001e-06
BARD1 O 0 0.00020024397235829383
. O 0 5.324827156982792e-07

Here O 0 4.1756482005439466e-07
we O 0 5.11188424923148e-09
show O 0 5.297260408099191e-09
that O 0 9.681233592573335e-11
the O 0 4.783592966184358e-10
steady O 0 4.350251359142021e-08
- O 0 1.219848133615642e-08
state O 0 6.948400743667094e-10
levels O 0 6.794024010048361e-09
of O 0 1.808244387557778e-10
BARD1 O 0 6.777847261218994e-07
, O 0 1.5034368194832837e-10
unlike O 0 4.4186015957237146e-10
those O 0 6.947774300325449e-11
of O 0 1.0708670755699146e-10
BRCA1 O 0 3.059179505271459e-07
, O 0 3.8647937627978024e-10
remain O 0 7.844997984562951e-10
relatively O 0 1.5514663997961975e-09
constant O 0 8.344735569210116e-09
during O 0 6.491740123237832e-08
cell O 0 9.67062806012109e-06
cycle O 0 1.248324042535387e-05
progression O 0 2.7509586288942955e-06
. O 0 1.2852261477291904e-07

However O 0 6.287524456638494e-07
, O 0 2.440646973411731e-08
immunostaining O 0 2.3924696961330483e-06
revealed O 0 1.4502813883154886e-07
that O 0 2.271025811850791e-09
BARD1 O 0 3.3942451409529895e-06
resides O 0 9.614063856133725e-08
within O 0 2.0690361424158255e-08
BRCA1 O 0 3.0008504836587235e-06
nuclear O 0 2.7450886364022153e-07
dots O 0 2.8419856334949145e-06
during O 0 1.4525653568853159e-07
S O 0 1.0918849966401467e-06
phase O 0 9.787295418561825e-09
of O 0 1.1103210711960187e-10
the O 0 1.8117733979750028e-09
cell O 0 3.5449627944217355e-07
cycle O 0 8.725501032813554e-08
, O 0 1.1053743337319233e-10
but O 0 1.4638357193064166e-10
not O 0 1.2963723150516415e-10
during O 0 2.600899717819516e-09
the O 0 4.347826987327608e-09
G1 O 0 1.8268990515935002e-06
phase O 0 1.3013412569762295e-07
. O 0 1.2515651803823857e-07

Nevertheless O 0 1.1244670531596057e-05
, O 0 1.037596888409098e-07
BARD1 O 0 8.117352081171703e-06
polypeptides O 0 7.130420840439911e-07
are O 0 1.1734202498558943e-09
found O 0 1.472826527404436e-09
exclusively O 0 9.123349853368268e-10
in O 0 6.014968523260222e-10
the O 0 5.264843006003161e-10
nuclear O 0 6.929345985895452e-09
fractions O 0 3.5980871615493015e-09
of O 0 5.622381032965862e-11
both O 0 1.5105198203357872e-09
G1 O 0 1.5322218587243697e-06
- O 0 1.2154027899669018e-06
and O 0 3.176326046627764e-08
S O 0 7.805400855431799e-06
- O 0 6.348814167722594e-07
phase O 0 1.1585743209252541e-07
cells O 0 2.535689986871148e-07
. O 0 6.895201920542604e-08

Therefore O 0 7.979030556271027e-07
, O 0 2.9772364129598827e-08
progression O 0 2.1041722675363417e-07
to O 0 6.553956932719984e-09
S O 0 2.117921894750907e-06
phase O 0 1.6255205181892052e-08
is O 0 6.910086391975767e-10
accompanied O 0 2.0178281268101728e-09
by O 0 1.784132841464725e-10
the O 0 5.561546223553648e-10
aggregation O 0 1.0654813920041306e-08
of O 0 3.338721799028832e-10
nuclear O 0 7.414126201865656e-08
BARD1 O 0 2.610374394862447e-06
polypeptides O 0 3.4780850910465233e-07
into O 0 6.256802009829698e-08
BRCA1 O 0 8.529848855687305e-06
nuclear O 0 1.6572450931562344e-06
dots O 0 1.8097498468705453e-05
. O 0 3.724553607753478e-07

This O 0 7.43851614970481e-07
cell O 0 2.5217721486114897e-05
cycle O 0 2.1844205548404716e-05
- O 0 1.1525257832545321e-06
dependent O 0 5.829679849966851e-08
colocalization O 0 1.017714680529025e-06
of O 0 1.4758411159832008e-09
BARD1 O 0 4.208356131130131e-06
and O 0 5.608527420264409e-09
BRCA1 O 0 5.656173698298517e-07
indicates O 0 3.4583662600340404e-09
a O 0 1.7445136446525566e-09
role O 0 4.025026978382584e-09
for O 0 6.137417796203692e-10
BARD1 O 0 2.0245640826033195e-06
in O 0 3.190966424426733e-08
BRCA1 O 0 0.00012683653039857745
- O 0 3.597484464989975e-05
mediated O 0 4.3035175622208044e-05
tumor B-Disease 0 0.00011581768922042102
suppression O 0 8.456248906441033e-06
. O 0 4.3962117501905595e-07

Ethnic O 0 2.3606896775163477e-06
differences O 0 1.4951102684790385e-06
in O 0 7.409856550566474e-08
the O 0 1.40134034154471e-07
HFE O 0 0.0005717831081710756
codon O 0 5.6617020163685083e-05
282 O 0 1.228340533998562e-05
( O 0 1.8649363937583985e-06
Cys O 1 0.9947102069854736
/ O 0 0.000751327839680016
Tyr O 0 5.996638719807379e-05
) O 0 2.011094295539806e-07
polymorphism O 0 1.968446849787142e-05
. O 0 5.95445840190223e-07

Recent O 0 1.7399556782038417e-06
studies O 0 1.253728640904228e-07
have O 0 5.705961481083932e-09
shown O 0 5.607267894447432e-08
that O 0 4.85780731196428e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.0013036844320595264
HH B-Disease 1 0.9999899864196777
) O 0 1.3210146754261132e-08
is O 0 7.186257144908836e-10
likely O 0 4.532680897284536e-09
to O 0 1.586351050519852e-09
be O 0 5.604022801364295e-10
caused O 0 3.874626841593454e-09
by O 0 4.854792123865082e-10
homozygosity O 0 1.5142973097681534e-07
for O 0 1.354635292827311e-10
a O 0 2.9677327262334074e-09
Cys282Tyr O 0 1.0278813533659559e-06
mutation O 0 9.927139643650662e-08
in O 0 5.2223407820406464e-09
the O 0 1.2965838180889477e-08
HFE O 0 1.601094481884502e-05
gene O 0 5.530937414732762e-07
located O 0 2.483317871337931e-07
4 O 0 1.8038234372852457e-07
. O 0 8.947782959012329e-08

5 O 0 4.6704630221938714e-05
Mb O 0 0.0007573112961836159
telomeric O 0 0.000404117105063051
to O 0 1.2225719956404646e-06
HLA O 0 9.081824100576341e-05
- O 0 2.833701501003816e-06
A O 0 3.114914477464481e-07
. O 0 1.681962942257087e-07

Population O 0 8.91133637992425e-08
studies O 0 9.180644688910888e-09
of O 0 2.2908192010007156e-10
this O 0 5.26079790841294e-10
polymorphism O 0 6.996202017717223e-08
are O 0 9.674551437743872e-11
facilitated O 0 1.1348563200286321e-09
by O 0 2.0169499403976943e-10
the O 0 4.440814105333146e-10
fact O 0 3.3953634348549144e-10
that O 0 5.4800320531400715e-11
the O 0 1.8626582498626476e-09
Cys282Tyr O 0 1.443962332814408e-06
mutation O 0 1.8228669773634465e-07
creates O 0 1.9415269392197843e-08
a O 0 1.3945857801900274e-08
Rsal O 0 4.47023694505333e-06
restriction O 0 3.738667260222428e-07
site O 0 3.3723583214850805e-07
. O 0 1.3415341015843296e-07

We O 0 4.477655011214665e-07
have O 0 8.485431024496393e-09
studied O 0 4.108809292802107e-08
the O 0 9.643795095826135e-09
codon O 0 4.306712071411312e-06
282 O 0 1.1921835039174766e-06
( O 0 6.080047114664922e-07
Cys O 1 0.8984888195991516
/ O 0 0.0001894533052109182
Tyr O 0 1.0071866199723445e-05
) O 0 1.4141366300179925e-08
polymorphism O 0 2.062744073327849e-07
in O 0 2.0450277027350694e-09
different O 0 7.777699040367736e-10
ethnic O 0 2.6090283267166114e-09
groups O 0 4.2841774572366376e-09
. O 0 3.238973533825629e-08

In O 0 1.3744732996201492e-07
agreement O 0 1.6388071344408672e-08
with O 0 9.163286240898572e-10
previous O 0 1.0643764092321817e-08
observations O 0 8.356059844061292e-09
the O 0 3.825712191485309e-09
Tyr O 0 1.0308086757504498e-06
allele O 0 3.262093457578885e-07
appeared O 0 6.508390981707635e-08
to O 0 6.829060095192574e-10
be O 0 2.794004749784307e-10
rare O 0 1.99908800624371e-09
or O 0 2.0961783420148095e-08
absent O 0 7.226495313261694e-08
in O 0 9.13970854554691e-09
Asiatic O 0 2.4536655018891906e-07
( O 0 1.7498457127729239e-09
Indian O 0 4.39682762420901e-10
, O 0 2.513641517154497e-10
Chinese O 0 5.240587963584176e-10
) O 0 1.9677233176196296e-09
populations O 0 1.829505258399422e-08
. O 0 2.580016023046028e-08

The O 0 8.178466828212549e-07
highest O 0 7.597723197250161e-07
allele O 0 5.639456958306255e-06
frequency O 0 8.44209898787085e-06
( O 0 3.487447131078625e-08
7 O 0 9.873733830545461e-09
. O 0 2.1361339086478637e-10
5 O 0 1.5707309897194932e-09
% O 0 1.883708189431843e-10
) O 0 2.2639921881673075e-10
was O 0 9.154521585230668e-09
found O 0 1.457256537662488e-09
in O 0 5.208215192453736e-09
Swedes O 0 1.825115759856999e-06
. O 0 1.0633703340090506e-07

Saamis O 0 0.0004840540641453117
( O 0 1.273585212402395e-06
2 O 0 9.256783783939682e-08
% O 0 2.7775715061295614e-09
) O 0 1.7791179640624932e-09
and O 0 1.1079417383541568e-09
Mordvinians O 0 4.974410785507644e-07
( O 0 2.1108454983931324e-09
1 O 0 9.772423981146972e-10
. O 0 8.850208066402132e-11
8 O 0 3.1173790215888175e-09
% O 0 1.0830687041663012e-10
) O 0 1.562530937970763e-10
had O 0 2.509470631295585e-09
significantly O 0 2.3979414010000255e-08
lower O 0 4.510536371071794e-07
frequencies O 0 1.493515497941189e-07
of O 0 7.050811601239104e-10
the O 0 1.2370036550635177e-08
Tyr O 0 4.499667284108e-06
allele O 0 3.4090835470124148e-06
. O 0 8.326549760795388e-08

Comparisons O 0 2.4319515432580374e-06
with O 0 8.999060696623928e-08
allele O 0 2.8858294172096066e-06
frequencies O 0 1.0139897312910762e-06
based O 0 1.19230882944521e-08
on O 0 2.9544843016537925e-08
prevalence O 0 3.5216854143982346e-07
estimates O 0 1.7242758332258745e-08
of O 0 3.3512153052583926e-09
HH B-Disease 1 0.9999659061431885
showed O 0 2.151941316697048e-06
some O 0 3.7624128812474567e-10
disagreements O 0 7.327605633378198e-09
with O 0 1.4672964232520513e-10
the O 0 8.046661115201914e-10
RFLP O 0 2.8742036306539376e-07
data O 0 3.5381869878392536e-08
, O 0 2.627419393164132e-10
particularly O 0 8.156527120384283e-10
in O 0 3.2577014419388206e-09
Finns O 0 1.1399439472370432e-06
. O 0 1.2534273707842658e-07

The O 0 9.169708619083394e-07
newly O 0 1.5883886135270586e-06
described O 0 1.0335926390325767e-06
HFE O 0 9.264155232813209e-05
marker O 0 8.467050065519288e-07
provides O 0 3.6711531592459323e-09
a O 0 3.521031244346773e-09
new O 0 5.340192288372236e-09
approach O 0 2.8157158826758177e-09
to O 0 7.635329035693417e-10
the O 0 9.115870280851368e-10
screening O 0 1.9361831249398165e-08
of O 0 8.751611102475465e-10
HH B-Disease 0 0.01879442110657692
as O 0 1.4937391323854854e-09
well O 0 3.8847483563309027e-10
as O 0 1.167436841642555e-10
studies O 0 9.404086537267986e-11
of O 0 1.3998417008886932e-11
the O 0 2.101171875379393e-10
relationship O 0 4.882995119359634e-10
between O 0 4.771564254824057e-10
the O 0 1.5943294684461762e-08
HFE O 0 3.1524570658802986e-05
Tyr O 0 1.7901306819112506e-06
allele O 0 6.251619311115064e-07
and O 0 3.128362680016039e-09
different O 0 1.091485213322585e-08
disorders O 0 0.0001404721988365054
including O 0 1.780732219458514e-07
cancer B-Disease 0 0.005053191911429167

Autosomal B-Disease 1 0.9999979734420776
dominant I-Disease 1 0.9999878406524658
neurohypophyseal I-Disease 1 0.9999997615814209
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9984098672866821
associated O 0 3.3849385090434225e-06
with O 0 2.1456258991747745e-08
a O 0 2.629122377584281e-07
missense O 0 0.00015695946058258414
mutation O 0 1.3287077308632433e-05
encoding O 0 1.0237403330393136e-05
Gly23 O 0 0.0008162292069755495
- O 0 0.0005094028892926872
- O 0 3.8246249459916726e-05
> O 0 3.0231290111260023e-06
Val O 0 1.652097489568405e-05
in O 0 1.2535468840724207e-07
neurophysin O 0 3.5668970667757094e-05
II O 0 2.0662993847508915e-05
. O 0 2.0186574545277836e-07

Autosomal B-Disease 1 0.9999967813491821
dominant I-Disease 1 0.9999909400939941
neurohypophyseal I-Disease 1 0.9999996423721313
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999780654907227
( O 0 1.3286950888868887e-05
ADNDI B-Disease 0 0.00038708295323885977
) O 0 1.9890935121225084e-08
is O 0 5.8597762198076e-09
an O 0 1.9857922950450302e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 1.2586091543198563e-05
by O 0 1.051005682484174e-07
progressive O 0 0.00024620984913781285
degeneration O 0 1.1222280591027811e-05
of O 0 9.228287578544325e-10
the O 0 1.295152696201285e-08
magnocellular O 0 6.4442347138538025e-06
neurons O 0 1.8669457801934186e-07
of O 0 4.719005741726789e-10
the O 0 3.3803093657525096e-09
hypothalamus O 0 3.742013063856575e-07
leading O 0 7.515495781262871e-09
to O 0 1.344601874286866e-09
decreased O 0 2.0090503483061184e-08
ability O 0 3.3897615825395633e-09
to O 0 2.4588637792533063e-09
produce O 0 6.466367441504417e-09
the O 0 1.9013615570884213e-08
hormone O 0 2.0715021946671186e-06
arginine O 0 1.6386483139285701e-06
vasopressin O 0 1.861308078332513e-06
( O 0 7.755471642667544e-08
AVP O 0 3.107365500909509e-06
) O 0 3.9147575847664484e-08
. O 0 6.776929950547128e-08

Affected O 0 2.6510820134717505e-06
individuals O 0 1.949616645902097e-08
are O 0 1.4833082540022247e-09
not O 0 2.3682635852395606e-09
symptomatic O 0 1.4307329365692567e-07
at O 0 1.899357613410757e-07
birth O 0 5.948584202997154e-07
, O 0 3.558364713995843e-10
but O 0 1.3119169084419013e-09
usually O 0 1.2276386485154944e-07
develop O 0 3.0308829082059674e-06
diabetes B-Disease 0 0.018925895914435387
insipidus I-Disease 0 0.0003827267501037568
at O 0 4.110097961529391e-06
1 O 0 1.0330761597288074e-06
- O 0 0.00017064074927475303
6 O 0 1.1274757980572758e-06
yr O 0 1.2930646335007623e-05
of O 0 3.0328071165541814e-09
age O 0 6.857808898530493e-08
. O 0 5.562474925113747e-08

The O 0 1.8652087874215795e-07
genetic O 0 8.281171517410257e-07
locus O 0 5.527857638298883e-07
of O 0 1.9299180031850938e-09
the O 0 4.647595375217861e-08
disease O 0 7.996985914360266e-06
is O 0 4.41985159582714e-09
the O 0 4.7342105347070174e-08
AVP O 0 3.289073720225133e-05
- O 0 3.2582483981968835e-05
neurophysin O 0 6.018419662723318e-05
II O 0 8.352240911335684e-06
( O 0 1.8601207685264853e-08
NPII O 0 1.2055236311425688e-06
) O 0 1.9402710549343283e-09
gene O 0 2.945970578593915e-08
, O 0 4.479239201771179e-10
and O 0 8.663917361317885e-10
mutations O 0 1.244878831130336e-07
that O 0 8.630172687595916e-10
cause O 0 2.4854873714730275e-08
ADNDI B-Disease 0 5.674377007380826e-06
have O 0 1.7369038429748684e-09
been O 0 7.869935814142082e-10
found O 0 6.689084841582371e-10
in O 0 5.690221627219216e-10
both O 0 2.484427941151779e-10
the O 0 1.0609869649513826e-09
signal O 0 1.5805989050932112e-07
peptide O 0 1.855977771469952e-08
of O 0 2.1711640818544709e-10
the O 0 5.827408333658468e-09
prepro O 0 5.05525122207473e-06
- O 0 2.94468395622971e-06
AVP O 0 8.794773748377338e-06
- O 0 1.5067673757584998e-06
NPII O 0 2.6130294372705976e-06
precursor O 0 1.4034989703759493e-07
and O 0 2.554054967518482e-09
within O 0 5.642842193509523e-09
NPII O 0 5.174066700419644e-06
itself O 0 3.8389813994399447e-07
. O 0 8.625013236951418e-08

An O 0 3.839501232505427e-07
affected O 0 9.436429309062078e-07
girl O 0 4.804423952009529e-05
who O 0 1.1571692937195621e-08
presented O 0 7.335352769644032e-09
at O 0 2.094296114307781e-08
9 O 0 1.509647873376707e-08
months O 0 2.0543164946928982e-09
of O 0 1.579996827816288e-10
age O 0 2.0063954941917927e-09
and O 0 3.4468861098702064e-10
her O 0 7.560554848851098e-09
similarly O 0 5.3562512647431504e-08
affected O 0 2.2442604219463647e-08
younger O 0 5.1390451005772775e-08
brother O 0 1.6626131582597736e-07
and O 0 4.143885234952904e-09
father O 0 6.629444726513611e-08
were O 0 4.381624507665549e-10
all O 0 2.5513258172793485e-11
found O 0 2.288007144857218e-10
to O 0 1.4779304169376672e-10
have O 0 1.5851707446667973e-10
a O 0 3.0440268083964384e-09
novel O 0 6.426519405522413e-08
missense O 0 6.445617600547848e-06
mutation O 0 1.5692082797613693e-06
( O 0 6.083207182427941e-08
G1758 O 0 4.899185569229303e-06
- O 0 2.5659061066107824e-05
- O 0 1.9153139874106273e-05
> O 0 1.4550918194800033e-06
T O 0 4.047534730489133e-06
) O 0 1.95008431624899e-09
encoding O 0 2.275115384975379e-08
the O 0 2.2199835303382542e-09
amino O 0 1.8467051887682828e-08
acid O 0 2.92147301905743e-08
substitution O 0 6.269919339274566e-08
Gly23 O 0 6.964786734897643e-06
- O 0 1.0023743925557937e-05
- O 0 7.978270332387183e-06
> O 0 1.7561980030222912e-06
Val O 0 1.2610914382094052e-05
within O 0 1.0940556194327655e-07
NPII O 0 4.306704067857936e-05
. O 0 2.590519727618812e-07

The O 0 7.419246230710996e-07
mutation O 0 8.589602657593787e-06
was O 0 1.202559474222653e-07
confirmed O 0 9.351172991500789e-08
by O 0 7.335436702504694e-09
restriction O 0 3.4559087680463563e-07
endonuclease O 0 2.372609196754638e-05
analysis O 0 4.7022948024277866e-07
. O 0 1.3444440583043615e-07

A O 0 1.6255711670964956e-05
T1 O 0 0.011315877549350262
- O 0 1.9653367417049594e-05
weighted O 0 2.7370708721718984e-06
magnetic O 0 7.500662491111143e-07
resonance O 0 9.685807071946329e-07
imaging O 0 2.0018417217215756e-06
of O 0 2.19880380569748e-09
the O 0 4.690859611855558e-08
fathers O 0 5.842725840921048e-07
pituitary O 0 1.7329622323813965e-06
gland O 0 6.395046625584655e-07
demonstrates O 0 6.681172237676947e-08
an O 0 1.6459054563711106e-08
attenuated O 0 3.389433913980611e-05
posterior O 0 7.336719136219472e-05
pituitary O 0 0.00032685522455722094
bright O 0 9.132097329711542e-05
spot O 0 4.542289752862416e-05
. O 0 5.544573014049092e-07

This O 0 5.235767730482621e-07
mutation O 0 2.79530377156334e-05
may O 0 3.683366287532408e-07
be O 0 7.648505162549668e-10
valuable O 0 7.00729363423136e-10
for O 0 1.4164458495002918e-10
developing O 0 2.898753015401212e-09
models O 0 1.9138559181897108e-08
of O 0 2.2912880481840148e-09
dominantly B-Disease 0 0.046598806977272034
inherited I-Disease 1 0.9995219707489014
neurodegeneration I-Disease 1 1.0
, O 0 5.885291809448745e-09
as O 0 4.3897888102328864e-10
the O 0 4.195874203638539e-10
early O 0 1.4297944517238648e-07
age O 0 5.1083755003844544e-09
of O 0 2.00354149937354e-10
onset O 0 2.3711495487077627e-06
of O 0 5.462870600325687e-09
symptoms O 0 0.00019825414346996695
suggests O 0 1.5895745164584696e-08
that O 0 2.630141937576269e-10
this O 0 1.0344874956658145e-09
mutation O 0 5.489496857080667e-07
may O 0 1.6548177939057496e-07
be O 0 1.3075875937573755e-09
particularly O 0 2.901507922814517e-09
deleterious O 0 4.2750212969622226e-07
to O 0 3.178669993886274e-09
the O 0 1.1837954616567004e-08
magnocellular O 0 8.753981092013419e-06
neuron O 0 4.8289657570421696e-06
. O 0 1.643063818335122e-08
. O 0 1.3087912975606741e-07

Frequent O 0 0.0001862625067587942
inactivation O 0 0.00039782526437193155
of O 0 3.7945596886856947e-07
PTEN O 0 0.0024170074611902237
/ O 0 0.00013066000246908516
MMAC1 O 0 7.106344128260389e-05
in O 0 1.845210931605834e-06
primary O 1 0.9880931973457336
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.6444328139186837e-06

Sporadic B-Disease 1 0.9999997615814209
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.2299226170853217e-07
the O 0 3.3756830664088966e-09
most O 0 8.215529923027987e-10
common O 0 1.9308911802795592e-08
male B-Disease 0 9.261569289265026e-08
cancer I-Disease 0 7.308877059131191e-08
in O 0 9.885223750671912e-10
the O 0 1.1995436866030218e-09
Western O 0 9.143004575662417e-09
world O 0 5.039692219099834e-09
, O 0 9.042130932890302e-11
yet O 0 1.4979209539411897e-10
many O 0 8.776073617822178e-12
of O 0 8.55792520182419e-12
the O 0 1.2540712912567642e-10
major O 0 3.0082114577112407e-10
genetic O 0 1.1719261117093538e-09
events O 0 5.807333502971801e-10
involved O 0 2.622602968127552e-10
in O 0 7.500426946194239e-10
the O 0 2.0198305250573867e-09
progression O 0 2.784686614631937e-08
of O 0 1.1456690457434249e-10
this O 0 1.1635648000662968e-09
often O 0 1.297442651093661e-07
fatal O 0 0.01796996220946312
cancer B-Disease 0 0.00013098632916808128
remain O 0 4.0409517509942816e-08
to O 0 5.9786562367492024e-09
be O 0 8.06334998770808e-09
elucidated O 0 1.2764476196025498e-06
. O 0 3.445601137741505e-08

Numerous O 0 3.576547214834136e-06
cytogenetic O 0 0.0006810922059230506
and O 0 1.439135246528167e-07
allelotype O 0 8.311432793561835e-06
studies O 0 3.229350298283862e-08
have O 0 2.7675925995396256e-09
reported O 0 1.5585743540214025e-07
frequent O 0 1.2112887759485602e-07
loss O 0 3.2524698667657503e-07
of O 0 3.1492806140676066e-09
heterozygosity O 0 3.751879603441921e-06
on O 0 3.766366205582017e-07
chromosomal O 0 0.01616436429321766
arm O 0 0.0010587131837382913
10q O 0 8.896525287127588e-06
in O 0 6.117543875916454e-07
sporadic B-Disease 1 0.9999994039535522
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.2978422293817857e-06

Deletion O 0 0.00028037693118676543
mapping O 0 1.6524078091606498e-05
studies O 0 3.6765615618605807e-07
have O 0 2.72154938585345e-08
unambiguously O 0 6.75208013944939e-07
identified O 0 7.630586829066033e-09
a O 0 1.6492263110734484e-09
region O 0 4.356094596147386e-09
of O 0 4.3126899273993047e-10
chromosome O 0 8.144515390995366e-07
10q23 O 0 1.6077176212547784e-07
to O 0 1.825760320706138e-09
be O 0 2.1225526891655022e-10
the O 0 2.84583134835259e-10
minimal O 0 1.1097738727983142e-08
area O 0 4.044311552320323e-09
of O 0 1.2919987302240088e-09
loss O 0 5.567617336055264e-07
. O 0 1.1551078671345749e-07

A O 0 2.897837248383439e-06
new O 0 1.8448008631821722e-06
tumor B-Disease 0 5.1020200771745294e-05
suppressor O 0 0.00010794038826134056
gene O 0 2.585450783954002e-05
, O 0 1.8354231201556104e-07
PTEN O 0 0.00041893281741067767
/ O 0 0.00016680904082022607
MMAC1 O 0 6.932408723514527e-05
, O 0 1.7658662088138044e-08
was O 0 2.8219538705798186e-08
isolated O 0 9.910907294852223e-08
recently O 0 2.0915541654176195e-07
at O 0 7.910256449861208e-09
this O 0 2.9627653108654783e-10
region O 0 2.0985415627450266e-09
of O 0 4.686910859419413e-10
chromosome O 0 3.7423845355988306e-07
10q23 O 0 9.564717373677922e-08
and O 0 7.243614597030046e-10
found O 0 6.033870625365978e-10
to O 0 6.252728335098823e-10
be O 0 4.000280939830958e-10
inactivated O 0 2.4395998110549044e-08
by O 0 1.667167792707147e-10
mutation O 0 9.003950474095745e-09
in O 0 7.606407059768117e-09
three O 0 1.1597318007261492e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 4.787939178640954e-05
lines O 0 6.49692228762433e-05
. O 0 3.258219294366427e-07

We O 0 7.66722223488614e-07
screened O 0 4.733385139843449e-06
80 O 0 3.9198271224449854e-06
prostate B-Disease 1 0.9997707009315491
tumors I-Disease 1 1.0
by O 0 2.17492548415521e-08
microsatellite O 0 2.74308899861353e-06
analysis O 0 4.3000614624588707e-08
and O 0 1.246110548080992e-09
found O 0 4.906327788489762e-09
chromosome O 0 6.474070914919139e-07
10q23 O 0 1.9003051932031667e-07
to O 0 6.4596368254399295e-09
be O 0 1.4405923121074693e-09
deleted O 0 2.112087429395615e-07
in O 0 9.153193758493217e-09
23 O 0 4.2220737128673136e-08
cases O 0 7.064276275059456e-09
. O 0 6.556472698093785e-08

We O 0 4.518079208537529e-07
then O 0 2.4556030098210613e-08
proceeded O 0 3.4799722214984286e-08
with O 0 7.301735327480685e-10
sequence O 0 7.251469646973874e-09
analysis O 0 4.243231543910042e-09
of O 0 3.127013092907305e-10
the O 0 5.633400412818901e-09
entire O 0 2.904140217196982e-07
PTEN O 0 7.649997132830322e-05
/ O 0 8.922746019379701e-06
MMAC1 O 0 8.136851647577714e-06
coding O 0 2.0111299363634316e-06
region O 0 3.447165752845649e-08
and O 0 8.165153886352527e-09
tested O 0 8.854053845652743e-08
for O 0 6.493604542967546e-10
homozygous O 0 2.055184324945003e-07
deletion O 0 8.049185851177754e-08
with O 0 7.354429842898469e-10
new O 0 6.303061184098624e-08
intragenic O 0 5.156658517080359e-06
markers O 0 2.0464847239054507e-07
in O 0 3.852064001108602e-09
these O 0 8.379964500093706e-10
23 O 0 7.762261056143416e-09
cases O 0 5.139608183490907e-10
with O 0 1.408982819306459e-09
10q23 O 0 1.4326433301903307e-06
loss O 0 1.494909156463109e-07
of O 0 5.10187136981699e-09
heterozygosity O 0 1.1261314284638502e-05
. O 0 3.038686031686666e-07

The O 0 1.0797307936627476e-07
identification O 0 3.2134671812400484e-08
of O 0 7.886209463237037e-10
the O 0 2.2623789508458003e-09
second O 0 1.2673337934643314e-08
mutational O 0 2.7621285880741198e-06
event O 0 1.9053912225786007e-08
in O 0 8.201240575544944e-09
10 O 0 5.7844755652070035e-09
( O 0 2.624896078273764e-09
43 O 0 2.224439299425285e-08
% O 0 6.896159643332567e-09
) O 0 1.7499307602975023e-07
tumors B-Disease 1 1.0
establishes O 0 9.571992995915934e-05
PTEN O 0 0.0052393111400306225
/ O 0 4.7324727347586304e-05
MMAC1 O 0 4.985323357686866e-06
as O 0 3.1720983617589127e-09
a O 0 3.114229318867956e-09
main O 0 1.2893333511954097e-08
inactivation O 0 2.888897370212362e-07
target O 0 1.5414443055306037e-08
of O 0 2.408352961502658e-10
10q O 0 1.7125918816418562e-07
loss O 0 6.097518223668885e-08
in O 0 2.2867995141950814e-07
sporadic B-Disease 1 0.9999994039535522
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.636240522719163e-08
. O 0 1.9303908516121737e-07

Risk O 0 4.547039861790836e-05
reversals O 0 1.526004052720964e-05
in O 0 8.222404801472294e-08
predictive O 0 3.7427594179462176e-06
testing O 0 5.777901151304832e-06
for O 0 1.0473091833773651e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 9.070209330275247e-07

The O 0 1.7149845632502547e-07
first O 0 3.259032865798872e-08
predictive O 0 8.988594117909088e-07
testing O 0 4.845078933612967e-07
for O 0 1.964166358447983e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.5377743523004028e-07
HD B-Disease 0 0.005093362648040056
) O 0 8.844952326114708e-09
was O 0 1.1705193259103908e-08
based O 0 2.0220969343398565e-09
on O 0 3.2189990673003877e-09
analysis O 0 1.0437969377719014e-09
of O 0 2.05343020365234e-10
linked O 0 2.550126225742133e-07
polymorphic O 0 1.1449208159319824e-06
DNA O 0 2.111265899884529e-07
markers O 0 2.2248090658649744e-07
to O 0 2.2687052236847194e-09
estimate O 0 5.417422510589631e-09
the O 0 1.2412973982023345e-09
likelihood O 0 8.01385624527029e-09
of O 0 2.7108226774430477e-10
inheriting O 0 7.495170706306453e-08
the O 0 3.343273435874039e-09
mutation O 0 2.608378508739406e-07
for O 0 6.655389128695788e-09
HD B-Disease 0 8.520987466908991e-05
. O 0 3.7166128663557174e-07

Limits O 0 1.370533709632582e-06
to O 0 1.9192002653767304e-08
accuracy O 0 8.591420908032887e-08
included O 0 2.759775297178635e-09
recombination O 0 2.050872360825906e-08
between O 0 1.0195920774336287e-09
the O 0 3.259889469475752e-09
DNA O 0 6.729721491183227e-08
markers O 0 1.3235549545242975e-07
and O 0 5.667637470452291e-10
the O 0 2.717859715062332e-09
mutation O 0 1.4608284004680172e-07
, O 0 7.76518904732626e-10
pedigree O 0 1.5670906350351288e-07
structure O 0 2.1501076474805814e-08
, O 0 1.7038216670872686e-10
and O 0 5.885476828115799e-11
whether O 0 1.684106465393853e-10
DNA O 0 3.2118847581585896e-09
samples O 0 2.395608600380683e-09
were O 0 1.6614094822120506e-10
available O 0 2.2474194727450936e-10
from O 0 6.874840696724505e-10
family O 0 3.0825655361610416e-09
members O 0 2.3161090823009545e-09
. O 0 1.7685966469116465e-08

With O 0 9.202860695722848e-08
direct O 0 8.198085055255433e-08
tests O 0 9.979974890939047e-08
for O 0 9.685413582261049e-10
the O 0 3.212215604619928e-09
HD B-Disease 0 0.0004335835110396147
mutation O 0 4.817144940716389e-07
, O 0 7.985960226442046e-10
we O 0 3.988373242780341e-10
have O 0 1.4920099877802073e-10
assessed O 0 1.4865483288772907e-09
the O 0 7.60959517620563e-10
accuracy O 0 1.4539617509967684e-08
of O 0 1.8065619833418367e-10
results O 0 8.930149952846023e-09
obtained O 0 1.4288253913363747e-09
by O 0 3.7855049650481476e-10
linkage O 0 2.1801046301561655e-08
approaches O 0 3.4420852834671223e-09
when O 0 7.221170883475736e-10
requested O 0 1.0997893706843342e-09
to O 0 8.20483458952026e-10
do O 0 7.24173609967238e-10
so O 0 1.6054660378905794e-10
by O 0 1.3473533400087945e-10
the O 0 1.085103895626105e-09
test O 0 5.977926598177419e-09
individuals O 0 3.773192869260811e-10
. O 0 1.0106456116432128e-08

For O 0 2.8321343492621054e-08
six O 0 3.4470983845125147e-09
such O 0 1.327838949904958e-10
individuals O 0 7.603701696057286e-11
, O 0 1.0623674162602015e-10
there O 0 2.7082902587238777e-10
was O 0 5.459339202928959e-09
significant O 0 1.3184867642124232e-09
disparity O 0 3.936281522953777e-09
between O 0 1.9441421805765913e-09
the O 0 4.3089944057328466e-08
tests O 0 1.4810890434091561e-06
. O 0 7.408358726479491e-08

Three O 0 1.0941328554281426e-07
went O 0 4.691289134939325e-08
from O 0 8.950677421459829e-10
a O 0 2.460111669932985e-09
decreased O 0 8.638119197712513e-08
risk O 0 1.5999643832032007e-09
to O 0 1.5746418058348866e-10
an O 0 1.927871473572651e-10
increased O 0 2.1891967350029518e-08
risk O 0 1.0107342518494988e-08
, O 0 1.9612662882639853e-10
while O 0 1.8127058187822342e-10
in O 0 3.5928321429068433e-10
another O 0 2.5540927706124705e-10
three O 0 1.965632934197714e-10
the O 0 2.9974280835176614e-09
risk O 0 2.4064865655759604e-08
was O 0 5.4933099846721234e-08
decreased O 0 2.158945449082239e-07
. O 0 4.086807692260663e-08

Knowledge O 0 1.1397836630067104e-07
of O 0 1.1399762245289935e-09
the O 0 7.004206659111389e-10
potential O 0 6.231821170210594e-10
reasons O 0 2.345860450336801e-10
for O 0 7.094515946937108e-11
these O 0 7.043576832899134e-11
changes O 0 2.3966324480539924e-09
in O 0 2.2450641345983513e-09
results O 0 2.772137541739994e-08
and O 0 6.59451826479085e-10
impact O 0 1.3535280674048522e-09
of O 0 1.254662207461621e-10
these O 0 1.0193373922717797e-09
risk O 0 4.622644489415961e-09
reversals O 0 2.6216252280164554e-08
on O 0 1.9489696967411874e-08
both O 0 2.391773445964418e-09
patients O 0 2.09120143424002e-09
and O 0 2.2603420524180962e-10
the O 0 1.200532451228753e-09
counseling O 0 3.3130698184891116e-09
team O 0 7.317169092857512e-10
can O 0 2.939664067724834e-10
assist O 0 1.4816475824019903e-10
in O 0 1.5174234091475114e-10
the O 0 3.0622290814186215e-10
development O 0 5.510669351393993e-11
of O 0 3.794293004788507e-11
strategies O 0 1.560470641592815e-09
for O 0 7.290307246776706e-11
the O 0 1.7701311527673624e-09
prevention O 0 3.9180743982569766e-08
and O 0 5.616060394508793e-10
, O 0 5.0441397586586945e-11
where O 0 1.79687112411564e-10
necessary O 0 6.180495004670661e-10
, O 0 1.988302439359657e-10
management O 0 6.369513250170655e-10
of O 0 2.2643798294752493e-11
a O 0 2.474927374152003e-09
risk O 0 8.465546486036146e-09
reversal O 0 1.775125824110546e-08
in O 0 1.4334275988403533e-09
any O 0 2.745688565397586e-09
predictive O 0 1.802269196105044e-07
testing O 0 1.27850739772839e-07
program O 0 1.6994352591837014e-08
. O 0 2.6469775260551387e-09
. O 0 2.2798893439812673e-08

A O 0 2.5211934371327516e-06
novel O 0 1.5672954987167032e-06
common O 0 5.767589073002455e-07
missense O 0 7.342430035350844e-05
mutation O 0 1.4727502275491133e-05
G301C O 0 2.7990806756861275e-06
in O 0 3.848496987757244e-08
the O 0 2.0014505608401123e-08
N O 0 4.927027021039976e-06
- O 0 4.8226656872429885e-06
acetylgalactosamine O 0 0.00026069176965393126
- O 0 1.60961426445283e-05
6 O 0 1.119218268286204e-06
- O 0 7.85983957030112e-06
sulfate O 0 1.0571529855951667e-05
sulfatase O 0 3.164336521876976e-05
gene O 0 1.4656556004410959e-06
in O 0 1.5218283522244747e-07
mucopolysaccharidosis B-Disease 0 6.860135908937082e-05
IVA I-Disease 0 0.00013026065425947309
. O 0 1.1569815114853554e-06

Mucopolysaccharidosis B-Disease 0 0.020362110808491707
IVA I-Disease 1 0.9769219756126404
( O 0 0.0007800414459779859
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 0.9999992847442627
) O 0 4.790445728986015e-08
is O 0 5.02030284010857e-09
an O 0 2.3429114648365612e-08
autosomal B-Disease 1 0.999993085861206
recessive I-Disease 1 1.0
lysosomal I-Disease 1 0.9999998807907104
storage I-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9999692440032959
caused O 0 2.5503093183942838e-06
by O 0 1.4131929404470611e-08
a O 0 6.485406629508361e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 4.302637819364463e-07
N O 0 0.00011310660192975774
- O 0 4.73999280075077e-05
acetylgalactosamine O 0 0.000781178823672235
- O 0 9.156391024589539e-05
6 O 0 2.3958762085385388e-06
- O 0 6.447442137869075e-05
sulfate O 0 6.406403554137796e-05
sulfatase O 0 0.00010185298015130684
( O 0 1.969001317547736e-07
GALNS O 0 1.860614247561898e-05
) O 0 7.854962547071409e-08
. O 0 7.018415004722556e-08

In O 0 5.848501132277306e-07
previous O 0 2.7130943180964096e-07
studies O 0 1.9136917828177502e-08
, O 0 9.323880556522113e-10
we O 0 1.5637831307646621e-10
have O 0 7.689839737201609e-11
found O 0 2.0198448469344044e-10
two O 0 1.9261586770014105e-10
common O 0 5.775699918331156e-09
mutations O 0 9.081169594082894e-08
in O 0 5.216785226025422e-09
Caucasians O 0 3.1874623829253323e-08
and O 0 1.0740996980729278e-09
Japanese O 0 5.384214318837621e-08
, O 0 3.54128371071738e-09
respectively O 0 1.1131534449759783e-07
. O 0 4.50337545032653e-08

To O 0 6.75300725561101e-07
characterize O 0 3.4273514302185504e-06
the O 0 4.5977795792850884e-08
mutational O 0 1.9496019376674667e-05
spectrum O 0 6.968261345718929e-07
in O 0 2.0023620539433296e-09
various O 0 3.4206754095933434e-10
ethnic O 0 3.3037036994976177e-10
groups O 0 2.330563242392003e-10
, O 0 1.5802499586659025e-10
mutations O 0 1.3272073218217884e-08
in O 0 5.26711341208852e-10
the O 0 3.137254012131052e-09
GALNS O 0 1.066974050445424e-06
gene O 0 1.6169434502444346e-07
in O 0 1.5760976523893078e-08
Colombian O 0 1.4970348729548277e-06
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 0.9999998807907104
patients O 0 2.382901357123046e-06
were O 0 1.7191725376619615e-08
investigated O 0 5.4140890881626547e-08
, O 0 7.971228677128295e-10
and O 0 8.089656722276573e-10
genetic O 0 1.6381571654733307e-08
backgrounds O 0 1.5748476300814218e-08
were O 0 1.290983875357199e-09
extensively O 0 1.364933144287761e-08
analyzed O 0 1.513759428917183e-08
to O 0 1.5785789342359635e-09
identify O 0 5.612465159288149e-09
racial O 0 4.089284910691049e-09
origin O 0 6.820872200385963e-10
, O 0 6.366206867225443e-11
based O 0 2.502066054343999e-10
on O 0 2.6402158237459616e-09
mitochondrial O 0 8.995302636094493e-08
DNA O 0 9.526300459583581e-08
( O 0 1.1720385550972878e-08
mtDNA O 0 3.1232909236678097e-07
) O 0 1.7025239884560506e-08
lineages O 0 5.81732763293985e-07
. O 0 1.3468489612478152e-07

Three O 0 6.445750386774307e-07
novel O 0 1.8228754470328568e-06
missense O 0 0.00011486215225886554
mutations O 0 8.453586633550003e-05
never O 0 2.9219643238320714e-07
identified O 0 2.2513988895411785e-08
previously O 0 6.180793210575075e-09
in O 0 6.869951829635568e-10
other O 0 8.238467547050377e-11
populations O 0 5.412297277018752e-10
and O 0 2.3428287088123056e-10
found O 0 1.2752865430343263e-09
in O 0 2.8904605375856818e-09
16 O 0 6.584027101297352e-09
out O 0 5.022484095285051e-10
of O 0 2.9607769014283747e-10
19 O 0 3.4419361583104546e-08
Colombian O 0 4.1109345261247654e-07
MPS B-Disease 1 0.9999651908874512
IVA I-Disease 1 0.9997597336769104
unrelated O 0 1.0380377943874919e-06
alleles O 0 9.357914336760587e-07
account O 0 4.179161550155186e-08
for O 0 9.88413439984015e-09
84 O 0 7.054328534650267e-07
. O 0 1.1101828079063125e-07

2 O 0 5.19957325195719e-07
% O 0 5.717094797574873e-09
of O 0 1.422423845376386e-10
the O 0 1.33277222591488e-09
alleles O 0 5.900097121980252e-08
in O 0 1.4283894067546044e-09
this O 0 1.914373548572712e-09
study O 0 1.7545287889220162e-08
. O 0 7.091603748676789e-08

The O 0 7.781726480970974e-07
G301C O 0 9.195750863000285e-06
and O 0 3.186903185792289e-08
S162F O 0 2.2766359961678972e-06
mutations O 0 8.849898449625471e-07
account O 0 3.078465837802469e-08
for O 0 3.00417046794621e-09
68 O 0 3.904981440427946e-07
. O 0 7.002262947253257e-08

4 O 0 4.005968548881356e-06
% O 0 1.0074837319962171e-07
and O 0 2.9319174643660517e-08
10 O 0 1.4643978829553816e-07
. O 0 1.756957459519981e-07

5 O 0 1.3034120911470382e-06
% O 0 1.1951867939785643e-08
of O 0 9.135677769833705e-10
mutations O 0 3.2648009096192254e-07
, O 0 1.0634646496754385e-09
respectively O 0 6.035047572794383e-09
, O 0 3.2964397878032514e-10
whereas O 0 3.0688789287580676e-09
the O 0 1.8145261959645609e-09
remaining O 0 5.789133172839911e-09
F69V O 0 1.1067277227994055e-06
is O 0 3.2428024154818047e-10
limited O 0 5.65336444324771e-10
to O 0 3.046470853362848e-10
a O 0 2.310444058295502e-09
single O 0 5.841098982273252e-08
allele O 0 3.3552641980350018e-06
. O 0 9.773140163815697e-08

The O 0 9.071281965589151e-07
skewed O 0 4.820297817786923e-06
prevalence O 0 1.6301037248922512e-06
of O 0 1.3908422191732939e-09
G301C O 0 1.5982638501554902e-07
in O 0 1.2076980526742886e-09
only O 0 5.426644689165983e-10
Colombian O 0 8.566545695032346e-09
patients O 0 1.4006102944108534e-08
and O 0 1.585280240412601e-09
haplotype O 0 1.0519941042730352e-06
analysis O 0 5.645178102753334e-09
by O 0 1.0788548943096998e-09
restriction O 0 3.009815685572903e-08
fragment O 0 1.3092432027406176e-07
length O 0 2.3155097395033408e-08
polymorphisms O 0 6.125588356553635e-07
in O 0 6.268279229004747e-09
the O 0 6.3172853614901214e-09
GALNS O 0 3.4146410143875983e-06
gene O 0 2.3049086905757576e-07
suggest O 0 1.680225913958111e-08
that O 0 4.707921275048932e-10
G301C O 0 5.4579988528757895e-08
originated O 0 1.6465900642970155e-08
from O 0 9.316041271745235e-10
a O 0 2.09425099484406e-09
common O 0 9.903420306045518e-09
ancestor O 0 2.0044652160322585e-07
. O 0 1.147059265349526e-07

Investigation O 0 1.700789766800881e-06
of O 0 1.1354154949572148e-08
the O 0 1.1562029555989284e-08
genetic O 0 7.845019922569918e-08
background O 0 2.1150217577314834e-08
by O 0 8.751276925345053e-10
means O 0 5.851419349056641e-10
of O 0 9.729474864661469e-11
mtDNA O 0 2.956265632292343e-08
lineages O 0 2.1532757799036517e-08
indicate O 0 2.1029821439810803e-08
that O 0 5.769696387325496e-10
all O 0 3.8368905275198983e-10
our O 0 6.39438546556903e-09
patients O 0 2.498671713979661e-09
are O 0 5.97303040361652e-11
probably O 0 1.128075632905734e-09
of O 0 1.0033861935765387e-10
native O 0 3.3838314372758305e-09
American O 0 2.1829590579613978e-08
descent O 0 3.0048538519622525e-06

Low O 0 4.62058924313169e-05
frequency O 0 6.6447132667235564e-06
of O 0 5.187893137303945e-08
BRCA1 O 0 5.106936805532314e-05
germline O 0 2.5938918042811565e-05
mutations O 0 2.6260424874635646e-06
in O 0 3.020915784190947e-08
45 O 0 5.837229082317208e-07
German O 1 1.0
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.833140110349632e-07
. O 0 2.508921852495405e-07

In O 0 3.2460863508276816e-07
this O 0 3.5724163627293137e-09
study O 0 2.507829277575979e-09
we O 0 8.007909335638885e-10
investigated O 0 1.850015607374189e-08
45 O 0 9.413592749751842e-08
German O 1 0.9999991655349731
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.403555221519582e-08
for O 0 2.155650102864115e-09
germline O 0 2.590104713817709e-06
mutations O 0 9.954706001735758e-07
in O 0 8.072890800292498e-09
the O 0 2.7007718728100372e-08
BRCA1 O 0 2.361334190936759e-05
gene O 0 3.2649086278979667e-06
. O 0 1.6622421128431597e-07

We O 0 2.4877743953766185e-07
identified O 0 6.787628592519468e-08
four O 0 5.012074755228468e-09
germline O 0 1.9367246295587393e-06
mutations O 0 8.945783633862447e-07
in O 0 1.3694731570979002e-08
three O 0 1.9331321254867362e-07
breast B-Disease 1 0.9844956398010254
cancer I-Disease 0 2.7572150429477915e-06
families O 0 1.1113534537088299e-09
and O 0 2.9858435168783615e-10
in O 0 4.243530860037481e-09
one O 0 1.0392627700639423e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.1807098587723885e-07
. O 0 1.183304287888376e-10
among O 0 2.3795672030035853e-11
these O 0 5.229103261505941e-11
were O 0 5.479857678736266e-10
one O 0 1.0993489452104654e-09
frameshift O 0 1.1483367416076362e-05
mutation O 0 1.6623214094124705e-07
, O 0 1.1052758708274268e-09
one O 0 3.575872487004972e-09
nonsense O 0 1.1419754173402907e-06
mutation O 0 2.747377436662646e-07
, O 0 1.198466437202228e-09
one O 0 1.3580689905978716e-09
novel O 0 1.9753089830487625e-08
splice O 0 6.913869583513588e-06
site O 0 3.6989678164900397e-07
mutation O 0 6.576329383278789e-07
, O 0 1.5456713686745616e-09
and O 0 1.320643705504665e-09
one O 0 1.3406306287322423e-08
missense O 0 1.9203562260372564e-05
mutation O 0 1.1629435903159901e-05
. O 0 4.534014976798062e-07

The O 0 1.4430826240641181e-06
missense O 0 0.0002937571262009442
mutation O 0 6.646245310548693e-05
was O 0 3.0323080864036456e-06
also O 0 1.4690340499612375e-08
found O 0 4.650058116340006e-09
in O 0 1.1169002611666201e-08
2 O 0 1.4939999459784303e-07
. O 0 8.125974915174083e-08

8 O 0 1.827538653742522e-06
% O 0 4.268964737264014e-09
of O 0 6.060326546153405e-11
the O 0 3.704428153117334e-10
general O 0 2.760505712906536e-10
population O 0 9.341587919875494e-11
, O 0 7.602744128698546e-11
suggesting O 0 5.569808614325211e-09
that O 0 2.883311922552423e-10
it O 0 2.4388449038070803e-09
is O 0 1.463937082668565e-09
not O 0 1.1873025229647283e-08
disease O 0 8.086021807685029e-07
associated O 0 8.841649901114579e-08
. O 0 1.88898866326781e-07

The O 0 3.3695744150463725e-07
average O 0 7.652086537746072e-07
age O 0 5.494892363344661e-08
of O 0 3.232281775567003e-09
disease O 0 6.6601296566659585e-06
onset O 0 4.076134064234793e-05
in O 0 4.665002251158512e-08
those O 0 3.192925257522461e-09
families O 0 5.862951013568818e-09
harbouring O 0 2.542482206990826e-06
causative O 0 1.3355131613934645e-06
mutations O 0 4.998043095838511e-06
was O 0 2.22813000050337e-07
between O 0 3.03131066914375e-08
32 O 0 6.689983251817466e-07
. O 0 1.7017812581343605e-07

3 O 0 5.504203727468848e-06
and O 0 7.12725380935808e-08
37 O 0 9.5890811735444e-07
. O 0 1.2361455503651086e-07

4 O 0 2.7774997306551086e-06
years O 0 1.0273522477177721e-08
, O 0 5.821296222840999e-10
whereas O 0 1.4784951041235672e-09
the O 0 1.5145298348784308e-09
family O 0 7.353647912822225e-09
harbouring O 0 1.0393517158036047e-07
the O 0 3.262004000248453e-09
missense O 0 3.092654424108332e-06
mutation O 0 2.658634912222624e-07
had O 0 1.1891269302566343e-08
an O 0 6.470373126177265e-10
average O 0 4.342955861602604e-08
age O 0 4.573322609502384e-09
of O 0 5.186859275418954e-10
onset O 0 2.877326778616407e-06
of O 0 7.074200780721185e-09
51 O 0 1.1849123211504775e-06
. O 0 1.2656674641675636e-07

2 O 0 7.509131592087215e-06
years O 0 5.921020260757359e-07
. O 0 4.6186281110749405e-07

These O 0 4.7501295341589866e-08
findings O 0 8.299041098780435e-08
show O 0 8.403357298902847e-08
that O 0 3.3882681105268375e-09
BRCA1 O 0 1.5671968185415608e-06
is O 0 3.486838318078611e-10
implicated O 0 3.257167202619371e-09
in O 0 1.9646959059649305e-10
a O 0 2.042609831276465e-10
small O 0 2.5255167401816436e-10
fraction O 0 4.771093298217011e-09
of O 0 2.8661756346082257e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.66640900657012e-09
suggesting O 0 3.516321456231708e-08
the O 0 1.490233270118324e-09
involvement O 0 5.251427293018196e-09
of O 0 2.527246745209766e-10
another O 0 1.198720944728393e-08
susceptibility O 0 2.0488059817580506e-06
gene O 0 6.038267201802228e-06
( O 0 5.204891522225807e-07
s O 0 7.315047696465626e-05
) O 0 2.0384220533742337e-06

Paternal O 0 0.42938849329948425
transmission O 1 0.9997332692146301
of O 0 5.1319126214366406e-05
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00016367557691410184

We O 0 4.680394454226189e-07
report O 0 6.800431862075129e-08
a O 0 3.54899909460471e-09
rare O 0 1.3517666097584424e-08
case O 0 3.637434176084753e-08
of O 0 4.941247411238692e-08
paternally O 1 0.9999949932098389
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9539387226104736
DM B-Disease 1 1.0
) O 0 2.2886524675413966e-06
. O 0 3.9363968085126544e-07

The O 0 3.35941280127372e-07
proband O 0 6.8242757151892874e-06
is O 0 2.6827191579315013e-09
a O 0 5.177362982777822e-09
23 O 0 4.407848308574103e-08
year O 0 3.6097591582517907e-09
old O 0 1.8859768715628888e-06
, O 0 5.177039952286577e-08
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 1.185238829748414e-06
who O 0 3.732500601927313e-07
suffers O 0 0.09799928963184357
severe O 1 0.9871537089347839
muscular B-Disease 1 0.9999949932098389
weakness I-Disease 1 0.9999797344207764
. O 0 1.6065756653915741e-06

He O 0 8.900326520233648e-07
presented O 0 1.610765565374095e-07
with O 0 4.153319466126959e-08
respiratory O 0 0.4437454044818878
and O 0 4.6318607616058216e-08
feeding O 0 1.663624971115496e-06
difficulties O 0 1.3332896742213052e-07
at O 0 3.1606379025106435e-07
birth O 0 5.270729616313474e-06
. O 0 1.509853007064521e-07

His O 0 5.203156888455851e-06
two O 0 3.17345637768085e-07
sibs O 0 0.003671936923637986
suffer O 0 4.406223524711095e-05
from O 0 8.871497243490012e-07
childhood O 0 0.0070527903735637665
onset O 1 0.9999959468841553
DM B-Disease 1 1.0
. O 0 1.1030357200070284e-05

Their O 0 1.6609997999239567e-07
late O 0 2.9733504561590962e-05
father O 0 3.9894581504995585e-07
had O 0 3.155605998728106e-09
the O 0 4.001417808208174e-10
adult O 0 5.866821695121871e-09
type O 0 2.840124864178506e-07
of O 0 2.7676364311446378e-08
DM B-Disease 1 1.0
, O 0 2.5228745759164894e-09
with O 0 8.801663287094641e-10
onset O 0 3.1684319310443243e-06
around O 0 1.2211475564072316e-07
30 O 0 3.668257164690658e-08
years O 0 9.93101867408086e-09
. O 0 2.262190257340535e-08

Only O 0 3.121426672691996e-08
six O 0 1.6322242446520363e-09
other O 0 6.091988719036934e-11
cases O 0 2.066510018661205e-10
of O 0 3.7887989967622104e-10
paternal O 0 0.00016696930106263608
transmission O 1 0.998428463935852
of O 0 6.956959737181023e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 4.008435041669145e-07
been O 0 3.813365623273057e-08
reported O 0 9.555760698276572e-07
recently O 0 9.12101484118466e-07
. O 0 1.0990773091634765e-07

We O 0 2.0025051128413907e-07
review O 0 4.336780534686113e-08
the O 0 2.346197014446716e-09
sex O 0 2.2565190604950658e-08
related O 0 1.4633906531003049e-08
effects O 0 1.8171461135807476e-07
on O 0 1.1502023653520155e-06
transmission O 1 0.9857777953147888
of O 0 5.689205977432721e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 4.293163328839e-06

Decreased O 0 7.353164255619049e-05
fertility O 0 1.746104544508853e-06
of O 0 7.2872698986259365e-09
males O 0 4.0576654924961986e-08
with O 0 3.409044380120463e-09
adult O 0 9.152006896329112e-06
onset O 1 0.9999802112579346
DM B-Disease 1 1.0
and O 0 1.6880773046068498e-07
contraction O 0 2.1478283542819554e-06
of O 0 4.095886962929285e-10
the O 0 2.279818556161217e-09
repeat O 0 6.022412435413571e-08
upon O 0 1.3912667684579105e-09
male O 0 8.283524088881222e-09
transmission O 0 3.991657990809472e-07
contribute O 0 1.1961143187022572e-09
to O 0 3.861846398223179e-10
the O 0 1.1405307809297938e-09
almost O 0 2.293802481290186e-09
absent O 0 6.930997997756094e-09
occurrence O 0 1.243433089825885e-08
of O 0 1.5096356387189758e-09
paternal O 0 0.00020009453874081373
transmission O 1 0.9974307417869568
of O 0 2.8256217774469405e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 4.823792551178485e-06

Also O 0 1.6325806484474015e-07
the O 0 5.456539220460854e-09
fathers O 0 8.479703161867747e-09
of O 0 6.840267935404043e-11
the O 0 1.97379401711828e-09
reported O 0 2.6442849048180506e-06
congenitally O 0 0.0002087743632728234
affected O 0 8.514974325635194e-08
children O 0 7.4491341983673465e-09
showed O 0 1.7103492666592501e-07
, O 0 6.544247366235822e-10
on O 0 3.9845829746809613e-08
average O 0 1.3357777106648427e-07
, O 0 4.5490766709122e-09
shorter O 0 2.7709384085028432e-06
CTG O 0 1.3726586985285394e-05
repeat O 0 1.7716810134515981e-06
lengths O 0 2.8591429668267665e-07
and O 0 2.069449722696959e-09
hence O 0 1.3586759273209736e-08
less O 0 3.6338629882948226e-08
severe O 0 0.0008676948491483927
clinical O 0 1.4734175238118041e-05
symptoms O 0 0.4396384060382843
than O 0 5.3498268037799335e-09
the O 0 2.1767640134839894e-08
mothers O 0 2.8246788019714586e-08
of O 0 2.639323204434163e-10
children O 0 1.0031403263610628e-08
with O 0 1.2889199751953129e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 3.141848083032528e-06

We O 0 9.750220897331019e-08
conclude O 0 1.1126397225780238e-07
that O 0 5.91761972756899e-09
paternal O 0 3.370387639733963e-05
transmission O 1 0.9257513880729675
of O 0 4.1211447410205437e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 3.4433281115298087e-08
rare O 0 1.4057783381815625e-08
and O 0 4.138601461534108e-09
preferentially O 0 1.0950368078965766e-07
occurs O 0 8.601107381878137e-09
with O 0 1.8418356839688954e-09
onset O 0 1.8790035028359853e-05
of O 0 6.137143060414019e-08
DM B-Disease 1 1.0
past O 0 1.3236852964837453e-06
30 O 0 1.2156347928282685e-08
years O 0 3.6035180395188604e-10
in O 0 2.6637911321181207e-10
the O 0 1.3571368473463963e-09
father O 0 3.747863175362909e-08
. O 0 2.0285559898525207e-09
. O 0 2.2328432436324874e-08

The O 0 6.263850991672371e-06
RB1 O 0 0.0009715618216432631
gene O 0 2.7685566237778403e-05
mutation O 0 6.228277925401926e-06
in O 0 3.8313732630967934e-08
a O 0 7.653883216107715e-08
child O 0 8.006616667444177e-07
with O 0 3.0390631877708074e-07
ectopic B-Disease 1 0.9999971389770508
intracranial I-Disease 1 0.9999573230743408
retinoblastoma I-Disease 1 0.9502347707748413
. O 0 8.940496627474204e-06

The O 0 4.8475744733877946e-06
RB1 O 0 0.0011724341893568635
gene O 0 3.495558485155925e-05
mutation O 0 1.305427576880902e-05
was O 0 1.8084018904573895e-07
investigated O 0 5.6737974318821216e-08
in O 0 3.1456905968951787e-09
a O 0 1.709014618711535e-08
child O 0 1.5931020413972874e-07
with O 0 2.4555374622536874e-08
ectopic B-Disease 1 0.9999325275421143
intracranial I-Disease 0 0.26625192165374756
retinoblastoma I-Disease 0 1.964171497093048e-05
using O 0 1.1292282664498998e-07
DNA O 0 1.0210526113496599e-07
obtained O 0 9.32920407592519e-09
from O 0 1.2768881507696506e-09
both O 0 5.425526694580185e-10
the O 0 2.8974926902236575e-09
pineal B-Disease 0 8.003494258446153e-06
and I-Disease 0 7.703092563815517e-08
retinal I-Disease 0 0.00018360067042522132
tumours I-Disease 1 1.0
of O 0 1.8320255312787026e-09
the O 0 8.223800307405327e-08
patient O 0 3.878906227328116e-06
. O 0 1.6753112674905424e-07

A O 0 4.8981019062921405e-06
nonsense O 0 2.7572268663789146e-05
mutation O 0 6.647451300523244e-06
in O 0 1.4890072463913384e-07
exon O 0 1.1105498742836062e-05
17 O 0 8.425663509115111e-07
( O 0 4.980192258585703e-08
codon O 0 5.179438630875666e-06
556 O 0 3.199285742994107e-07
) O 0 1.0055976051859261e-09
of O 0 1.6737694563673244e-10
the O 0 9.134132561428032e-09
RB1 O 0 4.09351241614786e-06
gene O 0 1.8910364474322705e-07
was O 0 5.6831986228189635e-08
found O 0 6.544160213728389e-10
to O 0 5.283292692226382e-10
be O 0 2.0755282215123572e-10
present O 0 7.900783915992804e-10
homozygously O 0 1.931904591856437e-07
in O 0 4.998153557700391e-10
both O 0 2.496326756418199e-10
the O 0 1.8654138234097672e-09
retinal B-Disease 0 9.230777209268126e-08
and I-Disease 0 3.3291593926065843e-09
the I-Disease 0 7.954196235004929e-08
pineal I-Disease 0 0.013721571303904057
tumours I-Disease 1 0.9999998807907104
. O 0 4.0017357605393045e-07

The O 0 1.2030871232582285e-07
same O 0 4.163908684517992e-08
mutation O 0 4.0790598632156616e-07
was O 0 3.1504598041465215e-08
present O 0 2.470220694661407e-09
heterozygously O 0 9.959399704939642e-08
in O 0 5.841327421762799e-10
the O 0 4.95978758063842e-10
DNA O 0 9.866880645859055e-09
from O 0 8.792468975116208e-10
the O 0 5.630174659820852e-10
constitutional O 0 1.1780713071729565e-09
cells O 0 1.2456281561767923e-09
of O 0 5.308421410776809e-11
the O 0 1.5117562757183123e-09
patient O 0 2.7343075359453906e-08
, O 0 7.349241215592883e-10
proving O 0 7.256506062702783e-09
it O 0 5.108100054052045e-10
to O 0 3.491590350179763e-10
be O 0 1.2473941324309124e-10
of O 0 6.160930793308594e-11
germline O 0 2.1596682131530542e-07
origin O 0 2.9675758739244884e-08
. O 0 7.475753704966337e-08

The O 0 2.091250905777997e-07
initial O 0 2.5467406317147834e-07
mutation O 0 1.2310977126617217e-06
was O 0 5.5696094847235145e-08
shown O 0 5.63198199188264e-09
to O 0 9.772628262183503e-10
have O 0 2.5484769849981603e-10
occurred O 0 6.593527945852884e-09
in O 0 1.7866603752025867e-09
the O 0 9.875767759126575e-09
paternally O 0 5.691073965863325e-06
derived O 0 3.7642979577867663e-07
RB1 O 0 6.428398046409711e-05
allele O 0 1.5940982848405838e-05
. O 0 2.7689890202964307e-07

The O 0 5.195548169467656e-07
mutation O 0 1.998183279283694e-06
is O 0 3.3626637030437223e-09
in O 0 1.0264488148337136e-09
an O 0 1.1037521591150679e-10
area O 0 5.528991708914077e-10
of O 0 2.6176638981412204e-11
the O 0 3.898710798644345e-10
gene O 0 1.8996287209915863e-08
that O 0 2.4595661618498355e-10
encodes O 0 4.683473164845964e-09
the O 0 1.0135986494574922e-09
protein O 0 3.1131381916793543e-08
- O 0 8.666371797971806e-08
binding O 0 2.2319490255995333e-08
region O 0 2.7779478717349093e-09
known O 0 2.1218209411699718e-09
as O 0 4.976825618285829e-10
the O 0 1.1518661580112166e-09
pocket O 0 6.601825589314103e-06
region O 0 1.50930805631333e-08
and O 0 5.851890527708292e-09
has O 0 9.61807300470241e-10
been O 0 2.4349949834245876e-10
detected O 0 5.737019304064006e-09
in O 0 2.8824320708054074e-10
other O 0 5.149869419796005e-11
cases O 0 2.482746230825228e-10
of O 0 4.46587156144318e-10
retinoblastoma B-Disease 0 6.60664738916239e-07
. O 0 6.429521359763157e-09
. O 0 9.438097237080001e-08

Low O 0 0.00010559416841715574
levels O 0 5.682395567419007e-07
of O 0 1.9994235156417517e-09
beta O 0 6.687623965717648e-08
hexosaminidase O 0 3.8553045556000143e-07
A O 0 1.2836381735326086e-08
in O 0 4.406165210468771e-09
healthy O 0 9.326606154047568e-09
individuals O 0 1.1579849579224089e-10
with O 0 2.07997574719343e-09
apparent O 0 4.654798613046296e-05
deficiency O 0 0.00010389085218776017
of O 0 5.069005770685919e-10
this O 0 4.884767701440751e-09
enzyme O 0 9.90090939012589e-07
. O 0 1.577869994662251e-07

Appreciable O 0 8.338106272276491e-05
beta O 0 1.7561615095473826e-05
hexosaminidase O 0 9.535824210615829e-05
A O 0 1.8833293324860279e-06
( O 0 1.3803423826175276e-07
hex O 0 8.6887962424953e-07
A O 0 1.3576552326810543e-08
) O 0 1.2471496058097387e-09
activity O 0 1.6209879660777915e-08
has O 0 8.58600635034179e-10
been O 0 8.440358967298778e-10
detected O 0 3.6245872081508423e-08
in O 0 1.1391377618963361e-08
cultured O 0 4.768162398249842e-06
skin O 1 0.7959321141242981
fibroblasts O 0 2.7135545224155067e-06
and O 0 1.2944492766564508e-07
melanoma B-Disease 0 0.00010503831435926259
tissue O 0 5.036109996581217e-06
from O 0 1.4546635895840154e-08
healthy O 0 1.0199625677387303e-07
individuals O 0 2.139828314540182e-10
previously O 0 6.174772249067928e-09
reported O 0 2.9066450224490836e-07
as O 0 2.8674541852069524e-08
having O 0 5.637024855786876e-07
deficiency B-Disease 0 3.0586331831727875e-06
of I-Disease 0 4.309746171049511e-10
hex I-Disease 0 4.0403591583526577e-07
A I-Disease 0 1.0733486988101504e-08
activity O 0 2.794401865457985e-08
indistinguishable O 0 2.3780463820344266e-08
from O 0 3.7004244113347795e-10
that O 0 5.493553181801225e-11
of O 0 2.1007789952065536e-10
patients O 0 2.3337372923037947e-08
with O 0 4.3477152757986914e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.999988317489624
( O 0 7.891180189290026e-07
TSD B-Disease 0 0.00019219741807319224
) O 0 1.5909978401396074e-07
. O 0 1.583806863436621e-07

Identification O 0 4.330525371187832e-06
and O 0 1.4210264964731323e-07
quantitation O 0 1.71759875229327e-05
of O 0 1.3740257820415991e-08
hex O 0 2.9660081963811535e-06
A O 0 4.151086230308465e-08
, O 0 1.9486046110017696e-09
amounting O 0 9.140528334228293e-09
to O 0 7.255440692688353e-09
3 O 0 1.2049025599480956e-07
. O 0 7.55277511643726e-08

5 O 0 1.0854711035790388e-05
% O 0 2.580447358013771e-07
- O 0 7.65911227063043e-06
6 O 0 7.082059596541512e-07
. O 0 1.7491514370249206e-07

9 O 0 4.824427378480323e-06
% O 0 1.083224621112322e-08
of O 0 1.990438786014792e-10
total O 0 5.841026551323125e-10
beta O 0 2.2057694337718203e-08
hexosaminidase O 0 4.856037776335143e-07
activity O 0 5.730056429342767e-08
, O 0 2.961375589194404e-10
has O 0 2.699718781862259e-10
been O 0 1.2168492602437908e-10
obtained O 0 4.861185343152385e-10
by O 0 1.5297747513187687e-09
cellulose O 0 8.78444334375672e-05
acetate O 0 1.6738429621909745e-05
gel O 0 4.365173026599223e-06
electrophoresis O 0 9.779001857168623e-07
, O 0 4.094811156818423e-09
DEAE O 0 6.168674644868588e-06
- O 0 1.0475748695171205e-06
cellulose O 0 4.8147066991077736e-05
ion O 0 3.219337258997257e-06
- O 0 1.8525104223954258e-06
exchange O 0 2.673694723398512e-07
chromatography O 0 3.5682850807461364e-07
, O 0 1.2366065949009908e-09
radial O 0 2.6176584810855275e-07
immunodiffusion O 0 1.6527720845260774e-06
, O 0 2.599317650009425e-09
and O 0 7.096593535038664e-09
radioimmunoassay O 0 1.2395337762427516e-05
. O 0 2.504766882793774e-07

Previous O 0 3.182170758009306e-06
family O 0 1.681945178688693e-07
studies O 0 4.691054211747314e-09
suggested O 0 3.190185893231501e-09
that O 0 1.8689279290828864e-10
these O 0 1.4034354234304658e-10
individuals O 0 1.108211647449231e-10
may O 0 7.612909413978741e-09
be O 0 1.387296527655124e-10
compound O 0 9.67422941755558e-09
heterozygotes O 0 4.8696161769612445e-08
for O 0 1.207879490872088e-10
the O 0 6.326820178870207e-10
common O 0 9.115927568359439e-09
mutant O 0 3.066838587528764e-07
TSD B-Disease 0 4.861922661802964e-06
gene O 0 4.617430136022449e-07
and O 0 2.59823718096186e-09
a O 0 4.869149528019534e-09
rare O 0 5.0306386611964626e-08
( O 0 2.320603265104637e-08
allelic O 0 2.169197841794812e-06
) O 0 2.779539265418407e-08
mutant O 0 2.0785685137525434e-06
gene O 0 7.404610641970066e-06
. O 0 5.642919518322742e-07

Thus O 0 7.226302045637567e-07
, O 0 7.654901601483743e-09
the O 0 1.6994150531246532e-09
postulated O 0 5.399331826083653e-08
rate O 0 4.9662574497233436e-08
mutant O 0 6.029826238318492e-08
gene O 0 1.5089850080585165e-07
appears O 0 3.5974299095187234e-08
to O 0 1.1599308180620937e-09
code O 0 9.077495199960595e-09
for O 0 1.0501306768606611e-10
the O 0 2.610256455426452e-10
expression O 0 2.392261722050648e-09
of O 0 1.651690312298726e-10
low O 0 3.271351900480113e-08
amounts O 0 1.875227528813639e-09
of O 0 1.142150374278117e-09
hex O 0 9.614373084332328e-07
A O 0 1.3156969203009794e-07
. O 0 8.970955178710938e-08

Heterozygotes O 0 5.512085772352293e-05
for O 0 2.5000362668947673e-08
the O 0 2.3525243975086596e-09
rare O 0 1.4154049488013243e-08
mutant O 0 4.751788083012798e-07
may O 0 1.4076141496843775e-07
be O 0 5.644238965096804e-10
indistinguishable O 0 9.00974050921377e-09
from O 0 1.998782916956543e-09
heterozygotes O 0 8.561828224173951e-08
for O 0 2.889323780230768e-10
the O 0 1.642790237177394e-09
common O 0 6.757930037792903e-08
TSD B-Disease 0 4.047921902383678e-05
mutant O 0 3.904313871316845e-06
. O 0 1.771689994711778e-07

However O 0 4.041253021114244e-07
, O 0 8.437884169154586e-09
direct O 0 2.290271083893458e-08
visualization O 0 4.249851031090657e-07
and O 0 1.2225780388064322e-08
quantitation O 0 2.4755670438025845e-06
of O 0 1.6579407846606387e-09
hex O 0 1.1440411071816925e-06
A O 0 5.706603634081375e-09
by O 0 2.969633705607322e-10
the O 0 3.9910366678164166e-10
methods O 0 9.52551637567467e-09
described O 0 4.9218986220012084e-08
may O 0 2.3434076013018057e-08
prevent O 0 1.1535750132907197e-08
false O 0 5.376907452614432e-08
- O 0 1.302008172388014e-06
positive O 0 2.1204228062288166e-07
prenatal O 0 1.2996316399949137e-05
diagnosis O 0 3.712776333486545e-06
of O 0 3.0195317357595286e-09
TSD B-Disease 0 3.41177437803708e-05
in O 0 1.3804515219817404e-07
fetuses O 0 8.476034736304427e-07
having O 0 6.1878115964475455e-09
the O 0 2.1188646393e-09
incomplete O 0 1.2557987361105916e-07
hex B-Disease 0 1.098243137676036e-05
A I-Disease 0 2.17289539250487e-06
deficiency I-Disease 0 1.0737400771176908e-05
of O 0 1.258079335153539e-10
the O 0 4.92179319522279e-09
type O 0 7.171446213760646e-06
described O 0 4.785961493780633e-08
in O 0 2.596032722124164e-09
the O 0 2.176335334169721e-09
four O 0 7.571911986303803e-09
healthy O 0 1.266087679141492e-07
individuals O 0 3.7159740173819955e-08

The O 0 5.9912090364377946e-06
tumor B-Disease 0 0.0004159925156272948
suppressor O 0 0.001260049524717033
gene O 0 0.00040188367711380124
Smad4 O 0 0.002120557241141796
/ O 0 0.0003085233038291335
Dpc4 O 0 5.764933575846953e-06
is O 0 3.3646141428533838e-09
required O 0 8.442419541232482e-10
for O 0 1.6813334058340956e-10
gastrulation O 0 9.732884365121208e-08
and O 0 2.905118368090598e-09
later O 0 1.4475945775416221e-08
for O 0 2.4378110641265494e-10
anterior O 0 2.6665286867455507e-08
development O 0 4.044865276053855e-10
of O 0 1.2149961592378133e-10
the O 0 6.855765732893815e-09
mouse O 0 1.0619515705911908e-05
embryo O 0 1.9221477032260736e-06
. O 0 1.6569875072036666e-07

Mutations O 0 0.000250967510510236
in O 0 4.818780894311203e-07
the O 0 2.542819004247576e-07
SMAD4 O 0 0.0037383970338851213
/ O 0 0.00022910727420821786
DPC4 O 0 0.000194068779819645
tumor B-Disease 0 4.580621680361219e-05
suppressor O 0 2.0235263946233317e-05
gene O 0 1.3880425058232504e-06
, O 0 1.9410224538773946e-09
a O 0 2.4733228798368145e-09
key O 0 3.056029740378108e-08
signal O 0 2.8802974156860728e-06
transducer O 0 1.7449724509788211e-06
in O 0 5.6376783241773865e-09
most O 0 3.748332755293404e-09
TGFbeta O 0 6.530701284646057e-06
- O 0 7.688976779718359e-07
related O 0 2.5640771283974573e-08
pathways O 0 3.0204084566776146e-08
, O 0 1.7306266142380622e-10
are O 0 1.640349661657936e-11
involved O 0 5.871338137897197e-11
in O 0 2.562519918480888e-10
50 O 0 1.4536976067347496e-09
% O 0 9.793285071779678e-10
of O 0 5.5340585447538615e-09
pancreatic B-Disease 0 0.015351496636867523
cancers I-Disease 0 0.0008118620608001947
. O 0 8.431177320744609e-07

Homozygous O 0 0.0009656353504396975
Smad4 O 0 0.0005424136761575937
mutant O 0 7.424016075674444e-05
mice O 0 0.0010226230369880795
die O 0 1.2012316801701672e-05
before O 0 8.451095823147625e-08
day O 0 1.1125251120347457e-07
7 O 0 2.122591808983998e-07
. O 0 8.546703611500561e-08

5 O 0 3.496350018394878e-06
of O 0 6.60905499216824e-08
embryogenesis O 0 2.4474109522998333e-05
. O 0 9.64705122896703e-07

Mutant O 0 8.04952833277639e-06
embryos O 0 6.962787324482633e-07
have O 0 1.0546138184963638e-08
reduced O 0 3.626267286449547e-08
size O 0 3.015872351852522e-08
, O 0 1.7414685249406148e-09
fail O 0 8.548008167963417e-08
to O 0 5.264012781225347e-09
gastrulate O 0 7.596429441036889e-06
or O 0 1.7267046459323865e-08
express O 0 1.2928918380339383e-08
a O 0 6.245032491136726e-09
mesodermal O 0 9.522137816020404e-07
marker O 0 2.0479335205436655e-07
, O 0 1.2555845252393283e-09
and O 0 2.6821564969026213e-09
show O 0 5.800342819384241e-07
abnormal O 0 4.883573183178669e-06
visceral O 0 1.8557568637334043e-06
endoderm O 0 2.1423851649160497e-05
development O 0 1.73205890519057e-07
. O 0 1.9610519075285993e-07

Growth B-Disease 1 0.9999998807907104
retardation I-Disease 1 0.9999997615814209
of O 0 1.1618711326377706e-08
the O 0 3.435036433074856e-08
Smad4 O 0 0.00011362897203071043
- O 0 1.1629058462858666e-05
deficient O 0 6.596614639420295e-06
embryos O 0 2.1960387286412697e-08
results O 0 1.916515302013977e-08
from O 0 1.125097237597572e-09
reduced O 0 2.4757220273841085e-08
cell O 0 9.610690909767072e-08
proliferation O 0 3.184187491456214e-08
rather O 0 1.1058135518382528e-09
than O 0 7.760835862846704e-10
increased O 0 1.2012133510097556e-08
apoptosis O 0 3.9569701471009466e-07
. O 0 4.394442498778517e-08

Aggregation O 0 5.312014036462642e-05
of O 0 6.730543589128501e-08
mutant O 0 3.2702344014978735e-06
Smad4 O 0 1.6709132978576235e-05
ES O 0 1.3307543440532754e-06
cells O 0 9.505881592986043e-08
with O 0 2.8030375798238083e-09
wild O 0 1.6164592864242877e-07
- O 0 2.5986655600718223e-05
type O 0 2.099142329825554e-05
tetraploid O 0 1.9790439182543196e-05
morulae O 0 4.221346171107143e-05
rescues O 0 5.483560471475357e-06
the O 0 1.9676085116770992e-07
gastrulation B-Disease 0 0.00013123937242198735
defect I-Disease 0 5.224957931204699e-05
. O 0 4.939353743793617e-07

These O 0 9.56608516844426e-08
results O 0 1.614565690033487e-07
indicate O 0 1.529974582581417e-07
that O 0 4.031634581735943e-09
Smad4 O 0 1.3598188388641574e-06
is O 0 4.5296016937257377e-10
initially O 0 1.237607127890783e-09
required O 0 8.775608711930616e-11
for O 0 1.3190664706341781e-11
the O 0 8.419002300863454e-11
differentiation O 0 7.56431639548083e-10
of O 0 4.970106617929737e-11
the O 0 1.4660467284599576e-09
visceral O 0 7.579718186434548e-08
endoderm O 0 4.489576213018154e-07
and O 0 9.149838109401287e-10
that O 0 1.0970693797851538e-10
the O 0 2.4321646918679107e-09
gastrulation B-Disease 0 1.1137623232571059e-06
defect I-Disease 0 2.723092222822743e-07
in O 0 2.007126465031206e-09
the O 0 8.000355933290848e-09
epiblast O 0 7.393701707769651e-06
is O 0 4.160120248286603e-09
secondary O 0 2.0853196502912397e-08
and O 0 1.7721952794147455e-09
non O 0 4.871221204183485e-09
- O 0 7.933844585750194e-07
cell O 0 1.4069956932871719e-06
autonomous O 0 7.34798618395871e-07
. O 0 1.251751342579155e-07

Rescued O 0 4.6341316192410886e-05
embryos O 0 7.951638508529868e-06
show O 0 2.9107108275638893e-05
severe O 0 0.0016061938367784023
anterior O 0 0.0023932389449328184
truncations O 0 0.00028417608700692654
, O 0 2.8222983061709783e-08
indicating O 0 2.2423270706894982e-07
a O 0 8.204337653694438e-09
second O 0 4.784580287520157e-09
important O 0 2.3121443648577156e-10
role O 0 1.125213144881343e-09
for O 0 4.62802351997027e-10
Smad4 O 0 5.65201105473534e-07
in O 0 1.7888504899588042e-08
anterior O 0 3.6464969070948428e-06
patterning O 0 2.5078863473027013e-05
during O 0 6.692868055324652e-07
embryogenesis O 0 1.538609285489656e-05
. O 0 4.031152798233961e-07

Prevalence O 0 0.00017777307948563248
of O 0 1.2985839248358388e-07
p16 O 0 1.964433613466099e-05
and O 0 1.0921853998979714e-07
CDK4 O 0 4.600328975357115e-05
germline O 0 5.8861922298092395e-05
mutations O 0 1.1781204193539452e-05
in O 0 1.8733163642536965e-07
48 O 0 2.0147592294961214e-05
melanoma B-Disease 1 0.9920641779899597
- O 1 0.7418174743652344
prone O 0 0.002052617957815528
families O 0 9.717767568417912e-08
in O 0 1.412583117144095e-07
France O 0 1.5122469449124765e-05
. O 0 2.2235089147670806e-07

The O 0 1.0367853064963128e-06
French O 0 2.496332672308199e-05
Familial B-Disease 0 0.004142307676374912
Melanoma I-Disease 0 0.004146512132138014
Study O 0 2.691944871457963e-07
Group O 0 1.909747027184494e-07
. O 0 1.8630363740612665e-07

Germline O 0 0.002612676238641143
mutations O 0 0.0003349586622789502
in O 0 1.2259738468856085e-07
the O 0 3.713891061352115e-08
p16 O 0 2.4068001494015334e-06
and O 0 1.2934147086696157e-08
CDK4 O 0 5.446956038213102e-06
genes O 0 9.986639071257741e-08
have O 0 2.032219503789179e-09
been O 0 1.3585352842682141e-09
reported O 0 9.99052218730867e-09
in O 0 5.869437713634795e-10
a O 0 2.273496058080582e-09
subset O 0 8.620915536994289e-09
of O 0 2.179762592646739e-09
melanoma B-Disease 0 7.716805157542694e-06
pedigrees O 0 1.7040530337908422e-06
, O 0 8.93164486814868e-10
but O 0 7.282375258377272e-10
their O 0 9.595539474105408e-09
prevalence O 0 3.4697458772825485e-07
is O 0 7.387045974915907e-10
not O 0 2.5892715749264994e-10
well O 0 5.432381766645733e-10
known O 0 1.365383628382233e-08
. O 0 1.960131434941559e-08

We O 0 1.072708428750957e-07
searched O 0 1.564874310133746e-07
for O 0 1.0509647596634863e-09
such O 0 1.677912697672923e-09
germline O 0 2.090472207783023e-06
mutations O 0 6.077611942600925e-07
in O 0 1.9736217993227e-08
48 O 0 3.3166693924613355e-07
French O 0 0.001400884473696351
melanoma B-Disease 1 0.9985352754592896
- O 1 0.8719937801361084
prone O 0 0.0006547237862832844
families O 0 5.308386175073565e-09
selected O 0 1.762870294186314e-09
according O 0 2.668734122579508e-10
to O 0 3.0951596841077844e-10
two O 0 2.987255998121441e-10
major O 0 7.26763871305991e-10
criteria O 0 3.711863927335912e-09
families O 0 1.1465129540200181e-10
with O 0 1.1810540045953388e-10
at O 0 3.7089780136057016e-08
least O 0 1.4395923342291894e-09
three O 0 6.802863827815031e-10
affected O 0 4.296517808199951e-09
members O 0 8.791529726437375e-10
( O 0 2.1599222410628727e-09
n O 0 1.6897072896426835e-07
= O 0 1.0324758648039278e-07
20 O 0 5.9983937816809885e-09
) O 0 3.521210822921006e-10
or O 0 1.7163900301042645e-09
families O 0 1.5880334547357933e-10
with O 0 8.908825066544779e-11
two O 0 4.5072465204576417e-10
affected O 0 1.4699358397152196e-09
members O 0 6.786674000558435e-11
, O 0 3.899564005038769e-11
one O 0 3.246514168608883e-11
of O 0 1.310517493136043e-11
them O 0 7.500080417832677e-11
affected O 0 4.909976314415587e-10
before O 0 6.019030829307326e-10
the O 0 5.879869369174173e-10
age O 0 4.918186968794203e-10
of O 0 3.344768906288209e-11
50 O 0 1.68267533240396e-09
( O 0 1.2808640814654382e-09
n O 0 1.380352898650017e-07
= O 0 1.6919068457355024e-07
28 O 0 3.472519338743041e-08
) O 0 4.5912021406913084e-10
, O 0 1.25110158344377e-10
and O 0 1.9532399309074577e-10
one O 0 3.178619867316712e-10
additional O 0 1.966083962301468e-09
minor O 0 1.3053758607384225e-07
criterion O 0 3.9315423805419414e-07
. O 0 1.1425948542864717e-07

Sixteen O 0 7.946240657474846e-06
different O 0 3.893951543432195e-07
p16 O 0 2.857270919776056e-05
germline O 0 6.416111864382401e-05
mutations O 0 2.80118256341666e-05
were O 0 1.290748219417992e-08
found O 0 4.033696043848067e-09
in O 0 2.520017972074129e-09
21 O 0 2.6027024091490603e-08
families O 0 2.3155470596503136e-10
, O 0 1.8332130258258417e-10
while O 0 4.692125576966077e-10
one O 0 1.6049248596772259e-09
germline O 0 1.031756823977048e-06
mutation O 0 1.4235696710329648e-07
, O 0 1.3242128504842299e-09
Arg24His O 0 5.506679485733912e-07
, O 0 8.694376885109989e-10
was O 0 1.0462970045921338e-08
detected O 0 4.7790198465236244e-08
in O 0 2.3125337200724516e-09
the O 0 9.810695367207245e-09
CDK4 O 0 1.0800848940561991e-05
gene O 0 1.9169960978615563e-06
. O 0 8.998409128935236e-08

The O 0 1.8459661532688187e-07
frequency O 0 9.149564448307501e-07
of O 0 4.475842363405036e-09
p16 O 0 2.9829773211531574e-06
gene O 0 9.528860687169072e-07
mutation O 0 2.0829192237670213e-07
in O 0 2.521883590844709e-09
our O 0 2.004280297285277e-09
sample O 0 1.331997889764125e-08
( O 0 2.3688599970483892e-09
44 O 0 2.8859707956740976e-09
% O 0 2.355814432419834e-10
) O 0 1.5555456922555777e-10
is O 0 8.313937732706833e-11
among O 0 4.639440220888247e-11
the O 0 4.821865129400749e-10
highest O 0 2.3421698358561116e-08
rates O 0 5.924595370743191e-06
yet O 0 1.5740937442387803e-08
reported O 0 2.9024346304140636e-07
and O 0 8.013608665535799e-10
the O 0 2.834510848259697e-09
CDK4 O 0 5.597966719506076e-06
mutation O 0 6.774255467689727e-08
is O 0 2.882014349392392e-10
the O 0 5.933597502227883e-10
second O 0 8.729508671478925e-09
mutation O 0 1.2313449815337663e-07
detected O 0 7.472247176565361e-08
in O 0 1.3087053662985682e-09
this O 0 1.9788148897248448e-09
gene O 0 2.0745891049500642e-07
worldwide O 0 8.72829701847877e-08
. O 0 8.835193909817463e-08

In O 0 7.389433562821068e-07
summary O 0 1.0280931519446312e-06
, O 0 2.1009884942913004e-09
our O 0 2.007873201037569e-09
results O 0 1.36933744343537e-08
show O 0 3.199529174935378e-08
frequent O 0 8.439364762580226e-09
involvement O 0 1.7974409738386044e-09
of O 0 1.0604481875953198e-10
the O 0 1.4929502079041868e-09
p16 O 0 3.0627700198238017e-07
gene O 0 1.5310489231978863e-07
in O 0 3.1800603039755515e-08
familial B-Disease 0 9.685958502814174e-05
melanoma I-Disease 0 0.0027039225678890944
and O 0 1.5348698312322995e-08
confirm O 0 2.2362726781466336e-07
the O 0 2.2521062792435487e-09
role O 0 7.009672842173131e-10
of O 0 6.098266336351799e-11
the O 0 1.040415864572708e-09
CDK4 O 0 5.48252842236252e-07
gene O 0 4.941747278053299e-08
as O 0 1.2900140955451889e-09
a O 0 3.25826228220194e-08
melanoma B-Disease 0 0.0001957220956683159
- O 0 4.8728961701272056e-06
predisposing O 0 1.529789415144478e-06
gene O 0 1.456973336644296e-06
. O 0 1.2416934147552183e-08
. O 0 7.917414990288307e-08

Progression O 0 0.00016290142957586795
of O 0 2.3643748647828033e-07
somatic O 0 4.27290506195277e-05
CTG O 0 0.0001981230016099289
repeat O 0 6.66745063426788e-06
length O 0 2.163849330827361e-07
heterogeneity O 0 2.5634372491367685e-07
in O 0 2.4768163076061e-09
the O 0 3.3072233840414356e-09
blood O 0 2.1667898408850306e-07
cells O 0 5.37964524482959e-07
of O 0 3.494855889130122e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0005410544108599424
. O 0 1.5345352721851668e-06

The O 0 1.4303263640158548e-07
genetic O 0 1.0123831089003943e-06
basis O 0 2.669933962806681e-07
of O 0 6.195071478032332e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9148245453834534
DM B-Disease 1 1.0
) O 0 4.105026008005552e-08
is O 0 6.519865758392029e-10
the O 0 2.896308748390197e-10
expansion O 0 3.1108333686802325e-09
of O 0 2.365621309952104e-10
an O 0 3.613478849473495e-09
unstable O 0 6.781162664992735e-05
CTG O 0 1.1737783097487409e-05
repeat O 0 7.376027610916935e-07
in O 0 9.374188536526162e-09
the O 0 6.956055731421884e-09
34 O 0 2.0020193503000883e-08
UTR O 0 1.1335895777619953e-07
of O 0 8.346864310837532e-10
the O 0 6.345134551111187e-08
DM B-Disease 1 0.9999998807907104
protein O 0 1.3822144637742895e-06
kinase O 0 4.902588443655986e-06
gene O 0 6.967250669731584e-07
on O 0 1.923683043969504e-07
chromosome O 0 1.8681706933421083e-05
19 O 0 7.972001867528888e-07
. O 0 9.919549626147273e-08

One O 0 8.279214824824521e-08
of O 0 8.810934759573286e-10
the O 0 8.909254445299553e-10
principal O 0 2.0549044688067397e-09
features O 0 1.3020724498602476e-09
of O 0 1.7825545206573423e-10
the O 0 5.795864126412198e-07
DM B-Disease 1 1.0
mutation O 0 2.6268417059327476e-06
is O 0 1.1170658842374337e-09
an O 0 4.878089598925328e-10
extraordinarily O 0 2.1737855604442302e-07
high O 0 1.0448914622429584e-07
level O 0 2.509103147474434e-08
of O 0 8.998949918570531e-10
somatic O 0 5.19498314588418e-07
mosaicism O 0 2.146460474250489e-06
, O 0 1.0893341784168342e-09
due O 0 7.087030517993753e-09
to O 0 1.2750627220725619e-09
an O 0 4.692054522692501e-10
extremely O 0 6.99662834335868e-08
high O 0 3.881078924905523e-08
degree O 0 3.3281184474986958e-09
of O 0 1.1932114185597698e-09
somatic O 0 1.0217047474725405e-06
instability O 0 3.559672450137441e-07
both O 0 1.9677421914110482e-09
within O 0 4.6457580005210275e-09
and O 0 8.768770709544071e-10
between O 0 1.3195785575348395e-09
different O 0 9.667828315684801e-09
tissues O 0 4.059894763486227e-06
. O 0 1.2625113754438644e-07

This O 0 3.5246318930148846e-07
instability O 0 1.8247121715830872e-06
appears O 0 1.5205604597667843e-07
to O 0 3.306617868403805e-09
be O 0 7.085837472331491e-10
biased O 0 1.2915855052142433e-08
towards O 0 9.529509403805037e-10
further O 0 6.51017295627554e-10
expansion O 0 1.9949968343979663e-09
and O 0 1.2690813677718182e-10
continuous O 0 2.200326587598056e-09
throughout O 0 3.2107088099309067e-09
the O 0 2.6294759702949477e-09
life O 0 1.7881221503479594e-10
of O 0 9.171057142876027e-12
an O 0 3.5257050751136276e-11
individual O 0 9.213579899025603e-11
, O 0 7.069499152745351e-11
features O 0 6.322987022855386e-09
that O 0 2.8875826729723997e-10
could O 0 8.172632348646403e-09
be O 0 4.560776478701456e-10
associated O 0 1.0647108750205803e-09
with O 0 1.5072525172410423e-10
the O 0 4.803572650757815e-09
progressive O 0 8.721175248638247e-08
nature O 0 9.294139902138454e-10
of O 0 3.0236566028740697e-10
the O 0 5.607075337366041e-08
disease O 0 1.2022527698718477e-05
. O 0 1.2585516628860205e-07

Although O 0 5.24301299265062e-07
increasing O 0 9.904349695943893e-08
measured O 0 3.208770351648127e-07
allele O 0 1.5425789570144843e-06
size O 0 1.3634272022500227e-07
between O 0 2.8535630747228424e-08
patients O 0 6.45023305878567e-08
clearly O 0 1.1714886838376515e-08
correlates O 0 1.6640495204001127e-08
with O 0 4.689638122279405e-10
an O 0 4.350828031185472e-10
increased O 0 3.9240422466946256e-08
severity O 0 3.462966560618952e-06
of O 0 3.135100623552489e-09
symptoms O 0 0.0007667369209229946
and O 0 7.197436535655299e-10
an O 0 2.217172695440084e-10
earlier O 0 2.0985230264614074e-07
age O 0 4.866429481609202e-09
of O 0 1.0760759644456996e-10
onset O 0 5.095095616525214e-07
, O 0 3.922055458183138e-10
this O 0 2.183664915555994e-10
correlation O 0 6.159198484567696e-09
is O 0 4.018197996558115e-10
not O 0 3.753310440224311e-10
precise O 0 1.3474753757236613e-08
and O 0 2.2561177370761243e-09
measured O 0 7.209795427343124e-08
allele O 0 1.7173151434235479e-07
length O 0 1.174851860241688e-08
cannot O 0 4.0791894306835275e-09
be O 0 2.2696215740136694e-10
used O 0 6.945869990282461e-10
as O 0 1.612672079209787e-10
an O 0 1.504902730209423e-10
accurate O 0 6.91826897991632e-08
predictor O 0 3.5771537909567996e-07
of O 0 5.467860608732167e-10
age O 0 9.908937670388696e-09
of O 0 2.061727677471481e-09
onset O 0 5.424160190159455e-05
. O 0 5.715015163332282e-07

In O 0 4.019034065549931e-07
order O 0 2.4737724757528667e-08
to O 0 2.0944188605653835e-09
further O 0 2.455592396088946e-09
characterize O 0 6.53635652270168e-08
the O 0 1.1178230785446885e-08
dynamics O 0 8.910790256777545e-07
of O 0 6.556371801025307e-08
DM B-Disease 1 1.0
CTG O 0 0.000212333703530021
repeat O 0 1.672925463935826e-05
somatic O 0 6.623038188990904e-06
instability O 0 4.359672857390251e-06
, O 0 7.206617080868227e-09
we O 0 1.1725656001715379e-09
have O 0 3.4357014455643764e-10
studied O 0 6.435312727148812e-09
repeat O 0 1.211699895975471e-07
length O 0 1.5402569886191486e-08
changes O 0 1.073518607341839e-08
over O 0 1.477088673595972e-09
time O 0 4.438148959451382e-09
in O 0 2.1216965961912138e-08
111 O 0 0.012834160588681698
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 6.311265678959899e-07
with O 0 4.682668919286925e-09
varying O 0 1.7431050025606964e-07
clinical O 0 9.627070767237456e-07
severity O 0 2.898276761698071e-05
and O 0 1.3483345639997424e-07
CTG O 0 1.4560659110429697e-05
repeat O 0 1.0569698360995972e-06
size O 0 1.0525143068207399e-07
over O 0 5.957085935648365e-09
time O 0 5.008558012775666e-09
intervals O 0 3.6038922957004615e-08
of O 0 3.255153091519247e-10
1 O 0 2.1856379817108973e-08
- O 0 1.1008182809746359e-06
7 O 0 1.2089239476154034e-07
years O 0 1.0246946402503454e-08
. O 0 2.748582161871127e-08

We O 0 1.598574925765206e-07
have O 0 1.8482193553381876e-09
found O 0 7.44134864838486e-10
a O 0 6.656071249722117e-10
direct O 0 5.1652011556768684e-09
progression O 0 4.0397495126853755e-08
of O 0 6.563082022292832e-11
the O 0 8.943817353390671e-10
size O 0 2.032577128829871e-08
heterogeneity O 0 2.9049534333580596e-08
over O 0 1.4124591496411654e-09
time O 0 1.8097391363269821e-09
related O 0 1.1496931184851178e-09
to O 0 7.132999191306055e-10
initial O 0 2.0454928417734664e-08
CTG O 0 1.0627270512486575e-06
repeat O 0 1.016395074771026e-07
size O 0 1.0294274765954015e-08
and O 0 8.518913352517643e-10
the O 0 1.813495242863894e-09
time O 0 6.067758295813519e-09
interval O 0 3.036744544715475e-08
and O 0 1.3465498716058732e-09
always O 0 2.9241085108822062e-09
biased O 0 1.614773026403782e-08
towards O 0 1.6433324701026208e-09
further O 0 7.369935772771896e-09
expansion O 0 1.2480883526677644e-07
. O 0 8.460982314772991e-08

Attempts O 0 2.738796865742188e-06
to O 0 5.347003551037233e-08
mathematically O 0 1.0775151082498269e-07
model O 0 2.6042419776217685e-08
the O 0 2.2515824760205305e-09
dynamics O 0 1.6020453585952055e-07
have O 0 1.8705337279101286e-09
proved O 0 1.2268481341948245e-08
only O 0 4.4527986853282187e-10
partially O 0 4.888843463390913e-08
successful O 0 2.2816630806943294e-09
suggesting O 0 3.374923451815448e-09
that O 0 8.430684622640072e-11
individual O 0 3.899803813212088e-10
specific O 0 2.802807763657711e-09
genetic O 0 8.724818911787224e-08
and O 0 4.543849385640897e-08
/ O 0 5.417057400336489e-05
or O 0 6.473799629702626e-08
environmental O 0 7.81070585986754e-09
factors O 0 1.6493458820932005e-09
also O 0 1.2527354709135352e-09
play O 0 3.2941789296359048e-09
a O 0 5.943273428954399e-09
role O 0 1.1173925784646599e-08
in O 0 9.681834001185052e-09
somatic O 0 1.0752962680271594e-06
mosaicism O 0 7.428729531966383e-06
. O 0 1.8579294547294012e-08
. O 0 1.110007090687759e-07

Aspartylglucosaminuria B-Disease 1 0.9999785423278809
among O 0 2.925790170138498e-07
Palestinian O 0 5.506059892468329e-07
Arabs O 0 4.838166773879493e-07
. O 0 1.916400833579246e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.10455160588026047
AGU B-Disease 1 1.0
) O 0 2.8663859552580107e-07
is O 0 3.2049878306850133e-09
a O 0 1.0988820520196896e-08
rare O 0 4.644919044949347e-07
disorder B-Disease 0 0.00038804803625680506
of I-Disease 0 1.2522392012215278e-08
glycoprotein I-Disease 0 2.1254296370898373e-05
metabolism I-Disease 0 0.0026456129271537066
caused O 0 3.8744337871321477e-07
by O 0 1.037165109352145e-08
the O 0 4.1753534674171533e-07
deficiency B-Disease 0 4.870659176958725e-05
of I-Disease 0 8.311944466043997e-10
the I-Disease 0 3.050398689197209e-08
lysosomal I-Disease 0 7.216510857688263e-05
enzyme I-Disease 0 2.201983534177998e-06
aspartylglucosaminidase I-Disease 0 2.7736778065445833e-05
( O 0 9.761329522461892e-08
AGA O 0 2.1795970042148838e-06
) O 0 6.952675590810031e-08
. O 0 1.374909714968453e-07

AGU B-Disease 1 1.0
is O 0 5.696476819139207e-06
inherited O 0 1.4880071830702946e-05
as O 0 1.25273613704735e-08
an O 0 1.0301778985422061e-08
autosomal O 1 0.9990177154541016
recessive O 1 0.9999994039535522
trait O 0 0.0013329902430996299
and O 0 3.6334540709503926e-08
occurs O 0 1.093235368898604e-08
with O 0 6.767456040002173e-10
a O 0 1.4454839103450468e-08
high O 0 3.494922680147283e-07
frequency O 0 0.00010844488861039281
in O 0 8.483961977390209e-08
Finland O 0 1.8059870399156353e-06
because O 0 4.296433486761231e-10
of O 0 5.041696574115129e-11
a O 0 2.610098359667745e-09
founder O 0 6.089720017143918e-08
effect O 0 8.882793167686032e-08
. O 0 5.2988294640954337e-08

While O 0 1.9288120256533148e-07
very O 0 4.2095457786217594e-08
few O 0 4.379297635637158e-08
patients O 0 6.121593543184645e-08
with O 0 9.208145712591431e-08
AGU B-Disease 1 1.0
have O 0 1.1272544675478002e-08
been O 0 1.1382207398824562e-09
reported O 0 1.4753801735878369e-08
from O 0 1.1022632806501065e-09
non O 0 3.303478601779375e-09
- O 0 7.422884351626635e-08
Finnish O 0 1.5805115083367127e-07
origin O 0 1.6064592989195603e-09
, O 0 9.676328627250541e-10
we O 0 3.1428719626802604e-09
diagnosed O 0 5.881400397811376e-07
the O 0 3.008151239214385e-08
disorder O 0 8.328936019097455e-06
in O 0 1.1856234216622852e-08
8 O 0 7.170491045371818e-08
patients O 0 4.472070713745779e-09
originating O 0 1.8737768670007426e-08
from O 0 3.4530074355387796e-09
3 O 0 7.542708679864063e-09
unrelated O 0 7.257295209228687e-09
families O 0 8.020550334997267e-10
, O 0 7.941329538407871e-11
all O 0 4.918409429732762e-11
Palestinian O 0 1.7573009714055843e-09
Arabs O 0 1.2388587933287454e-09
from O 0 5.062281149825765e-10
the O 0 4.5463763309605554e-10
region O 0 2.0425836577686596e-09
of O 0 4.238092932151716e-10
Jerusalem O 0 3.5504098150340724e-07
. O 0 5.6701839667994136e-08

The O 0 1.4348884178616572e-06
clinical O 0 4.2213221604470164e-05
diagnosis O 0 0.022789159789681435
of O 0 3.5739182635552424e-07
AGU B-Disease 1 1.0
is O 0 1.292806075525732e-07
often O 0 6.0135834090147e-09
difficult O 0 4.5626755706962285e-09
, O 0 1.4208212384403396e-10
in O 0 1.8925529199353974e-10
particular O 0 2.218094735662035e-10
early O 0 1.7333503521399507e-08
in O 0 9.939711276274465e-10
the O 0 7.942469459898405e-10
course O 0 1.3151763011975959e-09
of O 0 3.542543342005544e-11
the O 0 1.896244050669793e-08
disease O 0 8.504325137437263e-07
, O 0 1.7063844781617377e-10
and O 0 9.87948819974882e-11
most O 0 6.44931399951254e-11
of O 0 6.372802979770498e-11
the O 0 9.648946530660396e-09
patients O 0 1.889503487007005e-08
are O 0 1.3468528514692935e-09
diagnosed O 0 2.743837512753089e-07
after O 0 3.6114531365427638e-09
the O 0 6.354603065972242e-09
age O 0 2.522576370012075e-09
of O 0 1.1188480003587742e-10
5 O 0 1.4931702096987465e-08
years O 0 6.047123246588626e-09
. O 0 2.088810724387713e-08

However O 0 3.8950881275923166e-07
, O 0 5.2327098210014356e-09
since O 0 6.656671214244625e-09
these O 0 7.544878055654181e-10
patients O 0 9.258634747766337e-09
excrete O 0 1.0278348128167636e-07
early O 0 1.1349953865646967e-08
large O 0 7.170594118477425e-10
amounts O 0 1.3593335346229196e-09
of O 0 3.4009503546705844e-10
aspartylglucosamine O 0 3.561020491815725e-07
in O 0 2.7760462817383313e-09
urine O 0 6.958340037499511e-08
, O 0 2.5525440094931184e-10
biochemical O 0 2.0413889245674e-08
screening O 0 3.1115114040858316e-08
is O 0 1.0607804634688023e-09
easy O 0 1.5662264374327606e-08
by O 0 9.358146257909539e-09
urine O 0 1.8483209487385466e-06
chromatography O 0 8.483587521368463e-07
. O 0 7.243700750336757e-09
. O 0 5.198214481083596e-08

Detection O 0 5.711022367904661e-06
of O 0 3.9466204526661386e-08
heterozygous O 0 1.5726405990790226e-06
carriers O 0 1.0259975624649087e-07
of O 0 3.644071044917041e-09
the O 0 1.821789555833675e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 1.4988305565566407e-06
ATM O 0 5.410887752077542e-05
) O 0 1.8186746331139148e-08
gene O 0 1.6603155472694198e-07
by O 0 7.319308714670569e-09
G2 O 0 5.6845701692509465e-06
phase O 0 3.558036496542627e-07
chromosomal O 0 2.6364705263404176e-05
radiosensitivity O 0 2.948663222923642e-06
of O 0 7.962799308813828e-09
peripheral O 0 0.00013803633919451386
blood O 0 6.783672142773867e-05
lymphocytes O 0 7.561441452708095e-05
. O 0 9.009483505906246e-07

In O 0 0.0008264504722319543
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.019660497084259987
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.595108624831482e-08
patients O 0 4.5259017866783324e-08
, O 0 6.253265683042741e-10
mutations O 0 6.862715196120917e-08
in O 0 6.76634637208906e-10
a O 0 1.3629319894903347e-09
single O 0 7.492995557356608e-09
gene O 0 5.097652433505573e-08
, O 0 2.062245790801498e-10
ATM O 0 1.3468951465256396e-07
, O 0 1.0618730894584871e-10
result O 0 6.282088182985035e-10
in O 0 6.521759576827435e-09
an O 0 1.1707576049957424e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.3023021949720714e-07
embraces O 0 1.0526809290922756e-07
a O 0 4.180052304292303e-09
variety O 0 1.9324448707891406e-09
of O 0 2.4029753187271297e-10
clinical O 0 2.3478412103372648e-08
features O 0 6.38764049654128e-07
and O 0 3.345660815057272e-08
manifests O 0 7.45871886920213e-07
extreme O 0 8.338627139892196e-07
radiosensitivity O 0 3.322112434034352e-06
and O 0 1.1475635997015843e-09
a O 0 3.1755671425770515e-09
strong O 0 6.331775637136161e-08
pre O 0 6.015511098667048e-05
- O 0 2.5740944693097845e-05
disposition O 0 2.2457006707554683e-06
to O 0 1.126483368807385e-07
malignancy B-Disease 0 3.232091694371775e-05
. O 0 3.246073845275532e-07

Heterozygotes O 0 4.126403291593306e-05
for O 0 2.1275969430689656e-08
the O 0 7.684964664633753e-09
ATM O 0 7.931704203656409e-06
gene O 0 7.665511247978429e-07
have O 0 2.7047295514393e-09
no O 0 6.584312539636983e-10
clinical O 0 7.272023871962574e-09
expression O 0 5.6392805980465255e-09
of O 0 1.467627464002419e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 3.6005994843435474e-06
may O 0 4.406446169014089e-05
be O 0 5.012928383507642e-08
cancer B-Disease 0 6.843538926659676e-07
prone O 0 7.245223798690859e-08
with O 0 3.8586950301677803e-10
a O 0 3.317736751995426e-09
moderate O 0 1.901249504498992e-07
increase O 0 9.249509602682338e-09
in O 0 4.167807876598317e-09
in O 0 1.1714217151848061e-08
vitro O 0 4.367771452962188e-06
radiosensitivity O 0 1.6780801161075942e-05
. O 0 3.065663349843817e-07

We O 0 3.087775155563577e-07
performed O 0 2.4145421662069566e-07
a O 0 4.9582315142515654e-08
blind O 0 5.53560198568448e-07
chromosomal O 0 1.3608044355351012e-05
analysis O 0 1.9482567381601257e-07
on O 0 2.983045988003141e-07
G2 O 0 6.15830285823904e-05
- O 0 2.644938149387599e-06
phase O 0 1.9051920219226304e-07
lymphocytes O 0 6.426863592423615e-07
from O 0 1.0622063228993284e-08
7 O 0 5.4239492897067976e-08
unrelated O 0 4.6575166834372794e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.3825787138775922e-06
, O 0 1.3434456880290213e-09
13 O 0 4.473998949094948e-09
obligate O 0 8.34001312455257e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 7.956277841003612e-05
( O 0 1.630227508542248e-08
parents O 0 2.5767883382599166e-09
of O 0 5.0345089208647664e-11
the O 0 3.037843976372301e-09
patients O 0 7.844283445024303e-09
) O 0 3.941125481521368e-10
, O 0 2.2353892348281335e-10
and O 0 9.59319290672056e-10
14 O 0 6.119174944529959e-09
normal O 0 8.024460385058774e-08
controls O 0 2.0843408492510207e-05
following O 0 7.320931416643361e-08
X O 0 1.2175247320556082e-05
- O 0 3.206708356628951e-07
irradiation O 0 3.1762658636580454e-07
with O 0 7.898436571451839e-09
1 O 0 1.9721955624163456e-08
Gy O 0 8.955788644016138e-07
in O 0 8.140394469613454e-10
order O 0 2.775732699245026e-10
to O 0 3.0661218008987134e-10
evaluate O 0 4.0421217484265526e-09
this O 0 3.1863531257947386e-10
cytogenetic O 0 2.1861137611267623e-07
method O 0 3.517266033981059e-09
as O 0 5.450710993670782e-10
a O 0 1.2055116904718943e-09
tool O 0 1.5191451652185606e-08
for O 0 1.4076013965524936e-10
detection O 0 1.0147404694293982e-08
of O 0 1.593562615198607e-09
ATM O 0 1.0618077794788405e-05
carriers O 0 4.4770871454602457e-07
. O 0 1.0943499262339174e-07

Both O 0 2.460498762957286e-06
A B-Disease 1 0.9999842643737793
- I-Disease 1 0.9999796152114868
T I-Disease 1 1.0
homozygotes O 0 9.572486305842176e-05
and O 0 1.9369551296222198e-08
heterozygotes O 0 8.487674563184555e-07
showed O 0 1.3441568569305673e-07
significantly O 0 6.691273313208512e-08
increased O 0 1.5916860718334647e-08
levels O 0 1.222083856333711e-08
of O 0 1.50141143961946e-09
radiation O 0 0.0008349581621587276
- O 0 0.0035711706150323153
induced O 0 7.62556737754494e-05
chromatid O 0 2.2051141058909707e-05
damage O 0 1.890946350613376e-07
relative O 0 2.24065477283375e-08
to O 0 1.1958292134295334e-09
that O 0 2.4311339053006975e-10
of O 0 5.064870189919191e-10
normal O 0 2.6255239049532975e-07
controls O 0 0.0006298411171883345
. O 0 1.5880675618973328e-07

These O 0 5.420619331175658e-08
results O 0 6.60726513501686e-08
show O 0 4.524563834706896e-08
that O 0 4.576356793517533e-10
the O 0 2.538707466470669e-09
G2 O 0 3.7102809073985554e-06
- O 0 9.150803634838667e-07
phase O 0 2.424979754778178e-07
chromosomal O 0 2.1879144696868025e-05
radiosensitivity O 0 1.0134300282516051e-05
assay O 0 5.154563950782176e-06
can O 0 6.4258927068294724e-09
be O 0 2.1672499905811549e-10
used O 0 7.673433555233089e-10
for O 0 2.2399890969859726e-11
the O 0 9.042027543371134e-11
detection O 0 5.389338753047923e-09
of O 0 6.46838693718621e-10
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
heterozygotes O 0 0.0001387706579407677
. O 0 4.340066084296268e-07

In O 0 3.4966328144037107e-07
combination O 0 2.312888369715438e-07
with O 0 6.874607993978543e-09
molecular O 0 1.2821460870782175e-07
genetic O 0 1.5532918951066677e-07
analyses O 0 9.969263459197464e-08
, O 0 1.591727749605809e-09
this O 0 1.9435340004037016e-09
test O 0 1.1623230875557056e-06
may O 0 2.2963737933423545e-07
be O 0 7.72898273160294e-11
of O 0 1.0909341138787276e-11
value O 0 9.568389136571653e-11
in O 0 8.513646732044577e-11
studies O 0 1.621771605897493e-10
of O 0 5.5609072902029766e-11
familial B-Disease 0 1.2485109834869945e-07
and I-Disease 0 1.0466682631715685e-08
sporadic I-Disease 0 7.627953891642392e-05
cancers I-Disease 0 0.0014815219910815358
aimed O 0 3.2455167797706963e-07
at O 0 3.7858919199607044e-07
determination O 0 1.1392876864135815e-08
of O 0 1.0854035031870879e-10
the O 0 3.865501529976001e-10
potential O 0 3.688993832628995e-10
involvement O 0 2.0562060942808102e-09
of O 0 6.569685351287546e-10
ATM O 0 2.4936367481132038e-05
mutations O 0 2.168403625546489e-06
in O 0 5.5286172084834106e-08
tumor B-Disease 0 2.471922925906256e-05
risk O 0 1.3128516229699017e-07
or O 0 1.1160612878313714e-08
development O 0 4.7016417425993495e-09
. O 0 5.269909397753736e-09
. O 0 7.06609881717668e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 6.751178602826258e-07
identification O 0 1.10081657567207e-07
and O 0 2.3160915407771654e-09
detection O 0 5.8301910854652306e-08
of O 0 1.3000572840482505e-09
founder O 0 3.778631025852519e-07
- O 0 3.6509365486381284e-07
effect O 0 8.741975676684888e-08
mutations O 0 1.7357001524942461e-07
in O 0 2.3424098216651146e-09
the O 0 3.568112472152052e-09
ATM O 0 1.5012853964435635e-06
gene O 0 1.2298757212647615e-07
in O 0 2.182150238283498e-09
ethnic O 0 3.97836119603312e-09
populations O 0 4.566717848319968e-08
. O 0 4.977590251087349e-08

To O 0 1.7363325355290726e-07
facilitate O 0 7.250020672699975e-08
the O 0 1.1009232636638444e-08
evaluation O 0 2.0853114790497784e-08
of O 0 4.880332249435071e-10
ATM O 0 2.593965973574086e-06
heterozygotes O 0 8.103746722554206e-07
for O 0 1.5810196485332995e-09
susceptibility O 0 1.1174995506735286e-07
to O 0 3.193893816089144e-09
other O 0 2.290689193884532e-09
diseases O 0 2.3314687780384702e-07
, O 0 1.4242426682464782e-10
such O 0 3.916957036498303e-10
as O 0 5.992460046400083e-06
breast B-Disease 1 0.999515175819397
cancer I-Disease 0 1.8895174434874207e-05
, O 0 1.4490967314984005e-09
we O 0 2.693012202126255e-10
have O 0 1.7094400894812622e-10
attempted O 0 4.451170543262606e-09
to O 0 5.206265973889401e-10
define O 0 2.15878959153315e-09
the O 0 3.5390063102269664e-10
most O 0 3.7785005679857875e-10
common O 0 3.78921960475509e-09
mutations O 0 4.9584301109462103e-08
and O 0 5.713582384991867e-10
their O 0 2.120546627182307e-09
frequencies O 0 3.9184200431918725e-05
in O 0 0.000139284209581092
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 4.391207039589062e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 3.0262558681215523e-08
homozygotes O 0 7.798814181114722e-07
from O 0 5.219492393848668e-09
10 O 0 3.1627283014756813e-09
ethnic O 0 2.2047081937870416e-09
populations O 0 3.664187531171592e-08
. O 0 8.678927088112687e-08

Both O 0 3.492760356493818e-07
genomic O 0 1.0464772458362859e-05
mutations O 0 1.5003670341684483e-05
and O 0 1.2893752732168196e-08
their O 0 1.0273385697701087e-08
effects O 0 2.3436786023012246e-07
on O 0 3.801528336566662e-08
cDNA O 0 3.6368138012221607e-07
were O 0 1.2168736240880662e-08
characterized O 0 3.0219246127671795e-07
. O 0 1.4824892957676639e-07

Protein O 0 0.00011191604426130652
- O 0 3.4468092053430155e-05
truncation O 0 1.0550650586083066e-05
testing O 0 2.127589340261693e-07
of O 0 5.684710480124977e-10
the O 0 2.1027444230270476e-09
entire O 0 2.8623068359934223e-08
ATM O 0 2.1353309875848936e-06
cDNA O 0 1.107919956666592e-06
detected O 0 1.1323616035952e-06
92 O 0 6.620775820920244e-07
( O 0 1.3449590774428088e-08
66 O 0 5.5439393520373415e-08
% O 0 1.6481351838848468e-09
) O 0 2.6436171030042033e-09
truncating O 0 7.809128987901204e-07
mutations O 0 6.033473596289696e-07
in O 0 9.874712603163971e-09
140 O 0 1.4634470346663875e-07
mutant O 0 2.5892502435453935e-06
alleles O 0 3.8121986563055543e-06
screened O 0 4.465664915187517e-06
. O 0 2.5496666467006435e-07

The O 0 2.208493725674998e-07
haplotyping O 0 5.473064447869547e-06
of O 0 2.2882440386950975e-09
patients O 0 1.2579318919847537e-08
with O 0 2.846766378183929e-09
identical O 0 2.009384479606524e-05
mutations O 0 6.985440450080205e-06
indicates O 0 1.4617698163021942e-08
that O 0 2.9422445035898193e-10
almost O 0 5.371192934866542e-10
all O 0 1.904799755425568e-11
of O 0 5.260943590490452e-12
these O 0 2.6592564955629783e-11
represent O 0 1.3911440055469626e-10
common O 0 1.1250457232492295e-09
ancestry O 0 5.242800416027649e-09
and O 0 2.2162764679034552e-10
that O 0 8.284779806633225e-11
very O 0 1.825680384648365e-09
few O 0 1.4095372868894174e-08
spontaneously O 0 2.1117290316396975e-07
recurring O 0 1.3254195891931886e-06
ATM O 0 3.487423964543268e-05
mutations O 0 1.1151792023156304e-05
exist O 0 1.8502596788039227e-07
. O 0 2.6078114956362697e-07

Assays O 0 0.00011181375884916633
requiring O 0 1.2247553513589082e-06
minimal O 0 2.409334740605118e-07
amounts O 0 9.938162293110508e-09
of O 0 8.110792593107874e-10
genomic O 0 9.259026967356476e-08
DNA O 0 1.151972668367307e-07
were O 0 1.1447442105350092e-08
designed O 0 4.343792525673962e-08
to O 0 1.0111386172795278e-09
allow O 0 2.0888175633615447e-09
rapid O 0 4.103460327087305e-08
screening O 0 5.766753474745201e-08
for O 0 7.355257514163327e-10
common O 0 1.2165649820872204e-08
ethnic O 0 1.5126742525239933e-08
mutations O 0 3.952341558033368e-06
. O 0 1.5863993496623152e-07

These O 0 2.410373269867705e-07
rapid O 0 1.6044475614762632e-06
assays O 0 1.4404892681341153e-05
detected O 0 1.4214172551874071e-05
mutations O 0 1.855700247688219e-06
in O 0 9.021398739150754e-09
76 O 0 7.924243305978962e-08
% O 0 5.902623945175378e-10
of O 0 1.6960433057988666e-10
Costa O 0 3.166822537536973e-08
Rican O 0 1.2632678192403546e-07
patients O 0 3.5572284673435206e-08
( O 0 1.7976330424218645e-09
3 O 0 4.700834832505052e-09
) O 0 2.383075126122236e-10
, O 0 7.790404432661546e-11
50 O 0 3.1522959242913373e-10
% O 0 5.759467902599624e-11
of O 0 4.8453904083478605e-11
Norwegian O 0 6.4868913796090055e-06
patients O 0 9.972058734319944e-08
( O 0 3.516534841097041e-09
1 O 0 4.061349034856221e-09
) O 0 3.6602371134009104e-10
, O 0 8.776513543695685e-11
25 O 0 8.723212707728578e-10
% O 0 7.188940415181477e-11
of O 0 1.299441942936852e-10
Polish O 0 5.318122202879749e-05
patients O 0 7.75449535694861e-08
( O 0 6.710761724093572e-09
4 O 0 2.0619488338979863e-08
) O 0 6.793048901165832e-10
, O 0 1.500139734655903e-10
and O 0 3.30765054235016e-10
14 O 0 1.9039372300966306e-09
% O 0 8.27232171651815e-11
of O 0 7.700201587468314e-11
Italian O 0 2.9412990443233866e-06
patients O 0 1.247659895398101e-07
( O 0 4.2750110118561224e-09
1 O 0 5.730960594974022e-09
) O 0 4.45111753011318e-10
, O 0 7.224763148849789e-11
as O 0 3.142906490616326e-10
well O 0 2.4752475069611535e-10
as O 0 2.995357850643643e-10
in O 0 1.3806347176625877e-09
patients O 0 1.7251697848053027e-09
of O 0 6.922130091346901e-10
Amish O 0 0.0002691120025701821
/ O 0 1.843065365392249e-05
Mennonite O 0 6.861635483801365e-06
and O 0 1.1353808559988465e-08
Irish O 0 2.845362701009435e-07
English O 0 3.878655832068034e-07
backgrounds O 0 2.953082685053232e-07
. O 0 1.1846451286601223e-07

Additional O 0 8.863108291734534e-07
mutations O 0 1.1957557035202626e-05
were O 0 2.0919804555319388e-08
observed O 0 1.8282843683437022e-08
in O 0 1.7811381258781012e-09
Japanese O 0 1.8610469609825486e-08
, O 0 3.0937905015626654e-10
Utah O 0 7.050358075133545e-09
Mormon O 0 6.543289909899386e-09
, O 0 9.540853523892778e-11
and O 0 1.6202442165713649e-10
African O 0 6.79056144647916e-10
American O 0 1.2391217829588186e-08
patients O 0 6.892743442676874e-08
. O 0 6.356278703378848e-08

These O 0 2.5442889750593167e-07
assays O 0 2.384074377914658e-06
should O 0 4.129659281204567e-09
facilitate O 0 3.26806959272119e-09
screening O 0 2.505726826029786e-08
for O 0 2.507580587618463e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
heterozygotes O 0 1.155955828835431e-06
in O 0 3.202708542815458e-09
the O 0 9.027108505144099e-10
populations O 0 4.196028413616659e-09
studied O 0 9.596289984870054e-09
. O 0 2.30206853579773e-09
. O 0 3.108426938069897e-08

The O 0 3.7233851344353752e-06
von B-Disease 1 0.9984149932861328
Hippel I-Disease 1 0.9999017715454102
- I-Disease 1 0.9995062351226807
Lindau I-Disease 1 0.9999029636383057
tumor I-Disease 0 0.003994629718363285
suppressor O 0 0.00019082354265265167
gene O 0 6.891572411404923e-06
is O 0 6.4579985803447926e-09
required O 0 1.9688082275592933e-09
for O 0 6.581286626783367e-10
cell O 0 7.122238230294897e-07
cycle O 0 8.2459763461884e-07
exit O 0 1.5196906133496668e-07
upon O 0 1.5251433893581634e-08
serum O 0 1.3761969057668466e-06
withdrawal O 0 5.043070245847048e-07
. O 0 1.2657544345984206e-07

The O 0 5.901565600652248e-07
inactivation O 0 1.294213052460691e-05
of O 0 8.088426817209893e-09
the O 0 1.977993946411516e-07
von B-Disease 1 0.9997287392616272
Hippel I-Disease 1 0.9999501705169678
- I-Disease 1 0.9999667406082153
Lindau I-Disease 1 0.9998308420181274
( I-Disease 0 5.110569418320665e-06
VHL I-Disease 0 0.0021300469525158405
) I-Disease 0 7.732679705441114e-07
tumor I-Disease 0 6.318139639915898e-05
suppressor O 0 0.00023465654521714896
gene O 0 4.7252622607629746e-05
predisposes O 0 1.4068108612264041e-05
affected O 0 1.7064813562228665e-07
individuals O 0 1.6689692960980551e-09
to O 0 1.3094942907798668e-09
the O 0 1.6251920698096e-08
human O 0 5.245501142780995e-06
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
and O 0 1.2214989020264966e-08
is O 0 1.4299595951783317e-09
associated O 0 1.0105761560907922e-08
with O 0 1.3029227474703475e-08
sporadic B-Disease 1 0.9994621872901917
renal I-Disease 1 0.9999998807907104
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.00010176181240240112
RCC B-Disease 1 0.6892433762550354
) O 0 4.951474608105855e-08
and O 0 5.051060014693576e-08
brain B-Disease 0 7.90105332271196e-05
hemangioblastomas I-Disease 0 0.0001576114009367302
. O 0 5.368293614083086e-07

VHL O 1 0.7633100748062134
- O 0 0.0019473436987027526
negative O 0 4.1110299207502976e-05
786 O 0 0.0001274918031413108
- O 0 0.00016858587332535535
0 O 0 8.192017730834777e-07
RCC B-Disease 0 3.160500273224898e-05
cells O 0 1.2638413693366601e-07
are O 0 9.79046510529713e-10
tumorigenic O 0 5.13758493525529e-07
in O 0 1.1004571476291858e-08
nude O 0 1.0009110155806411e-05
mice O 0 7.995224223122932e-06
which O 0 9.34205957037193e-09
is O 0 7.96749000109287e-10
suppressed O 0 2.061606707570718e-08
by O 0 3.2488078893777583e-10
the O 0 6.645327066401308e-10
reintroduction O 0 6.046860079322869e-08
of O 0 3.4271425697340874e-09
VHL B-Disease 0 7.218629616545513e-05
. O 0 1.553632529294191e-07

Remarkably O 0 0.00015687865379732102
, O 0 2.1894933865951316e-08
this O 0 1.6191454843550446e-09
occurs O 0 2.7588435980163695e-09
without O 0 4.455925350921319e-10
affecting O 0 2.6331850033756155e-09
the O 0 8.983310761934149e-10
growth O 0 4.1609947487586396e-08
rate O 0 1.43495114457437e-07
and O 0 1.548861594535822e-09
cell O 0 2.8017302611260675e-07
cycle O 0 2.14772683193587e-07
profile O 0 1.4099513556686816e-08
of O 0 8.232404341557142e-11
these O 0 3.37892797075412e-10
cells O 0 8.508995286149457e-09
in O 0 3.188932673481304e-09
culture O 0 8.581348964753488e-08
. O 0 7.28621643020233e-08

The O 0 2.9866805562051013e-06
786 O 0 8.64732573973015e-05
- O 0 1.3969111932965461e-05
0 O 0 2.2363089158261573e-07
cell O 0 1.725630340843054e-06
line O 0 8.64668982103467e-06
, O 0 8.070146773064835e-10
like O 0 7.867729800992151e-10
many O 0 6.360044157993627e-10
cancer B-Disease 0 1.0341531009316896e-07
cells O 0 6.12536377175843e-09
, O 0 6.457169243745398e-10
fails O 0 2.509227670088876e-08
to O 0 7.361699583263714e-10
exit O 0 2.50085196995542e-08
the O 0 2.733523851716768e-09
cell O 0 2.534125940201193e-07
cycle O 0 1.0989893439727894e-07
upon O 0 3.501796408400537e-09
serum O 0 3.9434985410480294e-07
withdrawal O 0 2.823569786869484e-07
. O 0 1.4155270378068963e-07

Here O 0 5.209664095673361e-07
, O 0 8.89423290573177e-09
it O 0 1.1660887810904796e-09
is O 0 2.1598674238010318e-10
shown O 0 5.780402823063469e-10
that O 0 1.0893980856296892e-10
reintroduction O 0 7.550985614557248e-09
of O 0 9.136527645559056e-11
the O 0 8.542946350331704e-10
wild O 0 8.369014636855354e-08
- O 0 4.188453021924943e-05
type O 0 6.874700193293393e-05
VHL B-Disease 0 0.00033741359948180616
gene O 0 2.9549405553552788e-06
restores O 0 1.679455863268231e-06
the O 0 6.3937628524968204e-09
ability O 0 2.0947155121575634e-08
of O 0 3.9556544706442764e-09
VHL O 0 0.2599920928478241
- O 0 0.26156070828437805
negative O 0 0.002509579062461853
RCC B-Disease 1 0.8362131714820862
cancer I-Disease 0 1.8018816263065673e-05
cells O 0 5.61335653515016e-08
to O 0 2.5896185196216948e-09
exit O 0 5.274336700722415e-08
the O 0 4.990687418882089e-09
cell O 0 6.62623335756507e-07
cycle O 0 3.086674098540243e-07
and O 0 1.8225385645109782e-09
enter O 0 1.0550850504387199e-07
G0 O 0 3.5809869586955756e-05
/ O 0 4.57931400887901e-06
quiescence O 0 3.775352979573654e-06
in O 0 1.0594389010520899e-07
low O 0 4.2277515603927895e-05
serum O 0 9.159761248156428e-06
. O 0 2.8497294124463224e-07

Both O 0 5.143574071553303e-06
VHL O 0 0.31143876910209656
- O 0 0.0022015708964318037
positive O 0 1.4250233562052017e-06
and O 0 7.091455245245015e-08
VHL O 0 0.005682201124727726
- O 0 0.00034376734402030706
negative O 0 1.8197790268459357e-05
RCC B-Disease 0 6.919872248545289e-05
cells O 0 1.795818036498531e-07
exit O 0 6.199260838002374e-08
the O 0 4.0479388729863786e-09
cell O 0 4.401959188271576e-07
cycle O 0 1.867013423861863e-07
by O 0 2.531029608121571e-09
contact O 0 4.2796307297976455e-07
inhibition O 0 4.035301572002936e-06
. O 0 1.968306690969257e-07

The O 0 4.901232841802994e-06
cyclin O 0 0.000680022407323122
- O 0 1.3450584447127767e-05
dependent O 0 1.3327128272067057e-06
kinase O 0 1.862201315816492e-05
inhibitor O 0 1.3334146160559612e-06
, O 0 2.9306299609288544e-09
p27 O 0 5.705691705770732e-07
, O 0 1.0630772928621468e-09
accumulates O 0 1.3367214890536161e-08
upon O 0 9.836548242603271e-10
serum O 0 3.967186756881347e-08
withdrawal O 0 9.027457892329949e-09
, O 0 1.0377101955505452e-10
only O 0 4.2799343930033373e-11
in O 0 1.2777742752767551e-10
the O 0 1.853421860431581e-10
presence O 0 7.631368870164579e-10
of O 0 6.202058311366443e-10
VHL B-Disease 0 3.837151325569721e-06
, O 0 4.5044273866423623e-10
as O 0 2.291885708993746e-10
a O 0 3.673827075889591e-10
result O 0 3.94484056531752e-10
of O 0 3.147476029807805e-11
the O 0 8.425319886207205e-10
stabilization O 0 7.3717356663394185e-09
of O 0 4.220135005339465e-11
the O 0 1.7737948887486255e-09
protein O 0 2.462165014094353e-07
. O 0 4.086527027880038e-08

We O 0 1.622730110284465e-07
propose O 0 1.6339856756530935e-07
that O 0 6.074170055825334e-10
the O 0 1.65818114794547e-09
loss O 0 8.365420356426512e-09
of O 0 2.308293278741047e-10
wild O 0 1.5295748312382784e-07
- O 0 0.0008106267196126282
type O 0 0.00021096449927426875
VHL B-Disease 0 0.0001916104374686256
gene O 0 8.489787433063611e-07
results O 0 2.8774035598644332e-08
in O 0 8.004076290646367e-10
a O 0 9.779117515762437e-10
specific O 0 3.4994993569625876e-09
cellular O 0 1.5084928008946008e-06
defect O 0 5.161102762940573e-07
in O 0 9.162818948027507e-09
serum O 0 8.736922723073803e-07
- O 0 1.7158647835913143e-07
dependent O 0 1.5848307555188512e-08
growth O 0 2.3492836120908578e-08
control O 0 5.366497646264179e-08
, O 0 2.581499736198367e-10
which O 0 1.9565744580063438e-09
may O 0 1.950442474196734e-08
initiate O 0 1.1777746777852371e-07
tumor B-Disease 0 2.0334553028078517e-06
formation O 0 2.0986111337606417e-07
. O 0 1.4939030279492727e-07

This O 0 4.1765559899431537e-07
is O 0 2.408566679434898e-08
corrected O 0 2.9776094834232936e-07
by O 0 5.978721406840748e-10
the O 0 8.850077337640982e-10
reintroduction O 0 3.6314727225317256e-08
of O 0 3.525411074178919e-10
wild O 0 1.0257040372607662e-07
- O 0 0.0006776335649192333
type O 0 0.02053392492234707
VHL B-Disease 0 0.11647038161754608
, O 0 4.215105775529082e-08
implicating O 0 2.7904450234927936e-06
VHL B-Disease 0 2.803686584229581e-05
as O 0 6.191258616894402e-09
the O 0 1.93200255793613e-09
first O 0 6.188708656651443e-09
tumor B-Disease 0 7.545258426944201e-07
suppressor O 0 1.0311882761016022e-06
involved O 0 2.377763985705883e-09
in O 0 1.5349772564121622e-09
the O 0 1.909960412049827e-09
regulation O 0 4.0635125486687684e-08
of O 0 5.116593260190427e-10
cell O 0 5.806708145428274e-07
cycle O 0 1.4332855471366202e-06
exit O 0 1.933543387622194e-07
, O 0 5.164489391695781e-10
which O 0 4.4212319916248077e-10
is O 0 1.9718136845536804e-10
consistent O 0 1.1152393453173204e-09
with O 0 2.4109453322651575e-10
its O 0 3.829934058785511e-08
gatekeeper O 0 3.318482413305901e-07
function O 0 7.797161138967112e-09
in O 0 2.3267714421848495e-09
the O 0 8.61895887993569e-09
kidney O 0 2.446620328555582e-07
. O 0 7.714424654636787e-09
. O 0 5.44888720810377e-08

Piebaldism B-Disease 1 1.0
with O 0 0.008202793076634407
deafness B-Disease 1 1.0
: O 0 1.7151899456280262e-08
molecular O 0 3.050852370733992e-08
evidence O 0 2.0698680547326376e-09
for O 0 5.138569014739858e-10
an O 0 5.99670046952383e-09
expanded O 0 0.00037278764648362994
syndrome O 1 0.9997705817222595
. O 0 2.3835667661842308e-07

In O 0 2.5207916110048245e-07
a O 0 5.8616343778794544e-08
South O 0 1.769116053651487e-08
African O 0 4.44162084889399e-09
girl O 0 9.509145826314125e-08
of O 0 9.193397154660943e-10
Xhosa O 0 6.317543920886237e-06
stock O 0 1.2567780913741444e-06
with O 0 6.98216195971213e-09
severe O 0 2.021815271291416e-05
piebaldism B-Disease 0 0.0009652711451053619
and O 0 8.808261213744117e-07
profound O 0 0.0005099769332446158
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.1841998457384761e-05
identified O 0 2.306434652155076e-07
a O 0 2.0992670712871586e-08
novel O 0 7.278674729604973e-08
missense O 0 2.0850209239142714e-06
substitution O 0 1.775472071585682e-07
at O 0 5.99279204038794e-08
a O 0 1.9879708546000074e-08
highly O 0 2.119480235762694e-08
conserved O 0 8.47786338908918e-08
residue O 0 1.367649105077362e-07
in O 0 1.679302252810544e-09
the O 0 2.064505899568303e-09
intracellular O 0 2.737308761879831e-07
kinase O 0 9.231734452441742e-07
domain O 0 2.0236759823433204e-08
of O 0 7.386594669256397e-10
the O 0 3.156275951710086e-08
KIT O 0 0.00023393408628180623
proto O 0 0.0020809436682611704
- O 0 1.2262197742529679e-05
oncogene O 0 1.2334656275925227e-05
, O 0 2.025131706773209e-08
R796G O 0 4.086678472958738e-06
. O 0 1.7778000938051264e-07

Though O 0 8.00925863586599e-06
auditory B-Disease 0 0.0005147276679053903
anomalies I-Disease 0 0.01163654588162899
have O 0 2.7537142344158383e-08
been O 0 3.0366273939819166e-09
observed O 0 8.163020481788408e-09
in O 0 6.686026843283344e-09
mice O 0 1.113643406824849e-06
with O 0 1.8525816436465448e-09
dominant O 0 1.7163113170681754e-06
white O 0 4.619152207396837e-07
spotting O 0 5.069599865237251e-06
( O 0 1.1252937071049018e-07
W O 0 0.044093914330005646
) O 0 4.05664168923181e-09
due O 0 2.018837719219846e-08
to O 0 3.368552015103887e-08
KIT O 0 0.4143006205558777
mutations O 0 0.0011546891182661057
, O 0 8.120798042909882e-07
deafness B-Disease 1 1.0
is O 0 9.300279657509236e-09
not O 0 7.105976362886679e-10
typical O 0 1.1954649714596144e-08
in O 0 6.791160966912457e-09
human O 0 1.8293167869387617e-08
piebaldism B-Disease 0 8.088651156867854e-06
. O 0 9.187988325720653e-08

Thus O 0 4.3303626284796337e-07
, O 0 4.709558076854137e-09
the O 0 1.9432375708561267e-09
occurrence O 0 1.6360158383577073e-07
of O 0 2.6847679635011445e-08
sensorineural B-Disease 1 0.9999997615814209
deafness I-Disease 1 1.0
in O 0 1.5472229506485746e-06
this O 0 2.6829047428122976e-08
patient O 0 4.156664772381191e-07
extends O 0 7.419218661652849e-08
considerably O 0 1.5151192656048806e-07
the O 0 4.342307846627591e-09
phenotypic O 0 7.27659212884646e-08
range O 0 2.049761604894229e-08
of O 0 4.397859298954643e-10
piebaldism B-Disease 0 1.1020483725587837e-06
due O 0 1.4888134280965915e-08
to O 0 6.433618526813234e-09
KIT O 0 7.857905075070448e-06
gene O 0 3.997875523964467e-07
mutation O 0 1.0174075271152105e-07
in O 0 2.7638789035222544e-09
humans O 0 4.044496737520831e-09
and O 0 3.796946757006481e-09
tightens O 0 8.426238491665572e-05
the O 0 2.82244760896333e-09
clinical O 0 5.709183792390604e-09
similarity O 0 3.6108402934331707e-09
between O 0 4.4214703009970435e-09
piebaldism B-Disease 0 2.271496214234503e-06
and O 0 3.6314479201493555e-10
the O 0 2.145042615753212e-10
various O 0 4.3373057923012936e-10
forms O 0 1.049593034707641e-08
of O 0 8.095467762814224e-08
Waardenburg B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999703168869019
. O 0 2.6725979651587295e-08
. O 0 1.3234905793524376e-07

Cycloheximide O 0 0.00023448726278729737
facilitates O 0 5.031616638007108e-06
the O 0 1.992450116006239e-08
identification O 0 3.3444418789940755e-08
of O 0 1.3746698224181841e-09
aberrant O 0 1.5834942814763053e-06
transcripts O 0 7.338951490964973e-07
resulting O 0 4.71673438084963e-08
from O 0 6.24910745372631e-09
a O 0 1.1313944447977065e-08
novel O 0 1.207832696081823e-07
splice O 0 7.042229117359966e-05
- O 0 6.6814418460126035e-06
site O 0 2.28518388212251e-07
mutation O 0 4.516829505973874e-07
in O 0 1.2569437934928374e-08
COL17A1 O 0 1.4290993703980348e-06
in O 0 6.14274986432406e-09
a O 0 2.5817785243020808e-08
patient O 0 6.608033800148405e-07
with O 0 1.5512696904806944e-07
generalized O 0 0.0024099547881633043
atrophic B-Disease 1 0.9999788999557495
benign I-Disease 1 0.9999862909317017
epidermolysis I-Disease 1 0.9998652935028076
bullosa I-Disease 1 0.9957360029220581
. O 0 3.713383193826303e-05

Patients O 0 0.00011179541616002098
with O 0 2.8640381515288027e-06
generalized O 0 0.009401924908161163
atrophic B-Disease 1 0.9999984502792358
benign I-Disease 1 0.9999966621398926
epidermolysis I-Disease 1 0.9999333620071411
bullosa I-Disease 1 0.9952296018600464
often O 0 9.909667824103963e-06
show O 0 1.3446020830087946e-06
decreased O 0 6.243951133910741e-07
expression O 0 3.039851037556218e-08
of O 0 2.2958506207260143e-09
type O 0 3.038673457922414e-05
XVII O 0 0.00010843920608749613
collagen O 0 4.358912065072218e-06
, O 0 3.176427343376531e-09
a O 0 1.2238075441928231e-08
transmembrane O 0 3.542201909567666e-07
hemidesmosomal O 0 1.4208519587555202e-06
protein O 0 2.1200104072249815e-07
encoded O 0 1.0341609169017829e-07
by O 0 2.149160671649497e-08
COL17A1 O 0 5.8447512856218964e-05
. O 0 2.620551242671354e-07

This O 0 3.4724902775451483e-07
report O 0 8.415097596525811e-08
documents O 0 1.1799722088312592e-08
a O 0 1.0841238129444264e-08
novel O 0 7.746379537820758e-08
splice O 0 3.114489663857967e-05
- O 0 4.665999767894391e-06
site O 0 3.1233656727636117e-07
mutation O 0 3.53072465486548e-07
in O 0 7.845884830715022e-09
COL17A1 O 0 1.1299150628474308e-06
in O 0 2.4678379340059564e-09
a O 0 1.3575155222156354e-08
patient O 0 5.202261377235118e-07
with O 0 9.052859439862004e-08
generalized O 0 0.0013911466812714934
atrophic B-Disease 1 0.9999836683273315
benign I-Disease 1 0.9999891519546509
epidermolysis I-Disease 1 0.9995237588882446
bullosa I-Disease 0 0.49016013741493225
, O 0 1.3220537198321836e-07
and O 0 2.487653638638676e-09
applies O 0 1.8480783570140602e-09
a O 0 1.45226752845673e-09
new O 0 1.6186335827228504e-08
methodology O 0 1.4072861098668454e-08
to O 0 1.2696921292132402e-09
define O 0 3.263872727643502e-08
and O 0 1.5187098245661446e-09
characterize O 0 6.647627515121712e-08
the O 0 3.2238531844086538e-09
resulting O 0 2.9678247415176884e-08
mRNA O 0 6.219192414391728e-07
splice O 0 2.735593261604663e-05
variants O 0 5.770752977696247e-06
. O 0 3.697324473250774e-07

Mutational O 0 0.003910582512617111
analysis O 0 6.749093699909281e-06
of O 0 5.357354737611786e-08
COL17A1 O 0 2.0185190805932507e-05
identified O 0 2.2367781582488533e-07
a O 0 8.006328044984912e-08
maternally O 0 4.688115950557403e-05
inherited O 0 0.00017904640117194504
G O 0 0.0001271111541427672
- O 0 1.4777489013795275e-05
to O 0 1.593132452626378e-07
- O 0 0.0001305337209487334
T O 0 0.0002375222247792408
transversion O 0 2.044422217295505e-06
at O 0 1.8546083779824585e-08
the O 0 5.4925632930746815e-09
- O 0 1.444216763957229e-07
1 O 0 3.975584750293137e-09
position O 0 3.6449050444531395e-09
of O 0 3.572618589853249e-10
exon O 0 8.567200211473391e-07
32 O 0 2.7996924245599075e-07
. O 0 8.07315601036862e-08

This O 0 3.156029606543598e-07
acceptor O 0 6.019156899128575e-06
splice O 0 0.00012826710008084774
- O 0 2.1061403458588757e-05
site O 0 2.614133620681969e-07
mutation O 0 6.753348884558363e-07
led O 0 6.8463834601573126e-09
to O 0 4.6133583064822403e-10
the O 0 4.4418729805428825e-10
formation O 0 2.2764858886858974e-09
of O 0 2.2818359701748392e-10
aberrant O 0 1.5432277677973616e-07
transcripts O 0 1.5356640403751953e-07
present O 0 1.0755353052616101e-08
at O 0 7.560515769000631e-08
extremely O 0 3.330800097955944e-07
low O 0 7.926484249765053e-05
levels O 0 2.1248042685328983e-06
. O 0 1.2775701918599225e-07

Based O 0 1.1213486459382693e-06
on O 0 1.7185946887821046e-07
our O 0 7.23525062085173e-09
recent O 0 4.923577101578758e-09
finding O 0 2.137638954735621e-09
that O 0 2.0391928146068494e-09
cycloheximide O 0 4.645753051590873e-06
stabilized O 0 2.0132783902226947e-05
mutant O 0 1.446261080673139e-06
COL17A1 O 0 4.4573084778676275e-06
transcripts O 0 3.6785570500796894e-07
in O 0 2.6981357592603672e-08
keratinocytes O 0 1.308990249526687e-06
homozygous O 0 8.582688906244584e-07
for O 0 2.464625170617296e-09
a O 0 2.9040007731850892e-08
frameshift O 0 0.0002966989704873413
mutation O 0 2.8596657557500293e-06
, O 0 2.6744222392238726e-09
the O 0 1.7244855543552262e-09
effects O 0 6.324437151761231e-08
of O 0 2.371643437193427e-10
the O 0 6.124546647612306e-09
splice O 0 9.968951781047508e-05
- O 0 2.91976289190643e-06
site O 0 2.906373310906929e-07
mutation O 0 1.0749881340643697e-07
on O 0 9.783525989348618e-09
splicing O 0 1.300869740816779e-07
of O 0 1.2729147735868196e-09
COL17A1 O 0 2.2607832761423197e-06
transcripts O 0 2.3608509991390747e-07
were O 0 2.0912653830862382e-09
determined O 0 4.499088657183847e-09
using O 0 9.482825191753363e-09
reverse O 0 1.2471524541979306e-06
transcriptase O 0 6.409776233340381e-06
polymerase O 0 1.559216570967692e-06
chain O 0 2.2213034753804095e-06
reaction O 0 3.0707717257882905e-08
of O 0 4.710453693768102e-10
total O 0 3.3922434305999616e-10
RNA O 0 5.7228692895705535e-08
from O 0 8.032740694829954e-09
keratinocytes O 0 1.0345115697418805e-06
incubated O 0 3.3627139828240615e-07
for O 0 2.3409270077934252e-09
2 O 0 4.494356886652895e-08
. O 0 3.752354871267016e-08

5 O 0 5.976782631478272e-06
h O 0 4.104559138795594e-06
in O 0 8.683906926876261e-09
the O 0 2.8951285813150207e-09
presence O 0 7.1128418710486585e-09
or O 0 6.776643246553249e-09
absence O 0 3.939023329735392e-09
of O 0 2.117191005845953e-10
10 O 0 9.632250552726873e-09
microg O 0 2.348832140341983e-06
cycloheximide O 0 5.729351869376842e-06
per O 0 3.088732398737193e-07
ml O 0 4.823704875889234e-05
. O 0 3.5173152923562157e-07

Using O 0 4.120704488741467e-07
this O 0 9.233926512308699e-09
approach O 0 9.887584973000685e-09
, O 0 3.737365694700401e-10
an O 0 7.218292075172883e-10
abnormally O 0 1.22413293865975e-05
spliced O 0 0.00012579454050865024
transcript O 0 0.0022367665078490973
was O 0 4.5449590402313333e-07
identified O 0 3.2702771601833547e-09
that O 0 6.620363285358977e-11
contains O 0 2.2709292779587997e-10
an O 0 5.959124860233089e-11
extra O 0 2.2378390251986957e-09
264 O 0 2.069979565533231e-08
bases O 0 8.117358341053205e-09
upstream O 0 2.2571217783706743e-08
from O 0 3.536538617510132e-09
exon O 0 3.649554400908528e-07
32 O 0 3.043366447741391e-08
, O 0 4.829265320971388e-10
resulting O 0 4.67205252263625e-09
in O 0 6.497176574526975e-09
a O 0 1.1552092615829679e-07
premature O 0 7.366421414189972e-06
termination O 0 1.9264712136646267e-06
codon O 0 1.0558451322140172e-05
27 O 0 2.8514531891232764e-07
bp O 0 3.330241327148542e-07
downstream O 0 7.309476046657437e-08
from O 0 3.525177483254538e-09
the O 0 2.2203052729707906e-09
cryptic O 0 7.448596193171397e-07
splice O 0 1.267474453925388e-05
site O 0 9.74724343905109e-07
. O 0 1.1189796822463904e-07

Three O 0 8.951026586601074e-08
other O 0 6.253233042485817e-09
splice O 0 1.6734603605073062e-06
variants O 0 1.82077158683569e-07
, O 0 7.127138323959059e-10
including O 0 9.496119168783679e-11
one O 0 1.1150600581766312e-10
derived O 0 9.255292088283795e-10
from O 0 2.2944050825923767e-10
the O 0 5.851753526187053e-10
skipping O 0 2.220526695850822e-08
of O 0 4.629577554648989e-10
exon O 0 2.3400582449539797e-07
32 O 0 7.391224698949372e-08
, O 0 1.1688009449173364e-09
were O 0 2.7186217721464345e-09
also O 0 9.420539903715053e-09
identified O 0 9.050650362496526e-08
. O 0 5.3196394844690076e-08

These O 0 1.4462980857388175e-07
results O 0 1.0692031793269052e-07
indicate O 0 2.999706083528508e-08
the O 0 2.130487120055591e-09
usefulness O 0 2.4585368407770147e-08
of O 0 3.6194092167818326e-10
cycloheximide O 0 1.0482995094207581e-06
treatment O 0 1.5901900241033218e-08
in O 0 2.958655986873282e-09
evaluating O 0 5.3417408274469835e-09
the O 0 2.2567632207426414e-09
abnormal O 0 8.834604159346782e-08
processing O 0 4.276421439186606e-09
of O 0 1.3188783398732085e-10
mRNA O 0 1.795420345729326e-08
due O 0 5.2555755303274054e-09
to O 0 3.168573181611123e-09
splice O 0 5.3834701247978956e-05
- O 0 5.263069397187792e-06
site O 0 8.733323966225726e-07
mutations O 0 1.5179625734162983e-06
, O 0 1.3253448338801377e-09
because O 0 3.0025548714007755e-09
( O 0 8.592416556041371e-09
i O 0 2.5170937334451082e-08
) O 0 1.7455654699460865e-09
aberrant O 0 3.2349115031138354e-07
splicing O 0 4.946018634655047e-07
often O 0 1.2616371058982168e-08
generates O 0 1.0046361609283849e-07
a O 0 3.9012512331737526e-08
premature O 0 3.906191068381304e-06
termination O 0 1.26739860206726e-06
codon O 0 6.952476724109147e-06
, O 0 6.980164002357014e-09
( O 0 5.369197975113593e-09
ii O 0 1.4605998899241968e-07
) O 0 1.169550234436656e-09
transcripts O 0 7.123135503661615e-08
with O 0 1.521685533134587e-08
premature O 0 3.394054601812968e-06
termination O 0 8.928704460231529e-07
codons O 0 8.18624641851784e-07
can O 0 1.6466527696934463e-08
occur O 0 2.161769607766928e-08
at O 0 9.503126108256765e-08
low O 0 6.926758487679763e-06
or O 0 3.235460255268663e-08
undetectable O 0 9.311098665421014e-07
levels O 0 2.7121028978172035e-08
due O 0 9.497759023702201e-09
to O 0 6.401340790773702e-09
nonsense O 0 1.7624046222408651e-07
- O 0 1.0124557547896984e-07
mediated O 0 2.84146892681747e-07
mRNA O 0 1.1542379496631838e-07
decay O 0 1.569753180774569e-07
, O 0 3.3729849469033013e-10
and O 0 2.1395590854567104e-10
( O 0 5.752247012047462e-10
iii O 0 1.3085987404792832e-08
) O 0 1.5026110911087187e-10
the O 0 4.971702494138697e-10
levels O 0 2.037567670143403e-09
of O 0 4.28527630047526e-11
these O 0 8.840929377473827e-11
transcripts O 0 8.258912664871332e-09
can O 0 5.473224096164131e-10
be O 0 1.3926226838378852e-10
increased O 0 8.570397724838585e-10
by O 0 1.6058894214410202e-09
cycloheximide O 0 2.470201934556826e-06
. O 0 7.178838501431528e-08

A O 0 3.7164675177336903e-06
deletion O 0 4.54191722383257e-05
mutation O 0 7.967245437612291e-06
in O 0 1.53296582539042e-07
COL17A1 O 0 1.215649626828963e-05
in O 0 1.6021882487393668e-08
five O 0 3.6521496937780284e-09
Austrian O 0 7.743254855085979e-07
families O 0 8.529486450470358e-09
with O 0 4.4398870358008935e-08
generalized O 0 0.0005881906836293638
atrophic B-Disease 1 0.9999964237213135
benign I-Disease 1 0.9999973773956299
epidermolysis I-Disease 1 0.9999674558639526
bullosa I-Disease 1 0.9111095070838928
represents O 0 3.438564135649358e-07
propagation O 0 2.1744862976902368e-07
of O 0 6.742718050567476e-10
an O 0 2.489300543473405e-09
ancestral O 0 7.522970122408879e-07
allele O 0 1.3134058463037945e-05
. O 0 1.528609629986022e-07

Patients O 0 7.308982458198443e-05
with O 0 2.503768882888835e-06
generalized O 0 0.05455538257956505
atrophic B-Disease 1 0.9999991655349731
benign I-Disease 1 0.9999992847442627
epidermolysis I-Disease 1 0.999988317489624
bullosa I-Disease 1 0.9987503290176392
, O 0 2.1577372422143526e-07
a O 0 5.360912069818369e-08
usually O 0 3.163128070582388e-08
nonlethal O 0 2.5534384917591524e-07
form O 0 1.54947457531307e-07
of O 0 8.032377252220613e-08
junctional B-Disease 1 0.6014279723167419
epidermolysis I-Disease 1 0.9409729242324829
bullosa I-Disease 0 0.06153783202171326
, O 0 8.589930189373263e-08
have O 0 1.209060851437016e-08
generalized O 0 5.024386382501689e-07
blistering B-Disease 0 0.0002935969678219408
, O 0 1.800702307264146e-07
nail B-Disease 1 1.0
dystrophy I-Disease 1 0.9999692440032959
, O 0 9.363523645333771e-08
patchy B-Disease 1 0.9993372559547424
alopecia I-Disease 1 0.999998927116394
, O 0 1.4904478007338184e-07
and O 0 1.6217043139477028e-06
dental B-Disease 1 0.9991664886474609
abnormalities I-Disease 1 0.9999853372573853
. O 0 1.823090997277177e-06

Skin B-Disease 1 0.9999983310699463
fragility I-Disease 0 0.0027167131192982197
in O 0 4.917460572073651e-08
most O 0 1.777533897850958e-09
cases O 0 1.7599609547502837e-09
is O 0 2.772568286069088e-10
due O 0 2.426150835788121e-09
to O 0 1.1473096916958525e-09
mutations O 0 6.838216393134644e-08
in O 0 8.269501194924089e-10
the O 0 3.0822007168751497e-09
gene O 0 6.595114996343909e-07
encoding O 0 2.5896133593050763e-06
type O 0 0.0003509931266307831
XVII O 0 0.0003613719018176198
collagen O 0 4.6528100938303396e-05
( O 0 2.5429014272049244e-07
COL17A1 O 0 3.966036456404254e-05
) O 0 1.9013765495401458e-07
. O 0 1.387250847528776e-07

Recently O 0 2.443413541186601e-05
, O 0 4.219972282726303e-08
we O 0 1.5758804261523096e-09
reported O 0 3.905837431261716e-08
five O 0 2.280349242766988e-09
Austrian O 0 1.143286226579221e-06
families O 0 7.0281780395475835e-09
with O 0 3.4920066838139974e-08
generalized O 0 0.00048485994921065867
atrophic B-Disease 1 0.9999573230743408
benign I-Disease 1 0.9999473094940186
epidermolysis I-Disease 1 0.9996190071105957
bullosa I-Disease 1 0.9712010025978088
who O 0 1.8309281131223543e-06
share O 0 9.478090845504994e-08
the O 0 8.664317263651355e-09
same O 0 7.874808716223924e-08
COL17A1 O 0 5.988033444737084e-05
mutation O 0 1.2708656868198887e-05
. O 0 2.8566216769831954e-07

Affected O 0 4.538619577942882e-06
individuals O 0 1.7454532041938364e-08
in O 0 4.573723622058878e-09
three O 0 1.2271237359584575e-09
families O 0 7.684213265690687e-10
are O 0 2.0481689955165194e-10
homozygous O 0 4.301177369825382e-08
for O 0 3.443068608000033e-10
4003delTC O 0 1.6170636740753253e-07
, O 0 3.704223594525047e-10
whereas O 0 3.2707134778320324e-09
those O 0 1.9643811577374493e-10
in O 0 4.973712552924781e-10
two O 0 3.642832147043862e-10
others O 0 6.716789346938867e-10
are O 0 3.086140509811486e-10
compound O 0 1.352734386728116e-07
heterozygotes O 0 4.217536570649827e-06
. O 0 1.3348557104109204e-07

To O 0 1.2246836433860153e-07
determine O 0 2.323154113526016e-08
if O 0 1.4168357598265402e-09
the O 0 9.368071873794293e-10
occurrence O 0 1.3252241970462819e-08
of O 0 3.3332370197314276e-10
4003delTC O 0 2.6459397872713453e-07
in O 0 1.789702719356967e-09
these O 0 7.254482015106589e-10
unrelated O 0 1.0556583163179312e-08
families O 0 7.016521808012044e-10
signifies O 0 2.448959923739835e-09
propagation O 0 2.7259379198341094e-09
of O 0 3.1509839876209256e-11
an O 0 3.578647655988476e-10
ancestral O 0 7.187922079765485e-08
allele O 0 3.911007979695569e-07
or O 0 9.89858595090709e-09
a O 0 2.5095244993167398e-08
mutational O 0 3.6434521462069824e-05
hot O 0 5.687145676347427e-05
spot O 0 2.662489123395062e-06
, O 0 2.3010238159315577e-09
haplotypes O 0 1.9423460173584317e-07
were O 0 2.063190951417937e-09
determined O 0 3.873755538563728e-09
for O 0 6.939182561893631e-10
polymorphisms O 0 2.5349379484396195e-07
both O 0 1.3914100982503896e-09
within O 0 7.777451571655547e-09
and O 0 1.2626458101294702e-08
flanking O 0 5.383691313909367e-05
COL17A1 O 0 0.0006393479998223484
. O 0 5.110434813104803e-07

Five O 0 1.6084306935226778e-06
intragenic O 0 3.363109135534614e-05
polymorphisms O 0 1.516599968454102e-05
were O 0 1.606061950099047e-08
chosen O 0 1.1118798326492652e-08
based O 0 3.759524247470836e-09
on O 0 2.4110027752044516e-08
their O 0 2.8740027246954014e-08
informativeness O 0 1.226040785695659e-05
. O 0 1.0101641834125985e-07

One O 0 6.56926530950841e-08
of O 0 4.860035707210386e-10
these O 0 2.066829346558663e-10
, O 0 6.519812467686847e-11
not O 0 1.048029649175497e-10
previously O 0 1.196874266362613e-09
reported O 0 4.5906116241667405e-08
, O 0 5.174408679309295e-10
was O 0 6.660443307993091e-09
2988 O 0 4.977665923888708e-08
A O 0 1.3812727850393003e-08
or O 0 1.4245647328436917e-08
C O 0 5.346911962078593e-07
that O 0 2.4838359147238975e-10
introduces O 0 1.255973192115789e-08
a O 0 1.6730680174603663e-09
new O 0 4.266384578954785e-09
restriction O 0 6.2612768303438315e-09
site O 0 7.818158564987243e-09
for O 0 7.363833987028556e-10
Eco0109 O 0 5.045061470809742e-07
I O 0 5.880368689759052e-07
. O 0 6.413772268842877e-08

All O 0 5.889461007768659e-08
the O 0 3.768205303344985e-08
4003delTC O 0 2.1656630906363716e-06
alleles O 0 4.4445093294598337e-07
showed O 0 9.002717860084886e-08
the O 0 2.3485207112372564e-09
same O 0 6.5950369609879544e-09
haplotype O 0 8.3269458173163e-07
for O 0 3.0213620494379256e-10
these O 0 5.082899656727591e-10
five O 0 4.972691147742125e-09
polymorphic O 0 5.549574325414142e-06
markers O 0 7.2555162660137285e-06
. O 0 2.059333894521842e-07

Fourteen O 0 8.225655619753525e-06
microsatellite O 0 3.456275589996949e-05
polymorphisms O 0 2.8119873604737222e-05
were O 0 4.6576765555528254e-08
selected O 0 1.0503440783793394e-08
based O 0 7.702882776072784e-09
on O 0 3.126479342085986e-08
their O 0 1.066196997356883e-08
high O 0 1.5838521960631624e-07
heterozygosity O 0 3.153652698983933e-07
and O 0 7.860424533490118e-10
their O 0 8.735034362494787e-10
location O 0 1.4569961237498319e-08
within O 0 1.1959301993158533e-08
10q23 O 0 1.1304118743282743e-06
- O 0 7.825866532584769e-07
q25 O 0 3.2740413189458195e-06
near O 0 3.2766340609668987e-06
COL17A1 O 0 5.6808141380315647e-05
. O 0 3.748342294329632e-07

Three O 0 2.863173165223998e-07
families O 0 4.372545703290598e-08
shared O 0 6.201176461217983e-08
microsatellite O 0 1.4756350537936669e-05
polymorphisms O 0 5.2192805014783517e-05
covering O 0 8.981705263977346e-07
at O 0 7.285633074616271e-08
most O 0 1.7701885512977356e-09
19 O 0 1.824946593842469e-08
cM O 0 4.797248465138182e-08
, O 0 2.6535526553850275e-10
whereas O 0 1.7696349940976575e-09
the O 0 1.3465215609187453e-09
others O 0 6.734556801113456e-10
shared O 0 4.3141212824338027e-10
smaller O 0 2.9074240792681394e-09
regions O 0 6.891162751543334e-09
consistent O 0 1.0301133812617991e-07
with O 0 1.0137070072246956e-09
cross O 0 1.3328624959285662e-07
- O 0 1.5432924556080252e-06
over O 0 8.745170143598102e-10
events O 0 5.052808726979663e-10
during O 0 4.313372714559449e-10
passage O 0 2.3185345310317018e-10
of O 0 2.8832334089679e-11
this O 0 1.6562710924983293e-10
mutation O 0 5.178784956427762e-09
through O 0 4.924927132776702e-10
several O 0 7.984878869216061e-10
generations O 0 1.585456566033372e-08
. O 0 2.6424791244039625e-08

These O 0 1.528420057184121e-07
results O 0 1.2586691866545152e-07
indicate O 0 1.0057097199478449e-07
that O 0 1.9687180774496937e-09
4003delTC O 0 3.007939426424855e-07
occurs O 0 5.322011720210185e-09
on O 0 1.748537759027613e-09
a O 0 1.1998136928426106e-09
single O 0 5.688900461819912e-09
ancestral O 0 1.4274537818437238e-07
allele O 0 1.3482256235874956e-06
. O 0 5.950328674231287e-09
. O 0 3.442986695745276e-08

The O 0 2.442508730382542e-06
haptoglobin O 0 0.00028680209652520716
- O 0 1.996415448957123e-05
gene O 0 1.079040885088034e-05
deletion O 0 8.554907253710553e-06
responsible O 0 2.7655423195938056e-07
for O 0 1.4776952106387853e-08
anhaptoglobinemia B-Disease 0 2.7030451747123152e-05
. O 0 2.0823294732963404e-07

We O 0 1.4665403114122455e-07
have O 0 2.0764796548888853e-09
found O 0 1.5894584537434753e-09
an O 0 9.617412422002758e-10
allelic O 0 9.048040965353721e-07
deletion O 0 6.025302923262643e-07
of O 0 1.8022471293122067e-09
the O 0 3.4762372536079056e-08
haptoglobin O 0 7.926380931166932e-06
( O 0 3.060673492427668e-08
Hp O 0 3.135216388727713e-07
) O 0 1.2776920632617816e-09
gene O 0 2.112513897145618e-08
from O 0 3.3665831233875565e-10
an O 0 1.2802918447629708e-10
individual O 0 4.619081506174183e-10
with O 0 4.687083166032835e-09
anhaptoglobinemia B-Disease 0 2.886620131903328e-05
. O 0 1.775624554056776e-07

The O 0 2.2852020720165456e-06
Hp O 0 2.1803100025863387e-05
gene O 0 2.6410893951833714e-06
cluster O 0 1.6833574534302898e-07
consists O 0 6.04998451336769e-09
of O 0 7.504490917575879e-10
coding O 0 2.5812397552726907e-07
regions O 0 3.159894346183023e-09
of O 0 1.3228085293803815e-10
the O 0 4.551081289605463e-09
alpha O 0 2.651187891444806e-08
chain O 0 2.7131383717460267e-07
and O 0 7.640515442552953e-10
beta O 0 4.646910412020588e-09
chain O 0 5.885553022721979e-08
of O 0 3.1929967003740956e-10
the O 0 8.227781123082423e-09
haptoglobin O 0 1.6888870959519409e-06
gene O 0 3.249437838803715e-07
( O 0 5.692438964643998e-09
Hp O 0 1.5248036788761965e-07
) O 0 7.156070180869278e-10
and O 0 1.1589947751522445e-10
of O 0 3.6591115554207576e-11
the O 0 1.389590664757634e-09
alpha O 0 1.9412528473594648e-08
chain O 0 3.351272255258664e-07
and O 0 1.7088801484987926e-09
beta O 0 9.029955450046145e-09
chain O 0 7.166853777107463e-08
of O 0 3.825053607187101e-10
the O 0 5.73982150697816e-09
haptoglobin O 0 1.0167097570956685e-05
- O 0 6.724050649609126e-07
related O 0 7.885359565307226e-08
gene O 0 7.402368851217034e-07
( O 0 2.0109133913592814e-08
Hpr O 0 2.8943240977241658e-06
) O 0 3.1528024635463225e-09
, O 0 2.5389385038820933e-10
in O 0 9.956048208081825e-10
tandem O 0 4.517191314334923e-07
from O 0 4.112084894813961e-09
the O 0 1.646304248481556e-08
5 O 0 1.1914431752302335e-07
side O 0 4.590629316680861e-07
. O 0 4.7455564811116346e-08

Southern O 0 1.76775884028757e-05
blot O 0 0.001221165177412331
and O 0 1.5296653543828143e-07
PCR O 0 2.4714632672839798e-05
analyses O 0 3.123487601897068e-07
have O 0 2.216996142223593e-09
indicated O 0 3.969707407236456e-08
that O 0 8.095826786735927e-11
the O 0 1.699258511678181e-10
individual O 0 5.728353902334504e-11
with O 0 2.163982742997561e-10
anhaptoglobinemia B-Disease 0 2.298314996096451e-07
was O 0 5.708007844162921e-09
homozygous O 0 1.6453718387765548e-08
for O 0 6.483799608325569e-11
the O 0 5.561991978098035e-10
gene O 0 4.5940975468283796e-08
deletion O 0 4.3959094142564936e-08
and O 0 1.2638998181380146e-10
that O 0 3.014763785835761e-11
the O 0 3.5077840632169455e-10
gene O 0 6.904414107111734e-08
deletion O 0 1.0287330809433115e-07
was O 0 9.85582104817695e-09
included O 0 2.3259359716032435e-10
at O 0 2.1292685392637622e-09
least O 0 4.3368755808792514e-10
from O 0 2.833179524319718e-10
the O 0 7.430711046474414e-10
promoter O 0 4.874708992019805e-08
region O 0 1.7151366993317652e-09
of O 0 2.105681323749664e-10
Hp O 0 4.485339673010458e-07
to O 0 4.634845396367382e-09
Hpr O 0 8.651521739011514e-07
alpha O 0 1.4792631120030819e-08
but O 0 6.378388373029509e-10
not O 0 6.661761142723321e-10
to O 0 2.6743813830165664e-09
Hpr O 0 4.737715698865941e-06
beta O 0 2.2367738949924387e-07
( O 0 2.901741780192424e-08
Hpdel O 0 4.895355687040137e-06
) O 0 3.584922581012506e-08
. O 0 9.542449674881937e-08

In O 0 2.706677264541213e-07
addition O 0 8.03491673195822e-09
, O 0 1.2357954659591996e-09
we O 0 1.4916828883215771e-10
found O 0 2.3246188307624038e-10
seven O 0 1.6987530826462205e-10
individuals O 0 1.4826109090426698e-11
with O 0 8.943266960326213e-11
hypohaptoglobinemia B-Disease 0 3.482210217953252e-07
in O 0 2.217173777907533e-09
three O 0 2.298417151047616e-10
families O 0 1.661079884751615e-10
, O 0 5.0453138195072356e-11
and O 0 1.6372121713903454e-10
the O 0 1.0154291851804942e-09
genotypes O 0 1.8925765843391673e-08
of O 0 6.700293098127474e-11
six O 0 2.4757948469122937e-10
of O 0 2.4234012366286528e-11
the O 0 3.916777735479826e-10
seven O 0 2.5160351579955886e-10
individuals O 0 2.8991593847838004e-11
were O 0 2.1103734038074862e-10
found O 0 5.586275331204149e-10
to O 0 1.836044871694753e-09
be O 0 1.6659932100537844e-08
Hp2 O 0 2.029563984251581e-05
/ O 0 1.3308165762282442e-05
Hpdel O 0 2.4491433578077704e-05
. O 0 2.197040487317281e-07

The O 0 5.495861046256323e-07
phenotypes O 0 1.2131505172874313e-05
and O 0 2.316684799552604e-08
genotypes O 0 7.753266118015745e-07
in O 0 2.965497625240232e-09
one O 0 4.254875340947706e-10
of O 0 6.200021052116256e-11
these O 0 1.1099483832044399e-10
three O 0 1.9045028054609503e-10
families O 0 1.7351149683708655e-10
showed O 0 1.7444378386244352e-08
the O 0 2.2140382860413865e-09
father O 0 5.6062415154656264e-08
to O 0 1.8225385645109782e-09
be O 0 1.87748949720401e-09
hypohaptoglobinemic B-Disease 0 3.419798986215028e-07
( O 0 4.7724948437632975e-09
Hp2 O 0 3.717945560310909e-07
) O 0 3.3335691984603955e-09
and O 0 5.903831645781565e-09
Hp2 O 0 9.511061762168538e-06
/ O 0 3.1387037324748235e-06
Hpdel O 0 1.3070466593489982e-06
, O 0 1.036642438556612e-09
the O 0 1.3348177008154494e-09
mother O 0 3.2352009071701104e-08
to O 0 1.7658250417440513e-09
be O 0 1.574102070911465e-09
Hp2 O 0 8.323182782987715e-07
- O 0 4.1756956647986954e-07
1 O 0 1.0692028595826741e-08
and O 0 4.990611479627205e-09
Hp1 O 0 8.364006134797819e-06
/ O 0 6.264376679609995e-06
Hp2 O 0 8.16279680293519e-07
, O 0 4.898452199419978e-10
one O 0 1.0704300640318465e-10
of O 0 1.4455285059222778e-11
the O 0 1.8516445321470343e-10
two O 0 4.0487940777822473e-10
children O 0 1.6458348572889747e-10
to O 0 4.1533473882360283e-10
be O 0 1.0274379125263522e-09
hypohaptoglobinemic B-Disease 0 4.0059967432171106e-07
( O 0 4.014676147079399e-09
Hp2 O 0 2.614320635530021e-07
) O 0 1.2116665448758113e-09
and O 0 2.1939652317115588e-09
Hp2 O 0 2.9774719223496504e-06
/ O 0 3.634408358266228e-06
Hpdel O 0 9.922915751303663e-07
, O 0 3.4204927779057925e-10
and O 0 6.674858582522702e-11
the O 0 2.0694762570272474e-10
other O 0 1.2830053686130327e-10
child O 0 1.479730782349975e-09
to O 0 4.184022572850665e-10
be O 0 4.963269795155156e-10
Hp1 O 0 1.99035397940861e-07
and O 0 3.703094941798213e-09
Hp1 O 0 6.4871637732721865e-06
/ O 0 2.018804934778018e-06
Hpdel O 0 9.421025879419176e-07
, O 0 1.0860728982819978e-09
showing O 0 2.069340077071047e-08
an O 0 1.1667117272295968e-09
anomalous O 0 4.0367461906498647e-07
inheritance O 0 9.746427309664796e-08
of O 0 2.3354815859022438e-09
Hp O 0 2.5511849344184157e-06
phenotypes O 0 2.2841250313376804e-07
in O 0 3.7231944194360267e-09
the O 0 1.5593348834386234e-08
child O 0 6.639403693498025e-08
with O 0 1.2187481246428433e-08
Hp1 O 0 2.4923127057263628e-05
. O 0 2.393518627741287e-07

The O 0 2.121645593433641e-06
Hp2 O 0 0.00031564474920742214
/ O 0 4.317864659242332e-05
Hpdel O 0 9.509083611192182e-06
individuals O 0 8.223577374621982e-09
had O 0 6.956413667325023e-09
an O 0 1.1638844332750864e-09
extremely O 0 1.3180402902435162e-07
low O 0 1.621440242161043e-05
level O 0 1.4391434888239019e-07
of O 0 2.3368629253894824e-09
Hp O 0 6.285393283178564e-06
( O 0 1.4678353643660103e-08
mean O 0 4.277712761791008e-08
+ O 0 4.3893828660657164e-07
/ O 0 1.055002667271765e-05
- O 0 1.5363950296887197e-05
SD O 0 0.009280429221689701
= O 0 1.954701247086632e-06
0 O 0 1.559484275048817e-07
. O 0 1.5388886609457586e-08
049 O 0 2.2164505935506895e-05
+ O 0 1.451893922421732e-06
/ O 0 1.113356847781688e-05
- O 0 2.9352970614127116e-06
0 O 0 2.2922866094177152e-07
. O 0 1.5844801026787536e-08
043 O 0 1.214305666508153e-05
mg O 0 0.006718943361192942
/ O 0 3.6035518860444427e-05
ml O 0 1.3816088539897464e-05
; O 0 3.3670552568310086e-08
n O 0 3.3599476978452003e-07
= O 0 2.4921220642681874e-07
6 O 0 1.6888559883909693e-08
) O 0 6.36169394940822e-10
, O 0 1.4334705644714063e-10
compared O 0 1.8395677203741911e-09
with O 0 1.9412695062559493e-10
the O 0 5.648280065884137e-09
level O 0 3.7518539386383054e-08
( O 0 2.029093781885649e-09
1 O 0 1.8504274779118646e-09
. O 0 2.687162714565261e-10
64 O 0 2.1616457956952218e-08
+ O 0 1.1368548058499073e-07
/ O 0 6.35620926914271e-06
- O 0 1.3140884220774751e-06
1 O 0 3.988164110069192e-08
. O 0 5.428469673773861e-09
07 O 0 1.1944687230425188e-06
mg O 0 0.00015917775453999639
/ O 0 6.4218729676213115e-06
ml O 0 9.107559435506118e-07
) O 0 9.042014359472716e-10
obtained O 0 9.709791859435768e-10
from O 0 1.2028290585774926e-09
52 O 0 2.72927422884095e-08
healthy O 0 3.1394346677871e-08
volunteers O 0 4.510198436946666e-09
having O 0 1.6751412701410118e-08
phenotype O 0 2.226075139333261e-06
Hp2 O 0 1.302845362260996e-06
, O 0 8.460425693357365e-10
whereas O 0 3.3349429884310666e-09
the O 0 4.33700986235408e-09
serum O 0 3.0068267165006546e-07
Hp O 0 2.1213087109117623e-07
level O 0 2.8700077869814322e-09
of O 0 5.495282701106774e-11
an O 0 2.1951236661710283e-10
individual O 0 3.616262844730045e-10
with O 0 1.8923012046201393e-09
Hp1 O 0 9.053911344381049e-05
/ O 0 2.396552372374572e-05
Hpdel O 0 8.034787242650054e-06
was O 0 4.2818800238819676e-07
0 O 0 2.0263340161363885e-07
. O 0 6.673225527720206e-08

50 O 0 1.1332969734212384e-05
mg O 1 0.7361689209938049
/ O 0 0.00819779746234417
ml O 0 4.9126985686598346e-05
, O 0 2.0733847971854402e-09
which O 0 9.669538503231934e-10
was O 0 1.372354119233421e-09
approximately O 0 1.40595382558395e-10
half O 0 3.9847536381643067e-10
the O 0 2.4105495377568786e-10
level O 0 1.716871422807742e-09
of O 0 2.5920388058153776e-10
Hp O 0 2.685893036868947e-07
in O 0 4.807513942495234e-09
control O 0 1.311680648541369e-06
sera O 0 4.60034101479323e-07
from O 0 1.9514831972600177e-09
the O 0 7.440160487703906e-09
Hp1 O 0 5.192107892071363e-06
phenotype O 0 6.001863539495389e-07
( O 0 5.688206350384917e-09
1 O 0 8.123336669996206e-09
. O 0 9.192659966572592e-10
26 O 0 4.3086000545145e-08
+ O 0 1.3132023468642728e-07
/ O 0 2.267094259877922e-06
- O 0 1.088624344447453e-06
0 O 0 2.3727952935814756e-08
. O 0 1.4112151447420729e-09
33 O 0 1.305028547449183e-07
mg O 0 0.0013453259598463774
/ O 0 3.3710432035150006e-05
ml O 0 1.1114663720945828e-05
; O 0 1.856941089783959e-08
n O 0 2.528074105612177e-07
= O 0 3.7776939620925987e-07
9 O 0 5.8478768494296673e-08
) O 0 5.758899468411016e-10
, O 0 1.2258505321938173e-10
showing O 0 1.0041740772237517e-08
a O 0 8.945835183737927e-09
gene O 0 2.0032969132444123e-06
- O 0 9.22035633266205e-06
dosage O 0 1.6851106920512393e-05
effect O 0 4.723567599285161e-07
. O 0 7.179659888834067e-08

The O 0 2.1610816247630282e-07
other O 0 1.7844136834810342e-08
allele O 0 2.076383452731534e-06
( O 0 2.3286371941821926e-08
Hp2 O 0 7.19151501016313e-07
) O 0 1.3308746327211907e-09
of O 0 9.58042395415859e-11
individuals O 0 8.12335962385724e-11
with O 0 6.561783894021289e-10
Hp2 O 0 0.0001266127364942804
/ O 0 1.769710252119694e-05
Hpdel O 0 2.8568772449943935e-06
was O 0 3.0444351040159745e-08
found O 0 8.834780684807697e-10
to O 0 1.689627604495314e-10
have O 0 6.897941245975758e-11
, O 0 2.236505425301516e-11
in O 0 2.54145815503648e-10
all O 0 1.0178099335567126e-10
exons O 0 2.4188100411492996e-08
, O 0 1.5166942701760888e-10
no O 0 2.0593685090553038e-10
mutation O 0 1.0977529107947248e-08
, O 0 9.03282240671821e-11
by O 0 4.4074571770025273e-10
DNA O 0 1.1633684238177011e-07
sequencing O 0 4.5961749606249214e-07
. O 0 1.367005069141669e-07

On O 0 3.781475470532314e-07
the O 0 3.453962449384562e-09
basis O 0 8.451957467237037e-10
of O 0 5.859680796138633e-11
the O 0 2.996226322604656e-10
present O 0 3.6427766358926306e-10
study O 0 1.3714898661199015e-10
, O 0 3.9770828991203544e-11
the O 0 2.4908949902702204e-10
mechanism O 0 3.047407881595632e-09
of O 0 2.937747267672819e-10
anhaptoglobinemia B-Disease 0 4.899550845038902e-07
and O 0 3.6766309441382816e-10
the O 0 3.318178232181168e-10
mechanism O 0 4.494508765162664e-09
of O 0 2.0836912750787917e-10
anomalous O 0 7.799157941690282e-08
inheritance O 0 3.3191181358915856e-08
of O 0 1.762695545082238e-09
Hp O 0 7.424253453791607e-06
phenotypes O 0 7.793163376845769e-07
were O 0 1.4099674316980781e-08
well O 0 1.4103009426946755e-08
explained O 0 1.7772271121430094e-07
. O 0 6.00811773665555e-08

However O 0 5.548688477574615e-07
, O 0 8.712341958982961e-09
the O 0 3.299738038364808e-09
mechanism O 0 4.333721292937298e-08
of O 0 3.2404054994827902e-09
hypohaptoglobinemia B-Disease 0 6.839364687039051e-06
remains O 0 6.361190116876969e-07
unknown O 0 1.488636826252332e-06

ATM O 0 0.0033530867658555508
mutations O 0 0.0013388582738116384
and O 0 1.1149398915222264e-06
phenotypes O 0 0.0001708490017335862
in O 0 0.00011713537969626486
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 4.845896910410374e-07
in O 0 8.675199225649521e-09
the O 0 8.220660596691687e-09
British O 0 3.867253894895839e-07
Isles O 0 6.911870968906442e-07
: O 0 5.520666701563925e-10
expression O 0 9.697983527345855e-10
of O 0 1.1217048123679518e-10
mutant O 0 3.5540949738788186e-08
ATM O 0 4.752604070290545e-07
and O 0 3.5386013563787344e-10
the O 0 9.856455651657825e-10
risk O 0 1.0982493137134952e-08
of O 0 2.2543196198654414e-09
leukemia B-Disease 0 0.04547230899333954
, O 0 1.3817544868288678e-06
lymphoma B-Disease 1 1.0
, O 0 3.3913485708580993e-07
and O 0 1.7215970729012042e-05
breast B-Disease 1 0.9999289512634277
cancer I-Disease 0 0.00028266938170418143
. O 0 3.023602346274856e-07

We O 0 5.992261549181421e-07
report O 0 1.8211153474112507e-07
the O 0 6.743043012846783e-09
spectrum O 0 5.928049162662319e-08
of O 0 1.0707738029580582e-09
59 O 0 1.4443050133650104e-07
ATM O 0 2.6513414923101664e-05
mutations O 0 5.909742867515888e-06
observed O 0 4.012024874100462e-06
in O 0 0.00011643269681371748
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.007531092502176762
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.6026929823028695e-08
patients O 0 1.9955116670189454e-08
in O 0 1.8167841675520435e-09
the O 0 6.367524285622039e-09
British O 0 4.590164905948768e-07
Isles O 0 3.6483054373093182e-06
. O 0 8.123076611354918e-08

Of O 0 2.0381098408961407e-07
51 O 0 1.083829147319193e-06
ATM O 0 1.5367673768196255e-05
mutations O 0 2.7748096727009397e-06
identified O 0 3.170412909980769e-08
in O 0 1.9813681806368777e-09
families O 0 2.017496308903688e-10
native O 0 2.949436528343341e-10
to O 0 2.182590497223913e-10
the O 0 1.2403151838924487e-09
British O 0 3.372310288796143e-07
Isles O 0 4.2526690435806813e-07
, O 0 5.866437891022258e-10
11 O 0 1.7181587264047948e-09
were O 0 7.712464000775299e-10
founder O 0 4.892005378565045e-08
mutations O 0 7.331425422307802e-08
, O 0 6.135322805356225e-10
and O 0 7.655525657845885e-10
2 O 0 1.439674823799919e-09
of O 0 1.3373654961235104e-10
these O 0 2.9700755743711227e-10
11 O 0 1.3572041268616886e-09
conferred O 0 2.739468873969031e-09
a O 0 5.16279818896237e-09
milder O 0 4.6512177505064756e-05
clinical O 0 9.486606700193079e-07
phenotype O 0 2.1365369775594445e-06
with O 0 1.0185872145740404e-09
respect O 0 5.245178180679488e-10
to O 0 1.4321431818231645e-09
both O 0 1.8892729158892507e-08
cerebellar B-Disease 0 0.0005250420654192567
degeneration I-Disease 0 0.00028172097518108785
and O 0 3.198034548290707e-08
cellular O 0 7.187755727500189e-06
features O 0 1.2394321856845636e-05
. O 0 6.746075200680934e-07

We O 0 4.0523102029510483e-07
report O 0 6.567424293280055e-08
, O 0 4.840589595822564e-10
in O 0 4.357105787278215e-10
two O 0 2.5136239756307077e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
families O 0 6.039100775012685e-09
, O 0 2.2987503567328815e-10
an O 0 5.356164400893704e-10
ATM O 0 3.2138101232703775e-05
mutation O 0 6.021987815074681e-07
( O 0 1.0987667664608125e-08
7271T O 0 1.5312168670789106e-06
- O 0 6.3464572122029494e-06
- O 0 6.061588464945089e-06
> O 0 4.967461109117721e-07
G O 0 5.196933216211619e-06
) O 0 1.3871543913523965e-09
that O 0 6.37038810591406e-10
may O 0 2.0706746539644882e-08
be O 0 1.3627961259476962e-10
associated O 0 2.93286506192203e-10
with O 0 4.5735710357819315e-11
an O 0 9.498546393871266e-11
increased O 0 1.0701494801423905e-08
risk O 0 2.4690820055184304e-08
of O 0 9.01871466396642e-09
breast B-Disease 1 0.564527153968811
cancer I-Disease 0 1.4849842955300119e-06
in O 0 4.39029346210873e-09
both O 0 5.51084333721974e-09
homozygotes O 0 9.322747587248159e-07
and O 0 3.2324607435185726e-09
heterozygotes O 0 3.1904588126963063e-07
( O 0 5.1979736070961735e-09
relative O 0 2.7009573244640706e-08
risk O 0 3.7327673396703176e-08
12 O 0 8.197361900386113e-09
. O 0 7.343216035238243e-10
7 O 0 4.3809937011474176e-08
; O 0 2.268931353910375e-08
P O 0 0.0006999516044743359
= O 0 9.599128816262237e-07
. O 0 1.126579629584512e-08
0025 O 0 2.0457038772292435e-05
) O 0 2.2727590920368357e-09
, O 0 2.4254509511933975e-10
although O 0 4.636629136189896e-10
there O 0 6.174553229820745e-11
is O 0 5.926853452464798e-11
a O 0 8.255853223282372e-10
less O 0 2.7306644057034646e-08
severe O 0 0.0018884255550801754
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 0.00022741970315109938
in O 0 7.932981382907656e-09
terms O 0 1.7887540337824248e-09
of O 0 1.116911979570645e-10
the O 0 5.236880928904952e-10
degree O 0 4.637887407454855e-09
of O 0 6.184212697490921e-09
cerebellar B-Disease 0 0.0019292026991024613
degeneration I-Disease 0 0.010938993655145168
. O 0 1.0356507118558511e-06

This O 0 1.1386410960767535e-06
mutation O 0 2.3471226086257957e-05
( O 0 5.288263196234766e-07
7271T O 0 2.3657859856029972e-05
- O 0 4.201434421702288e-05
- O 0 1.4271750842453912e-05
> O 0 2.5758765787031734e-06
G O 0 1.580756543262396e-05
) O 0 2.619464645192693e-09
also O 0 5.333918862149289e-10
allows O 0 4.949543552790203e-10
expression O 0 1.8183234917756863e-09
of O 0 1.0195411181967984e-10
full O 0 4.27718038764624e-09
- O 0 4.489404759056015e-08
length O 0 1.0621253210274517e-08
ATM O 0 7.102148060766922e-07
protein O 0 4.708698497779551e-08
at O 0 1.5314805423827238e-08
a O 0 2.2808277488906015e-09
level O 0 3.6804077563346027e-09
comparable O 0 7.60988960735176e-09
with O 0 1.1581881981248543e-10
that O 0 2.041659341589508e-10
in O 0 3.5509355456042613e-09
unaffected O 0 4.1384777205166756e-07
individuals O 0 2.778689722759964e-09
. O 0 1.9895752600973537e-08

In O 0 1.1071757910485758e-07
addition O 0 5.059542562690922e-09
, O 0 6.497246629599829e-10
we O 0 1.2693621154191703e-10
have O 0 1.3857415215312585e-10
studied O 0 4.224214311676633e-09
18 O 0 2.9809186230522755e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.115177709238196e-07
, O 0 2.5339944031976813e-10
in O 0 5.324100049719505e-10
15 O 0 1.0802263528120193e-09
families O 0 1.5857573587574336e-10
, O 0 8.623586567058084e-11
who O 0 1.920092751461766e-09
developed O 0 3.519728352330276e-06
leukemia B-Disease 0 0.1960553675889969
, O 0 1.9865626654791413e-06
lymphoma B-Disease 1 1.0
, O 0 6.741090885498124e-08
preleukemic O 0 0.00033405335852876306
T O 0 0.009364445693790913
- O 0 3.1331051104643848e-06
cell O 0 2.6976370008924277e-06
proliferation O 0 8.324627174260968e-07
, O 0 3.335587095421033e-08
or O 0 0.0016325759934261441
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.0912438064281105e-08
mostly O 0 2.9088664810217324e-09
in O 0 2.617977479246747e-08
childhood O 0 5.906069418415427e-06
. O 0 1.2199230070564226e-07

A O 0 2.4655114430061076e-06
wide O 0 4.4596967541110644e-07
variety O 0 4.528924080204888e-08
of O 0 3.006027649021803e-09
ATM O 0 0.00019989602151326835
mutation O 0 2.251735395475407e-06
types O 0 6.888787140724162e-08
, O 0 6.736817770303105e-10
including O 0 1.048214071097675e-09
missense O 0 3.366529927006923e-05
mutations O 0 9.19254216569243e-06
and O 0 7.706248084105027e-09
in O 0 6.202217406325872e-08
- O 0 2.3539369067293592e-05
frame O 0 0.00017052282055374235
deletions O 0 4.6053716573624115e-07
, O 0 3.937714043722451e-10
were O 0 4.320148960790249e-10
seen O 0 4.818493160030357e-09
in O 0 1.2601502064057968e-09
these O 0 1.870687160732132e-09
patients O 0 1.865467957884448e-08
. O 0 4.0893336716862905e-08

We O 0 2.143317487934837e-07
also O 0 9.026183356297679e-09
show O 0 1.5187104906999593e-08
that O 0 3.8465117202513e-10
25 O 0 1.3751156879848736e-09
% O 0 6.715338701779316e-11
of O 0 2.4179437965732298e-11
all O 0 1.451337161562094e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 9.672274927652325e-07
carried O 0 2.5949802306968195e-07
in O 0 1.5338747161308675e-08
- O 0 1.3663888012160896e-06
frame O 0 1.2056352716172114e-05
deletions O 0 1.3514516012946842e-06
or O 0 5.825256010894009e-08
missense O 0 7.77213881519856e-06
mutations O 0 1.0156292091778596e-06
, O 0 2.9017274694176365e-10
many O 0 3.488313457533643e-11
of O 0 3.6562856908783914e-11
which O 0 4.199487424472181e-09
were O 0 2.041909530348107e-09
also O 0 6.065579150060785e-10
associated O 0 6.048112011214357e-10
with O 0 1.2923480341431315e-10
expression O 0 1.7476842195662812e-09
of O 0 4.0645398158289936e-10
mutant O 0 1.667421258844115e-07
ATM O 0 3.5362716062081745e-06
protein O 0 1.1156780601595528e-06
. O 0 1.4243723001072794e-07

The O 0 1.6258062487395364e-06
DMPK O 0 5.912920823902823e-05
gene O 0 5.671158305631252e-06
of O 0 9.954404589507249e-08
severely O 1 0.9967419505119324
affected O 1 0.7754024863243103
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.759589672088623
is O 0 1.0207819656216088e-07
hypermethylated O 0 2.8533935619634576e-05
proximal O 0 8.459822311124299e-06
to O 0 1.082324274648272e-08
the O 0 6.665933582894468e-09
largely O 0 4.369011108451559e-08
expanded O 0 4.535692994522833e-07
CTG O 0 2.4302788006025366e-05
repeat O 0 6.375076736730989e-06
. O 0 2.2362877416526317e-07

Using O 0 1.6371972151318914e-06
methylation O 0 3.1194827897707e-05
- O 0 1.9451301341177896e-05
sensitive O 0 3.3495289244456217e-06
restriction O 0 4.510458779805049e-07
enzymes O 0 1.8405658863684948e-07
, O 0 6.341946412469213e-10
we O 0 1.7678326857950566e-10
characterized O 0 6.108376471303245e-09
the O 0 1.6289867232899269e-09
methylation O 0 8.352515692422458e-07
pattern O 0 4.051667474413989e-06
on O 0 1.0688850693441054e-07
the O 0 6.395665774761028e-09
5 O 0 1.1855669335147923e-08
side O 0 1.0700964558907344e-08
of O 0 2.499166151803678e-10
the O 0 1.2133323679108798e-08
CTG O 0 1.91427398021915e-06
repeat O 0 9.520397270534886e-08
in O 0 2.3017523442803167e-09
the O 0 2.687594813366445e-09
DMPK O 0 4.091819505447347e-07
gene O 0 1.4859255159649365e-08
of O 0 9.807617912249711e-11
normal O 0 1.0307813269605504e-08
individuals O 0 5.900729904695368e-11
and O 0 2.525107345441313e-10
of O 0 2.1086152268701142e-10
patients O 0 1.2745333677344206e-08
affected O 0 6.328298240987351e-08
with O 0 1.1317200915073045e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.2290486728925316e-08
showing O 0 6.989325811446179e-07
expansions O 0 2.3486749967105425e-07
of O 0 1.045020070478131e-09
the O 0 1.248290182331857e-08
repetitive O 0 3.097664375673048e-05
sequence O 0 2.2998196982371155e-06
. O 0 3.6711412576551083e-07

The O 0 7.570571369797108e-07
gene O 0 1.1193805221410003e-05
segment O 0 1.5843371556911734e-06
analyzed O 0 1.8494834819193784e-07
corresponds O 0 7.776549892923867e-08
to O 0 4.677580989209673e-09
the O 0 9.224807584473638e-09
genomic O 0 1.5709377976236283e-06
SacI O 0 3.166243914165534e-05
- O 0 1.3988102409712155e-06
HindIII O 0 1.7999844885707716e-06
fragment O 0 3.707217501869309e-07
carrying O 0 2.2321449577589192e-08
exons O 0 4.922941343465936e-07
11 O 0 9.418693025509128e-08
- O 0 8.019523534130713e-07
15 O 0 1.148490937907809e-07
. O 0 4.1633764880089075e-08

There O 0 2.9982021487739985e-07
is O 0 1.2770739132861308e-08
constitutive O 0 2.681421733541356e-07
methylation O 0 8.319595394823409e-07
in O 0 3.264955950044168e-08
intron O 0 5.283744030748494e-06
12 O 0 3.7158464749609266e-08
at O 0 7.929410905660461e-09
restriction O 0 6.983600364662834e-09
sites O 0 2.315106550909718e-09
of O 0 3.936520276415223e-10
SacII O 0 6.414653626052313e-07
and O 0 2.266179466303697e-09
HhaI O 0 5.946337751083774e-07
, O 0 1.123973358829744e-09
localized O 0 7.88636782544927e-08
1 O 0 1.335750443587358e-08
, O 0 9.691991653681953e-10
159 O 0 1.543157139849427e-07
- O 0 7.953860290399462e-07
1 O 0 1.2092914225547702e-08
, O 0 3.182472063656405e-10
232 O 0 1.1884988104782224e-08
bp O 0 7.208571872752145e-08
upstream O 0 1.001335814265758e-08
of O 0 2.7290733561891045e-10
the O 0 5.97155569437291e-09
CTG O 0 1.3440251223073574e-06
repeat O 0 7.432192461465092e-08
, O 0 3.3939390187143204e-10
whereas O 0 9.172046455674376e-10
most O 0 7.700583226633029e-11
, O 0 9.848069582041319e-11
if O 0 7.729130530043093e-11
not O 0 5.824736526438556e-11
all O 0 2.20679273466029e-11
, O 0 8.991220094844987e-12
of O 0 4.685038381552209e-12
the O 0 6.199701862996676e-11
other O 0 2.0855431964728055e-11
sites O 0 4.866547720361325e-10
of O 0 8.639489817996449e-11
SacII O 0 2.446002156375471e-07
, O 0 1.0682442708187523e-09
HhaI O 0 2.817305357893929e-07
, O 0 7.496064879930486e-10
and O 0 5.781957690409456e-10
HpaII O 0 1.0632446389990946e-07
in O 0 8.014036101400279e-10
this O 0 4.5360690203999354e-10
region O 0 3.149436711424869e-09
are O 0 3.2360431001521306e-10
unmethylated O 0 2.0803385325507406e-07
, O 0 2.3125236447985031e-10
in O 0 7.090244502627741e-10
normal O 0 2.5033765282955756e-08
individuals O 0 1.2251492875758885e-10
and O 0 7.715270089470039e-11
most O 0 3.095524531149252e-11
of O 0 6.956313997052987e-11
the O 0 1.4105430601318858e-08
patients O 0 7.119237466213235e-08
. O 0 5.7411494225334536e-08

In O 0 2.658637185959378e-07
a O 0 9.766782049780431e-09
number O 0 5.267424829646927e-10
of O 0 2.1623033918949375e-10
young O 0 4.991886903837894e-09
and O 0 3.0866971201248816e-08
severely O 0 0.2298210859298706
affected O 0 3.1364902497443836e-07
patients O 0 2.8778973870657865e-08
, O 0 6.097222726708651e-10
however O 0 1.3976767521128863e-09
, O 0 1.8588740269276371e-10
complete O 0 1.588591591605848e-09
methylation O 0 3.456527863932024e-08
of O 0 1.2156475825975122e-10
these O 0 3.0915547899468265e-10
restriction O 0 4.268533526641249e-09
sites O 0 1.7007510955124872e-09
was O 0 6.339760716400633e-09
found O 0 3.4937419624014865e-10
in O 0 6.328509383202174e-10
the O 0 3.841806428539485e-09
mutated O 0 1.8410836446491885e-06
allele O 0 6.664603006356629e-06
. O 0 1.5666947206227633e-07

In O 0 2.4034505941017414e-07
most O 0 2.283317535045626e-09
of O 0 2.4628335482113073e-10
these O 0 7.960031522813438e-10
patients O 0 1.5550482013182432e-09
, O 0 9.671230483121462e-11
the O 0 7.623134901102446e-10
onset O 0 7.976017286637216e-07
of O 0 4.439348888496397e-10
the O 0 8.767287908995058e-07
disease O 0 0.16266249120235443
was O 0 0.0009755631908774376
congenital O 1 0.9992284774780273
. O 0 3.611789338719973e-07

Preliminary O 0 9.612680514692329e-06
in O 0 9.443973567613284e-07
vivo O 0 4.1802763007581234e-05
footprinting O 0 5.321424760040827e-05
data O 0 1.721933244880347e-07
gave O 0 8.134112938762428e-09
evidence O 0 1.999156395982027e-09
for O 0 2.4805216214396353e-10
protein O 0 2.3064734122613118e-08
- O 0 8.291778641478231e-08
DNA O 0 4.311361934128399e-08
contact O 0 7.013183278559154e-08
in O 0 2.1994750465381685e-09
normal O 0 3.595372177755962e-08
genes O 0 3.348546329107194e-08
at O 0 2.0143991363852365e-08
an O 0 1.283916639671645e-09
Sp1 O 0 3.093749683102942e-07
consensus O 0 4.8549049225243834e-09
binding O 0 1.7930727125303747e-08
site O 0 7.533306423113117e-09
upstream O 0 3.6046332585470964e-09
of O 0 2.3839388796353944e-10
the O 0 4.8935242524805744e-09
CTG O 0 1.3861905472367653e-06
repeat O 0 9.128788747148064e-08
and O 0 2.3735940990476934e-10
for O 0 2.522121747561279e-11
a O 0 1.2066106447328195e-10
significant O 0 1.560190032723341e-10
reduction O 0 5.885827936147336e-10
of O 0 3.2192411930642706e-11
this O 0 1.1698084168010325e-10
interaction O 0 7.913829591643662e-10
in O 0 2.1301052033351198e-09
cells O 0 8.032648324274305e-09
with O 0 1.0185872145740404e-09
a O 0 1.91036946262102e-08
hypermethylated O 0 7.2977159106812906e-06
DMPK O 0 5.757017333962722e-06
gene O 0 6.984348033256538e-07
. O 0 1.4543168447289645e-08
. O 0 5.048497797588425e-08

The O 0 1.6318927009706385e-05
hemochromatosis B-Disease 1 0.9999998807907104
gene O 0 4.8763849918032065e-05
product O 0 7.737297664789367e-07
complexes O 0 1.9349027979842504e-07
with O 0 2.1588595355837015e-09
the O 0 8.551819696833718e-09
transferrin O 0 1.153440621237678e-06
receptor O 0 2.3517162617281429e-07
and O 0 1.0016069751372925e-08
lowers O 0 1.5169496236921987e-06
its O 0 2.482008820692272e-09
affinity O 0 9.891262919836663e-09
for O 0 2.7329696838940265e-10
ligand O 0 7.10685057470073e-08
binding O 0 3.3144024769171665e-07
. O 0 1.388937391766376e-07

We O 0 4.497156851357431e-07
recently O 0 4.972447413820191e-07
reported O 0 1.9787844962593226e-07
the O 0 4.5904693379839046e-09
positional O 0 2.515467372177227e-07
cloning O 0 3.380904090022341e-08
of O 0 2.038690327665904e-10
a O 0 2.756466388476042e-09
candidate O 0 3.4823354866375666e-08
gene O 0 2.787192443065578e-06
for O 0 8.451802955278254e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.007843692786991596
HFE O 0 0.32468438148498535
. O 0 2.238789420516696e-06

The O 0 1.8889815578404523e-07
gene O 0 1.167979007732356e-06
product O 0 3.4819237271221937e-08
, O 0 2.9313215743620447e-10
a O 0 7.365337229003899e-10
member O 0 7.857786643583609e-10
of O 0 4.9676616986626954e-11
the O 0 2.3143074123765928e-09
major O 0 6.522804518738212e-09
histocompatibility O 0 4.58684809245824e-07
complex O 0 5.834629845935524e-08
class O 0 2.281155673244939e-07
I O 0 8.150691428454593e-06
- O 0 8.202758863262716e-07
like O 0 7.642063870605398e-09
family O 0 9.402230105592935e-09
, O 0 1.2741965815799006e-10
was O 0 1.719086539786474e-09
found O 0 9.180530641250684e-11
to O 0 1.2799696025300733e-10
have O 0 9.600435724177458e-11
a O 0 1.4194649899934575e-09
mutation O 0 1.8082707242683682e-07
, O 0 4.5311856489149704e-09
Cys O 0 7.581093086628243e-05
- O 0 1.4224353890313068e-06
282 O 0 2.0937422959832475e-06
- O 0 2.2795256882091053e-05
- O 0 1.4339978406496812e-05
> O 0 1.6721427300581126e-06
Tyr O 0 1.6745522088967846e-06
( O 0 1.0134542094419885e-08
C282Y O 0 4.8668027829990024e-08
) O 0 4.956137167333452e-10
, O 0 4.61835673870592e-11
in O 0 1.6575604777635533e-10
85 O 0 3.9637133575354255e-09
% O 0 2.0269111389303873e-10
of O 0 2.1218887757967764e-10
patient O 0 1.679223942119279e-07
chromosomes O 0 1.126600977841008e-06
. O 0 2.392110900473199e-07

This O 0 4.0493432607036084e-07
mutation O 0 4.176255970378406e-06
eliminates O 0 6.949678663659142e-07
the O 0 1.1217808015828723e-08
ability O 0 3.007956195233419e-08
of O 0 1.3683290056576425e-09
HFE O 0 1.5852825526962988e-05
to O 0 5.002781744423146e-09
associate O 0 7.023889914137271e-09
with O 0 2.7395001822583254e-09
beta2 O 0 0.0002331976284040138
- O 0 7.963624375406653e-05
microglobulin O 0 0.0002162349846912548
( O 0 4.318522073276654e-08
beta2m O 0 2.204471456934698e-06
) O 0 1.5038762457564303e-09
and O 0 6.213258796350374e-10
prevents O 0 6.805333629955612e-09
cell O 0 5.106128355691908e-07
- O 0 2.2802798866905505e-06
surface O 0 3.8233730492720497e-07
expression O 0 4.195918847926805e-07
. O 0 9.007681711636906e-08

A O 0 1.2827126738557126e-06
second O 0 1.6461716256799264e-07
mutation O 0 5.548508283936826e-07
that O 0 6.938348784402137e-10
has O 0 8.035096477065906e-10
no O 0 5.586893170317353e-10
effect O 0 1.0255041260620601e-08
on O 0 7.335663809726611e-08
beta2m O 0 3.4211207093903795e-06
association O 0 8.56247783787012e-09
, O 0 5.700802052643894e-10
H63D O 0 7.613521688654146e-07
, O 0 4.315734714044339e-10
was O 0 6.239889049908243e-09
found O 0 4.04951239207918e-10
in O 0 3.610012011545649e-10
eight O 0 5.653310597431016e-10
out O 0 4.774313722144541e-10
of O 0 9.951999641044651e-11
nine O 0 3.7187233292712563e-09
patients O 0 4.510241069510812e-09
heterozygous O 0 4.6760668226397684e-08
for O 0 3.1232935682190544e-10
the O 0 4.752112037209599e-09
C282Y O 0 2.0777381450898247e-06
mutant O 0 2.4205005502153654e-06
. O 0 2.5510240675430396e-07

In O 0 1.920042933534205e-07
this O 0 5.1150927937726465e-09
report O 0 2.013500122188816e-08
, O 0 3.174378815362644e-10
we O 0 1.2450646069694926e-10
demonstrate O 0 6.4553840051218e-10
in O 0 2.0000490152938255e-09
cultured O 0 1.4670999348709302e-07
293 O 0 2.692594307518448e-07
cells O 0 1.4278064952577552e-07
overexpressing O 0 5.1397787501628045e-06
wild O 0 1.6179089357137855e-07
- O 0 1.0044096597994212e-05
type O 0 1.4843250028206967e-05
or O 0 4.343469228729191e-08
mutant O 0 2.45467646209363e-07
HFE O 0 2.544406015658751e-06
proteins O 0 7.4350534617906305e-09
that O 0 1.3669847198638507e-10
both O 0 2.2227787666029286e-10
the O 0 9.346190488201955e-10
wild O 0 4.094828653933291e-08
- O 0 7.145122708607232e-06
type O 0 1.8607934180181473e-05
and O 0 2.7985624484472282e-08
H63D O 0 3.70223460777197e-05
HFE O 0 1.3844038221577648e-05
proteins O 0 6.556472698093785e-08
form O 0 2.1865679045163233e-08
stable O 0 7.291930046449124e-07
complexes O 0 2.889734318500814e-08
with O 0 4.501249928345885e-10
the O 0 1.0053814669674921e-08
transferrin O 0 2.5270378500863444e-06
receptor O 0 1.8015626892520231e-06
( O 0 1.4989591079483944e-07
TfR O 0 1.1786396498791873e-05
) O 0 6.149516451614545e-08
. O 0 1.0152171370236829e-07

The O 0 1.3032952210778603e-06
C282Y O 0 1.8227958207717165e-05
mutation O 0 5.375294676923659e-06
nearly O 0 1.4036676532214187e-07
completely O 0 1.0798090954722284e-07
prevents O 0 1.3874408288927498e-08
the O 0 1.6482483156110561e-09
association O 0 2.7174398287144186e-09
of O 0 8.419388103364511e-11
the O 0 2.278731647820109e-09
mutant O 0 3.4906256018985005e-07
HFE O 0 7.206624559330521e-06
protein O 0 7.101213839177944e-08
with O 0 3.2288498541532817e-09
the O 0 1.145518808698398e-07
TfR O 0 7.260771235451102e-05
. O 0 9.904652387149326e-08

Studies O 0 2.4696578293514904e-06
on O 0 4.065079224346846e-07
cell O 0 5.849388344358886e-06
- O 0 2.160101985282381e-06
associated O 0 1.2436257179615495e-07
transferrin O 0 7.137999773476622e-07
at O 0 3.922291469393713e-08
37 O 0 3.011883009662597e-08
degrees O 0 3.598761466605538e-08
C O 0 1.6924858528000186e-06
suggest O 0 1.0009385320586262e-08
that O 0 4.3885831080281434e-10
the O 0 5.491788357403493e-09
overexpressed O 0 3.4695649446803145e-06
wild O 0 8.597945111432637e-08
- O 0 3.5042214676650474e-06
type O 0 5.5954797062440775e-06
HFE O 0 2.0596376998582855e-05
protein O 0 1.6794834323263785e-07
decreases O 0 3.164166173519334e-08
the O 0 1.0508806047582198e-09
affinity O 0 1.1306609870587181e-08
of O 0 4.880397752593524e-10
the O 0 1.344807731840092e-08
TfR O 0 2.585874426586088e-06
for O 0 7.542032776086671e-09
transferrin O 0 3.7686945688619744e-06
. O 0 1.2710781049918296e-07

The O 0 1.5740090475446777e-06
overexpressed O 0 0.00018620374612510204
H63D O 0 4.311149677960202e-05
protein O 0 5.216748490965983e-07
does O 0 1.680463057596171e-08
not O 0 5.211949205552457e-10
have O 0 5.831116839383199e-11
this O 0 5.868382862983523e-11
effect O 0 2.6966218147350673e-09
, O 0 4.9465018886474255e-11
providing O 0 3.419466793053161e-11
the O 0 9.884049828601249e-11
first O 0 1.3479263538673791e-10
direct O 0 2.4711524493348236e-10
evidence O 0 1.6715584472137834e-10
for O 0 4.6190613833818617e-11
a O 0 1.3460772496642903e-09
functional O 0 7.655281741847375e-09
consequence O 0 2.034197255085246e-09
of O 0 2.2909765751144562e-10
the O 0 1.9661072769849852e-08
H63D O 0 5.498026803252287e-05
mutation O 0 3.015139100170927e-06
. O 0 1.873166297627904e-07

Addition O 0 3.286857008788502e-07
of O 0 3.733906694947109e-08
soluble O 0 2.502823463146342e-06
wild O 0 1.38678160510608e-06
- O 0 0.0003525389183778316
type O 0 0.02526095137000084
HFE O 1 0.9777581095695496
/ O 0 0.0007457858300767839
beta2m O 0 2.5977387849707156e-05
heterodimers O 0 5.443424925033469e-06
to O 0 2.1847460729418344e-08
cultured O 0 7.970337492224644e-07
cells O 0 2.028693018019112e-07
also O 0 4.413179599538353e-09
decreased O 0 2.940452326072318e-08
the O 0 9.460509042824583e-10
apparent O 0 9.469252049143506e-09
affinity O 0 6.76434952495697e-09
of O 0 3.0124203131975946e-10
the O 0 4.387648022685653e-09
TfR O 0 4.178021981715574e-07
for O 0 1.427931106690039e-10
its O 0 5.685491522022801e-10
ligand O 0 4.724691304858197e-09
under O 0 1.2275029881436694e-09
steady O 0 4.132246544941154e-07
- O 0 1.4539706683081022e-07
state O 0 1.1135643518400684e-09
conditions O 0 1.3975441248703646e-08
, O 0 7.570128551792621e-11
both O 0 6.770809607425932e-11
in O 0 3.5979205725844565e-10
293 O 0 1.6640939293210977e-08
cells O 0 1.1256666709869023e-08
and O 0 1.8048132988113252e-09
in O 0 1.1562734769654526e-08
HeLa O 0 8.966369023255538e-06
cells O 0 1.1151121270813746e-06
. O 0 2.8443778887776716e-07

Furthermore O 0 4.363466359791346e-06
, O 0 3.982075824637832e-08
at O 0 7.059955464683298e-08
4 O 0 4.292874677958025e-08
degrees O 0 2.028416332677807e-07
C O 0 4.047921902383678e-05
, O 0 8.386568106644177e-10
the O 0 2.8176927457934653e-09
added O 0 6.287847753583264e-08
soluble O 0 9.681155432872401e-08
complex O 0 1.9621138491743295e-08
of O 0 8.446385812987955e-09
HFE O 0 0.0026184527669101954
/ O 0 2.354830394324381e-05
beta2m O 0 6.558600489370292e-06
inhibited O 0 6.003833163958916e-07
binding O 0 4.610108206293262e-08
of O 0 1.2913138336401175e-09
transferrin O 0 8.360875654034317e-07
to O 0 8.819312391494805e-09
HeLa O 0 3.9988840399018954e-06
cell O 0 1.6655505987728247e-06
TfR O 0 1.533854856461403e-06
in O 0 2.148671685020531e-09
a O 0 6.648385841856452e-09
concentration O 0 3.968931991948921e-07
- O 0 9.840118764259387e-07
dependent O 0 1.131645319674135e-07
manner O 0 6.011441655573435e-07
. O 0 1.6268147362552554e-07

Scatchard O 0 0.00020427284471224993
plots O 0 1.6160906852746848e-06
of O 0 1.8846291194307696e-09
these O 0 4.105890905048426e-10
data O 0 9.68231450571011e-09
indicate O 0 7.672457336127536e-09
that O 0 2.029073575826601e-10
the O 0 2.0161585734257415e-09
added O 0 1.4948200899311814e-08
heterodimer O 0 2.0782445631084556e-07
substantially O 0 1.644533540456905e-07
reduced O 0 1.423233975117455e-08
the O 0 2.178864644264422e-09
affinity O 0 9.549165014277605e-09
of O 0 2.357667616692538e-09
TfR O 0 2.5316066967207007e-06
for O 0 4.950971188577569e-09
transferrin O 0 3.133511427222402e-06
. O 0 1.0415982387712575e-07

These O 0 1.1287050227792861e-07
results O 0 4.8348919534646484e-08
establish O 0 3.001302673055761e-08
a O 0 6.338297886543387e-09
molecular O 0 9.69780700188494e-08
link O 0 4.7467605668316537e-07
between O 0 3.443945573167184e-08
HFE O 0 0.00011173446546308696
and O 0 1.5867261948798728e-09
a O 0 9.875159578953685e-10
key O 0 3.903467327148746e-09
protein O 0 5.242980272157638e-09
involved O 0 9.054630378813044e-10
in O 0 4.7474375541867175e-09
iron O 0 6.44497231405694e-06
transport O 0 4.6448103141472075e-09
, O 0 3.0072364043398636e-10
the O 0 2.3684127992140702e-09
TfR O 0 1.2230058246132103e-06
, O 0 4.144104781556024e-10
and O 0 5.556234916603842e-10
raise O 0 2.5528570368749115e-09
the O 0 3.3419711442661537e-10
possibility O 0 1.1112729625395446e-09
that O 0 2.0756867058491224e-10
alterations O 0 2.3816959071609745e-08
in O 0 8.418846175750616e-10
this O 0 6.618194881014006e-10
regulatory O 0 4.1881708057189826e-07
mechanism O 0 3.6203937270329334e-07
may O 0 1.315798527912193e-07
play O 0 2.1753767676102598e-09
a O 0 7.432015003416836e-10
role O 0 7.909317645271585e-10
in O 0 7.421306347232814e-10
the O 0 3.3349047967590195e-09
pathogenesis O 0 8.695278665982187e-07
of O 0 1.068336814569193e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 5.271676855045371e-07
. O 0 2.285755016373514e-07

Genomic O 0 4.340016675996594e-05
organization O 0 2.4233477802226844e-07
of O 0 6.20601392498088e-09
the O 0 6.343706360212309e-08
UBE3A O 0 0.0004389431851450354
/ O 0 6.0380803915904835e-05
E6 O 0 1.1370491847628728e-05
- O 0 2.659427082107868e-05
AP O 0 4.0296814404428005e-05
gene O 0 1.0678311355150072e-06
and O 0 6.307135702598998e-09
related O 0 5.791532586840731e-08
pseudogenes O 0 5.976736701995833e-06
. O 0 4.3994367615596275e-07

The O 0 2.4984212814160855e-06
UBE3A O 0 0.0005851360619999468
gene O 0 9.627929102862254e-06
encodes O 0 1.599286974851566e-06
the O 0 4.681920984239696e-08
E6 O 0 6.345113888528431e-06
- O 0 1.2313525076024234e-05
AP O 0 3.796998134930618e-05
ubiquitin O 0 5.118119588587433e-06
- O 0 5.06025003232935e-07
protein O 0 1.43058557000586e-07
ligase O 0 9.415549584446126e-08
and O 0 3.3325202597467296e-09
has O 0 2.2671564625653673e-09
recently O 0 8.489413616530328e-09
been O 0 5.276424297484539e-10
shown O 0 5.310975548233898e-10
to O 0 3.485987332130236e-10
be O 0 1.1975913594142185e-09
mutated O 0 3.4589331789902644e-06
in O 0 0.019689051434397697
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 8.597413398092613e-06
who O 0 1.9554114771835884e-08
lack O 0 3.6885474230530235e-08
15q11 O 0 4.604722107615089e-06
- O 0 2.364876309002284e-06
q13 O 0 4.753769189846935e-06
deletions O 0 4.419130618771305e-06
or O 0 2.4301726853082073e-07
chromosome O 0 1.4063185517443344e-05
15 O 0 4.918032914247306e-07
paternal O 0 0.0001451504067517817
uniparental B-Disease 0 0.006842461880296469
disomy I-Disease 0 0.0008872830658219755
. O 0 2.0709728687506868e-06

Previous O 0 2.3538786990684457e-05
UBE3A O 0 0.00027130075613968074
cDNA O 0 1.3627368389279582e-05
analysis O 0 1.652266234941635e-07
has O 0 8.176187726860462e-09
shown O 0 7.835894599850235e-09
a O 0 1.1268159738619943e-08
coding O 0 5.683143626811216e-07
region O 0 2.8390788386900567e-08
of O 0 9.411017520832843e-10
approximately O 0 1.4589760510830274e-08
2 O 0 1.0512844283994127e-07
. O 0 8.437421428197922e-08

6 O 0 5.3049672715133056e-05
kb O 0 6.939208833500743e-05
and O 0 3.6077992149330385e-08
a O 0 4.080654392168981e-08
3 O 0 8.792080734565388e-07
- O 0 2.6345627702539787e-05
untranslated O 0 1.0719885722210165e-05
region O 0 2.726964396515541e-07
( O 0 4.803676034725868e-08
UTR O 0 1.4019675518284203e-06
) O 0 2.603505411258311e-09
of O 0 4.6110709694957563e-10
< O 0 4.953004761887314e-08
50 O 0 8.265532258633357e-09
bp O 0 1.7282111741678818e-07
, O 0 4.168187739406193e-10
whereas O 0 3.6012179904787445e-09
Northern O 0 1.23668275620048e-08
analysis O 0 8.089197756078192e-09
has O 0 1.5664017860572699e-09
indicated O 0 1.7330066270915268e-08
mRNA O 0 3.135269466270074e-08
sizes O 0 1.1806108091150236e-07
of O 0 9.861721439463622e-10
5 O 0 1.8237710719404276e-07
- O 0 1.6529909771634266e-05
8 O 0 1.2072562185494462e-06
kb O 0 6.629907875321805e-05
. O 0 1.51841007323128e-07

We O 0 1.2055586751102965e-07
have O 0 1.2869960652750478e-09
analyzed O 0 9.572890036224635e-09
additional O 0 1.35614830476527e-09
cDNA O 0 1.1053484882950215e-07
clones O 0 1.6180509021523903e-07
and O 0 4.392921304496866e-10
provide O 0 8.664970130300986e-11
evidence O 0 1.8356167974520332e-10
for O 0 5.280952758424107e-11
an O 0 2.0188742344551258e-10
additional O 0 2.3799509030197896e-09
0 O 0 8.71005383373813e-08
. O 0 5.055560947653248e-08

5 O 0 1.7980157281272113e-05
kb O 0 7.947934500407428e-05
of O 0 3.4243999635918954e-08
5 O 0 2.6266963004673016e-07
- O 0 2.159669520551688e-06
UTR O 0 7.804895176377613e-06
and O 0 3.722926678051408e-08
> O 0 4.2280734646737983e-07
2 O 0 9.00225458622117e-08
kb O 0 4.3574282244662754e-06
of O 0 4.86850870728972e-09
3 O 0 6.677324790871353e-07
- O 0 3.336330337333493e-05
UTR O 0 6.421597208827734e-05
. O 0 6.646752126471256e-07

We O 0 1.8631571663263458e-07
have O 0 2.775818686018283e-09
established O 0 2.777863050695828e-09
the O 0 4.1280587281811165e-10
genomic O 0 2.3726052233996597e-08
organization O 0 1.6270365055248703e-09
of O 0 4.4063142023986757e-10
UBE3A O 0 2.158302322641248e-06
and O 0 1.0965282015718003e-09
the O 0 3.5151381805320625e-10
sequence O 0 1.0287720009216628e-08
of O 0 2.009018507109772e-09
intron O 0 4.074905882589519e-05
- O 0 1.6999245417537168e-05
exon O 0 9.823834261624143e-06
borders O 0 2.311835260115913e-06
. O 0 3.4598696174725774e-07

We O 0 4.193750271497265e-07
have O 0 4.568928790860127e-09
also O 0 1.8618413477611284e-09
mapped O 0 6.000340846412655e-08
two O 0 4.3811901329071645e-10
highly O 0 5.529099400547466e-09
homologous O 0 1.0508333048164786e-07
processed O 0 8.630444625623568e-08
pseudogenes O 0 2.756776211754186e-07
, O 0 4.265676700754284e-09
UBE3AP1 O 0 1.4812981135037262e-06
and O 0 3.756484900918622e-09
UBE3AP2 O 0 1.0399719485576497e-06
, O 0 7.061632389948613e-10
to O 0 1.380118686000742e-09
chromosomes O 0 3.9107348470679426e-08
2 O 0 5.227084098891055e-09
and O 0 7.25011106705864e-10
21 O 0 4.505907647001095e-09
, O 0 6.996605378395415e-11
respectively O 0 1.4377566914802742e-09
, O 0 2.1720918119694232e-10
and O 0 4.937878994581979e-10
determined O 0 7.3501142949794485e-09
their O 0 3.1006446299386425e-09
genomic O 0 4.458344449176366e-07
organization O 0 9.787448362885698e-08
. O 0 6.520965456502381e-08

These O 0 8.093970649269977e-08
results O 0 8.030400522329728e-08
will O 0 1.114214498443289e-09
form O 0 2.8906688154251015e-10
the O 0 1.974417990213695e-10
basis O 0 2.2934687482489835e-10
for O 0 4.233421252441971e-11
studies O 0 1.4856518792960571e-10
of O 0 9.964212094315528e-11
mutation O 0 1.1476566186274795e-07
and O 0 6.9637549060530546e-09
imprinting O 0 2.6069960767927114e-06
of O 0 1.8038367244344045e-08
UBE3A O 0 0.00022265124425757676
. O 0 3.986031629210629e-07

Mutation O 0 0.000382009195163846
spectrum O 0 2.15341970033478e-05
and O 0 1.3437109203096043e-07
genotype O 0 9.515241981716827e-05
- O 0 8.411338058067486e-05
phenotype O 0 6.114695133874193e-05
analyses O 0 1.0350582897444838e-06
in O 0 2.9846765414731635e-07
Cowden B-Disease 1 0.8997628688812256
disease I-Disease 0 0.0011407568817958236
and O 0 1.224110377506804e-07
Bannayan B-Disease 1 0.99822598695755
- I-Disease 1 0.9999984502792358
Zonana I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
, O 0 1.8536253421075344e-08
two O 0 4.854555868405441e-08
hamartoma B-Disease 1 0.7671559453010559
syndromes I-Disease 0 0.0006087563815526664
with O 0 2.286967344389268e-07
germline O 0 0.003368774661794305
PTEN O 0 0.009560766629874706
mutation O 0 0.000458122871350497
. O 0 2.8838267098763026e-06

The O 0 3.4277967642992735e-05
tumour B-Disease 1 0.9999998807907104
suppressor O 0 0.0077952006831765175
gene O 0 0.00011069768515881151
PTEN O 0 0.0001758159778546542
, O 0 1.743662814135405e-08
which O 0 2.2899731000336487e-09
maps O 0 4.6788681373755026e-08
to O 0 1.1884694117725303e-08
10q23 O 0 4.463834102352848e-06
. O 0 1.8680570690321474e-07

3 O 0 3.0095000056462595e-06
and O 0 2.218050632052382e-08
encodes O 0 1.3362834749841568e-07
a O 0 1.6190721652264983e-08
403 O 0 1.187409495173597e-07
amino O 0 1.4581866025764612e-07
acid O 0 1.7023008069827483e-07
dual O 0 5.103178182253032e-07
specificity O 0 9.864209005172597e-07
phosphatase O 0 0.0003854766546282917
( O 0 1.5428894073465926e-07
protein O 0 2.7142043563799234e-06
tyrosine O 0 7.829515379853547e-05
phosphatase O 0 0.0007570587913505733
; O 0 1.1538416799794504e-07
PTPase O 0 2.8507238312158734e-06
) O 0 3.918102287059355e-09
, O 0 5.915291589886351e-10
was O 0 6.431998933464911e-09
shown O 0 4.853664581361272e-09
recently O 0 1.3743140847566337e-08
to O 0 5.524564139491872e-10
play O 0 4.562605848690282e-09
a O 0 3.354886368711618e-09
broad O 0 1.8415907021562816e-08
role O 0 9.473587248010062e-09
in O 0 1.3530124576277558e-08
human O 0 7.237876076260363e-08
malignancy B-Disease 0 1.2626751413336024e-05
. O 0 1.7473125524247735e-07

Somatic O 0 0.00248121889308095
PTEN O 0 0.00789609644562006
deletions O 0 0.0006336910300888121
and O 0 5.758882366535545e-07
mutations O 0 7.989020559762139e-06
were O 0 1.628574253231818e-08
observed O 0 5.0537387608073914e-08
in O 0 1.1081198181273066e-08
sporadic B-Disease 0 0.0028227106668055058
breast I-Disease 1 0.5034036636352539
, I-Disease 0 5.4257913717492556e-08
brain I-Disease 0 0.005972619168460369
, I-Disease 0 2.0984990101169387e-07
prostate I-Disease 1 0.968798816204071
and I-Disease 0 5.318753210303839e-06
kidney I-Disease 0 0.014521017670631409
cancer I-Disease 0 0.0005672651459462941
cell O 0 3.748843664652668e-05
lines O 0 1.4403655768546741e-05
and O 0 1.5695750255062535e-09
in O 0 6.481045145001474e-10
several O 0 1.4046894758479311e-09
primary O 0 4.7518335577478865e-07
tumours B-Disease 1 0.9999934434890747
such O 0 3.2408813410711446e-09
as O 0 7.994324732862879e-06
endometrial B-Disease 1 0.9999938011169434
carcinomas I-Disease 1 1.0
, O 1 0.7980973124504089
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9995319843292236
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 7.447073585353792e-06

In O 0 5.077943114883965e-07
addition O 0 3.6185500817964567e-08
, O 0 1.0175741138596095e-08
PTEN O 0 6.687855147902155e-06
was O 0 6.5917198810439e-08
identified O 0 3.6426952565449255e-09
as O 0 2.1554638629517342e-10
the O 0 1.115154302233634e-09
susceptibility O 0 9.054949146047875e-08
gene O 0 8.237804394184423e-08
for O 0 3.892204336608529e-09
two O 0 2.18718568589793e-07
hamartoma B-Disease 1 0.9999878406524658
syndromes I-Disease 1 0.9999397993087769
Cowden B-Disease 1 0.9999721050262451
disease I-Disease 1 0.9999923706054688
( O 0 1.1996435205219314e-06
CD B-Disease 0 0.0006749638705514371
; O 0 2.544146013860882e-07
MIM O 0 5.2053230319870636e-05
158350 O 0 2.6948446247843094e-06
) O 0 1.9969775166828185e-08
and O 0 2.1853587384157436e-08
Bannayan B-Disease 0 0.000248337077209726
- I-Disease 0 0.00028103854856453836
Zonana I-Disease 0 0.0012054339749738574
( I-Disease 0 5.566502636611403e-07
BZS I-Disease 0 1.4845345503999852e-05
) I-Disease 0 3.3172700142358735e-08
or I-Disease 0 6.092356841236324e-08
Ruvalcaba I-Disease 0 4.254948362358846e-05
- I-Disease 0 3.440116415731609e-05
Riley I-Disease 0 0.0002605356858111918
- I-Disease 1 0.9921165108680725
Smith I-Disease 1 0.9617487192153931
syndrome I-Disease 1 0.9999942779541016
( O 0 2.1168747821320721e-07
MIM O 0 0.00011646168422885239
153480 O 0 1.0925298738584388e-05
) O 0 1.1802482902112388e-07
. O 0 1.3339713689219934e-07

Constitutive O 0 3.66559652320575e-05
DNA O 0 4.206743142276537e-06
from O 0 1.372556823753257e-07
37 O 0 2.4161386136256624e-07
CD B-Disease 0 1.8383466340310406e-06
families O 0 3.918289248616702e-09
and O 0 1.216200140596868e-09
seven O 0 2.245728047967077e-09
BZS B-Disease 0 1.4915782458047033e-06
families O 0 3.3110925112822542e-09
was O 0 1.9126954242665306e-08
screened O 0 1.903891444499095e-07
for O 0 1.8002518586968108e-08
germline O 0 7.169127638917416e-05
PTEN O 0 0.0005361504154279828
mutations O 0 6.735635543009266e-05
. O 0 7.739599823253229e-07

PTEN O 0 0.00958350207656622
mutations O 0 0.0008754167938604951
were O 0 1.6756690968122712e-07
identified O 0 2.4462254444301834e-08
in O 0 2.3373398772008613e-09
30 O 0 3.705949769283734e-09
of O 0 1.5094676897309256e-10
37 O 0 1.8700422543815876e-08
( O 0 1.9083945534958957e-09
81 O 0 2.4398415732207468e-08
% O 0 7.379751254532607e-10
) O 0 6.245243766578312e-10
CD B-Disease 0 2.6089333005074877e-06
families O 0 1.0332313893357536e-09
, O 0 9.346613066840703e-11
including O 0 2.7144028691417077e-10
missense O 0 1.0350426009608782e-06
and O 0 1.4546746029964197e-08
nonsense O 0 1.0397061487310566e-06
point O 0 9.162472736079508e-08
mutations O 0 9.366914923703007e-07
, O 0 3.332857323457006e-09
deletions O 0 4.235745905134536e-07
, O 0 2.036883994804839e-09
insertions O 0 1.4436191975164547e-07
, O 0 1.5920648133160853e-09
a O 0 1.883573474970035e-08
deletion O 0 1.2201027857372537e-05
/ O 0 8.027144758671056e-06
insertion O 0 5.03662931805593e-07
and O 0 2.551407618511803e-08
splice O 0 9.272160968976095e-05
site O 0 3.6290537082095398e-06
mutations O 0 1.7767739336704835e-05
. O 0 2.696310161809379e-07

These O 0 8.422259156759537e-08
mutations O 0 1.8100683973898413e-06
were O 0 4.431043976182991e-09
scattered O 0 1.496814405754776e-08
over O 0 2.722690295442476e-09
the O 0 3.6781340195801704e-09
entire O 0 1.095000978779126e-08
length O 0 1.0817608142588142e-08
of O 0 5.690872773023159e-10
PTEN O 0 2.2200117655302165e-06
, O 0 2.76587641678816e-10
with O 0 4.821090054951682e-11
the O 0 2.0724585936271467e-10
exception O 0 2.7461008467177805e-10
of O 0 1.3454188284300894e-11
the O 0 2.09500097825277e-10
first O 0 1.379786951360984e-09
, O 0 1.7458941237169512e-10
fourth O 0 2.0962502844668052e-08
and O 0 2.4546185084517447e-09
last O 0 1.504604938418197e-07
exons O 0 3.7780182537971996e-06
. O 0 2.0054673655067745e-07

A O 0 4.8304400479537435e-06
hot O 0 8.316625098814256e-06
spot O 0 5.426929305940575e-07
for O 0 9.194979888604848e-09
PTEN O 0 1.695931496215053e-05
mutation O 0 6.209366461007448e-07
in O 0 1.6444433370566003e-08
CD B-Disease 0 8.848937795846723e-06
was O 0 4.342400572454608e-08
identified O 0 1.928365245262853e-09
in O 0 2.1966406471563005e-09
exon O 0 3.0144525453579263e-07
5 O 0 1.547772754406651e-08
that O 0 2.2049005676816336e-10
contains O 0 2.610910154743351e-09
the O 0 6.998815305081507e-09
PTPase O 0 2.0474972188821994e-06
core O 0 1.144895236393495e-07
motif O 0 1.403110871933677e-07
, O 0 2.290661965664853e-10
with O 0 1.2997790344027038e-10
13 O 0 1.2776676383552399e-09
of O 0 1.0710836384486555e-10
30 O 0 3.4597846809703015e-09
( O 0 1.4559896621690882e-09
43 O 0 6.838996036151457e-09
% O 0 6.215392089892191e-10
) O 0 1.0479181966616125e-09
CD B-Disease 0 5.198033704800764e-06
mutations O 0 1.871337929060246e-07
identified O 0 5.705265149202887e-09
in O 0 3.4420721828354317e-09
this O 0 9.158712899193233e-09
exon O 0 7.718585948168766e-06
. O 0 2.567655315033335e-07

Seven O 0 4.220640619223559e-07
of O 0 4.839400880030098e-09
30 O 0 1.9022321495754113e-08
( O 0 4.289312016680924e-09
23 O 0 1.1461643190102677e-08
% O 0 1.698928081550477e-10
) O 0 1.8642426491410902e-10
were O 0 3.895269107268007e-10
within O 0 4.785126184181365e-10
the O 0 4.422069377341131e-09
core O 0 8.767943171505976e-08
motif O 0 8.677105967080934e-08
, O 0 1.9374706006214382e-10
the O 0 4.1798428607187077e-10
majority O 0 8.826712694087746e-10
( O 0 2.262843940004089e-10
five O 0 5.5875297444440974e-11
of O 0 4.993186766832913e-11
seven O 0 5.026720151235509e-10
) O 0 1.7418062825402814e-10
of O 0 1.2686916794901748e-10
which O 0 2.2811408317835458e-09
were O 0 4.283238208557805e-09
missense O 0 1.24746884466731e-06
mutations O 0 1.582688042844893e-07
, O 0 5.879207676251497e-10
possibly O 0 7.680407421162272e-09
pointing O 0 3.4902619461263384e-08
to O 0 1.3952422550644883e-09
the O 0 1.243733671607572e-09
functional O 0 2.979302804462236e-09
significance O 0 1.290727746905418e-09
of O 0 1.4902894196477945e-10
this O 0 8.465219636377697e-10
region O 0 4.8747459402420645e-08
. O 0 7.51978603830139e-08

Germline O 0 0.06615552306175232
PTEN O 0 0.17755375802516937
mutations O 0 0.003380844835191965
were O 0 1.4009687276939076e-07
identified O 0 4.3793562554128584e-08
in O 0 3.0606659429111005e-09
four O 0 7.287057623983628e-10
of O 0 9.993657290596758e-11
seven O 0 2.478886207413211e-09
( O 0 3.4846991958659146e-09
57 O 0 2.6448894629993447e-08
% O 0 1.5084151705480053e-09
) O 0 2.8804880702892888e-09
BZS B-Disease 0 1.5816499399079476e-06
families O 0 1.046891817679807e-08
studied O 0 1.02526399814451e-07
. O 0 8.412465746232556e-08

Interestingly O 0 2.0268867956474423e-05
, O 0 2.5359890187814926e-08
none O 0 3.891380107035047e-09
of O 0 1.4821931182407155e-10
these O 0 8.091909919905049e-10
mutations O 0 2.3292197681712423e-07
was O 0 3.30697247363787e-08
observed O 0 1.841924479606405e-08
in O 0 4.7980965867111536e-09
the O 0 2.1777523784294317e-08
PTPase O 0 5.64029051020043e-06
core O 0 7.25056679584668e-07
motif O 0 4.4621228880714625e-06
. O 0 1.1202652672182012e-07

It O 0 7.611387218275922e-07
is O 0 1.0908358660799422e-08
also O 0 1.5713272905060194e-09
worthy O 0 1.8043864180583569e-09
of O 0 2.555642364399091e-10
note O 0 7.197704121608695e-08
that O 0 1.631043911043406e-10
a O 0 2.23136908950039e-09
single O 0 2.5555230820373254e-08
nonsense O 0 1.750555043145141e-07
point O 0 1.622834666648032e-08
mutation O 0 6.3739300060206e-08
, O 0 6.968933208284511e-10
R233X O 0 4.584714119459932e-08
, O 0 6.670025642918631e-10
was O 0 3.2783520342860584e-09
observed O 0 2.1332726696243753e-09
in O 0 5.696606519833836e-10
the O 0 1.1390763887675348e-09
germline O 0 9.866451478046656e-08
DNA O 0 1.02590718142892e-08
from O 0 9.03835950527565e-10
two O 0 6.822732379063723e-10
unrelated O 0 1.1839827784854151e-08
CD B-Disease 0 2.0341517483757343e-06
families O 0 2.3765125423125255e-09
and O 0 1.580606645568139e-09
one O 0 5.960688387318669e-09
BZS B-Disease 0 6.68422035232652e-06
family O 0 1.5268379627286777e-07
. O 0 1.0216857049272221e-07

Genotype O 0 0.010377359576523304
- O 0 0.035093650221824646
phenotype O 0 0.00014625099720433354
studies O 0 8.770836501525991e-08
were O 0 6.218431547466707e-09
not O 0 7.888511510678597e-10
performed O 0 6.056449564084687e-09
on O 0 1.6276853198604613e-09
this O 0 8.451470079329226e-11
small O 0 4.174767476161634e-10
group O 0 1.2639967961192156e-09
of O 0 2.0833306191292422e-09
BZS B-Disease 0 5.480193976836745e-06
families O 0 5.838181138528853e-08
. O 0 1.137685572416558e-07

However O 0 1.4292656942416215e-06
, O 0 6.19098941001539e-08
genotype O 0 3.18963429890573e-05
- O 0 1.2050720215484034e-05
phenotype O 0 1.0020399713539518e-05
analysis O 0 5.350115017677126e-08
inthe O 0 6.255106654862175e-06
group O 0 1.2793289982937495e-08
of O 0 1.2176810670894156e-09
CD B-Disease 0 1.7111311535700224e-05
families O 0 4.954381349620007e-09
revealed O 0 1.835965157681585e-08
two O 0 3.3986291558818493e-10
possible O 0 1.5916548079530912e-09
associations O 0 3.232657919127746e-09
worthy O 0 2.851167968387358e-09
of O 0 1.0335698963359619e-10
follow O 0 3.17868966703827e-08
- O 0 1.584693791301106e-06
up O 0 1.775643987400599e-08
in O 0 4.428078792528822e-09
independent O 0 2.2229381002603077e-08
analyses O 0 1.9432761177995417e-07
. O 0 3.139051329981157e-08

The O 0 2.0111977505621326e-07
first O 0 2.6393863095108827e-08
was O 0 1.76266272688963e-08
an O 0 4.4067596793873065e-10
association O 0 1.6196644025967544e-09
noted O 0 7.132523460740003e-10
in O 0 2.4597915371238344e-10
the O 0 7.342768615359319e-10
group O 0 5.864603247474065e-10
of O 0 1.0087226193222776e-10
CD B-Disease 0 1.8336785387873533e-06
families O 0 5.283980364367835e-09
with O 0 1.1640964459047609e-07
breast B-Disease 1 0.9670558571815491
disease I-Disease 0 0.0003659966168925166
. O 0 3.532846619691554e-07

A O 0 1.1511637012517895e-06
correlation O 0 1.0793020237542805e-06
was O 0 1.1769213159595893e-07
observed O 0 8.3726829913644e-09
between O 0 7.482280905968253e-10
the O 0 9.650726884302685e-10
presence O 0 1.5172224365755937e-08
/ O 0 7.244062771860627e-07
absence O 0 3.976540430272735e-09
of O 0 1.7762823156797225e-10
a O 0 6.834380616993485e-09
PTEN O 0 3.336556255817413e-05
mutation O 0 1.37313548975726e-07
and O 0 3.0554614394162627e-10
the O 0 5.806635727800824e-10
type O 0 2.2675129685012507e-07
of O 0 3.638029211217031e-09
breast O 0 2.9415370590868406e-05
involvement O 0 2.3918028091429733e-07
( O 0 8.741975676684888e-08
unaffected O 0 0.00010221540287602693
versus O 0 9.794367360882461e-05
benign O 1 0.9941779375076294
versus O 0 0.007232955191284418
malignant O 1 0.6290672421455383
) O 0 2.8408294383552857e-07
. O 0 2.782797139389004e-07

Specifically O 0 6.476158205259708e-07
and O 0 4.46416192900756e-09
more O 0 2.664685416764456e-10
directly O 0 9.208647178127194e-10
, O 0 1.982954911383672e-10
an O 0 4.062075398270082e-10
association O 0 1.855779707682359e-08
was O 0 1.630256321050183e-07
also O 0 4.661804831052052e-10
observed O 0 5.967010219265489e-10
between O 0 8.020240721551275e-11
the O 0 1.7910882499361236e-10
presence O 0 4.442381462688161e-10
of O 0 1.1382873810195093e-10
a O 0 7.633658150041356e-09
PTEN O 0 0.00012905681796837598
mutation O 0 9.538794074614998e-06
and O 0 4.416442607180215e-06
malignant B-Disease 1 0.9999961853027344
breast I-Disease 1 0.9999966621398926
disease I-Disease 1 0.6585240960121155
. O 0 9.410555890099204e-07

Secondly O 0 7.483716035494581e-05
, O 0 1.679841332702381e-08
there O 0 1.0394063387764163e-09
appeared O 0 6.277829101009047e-08
to O 0 1.0388315763165679e-09
be O 0 2.8782129457560757e-10
an O 0 6.056885548666457e-10
interdependent O 0 1.2228163370764378e-07
association O 0 3.60123175724425e-09
between O 0 1.4211037902001067e-09
mutations O 0 1.2528823845059378e-07
upstream O 0 2.8933852647128333e-08
and O 0 8.335441226137164e-10
within O 0 8.333057022191781e-10
the O 0 4.044535373282088e-09
PTPase O 0 1.1682107015076326e-06
core O 0 6.71669297958033e-08
motif O 0 1.5988828749868844e-07
, O 0 2.2383331299558051e-10
the O 0 6.848417388738426e-10
core O 0 3.0503056080988245e-08
motif O 0 2.6850649703646923e-08
containing O 0 8.234497528292195e-10
the O 0 4.664001407306273e-10
majority O 0 1.0257735771901366e-09
of O 0 4.145385701370685e-10
missense O 0 2.7253029202256585e-06
mutations O 0 6.871804885122401e-07
, O 0 7.797082979266179e-10
and O 0 3.85220910725792e-10
the O 0 1.1077726513875064e-09
involvement O 0 2.128781151355952e-09
of O 0 1.2706072305412874e-10
all O 0 1.6938675462263575e-10
major O 0 2.986055402942611e-09
organ O 0 1.5518317013629712e-05
systems O 0 2.3157135728979483e-05
( O 0 1.3948651123030231e-08
central O 0 1.2714384638456977e-06
nervous O 0 0.08023492246866226
system O 0 0.0014489457244053483
, O 0 1.4452915308993397e-07
thyroid O 0 0.0007212591590359807
, O 0 2.6544768161329557e-08
breast O 0 0.006091172341257334
, O 0 2.8323674428065715e-07
skin O 1 1.0
and O 0 0.052396126091480255
gastrointestinal O 1 0.999968409538269
tract O 0 0.2306745946407318
) O 0 3.152720466914616e-07
. O 0 3.4541264426479756e-07

However O 0 6.247691430871782e-07
, O 0 4.1620644708473264e-09
these O 0 2.3952284600170515e-10
observations O 0 4.333983394388952e-09
would O 0 9.701387471139356e-10
need O 0 2.911618168788266e-10
to O 0 2.834703860532528e-10
be O 0 1.7419292397402586e-10
confirmed O 0 1.3538222765063779e-09
by O 0 1.0965108682148283e-10
studying O 0 2.4117821628699687e-10
a O 0 2.7013463688163597e-10
larger O 0 4.240478246320123e-10
number O 0 1.298864626964047e-10
of O 0 1.8664628176345843e-10
CD B-Disease 0 4.50472543889191e-06
families O 0 1.4659272018491265e-08
. O 0 3.751968336018763e-08

Molecular O 0 0.003194705117493868
defects O 1 0.9831768274307251
leading O 0 2.0577770953877916e-07
to O 0 8.88534756882109e-09
human O 0 2.0077861151435172e-08
complement B-Disease 0 2.326374442418455e-06
component I-Disease 1 0.9836966395378113
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.849021794153032e-09
an O 0 1.298865126564408e-09
African O 0 4.377783913156463e-09
- O 0 1.5746620363188413e-07
American O 0 1.012096184638267e-08
family O 0 8.75958505730523e-08
. O 0 4.24874038174039e-08

Complement B-Disease 0 0.0006496421992778778
component I-Disease 1 0.9996451139450073
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 8.43811960749008e-07
C6D B-Disease 0 0.0003809453046415001
) O 0 8.21069789935791e-08
was O 0 2.1937253222859e-06
diagnosed O 0 2.7855874122906243e-06
in O 0 2.3726085540687336e-09
a O 0 1.0158093921575073e-08
16 O 0 2.0516164056516573e-07
- O 0 8.61125272422214e-07
year O 0 3.0663528605145984e-08
- O 0 1.625825234441436e-07
old O 0 3.209705923268302e-08
African O 0 6.255161943968801e-10
- O 0 1.2648465386178032e-08
American O 0 1.3488272720962868e-09
male O 0 7.471503415956704e-09
with O 0 3.527122771629365e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 6.472866971307667e-07

The O 0 4.551109498152073e-07
patients O 0 6.003432417855947e-07
father O 0 5.09364326717332e-07
and O 0 2.201774984555982e-09
two O 0 2.057320092063719e-09
brothers O 0 4.004059064754983e-06
also O 0 1.8564868531356638e-09
had O 0 5.318784523922204e-09
C6D B-Disease 0 1.0975707027682802e-06
, O 0 2.553663946969209e-10
but O 0 2.897745376984062e-10
gave O 0 1.6991752449513342e-09
no O 0 2.5203819586927523e-10
history O 0 1.3900253170717747e-09
of O 0 1.7751995429193812e-09
meningitis B-Disease 1 0.9999998807907104
or O 0 5.6793190594817133e-08
other O 0 7.489308728736432e-09
neisserial B-Disease 0 0.002149536507204175
infection I-Disease 0 0.0007128269062377512
. O 0 4.4500524154500454e-07

By O 0 2.2069272631597414e-07
using O 0 2.0768456465702911e-07
exon O 0 6.162001227494329e-06
- O 0 7.216722224256955e-07
specific O 0 2.8442766364378258e-08
polymerase O 0 8.420839549216907e-06
chain O 0 6.346219743136317e-05
reaction O 0 3.0167527711455477e-06
( O 0 1.5357372262769786e-07
PCR O 0 2.927281821030192e-05
) O 0 3.231278711268715e-08
/ O 0 5.417455781753233e-07
single O 0 3.741584464478365e-08
- O 0 2.2849550873615954e-07
strand O 0 8.266416671176557e-07
conformation O 0 8.422321684520284e-07
polymorphism O 0 1.7973738408727513e-07
as O 0 1.4061852793290086e-09
a O 0 2.0584505211473925e-09
screening O 0 6.30824530389873e-08
step O 0 5.992767171392188e-09
and O 0 5.633805644222889e-10
nucleotide O 0 1.320878695310057e-08
sequencing O 0 4.001786457763501e-09
of O 0 2.2265682353417304e-10
target O 0 2.417209721272684e-08
exons O 0 9.609242113128857e-08
, O 0 5.157126392596467e-10
we O 0 1.4977610818256437e-10
determined O 0 6.311561273619759e-10
that O 0 5.160184085584163e-11
the O 0 1.1528595855736512e-09
proband O 0 2.4537777676414407e-07
was O 0 1.663217452652077e-09
a O 0 3.6004194070571316e-10
compound O 0 7.391164569270359e-09
heterozygote O 0 8.047497601637588e-08
for O 0 6.939619434653821e-10
two O 0 1.1416783962658883e-08
C6 O 0 0.00013331991794984788
gene O 0 2.007325747399591e-05
mutations O 0 3.005780126841273e-05
. O 0 4.239213069467951e-07

The O 0 2.0875047823665227e-07
first O 0 2.278924249310421e-08
, O 0 2.074460603296302e-09
1195delC O 0 2.3227246970236592e-07
located O 0 2.0926149701949726e-08
in O 0 8.780707716482539e-09
exon O 0 5.737443302678003e-07
7 O 0 8.370419379843952e-08
, O 0 4.498692252052905e-10
is O 0 1.7981292843582963e-10
a O 0 1.8821793013046317e-09
novel O 0 1.2929313619736149e-08
mutation O 0 7.214651276399309e-08
, O 0 4.5919118507598e-10
while O 0 1.7607355851101403e-10
the O 0 6.690322740254828e-10
second O 0 4.412775922446599e-09
, O 0 3.498409895108523e-10
1936delG O 0 3.163140505080264e-08
in O 0 1.5146338627758382e-09
exon O 0 2.3401943849421514e-07
12 O 0 1.3913576957236273e-08
, O 0 4.0946840362821035e-10
has O 0 4.785454255085142e-10
been O 0 2.145001676279179e-10
described O 0 1.4736920572744339e-09
before O 0 1.0802365668638458e-09
to O 0 1.1761988050196237e-09
cause O 0 5.316481921369132e-09
C6D B-Disease 0 2.386512392149598e-07
in O 0 4.5059056485996507e-10
an O 0 1.592261322791444e-10
unrelated O 0 7.186370609701953e-09
African O 0 1.6024381821466704e-09
- O 0 3.328621289711009e-08
American O 0 2.081317118651782e-09
individual O 0 3.356768196738358e-09
. O 0 1.763705270718674e-08

Both O 0 4.530919852641091e-07
mutations O 0 1.4947659110475797e-05
result O 0 9.492583075143557e-08
in O 0 1.579160056053297e-07
premature O 0 5.33767779415939e-05
termination O 0 1.1402068594179582e-05
codons O 0 3.0166835131240077e-05
and O 0 4.378968014862039e-07
C6 O 0 0.0006211971049197018
null O 0 1.3764957657258492e-05
alleles O 0 9.200101885653567e-06
. O 0 2.484054562046367e-07

Allele O 0 0.0003984861250501126
- O 0 6.48585228191223e-06
specific O 0 9.533680866979921e-08
PCR O 0 1.0128386747965124e-05
indicated O 0 3.3353234130117926e-07
that O 0 5.387003065848717e-10
the O 0 1.3349501504222872e-09
probands O 0 6.805543648624734e-07
two O 0 4.0128234068959046e-09
brothers O 0 8.080587008407747e-07
also O 0 2.686221467484984e-09
inherited O 0 7.830249870721673e-08
the O 0 3.5754086358252835e-09
1195delC O 0 5.906244382458681e-07
mutation O 0 9.770661790753365e-08
from O 0 2.4346480387293923e-09
their O 0 3.290712369263815e-09
heterozygous O 0 8.952287657848501e-07
mother O 0 3.668956694014014e-08
and O 0 3.148906690952913e-10
the O 0 1.0824166007949998e-09
1936delG O 0 1.9808820184152864e-07
mutation O 0 6.43614939122017e-08
from O 0 1.7732096901923455e-09
their O 0 3.318837871191249e-09
homozygous O 0 4.7532657276860846e-07
father O 0 9.092921970932366e-08
. O 0 4.05246591839159e-09
. O 0 4.39671445917611e-08

PAX6 O 0 0.12060890346765518
mutations O 0 0.02272101305425167
reviewed O 0 0.00010881719208555296
. O 0 3.864510290441103e-06

Mutations O 0 0.0014734838623553514
in O 0 7.031692916825705e-07
PAX6 O 0 0.0001259885320905596
are O 0 6.575693767274515e-09
responsible O 0 1.0188752952444702e-08
for O 0 5.996148022546777e-10
human O 0 7.79068010103856e-09
aniridia B-Disease 1 1.0
and O 0 6.952635800416829e-08
have O 0 7.029193893615115e-10
also O 0 5.55603285601336e-10
been O 0 3.2716354625428323e-10
found O 0 5.005824088577526e-10
in O 0 1.898939672173583e-09
patients O 0 7.919949140955396e-09
with O 0 3.055895803072417e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999998807907104
, O 0 1.8732979611968403e-08
with O 0 4.703726062871283e-06
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9947448968887329
, O 0 6.518824591239536e-09
with O 0 7.862907125399943e-08
autosomal B-Disease 1 0.9999071359634399
dominant I-Disease 1 0.9599573016166687
keratitis I-Disease 1 0.9143080115318298
, O 0 2.9945610435788694e-08
and O 0 4.924723295829381e-09
with O 0 2.5550310311928115e-08
isolated B-Disease 0 0.4511227607727051
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 2.1049681890872307e-06

No O 0 3.2633005275783944e-07
locus O 0 6.962349061723216e-07
other O 0 1.537107330307208e-09
than O 0 2.0551631507714774e-09
chromosome O 0 9.907087132887682e-07
11p13 O 0 4.0482814256392885e-07
has O 0 3.561598793666576e-09
been O 0 2.1256894022769757e-09
implicated O 0 6.725282020170198e-08
in O 0 5.4238462610101124e-08
aniridia B-Disease 1 1.0
, O 0 5.216854948031369e-09
and O 0 2.136330445878798e-09
PAX6 O 0 1.9723966033780016e-06
is O 0 9.64975099826404e-10
clearly O 0 1.1171404912246885e-09
the O 0 1.9985797738986122e-10
major O 0 3.157218098071013e-10
, O 0 1.2159026563374198e-10
if O 0 1.9261073291865216e-10
not O 0 1.2543703575840226e-10
only O 0 1.1752071538140285e-10
, O 0 2.409850929918633e-10
gene O 0 5.6960473671097134e-08
responsible O 0 7.147333036527925e-08
. O 0 7.160335968592335e-08

Twenty O 0 4.029049250675598e-06
- O 0 2.172302856706665e-06
eight O 0 2.5562007621715566e-08
percent O 0 2.4684323918222617e-08
of O 0 5.286356907774348e-10
identified O 0 5.137927416853927e-08
PAX6 O 0 9.657954251451883e-06
mutations O 0 1.4093216123001184e-06
are O 0 7.130473100858126e-09
C O 0 0.00046859553549438715
- O 0 0.0018091462552547455
T O 0 0.0015425847377628088
changes O 0 3.8375463873308036e-07
at O 0 1.6148074166721926e-07
CpG O 0 5.1142847041774075e-06
dinucleotides O 0 3.3617135386521113e-07
, O 0 6.57833731931845e-10
20 O 0 5.11404696368345e-10
% O 0 1.2137893468100458e-10
are O 0 4.8342392588995864e-11
splicing O 0 1.5413289133903163e-07
errors O 0 1.904557933585238e-07
, O 0 4.315290069722977e-10
and O 0 1.3470680126914658e-10
more O 0 7.36824212754783e-11
than O 0 1.4746921739305918e-10
30 O 0 1.6277226233540887e-09
% O 0 1.738596766553968e-10
are O 0 9.821638641271946e-11
deletion O 0 4.859308333493573e-08
or O 0 9.65607149794323e-09
insertion O 0 1.317897044827987e-07
events O 0 5.8850144313282726e-08
. O 0 1.2588397169110976e-07

There O 0 2.869019510853832e-07
is O 0 1.0645510251094947e-08
a O 0 1.3985495428414652e-08
noticeably O 0 2.4185983420466073e-05
elevated O 0 2.472624828442349e-06
level O 0 1.1134375199617352e-08
of O 0 3.116319147178359e-10
mutation O 0 3.3675174648806205e-08
in O 0 1.4956578198166426e-09
the O 0 2.0416448531790365e-09
paired O 0 2.1595111476813145e-08
domain O 0 2.1427467800094746e-08
compared O 0 7.544104896339832e-09
with O 0 2.8590846357090527e-10
the O 0 2.264477050317737e-09
rest O 0 2.2162183199725405e-09
of O 0 1.1323173648714047e-10
the O 0 2.314457514529522e-09
gene O 0 4.5009795712758205e-07
. O 0 4.896626393247061e-08

Increased O 0 7.002101938269334e-06
mutation O 0 6.474036581494147e-06
in O 0 3.194364239789138e-08
the O 0 2.677169419484926e-08
homeodomain O 0 1.7417537492292468e-06
is O 0 2.5042157236754292e-09
accounted O 0 5.343310238714594e-09
for O 0 1.5803494624044845e-10
by O 0 7.59735552247065e-10
the O 0 1.558906603804644e-08
hypermutable O 0 2.0351455532363616e-05
CpG O 0 2.0004288671771064e-05
dinucleotide O 0 3.2310313144989777e-06
in O 0 9.979784465485864e-08
codon O 0 1.3105142897984479e-05
240 O 0 8.356483363058942e-07
. O 0 1.3013560362651333e-07

Very O 0 3.062489781768818e-07
nearly O 0 2.0902694686242285e-08
all O 0 1.0477783085605097e-09
mutations O 0 1.5738123693154193e-07
appear O 0 7.859203066118425e-08
to O 0 1.5684056720033368e-08
cause O 0 2.8815699693041097e-07
loss O 0 2.3176571772864918e-08
of O 0 8.895852110502034e-11
function O 0 7.639655574820381e-10
of O 0 3.1465156868915045e-11
the O 0 5.771313982272375e-10
mutant O 0 4.410648912767101e-08
allele O 0 7.700888460249189e-08
, O 0 1.2776402158465316e-10
and O 0 5.486590001768654e-11
more O 0 3.7823705972828137e-11
than O 0 6.906748784007988e-11
80 O 0 8.983807586737669e-10
% O 0 8.772781112664774e-11
of O 0 1.1081650874711357e-10
exonic O 0 6.225091055966914e-07
substitutions O 0 9.605138018287107e-08
result O 0 2.1258284021996587e-08
in O 0 1.6589348561524275e-08
nonsense O 0 3.824502982752165e-06
codons O 0 8.920720574678853e-06
. O 0 2.8479797720137867e-07

In O 0 1.9560722819278453e-07
a O 0 2.899860618299499e-08
gene O 0 1.4283375548984623e-07
with O 0 7.210338992535981e-10
such O 0 1.3139502819115023e-09
extraordinarily O 0 3.2709527886254364e-07
high O 0 2.2866052518111246e-07
sequence O 0 3.6776658163262255e-08
conservation O 0 7.751337904871036e-10
throughout O 0 7.505750465597316e-10
evolution O 0 1.1734874183488841e-09
, O 0 1.2039806651653606e-10
there O 0 1.6637433097876908e-10
are O 0 1.7101313420919695e-10
presumed O 0 5.614630893546746e-08
undiscovered O 0 2.2696332280247589e-07
missense O 0 4.532935236056801e-06
mutations O 0 1.0014829285864835e-06
, O 0 1.210823219466306e-09
these O 0 3.491883171502508e-10
are O 0 6.383545081423136e-11
hypothesized O 0 2.4316266777901774e-09
to O 0 2.141343075079405e-10
exist O 0 3.645806989638345e-10
in O 0 8.692916941832607e-10
as O 0 2.7358293408497047e-09
- O 0 1.3153368172424962e-07
yet O 0 9.335434647539387e-09
unidentified O 0 2.01523363330125e-07
phenotypes O 0 1.0688988822948886e-06
. O 0 8.200911949529655e-09
. O 0 6.048486511645024e-08

Genetic O 0 5.8817939134314656e-05
heterogeneity O 0 4.622563210432418e-05
and O 0 2.468195248184202e-07
penetrance O 0 1.7507032680441625e-05
analysis O 0 2.8969417087409965e-08
of O 0 6.599588653344313e-10
the O 0 1.0410298401097862e-08
BRCA1 O 0 5.934383807471022e-06
and O 0 1.8901740617138785e-08
BRCA2 O 0 7.318499228858855e-06
genes O 0 5.70168253943848e-07
in O 0 2.6814193461177638e-06
breast B-Disease 1 0.99716717004776
cancer I-Disease 0 0.0001209578913403675
families O 0 9.593475169822341e-08
. O 0 1.3882197436032584e-07

The O 0 0.0004322835011407733
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 9.341972327092662e-05
Consortium O 0 4.177785740466788e-06
. O 0 2.4384607399952074e-07

The O 0 5.956111337468428e-08
contribution O 0 2.0413576606870265e-08
of O 0 3.1390976484857447e-09
BRCA1 O 0 3.5033560834563104e-06
and O 0 3.4626513212288046e-08
BRCA2 O 0 0.0004467378312256187
to O 0 0.00012084491027053446
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 9.146667252935003e-06
assessed O 0 5.034919681179417e-08
by O 0 2.8409841146270765e-09
linkage O 0 3.3698250945235486e-07
and O 0 2.896443085376177e-09
mutation O 0 9.751634166832446e-08
analysis O 0 2.964553047490881e-09
in O 0 2.8287641118396323e-09
237 O 0 2.1544016348684636e-08
families O 0 1.0417959828146195e-09
, O 0 1.7778416239178085e-10
each O 0 8.847608756745728e-11
with O 0 3.621107858009509e-10
at O 0 1.3662744713371922e-08
least O 0 4.1196976385826645e-10
four O 0 1.6337994845905257e-10
cases O 0 3.9858788491997643e-10
of O 0 6.6058891690090604e-09
breast B-Disease 1 0.876188337802887
cancer I-Disease 0 4.921016625303309e-07
, O 0 1.8368741250274212e-10
collected O 0 2.376353003263887e-10
by O 0 1.3096792539357693e-09
the O 0 3.566363011486828e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999996423721313
Linkage O 0 9.08854872250231e-06
Consortium O 0 5.226339112596179e-07
. O 0 1.2791257120170485e-07

Families O 0 5.231844397712848e-07
were O 0 1.2449898001420934e-08
included O 0 1.942555671874402e-09
without O 0 6.108489825074059e-10
regard O 0 6.820312647981552e-10
to O 0 2.782379604493457e-10
the O 0 5.079400788865485e-10
occurrence O 0 5.995193674834809e-08
of O 0 8.960384434431035e-09
ovarian B-Disease 0 0.00016945129027590156
or I-Disease 0 4.947877485506069e-08
other I-Disease 0 1.8303184745604995e-08
cancers I-Disease 0 0.00011822881788248196
. O 0 2.968335479636153e-07

Overall O 0 8.095335215330124e-05
, O 0 6.841386266387417e-07
disease O 0 0.00012195856106700376
was O 0 1.4709777929056145e-07
linked O 0 3.180424528181902e-07
to O 0 5.282871917700049e-09
BRCA1 O 0 4.6681802245984727e-07
in O 0 7.279930547277047e-10
an O 0 1.1396842497513049e-10
estimated O 0 1.933424670363948e-10
52 O 0 1.0664241711921818e-09
% O 0 2.922823094664295e-11
of O 0 5.434957171812638e-12
families O 0 7.122555323313406e-11
, O 0 5.827714005812723e-11
to O 0 5.569784078396367e-10
BRCA2 O 0 9.079334262196426e-08
in O 0 4.9518472655663e-10
32 O 0 2.1758246315783936e-09
% O 0 5.4074862643194166e-11
of O 0 1.6772135763565288e-11
families O 0 1.4918392909901712e-10
, O 0 8.949546659309249e-11
and O 0 8.729599682011369e-11
to O 0 3.6238717582293134e-10
neither O 0 8.996582367970518e-10
gene O 0 1.106356339874992e-08
in O 0 1.0719793941404987e-09
16 O 0 3.78344244822415e-09
% O 0 1.9724757938099913e-10
( O 0 5.987794149397985e-10
95 O 0 3.721066477169188e-08
% O 0 5.6024114236663536e-09
confidence O 0 5.341642008716008e-07
interval O 0 1.639425136090722e-06
[ O 0 2.8411002972461574e-07
CI O 0 1.2817055903724395e-05
] O 0 9.549751212034607e-08
6 O 0 2.579755253862004e-08
% O 0 2.3672475091274237e-09
- O 0 1.7647323602432152e-07
28 O 0 6.12443145087127e-08
% O 0 6.763984927715683e-10
) O 0 1.2889166123297713e-10
, O 0 5.916935691407943e-11
suggesting O 0 5.4301159124747755e-09
other O 0 1.3740433235653882e-09
predisposition O 0 1.2589156312969862e-06
genes O 0 8.6686674194425e-07
. O 0 2.5623521082707157e-07

The O 0 1.2606898280864698e-07
majority O 0 4.5401247206200424e-08
( O 0 9.239387921411435e-09
81 O 0 3.203724219247306e-08
% O 0 5.198664831951305e-10
) O 0 1.0666922206636897e-10
of O 0 8.984505500686524e-11
the O 0 6.917140126461163e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.165527892207592e-09
were O 0 1.5551104848299246e-09
due O 0 9.117631094568424e-09
to O 0 6.7001462156213165e-09
BRCA1 O 0 1.1609694183789543e-06
, O 0 2.1598302313297069e-10
with O 0 7.829985965157604e-11
most O 0 5.510252254481429e-10
others O 0 6.070718372441775e-10
( O 0 8.029550913057903e-10
14 O 0 1.183727005305002e-09
% O 0 1.0813636097672941e-10
) O 0 1.5129872354968654e-10
due O 0 6.424274889837989e-09
to O 0 2.2618579009758832e-08
BRCA2 O 0 1.3771467820333783e-05
. O 0 1.0993037591333632e-07

Conversely O 0 6.836665306764189e-06
, O 0 4.5364605405495695e-09
the O 0 6.29400975782346e-10
majority O 0 2.495488815590363e-10
of O 0 1.8345342606140846e-11
families O 0 8.254621292058673e-11
with O 0 7.401709106735765e-11
male B-Disease 0 3.903720457998361e-09
and I-Disease 0 8.468356682556077e-09
female I-Disease 0 8.812378382572206e-07
breast I-Disease 0 0.25926390290260315
cancer I-Disease 0 1.1274672715444467e-06
were O 0 2.139511234844349e-09
due O 0 2.352597228139075e-08
to O 0 2.3001692994739642e-08
BRCA2 O 0 5.935510216659168e-06
( O 0 1.7189627499192284e-08
76 O 0 9.774650777671923e-08
% O 0 3.47283579671398e-09
) O 0 1.52855932356033e-08
. O 0 1.207936435321244e-07

The O 0 1.29284060790269e-07
largest O 0 2.848375579844742e-08
proportion O 0 1.9083190139213002e-08
( O 0 3.4175990926144095e-09
67 O 0 2.736791060442556e-08
% O 0 3.272140891574793e-10
) O 0 6.643244981896501e-11
of O 0 4.53902644637072e-11
families O 0 2.4884638794020475e-10
due O 0 1.6932514279588418e-09
to O 0 4.247350804398309e-10
other O 0 1.0366853903098772e-10
genes O 0 4.051778024205532e-09
was O 0 2.705845680850416e-08
found O 0 6.581863942756172e-10
in O 0 5.573758676824525e-10
families O 0 2.436467694266753e-10
with O 0 1.629896356769578e-10
four O 0 3.4073915911037034e-10
or O 0 9.33900956567868e-10
five O 0 1.9531505579539754e-10
cases O 0 2.0036829140313017e-10
of O 0 5.737826325180606e-10
female O 0 2.4819876216497505e-06
breast B-Disease 0 0.2346440851688385
cancer I-Disease 0 3.2762466162239434e-06
only O 0 1.9680621576867452e-08
. O 0 1.0420473728345314e-07

These O 0 1.0005972228555038e-07
estimates O 0 9.865002681408441e-08
were O 0 2.4580011359631726e-09
not O 0 1.888259548721294e-09
substantially O 0 2.018153111293941e-07
affected O 0 5.062728014593176e-09
either O 0 1.366790014500907e-09
by O 0 8.610590573887578e-10
changing O 0 2.0303685843714447e-08
the O 0 4.333776892906371e-09
assumed O 0 3.710513496457679e-08
penetrance O 0 2.2912242059192067e-07
model O 0 1.1997959958875981e-08
for O 0 5.701520366940827e-10
BRCA1 O 0 2.8889968461953686e-07
or O 0 1.58805246730509e-09
by O 0 2.7198029939334845e-10
including O 0 2.1178049591785708e-10
or O 0 1.3871789050767802e-08
excluding O 0 3.0157463015711983e-07
BRCA1 O 0 1.7128353647422045e-05
mutation O 0 1.7978828736886499e-06
data O 0 1.6864132703631185e-06
. O 0 5.122154789205524e-07

Among O 0 6.386087392229456e-08
those O 0 3.6206262432614267e-09
families O 0 1.3663025155707942e-09
with O 0 2.0354158358770746e-09
disease O 0 1.5527468804066302e-06
due O 0 5.205814801456654e-08
to O 0 3.118933022960846e-08
BRCA1 O 0 5.157888153917156e-06
that O 0 1.0656820981225223e-09
were O 0 1.3086504102588492e-09
tested O 0 5.43107958606015e-09
by O 0 7.31039950796486e-11
one O 0 7.069687890659537e-11
of O 0 3.4716268054735266e-11
the O 0 8.205022217211422e-10
standard O 0 1.595680885202455e-07
screening O 0 6.551319486902685e-09
methods O 0 3.2245417447285263e-09
, O 0 1.707139707374239e-10
mutations O 0 1.0452239074254521e-08
were O 0 1.0743373968225e-09
detected O 0 2.89252444218846e-08
in O 0 1.9285821828418648e-09
the O 0 5.605276243159096e-09
coding O 0 4.018210404410638e-07
sequence O 0 3.5802898423753504e-08
or O 0 1.0174536768658982e-08
splice O 0 6.764518616364512e-07
sites O 0 9.016926760807564e-09
in O 0 8.187716615815077e-10
an O 0 3.4044292385182473e-10
estimated O 0 1.190140652695959e-09
63 O 0 1.4757742583526579e-08
% O 0 6.293649490451969e-10
( O 0 9.334752970602267e-10
95 O 0 6.205471692055653e-08
% O 0 1.0648596671103405e-08
CI O 0 3.7231648093438707e-06
51 O 0 1.2234275459377386e-07
% O 0 4.365418249108188e-09
- O 0 3.592325867884938e-07
77 O 0 2.1103397784827393e-07
% O 0 5.160120331026974e-09
) O 0 9.980104742624007e-09
. O 0 4.539033326977915e-08

The O 0 1.7740029534252244e-07
estimated O 0 3.193645525811917e-08
sensitivity O 0 1.1292949864127877e-07
was O 0 3.801861936381101e-08
identical O 0 1.0397399385908557e-08
for O 0 9.103216791483959e-11
direct O 0 2.422608558205752e-09
sequencing O 0 1.1520996601177558e-08
and O 0 6.36633135098208e-10
other O 0 4.739871273251595e-10
techniques O 0 1.4494987965463224e-07
. O 0 8.427561937196515e-08

The O 0 1.3620810932479799e-06
penetrance O 0 8.115369564620778e-05
of O 0 3.724304420416047e-08
BRCA2 O 0 1.7845241018221714e-05
was O 0 4.4240202612400026e-08
estimated O 0 2.2509554220562222e-09
by O 0 7.909075616652217e-10
maximizing O 0 2.3800794224371202e-08
the O 0 7.291885761873118e-09
LOD O 0 1.4748936337127816e-05
score O 0 5.54473231773045e-08
in O 0 6.548935971295577e-08
BRCA2 O 0 0.0002037233643932268
- O 0 1.1123347576358356e-05
mutation O 0 6.381217190210009e-07
families O 0 2.255037934162374e-09
, O 0 3.4591363107239204e-10
over O 0 4.459224101083237e-10
all O 0 2.935282850113907e-10
possible O 0 1.6788227696906688e-08
penetrance O 0 6.477334409282776e-06
functions O 0 1.723865494795973e-07
. O 0 1.7780341465822858e-07

The O 0 1.2022773887565563e-07
estimated O 0 5.233700761664295e-08
cumulative O 0 1.9836856779420486e-07
risk O 0 1.1973696700806613e-07
of O 0 1.7332082435927987e-08
breast B-Disease 1 0.9926518797874451
cancer I-Disease 0 2.86042268271558e-05
reached O 0 9.257984601163116e-08
28 O 0 7.85154696814061e-08
% O 0 1.1468721528018477e-09
( O 0 1.3905663287516745e-09
95 O 0 3.7811791031572284e-08
% O 0 5.023751192823056e-09
CI O 0 2.153265313609154e-06
9 O 0 9.301135150963091e-08
% O 0 1.484162903686581e-09
- O 0 6.69386466256583e-08
44 O 0 7.186768513633979e-09
% O 0 2.2193601123543516e-10
) O 0 8.194492306934364e-11
by O 0 2.39556652292805e-10
age O 0 9.36007049645582e-10
50 O 0 4.241570150664842e-10
years O 0 1.9999564504491474e-10
and O 0 2.952977307124627e-10
84 O 0 4.060852987208818e-09
% O 0 2.68392558178121e-10
( O 0 5.721095819311017e-10
95 O 0 1.8388039535466305e-08
% O 0 2.3402664250937733e-09
CI O 0 1.06545485323295e-06
43 O 0 1.8379623156761227e-08
% O 0 1.6402073033106035e-09
- O 0 4.3477296429728085e-08
95 O 0 5.4404651450568053e-08
% O 0 8.302073473132054e-10
) O 0 1.790937953494165e-10
by O 0 5.939848057856523e-10
age O 0 2.6306399281139647e-09
70 O 0 5.234426669886716e-09
years O 0 5.20245668766961e-09
. O 0 3.307805229724181e-08

The O 0 1.9439896277617663e-05
corresponding O 1 0.9996927976608276
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 2.1833520804648288e-05
were O 0 1.7677743358035514e-07
0 O 0 7.060749567244784e-07
. O 0 2.0553548552015855e-07

4 O 0 3.214980552002089e-06
% O 0 3.92116916714258e-08
( O 0 1.0136881556377375e-08
95 O 0 5.795079616177645e-08
% O 0 6.075887792889034e-09
CI O 0 2.121787247233442e-06
0 O 0 4.5484799926498454e-08
% O 0 2.845593982669925e-09
- O 0 6.933394303132445e-08
1 O 0 7.1959718184189114e-09
% O 0 2.9735330864255616e-10
) O 0 1.0936889588419874e-10
by O 0 2.7767599330985604e-10
age O 0 1.430884521980147e-09
50 O 0 7.04320379796286e-10
years O 0 3.784884350377382e-10
and O 0 4.841466672012018e-10
27 O 0 1.2046251107733497e-08
% O 0 2.1180192322223235e-10
( O 0 6.347561365416254e-10
95 O 0 2.7573248573276032e-08
% O 0 3.6602318953526947e-09
CI O 0 1.9012509255844634e-06
0 O 0 2.1435234032196604e-08
% O 0 2.6791500129519363e-09
- O 0 1.366413187042781e-07
47 O 0 4.792529395558631e-08
% O 0 4.682952359225112e-10
) O 0 1.5955690935154365e-10
by O 0 6.549142339551395e-10
age O 0 6.212693026697025e-09
70 O 0 7.325565487548147e-09
years O 0 7.822827718939607e-09
. O 0 3.122998748494865e-08

The O 0 9.855164080363465e-07
lifetime O 0 1.4937761534383753e-06
risk O 0 5.69780695514055e-07
of O 0 6.856330969640112e-08
breast B-Disease 1 0.9995346069335938
cancer I-Disease 0 0.0001105242918129079
appears O 0 7.29717655190143e-08
similar O 0 4.826762545206975e-09
to O 0 1.33023259074605e-09
the O 0 1.4474034193412422e-09
risk O 0 8.53057535721291e-09
in O 0 2.8454689715573522e-09
BRCA1 O 0 3.086438482569065e-07
carriers O 0 6.479132785841557e-09
, O 0 3.2324096177482886e-10
but O 0 2.34417874001025e-10
there O 0 2.1814085260363214e-10
was O 0 1.8123333944686237e-09
some O 0 1.627190049369176e-11
suggestion O 0 3.64169278066484e-10
of O 0 2.303401393233262e-11
a O 0 2.647174479619707e-09
lower O 0 1.932835584739223e-05
risk O 0 2.6397840358072244e-08
in O 0 7.150166236868927e-09
BRCA2 O 0 1.5604675809299806e-06
carriers O 0 2.7805468150177148e-08
< O 0 4.7687123583273205e-08
50 O 0 5.7414637488761855e-09
years O 0 9.32702914901995e-10
of O 0 6.716828204744729e-10
age O 0 2.9200524664929617e-08
. O 0 2.470825144484934e-08

Eye B-Disease 1 0.9793108105659485
movement I-Disease 0 0.0002524944138713181
abnormalities I-Disease 1 0.9501886963844299
correlate O 0 3.645884589786874e-06
with O 0 3.4664839887454946e-08
genotype O 0 0.00018219053163193166
in O 0 8.910229212233389e-07
autosomal O 1 0.9999983310699463
dominant O 1 0.9999960660934448
cerebellar B-Disease 1 0.9999997615814209
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9697701930999756
. O 0 8.821635901767877e-07

We O 0 5.878193292119249e-07
compared O 0 1.0525068319111597e-06
horizontal O 0 4.941821316606365e-05
eye O 0 0.013199535198509693
movements O 0 0.00012037176929879934
( O 0 8.471559453937516e-08
visually O 0 3.389786513707804e-07
guided O 0 7.013249501142127e-07
saccades O 0 2.321101419511251e-05
, O 0 4.155116251070012e-09
antisaccades O 0 8.967335247689334e-07
, O 0 9.197500538959957e-10
and O 0 7.735417306697911e-10
smooth O 0 4.7321254470489293e-08
pursuit O 0 1.3617476923855065e-08
) O 0 1.6225460974794714e-09
in O 0 3.1155127366844226e-09
control O 0 3.9760502090757655e-07
subjects O 0 6.586743239722637e-08
( O 0 1.404805427540623e-08
n O 0 8.580429948779056e-07
= O 0 4.629396528343932e-07
14 O 0 3.321347108453665e-08
) O 0 1.2019346629088545e-09
and O 0 1.7457651990682166e-09
patients O 0 8.913656479592191e-10
with O 0 3.076467136597927e-10
three O 0 9.131497225034479e-10
forms O 0 1.0717223553058375e-08
of O 0 6.027432331023874e-09
autosomal O 1 0.5266792178153992
dominant O 0 0.03395170718431473
cerebellar B-Disease 0 0.2850951850414276
ataxias I-Disease 1 0.893696665763855
type I-Disease 1 0.999473512172699
I I-Disease 0 0.02729862742125988
spinocerebellar B-Disease 1 0.9993425011634827
ataxias I-Disease 0 0.00028742183349095285
1 I-Disease 0 1.5359715632712323e-07
and I-Disease 0 3.8827132620156135e-09
2 I-Disease 0 1.3939794207828982e-08
( O 0 5.7513060980340924e-09
SCA1 B-Disease 0 3.6269154861656716e-06
, O 0 2.9798028489125272e-09
n O 0 2.3265512538728217e-07
= O 0 3.8044339589760057e-07
11 O 0 4.0483268293201036e-08
; O 0 1.024032325602775e-08
SCA2 B-Disease 0 6.177794148243265e-06
, O 0 6.3147678197594814e-09
n O 0 2.2294734947081452e-07
= O 0 2.6750009851639334e-07
10 O 0 9.269077061446751e-09
) O 0 2.4763533446048314e-09
and O 0 3.745604715277295e-08
SCA3 B-Disease 1 1.0
/ O 0 0.3393983244895935
Machado B-Disease 0 6.436581315938383e-05
- I-Disease 0 0.02404043823480606
Joseph I-Disease 0 0.0016266080783680081
disease I-Disease 0 0.2516004145145416
( O 0 3.123464011878241e-07
MJD B-Disease 1 1.0
) O 0 3.671924986292652e-08
( O 0 1.8777337018605067e-08
n O 0 9.943121312971925e-07
= O 0 7.442035894200671e-07
16 O 0 1.177656727691101e-07
) O 0 2.4763501471625204e-08
. O 0 7.302230642380891e-08

In O 0 2.5998106139013544e-06
SCA1 B-Disease 0 2.3866494302637875e-05
, O 0 2.3727364961700914e-08
saccade O 0 3.7108823107701028e-06
amplitude O 0 2.979262490043766e-07
was O 0 3.861084607592602e-08
significantly O 0 1.0625898028138181e-07
increased O 0 2.1817186279804446e-08
, O 0 9.481482265982777e-10
resulting O 0 1.7136727592514944e-08
in O 0 1.954106387813681e-08
hypermetria B-Disease 0 3.027112688869238e-05
. O 0 1.7021497455971257e-07

The O 0 2.9858981065444823e-07
smooth O 0 1.7604588720132597e-06
pursuit O 0 5.587655209637887e-07
gain O 0 6.750167926838913e-07
was O 0 4.839449729843182e-07
decreased O 0 1.1268083426330122e-06
. O 0 1.392885025097712e-07

In O 0 1.282744392483437e-06
SCA2 B-Disease 0 2.4307239073095843e-05
, O 0 3.2558148177486146e-08
saccade O 0 5.7750585256144404e-06
velocity O 0 8.995901339403645e-07
was O 0 3.292510086794209e-07
markedly O 0 8.41895325720543e-06
decreased O 0 6.074168595660012e-06
. O 0 2.510429908397782e-07

The O 0 3.964018162605498e-07
percentage O 0 2.5245279289265454e-07
of O 0 3.14349546393089e-09
errors O 0 1.0158194641007867e-07
in O 0 1.3891381378527967e-08
antisaccades O 0 1.4931487385183573e-05
was O 0 5.605482300552467e-08
greatly O 0 4.41502345793765e-09
increased O 0 2.9001137047401926e-09
and O 0 9.166536973914674e-10
was O 0 1.3174767943269217e-08
significantly O 0 4.076018100818146e-08
correlated O 0 4.7466972574738975e-08
with O 0 5.147046788778198e-09
age O 0 1.8038923599306145e-07
at O 0 2.500814616723801e-06
disease O 0 9.051364759216085e-05
onset O 0 0.00021834278595633805
. O 0 9.676924719315139e-07

In O 0 3.249586484344036e-07
addition O 0 1.891010548149552e-08
, O 0 8.077445934340233e-10
a O 0 9.610718887387293e-10
correlation O 0 1.8703206094983216e-08
between O 0 2.559770839738462e-09
smooth O 0 7.782767141861768e-08
pursuit O 0 8.451607413917372e-09
gain O 0 1.56246677818217e-08
and O 0 2.4848306745539617e-10
the O 0 3.467260922818127e-10
number O 0 3.2963207163838604e-10
of O 0 3.1050342852445567e-10
trinucleotide O 0 7.821882718417328e-06
repeats O 0 1.0717768418544438e-05
was O 0 1.1184270931607898e-07
found O 0 2.7982743233678775e-08
. O 0 5.1145008228559163e-08

In O 0 6.4983946685970295e-06
SCA3 B-Disease 1 0.9999998807907104
, O 0 1.072783675226674e-06
gaze B-Disease 0 0.0004950191942043602
- I-Disease 0 0.00022484040528070182
evoked I-Disease 0 3.521986218402162e-05
nystagmus I-Disease 0 0.0001890561543405056
was O 0 2.729150025970739e-07
often O 0 3.296831474486339e-09
present O 0 1.3470635717993673e-09
as O 0 1.3589913638867301e-09
was O 0 1.4193086705915903e-08
saccade O 0 3.42266702091365e-07
hypometria O 0 4.1561892771824205e-07
and O 0 1.3558224543075426e-09
smooth O 0 2.4285316868599693e-08
pursuit O 0 3.6257624458357895e-08
gain O 0 2.3459818976334645e-07
was O 0 2.915479058174242e-07
markedly O 0 5.225359927862883e-06
decreased O 0 1.7223486565853818e-06
. O 0 1.3540405063849903e-07

Three O 0 1.0074933953774234e-07
major O 0 7.01296940519569e-08
criteria O 0 7.404826618540028e-08
, O 0 3.484273980447483e-09
saccade O 0 1.929751533680246e-06
amplitude O 0 1.4626280631091504e-07
, O 0 2.6341948622388145e-09
saccade O 0 4.7538370040456357e-07
velocity O 0 1.9207534762699652e-07
, O 0 1.7763543969095963e-09
and O 0 3.5834699096959355e-10
presence O 0 4.2425107871224554e-09
of O 0 1.8094836740090159e-09
gaze B-Disease 0 0.00015468604397028685
- I-Disease 0 4.824059215025045e-05
evoked I-Disease 0 5.821972990815993e-06
nystagmus I-Disease 0 3.840958925138693e-06
, O 0 9.56593138035089e-10
permitted O 0 1.7644714578324283e-09
the O 0 2.6489774818116985e-09
correct O 0 2.614769414321927e-07
assignment O 0 6.884305125964829e-09
of O 0 4.57422537347707e-11
90 O 0 1.2795210446725491e-09
% O 0 1.3003145782342074e-10
of O 0 1.7591870668520748e-11
the O 0 7.195885554089898e-10
SCA1 B-Disease 0 2.961921836686088e-07
, O 0 1.1297372065621758e-10
90 O 0 4.790486340944256e-10
% O 0 8.338426477072503e-11
of O 0 1.4701588904597607e-11
the O 0 9.612424189953117e-10
SCA2 B-Disease 0 7.322020110223093e-07
, O 0 2.0185046689658037e-10
and O 0 1.7275000874228397e-10
93 O 0 1.6392284196697915e-09
% O 0 4.5844182616772144e-11
of O 0 1.7193798468317922e-11
the O 0 2.9966393810809677e-09
patients O 0 7.423914816229171e-09
with O 0 5.413817838473278e-09
SCA3 B-Disease 1 1.0
to O 0 8.283018715360413e-09
their O 0 1.7425615395083582e-09
genetically O 0 2.090149742173253e-08
confirmed O 0 5.913627987297332e-08
patient O 0 4.9159037729396005e-08
group O 0 1.2873005994507025e-09
and O 0 2.494127959717929e-10
, O 0 8.075624197134701e-11
therefore O 0 5.681524140044303e-10
, O 0 3.755472877120525e-10
may O 0 1.522573889189971e-08
help O 0 3.569637252454072e-09
orient O 0 3.2780528727016645e-06
diagnoses O 0 4.1662534044917265e-07
of O 0 7.696622783548435e-10
SCA1 B-Disease 0 3.4895747376140207e-06
, O 0 1.6554949633373894e-09
SCA2 B-Disease 0 7.930743208817148e-07
, O 0 1.157932527640071e-09
and O 0 4.4713712732402655e-09
SCA3 B-Disease 1 1.0
at O 0 6.536394181466676e-08
early O 0 9.53351673160796e-08
clinical O 0 1.804635196833715e-08
stages O 0 5.0764588088725304e-09
of O 0 2.87327633907708e-10
the O 0 3.4690110339852254e-08
diseases O 0 8.324198574882757e-07
. O 0 2.53500109792526e-09
. O 0 5.048767803828014e-08

Genetic O 0 1.4176578588376287e-05
basis O 0 1.7628282478199253e-07
and O 0 2.5034813333491002e-08
molecular O 0 1.4440145150729222e-06
mechanism O 0 2.5916073354892433e-05
for O 0 1.610376057215035e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 5.969053381704725e-05

Ventricular B-Disease 1 0.9999845027923584
fibrillation I-Disease 1 0.9999779462814331
causes O 0 1.844614598667249e-05
more O 0 1.0571030273354154e-08
than O 0 2.3629620482523706e-09
300 O 0 2.8838853527446418e-09
, O 0 5.21797716146466e-10
000 O 0 3.841469364829209e-09
sudden O 0 5.555731874551384e-08
deaths O 0 1.3382113195348211e-08
each O 0 5.73010527915585e-10
year O 0 1.6707687455763676e-09
in O 0 1.654191450484177e-09
the O 0 9.761977892708273e-09
USA O 0 9.141871259998879e-07
alone O 0 5.00287029581159e-08
. O 0 3.2014888518006046e-08

In O 0 2.050364571459795e-07
approximately O 0 2.8411534458427923e-08
5 O 0 4.805481168546066e-08
- O 0 1.6995723228774295e-07
12 O 0 9.733122752209056e-09
% O 0 1.1683233547277183e-10
of O 0 1.1486661448401048e-11
these O 0 6.708003597033496e-11
cases O 0 1.2222550749285688e-10
, O 0 1.832845819560447e-10
there O 0 2.451987501927988e-10
are O 0 1.2796717852037176e-10
no O 0 2.8185420664073035e-09
demonstrable O 0 6.836886768724071e-06
cardiac O 0 1.6871606931090355e-05
or O 0 1.5959214749727835e-07
non O 0 3.9267908391593664e-07
- O 0 0.47549936175346375
cardiac O 0 0.007574652321636677
causes O 0 7.473529706203408e-08
to O 0 1.7493650972255637e-09
account O 0 1.0140163153593562e-09
for O 0 7.455409206658103e-11
the O 0 5.16683418272379e-10
episode O 0 8.247421412477252e-09
, O 0 2.2930400633836e-10
which O 0 2.014216571311067e-10
is O 0 1.9774291926122345e-10
therefore O 0 9.630628516887896e-10
classified O 0 3.958199812359453e-08
as O 0 3.151474857077119e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.003267839318141341
IVF B-Disease 1 1.0
) O 0 4.963682158631855e-07
. O 0 2.3982258312571503e-07

A O 0 6.320022976069595e-07
distinct O 0 1.23448089084377e-07
group O 0 3.4899422018952464e-08
of O 0 1.1846061909182026e-08
IVF B-Disease 1 1.0
patients O 0 1.7075474261218915e-06
has O 0 6.4182246184429914e-09
been O 0 3.5923800045800647e-10
found O 0 2.7579480366135556e-10
to O 0 1.3237172469260372e-10
present O 0 2.17002971147906e-10
with O 0 2.349527794542894e-10
a O 0 2.1492958524049754e-08
characteristic O 0 1.462982709199423e-06
electrocardiographic O 0 5.237100049271248e-05
pattern O 0 3.7442845496116206e-05
. O 0 3.181152692377509e-07

Because O 0 1.7488346770733187e-07
of O 0 1.5759495930467438e-09
the O 0 1.2494472123592004e-09
small O 0 1.304443886240847e-09
size O 0 5.90035309500081e-09
of O 0 7.953517011660693e-11
most O 0 2.599802317870825e-10
pedigrees O 0 2.1997661292516568e-07
and O 0 6.74222955243664e-10
the O 0 2.1250083914736706e-09
high O 0 4.885976636614942e-07
incidence O 0 7.172583309511538e-07
of O 0 4.96171770336673e-10
sudden B-Disease 0 5.06430524183088e-07
death I-Disease 0 1.3217183436609048e-07
, O 0 2.5278731885514105e-10
however O 0 2.7908303446011473e-10
, O 0 8.820935648579109e-11
molecular O 0 6.994371304358538e-09
genetic O 0 1.5513489159957317e-08
studies O 0 2.0238410947115426e-09
of O 0 1.5884764614781943e-09
IVF B-Disease 1 1.0
have O 0 5.557328819350005e-09
not O 0 1.0580808451621238e-09
yet O 0 3.0344504686752316e-09
been O 0 2.2596620130599376e-09
done O 0 1.9948190654872633e-08
. O 0 1.464317556099104e-08

Because O 0 6.399455014616251e-05
IVF B-Disease 1 1.0
causes O 0 0.0025615019258111715
cardiac O 1 0.8661202192306519
rhythm O 1 0.9593425393104553
disturbance O 0 0.0005994067178107798
, O 0 3.1688529134044074e-08
we O 0 3.064334119784462e-09
investigated O 0 1.8801420864633656e-08
whether O 0 4.435897871246652e-09
malfunction O 0 7.348985036514932e-06
of O 0 4.1023451302635294e-10
ion O 0 3.076262089507509e-07
channels O 0 2.0614402274077293e-07
could O 0 2.432737460367207e-07
cause O 0 1.304569536841882e-07
the O 0 4.18081995690045e-08
disorder O 0 1.3458054581860779e-06
by O 0 8.009879426396083e-10
studying O 0 5.139650038898935e-09
mutations O 0 7.490598363801837e-08
in O 0 1.5196544023154956e-09
the O 0 1.598281507142474e-08
cardiac O 0 9.716775821289048e-06
sodium O 0 2.4944408778537763e-06
channel O 0 6.6115408117184415e-06
gene O 0 8.315411832882091e-06
SCN5A O 0 5.568745109485462e-05
. O 0 2.5380705892530386e-07

We O 0 2.095675171176481e-07
have O 0 3.1623845764272573e-09
now O 0 1.920019476742141e-09
identified O 0 3.596605235856032e-09
a O 0 5.938537217531348e-09
missense O 0 4.871799319516867e-06
mutation O 0 5.057070779912465e-07
, O 0 1.2790892789382724e-09
a O 0 1.2987494635297026e-08
splice O 0 0.0007122273673303425
- O 0 1.8428912881063297e-05
donor O 0 2.951956048491411e-07
mutation O 0 9.229947295352758e-07
, O 0 1.3463854475759263e-09
and O 0 6.651528217105351e-10
a O 0 1.6852391482302664e-08
frameshift O 0 4.4680473365588114e-05
mutation O 0 5.562209253184847e-07
in O 0 5.839481342917452e-09
the O 0 7.03547398117621e-09
coding O 0 4.909438189315551e-07
region O 0 5.632046384818068e-09
of O 0 4.6350728810651276e-10
SCN5A O 0 1.2217735729791457e-06
in O 0 6.1091691705428275e-09
three O 0 6.595993085056762e-09
IVF B-Disease 1 0.9999984502792358
families O 0 3.221322231183876e-08
. O 0 4.794888042169987e-08

We O 0 2.8620127068279544e-07
show O 0 1.1760338480826249e-07
that O 0 7.094980158939279e-10
sodium O 0 3.5752606208916404e-08
channels O 0 2.8482668668061706e-08
with O 0 7.877219432295135e-10
the O 0 4.7130894742508644e-09
missense O 0 7.631413609487936e-06
mutation O 0 8.297710110127809e-07
recover O 0 4.556121098175936e-07
from O 0 1.2318378317388579e-08
inactivation O 0 7.688338996558741e-07
more O 0 5.99892857611195e-10
rapidly O 0 1.713809893999496e-08
than O 0 3.544086413231895e-10
normal O 0 1.2364751889037962e-08
and O 0 6.174674105352551e-10
that O 0 1.3240479546094974e-10
the O 0 6.368568783443607e-09
frameshift O 0 2.885249341488816e-05
mutation O 0 2.8638694971050427e-07
causes O 0 9.273356305072866e-09
the O 0 3.0772784320731716e-09
sodium O 0 2.765181079666945e-07
channel O 0 2.77483110266985e-07
to O 0 3.0825535457523756e-09
be O 0 1.2513289293636376e-09
non O 0 1.6319821938282075e-08
- O 0 7.869491014389496e-07
functional O 0 4.5921967739559477e-07
. O 0 8.935027295819964e-08

Our O 0 4.92324204515171e-07
results O 0 1.6255955870292382e-07
indicate O 0 3.7400361918571434e-08
that O 0 7.15960624120271e-10
mutations O 0 1.3231839091076836e-07
in O 0 7.511741451082798e-09
cardiac O 0 4.953948518959805e-06
ion O 0 5.041924396209652e-06
- O 0 6.766533260815777e-06
channel O 0 1.3966241567686666e-06
genes O 0 4.741693260257307e-08
contribute O 0 8.763253456223197e-10
to O 0 3.422268024522168e-10
the O 0 6.978536637447519e-10
risk O 0 4.710205114832888e-09
of O 0 4.713356926977497e-10
developing O 0 7.77256090600531e-08
IVF B-Disease 1 0.9999992847442627
. O 0 2.376060592723661e-08
. O 0 3.851419450029425e-08

Molecular O 0 3.7134501326363534e-05
heterogeneity O 0 2.4033635781961493e-05
in O 0 6.614767471546656e-07
mucopolysaccharidosis B-Disease 0 6.967096851440147e-05
IVA I-Disease 0 4.0396847907686606e-05
in O 0 2.2124821441593667e-07
Australia O 0 5.565319582956363e-08
and O 0 1.9647792282029286e-09
Northern O 0 5.3126228749533766e-08
Ireland O 0 1.836226601881208e-06
: O 0 8.883190849573452e-10
nine O 0 9.344300888614043e-10
novel O 0 6.259987195278427e-09
mutations O 0 3.4569499263170655e-08
including O 0 5.685513171371781e-10
T312S O 0 7.814554692231468e-08
, O 0 3.404987680699634e-10
a O 0 2.1144237472014993e-09
common O 0 1.4606467146904833e-08
allele O 0 2.341290468166335e-07
that O 0 1.2758509804200457e-09
confers O 0 8.61702247334506e-08
a O 0 8.274242446759672e-08
mild O 0 0.004503810778260231
phenotype O 0 0.0006421598372980952
. O 0 4.4687521949526854e-07

Mucopolysaccharidosis B-Disease 0 0.1040683165192604
IVA I-Disease 1 0.9825809597969055
( O 0 0.0007852479466237128
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 0.9999995231628418
) O 0 5.4706724483821745e-08
is O 0 3.3938891697005147e-09
an O 0 1.5821969512330725e-08
autosomal B-Disease 1 0.9999853372573853
recessive I-Disease 1 1.0
lysosomal I-Disease 1 0.9999998807907104
storage I-Disease 1 0.9999995231628418
disorder I-Disease 1 0.9999686479568481
caused O 0 1.7193027588291443e-06
by O 0 1.8471631335614802e-08
a O 0 2.5093961539823795e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 2.933448115527426e-07
N O 0 0.00011307058593956754
- O 0 3.80263700208161e-05
acetylgalactosamine O 0 0.0009789963951334357
- O 0 0.00017921667313203216
6 O 0 3.7863790112169227e-06
- O 0 8.448074368061498e-05
sulfate O 0 2.2414074919652194e-05
sulfatase O 0 3.554336944944225e-05
( O 0 9.986429461150692e-08
GALNS O 0 5.451357992569683e-06
) O 0 4.920594065538353e-08
. O 0 8.349961433395947e-08

Previous O 0 2.6882737529376755e-06
studies O 0 5.668194447139285e-08
of O 0 1.1321494852722935e-09
patients O 0 5.32036725786611e-09
from O 0 1.222787315846574e-09
a O 0 1.2322561637745366e-08
British O 0 2.6336947485106066e-06
- O 0 1.0883273944273242e-06
Irish O 0 4.010590970437988e-08
population O 0 3.0780400450680645e-10
showed O 0 4.296517808199951e-09
that O 0 7.896018561215357e-11
the O 0 9.197851924547251e-10
I113F O 0 1.383440775271083e-07
mutation O 0 3.7837619260017163e-08
is O 0 1.3850361135769873e-10
the O 0 1.7783977068752677e-10
most O 0 2.745655647284906e-10
common O 0 2.9292999137453535e-09
single O 0 4.551526089358049e-08
mutation O 0 9.392659308105067e-07
among O 0 4.86243258990271e-08
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 1.0
patients O 0 1.0192531590291765e-05
and O 0 1.612636957304403e-08
produces O 0 1.3878755567020562e-07
a O 0 1.3300358148171654e-07
severe O 0 0.0008515266817994416
clinical O 0 1.4343590009957552e-05
phenotype O 0 0.0004153858171775937
. O 0 7.691074301874323e-07

We O 0 3.661693881440442e-07
studied O 0 3.7164389254940033e-07
mutations O 0 6.286684879341919e-07
in O 0 5.617273757252406e-09
the O 0 6.956506037880672e-09
GALNS O 0 2.238750994365546e-06
gene O 0 3.680904967495735e-07
from O 0 9.3596819183972e-09
23 O 0 3.188879560411806e-08
additional O 0 3.672919746122716e-08
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
patients O 0 1.9180056369805243e-06
( O 0 1.2511171654239206e-08
15 O 0 8.237674542499462e-09
from O 0 1.2265246596143697e-09
Australia O 0 1.87282545027756e-09
, O 0 9.442838178053137e-11
8 O 0 2.3116077940699142e-09
from O 0 9.801488509708634e-10
Northern O 0 9.175974469144421e-08
Ireland O 0 8.801987974038639e-07
) O 0 2.5481661225512653e-10
, O 0 3.0398118050500855e-11
with O 0 7.312435379436266e-11
various O 0 2.6151913967709106e-09
clinical O 0 4.2638242803150206e-07
phenotypes O 0 5.8863779486273415e-06
( O 0 9.67325561873622e-08
severe O 0 0.0003224863321520388
, O 0 1.2496099266456895e-08
16 O 0 5.64413689119192e-08
cases O 0 4.114383500564145e-09
; O 0 4.472070713745779e-09
intermediate O 0 2.527866271861967e-08
, O 0 1.4260320702064178e-09
4 O 0 2.0117575161293644e-08
cases O 0 5.089236587707546e-09
; O 0 4.947377263420094e-08
mild O 0 0.06526992470026016
, O 0 1.7919989048209573e-08
3 O 0 6.702104116129703e-08
cases O 0 1.4168823447846535e-08
) O 0 2.766264017850517e-08
. O 0 7.494485032566445e-08

We O 0 6.377530326062697e-08
found O 0 5.605896191696047e-09
two O 0 3.71078584526785e-10
common O 0 5.446608497550187e-09
mutations O 0 5.1963208846927955e-08
that O 0 2.9003885404499385e-10
together O 0 8.81399397911764e-10
accounted O 0 1.4602782316686103e-09
for O 0 6.991416473534073e-11
32 O 0 1.920107406405691e-09
% O 0 4.224097460703291e-11
of O 0 1.1191205948057892e-11
the O 0 7.675365898407449e-10
44 O 0 6.715678679825032e-09
unrelated O 0 1.0244562531624979e-08
alleles O 0 2.585050218328888e-08
in O 0 4.5378021340525265e-09
these O 0 7.140040114705926e-09
patients O 0 8.842106069550937e-08
. O 0 7.15794712391471e-08

One O 0 1.9404539841616497e-07
is O 0 2.6422661836278394e-09
the O 0 2.472285265398e-09
T312S O 0 3.680532643102197e-07
mutation O 0 1.405156950795572e-07
, O 0 7.44151906761914e-10
a O 0 2.343522487180394e-09
novel O 0 7.264261192574395e-09
mutation O 0 7.20234538675868e-08
found O 0 2.1055375221123995e-09
exclusively O 0 4.133150266483199e-09
in O 0 1.72594738501175e-08
milder O 0 0.002436265582218766
patients O 0 3.8438865885837e-06
. O 0 2.419133409148344e-07

The O 0 5.7762864713595263e-08
other O 0 9.350791252416002e-10
is O 0 1.2579307040461174e-10
the O 0 2.5110252765969676e-10
previously O 0 3.2040221586981943e-09
described O 0 7.621656195055948e-09
I113F O 0 1.4705710782436654e-07
that O 0 8.846651189386989e-10
produces O 0 4.429761801816312e-08
a O 0 5.5771145923699805e-08
severe O 0 0.00010389729868620634
phenotype O 0 0.00015243017696775496
. O 0 4.89229478262132e-07

The O 0 1.3210294582677307e-06
I113F O 0 8.720409823581576e-06
and O 0 2.5178284346338842e-08
T312S O 0 1.418136321262864e-06
mutations O 0 8.54189352139656e-07
accounted O 0 3.230021761169155e-08
for O 0 1.967550788961603e-09
8 O 0 2.8895138726170444e-08
( O 0 6.933642549000751e-09
18 O 0 6.654043538389942e-09
% O 0 2.3624874279093433e-10
) O 0 2.0332188710447952e-10
and O 0 1.61512325735913e-09
6 O 0 2.7753859654922053e-08
( O 0 2.883280281196221e-09
14 O 0 6.430686205760594e-09
% O 0 1.6774896749449653e-10
) O 0 7.3494335617319e-11
of O 0 1.0292734026196015e-10
44 O 0 6.355475701269597e-09
unrelated O 0 9.849412840878813e-09
alleles O 0 6.934835283800567e-08
, O 0 2.617416949846074e-09
respectively O 0 6.810660124756396e-08
. O 0 4.345814730299935e-08

The O 0 5.118931767356116e-07
relatively O 0 2.609513103379868e-07
high O 0 3.6386524016052135e-07
residual O 0 1.408061507390812e-06
GALNS O 0 6.271824986470165e-06
activity O 0 1.962136906286105e-07
seen O 0 4.2852583703734126e-08
when O 0 2.2128898713447143e-09
the O 0 2.00629979296707e-09
T312S O 0 2.2478211292309425e-07
mutant O 0 5.516282897133351e-08
cDNA O 0 1.5888264215391246e-07
is O 0 4.065611847181572e-09
overexpressed O 0 5.208660240896279e-07
in O 0 3.0367433012656875e-09
mutant O 0 5.552744042347513e-08
cells O 0 1.1720161730011114e-08
provides O 0 4.808088926999687e-10
an O 0 1.0753496010318386e-10
explanation O 0 1.706183416771978e-09
for O 0 2.633359363901633e-10
the O 0 2.313536562326135e-08
mild O 0 0.08430260419845581
phenotype O 0 0.00021750439191237092
in O 0 5.5266564658040807e-08
patients O 0 3.068874576683811e-08
with O 0 1.821398809553898e-09
this O 0 1.1768816143842287e-08
mutation O 0 4.960283149557654e-06
. O 0 1.449431010769331e-07

The O 0 1.0714958875723823e-07
distribution O 0 2.7319616791032786e-08
and O 0 6.271516639344554e-10
relative O 0 2.342266824939543e-09
frequencies O 0 2.4601785497679884e-08
of O 0 1.0734969857484344e-10
the O 0 7.746313035461583e-10
I113F O 0 7.988953854010106e-08
and O 0 1.2918386360638578e-09
T312S O 0 2.047417950734598e-07
mutations O 0 1.214407063798717e-07
in O 0 3.6028668937149178e-09
Australia O 0 3.497590883583257e-09
corresponded O 0 7.763119924675266e-09
to O 0 3.8747730024546456e-10
those O 0 1.2090849155210748e-10
observed O 0 1.2007477234732278e-09
in O 0 9.101658871024654e-10
Northern O 0 2.3530954962325268e-08
Ireland O 0 2.2648848130302213e-07
and O 0 2.1558957397083134e-10
are O 0 9.684885705907309e-12
unique O 0 2.705346016651511e-11
to O 0 1.6375058253803587e-10
these O 0 2.836232984582132e-11
two O 0 3.2289018681019854e-11
populations O 0 2.0625681718122735e-10
, O 0 4.7252816243181783e-11
suggesting O 0 1.1422266465999087e-09
that O 0 4.7518353835096505e-11
both O 0 2.566236945167333e-10
mutations O 0 1.9617845126163047e-08
were O 0 9.76307146238753e-10
probably O 0 2.1114816561862426e-09
introduced O 0 2.049140235271807e-08
to O 0 4.80788797663223e-10
Australia O 0 4.573843803701294e-10
by O 0 1.2384471226312144e-10
Irish O 0 1.6227069687957396e-09
migrants O 0 3.035039441989795e-10
during O 0 8.657276007184578e-10
the O 0 1.4859871111383427e-09
19th O 0 9.279906976189523e-08
century O 0 3.24821058939051e-07
. O 0 9.36947301966029e-08

Haplotype O 0 0.0005146785988472402
analysis O 0 9.047057574207429e-07
using O 0 2.1598290800284303e-07
6 O 0 1.5220518889691448e-07
RFLPs O 0 8.615984370408114e-07
provides O 0 9.127004707565334e-10
additional O 0 5.238779410277061e-10
data O 0 8.402134987761656e-09
that O 0 2.87076196148206e-10
the O 0 2.430300627409565e-09
I113F O 0 3.951438145577413e-07
mutation O 0 4.654852148178179e-08
originated O 0 1.5815000864449758e-08
from O 0 1.8419833436311706e-09
a O 0 3.1206748296597198e-09
common O 0 1.728009380030926e-08
ancestor O 0 2.6601995273267676e-07
. O 0 9.560522329365995e-08

The O 0 7.364571530388275e-08
other O 0 6.3426028873436735e-09
9 O 0 6.752414805077933e-08
novel O 0 2.711663249499452e-08
mutations O 0 1.3229276873971685e-07
identified O 0 5.425736748776444e-09
in O 0 1.423895779062434e-09
these O 0 1.6818988424205372e-09
23 O 0 7.265843748882617e-08
patients O 0 2.486178374283554e-09
were O 0 6.194751378529872e-10
each O 0 9.174404291822924e-11
limited O 0 1.4673532389153365e-09
to O 0 5.073136355449037e-10
a O 0 3.6040694872951917e-09
single O 0 3.105553147975115e-08
family O 0 9.465318839829706e-08
. O 0 4.740870096497929e-08

These O 0 6.243033823238875e-08
data O 0 4.098563977095182e-08
provide O 0 6.116978035208831e-10
further O 0 2.8521562889238794e-10
evidence O 0 1.053257897565274e-10
for O 0 1.3806866761001402e-10
extensive O 0 1.1239761121828451e-08
allelic O 0 2.563941052358132e-06
heterogeneity O 0 1.9221661204937845e-06
in O 0 4.420825007400708e-06
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 0.9999992847442627
in O 0 5.745218345509784e-07
British O 0 3.8354504795279354e-05
- O 0 5.947230238234624e-05
Irish O 0 3.9729383161102305e-07
patients O 0 9.017751878559466e-09
and O 0 1.0723633092624141e-10
provide O 0 7.114598493673796e-11
evidence O 0 1.147333270057338e-10
for O 0 4.1460078425981095e-11
their O 0 1.4768070100146247e-09
transmission O 0 2.467683225404471e-05
to O 0 7.506036903137669e-10
Australia O 0 1.2479419719824136e-09
by O 0 2.1237998859557905e-10
British O 0 5.906447597681108e-08
- O 0 3.4081301691912813e-07
Irish O 0 5.539806124943425e-08
migrants O 0 6.0981095728607215e-09
. O 0 2.5769750777726586e-09
. O 0 2.1884245526848645e-08

Identification O 0 2.0895574834867148e-06
of O 0 4.9836700100058806e-08
constitutional O 0 6.695970569126075e-07
WT1 O 0 0.00019161739328410476
mutations O 0 3.83401629733271e-06
, O 0 1.490477630206044e-09
in O 0 3.5137188714173817e-09
patients O 0 1.3110970975560576e-08
with O 0 9.697192382418507e-09
isolated O 0 0.15414953231811523
diffuse B-Disease 1 0.9999997615814209
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.53094620209049e-08
and O 0 1.2515127822965155e-09
analysis O 0 3.181557017839509e-09
of O 0 2.413753197316737e-09
genotype O 0 0.00030634732684120536
/ O 0 0.000562349334359169
phenotype O 0 5.363926447898848e-06
correlations O 0 7.872030494127102e-08
by O 0 1.3533240084129261e-09
use O 0 5.102240852039586e-09
of O 0 7.569858628819759e-10
a O 0 3.9901120629792786e-08
computerized O 0 0.0002819091023411602
mutation O 0 1.0219746400252916e-05
database O 0 3.198094418621622e-06
. O 0 3.9456878653254535e-07

Constitutional O 0 1.1482798072393052e-05
mutations O 0 1.8858705516322516e-05
of O 0 9.707629367028403e-09
the O 0 3.5769726736134544e-08
WT1 O 0 2.4882845536922105e-05
gene O 0 6.041108235876891e-07
, O 0 3.2789710946445894e-09
encoding O 0 7.653620315295484e-08
a O 0 9.257119870653696e-08
zinc O 0 0.006214539520442486
- O 0 1.572184714859759e-06
finger O 0 1.5688799976487644e-05
transcription O 0 2.6446528522683366e-07
factor O 0 7.904013443749136e-09
involved O 0 1.5261493180318553e-09
in O 0 1.1746188022243587e-08
renal O 0 1.5660594726796262e-05
and O 0 9.79080549967648e-09
gonadal O 0 3.760088929993799e-06
development O 0 1.3142635868490515e-09
, O 0 1.4993216390646324e-10
are O 0 4.546946152927944e-11
found O 0 2.7515903444630396e-10
in O 0 4.606236503335026e-10
most O 0 5.768859834276441e-10
patients O 0 4.402922471058446e-09
with O 0 2.3596664178171523e-08
Denys B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999995231628418
Drash I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 6.558954623869795e-07
DDS B-Disease 1 1.0
) O 0 3.5919860863486974e-08
, O 0 5.025974747496775e-09
or O 0 4.9707864491210785e-06
diffuse B-Disease 1 0.999996542930603
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.7707856386550702e-05
DMS B-Disease 1 0.9770061373710632
) O 0 1.7526154749702982e-08
associated O 0 3.389892455629706e-08
with O 0 2.6343871084577586e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 2.476464487699559e-06
/ O 0 0.0008937316597439349
or O 0 4.726271527033532e-06
Wilms B-Disease 0 0.44097596406936646
tumor I-Disease 0 0.049736861139535904
( O 0 2.4594805836386513e-06
WT B-Disease 1 0.9999970197677612
) O 0 9.378627652267824e-08
. O 0 7.551867753363695e-08

Most O 0 1.8264879599882988e-06
mutations O 0 0.00025362989981658757
in O 0 5.396610504249111e-06
DDS B-Disease 1 1.0
patients O 0 5.953676736680791e-05
lie O 0 1.3016638433782646e-07
in O 0 2.4568493017795845e-08
exon O 0 4.15259364672238e-06
8 O 0 2.478900000824069e-07
or O 0 3.081038713048656e-08
exon O 0 1.405725583936146e-06
9 O 0 3.089318738602742e-07
, O 0 2.038166302398281e-09
encoding O 0 1.608728325663833e-06
zinc O 0 0.004122124053537846
finger O 0 0.050278179347515106
2 O 0 1.5241640483054653e-07
or O 0 5.154703330845223e-07
zinc O 0 0.0006242161616683006
finger O 0 0.005744873080402613
3 O 0 3.305830986732872e-08
, O 0 3.196665154803213e-10
respectively O 0 2.350976968656937e-09
, O 0 6.596137525072265e-11
with O 0 2.9814672952710453e-10
a O 0 7.99767434500609e-08
hot O 0 0.001033105654641986
spot O 0 4.815850388695253e-06
( O 0 5.5526352404910995e-09
R394W O 0 1.2819064920677192e-07
) O 0 1.2286671680072914e-09
in O 0 5.427309712757733e-09
exon O 0 1.5941218407533597e-06
9 O 0 4.397901420816197e-07
. O 0 6.969298738113139e-08

We O 0 3.3003382782226254e-07
analyzed O 0 2.9326704975574103e-07
a O 0 5.895695931457112e-09
series O 0 1.5012805221203962e-08
of O 0 6.806537555803516e-10
24 O 0 1.0413877760129253e-07
patients O 0 7.232104692889152e-09
, O 0 4.84822182400535e-10
10 O 0 2.77116352087603e-09
with O 0 8.444710708488401e-09
isolated B-Disease 0 0.00040845799958333373
DMS I-Disease 1 0.9999351501464844
( O 0 3.4920341818178713e-07
IDMS B-Disease 0 7.065436511766165e-05
) O 0 8.140708551707121e-09
, O 0 1.1681857703393916e-09
10 O 0 5.942072611730964e-09
with O 0 1.3121803199567239e-08
DDS B-Disease 1 1.0
, O 0 1.208509825545434e-08
and O 0 3.1837363856368484e-09
4 O 0 5.1103274500974294e-08
with O 0 3.7005694508707165e-08
urogenital B-Disease 1 0.9986873269081116
abnormalities I-Disease 1 0.9999977350234985
and O 0 3.4630591017048573e-06
/ O 1 0.5774564146995544
or O 0 0.00016199529636651278
WT B-Disease 1 0.9999997615814209
. O 0 6.508819865302939e-07

We O 0 1.848497163337015e-06
report O 0 1.956567984962021e-06
WT1 O 0 0.00021651842689607292
heterozygous O 0 2.321723513887264e-05
mutations O 0 8.385187356907409e-06
in O 0 3.7912460726374775e-08
16 O 0 7.27130640143514e-08
patients O 0 1.3398278930765173e-08
, O 0 6.12363160179541e-10
4 O 0 7.934827905842212e-09
of O 0 6.573696587075517e-10
whom O 0 7.832636761406775e-09
presented O 0 1.6749208242572422e-08
with O 0 1.7252627770858453e-08
IDMS B-Disease 0 0.0009655617759563029
. O 0 5.944273766544939e-07

One O 0 3.0570973308385874e-07
male O 0 2.0016419455259893e-07
and O 0 4.14780787494351e-09
two O 0 8.122995609483041e-09
female O 0 1.8200945817170577e-07
IDMS B-Disease 0 0.0008108578040264547
patients O 0 7.058904998302751e-07
with O 0 1.5497214178594731e-07
WT1 O 1 0.6695504188537598
mutations O 0 0.0041984329000115395
underwent O 0 0.000728394603356719
normal O 0 0.00013851573748979717
puberty O 0 0.0013797441497445107
. O 0 1.1189108590770047e-06

Two O 0 9.071100635082985e-07
mutations O 0 3.818338882410899e-05
associated O 0 4.1809317963270587e-07
with O 0 3.4387994674034417e-08
IDMS B-Disease 0 0.0007618810050189495
are O 0 8.45836012342005e-10
different O 0 3.183358299185812e-10
from O 0 1.1266004795729145e-09
those O 0 5.515740642003664e-10
described O 0 8.089170933089918e-08
in O 0 5.53994311758288e-07
DDS B-Disease 1 1.0
patients O 0 1.9725361198652536e-05
. O 0 3.1209685857902514e-07

No O 0 2.735111138463253e-06
WT1 O 0 0.0004816979053430259
mutations O 0 3.594590089051053e-05
were O 0 2.5553475779815926e-08
detected O 0 1.5014300913662737e-07
in O 0 4.045746848646559e-09
the O 0 2.5691524463411497e-09
six O 0 2.2880257688484562e-09
other O 0 1.3603580484300437e-09
IDMS B-Disease 0 0.0003054374537896365
patients O 0 4.4532448839618155e-08
, O 0 1.4013070703811081e-09
suggesting O 0 3.028935324778104e-08
genetic O 0 7.319744099731906e-08
heterogeneity O 0 1.6782890099875658e-07
of O 0 1.7932700879796926e-09
this O 0 8.414183128024888e-08
disease O 0 0.00014080735854804516
. O 0 2.4340786808352277e-07

We O 0 1.2078136251147953e-06
analyzed O 0 6.221812782314373e-06
genotype O 0 0.0002140940196113661
/ O 0 0.00022576458286494017
phenotype O 0 3.115517756668851e-05
correlations O 0 1.2961679658474168e-06
, O 0 2.394229259294889e-09
on O 0 1.0001943273607594e-08
the O 0 1.2754909350931598e-09
basis O 0 9.600789052655045e-10
of O 0 6.17513123968294e-11
the O 0 9.659805177975045e-10
constitution O 0 1.592802889582856e-09
of O 0 4.400373815327541e-11
a O 0 3.738387377438812e-09
WT1 O 0 6.585319169971626e-06
mutation O 0 9.830554859036056e-08
database O 0 1.4812790105622753e-08
of O 0 8.638901261015519e-10
84 O 0 1.5377889894807595e-07
germ O 0 3.367826866451651e-05
- O 0 0.00044431406422518194
line O 0 0.001190877053886652
mutations O 0 8.496121495227271e-07
, O 0 2.380117769540391e-10
to O 0 5.068087616244554e-10
compare O 0 7.962722925469734e-09
the O 0 5.577395767453197e-10
distribution O 0 1.0728630206457979e-09
and O 0 2.8753815994875254e-10
type O 0 1.0456985499729399e-08
of O 0 2.6513519157944643e-10
mutations O 0 4.730103952965692e-08
, O 0 1.3366870110775864e-10
according O 0 8.467378881382714e-11
to O 0 3.6495642619094326e-10
the O 0 1.7609547153796257e-09
different O 0 3.043912499833823e-08
symptoms O 0 6.441013829316944e-05
. O 0 9.103836617896377e-08

This O 0 2.662671647613024e-07
demonstrated O 0 2.749636962562363e-07
( O 0 3.198143971872014e-08
1 O 0 7.396156576078283e-09
) O 0 3.907219547905072e-10
the O 0 5.412638115487312e-10
association O 0 2.518240282967099e-09
between O 0 1.1290141044284496e-09
mutations O 0 1.9643724158413534e-07
in O 0 5.644908984692165e-09
exons O 0 4.693759478868742e-07
8 O 0 2.9475958740476926e-07
and O 0 5.695501403835124e-09
9 O 0 5.214540124143241e-07
and O 0 3.0122162542056685e-08
DMS B-Disease 0 0.15658371150493622
; O 0 2.1397081439999965e-08
( O 0 6.279372133377592e-09
2 O 0 1.3612361016157593e-08
) O 0 1.7396026841254297e-09
among O 0 3.0647417936791044e-10
patients O 0 3.1037452608018157e-09
with O 0 3.77739972634572e-09
DMS B-Disease 0 0.025502223521471024
, O 0 7.390456580047555e-10
a O 0 2.5056539065815286e-09
higher O 0 1.9069254619807907e-08
frequency O 0 3.0060638778195425e-07
of O 0 8.244932514500647e-10
exon O 0 5.759915211456246e-07
8 O 0 3.900559164549122e-08
mutations O 0 8.811649365725316e-08
among O 0 1.1868785954050054e-09
46 O 0 2.1875189659681382e-08
, O 0 4.834806777154199e-09
XY O 0 1.2115133358747698e-05
patients O 0 1.9159488218178922e-08
with O 0 1.5350591908713795e-09
female O 0 1.7566817334113694e-08
phenotype O 0 2.5814244963839883e-07
than O 0 9.974427950254494e-10
among O 0 5.559043780856143e-10
46 O 0 1.275613215057092e-08
, O 0 4.408333698080469e-09
XY O 0 1.260430144611746e-05
patients O 0 9.952843882388152e-09
with O 0 1.279374606255601e-09
sexual O 0 2.876097582316106e-08
ambiguity O 0 4.9532882684388824e-08
or O 0 7.737858709333523e-08
male O 0 1.1784701570149991e-07
phenotype O 0 3.0377352686628e-06
; O 0 1.4668110281945701e-08
and O 0 1.0583922183116101e-08
( O 0 7.722713135649428e-09
3 O 0 1.383983772029751e-08
) O 0 9.049036520103471e-10
statistically O 0 3.436561701875007e-09
significant O 0 3.8360492560229886e-10
evidence O 0 9.461663674770193e-10
that O 0 1.6002756897393056e-09
mutations O 0 1.4185026486757124e-07
in O 0 5.349714449209841e-09
exons O 0 6.43417990886519e-07
8 O 0 1.0802210681504221e-07
and O 0 4.219181448661402e-09
9 O 0 4.57737421299953e-08
preferentially O 0 1.731449543740382e-07
affect O 0 2.7886622788741988e-08
amino O 0 2.4673402876373984e-08
acids O 0 5.6276761029039335e-09
with O 0 2.3075626132129656e-10
different O 0 6.393796603276769e-10
functions O 0 3.763520606270276e-09
. O 0 3.16627146723647e-09
. O 0 3.4776231672140057e-08

The O 0 1.7453220380048151e-06
185delAG O 0 0.0001414174330420792
BRCA1 O 0 0.00016565229452680796
mutation O 0 2.782531282718992e-06
originated O 0 2.2098735996678442e-07
before O 0 1.6583019402105492e-08
the O 0 1.3662373454792487e-09
dispersion O 0 2.2561403412169057e-08
of O 0 5.367861016791764e-11
Jews O 0 4.831992583831379e-10
in O 0 2.5644023016191397e-10
the O 0 1.0206993028560873e-09
diaspora O 0 3.0437596887367135e-09
and O 0 6.0919680411331e-10
is O 0 1.6271536895651195e-10
not O 0 1.871282018228726e-10
limited O 0 3.366295908691086e-09
to O 0 9.074656581731233e-09
Ashkenazim O 0 1.2904529285151511e-05
. O 0 1.0727227817142193e-07

The O 0 8.258670618488395e-07
185delAG O 0 1.7418751667719334e-05
mutation O 0 5.954213065706426e-06
in O 0 7.06948242168437e-08
BRCA1 O 0 4.752658242068719e-06
is O 0 2.880652827386143e-09
detected O 0 7.805959256756978e-08
in O 0 3.3590354941992473e-09
Ashkenazi O 0 1.1998010052138852e-07
Jews O 0 5.879847164713681e-10
both O 0 3.082410993116014e-10
in O 0 1.4514154322853301e-08
familial B-Disease 1 0.9323723316192627
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.761033428086648e-09
in O 0 1.11176057249196e-09
the O 0 1.4346693832933965e-09
general O 0 2.5994018049146916e-09
population O 0 3.881165611119286e-09
. O 0 3.792395730783937e-08

All O 0 4.3874160837731324e-07
tested O 0 4.474561137612909e-06
Ashkenazi O 0 1.8229105990030803e-05
mutation O 0 1.2126241699661477e-06
carriers O 0 9.566814895833886e-08
share O 0 2.2267443000600906e-08
the O 0 2.2006414468478397e-09
same O 0 7.092277432008132e-09
allelic O 0 7.384149967037956e-07
pattern O 0 2.116679979735636e-06
at O 0 1.0060666255640172e-07
the O 0 1.3304342871833796e-07
BRCA1 O 0 4.5804645196767524e-05
locus O 0 1.2359972970443778e-05
. O 0 4.1880352341649996e-07

Our O 0 1.0355382755733444e-06
previous O 0 3.513135027333192e-07
study O 0 2.2869972582384435e-08
showed O 0 5.0124121742101124e-08
that O 0 6.245625128187271e-10
this O 0 1.750446565473851e-09
Ashkenazi O 0 4.174543846602319e-06
mutation O 0 2.5987148433159746e-07
also O 0 1.6731031005079444e-09
occurs O 0 1.8906274323882144e-09
in O 0 8.063807399594225e-10
Iraqi O 0 2.6698048216644565e-09
Jews O 0 6.112989003881353e-10
with O 0 1.1520456810742985e-10
a O 0 4.033973155515014e-09
similar O 0 6.010260733546602e-08
allelic O 0 1.2646298273466527e-05
pattern O 0 8.864637493388727e-05
. O 0 4.860096396441804e-07

We O 0 2.81599199070115e-07
extended O 0 1.1441355241004203e-07
our O 0 4.01636102154157e-09
analysis O 0 8.733501144497779e-10
to O 0 1.4848104690212693e-10
other O 0 1.0567774433312138e-10
non O 0 3.7126708374302098e-09
- O 0 1.6250857015620568e-07
Ashkenazi O 0 6.063017394808412e-07
subsets O 0 2.498520501603707e-08
354 O 0 1.3306875601415413e-08
of O 0 1.7890125492137088e-10
Moroccan O 0 1.509722657999646e-08
origin O 0 9.904134179450352e-10
, O 0 2.5938093339838986e-10
200 O 0 1.2134913074390852e-09
Yemenites O 0 9.931836331134036e-08
and O 0 6.964893661809413e-10
150 O 0 3.718262364671432e-09
Iranian O 0 3.977028129042992e-08
Jews O 0 4.380124707381583e-08
. O 0 5.243353129458228e-08

Heteroduplex O 0 0.0004494626191444695
analysis O 0 2.6402231014799327e-06
complemented O 0 5.382344738791289e-07
by O 0 6.415691089500797e-09
direct O 0 1.368543589563842e-08
DNA O 0 1.1646250186458929e-07
sequencing O 0 1.0003930128732463e-07
of O 0 3.5577558676891385e-09
abnormally O 0 1.271847168027307e-06
migrating O 0 4.963492372667133e-08
bands O 0 2.6529082219894917e-07
were O 0 1.372349434092257e-08
employed O 0 9.123009903078128e-08
. O 0 5.656843526935518e-08

Four O 0 9.683722623776703e-08
of O 0 2.63657740084966e-09
Moroccan O 0 8.279152297063774e-08
origin O 0 8.377875282405967e-09
( O 0 2.82739387458264e-09
1 O 0 2.0780168696887813e-09
. O 0 1.4049619800893254e-10
1 O 0 1.0080229984055222e-09
% O 0 1.4972012518654765e-10
) O 0 1.0200915112612563e-10
and O 0 2.966067669252226e-10
none O 0 3.4281150140813565e-10
of O 0 4.918203691528511e-11
the O 0 2.8083677605650337e-09
Yemenites O 0 2.482134107140155e-07
or O 0 2.6586659540583923e-09
Iranians O 0 9.441833981327363e-10
was O 0 2.512444696733951e-09
a O 0 6.0666438539414e-10
carrier O 0 6.560597842764082e-09
of O 0 1.7151619013944241e-10
the O 0 5.919380541286046e-09
185delAG O 0 3.7039631024526898e-06
mutation O 0 2.397766593276174e-06
. O 0 1.9595861999732733e-07

BRCA1 O 0 0.010667315684258938
allelic O 0 0.0004250739875715226
patterns O 0 0.0030232754070311785
were O 0 8.371856807798395e-08
determined O 0 2.3853738539969527e-08
for O 0 2.797673759324937e-10
four O 0 1.5824820620569113e-10
of O 0 3.5148009502883326e-11
these O 0 9.4998509059252e-11
individuals O 0 2.6499399896628972e-11
and O 0 1.2033905816277723e-10
for O 0 1.1595807647424294e-10
12 O 0 1.9265895545572675e-09
additional O 0 1.3252234865035462e-09
non O 0 1.6275929937137334e-08
- O 0 2.974307562908507e-06
Ashkenazi O 0 8.317743777297437e-06
185delAG O 0 1.471136442887655e-06
mutation O 0 4.987483634977252e-07
carriers O 0 7.546439206862487e-08
who O 0 8.068707302300027e-08
had O 0 0.020098427310585976
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.2086594551874441e-06

Six O 0 1.8921560922535718e-06
non O 0 4.163885876096174e-07
- O 0 9.604965271137189e-06
Ashkenazi O 0 7.332672794291284e-06
individuals O 0 1.1405590916169217e-09
shared O 0 1.694149487363461e-09
the O 0 1.6109452660728607e-09
common O 0 3.6755690047129974e-08
Ashkenazi O 0 8.588259333919268e-06
haplotype O 0 8.082312888291199e-06
, O 0 1.9472075063475813e-09
four O 0 6.757717718741674e-10
had O 0 2.3087436407109863e-09
a O 0 1.2532948012733414e-09
closely O 0 3.116691260629523e-08
related O 0 4.824608712539202e-09
pattern O 0 1.5687878658354748e-06
, O 0 4.308200740599233e-10
and O 0 4.67611560583947e-10
the O 0 3.721093211339621e-09
rest O 0 2.136478371994599e-08
( O 0 9.962094260629328e-09
n O 0 3.8483284470203216e-07
= O 0 3.7692478827011655e-07
6 O 0 3.97158537168707e-08
) O 0 7.886344910446041e-10
displayed O 0 2.1518880899407122e-08
a O 0 1.3576035406970277e-08
distinct O 0 2.402469760909298e-07
BRCA1 O 0 4.6140899939928204e-05
allelic O 0 1.9428220184636302e-05
pattern O 0 0.00011857282515848055
. O 0 6.230157509889978e-07

We O 0 1.313408972691832e-07
conclude O 0 8.255121031197632e-08
that O 0 1.2352252554137522e-09
the O 0 3.765645573139409e-09
185delAG O 0 4.578759217110928e-06
BRCA1 O 0 1.1307168279017787e-05
mutation O 0 1.8582277050427365e-07
occurs O 0 8.530804507245193e-09
in O 0 8.318558064601689e-10
some O 0 5.810690817398267e-10
non O 0 5.3918371989425395e-09
- O 0 6.504066618617799e-07
Ashkenazi O 0 1.2273394531803206e-06
populations O 0 1.1396072530089896e-08
at O 0 2.7969720761689132e-08
rates O 0 7.616804396093357e-07
comparable O 0 9.193190209089153e-09
with O 0 2.8739449708936604e-10
that O 0 3.7540690001058863e-10
of O 0 1.4893750677202888e-09
Ashkenazim O 0 1.977544161491096e-05
. O 0 1.647233176527152e-07

The O 0 8.13545071309818e-08
majority O 0 1.9935068706899983e-08
of O 0 8.031235676497772e-10
Jewish O 0 8.629110936908546e-08
185delAG O 0 1.909755610540742e-06
mutation O 0 5.416453063844529e-07
carriers O 0 3.332922204890565e-08
have O 0 1.0241705261648804e-09
a O 0 4.389857810593867e-09
common O 0 3.9532050521984274e-08
allelic O 0 3.908926373696886e-06
pattern O 0 1.8928252757177688e-05
, O 0 1.6122916335348236e-09
supporting O 0 1.6066645791568135e-09
the O 0 6.982624478624189e-10
founder O 0 1.8036715232483402e-08
effect O 0 2.7958879655898272e-09
notion O 0 1.0732764677001683e-09
, O 0 7.313621236404444e-11
but O 0 7.67925723010876e-11
dating O 0 6.055410395333638e-09
the O 0 4.475438908357887e-10
mutations O 0 5.256738599968003e-09
origin O 0 1.7136350671798084e-10
to O 0 2.0041722448294053e-10
an O 0 1.1004476496712101e-10
earlier O 0 1.278258210390959e-08
date O 0 6.852732159501329e-09
than O 0 2.6110283379843224e-10
currently O 0 1.156842066585284e-09
estimated O 0 3.3445743952142948e-09
. O 0 1.7491990078610797e-08

However O 0 2.5657948299340205e-07
, O 0 1.95704452643497e-09
the O 0 1.0349908707851796e-09
different O 0 2.2452524284233277e-09
allelic O 0 9.218273930855503e-07
pattern O 0 4.004085440101335e-06
at O 0 9.995385852334948e-08
the O 0 1.800440685428839e-08
BRCA1 O 0 4.5865081119700335e-06
locus O 0 1.486680218931724e-07
even O 0 1.989115316902712e-09
in O 0 4.148905663470259e-10
some O 0 1.3286623190555957e-10
Jewish O 0 3.408433313367709e-09
mutation O 0 2.4790296038190718e-08
carriers O 0 3.6961655958123174e-09
, O 0 2.5534302450225255e-10
might O 0 2.464498161103279e-09
suggest O 0 2.0839627801194638e-09
that O 0 1.6943813019310028e-10
the O 0 1.7654242512321616e-09
mutation O 0 7.517176214832944e-08
arose O 0 6.849073752590584e-09
independently O 0 2.7794968104899453e-08
. O 0 3.151257477185254e-09
. O 0 6.21160580749347e-08

Crystal O 0 0.00012004761083517224
structure O 0 6.774305916223966e-07
of O 0 5.0603046197750245e-09
the O 0 1.3095105089178105e-07
hemochromatosis B-Disease 1 1.0
protein O 0 1.1730486221495084e-05
HFE O 0 0.0001559811644256115
and O 0 9.040760140521797e-09
characterization O 0 2.4417831312462113e-08
of O 0 2.6278904052823293e-10
its O 0 5.936951819052183e-09
interaction O 0 8.399378970125326e-09
with O 0 7.009890889975168e-09
transferrin O 0 4.681323844124563e-06
receptor O 0 1.979763283088687e-06
. O 0 2.2834804269677988e-07

HFE O 0 0.014275223016738892
is O 0 3.809840052326763e-07
an O 0 4.687738197617364e-08
MHC O 0 2.8138814741396345e-05
- O 0 3.629974571595085e-06
related O 0 2.444005708923669e-08
protein O 0 2.3551431027613035e-08
that O 0 1.884168099319794e-10
is O 0 2.0082359386552895e-10
mutated O 0 2.1271182149007473e-08
in O 0 2.389338726871415e-09
the O 0 1.7111903005684326e-08
iron B-Disease 1 0.9966970682144165
- I-Disease 1 0.9999773502349854
overload I-Disease 1 0.9999938011169434
disease I-Disease 1 0.9999994039535522
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 1.3184656381781679e-05

HFE O 0 0.00432068994268775
binds O 0 1.946516385942232e-05
to O 0 4.7433576355615514e-07
transferrin O 0 1.6230400433414616e-05
receptor O 0 6.920908163010608e-06
( O 0 2.3708236085440149e-07
TfR O 0 3.902192474924959e-06
) O 0 3.428096917446055e-09
and O 0 4.676989906471363e-10
reduces O 0 1.608587929524674e-08
its O 0 2.6911237682725186e-09
affinity O 0 1.029564966614771e-08
for O 0 9.444570681083064e-10
iron O 0 8.634767254989129e-06
- O 0 2.694310126116761e-07
loaded O 0 8.461643830059984e-08
transferrin O 0 7.207079875115596e-07
, O 0 4.6039900780669996e-09
implicating O 0 1.9170602172380313e-06
HFE O 0 5.527508255909197e-05
in O 0 7.420860015372455e-08
iron O 0 0.00012024695752188563
metabolism O 0 3.442230081418529e-05
. O 0 1.3789464503588533e-07

The O 0 1.7972724890569225e-06
2 O 0 2.142073981303838e-06
. O 0 3.799788999003795e-07

6 O 0 6.457363269873895e-06
A O 0 5.012842620999436e-07
crystal O 0 1.8776619981508702e-05
structure O 0 1.5460030056146934e-07
of O 0 2.928395081980284e-09
HFE O 0 3.068911246373318e-05
reveals O 0 8.215631908115029e-08
the O 0 1.1060583560151827e-09
locations O 0 1.1827347101700525e-08
of O 0 1.3720196534450224e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 7.382660260191187e-05
and O 0 1.9578221710503385e-08
a O 0 2.1872649824672408e-07
patch O 0 0.1212693303823471
of O 0 1.1286329648640958e-09
histidines O 0 1.4661601426269044e-06
that O 0 6.253992879123871e-10
could O 0 7.676097535380677e-10
be O 0 1.010648439936368e-10
involved O 0 2.2731308502166314e-10
in O 0 7.635827969920683e-09
pH O 0 5.653419520967873e-06
- O 0 9.169227155325643e-07
dependent O 0 1.7492531867446814e-07
interactions O 0 1.2866928500443464e-07
. O 0 8.375466364896056e-08

We O 0 2.7936405899708916e-07
also O 0 1.120049120117983e-08
demonstrate O 0 1.399272520075101e-08
that O 0 3.6070888498329623e-09
soluble O 0 1.3970171721666702e-06
TfR O 0 9.342789780930616e-06
and O 0 1.0972254216312649e-08
HFE O 0 2.639386548253242e-05
bind O 0 7.499217531403701e-07
tightly O 0 2.071735252684448e-06
at O 0 3.965559969287824e-08
the O 0 3.866705178268148e-09
basic O 0 1.1385512976858081e-08
pH O 0 6.952463849074775e-08
of O 0 9.504019099493277e-11
the O 0 1.0003712302975032e-09
cell O 0 1.271382359391282e-07
surface O 0 1.7567522547778935e-08
, O 0 2.3734808562991816e-10
but O 0 2.386381647845326e-10
not O 0 2.0944818102108798e-10
at O 0 5.774609235231765e-09
the O 0 8.788800798242846e-09
acidic O 0 1.3917180012867902e-06
pH O 0 9.035055086314969e-07
of O 0 3.191488184839386e-09
intracellular O 0 1.8255615259477054e-06
vesicles O 0 5.416828116722172e-06
. O 0 5.372693294702913e-07

TfR O 0 0.22807876765727997
HFE O 0 0.017299899831414223
stoichiometry O 0 0.00010479919728823006
( O 0 2.2916226498637116e-06
2 O 0 3.311170360120741e-07
1 O 0 5.2667772365566634e-08
) O 0 4.425081190362334e-09
differs O 0 5.774039379957685e-08
from O 0 3.981156737609126e-08
TfR O 0 8.915872967918403e-06
transferrin O 0 1.6133649296534713e-06
stoichiometry O 0 5.43271823971736e-07
( O 0 1.2435801721721873e-08
2 O 0 1.2553575956530949e-08
2 O 0 9.487094665416862e-09
) O 0 7.747022467974318e-10
, O 0 2.0234232345206493e-10
implying O 0 2.930171660864289e-09
a O 0 1.1936439614501637e-09
different O 0 2.2858043235984837e-10
mode O 0 9.047004922990709e-09
of O 0 1.3562666267841195e-10
binding O 0 9.483240859253783e-09
for O 0 8.344460677989218e-10
HFE O 0 4.8046936171886045e-06
and O 0 3.0122895289252938e-09
transferrin O 0 2.2692348977670918e-07
to O 0 1.0904448011217482e-08
TfR O 0 2.0935267457389273e-06
, O 0 3.8084332909527063e-10
consistent O 0 2.199932236379709e-09
with O 0 1.4894196986858788e-10
our O 0 1.1432205182515531e-09
demonstration O 0 5.849658535339586e-09
that O 0 1.140733174587183e-09
HFE O 0 3.034689143532887e-06
, O 0 1.7652458383921044e-09
transferrin O 0 1.5509338879837742e-07
, O 0 1.2108117841691524e-09
and O 0 2.9461209027914492e-09
TfR O 0 1.157398628492956e-06
form O 0 8.779535320968535e-09
a O 0 3.5285964372633316e-08
ternary O 0 1.4313241081254091e-06
complex O 0 1.3310780104802689e-06
. O 0 5.37193500349531e-07

Identification O 0 7.431936523971672e-07
of O 0 4.252800334114681e-09
three O 0 5.193107721623846e-09
novel O 0 3.7590741186477317e-08
mutations O 0 7.081924877638812e-07
and O 0 2.788884012616677e-09
a O 0 1.6524987600519125e-08
high O 0 1.0257588911599669e-07
frequency O 0 1.802158976715873e-06
of O 0 5.600870323085871e-10
the O 0 1.0353151225217516e-08
Arg778Leu O 0 3.5079262943327194e-06
mutation O 0 1.7406897256933007e-07
in O 0 7.304358451420967e-09
Korean O 0 9.115877475096568e-08
patients O 0 7.122714151819309e-08
with O 0 3.127863124063879e-08
Wilson B-Disease 0 0.00011090742918895558
disease I-Disease 0 0.00011644802725641057
. O 0 3.0529076866514515e-07

Four O 0 2.1463233679241966e-06
mutations O 0 8.804084063740447e-05
- O 0 1.9039120161323808e-05
- O 0 3.794773192566936e-06
R778L O 0 2.305599764440558e-06
, O 0 4.086026184069169e-09
A874V O 0 2.3616750866040093e-07
, O 0 7.68740904266707e-10
L1083F O 0 6.074708380765514e-08
, O 0 2.930986287008608e-10
and O 0 3.3577657321259835e-10
2304delC O 0 2.6091771587744006e-07
- O 0 3.5394597830418206e-07
- O 0 2.0612458229152253e-07
in O 0 2.2003603383780046e-09
the O 0 3.5495406613961222e-09
copper O 0 3.6875491105092806e-07
- O 0 7.205146257405204e-09
transporting O 0 1.283853023892334e-09
enzyme O 0 1.3211783667088639e-08
, O 0 1.4215565391495488e-09
P O 0 5.478694220073521e-06
- O 0 6.299395636233385e-07
type O 0 7.3715655162232e-06
ATPase O 0 6.79389768265537e-06
( O 0 2.109309171771656e-08
ATP7B O 0 1.962583837666898e-06
) O 0 5.980899664415062e-10
, O 0 4.809315792830837e-11
were O 0 1.4009347848453757e-10
identified O 0 6.236554050964571e-10
in O 0 8.441196075459345e-10
Korean O 0 3.0161139363826805e-08
Patients O 0 2.3966565620980873e-08
with O 0 2.2098793905911407e-08
Wilson B-Disease 0 4.38684546679724e-05
disease I-Disease 0 3.710027885972522e-05
. O 0 2.135073344788907e-07

Arg778Leu O 0 0.0004393109411466867
, O 0 6.574367716893903e-08
the O 0 1.5952534848651112e-09
most O 0 4.3162451390799106e-10
frequently O 0 1.8243481392232752e-08
reported O 0 4.9735760399016726e-08
mutation O 0 2.3082250777406443e-08
of O 0 1.1771676688976385e-10
this O 0 3.400807968567676e-10
enzyme O 0 1.3238548923766302e-08
, O 0 6.262181329041994e-10
was O 0 1.1448490155885338e-08
found O 0 1.0198040190090296e-09
in O 0 6.723634426997194e-10
six O 0 4.289784638622507e-10
of O 0 5.7328135294465454e-11
eight O 0 1.1977010494490514e-09
unrelated O 0 1.956306761030646e-08
patients O 0 4.140180198675125e-09
studied O 0 6.227522941770758e-09
, O 0 1.4432867401215077e-10
an O 0 3.79627135282945e-10
allele O 0 3.4335371879024024e-07
frequency O 0 5.148081072547939e-07
of O 0 3.4658080849681028e-09
37 O 0 2.8216911118761345e-07
. O 0 6.415167064233174e-08

5 O 0 1.923888021337916e-06
% O 0 2.0134924838544066e-08
, O 0 7.396688816996289e-10
which O 0 5.096597033293904e-10
is O 0 1.7459907131200936e-10
considerably O 0 7.851573613493201e-09
higher O 0 7.903681265020168e-09
than O 0 1.5526704921775547e-10
those O 0 7.898157128316541e-11
in O 0 1.644228364572342e-10
other O 0 5.548088030660203e-11
Asian O 0 3.532493630942213e-09
populations O 0 3.0548932272722595e-08
. O 0 4.552437715688029e-08

The O 0 2.3592934894622886e-07
novel O 0 1.9212500035337143e-07
single O 0 4.503220907281502e-08
nucleotide O 0 1.6117427037443122e-07
deletion O 0 2.045126876737413e-07
, O 0 1.1771661423409796e-09
2304delC O 0 2.478278418038826e-07
, O 0 7.817573255408661e-10
was O 0 8.374807514144322e-09
found O 0 1.0196251620797625e-09
in O 0 2.8042246302817375e-09
one O 0 6.490784798529603e-09
patient O 0 5.786271231045248e-07
. O 0 9.261039934926885e-08

Since O 0 1.9146282284054905e-06
a O 0 2.0531194877548842e-07
mutation O 0 2.122892283296096e-06
at O 0 2.8497268544924736e-07
cDNA O 0 5.270855126582319e-06
nucleotide O 0 1.1511029697430786e-05
2302 O 0 0.00022690961486659944
( O 0 8.290276554134834e-08
2302insC O 0 1.3833591765433084e-06
) O 0 6.49180043055253e-09
had O 0 7.545025049182641e-09
been O 0 1.0831001651112615e-09
previously O 0 9.669174794169066e-09
described O 0 5.512840850485645e-09
, O 0 1.4942796999761754e-10
this O 0 6.597848656308969e-11
region O 0 7.414542868566798e-10
of O 0 9.350821505993423e-11
the O 0 3.4249794111929077e-09
ATP7B O 0 8.595528015575837e-06
gene O 0 8.81159678556287e-07
may O 0 8.043308241667546e-08
be O 0 1.0960471419352302e-09
susceptible O 0 1.721576978752637e-07
to O 0 1.707558183738911e-08
gene O 0 2.358028359594755e-05
rearrangements O 0 0.0002264164504595101
causing O 0 8.47487899591215e-05
Wilson B-Disease 0 0.0008359747589565814
disease I-Disease 0 0.0014452043687924743
. O 0 8.500513786202646e-07

Disruption O 0 4.88072146254126e-05
of O 0 3.999026176870757e-08
splicing O 0 3.872409251926001e-06
regulated O 0 1.0819753697433043e-06
by O 0 2.8545850128125494e-09
a O 0 1.3999772896511331e-08
CUG O 0 4.337949576438405e-06
- O 0 1.887209748474561e-07
binding O 0 1.4224799826934031e-07
protein O 0 1.2863289384767995e-06
in O 0 4.312145392759703e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 2.656062406458659e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999926090240479
DM B-Disease 1 1.0
) O 0 4.2621573470569274e-07
is O 0 5.719952955729468e-09
caused O 0 1.7158965803787396e-08
by O 0 1.5635810424186047e-09
a O 0 1.1646622333216783e-08
CTG O 0 2.132693452949752e-06
expansion O 0 3.7374263683886966e-08
in O 0 3.513021873402522e-09
the O 0 4.174204537576998e-09
3 O 0 1.2433358342889278e-08
untranslated O 0 1.3215318972470413e-07
region O 0 7.660773349016381e-09
of O 0 1.1668251920227135e-09
the O 0 3.626330453698756e-07
DM B-Disease 1 1.0
gene O 0 1.1911417459486984e-05
. O 0 1.192393312976492e-07

One O 0 2.6693737709138077e-07
model O 0 8.788551326688321e-07
of O 0 6.218908055188876e-08
DM B-Disease 1 1.0
pathogenesis O 0 1.6525400496902876e-05
suggests O 0 6.692179255196606e-08
that O 0 1.4558757532867617e-09
RNAs O 0 5.579017852141988e-07
from O 0 1.5948518061748018e-09
the O 0 7.786175038049237e-10
expanded O 0 8.94813823038021e-09
allele O 0 7.080170405515673e-08
create O 0 1.4379815116427608e-09
a O 0 1.5033542188902516e-09
gain O 0 4.672767772717634e-08
- O 0 7.691743775239956e-08
of O 0 6.368031657544293e-10
- O 0 3.2595556831438444e-07
function O 0 6.211579695047931e-09
mutation O 0 6.082844894450545e-09
by O 0 1.340977051622616e-10
the O 0 3.673686910232732e-10
inappropriate O 0 4.001740716574886e-09
binding O 0 3.1083304818935176e-09
of O 0 6.032233046404656e-11
proteins O 0 3.387395919318692e-09
to O 0 1.5815474485592063e-09
the O 0 1.6844069250510074e-08
CUG O 0 8.541081479052082e-05
repeats O 0 2.2422284018830396e-05
. O 0 1.9091024228146125e-07

Data O 0 2.7157111617270857e-06
presented O 0 4.831794342408102e-08
here O 0 4.196348601936961e-09
indicate O 0 6.837822752459033e-09
that O 0 1.968491897264002e-10
the O 0 1.0630063496108733e-09
conserved O 0 9.288583413535889e-08
heterogeneous O 0 1.7323877443686797e-07
nuclear O 0 3.487118647171883e-07
ribonucleoprotein O 0 1.648229385864397e-06
, O 0 4.794300512145355e-09
CUG O 0 5.274354862194741e-06
- O 0 4.1066084577323636e-07
binding O 0 2.2399333943212696e-07
protein O 0 1.8518942113132653e-07
( O 0 2.1871684907637245e-08
CUG O 0 1.9245402654632926e-05
- O 0 6.498686161648948e-06
BP O 0 1.0824149967447738e-06
) O 0 1.4012588867018394e-09
, O 0 3.4488986666580956e-10
may O 0 5.730698138251e-09
mediate O 0 4.77863686398905e-08
the O 0 1.6103008704249078e-08
trans O 0 1.6954810462266323e-06
- O 0 3.913118689524708e-06
dominant O 0 3.7640000982719357e-07
effect O 0 9.70440883207857e-09
of O 0 7.231545917640858e-11
the O 0 1.4096924738637995e-09
RNA O 0 6.405325052583066e-07
. O 0 7.491355091815421e-08

CUG O 0 0.014038946479558945
- O 0 0.00209827465005219
BP O 0 1.0685304005164653e-05
was O 0 4.158701827350342e-08
found O 0 6.947512565247393e-10
to O 0 3.986547758572101e-10
bind O 0 1.0075660306085865e-08
to O 0 5.301988292849558e-10
the O 0 2.374627827705922e-09
human O 0 3.657721592276175e-08
cardiac O 0 0.0001556059141876176
troponin O 0 0.001798777375370264
T O 0 0.0001630658662179485
( O 0 3.900752787444617e-08
cTNT O 0 3.2129531746249995e-07
) O 0 4.046904589216638e-09
pre O 0 1.0668131835700478e-06
- O 0 1.395547087668092e-06
messenger O 0 3.4443107210790913e-07
RNA O 0 1.235631685858607e-07
and O 0 2.6457762647424943e-09
regulate O 0 4.761514205142703e-08
its O 0 1.2420629857956555e-08
alternative O 0 4.7112497014722976e-08
splicing O 0 3.1710496841697022e-06
. O 0 1.9083415736531606e-07

Splicing O 0 4.440839620656334e-05
of O 0 6.503328364715344e-08
cTNT O 0 5.57036992177018e-06
was O 0 4.801862587555661e-07
disrupted O 0 2.2289716071099974e-05
in O 0 7.219721283036051e-06
DM B-Disease 1 1.0
striated O 1 0.9848899245262146
muscle O 0 0.19583196938037872
and O 0 1.2655173797782027e-08
in O 0 4.53660753407803e-09
normal O 0 1.5927831498174783e-07
cells O 0 7.24999296153328e-08
expressing O 0 1.4270939097116297e-08
transcripts O 0 8.269429940810369e-08
that O 0 2.43546982581222e-09
contain O 0 1.6338952946171048e-07
CUG O 0 0.0001145650603575632
repeats O 0 4.145548155065626e-05
. O 0 2.6786972284753574e-07

Altered O 0 8.066868758760393e-05
expression O 0 7.659110110580514e-07
of O 0 6.9663586010904055e-09
genes O 0 3.703613060679345e-07
regulated O 0 9.039864039550594e-07
posttranscriptionally O 0 2.4142530037352117e-06
by O 0 2.4666062969913582e-08
CUG O 0 4.212636122247204e-05
- O 0 1.0857339475478511e-05
BP O 0 2.2047363472665893e-06
therefore O 0 8.920566507697458e-09
may O 0 1.1376937614215876e-08
contribute O 0 2.3663264681061946e-09
to O 0 5.184045548389804e-08
DM B-Disease 1 1.0
pathogenesis O 0 1.457034068153007e-05
. O 0 1.7673826846476004e-08
. O 0 7.095771081822022e-08

Identification O 0 5.617297347271233e-07
of O 0 7.339719054755278e-09
a O 0 2.546458333085866e-08
novel O 0 2.679612123301922e-07
nonsense O 0 1.3767062227998395e-06
mutation O 0 5.851826472280663e-07
and O 0 2.0331112349225577e-09
a O 0 5.478271614123287e-09
missense O 0 1.3253325050754938e-06
substitution O 0 5.657717139229135e-08
in O 0 4.270357401026104e-09
the O 0 7.806089996620358e-09
vasopressin O 0 1.1544353810677421e-06
- O 0 1.4695491472593858e-06
neurophysin O 0 1.9000710835825885e-06
II O 0 3.551740803686698e-07
gene O 0 1.39183327974024e-07
in O 0 4.267882047770399e-09
two O 0 1.6594150498150384e-09
Spanish O 0 8.020267472375053e-08
kindreds O 0 1.4534316505887546e-06
with O 0 4.926811314476254e-08
familial B-Disease 0 0.06826663017272949
neurohypophyseal I-Disease 1 0.9999057054519653
diabetes I-Disease 1 0.9999886751174927
insipidus I-Disease 1 0.7358508706092834
. O 0 5.240431619313313e-06

Familial B-Disease 1 0.9999629259109497
neurohypophyseal I-Disease 1 0.999997615814209
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999969005584717
( O 0 0.00030201449408195913
FNDI B-Disease 1 1.0
) O 0 5.021464133392328e-08
is O 0 1.5176383483250788e-09
an O 0 5.657218249410789e-09
autosomal B-Disease 1 0.9997466206550598
dominant I-Disease 1 0.9999895095825195
disease I-Disease 1 0.999565064907074
caused O 0 2.214263986388687e-05
by O 0 3.6461486274674826e-07
deficiency O 0 0.008137130178511143
in O 0 2.0812823464666508e-08
the O 0 2.2434350910316425e-07
antidiuretic O 0 0.00036159143201075494
hormone O 0 1.4100332009547856e-05
arginine O 0 8.045346476137638e-06
vasopressin O 0 3.142947889500647e-06
( O 0 4.473795911508205e-08
AVP O 0 7.889478865763522e-07
) O 0 2.403288457131225e-09
encoded O 0 7.339719054755278e-09
by O 0 1.7541362806738903e-09
the O 0 1.2213147826400927e-08
AVP O 0 8.420583071711008e-06
- O 0 8.059114406933077e-06
neurophysin O 0 3.3254542358918115e-05
II O 0 1.1094457477156539e-05
( O 0 1.0700885866299359e-07
AVP O 0 8.687522495165467e-06
- O 0 3.600279796955874e-06
NPII O 0 6.605667294934392e-06
) O 0 1.1111505493488494e-08
gene O 0 2.687781375243503e-07
on O 0 6.307583078069001e-08
chromosome O 0 5.537283414014382e-06
20p13 O 0 4.228176749165868e-06
. O 0 2.380658798983859e-07

In O 0 1.3240446605777834e-07
this O 0 1.7118357842349496e-09
study O 0 9.498316577705168e-10
, O 0 2.790015996012585e-10
we O 0 2.0747763229689298e-10
analyzed O 0 3.816900129294254e-09
two O 0 4.115118801273354e-10
families O 0 4.30839808274186e-10
with O 0 1.015746931010142e-09
FNDI B-Disease 1 0.9999992847442627
using O 0 1.0712768450105159e-08
direct O 0 9.600793937636354e-09
automated O 0 7.322980764001841e-06
fluorescent O 0 1.5177685099843075e-06
, O 0 4.1742501122321585e-10
solid O 0 6.2949974122261665e-09
phase O 0 4.16682244264166e-09
, O 0 4.1172701359393216e-10
single O 0 4.530424924098497e-09
- O 0 3.452271712944821e-08
stranded O 0 9.579465221065675e-09
DNA O 0 7.940080593016319e-09
sequencing O 0 1.4400353798293963e-08
of O 0 1.0373228942484047e-09
PCR O 0 5.284659710014239e-05
- O 0 1.1125883247586899e-05
amplified O 0 4.189791434328072e-05
AVP O 0 1.3437250345305074e-05
- O 0 2.36373534789891e-06
NPII O 0 1.646612690819893e-05
DNA O 0 2.66698702944268e-06
. O 0 2.7297693350192276e-07

In O 0 1.9273593920843268e-07
one O 0 2.333081949856819e-09
of O 0 9.253346006099505e-11
the O 0 7.026351722672075e-10
families O 0 4.4335102256098935e-10
, O 0 1.8317869443507107e-10
affected O 0 1.6885878251216013e-09
individuals O 0 5.6716031177073134e-11
presented O 0 7.194101425689325e-10
a O 0 3.619369692842156e-09
novel O 0 4.615413473629815e-08
nonsense O 0 4.0577276649855776e-07
mutation O 0 1.283024317899617e-07
in O 0 1.0835160324518256e-08
exon O 0 4.205505206300586e-07
3 O 0 9.311408533108079e-09
of O 0 1.54056115087009e-10
the O 0 1.0712150055880443e-09
gene O 0 3.114872626497345e-08
, O 0 1.67393224281831e-10
consisting O 0 1.4905736367420985e-10
in O 0 3.2028105168002696e-10
a O 0 1.0333935485107304e-08
G O 0 9.739393135532737e-06
to O 0 2.37090418409025e-08
T O 0 1.8152102711610496e-05
transition O 0 4.66287595202175e-08
at O 0 4.913588469435126e-08
nucleotide O 0 3.7283913911778654e-07
2101 O 0 4.820817139261635e-06
, O 0 1.376726954660512e-09
which O 0 8.87641626867719e-10
produces O 0 9.607515671916644e-09
a O 0 3.92558252571007e-09
stop O 0 3.8222204068460996e-08
signal O 0 2.788005986076314e-06
in O 0 4.583629475973794e-08
codon O 0 5.061300726083573e-06
82 O 0 4.113562113161606e-07
( O 0 3.173679985479794e-08
Glu O 0 1.3500497516361065e-05
) O 0 5.541790581986561e-09
of O 0 4.605096748377946e-09
NPII O 0 8.551831706427038e-05
. O 0 3.3362778140144655e-07

The O 0 1.954462732101092e-06
premature O 0 6.73288814141415e-05
termination O 0 1.8540656583354576e-06
eliminates O 0 3.7104788930264476e-07
part O 0 6.197851565303836e-09
of O 0 5.120303070427212e-10
the O 0 1.0518977688889208e-08
C O 0 3.7914625863777474e-05
- O 0 1.010661094369425e-06
terminal O 0 2.3173393515207863e-07
domain O 0 1.8319914474318466e-08
of O 0 5.334834796144605e-10
NPII O 0 4.439692418145569e-07
, O 0 1.0913842052318046e-10
including O 0 6.875244124016078e-11
a O 0 6.404268226845033e-10
cysteine O 0 5.6807820669746434e-08
residue O 0 1.8496913867238618e-07
in O 0 1.7962209497568438e-09
position O 0 2.6285949417115262e-08
85 O 0 3.6998051289316436e-09
, O 0 9.986435289821571e-11
which O 0 2.0453544413712166e-10
could O 0 8.552630270663997e-10
be O 0 7.411146002445079e-11
involved O 0 6.07676270414359e-11
in O 0 7.526451129002965e-10
the O 0 2.9846503935004876e-08
correct O 0 3.0248244001995772e-05
folding O 0 1.550364459035336e-07
of O 0 4.0302791659563297e-10
the O 0 2.4408469911918473e-08
prohormone O 0 6.368164758896455e-05
. O 0 1.8930970213659748e-07

In O 0 2.6091248628290487e-07
the O 0 1.3591581193850288e-08
second O 0 1.629972778971478e-08
family O 0 7.639965104999646e-09
, O 0 2.3200695531411242e-10
a O 0 1.2113893221865624e-09
G279A O 0 6.35444834529153e-08
substitution O 0 2.4904416306981147e-08
at O 0 7.024588910553575e-08
position O 0 1.790537282886362e-07
- O 0 1.0084065849014223e-07
1 O 0 1.602425858671097e-09
of O 0 5.1283054192108324e-11
the O 0 9.133796496918478e-10
signal O 0 3.2891711043703253e-07
peptide O 0 2.9057625638984064e-08
was O 0 4.039685919110525e-09
observed O 0 2.300584833747621e-09
in O 0 5.895366972374916e-10
all O 0 2.1333895761088684e-10
affected O 0 6.879317115959793e-09
individuals O 0 1.4175494111867692e-09
. O 0 1.5450767776314933e-08

This O 0 1.4004988315718947e-06
missense O 0 0.000262991467025131
mutation O 0 6.395397940650582e-05
, O 0 4.8087180459788215e-08
which O 0 3.395399161831847e-08
replaces O 0 1.3480145753419492e-05
Ala O 0 1.1673882909235545e-05
with O 0 6.401206675832327e-09
Thr O 0 0.00025949280825443566
, O 0 3.545792104375778e-09
is O 0 6.477893776946075e-10
frequent O 0 7.168480919972353e-08
among O 0 1.9027654118985993e-08
FNDI B-Disease 1 1.0
patients O 0 2.513352683308767e-06
and O 0 4.460348979051787e-09
is O 0 3.158591166396718e-10
thought O 0 7.615751917988689e-10
to O 0 6.607019931159641e-10
reduce O 0 1.2439739016656404e-08
the O 0 1.2827026107942174e-09
efficiency O 0 6.426100540579682e-09
of O 0 1.7363763205047178e-10
cleavage O 0 1.1032611979544527e-07
by O 0 5.511484157949553e-09
signal O 0 4.4595194594876375e-06
peptidases O 0 4.098582394362893e-06
. O 0 1.4366417389055641e-08
. O 0 5.943367753502571e-08

Genetic O 0 3.274420669185929e-05
heterogeneity O 0 2.7491163564263843e-05
of O 0 2.1630363278291043e-07
Saethre B-Disease 1 0.966064453125
- I-Disease 1 0.9999879598617554
Chotzen I-Disease 1 0.9999966621398926
syndrome I-Disease 1 0.9999998807907104
, O 0 1.2091875944975072e-08
due O 0 8.360335357338045e-08
to O 0 1.4058963770935407e-08
TWIST O 0 9.781811968423426e-06
and O 0 7.595362916390513e-08
FGFR O 0 0.00018380735127720982
mutations O 0 1.8887069018092006e-05
. O 0 3.8921768918953603e-07

Thirty O 0 2.6659021386876702e-05
- O 0 1.978455293283332e-05
two O 0 1.723901021932761e-08
unrelated O 0 5.425826543614676e-07
patients O 0 4.3943757077613554e-08
with O 0 1.154879969433864e-09
features O 0 6.569327837269157e-08
of O 0 9.830682046185757e-09
Saethre B-Disease 1 0.9485229253768921
- I-Disease 1 0.9984745383262634
Chotzen I-Disease 1 0.9999037981033325
syndrome I-Disease 1 0.9999452829360962
, O 0 1.4578515061813846e-09
a O 0 7.651661526608677e-09
common O 0 1.912769107548229e-07
autosomal B-Disease 1 0.6417895555496216
dominant I-Disease 0 0.1225997731089592
condition I-Disease 0 0.000159603136125952
of O 0 2.661305487094978e-08
craniosynostosis B-Disease 1 0.8407576084136963
and O 0 2.4445100734737935e-06
limb B-Disease 1 0.7334809303283691
anomalies I-Disease 0 3.0054561648285016e-05
, O 0 1.2387241232758583e-09
were O 0 7.726481121572704e-10
screened O 0 3.5272169185418534e-08
for O 0 5.866371277640781e-10
mutations O 0 1.1067999139413587e-07
in O 0 9.650823251661222e-09
TWIST O 0 1.992429133679252e-06
, O 0 3.45811557167508e-09
FGFR2 O 0 3.0569797218049644e-06
, O 0 3.4356508749056047e-09
and O 0 1.0386854043531457e-08
FGFR3 O 0 2.7476513423607685e-05
. O 0 1.217391911723098e-07

Nine O 0 1.3434357697406085e-06
novel O 0 3.77363619463722e-07
and O 0 5.090847743360882e-09
three O 0 7.465349227686602e-09
recurrent O 0 6.751513865310699e-06
TWIST O 0 4.424886355991475e-05
mutations O 0 7.81383005232783e-06
were O 0 1.7140191488351775e-08
found O 0 4.613395887531624e-09
in O 0 4.191285096766251e-09
12 O 0 1.3031514534134203e-08
families O 0 7.763134135529981e-09
. O 0 4.9924608447327046e-08

Seven O 0 3.2536985372644267e-07
families O 0 8.268686180201712e-09
were O 0 1.2122860493235521e-09
found O 0 1.1279507328154637e-09
to O 0 6.14142348087654e-10
have O 0 2.0338628003990777e-10
the O 0 1.5357913829561198e-09
FGFR3 O 0 2.5878973701765062e-06
P250R O 0 3.7327711766010907e-07
mutation O 0 8.515721816593214e-08
, O 0 1.991726089611845e-10
and O 0 7.676621838204056e-11
one O 0 5.7728852947969145e-11
individual O 0 5.1989797883456035e-11
was O 0 1.4538924730800318e-08
found O 0 7.354991060637417e-10
to O 0 3.17847415054473e-10
have O 0 1.0985769932636558e-10
an O 0 6.273287445068831e-10
FGFR2 O 0 3.5680914152180776e-06
VV269 O 0 5.748051421505807e-07
- O 0 6.764970521544456e-07
270 O 0 5.23172502653324e-07
deletion O 0 6.760276846762281e-06
. O 0 3.3071120242311736e-07

To O 0 2.2872900728998502e-07
date O 0 9.639329334731883e-08
, O 0 7.725390882562522e-10
our O 0 1.9449506449831233e-09
detection O 0 5.5144631971870695e-08
rate O 0 1.6493254406668711e-07
for O 0 7.977100091594025e-10
TWIST O 0 5.678647312379326e-07
or O 0 1.1331442806294945e-07
FGFR O 0 6.027646122674923e-06
mutations O 0 2.9638829346367856e-07
is O 0 8.429322795322491e-10
68 O 0 1.3223381500893083e-08
% O 0 4.4586798142454143e-10
in O 0 1.7283644515586616e-09
our O 0 5.074776865399144e-08
Saethre B-Disease 1 0.7327368855476379
- I-Disease 1 0.9998977184295654
Chotzen I-Disease 1 0.9999973773956299
syndrome I-Disease 1 0.9999998807907104
patients O 0 6.378697747777551e-08
, O 0 1.341736999282972e-10
including O 0 8.194602635347437e-11
our O 0 1.039830666016428e-09
five O 0 7.680608926641241e-10
patients O 0 2.5986235385744294e-09
elsewhere O 0 1.1394028831546166e-08
reported O 0 1.9934161343826418e-07
with O 0 5.579143813605469e-09
TWIST O 0 7.836207805667073e-05
mutations O 0 1.0565774573478848e-05
. O 0 1.1990826465080318e-07

More O 0 9.93972051333003e-08
than O 0 7.2013266461112835e-09
35 O 0 1.7624946835326227e-08
different O 0 3.7523246732007465e-09
TWIST O 0 5.9400290410849266e-06
mutations O 0 1.0908775038842577e-06
are O 0 6.432731569638861e-10
now O 0 7.722326667014556e-10
known O 0 6.449391021234874e-10
in O 0 6.4336891369976e-10
the O 0 1.8116075306551238e-09
literature O 0 9.545158441426338e-09
. O 0 3.6294089511557104e-08

The O 0 9.541739842688912e-08
most O 0 4.4948174071635094e-09
common O 0 4.924769925196415e-09
phenotypic O 0 8.405520901533237e-08
features O 0 2.1628177648835845e-07
, O 0 7.530945866918159e-10
present O 0 3.1918639953332217e-10
in O 0 3.0419361474187667e-10
more O 0 5.727042798331361e-11
than O 0 9.106897874699982e-11
a O 0 7.88942911000845e-10
third O 0 3.1582192416834687e-09
of O 0 1.4646206469848266e-10
our O 0 8.09376654586913e-09
patients O 0 3.0416182905668165e-09
with O 0 1.12979814392844e-09
TWIST O 0 1.8123560948879458e-05
mutations O 0 1.224388711307256e-06
, O 0 1.165441743111728e-09
are O 0 4.506954254246409e-10
coronal B-Disease 0 2.2638555492449086e-06
synostosis I-Disease 0 1.4700075325890793e-06
, O 0 3.753369615111524e-09
brachycephaly B-Disease 0 1.8491443825041642e-06
, O 0 7.313670558062313e-09
low B-Disease 0 0.00017779173504095525
frontal I-Disease 1 0.9999974966049194
hairline I-Disease 1 1.0
, O 0 7.525682690356916e-07
facial B-Disease 1 0.9989778995513916
asymmetry I-Disease 0 0.0003431008954066783
, O 0 1.3492220318767068e-07
ptosis B-Disease 0 0.005412205588072538
, O 0 6.179546119255974e-08
hypertelorism B-Disease 0 9.899665019474924e-05
, O 0 1.978080099718227e-08
broad B-Disease 0 5.819846933263761e-07
great I-Disease 0 1.1851440149257542e-06
toes I-Disease 0 0.011342598125338554
, O 0 3.722292918340031e-09
and O 0 5.8447517936599525e-09
clinodactyly B-Disease 0 9.746250725584105e-06
. O 0 1.7825433928919665e-07

Significant O 0 1.9530091321939835e-06
intra O 0 0.0001361565082333982
- O 0 3.95215793105308e-05
and O 0 4.434360789673519e-08
interfamilial O 0 4.199051545583643e-06
phenotypic O 0 2.352158844587393e-06
variability O 0 1.0089065654028673e-06
is O 0 1.585981901364164e-09
present O 0 1.7090301396294194e-09
for O 0 5.313833262299283e-10
either O 0 2.1157116947279064e-08
TWIST O 0 5.9378682635724545e-05
mutations O 0 1.4016589375387412e-05
or O 0 3.310352667540428e-07
FGFR O 0 0.0003365807351656258
mutations O 0 3.6166104109724984e-05
. O 0 3.98766275111484e-07

The O 0 4.12011502248788e-07
overlap O 0 4.4313676994534035e-07
in O 0 2.5886322418955388e-08
clinical O 0 5.177375683729224e-08
features O 0 1.356087437898168e-07
and O 0 1.3074329396900453e-09
the O 0 5.999946650625532e-10
presence O 0 1.012034012148888e-09
, O 0 5.0547916546905824e-11
in O 0 1.0491016388947116e-10
the O 0 2.2374282981907356e-10
same O 0 1.0910309322653688e-09
genes O 0 2.5439716999642314e-09
, O 0 3.6398856151365067e-11
of O 0 3.659865119298722e-11
mutations O 0 1.170394270388897e-08
for O 0 5.371056377434513e-11
more O 0 7.008118391160778e-11
than O 0 3.3811459188015647e-10
one O 0 9.168565906492177e-10
craniosynostotic B-Disease 0 2.0466150090214796e-06
condition I-Disease 0 5.310677764214233e-08
- O 0 5.0473232704462134e-08
such O 0 7.90028598096626e-10
as O 0 4.968443878539119e-09
Saethre B-Disease 0 3.110407533313264e-06
- I-Disease 0 6.840009518782608e-07
Chotzen I-Disease 0 9.529260864837852e-07
, I-Disease 0 6.16015849441709e-10
Crouzon I-Disease 0 1.272787244488427e-07
, I-Disease 0 3.8838815497044266e-10
and I-Disease 0 2.9510136556609723e-09
Pfeiffer I-Disease 0 0.00010321406443836167
syndromes I-Disease 0 5.417541615315713e-06
- O 0 1.4362558431457728e-07
support O 0 1.1012922795927693e-09
the O 0 1.1940195498993944e-09
hypothesis O 0 4.297493028104782e-09
that O 0 2.1073688627470943e-10
TWIST O 0 1.3710693735902169e-07
and O 0 1.791177983712089e-09
FGFRs O 0 1.1213342077098787e-07
are O 0 4.5740859017096014e-11
components O 0 2.1581748887999908e-10
of O 0 6.173408572535122e-12
the O 0 1.225560625206512e-10
same O 0 8.562407449730358e-10
molecular O 0 4.6961030619740995e-09
pathway O 0 1.343384181673457e-09
involved O 0 1.505810059976298e-10
in O 0 3.6788544433008497e-10
the O 0 1.2866231413610763e-09
modulation O 0 2.9197582307460834e-07
of O 0 1.8646133526090125e-09
craniofacial O 0 8.112863724818453e-06
and O 0 5.875960162882166e-09
limb O 0 8.121301107166801e-07
development O 0 1.2809104887878675e-09
in O 0 2.4736672710190533e-09
humans O 0 1.0931478833242636e-08
. O 0 6.69166588807002e-09
. O 0 4.1045954191076817e-08

Mutation O 0 0.0003356837551109493
analysis O 0 4.0891113712859806e-06
of O 0 1.6308534611653158e-07
UBE3A O 1 0.6516119241714478
in O 1 0.8072205185890198
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0013727018376812339
. O 0 2.232452970929444e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.15413208305835724
AS B-Disease 1 0.9999998807907104
) O 0 3.1217954443718554e-08
is O 0 1.4259341485356458e-09
caused O 0 1.698411367101471e-08
by O 0 5.067616548615206e-09
chromosome O 0 5.931843134021619e-06
15q11 O 0 5.011655957787298e-06
- O 0 1.86368288268568e-06
q13 O 0 1.6629904848741717e-06
deletions O 0 1.1588665529416176e-06
of O 0 1.5281184095883305e-09
maternal O 0 1.927289474679128e-07
origin O 0 3.923366964642128e-09
, O 0 6.20340667722985e-10
by O 0 5.4094928536585485e-09
paternal O 0 5.032619446865283e-05
uniparental B-Disease 0 0.0016431910917162895
disomy I-Disease 0 0.006531645078212023
( O 0 2.220799387941952e-06
UPD B-Disease 1 1.0
) O 0 2.8808301522076363e-08
15 O 0 6.839791844015508e-09
, O 0 3.595903574904469e-10
by O 0 9.324685024125756e-09
imprinting O 1 0.9772128462791443
defects O 1 0.8591999411582947
, O 0 6.186958723120028e-10
and O 0 5.154491278247519e-10
by O 0 2.3686248518117736e-09
mutations O 0 2.7810196456812264e-07
in O 0 6.16505158035352e-09
the O 0 6.769966631736679e-08
UBE3A O 0 5.5085540225263685e-05
gene O 0 7.561295660707401e-06
. O 0 2.6215508341920213e-07

UBE3A O 0 0.003004108788445592
encodes O 0 3.946756987716071e-05
a O 0 1.4110631809671759e-06
ubiquitin O 0 2.1372305127442814e-05
- O 0 3.235348231100943e-06
protein O 0 4.757020519718935e-07
ligase O 0 4.117793537261605e-07
and O 0 8.795441708286944e-09
shows O 0 4.666181894208421e-07
brain O 0 6.015906183165498e-05
- O 0 3.833541086351033e-06
specific O 0 1.987127831171165e-07
imprinting O 0 9.129205864155665e-05
. O 0 4.1577868614695035e-07

Here O 0 4.305716743147059e-07
we O 0 3.4411218763352736e-08
describe O 0 2.258022249179703e-07
UBE3A O 0 4.284938404452987e-05
coding O 0 4.8018951929407194e-05
- O 0 1.7498217857792042e-05
region O 0 1.9144735574627703e-07
mutations O 0 3.6429862575459993e-06
detected O 0 5.373082672122109e-07
by O 0 3.5780352014569416e-09
SSCP O 0 1.1997178717138013e-06
analysis O 0 1.5052487256639324e-08
in O 0 3.5309510870717986e-09
13 O 0 9.759631325323426e-09
AS B-Disease 1 0.9426330924034119
individuals O 0 6.198073165819551e-10
or O 0 7.803320656307733e-09
families O 0 7.3589938587304005e-09
. O 0 4.052916224850378e-08

Two O 0 5.805921432511241e-07
identical O 0 5.989449164189864e-06
de O 0 1.1603048733377364e-05
novo O 0 3.174640369252302e-05
5 O 0 5.736184789384424e-07
- O 0 8.482357998218504e-07
bp O 0 1.226012841470947e-06
duplications O 0 6.498697189272207e-07
in O 0 8.20308621030108e-09
exon O 0 5.81351741857361e-07
16 O 0 7.83461260311924e-08
were O 0 3.331331877021171e-09
found O 0 2.1128444771534305e-08
. O 0 3.476542076441547e-08

Among O 0 1.248639591722167e-07
the O 0 4.6391086527819425e-09
other O 0 3.1415520185262835e-10
11 O 0 1.3339573889936673e-09
unique O 0 1.2421333961398773e-09
mutations O 0 1.9071879364673805e-07
, O 0 1.0854951382199829e-09
8 O 0 2.6978476341810165e-08
were O 0 1.187763998267144e-09
small O 0 1.5031708100465835e-09
deletions O 0 4.560707225209626e-07
or O 0 2.18101554594341e-08
insertions O 0 6.459245014411863e-07
predicted O 0 9.15027158043813e-07
to O 0 1.5043417178617347e-08
cause O 0 1.387343502301519e-07
frameshifts O 0 7.85250449553132e-06
, O 0 1.248663394903815e-09
1 O 0 4.754668658790706e-09
was O 0 5.864919661036083e-09
a O 0 1.2993086606627458e-09
mutation O 0 1.8917681643415563e-08
to O 0 8.099044213061291e-10
a O 0 4.075736192987733e-09
stop O 0 6.063665125566331e-08
codon O 0 5.460830720949161e-07
, O 0 7.621041575589516e-10
1 O 0 2.436055357435407e-09
was O 0 3.4316558483737936e-09
a O 0 4.17600398705531e-09
missense O 0 2.3907637114461977e-06
mutation O 0 3.954246494686231e-07
, O 0 2.2824204748417287e-09
and O 0 2.1750945489174e-09
1 O 0 1.9596901879026518e-08
was O 0 1.3834987555583211e-07
predicted O 0 7.011123415168186e-08
to O 0 1.127266724409992e-09
cause O 0 3.711304374931501e-09
insertion O 0 1.2140406902005907e-08
of O 0 2.279917643566165e-10
an O 0 1.3799265063951793e-09
isoleucine O 0 7.358634320553392e-06
in O 0 1.8677386304233323e-09
the O 0 1.7874511870630272e-09
hect O 0 4.424012161052815e-07
domain O 0 9.859243199628054e-09
of O 0 1.5461688873674717e-10
the O 0 2.618220751315903e-09
UBE3A O 0 1.8353878203924978e-06
protein O 0 3.116762314903099e-08
, O 0 1.8646409416511744e-10
which O 0 1.1950442024843966e-10
functions O 0 9.71397851046163e-10
in O 0 1.4970306105865916e-09
E2 O 0 2.506265275314945e-07
binding O 0 2.6574756617492312e-08
and O 0 1.5102979977754671e-09
ubiquitin O 0 2.772550828922249e-07
transfer O 0 5.257924584611828e-08
. O 0 8.201040913036195e-08

Eight O 0 1.3123634801104345e-07
of O 0 1.3698538969819651e-09
the O 0 1.3964456258008795e-09
cases O 0 1.8927632794429883e-09
were O 0 2.809160681849221e-09
familial O 0 5.824922482133843e-07
, O 0 3.632413037024662e-09
and O 0 1.3361244333154332e-09
five O 0 1.350155431900646e-09
were O 0 4.4158574574737486e-09
sporadic O 0 2.647343080752762e-06
. O 0 2.0264424449578655e-07

In O 0 3.699588830841094e-07
two O 0 2.326319936685195e-08
familial O 0 3.795004658968537e-06
cases O 0 2.4650260499470278e-08
and O 0 1.8291553827154416e-09
one O 0 5.978835204700772e-10
sporadic O 0 1.7955166242700216e-07
case O 0 8.96999363675377e-09
, O 0 2.2499895280247983e-09
mosaicism O 0 1.547101874166401e-06
for O 0 4.708767598060604e-09
UBE3A O 0 2.8609329092432745e-05
mutations O 0 2.277335170219885e-06
was O 0 3.854035668382494e-08
detected O 0 1.6416956327702792e-07
in O 0 3.2015359252568487e-09
the O 0 2.0137527201313787e-09
mother O 0 1.1834634605634164e-08
of O 0 6.607949604164887e-11
three O 0 9.003173762067718e-10
AS B-Disease 1 0.9999994039535522
sons O 0 7.234039145487259e-08
, O 0 3.061853895425237e-11
in O 0 8.899874587298129e-11
the O 0 2.205255089648972e-09
maternal O 0 1.648970027190444e-07
grandfather O 0 7.081803943265186e-08
of O 0 1.4531534309192295e-10
two O 0 1.2802681137458194e-09
AS B-Disease 1 0.9997521042823792
first O 0 8.406255247450645e-09
cousins O 0 5.080200082829833e-08
, O 0 1.0293832453101004e-10
and O 0 3.442364102101969e-11
in O 0 2.3600105203414046e-10
the O 0 9.67167901322341e-10
mother O 0 5.363056665430577e-09
of O 0 4.81001315166818e-11
an O 0 1.6170867978004821e-09
AS B-Disease 1 0.9999996423721313
daughter O 0 1.6436819350929e-05
. O 0 7.720404937572312e-08

The O 0 1.8781391020183946e-07
frequencies O 0 6.517869906019769e-07
with O 0 2.994342551687623e-09
which O 0 1.2789793668588345e-09
we O 0 6.001812380418414e-10
detected O 0 1.3189205105845758e-07
mutations O 0 5.5402818333050163e-08
were O 0 2.876776372673362e-09
5 O 0 4.645253515178638e-09
( O 0 1.2189613762814133e-09
14 O 0 3.0612612444969045e-09
% O 0 1.2557299644555542e-10
) O 0 6.307574601516208e-11
of O 0 4.161877786845736e-11
35 O 0 2.781775920723817e-09
in O 0 5.921613199788567e-10
sporadic O 0 2.549579107835598e-07
cases O 0 9.044605953079099e-09
and O 0 4.2783958598136e-09
8 O 0 2.6739337855019585e-08
( O 0 1.5804075825798236e-09
80 O 0 2.9012754421131604e-09
% O 0 2.3038068674985368e-10
) O 0 8.647073335144029e-11
of O 0 3.959296085431774e-11
10 O 0 1.6636331201524968e-09
in O 0 3.449242447217671e-09
familial O 0 6.340718528008438e-07
cases O 0 1.4707667972402305e-08
. O 0 1.1011248801651163e-08
. O 0 6.67341595317339e-08

The O 0 1.4306199773272965e-05
hemochromatosis B-Disease 1 1.0
845 O 0 0.0009619067423045635
G O 0 0.0061449347995221615
- O 0 8.473989873891696e-05
- O 0 8.753555448492989e-06
> O 0 3.1503222430728783e-07
A O 0 2.400531506907555e-08
and O 0 2.7433852967106986e-09
187 O 0 5.582148077110105e-08
C O 0 4.379454367153812e-06
- O 0 4.2467049752303865e-06
- O 0 8.48854506330099e-06
> O 0 3.2935763556452002e-06
G O 0 9.59301833063364e-05
mutations O 0 6.1947148424224e-06
: O 0 9.872979767067136e-09
prevalence O 0 2.6807518338500813e-07
in O 0 6.891872850189884e-09
non O 0 6.268281538268639e-08
- O 0 3.243250375817297e-06
Caucasian O 0 2.6268216970493086e-06
populations O 0 3.248111681841692e-07
. O 0 1.8743421037470398e-07

Hemochromatosis B-Disease 1 0.9891605973243713
, O 0 6.043816824785608e-07
the O 0 4.605460162565578e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 2.983330205097445e-08
iron I-Disease 1 0.7259052991867065
metabolism I-Disease 0 0.002717411145567894
, O 0 1.246039271762811e-09
leads O 0 2.4089836792029473e-09
, O 0 8.802704121180227e-10
if O 0 2.8437328047914434e-09
untreated O 0 9.20983183050339e-08
, O 0 4.789508789571073e-10
to O 0 8.22630674690572e-09
progressive O 0 0.0003764829889405519
iron B-Disease 1 0.9989519119262695
overload I-Disease 0 0.0031842824537307024
and O 0 9.089921348959251e-08
premature B-Disease 0 1.3234504876891151e-05
death I-Disease 0 1.7948026425074204e-06
. O 0 1.820601482904749e-07

The O 0 7.167671810748288e-06
hemochromatosis B-Disease 1 1.0
gene O 0 0.00016428474918939173
, O 0 1.1520890552674246e-07
HFE O 0 0.0001279122952837497
, O 0 1.553030415379908e-08
recently O 0 1.0783806914105298e-07
has O 0 1.3761546346913178e-09
been O 0 4.241441087238229e-10
identified O 0 1.2543996952274483e-09
, O 0 1.1391387139125797e-10
and O 0 2.5357832500461086e-10
characterization O 0 1.9859385247400496e-09
of O 0 3.821135421966382e-11
this O 0 3.5538474940643994e-10
gene O 0 4.0225270225846543e-08
has O 0 1.4706313944401472e-09
shown O 0 1.5430526856263782e-09
that O 0 4.763614155911533e-11
it O 0 1.6036419414611203e-10
contains O 0 1.1610747085999407e-10
two O 0 1.2864309617555136e-10
mutations O 0 1.6128584690022763e-08
that O 0 9.461406658139992e-11
result O 0 8.741751211793769e-10
in O 0 1.8891781472518687e-09
amino O 0 3.7981653377983093e-08
acid O 0 7.363770748725074e-08
substitutions O 0 1.7061786650174326e-07
- O 0 2.5456918706368015e-07
cDNA O 0 8.328550507030741e-07
nucleotides O 0 5.810762786495616e-07
845 O 0 3.7721356420661323e-06
G O 0 1.8126222130376846e-05
- O 0 6.119275894889142e-06
- O 0 2.7814382974611362e-06
> O 0 3.213829415926739e-07
A O 0 3.132782921966282e-08
( O 0 4.314008705819106e-09
C282Y O 0 5.5043013702515964e-08
) O 0 4.969388789355378e-10
and O 0 2.8774937987918747e-10
187 O 0 2.034632906600109e-08
C O 0 3.6364638162922347e-06
- O 0 1.705256727291271e-05
- O 0 3.4455995773896575e-05
> O 0 3.1921404115564656e-06
G O 0 3.806475433520973e-05
( O 0 7.308612026690753e-08
H63D O 0 1.0292899787600618e-05
) O 0 2.978213409221553e-08
. O 0 5.7485127769041355e-08

Although O 0 0.00010144828411284834
hemochromatosis B-Disease 1 1.0
is O 0 9.069365347613711e-08
common O 0 2.4130178744030673e-08
in O 0 1.0109906689592663e-08
Caucasians O 0 1.7307017685652681e-07
, O 0 2.0888895058135404e-09
affecting O 0 7.246218558520923e-08
> O 0 3.480470525119017e-07
= O 0 9.201490343002661e-07
1 O 0 9.508620024689662e-08
/ O 0 6.500289941868687e-07
300 O 0 1.6782649714386366e-09
individuals O 0 3.28892711676243e-11
of O 0 2.843019396292501e-11
northern O 0 4.863608182859025e-09
European O 0 5.151761239829966e-09
origin O 0 4.681416365670543e-10
, O 0 8.477172436238689e-11
it O 0 3.1756869356414086e-10
has O 0 2.5475344056502536e-10
not O 0 5.813348760708159e-11
been O 0 7.895717413219927e-11
recognized O 0 8.268709328351775e-11
in O 0 1.724280718207183e-10
other O 0 1.3838767631835225e-10
populations O 0 7.651602906832977e-09
. O 0 3.4042766827724336e-08

The O 0 1.4152691107938153e-07
present O 0 4.3231374036167836e-08
study O 0 4.749683313320929e-09
used O 0 1.2912801494735504e-08
PCR O 0 5.444006092147902e-06
and O 0 6.63337607065273e-09
restriction O 0 8.092288084071697e-08
- O 0 1.3056896364105341e-07
enzyme O 0 9.731752470543142e-08
digestion O 0 6.322338208519795e-08
to O 0 1.1120531162589486e-09
analyze O 0 1.083354916886492e-08
the O 0 2.1387931425920215e-09
frequency O 0 1.2223873113725858e-07
of O 0 2.1094358204631902e-10
the O 0 4.4058290349369145e-09
845 O 0 4.808204607797961e-07
G O 0 4.638926384359365e-06
- O 0 1.6381218301830813e-06
- O 0 1.4175386695569614e-06
> O 0 1.090557546490345e-07
A O 0 8.541663376604447e-09
and O 0 1.3462725378943219e-09
187 O 0 1.9066236589537766e-08
C O 0 1.505945647295448e-06
- O 0 1.1078428769906168e-06
- O 0 1.7144855064543663e-06
> O 0 6.817346616116993e-07
G O 0 4.148587777308421e-06
mutations O 0 1.1013055427611107e-06
in O 0 4.1900324987409476e-08
HLA O 0 6.106461569288513e-06
- O 0 2.8901595783281664e-07
typed O 0 2.506626231024711e-07
samples O 0 7.000029889070447e-09
from O 0 2.5953146298718366e-09
non O 0 8.674884810488948e-09
- O 0 2.782908552489971e-07
Caucasian O 0 2.4417184363301203e-07
populations O 0 6.372311567304223e-09
, O 0 9.73645469803941e-11
comprising O 0 2.0080596907501302e-10
Australian O 0 9.510606746587769e-10
Aboriginal O 0 1.697539331324549e-09
, O 0 9.148821283888608e-11
Chinese O 0 9.131022327135696e-11
, O 0 1.2712982055962385e-10
and O 0 1.7091279502778889e-09
Pacific O 0 6.653525730371257e-08
Islanders O 0 1.5143245946092065e-06
. O 0 6.750264702759523e-08

Results O 0 3.5252510315331165e-06
showed O 0 3.870338503020321e-07
that O 0 1.003067073845898e-09
the O 0 3.207550225425848e-09
845 O 0 9.757641237229109e-07
G O 0 8.722389793547336e-06
- O 0 2.3833924842620036e-06
- O 0 1.399133111590345e-06
> O 0 1.4749855381523957e-07
A O 0 3.662014691485638e-08
mutation O 0 2.0343696860436467e-07
was O 0 1.1938380950482497e-08
present O 0 4.012170595757425e-10
in O 0 3.4521627223504936e-10
these O 0 2.6353441651139065e-10
populations O 0 2.4252346797482005e-09
( O 0 1.7089910597789526e-09
allele O 0 8.510314586374079e-08
frequency O 0 1.6469002162011748e-07
0 O 0 4.943903508802805e-09
. O 0 1.6483103770781327e-10
32 O 0 1.7754433478955889e-09
% O 0 1.2641843127880747e-10
) O 0 1.1050287074265697e-10
, O 0 5.87187590217475e-11
and O 0 2.735326964931062e-10
, O 0 9.135377176949788e-11
furthermore O 0 7.181406580514249e-10
, O 0 1.4362128153422304e-10
it O 0 4.130092712273381e-09
was O 0 2.1103680580836226e-07
always O 0 5.66202973395491e-10
seen O 0 1.0629355173819022e-09
in O 0 3.787902769225582e-10
conjunction O 0 3.871347242778711e-09
with O 0 2.4007318355501184e-09
HLA O 0 1.983870333788218e-06
haplotypes O 0 2.279455202369718e-07
common O 0 1.3795403042138332e-08
in O 0 7.0904238036462175e-09
Caucasians O 0 4.7136225589383685e-08
, O 0 4.74468297984032e-10
suggesting O 0 9.543301260350745e-09
that O 0 1.3610172988620661e-09
845 O 0 4.199833938400843e-07
G O 0 8.767356121097691e-06
- O 0 2.8968590868316824e-06
- O 0 1.4150061815598747e-06
> O 0 1.1138436661894957e-07
A O 0 1.3368112661282794e-07
may O 0 1.7090154358356813e-07
have O 0 3.4792382863635396e-10
been O 0 5.308181116880917e-10
introduced O 0 3.5063409953295377e-09
into O 0 3.1876781769746287e-10
these O 0 8.148001717778186e-11
populations O 0 9.583938087587285e-10
by O 0 1.1947325351258087e-09
Caucasian O 0 6.849925284768688e-07
admixture O 0 2.772117113636341e-06
. O 0 3.453398562669463e-07

187 O 0 5.8169211115455255e-05
C O 0 0.00036727992119267583
- O 0 2.6763766072690487e-05
- O 0 5.135021638125181e-06
> O 0 1.0229117606286309e-06
G O 0 6.449620741477702e-06
was O 0 1.8772253085330703e-08
present O 0 7.892890785399231e-10
at O 0 1.5870591507649578e-09
an O 0 4.76521599956925e-10
allele O 0 1.735210162223666e-07
frequency O 0 3.2586919473942544e-07
of O 0 1.684492878517574e-09
2 O 0 5.770604261101653e-08
. O 0 3.355867406185098e-08

68 O 0 7.66152334108483e-06
% O 0 2.105530683138568e-08
in O 0 1.4660997971205347e-09
the O 0 1.405868754744688e-09
two O 0 6.03854466429965e-10
populations O 0 4.325452884756942e-09
analyzed O 0 4.289183763717119e-08
( O 0 4.742468640017705e-09
Australian O 0 6.2499418973516185e-09
Aboriginal O 0 5.3282884771022054e-09
and O 0 4.878647485995202e-10
Chinese O 0 8.040646481966007e-10
) O 0 5.960677285088423e-09
. O 0 3.321081365470491e-08

In O 0 1.260278708059559e-07
the O 0 1.394912985119845e-08
Australian O 0 1.3591010983304841e-08
Aboriginal O 0 9.734663741767235e-09
samples O 0 4.04746014481816e-09
, O 0 4.216331450646038e-10
187 O 0 3.0362755865098734e-08
C O 0 1.9276621969765984e-06
- O 0 2.9069933589198627e-06
- O 0 6.960875452932669e-06
> O 0 6.781170895919786e-07
G O 0 3.374333755346015e-05
was O 0 4.439852929749577e-08
found O 0 9.41460798209448e-10
to O 0 3.537272141862502e-10
be O 0 2.607982163560507e-10
associated O 0 2.0309793846706725e-09
with O 0 3.67918628896291e-09
HLA O 0 2.3763111585139995e-06
haplotypes O 0 4.6497945049850387e-07
common O 0 1.3321934666521429e-08
in O 0 9.81219283602286e-09
Caucasians O 0 3.024242190008408e-08
, O 0 1.1745661387951856e-10
suggesting O 0 4.545424925339603e-09
that O 0 3.444474150349208e-10
it O 0 1.2197985954642832e-09
was O 0 1.0140323247753713e-08
introduced O 0 1.2396631277056258e-08
by O 0 5.498954624982844e-10
recent O 0 1.6456356277672057e-08
admixture O 0 1.593717456671584e-06
. O 0 3.8757161746616475e-07

In O 0 4.096344810022856e-07
the O 0 1.1695240331732748e-08
Chinese O 0 1.7654443462689073e-09
samples O 0 1.1297362156881263e-08
analyzed O 0 3.151794203404279e-08
, O 0 4.662871755378717e-10
187 O 0 4.2010036338524515e-08
C O 0 1.000975885290245e-06
- O 0 1.0412918527435977e-06
- O 0 1.7432327013011673e-06
> O 0 5.158991598364082e-07
G O 0 1.821492514864076e-05
was O 0 7.497759213492827e-08
present O 0 6.789137030338566e-10
in O 0 1.6643917355452231e-09
association O 0 9.316680760207419e-10
with O 0 1.2786006975407105e-10
a O 0 1.2781696812069754e-09
wide O 0 4.315720225633868e-09
variety O 0 4.775244644150689e-09
of O 0 2.5568966943723126e-09
HLA O 0 2.4919538645917783e-06
haplotypes O 0 1.277612824424068e-07
, O 0 2.6586693957497687e-10
showing O 0 1.7397693952148074e-08
this O 0 5.669594238533193e-10
mutation O 0 1.1395093757471386e-08
to O 0 7.485720932010054e-10
be O 0 2.8076110880626004e-10
widespread O 0 1.9485897340132396e-09
and O 0 1.5180957602112244e-09
likely O 0 9.026046576821045e-09
to O 0 5.987987883315782e-10
predate O 0 8.147438990135925e-08
the O 0 6.15384077029546e-10
more O 0 2.1014483209125245e-10
genetically O 0 1.6501521926670648e-08
restricted O 0 3.084084099214124e-08
845 O 0 6.741489642081433e-07
G O 0 1.7433027096558362e-05
- O 0 9.34277159103658e-06
- O 0 4.446176717465278e-06
> O 0 5.563015861298481e-07
A O 0 2.1692710561183048e-07
mutation O 0 5.600460553978337e-06
. O 0 1.4449966556639993e-07

Genotype O 0 0.06320807337760925
- O 0 0.01131503377109766
phenotype O 0 0.0011896333890035748
correlations O 0 0.0001237494871020317
in O 0 2.916014454967808e-05
attenuated B-Disease 1 0.9999946355819702
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
. O 0 9.702015813672915e-05

Germ O 0 0.03639223426580429
- O 0 0.02536693960428238
line O 0 5.3155614295974374e-05
mutations O 0 4.465409347176319e-06
of O 0 3.7237486427699196e-09
the O 0 4.287727506380179e-08
tumor B-Disease 0 1.4218714568414725e-05
suppressor O 0 3.669087163871154e-05
APC O 0 2.3400277768814703e-06
are O 0 5.040547979007215e-09
implicated O 0 1.446521650905197e-06
in O 0 8.514355158695253e-07
attenuated B-Disease 1 0.9999983310699463
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.28842225670814514
AAPC B-Disease 1 1.0
) O 0 7.082979180950133e-08
, O 0 1.5290514410182254e-09
a O 0 8.464223100190793e-09
variant O 0 0.00036131299566477537
of O 0 1.7887790590975783e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0004168255254626274
FAP B-Disease 0 0.00023657275596633554
) O 0 3.846985521249735e-07
. O 0 2.5216570520569803e-07

AAPC B-Disease 1 0.9999998807907104
is O 0 6.201129281180329e-07
recognized O 0 2.8767722426437103e-08
by O 0 1.366753488163397e-09
the O 0 1.8105297261428177e-09
occurrence O 0 5.571086347799792e-08
of O 0 4.033111622447905e-09
< O 0 4.2782025388987677e-07
100 O 0 4.414528831375719e-08
colonic B-Disease 0 1.575299938849639e-05
adenomas I-Disease 0 2.3551442609459627e-06
and O 0 2.547438482380926e-09
a O 0 1.1744464067930949e-08
later O 0 6.85537600020325e-07
onset O 0 0.4851831793785095
of O 0 0.02982913702726364
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.5764981614884164e-07
age O 0 5.2752422874391414e-08
> O 0 9.897268427039307e-08
40 O 0 1.9172977872017327e-08
years O 0 6.135443264554397e-09
) O 0 8.053052447110076e-09
. O 0 2.7536932734051334e-08

The O 0 1.4427905625780113e-07
aim O 0 6.121967288663654e-08
of O 0 4.4523740250212995e-10
this O 0 2.048473890514657e-10
study O 0 9.311422188851282e-10
was O 0 4.761075533821213e-09
to O 0 1.3426413314476804e-09
assess O 0 1.9982984156285966e-07
genotype O 0 1.296402024308918e-05
- O 0 2.1732563254772685e-05
phenotype O 0 3.210201975889504e-05
correlations O 0 2.780494241960696e-06
in O 0 8.355104910151567e-07
AAPC B-Disease 1 0.9999998807907104
families O 0 2.840766910594539e-07
. O 0 1.943129745995975e-07

By O 0 5.923251364947646e-07
protein O 0 4.642076874006307e-06
- O 0 4.632621767086675e-06
truncation O 0 1.3365553968469612e-05
test O 0 2.316133986823843e-06
( O 0 5.31446744389541e-08
PTT O 0 6.547662110278907e-07
) O 0 1.6649123191214699e-09
assay O 0 7.355895803584644e-08
, O 0 1.8779180988026667e-10
the O 0 3.2959496243378794e-10
entire O 0 8.781813498615065e-09
coding O 0 2.0560841562655696e-07
region O 0 2.2137680577571928e-09
of O 0 2.495669781943377e-10
the O 0 4.2041516934432366e-09
APC B-Disease 0 1.8747033436739002e-07
gene O 0 1.2364638735107292e-07
was O 0 2.5182414375990447e-08
screened O 0 3.09124565944785e-08
in O 0 2.596275416877347e-09
affected O 0 5.675050207543109e-09
individuals O 0 4.477206105857334e-10
from O 0 8.625108627313693e-09
11 O 0 5.752164042860386e-07
AAPC B-Disease 1 0.9999998807907104
kindreds O 0 4.575132152240258e-06
, O 0 2.5270836534474483e-09
and O 0 6.422605780542767e-10
their O 0 1.210608613355646e-09
phenotypic O 0 1.7901854221236135e-07
differences O 0 1.070880912834582e-07
were O 0 3.8835075599763513e-08
examined O 0 1.4869029882902396e-06
. O 0 1.6832001392685925e-07

Five O 0 6.481212153630622e-07
novel O 0 1.14048100385844e-06
germ O 0 0.00010384520282968879
- O 0 0.00036442498094402254
line O 0 0.00032127537997439504
APC B-Disease 0 5.903979854338104e-06
mutations O 0 1.6423608713012072e-06
were O 0 4.5429202621960485e-09
identified O 0 1.0469678457525333e-08
in O 0 9.243865228825143e-09
seven O 0 5.905861755195474e-08
kindreds O 0 1.416047234670259e-05
. O 0 2.2482926453903929e-07

Mutations O 0 0.0008983163279481232
were O 0 3.335231326673238e-07
located O 0 6.363082860616487e-08
in O 0 2.8032676180345106e-09
three O 0 2.900311102393971e-10
different O 0 1.026033286111172e-10
regions O 0 6.651248996014658e-10
of O 0 1.1665286792084117e-10
the O 0 1.0541493011828607e-08
APC B-Disease 0 3.516148012749909e-07
gene O 0 1.8821125991053123e-07
( O 0 3.045885321739661e-09
1 O 0 3.429104111773995e-09
) O 0 4.1506625914067286e-10
at O 0 7.106116139965479e-09
the O 0 2.476339133750116e-09
5 O 0 2.0743231132769324e-08
end O 0 4.454969371181505e-08
spanning O 0 5.161619398563744e-08
exons O 0 1.6743464925639273e-07
4 O 0 2.5927237246037294e-08
and O 0 2.7249813516760923e-09
5 O 0 1.628580470480756e-08
, O 0 7.277237701330819e-10
( O 0 1.0254136428855531e-09
2 O 0 2.617077443645144e-09
) O 0 4.1017661489561874e-10
within O 0 1.1821543743906204e-09
exon O 0 1.7791772677355766e-07
9 O 0 1.989465943097457e-07
, O 0 5.878781905721553e-10
and O 0 1.994932219417933e-09
( O 0 1.3410340615749305e-09
3 O 0 5.899722932412033e-09
) O 0 4.221537841520018e-10
at O 0 8.497739401036597e-09
the O 0 4.171601730718066e-09
3 O 0 1.65423621467653e-08
distal O 0 4.584617840919236e-07
end O 0 4.639447226395532e-08
of O 0 3.023385430900305e-10
the O 0 7.477533259248048e-09
gene O 0 8.010175065464864e-07
. O 0 8.3784854609803e-08

Variability O 0 3.656801345641725e-05
in O 0 6.140398056686536e-08
the O 0 8.874525114777043e-09
number O 0 8.327658562734541e-09
of O 0 4.660689114643901e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 2.5356080186611507e-06
most O 0 4.383655660689101e-10
apparent O 0 4.717559676237215e-09
in O 0 1.4596071018502244e-09
individuals O 0 7.511461591613866e-11
with O 0 2.7739119334846407e-10
mutations O 0 5.016189419393413e-08
in O 0 2.609610527670725e-09
region O 0 6.761176063463381e-09
1 O 0 1.7329073287442043e-08
, O 0 6.372380956243262e-10
and O 0 8.127242878686047e-09
upper O 1 0.9911363124847412
- O 1 0.9998217225074768
gastrointestinal O 1 0.8256367444992065
manifestations O 0 7.021454280220496e-07
were O 0 1.0404382244644239e-08
more O 0 9.598499772778268e-10
severe O 0 1.9595445337472484e-06
in O 0 1.0841403330630328e-08
them O 0 7.998372630879658e-09
. O 0 7.496557685726657e-08

In O 0 1.8209765073606832e-07
individuals O 0 6.471796432094834e-09
with O 0 4.087756799719955e-09
mutations O 0 5.442436190605804e-07
in O 0 1.0387013027468583e-08
either O 0 2.2525629361780375e-08
region O 0 1.957986484057983e-08
2 O 0 3.287991390266143e-08
or O 0 9.939792100510658e-09
region O 0 9.691589752947039e-09
3 O 0 8.242106552813766e-09
, O 0 8.810308732565275e-11
the O 0 4.2304043601504304e-10
average O 0 5.443939521398988e-09
number O 0 3.141719662203002e-10
of O 0 4.029649391945611e-10
adenomas B-Disease 0 1.9950365981458162e-07
tended O 0 1.748269369272748e-07
to O 0 2.5393662728134814e-09
be O 0 1.0213808687709047e-09
lower O 0 1.2133598374930443e-06
than O 0 3.2745572919878896e-10
those O 0 6.090802862068756e-11
in O 0 1.4061363184936226e-10
individuals O 0 3.2802063149039995e-11
with O 0 1.9683041307949622e-10
mutations O 0 2.4340037541037418e-08
in O 0 9.018538693617018e-10
region O 0 1.7658553508326236e-09
1 O 0 3.36666849953815e-09
, O 0 8.524972394674535e-11
although O 0 9.885487983751773e-10
age O 0 9.894433716794993e-09
at O 0 7.255415823692601e-08
diagnosis O 0 2.3381717255688272e-06
was O 0 8.039182120000987e-08
similar O 0 8.672952844790416e-08
. O 0 1.110350140720584e-07

In O 0 1.1820715144494898e-06
all O 0 1.2865113774296333e-07
AAPC B-Disease 1 0.9999996423721313
kindreds O 0 9.310831046605017e-06
, O 0 4.09040845639197e-09
a O 0 4.277604492841647e-09
predominance O 0 3.3664457532722736e-07
of O 0 5.5954485489451145e-09
right O 0 0.10986737161874771
- O 1 0.9999997615814209
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 1.698518099146895e-05
rectal B-Disease 1 0.9994739890098572
polyp I-Disease 0 0.00200959132052958
sparing O 0 1.5083977586982655e-06
was O 0 6.507658554255613e-07
observed O 0 5.604102284451074e-07
. O 0 1.0874917677483609e-07

No O 0 1.0576521162874997e-05
desmoid B-Disease 1 0.7183251976966858
tumors I-Disease 1 1.0
were O 0 1.0423296714634489e-07
found O 0 1.4677401516394184e-08
in O 0 7.445271066330861e-09
these O 0 1.4463084951898963e-08
kindreds O 0 6.957305231480859e-06
. O 0 1.3811443011491065e-07

Our O 0 3.9104597249206563e-07
data O 0 1.5503734118738066e-07
suggest O 0 2.3903794499346986e-08
that O 0 4.414844323452627e-10
, O 0 3.305922480212331e-10
in O 0 9.07739128308549e-09
AAPC B-Disease 1 1.0
families O 0 1.6255632395711928e-09
, O 0 4.7252996654423285e-11
the O 0 8.342371932146264e-11
location O 0 1.0923907334259297e-09
of O 0 1.273426503134445e-10
the O 0 9.088444663518658e-09
APC B-Disease 0 3.986426236224361e-06
mutation O 0 2.8976271551073296e-06
may O 0 2.59666876445408e-07
partially O 0 4.536739766081155e-07
predict O 0 2.8179556466056965e-07
specific O 0 7.747812702518786e-08
phenotypic O 0 3.410240879020421e-06
expression O 0 2.000849235628266e-06
. O 0 3.4156562378484523e-07

This O 0 1.2608580846062978e-07
should O 0 7.174907334928093e-09
help O 0 1.1120807608122618e-09
in O 0 4.20283446933567e-10
the O 0 7.436949944761295e-10
design O 0 1.889918088693321e-08
of O 0 4.2909792385970036e-10
tailored O 0 4.1158460817314335e-07
clinical O 0 4.929565307065786e-07
- O 0 0.0001798955345293507
management O 0 2.42434396113822e-07
protocols O 0 3.5094604555752085e-08
in O 0 1.3961952705088265e-09
this O 0 2.8228985815559327e-10
subset O 0 4.624778782158501e-09
of O 0 1.2159774298581283e-09
FAP B-Disease 0 1.2820743222619058e-06
patients O 0 3.34910836841118e-08
. O 0 5.440306871662415e-09
. O 0 5.8684584303136944e-08

Wilms B-Disease 0 0.1383511871099472
' I-Disease 0 6.059168663341552e-05
tumor I-Disease 0 0.00011217343853786588
1 O 0 3.5199391845708305e-07
and O 0 2.7056133333758225e-08
Dax O 1 0.999830961227417
- O 0 2.788035317280446e-06
1 O 0 2.6488173432426265e-08
modulate O 0 1.044173700393003e-06
the O 0 2.288088118973519e-08
orphan O 0 3.749429424715345e-07
nuclear O 0 1.8502456100577547e-07
receptor O 0 7.792850738042034e-07
SF O 0 0.00019649378373287618
- O 0 1.0715464213717496e-06
1 O 0 1.0701250552358488e-08
in O 0 1.5375910544790372e-09
sex O 0 1.3520115693665957e-08
- O 0 2.7799051949273235e-08
specific O 0 4.377917584008628e-09
gene O 0 1.1391186660603125e-07
expression O 0 9.984315596511806e-08
. O 0 4.605353609576923e-08

Products O 0 7.672893843846396e-06
of O 0 8.012958829795025e-08
steroidogenic O 0 3.395198655198328e-05
factor O 0 3.709551776864828e-07
1 O 0 2.672726111541124e-07
( O 0 1.0758906654473321e-07
SF O 0 0.05253935605287552
- O 0 1.669234552537091e-05
1 O 0 8.051136290987415e-08
) O 0 6.069864610935838e-09
and O 0 1.5936970854113497e-08
Wilms B-Disease 0 4.685630847234279e-05
tumor I-Disease 0 7.677094799873885e-06
1 O 0 5.644254841286056e-08
( O 0 2.292745016063691e-08
WT1 O 0 3.5260040931461845e-06
) O 0 2.5761250910250055e-09
genes O 0 8.93359164422236e-09
are O 0 1.7923049155932347e-10
essential O 0 2.645159091763105e-10
for O 0 2.5392341007624e-10
mammalian O 0 1.4642637324868701e-07
gonadogenesis O 0 5.212188511904969e-07
prior O 0 1.2465818599594058e-08
to O 0 3.599521791741722e-09
sexual O 0 8.916725846574991e-08
differentiation O 0 4.6965448063929216e-07
. O 0 1.2643621971619723e-07

In O 0 1.6469690535814152e-06
males O 0 7.775035442136868e-07
, O 0 2.41337687612031e-08
SF O 0 0.008801187388598919
- O 0 4.551857728074538e-06
1 O 0 2.297954715402284e-08
participates O 0 1.4894581568114518e-08
in O 0 1.6278840497818692e-09
sexual O 0 3.3831473178480564e-09
development O 0 3.153474426031977e-10
by O 0 3.709766660531244e-10
regulating O 0 3.83638969481126e-08
expression O 0 1.012528727528661e-08
of O 0 7.630146514614466e-10
the O 0 2.9280613489390817e-08
polypeptide O 0 1.1385095604055095e-05
hormone O 0 4.317601451475639e-06
Mullerian O 0 2.4879051125026308e-05
inhibiting O 0 7.818325684638694e-06
substance O 0 4.577681011141976e-06
( O 0 4.0695013581171224e-07
MIS O 0 9.722083632368594e-05
) O 0 1.7782917893782724e-07
. O 0 2.091502295797909e-07

Here O 0 6.536905630127876e-07
, O 0 6.559784715420847e-09
we O 0 1.1248075804104474e-09
show O 0 2.8132104645806066e-08
that O 0 5.532454494527883e-09
WT1 O 0 4.8470374167663977e-05
- O 0 6.946338999114232e-06
KTS O 0 3.665631447802298e-05
isoforms O 0 1.1581184935494093e-06
associate O 0 6.774578054091762e-08
and O 0 4.047089774417145e-09
synergize O 0 1.6797073385532713e-06
with O 0 4.2316109727380535e-08
SF O 1 0.651775062084198
- O 0 2.9807888495270163e-05
1 O 0 4.1785796156545985e-08
to O 0 5.906095612573381e-09
promote O 0 4.0990485672409704e-08
MIS O 0 3.0031353162485175e-05
expression O 0 4.4142768729216186e-07
. O 0 6.75579059361553e-08

In O 0 6.661931593043846e-07
contrast O 0 1.6139928220582078e-06
, O 0 8.419014818628057e-08
WT1 O 0 0.0002222395414719358
missense O 0 0.0002307402464793995
mutations O 0 2.9736795113421977e-05
, O 0 5.31174881857055e-09
associated O 0 8.729591272071957e-09
with O 0 3.0924116600772322e-09
male B-Disease 0 3.0094861358520575e-07
pseudohermaphroditism I-Disease 1 1.0
in O 0 3.3833862289611716e-06
Denys B-Disease 1 0.9999978542327881
- I-Disease 1 0.9999973773956299
Drash I-Disease 1 0.999998927116394
syndrome I-Disease 1 0.9999998807907104
, O 0 1.09346061094584e-08
fail O 0 3.954042711029615e-07
to O 0 1.2148884565021945e-08
synergize O 0 7.219907274702564e-06
with O 0 1.4136760739802412e-07
SF O 1 0.9923363327980042
- O 0 0.00014800630742684007
1 O 0 3.244885533604247e-07
. O 0 1.1762581664243044e-07

Additionally O 0 2.7956286885455484e-06
, O 0 8.886043012523714e-09
the O 0 9.908426967797368e-09
X O 0 0.0008777717594057322
- O 0 1.4601389011659194e-05
linked O 0 5.669757683790522e-06
, O 0 1.975620778082998e-09
candidate O 0 1.7211281289064573e-08
dosage O 0 2.5438187094550813e-06
- O 0 7.659957645955728e-07
sensitive O 0 3.864256086671958e-06
sex O 0 2.105213923186966e-07
- O 0 1.6131143354414235e-07
reversal O 0 1.944462582059714e-07
gene O 0 1.8949972968584916e-07
, O 0 4.253035257306692e-09
Dax O 1 0.9646156430244446
- O 0 1.360498572466895e-06
1 O 0 1.25276002904684e-08
, O 0 1.023096718455463e-09
antagonizes O 0 2.4310813273586973e-07
synergy O 0 8.657152505975318e-08
between O 0 2.799229825711791e-08
SF O 0 0.008493535220623016
- O 0 6.207049864315195e-06
1 O 0 4.386411944778956e-08
and O 0 3.73057318370229e-09
WT1 O 0 1.122538378695026e-06
, O 0 4.6552561805413006e-10
most O 0 1.3442601198843107e-10
likely O 0 1.7696618614948534e-09
through O 0 4.5376091772908467e-10
a O 0 5.407674308344212e-10
direct O 0 1.2004408578292214e-09
interaction O 0 3.4520721836628354e-09
with O 0 1.7440020982917304e-08
SF O 1 0.920689582824707
- O 0 4.8466488806298e-05
1 O 0 2.9258850986479956e-07
. O 0 1.2447813446669898e-07

We O 0 6.611595040340035e-07
propose O 0 1.705519593997451e-06
that O 0 1.0662864369237468e-08
WT1 O 0 1.8901482690125704e-05
and O 0 5.320512030948521e-08
Dax O 1 0.9999134540557861
- O 0 8.541871466150042e-06
1 O 0 3.441594742525922e-08
functionally O 0 4.079673487922264e-08
oppose O 0 5.854436047059153e-09
each O 0 3.388828939687727e-10
other O 0 1.6147096160157304e-10
in O 0 1.4380803214919524e-09
testis O 0 1.3287908018355665e-07
development O 0 1.7148945596900944e-09
by O 0 5.033726768743918e-09
modulating O 0 0.00010771028610179201
SF O 0 0.19192497432231903
- O 0 1.3411798136075959e-05
1 O 0 2.3342410315763118e-07
- O 0 1.471052314627741e-06
mediated O 0 2.289239546371391e-06
transactivation O 0 2.6004678147728555e-05
. O 0 3.30492966327256e-08
. O 0 6.682804354340988e-08

A O 0 3.1300737646233756e-06
mouse O 0 8.161989535437897e-05
model O 0 5.876685918337898e-06
for O 0 7.023463126643037e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9997907280921936
- O 1 0.922229528427124
centre O 0 3.868374551529996e-05
mutations O 0 6.247514829738066e-05
. O 0 5.943219321125071e-07

Imprinting O 0 0.00022364484902936965
in O 0 3.4010520266747335e-07
the O 0 4.7493781352159203e-08
15q11 O 0 4.378206085675629e-06
- O 0 7.790844733790436e-07
q13 O 0 1.033356056723278e-06
region O 0 2.4057936087729104e-08
involves O 0 1.2365837243066835e-08
an O 0 5.843503458891064e-09
imprinting O 0 4.15887261624448e-05
centre O 0 2.048272563115461e-06
( O 0 1.2722599862513562e-08
IC O 0 5.815963390887191e-07
) O 0 8.553185382176309e-10
, O 0 1.6984226525185164e-10
mapping O 0 3.41739037068578e-09
in O 0 5.108119482954976e-10
part O 0 5.673369551928431e-10
to O 0 5.797008428842787e-10
the O 0 1.542078797989177e-09
promoter O 0 8.363573300584903e-08
and O 0 2.815236377351482e-10
first O 0 2.3335000598478928e-09
exon O 0 2.1827888474490464e-07
of O 0 6.704365063114892e-09
SNRPN O 0 3.538593591656536e-05
. O 0 1.9000134443558636e-07

Deletion O 0 3.9972292142920196e-05
of O 0 5.125917112991374e-08
this O 0 3.100882750572964e-08
IC O 0 2.2706042727804743e-05
abolishes O 0 1.809130480978638e-05
local O 0 1.2438724183994054e-07
paternally O 0 4.677418928622501e-06
derived O 0 6.39754773601453e-08
gene O 0 2.4509245122317225e-07
expression O 0 2.7862752105534128e-08
and O 0 3.2302664987327034e-09
results O 0 8.644480686825773e-08
in O 0 6.171836139401421e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.262177026248537e-05
PWS B-Disease 1 1.0
) O 0 4.967594122717855e-07
. O 0 1.9529724681888183e-07

We O 0 1.3497162854037015e-07
have O 0 3.0764799596738612e-09
created O 0 2.7609547981199967e-09
two O 0 9.591948346709955e-10
deletion O 0 3.556326646503294e-07
mutations O 0 3.9618637970306736e-07
in O 0 1.1510145725424081e-08
mice O 0 1.1399089999031276e-05
to O 0 4.8352795545270055e-08
understand O 0 1.1103052202088293e-06
PWS B-Disease 1 1.0
and O 0 1.541950034322781e-08
the O 0 1.3518612895779825e-09
mechanism O 0 8.436146003987233e-09
of O 0 2.7667151902832643e-10
this O 0 3.174271290262709e-09
IC O 0 9.117700756178237e-06
. O 0 1.2928208548146358e-07

Mice O 0 0.005665194243192673
harbouring O 0 0.00010711702634580433
an O 0 1.0223894264527189e-07
intragenic O 0 2.6290612368029542e-05
deletion O 0 6.140038294688566e-06
in O 0 5.279651205114533e-08
Snrpn O 0 5.179556865186896e-06
are O 0 4.8303543387362424e-09
phenotypically O 0 5.522920218936633e-07
normal O 0 2.4967465606096084e-07
, O 0 1.0643799175369395e-09
suggesting O 0 8.928072503522344e-09
that O 0 2.828816625388697e-10
mutations O 0 4.113459439736289e-08
of O 0 4.5403103499097597e-10
SNRPN O 0 1.4775987438042648e-06
are O 0 6.550725933918145e-11
not O 0 9.638635722897249e-11
sufficient O 0 1.0307079634230831e-09
to O 0 9.167101744367301e-09
induce O 0 7.885320883360691e-06
PWS B-Disease 1 0.9999998807907104
. O 0 6.837674391135806e-07

Mice O 0 0.0001480674254707992
with O 0 3.829473627092739e-08
a O 0 2.712728885967408e-08
larger O 0 2.359702477860992e-08
deletion O 0 4.243565570050123e-07
involving O 0 8.478118651567002e-09
both O 0 6.792780116171571e-09
Snrpn O 0 1.080388528862386e-06
and O 0 4.1366519099028665e-09
the O 0 5.011637682628134e-08
putative O 0 7.32430416974239e-05
PWS O 1 1.0
- O 0 0.019829001277685165
IC O 0 8.063977293204516e-05
lack O 0 6.101241467604268e-08
expression O 0 2.3889025868584213e-08
of O 0 4.470158410097014e-10
the O 0 8.75034622538351e-09
imprinted O 0 4.782558335136855e-06
genes O 0 3.1832161084821564e-07
Zfp127 O 0 3.854105671052821e-06
( O 0 3.511583201998292e-08
mouse O 0 3.884929810737958e-06
homologue O 0 3.709159273057594e-06
of O 0 8.869786682907943e-09
ZNF127 O 0 7.892475878179539e-06
) O 0 9.582882931624681e-09
, O 0 4.743563319919986e-09
Ndn O 0 1.0446186024637427e-05
and O 0 1.2038372076972337e-08
Ipw O 0 2.584404910521698e-06
, O 0 1.7428440912681253e-09
and O 0 9.19630815943151e-10
manifest O 0 4.2640760256063004e-08
several O 0 3.794528247169637e-09
phenotypes O 0 6.340948175420635e-07
common O 0 3.366940575233457e-07
to O 0 6.951840077817906e-06
PWS B-Disease 1 1.0
infants O 0 0.399407297372818
. O 0 2.7972131988462934e-07

These O 0 7.458663020543099e-08
data O 0 5.475432729440399e-08
demonstrate O 0 3.9017402642116394e-09
that O 0 5.934557012476915e-11
both O 0 8.460986078429045e-11
the O 0 4.860295499398148e-10
position O 0 5.012409598492695e-09
of O 0 3.006551951845182e-11
the O 0 1.4442899098909834e-09
IC O 0 2.525153774968203e-07
and O 0 3.077535171147616e-10
its O 0 1.1772133268195262e-09
role O 0 4.222069360793057e-10
in O 0 1.4940347570213675e-10
the O 0 1.80281692352402e-10
coordinate O 0 3.736426723577324e-09
expression O 0 1.6952064196829042e-09
of O 0 4.7454314783257345e-11
genes O 0 2.272017907145596e-09
is O 0 1.0118018922700145e-10
conserved O 0 2.0098465114415376e-09
between O 0 5.024707316891863e-10
mouse O 0 2.31951821660914e-06
and O 0 1.1252947462736529e-09
human O 0 3.3573682722831677e-10
, O 0 6.499301097306898e-11
and O 0 1.1974446434415142e-10
indicate O 0 2.1895296686835763e-09
that O 0 6.487436282620607e-11
the O 0 6.707431277064302e-10
mouse O 0 2.940413992291724e-07
is O 0 3.6852526585917644e-10
a O 0 4.406398301792791e-10
suitable O 0 3.9441503396631106e-09
model O 0 2.2934010246444814e-08
system O 0 2.020910372380058e-08
in O 0 1.0703979924642226e-09
which O 0 2.1079356316011655e-10
to O 0 1.6465948049493306e-10
investigate O 0 7.869410678651434e-10
the O 0 3.0751878821178025e-10
molecular O 0 5.236164390964859e-09
mechanisms O 0 5.6320894614714234e-09
of O 0 2.532013487765994e-10
imprinting O 0 3.9055998968251515e-07
in O 0 3.859050412557963e-09
this O 0 2.3487795042242965e-10
region O 0 6.076417702338688e-10
of O 0 9.577171694585829e-11
the O 0 1.924653991736136e-09
genome O 0 3.2720254949936134e-08
. O 0 3.417977234576597e-09
. O 0 1.6708110450736058e-08

Mutations O 0 0.00012393773067742586
of O 0 3.722067631883874e-08
the O 0 3.144072735494774e-08
ATM O 0 5.554143626795849e-06
gene O 0 8.000693014764693e-07
detected O 0 1.3789058357360773e-06
in O 0 1.4671529413590179e-07
Japanese O 0 0.14123369753360748
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.8869991302490234
: O 0 1.3048725655551152e-08
possible O 0 6.182314216118812e-09
preponderance O 0 9.235461817524993e-08
of O 0 2.7345967157366147e-10
the O 0 7.418433090045085e-10
two O 0 1.5778955919643067e-09
founder O 0 1.7790958395380585e-07
mutations O 0 3.2320988907486026e-07
4612del165 O 0 2.8122187245571695e-07
and O 0 9.470624284801943e-09
7883del5 O 0 3.784999762501684e-06
. O 0 1.3775951401839848e-07

The O 0 1.1731834774764138e-06
ATM O 0 0.00023817083274479955
( O 0 9.021107416629093e-07
A O 1 0.9999998807907104
- O 1 0.9999998807907104
T O 1 1.0
, O 0 1.7214038194879322e-08
mutated O 0 2.1381215731253178e-07
) O 0 1.9451957822269605e-09
gene O 0 4.588020630080791e-08
on O 0 1.0964052776785138e-08
human O 0 1.810931316015285e-08
chromosome O 0 6.18437297816854e-06
11q22 O 0 9.859641068032943e-06
. O 0 3.769399086195335e-07

3 O 0 1.1082909622928128e-05
has O 0 2.3480113853224793e-08
recently O 0 4.337202597071155e-08
been O 0 6.358225057567779e-10
identified O 0 7.690151293537895e-10
as O 0 1.402787747073475e-10
the O 0 2.258988690551078e-10
gene O 0 1.2965343465509704e-08
responsible O 0 1.7404456764680276e-09
for O 0 9.923737526174037e-11
the O 0 1.62712665563447e-09
human O 0 5.085881866762065e-07
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.02152155712246895
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.1415867479390727e-07
. O 0 1.3166231838113163e-07

In O 0 3.9149972508312203e-07
order O 0 1.0927392324333596e-08
to O 0 1.421014306224322e-09
define O 0 7.2019310515258894e-09
the O 0 1.1362294438654885e-09
types O 0 9.183025895254104e-09
of O 0 3.987363328405991e-09
disease O 0 4.679972698795609e-05
- O 0 8.711599548405502e-06
causing O 0 3.347877736814553e-06
ATM O 0 0.00011703378550009802
mutations O 0 3.789662741837674e-06
in O 0 2.1004607830832356e-08
Japanese O 0 3.0571022762160283e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 9.300635497311305e-07
as O 0 1.6403575164858353e-09
well O 0 3.188511121798854e-10
as O 0 3.0635202707962605e-10
to O 0 2.5288715566063047e-10
look O 0 6.765898064031717e-09
for O 0 1.6441718819759643e-10
possible O 0 5.140492920219231e-09
mutational O 0 2.705015049286885e-06
hotspots O 0 2.1642249237174838e-07
, O 0 1.2662844106614557e-09
reverse O 0 8.042262038543413e-07
- O 0 3.218847552943771e-07
transcribed O 0 4.945198384120886e-07
RNA O 0 1.3318231140146963e-07
derived O 0 8.301016762857216e-09
from O 0 1.3663676856623397e-09
ten O 0 1.7021399845162932e-09
patients O 0 8.039557908290362e-10
belonging O 0 1.595320431313496e-09
to O 0 6.928496665281614e-10
eight O 0 9.315169746670904e-10
unrelated O 0 7.3796138089221586e-09
Japanese O 0 3.168176476719964e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 2.7415348213821744e-08
was O 0 2.0811830481193283e-08
analyzed O 0 1.648368730400307e-08
for O 0 3.6760069987984423e-10
mutations O 0 2.085932138129465e-08
by O 0 4.6517059648643055e-10
the O 0 2.492013040367169e-09
restriction O 0 9.940895751014978e-08
endonuclease O 0 2.7571441023610532e-06
fingerprinting O 0 6.087566362111829e-07
method O 0 1.3248657637632277e-07
. O 0 7.365484577803727e-08

As O 0 5.787943564428133e-07
has O 0 1.9222628822035404e-08
been O 0 2.6688780074834995e-09
reported O 0 8.642103033196236e-09
by O 0 3.4008595939383213e-10
others O 0 7.865794127148718e-10
, O 0 1.4442010087822865e-10
mutations O 0 7.026167647694592e-09
that O 0 2.1427894181247353e-10
lead O 0 2.249667785392262e-09
to O 0 1.8941284096740674e-09
exon O 0 6.541582706631743e-07
skipping O 0 9.796018503038795e-07
or O 0 1.9817777285879856e-07
premature O 0 9.562799050399917e-07
protein O 0 1.3180051894323697e-07
truncation O 0 9.477256526224664e-07
were O 0 1.4841268658472018e-08
also O 0 2.9097431131219764e-09
predominant O 0 5.262318580889769e-08
in O 0 6.169992072813102e-09
our O 0 1.1829218493630833e-08
mutants O 0 1.1198011407032027e-06
. O 0 7.056819129047653e-08

Six O 0 2.9568869308604917e-07
different O 0 1.609932454016416e-08
mutations O 0 4.906372623736388e-07
were O 0 6.5500702639553765e-09
identified O 0 8.074708013339205e-09
on O 0 3.265018477804915e-08
12 O 0 3.9995429190753384e-09
of O 0 5.862185042948553e-11
the O 0 2.389356934529019e-09
16 O 0 6.149704034896786e-08
alleles O 0 5.652129857480759e-07
examined O 0 1.781412834134244e-06
. O 0 2.2066789995278668e-07

Four O 0 3.712439706760051e-07
were O 0 2.324678760601273e-08
deletions O 0 9.29756652112701e-07
involving O 0 2.3087668665766614e-08
a O 0 4.419946364464522e-08
loss O 0 1.0656037119360917e-07
of O 0 4.497782701839981e-10
a O 0 6.756947446007189e-09
single O 0 7.073596464124421e-08
exon O 0 1.8087051785187214e-06
exon O 0 1.7017210893754964e-06
7 O 0 1.7097360682782892e-07
, O 0 1.858559417478034e-09
exon O 0 5.58362728497741e-07
16 O 0 2.8765914095174594e-08
, O 0 1.3515261132468481e-09
exon O 0 5.769085191786871e-07
33 O 0 1.1162171631440287e-07
or O 0 4.16105834233349e-08
exon O 0 6.550068974320311e-06
35 O 0 1.0925839433184592e-06
. O 0 2.8281513664296654e-07

The O 0 2.0195624017560476e-07
others O 0 5.009477632711423e-08
were O 0 4.059010016987941e-09
minute O 0 4.1116393845186394e-08
deletions O 0 9.709519872558303e-07
, O 0 3.4334954879255974e-09
4649delA O 0 4.747684556605236e-07
in O 0 1.3961853007060654e-08
exon O 0 1.3722155927098356e-06
33 O 0 6.156886911412585e-08
and O 0 5.013317760926839e-09
7883del5 O 0 5.828111966366123e-07
in O 0 2.9355378572404334e-08
exon O 0 4.628691385732964e-06
55 O 0 6.020460432409891e-07
. O 0 9.27252870042139e-08

The O 0 5.585267786045733e-07
mutations O 0 7.131344318622723e-06
4612del165 O 0 1.041603695739468e-06
and O 0 4.501535144640911e-09
7883del5 O 0 1.6854970397162106e-07
were O 0 1.4120254965277468e-09
found O 0 9.945362311469808e-10
in O 0 3.824090488713239e-10
more O 0 5.8083166748490456e-11
than O 0 8.688404162793262e-11
two O 0 8.934571832375227e-11
unrelated O 0 4.480608772894357e-09
families O 0 8.551831465197779e-10
; O 0 9.595352290503456e-10
44 O 0 2.7136277669370656e-09
% O 0 5.202771546919394e-10
( O 0 1.2452480158131607e-09
7 O 0 6.40661745876514e-09
of O 0 1.7183611478177596e-10
16 O 0 7.2742856183083404e-09
) O 0 1.2027778772960573e-10
of O 0 2.4596494979656214e-11
the O 0 7.868780627084959e-10
mutant O 0 4.553028176701446e-08
alleles O 0 1.14621672153703e-08
had O 0 3.3443063873761503e-09
one O 0 6.734732910240737e-11
of O 0 2.82630203962686e-11
the O 0 5.878916242707533e-10
two O 0 5.0420481123580885e-09
mutations O 0 1.501778115198249e-06
. O 0 1.278783088309865e-07

The O 0 3.2435053753943066e-07
4612del165 O 0 4.309949872549623e-06
mutations O 0 1.7959292790692416e-06
in O 0 7.323679440673914e-09
three O 0 6.237255711916134e-10
different O 0 2.0559813573850505e-10
families O 0 2.76395129006346e-10
were O 0 3.7320943557794806e-10
all O 0 8.896683389991722e-11
ascribed O 0 2.547317023982032e-09
to O 0 1.8122287004374016e-10
the O 0 1.085571743608682e-09
same O 0 3.460155895140815e-08
T O 0 9.703829709906131e-05
- O 0 8.498787451571843e-07
- O 0 3.0931096262065694e-07
> O 0 3.177847318625027e-08
A O 0 5.14016962327446e-09
substitution O 0 6.1274438856173674e-09
at O 0 4.7985087014978944e-09
the O 0 1.777605174169139e-09
splice O 0 8.153732551363646e-07
donor O 0 3.151992444827556e-08
site O 0 3.6148868787222455e-08
in O 0 2.472814664145062e-08
intron O 0 2.2390315280063078e-05
33 O 0 1.2861277127740323e-06
. O 0 1.838317018609814e-07

Microsatellite O 0 0.0007989632431417704
genotyping O 0 7.142119284253567e-05
around O 0 3.9682464603174594e-07
the O 0 2.9186381311774312e-08
ATM O 0 1.4034433661436196e-05
locus O 0 5.334820230018522e-07
also O 0 3.2814113648527155e-09
indicated O 0 1.3653940200697434e-08
that O 0 1.4204770693027058e-10
a O 0 2.6422357635169647e-09
common O 0 2.0149830248783474e-08
haplotype O 0 1.3124178622092586e-05
was O 0 5.378025491609151e-08
shared O 0 5.975118733125839e-10
by O 0 1.712174430013036e-10
the O 0 6.905646054988779e-10
mutant O 0 5.8264561175747076e-08
alleles O 0 7.298707771496993e-08
in O 0 5.114205503531366e-09
both O 0 1.414330874638381e-08
mutations O 0 5.323990535543999e-06
. O 0 2.4899910044950957e-07

This O 0 2.150748059648322e-07
suggests O 0 7.91869823046909e-08
that O 0 5.447592932306122e-10
these O 0 2.811442745276338e-10
two O 0 2.70616279385294e-10
founder O 0 1.2563103268803388e-07
mutations O 0 4.4857972625322873e-07
may O 0 2.8423407627542474e-08
be O 0 5.657474488884873e-10
predominant O 0 3.9946197460949406e-08
among O 0 7.650519107116338e-10
Japanese O 0 2.7363839194549655e-08
ATM O 0 1.1819512110378128e-05
mutant O 0 3.8599687286478e-06
alleles O 0 3.870430191454943e-06
. O 0 2.4997771674861724e-07

W474C O 0 0.00023848576529417187
amino O 0 2.886289803427644e-05
acid O 0 6.260124337131856e-06
substitution O 0 7.070587457747024e-07
affects O 0 2.2228707052818208e-07
early O 0 5.59925261711669e-08
processing O 0 1.4152266913924905e-08
of O 0 2.4195226377976553e-10
the O 0 1.4255371327820399e-09
alpha O 0 1.236185198649764e-08
- O 0 1.3139284327223777e-08
subunit O 0 5.685830029023009e-09
of O 0 5.375979106325701e-10
beta O 0 5.394987567797216e-08
- O 0 4.312036310238909e-07
hexosaminidase O 0 8.47491889999219e-07
A O 0 1.3114546781878289e-08
and O 0 1.1772222086037232e-09
is O 0 5.320385243479109e-10
associated O 0 7.882032804218397e-09
with O 0 1.2779510782934267e-08
subacute O 0 0.00013490680430550128
G B-Disease 0 0.00016166121349669993
( I-Disease 0 1.505958664438367e-07
M2 I-Disease 0 3.625830868259072e-05
) I-Disease 0 1.2739262444938504e-07
gangliosidosis I-Disease 0 2.47919415414799e-05
. O 0 4.935275796924543e-07

Mutations O 0 0.00033468453329987824
in O 0 1.9141431550906418e-07
the O 0 5.194388918994264e-08
HEXA O 0 4.071503281011246e-05
gene O 0 8.350532425538404e-07
, O 0 1.2747272126745202e-09
encoding O 0 1.0349754830940583e-08
the O 0 1.0596561406117644e-09
alpha O 0 1.773511648650583e-08
- O 0 1.7373752214666638e-08
subunit O 0 1.4076995569212158e-08
of O 0 6.933718599277938e-10
beta O 0 1.028124998470048e-07
- O 0 8.054128670664795e-07
hexosaminidase O 0 1.0308893934052321e-06
A O 0 5.539891034800348e-08
( O 0 5.742438524691806e-09
Hex O 0 1.0030756669721086e-07
A O 0 1.2250196412821879e-08
) O 0 1.2979018970682432e-09
, O 0 1.8067997098469846e-10
that O 0 2.7214738795855453e-10
abolish O 0 2.539540275847685e-07
Hex O 0 9.91440529674037e-08
A O 0 3.738907849992756e-09
enzyme O 0 1.1131406552067347e-07
activity O 0 6.703459121126798e-07
cause O 0 0.003962763585150242
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999933242797852
( O 0 3.223886153591593e-07
TSD B-Disease 0 4.424607686814852e-05
) O 0 1.415242945057571e-08
, O 0 9.231667652542797e-10
the O 0 1.8559177306087804e-08
fatal O 0 0.05103448033332825
infantile B-Disease 0 0.30145809054374695
form I-Disease 0 1.8915378063866228e-07
of I-Disease 0 1.8935297774191895e-08
G I-Disease 0 0.0001657654211157933
( I-Disease 0 2.9438810500437285e-08
M2 I-Disease 0 8.448461812804453e-06
) I-Disease 0 1.8190457140576655e-08
gangliosidosis I-Disease 0 1.5850655472604558e-06
, I-Disease 0 3.0116058535867296e-09
Type I-Disease 0 7.421617169711681e-07
1 I-Disease 0 1.6275998859782703e-07
. O 0 1.0526467519866856e-07

Less O 0 1.5225036804622505e-05
severe O 0 0.03241411969065666
, O 0 7.422990506711358e-07
subacute O 0 0.2712448239326477
( O 0 2.3943139240145683e-06
juvenile O 0 0.012384007684886456
- O 1 0.94099360704422
onset O 1 0.9999326467514038
) O 0 5.13059774220892e-07
and O 0 3.900909462117852e-07
chronic O 0 0.007421840447932482
( O 0 8.861217537514676e-08
adult O 0 2.522914655855857e-05
- O 0 0.2713165283203125
onset O 0 0.22357246279716492
) O 0 1.3411063370938336e-08
variants O 0 2.461958388266794e-07
are O 0 5.137079650552323e-10
characterized O 0 1.1602545590960744e-08
by O 0 1.1807033128974354e-09
a O 0 2.6137165320960776e-08
broad O 0 2.026519609898969e-07
spectrum O 0 7.728138484708325e-07
of O 0 9.73504943324599e-10
clinical O 0 6.59379466583232e-08
manifestations O 0 1.209108546618154e-07
and O 0 6.3382250559129716e-09
are O 0 1.295435425596736e-10
associated O 0 9.946728996013121e-10
with O 0 5.887141329985468e-10
residual O 0 2.965551004763256e-07
levels O 0 5.932189495183593e-08
of O 0 6.312066425095963e-10
Hex O 0 2.934737892701378e-07
A O 0 1.3222599015705327e-08
enzyme O 0 1.3422892664038955e-07
activity O 0 4.872143790635164e-07
. O 0 9.771649445156072e-08

We O 0 3.9849484778642363e-07
identified O 0 1.9028675524168648e-07
a O 0 1.8551821767687215e-07
1422 O 0 0.0001636526285437867
G O 0 0.0001808253873605281
- O 0 1.9574248653952964e-05
- O 0 8.321751010953449e-06
> O 0 1.3818784054819844e-06
C O 0 2.621276053105248e-06
( O 0 8.831331221870187e-09
amino O 0 3.9489098213607576e-08
acid O 0 3.759038236239576e-08
W474C O 0 5.3255988063938275e-08
) O 0 3.165249173875395e-10
substitution O 0 2.253696340659417e-09
in O 0 4.4078943273184734e-10
the O 0 7.811298274873479e-10
first O 0 1.6430565796810015e-09
position O 0 4.966264732786385e-09
of O 0 2.450369629425353e-10
exon O 0 1.7908821803303e-07
13 O 0 1.1554401879720899e-08
of O 0 4.499867700680227e-10
HEXA O 0 3.1228373700287193e-06
of O 0 4.2106176878498047e-10
a O 0 4.001480924387124e-09
non O 0 3.248358737550916e-08
- O 0 5.081286076347169e-07
Jewish O 0 1.8689836167595786e-07
proband O 0 1.0478073818376288e-05
who O 0 1.269070537546213e-08
manifested O 0 1.2578917107930465e-07
a O 0 4.045378076966699e-08
subacute O 0 2.2180111045599915e-05
variant O 0 2.7664082153933123e-05
of O 0 5.439116179672965e-08
G B-Disease 0 0.0004911379655823112
( I-Disease 0 1.97069965679475e-07
M2 I-Disease 0 3.914696571882814e-05
) I-Disease 0 1.2629328693947173e-07
gangliosidosis I-Disease 0 2.9530860047088936e-05
. O 0 6.173243605189782e-07

On O 0 2.873800895031309e-07
the O 0 2.262190257340535e-08
second O 0 1.1290128298924174e-07
maternally O 0 1.9594379409682006e-05
inherited O 0 6.225855031516403e-06
allele O 0 1.3336549500309047e-06
, O 0 1.1554704970606622e-09
we O 0 2.453264535962063e-10
identified O 0 1.1870936456048753e-09
the O 0 6.203528357673349e-09
common O 0 4.157110652158735e-06
infantile O 1 0.9999986886978149
disease O 1 0.9991044402122498
- O 0 0.02632846124470234
causing O 0 2.9434817406581715e-05
4 O 0 7.527850698352268e-07
- O 0 3.7632532894349424e-06
bp O 0 6.562577254953794e-07
insertion O 0 1.1625620999211606e-07
, O 0 3.457066855006019e-09
+ O 0 8.779690574556298e-08
TATC O 0 3.1380061500385636e-06
1278 O 0 6.418486918846611e-06
, O 0 2.2391839493707266e-09
in O 0 8.36755909006115e-09
exon O 0 1.8397918211121578e-06
11 O 0 1.9353753089035308e-07
. O 0 6.286192899551679e-08

Pulse O 0 0.026353782042860985
- O 0 3.987782838521525e-05
chase O 0 6.501060397567926e-06
analysis O 0 5.065918173841055e-08
using O 0 3.605343223966884e-08
proband O 0 5.667524874297669e-06
fibroblasts O 0 6.05626780725288e-07
revealed O 0 5.3351659090594694e-08
that O 0 2.988464198327989e-10
the O 0 1.8932182488384797e-09
W474C O 0 1.3138637200427183e-07
- O 0 1.719126707655505e-08
containing O 0 3.7004121988815086e-09
alpha O 0 8.838240361797034e-09
- O 0 8.52065706880012e-09
subunit O 0 8.836487985774966e-09
precursor O 0 1.5241544915056693e-08
was O 0 1.2452225917058968e-08
normally O 0 3.0890927593674178e-09
synthesized O 0 1.8479596519682673e-08
, O 0 1.77756351305014e-10
but O 0 1.4786748214756784e-10
not O 0 1.7879345226567978e-10
phosphorylated O 0 3.4957118089096184e-08
or O 0 2.3938273585599745e-09
secreted O 0 7.704631599381173e-09
, O 0 1.729907050940227e-10
and O 0 1.7021065112921008e-10
the O 0 1.3674236187810607e-09
mature O 0 2.3376532709562525e-08
lysosomal O 0 8.775251671977458e-07
alpha O 0 6.225459259212585e-08
- O 0 1.4878517617944453e-07
subunit O 0 9.066251749345611e-08
was O 0 1.373905718082824e-07
not O 0 1.0206608891394353e-08
detected O 0 1.6896925671971985e-06
. O 0 7.646077193612655e-08

When O 0 8.530805075679382e-07
the O 0 5.6762978317692614e-08
W474C O 0 2.199511300204904e-06
- O 0 1.9488885527607636e-07
containing O 0 2.0272032941193174e-08
alpha O 0 4.945848885995474e-08
- O 0 1.2003445704067417e-07
subunit O 0 5.3723866244581586e-08
was O 0 1.0767159608349175e-07
transiently O 0 5.724888296754216e-07
co O 0 8.708990861805432e-08
- O 0 4.952258336743398e-08
expressed O 0 9.125212252492076e-10
with O 0 9.212349633136441e-11
the O 0 3.327684794385277e-10
beta O 0 6.6608754067942755e-09
- O 0 9.097567144067398e-09
subunit O 0 5.228440347337937e-09
to O 0 1.7563861476332931e-09
produce O 0 5.541314518353602e-09
Hex O 0 1.0749696599532399e-07
A O 0 1.0616170165178573e-08
( O 0 4.257312724575968e-09
alphabeta O 0 2.2386946341157454e-07
) O 0 1.568129626150494e-09
in O 0 8.066610490686799e-09
COS O 0 1.3483809198078234e-05
- O 0 3.623810016506468e-07
7 O 0 2.75941349769937e-08
cells O 0 1.208915634265395e-08
, O 0 2.689480582684922e-10
the O 0 8.133534401544296e-10
mature O 0 1.0994795296426219e-08
alpha O 0 9.312207893685809e-09
- O 0 2.5309249807037304e-08
subunit O 0 9.943661005706872e-09
was O 0 5.643746359140778e-09
present O 0 2.4893800909531194e-10
, O 0 3.269450335463553e-11
but O 0 5.646884695953425e-11
its O 0 1.4536865045045033e-09
level O 0 9.546979207186723e-09
was O 0 2.1457895016396833e-08
much O 0 8.807994889004078e-10
lower O 0 3.5126691955156275e-07
than O 0 1.2212926503440968e-10
that O 0 6.060777574257159e-11
from O 0 3.5664299291582324e-10
normal O 0 1.8710696991774967e-08
alpha O 0 3.139099291615821e-08
- O 0 5.128704216872393e-08
subunit O 0 5.005905379107389e-08
transfections O 0 1.4626630218117498e-07
, O 0 1.8894259767865407e-10
although O 0 2.3109496261053408e-10
higher O 0 1.4010558269106355e-09
than O 0 1.192141524386514e-10
in O 0 5.434226402201148e-10
those O 0 2.2744187089251966e-10
cells O 0 4.921079543862561e-09
transfected O 0 4.2993480775521675e-08
with O 0 1.657737419558103e-10
an O 0 3.3835587109898313e-10
alpha O 0 1.784488290468289e-08
- O 0 1.1484318207521937e-07
subunit O 0 8.447179311588116e-08
associated O 0 8.46836130108386e-08
with O 0 5.1558533442630505e-08
infantile O 1 0.552187979221344
TSD B-Disease 0 0.0009405915625393391
. O 0 1.4741418681296636e-06

Furthermore O 0 1.2409522014422691e-06
, O 0 8.113488547678571e-09
the O 0 1.6662878854489804e-09
precursor O 0 4.7367485933591524e-08
level O 0 6.516885253660121e-09
of O 0 4.0430989112216764e-10
the O 0 3.950030080801525e-09
W474C O 0 1.5590350699312694e-07
alpha O 0 3.123731318055434e-08
- O 0 3.1743820017027247e-08
subunit O 0 1.4252441893347623e-08
was O 0 8.363984171921857e-09
found O 0 1.1451978254584105e-09
to O 0 1.3395360376478038e-09
accumulate O 0 5.340592323932469e-08
in O 0 3.9997849476947067e-10
comparison O 0 1.0185774446114237e-09
to O 0 9.011557056126662e-10
the O 0 2.913230545686929e-09
normal O 0 4.5136516746424604e-08
alpha O 0 3.915564050771536e-08
- O 0 5.9019207299115806e-08
subunit O 0 9.967115488507261e-08
precursor O 0 1.7171873878396582e-07
levels O 0 2.87867237602768e-07
. O 0 6.120951212551518e-08

We O 0 2.362031068514625e-07
conclude O 0 2.9965241310492274e-07
that O 0 4.0798973088840285e-09
the O 0 1.252685954966637e-08
1422 O 0 3.740308966371231e-05
G O 0 7.649187318747863e-05
- O 0 1.4378238120116293e-05
- O 0 9.51984566199826e-06
> O 0 1.0904260534516652e-06
C O 0 1.6255402442766353e-05
mutation O 0 3.4239042179251555e-07
is O 0 5.623863597037371e-10
the O 0 6.389688222974144e-10
cause O 0 6.019527987177753e-09
of O 0 1.1004965827510205e-09
Hex B-Disease 0 6.679918897134485e-06
A I-Disease 0 6.0538927755260374e-06
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 9.981779847123562e-09
the O 0 2.2477005146015472e-08
proband O 0 3.144800211885013e-05
. O 0 1.186811715570002e-07

The O 0 2.671199865744711e-07
resulting O 0 4.2294084323657444e-07
W474C O 0 2.0771835806954186e-06
substitution O 0 2.859017342871084e-07
clearly O 0 1.476681461554108e-07
interferes O 0 2.566820569427364e-07
with O 0 1.4132541803490994e-09
alpha O 0 2.5157161687161533e-08
- O 0 1.6648113998485314e-08
subunit O 0 9.02487506948546e-09
processing O 0 4.719521662366333e-09
, O 0 1.9528152706005386e-10
but O 0 1.183778353119891e-10
because O 0 1.6791028289997456e-10
the O 0 3.820095351159125e-10
base O 0 4.2017469503718985e-09
substitution O 0 8.230261805408645e-09
falls O 0 7.970063506945735e-07
at O 0 4.21776524817119e-09
the O 0 4.214618931630554e-10
first O 0 1.3253523833967051e-09
position O 0 6.674483188362501e-09
of O 0 2.823830058673593e-10
exon O 0 2.0666507793976052e-07
13 O 0 8.085743630203979e-09
, O 0 4.4323772430132635e-10
aberrant O 0 1.719678408562686e-07
splicing O 0 1.3024105101067107e-06
may O 0 2.84085615476215e-07
also O 0 1.6137038372221468e-09
contribute O 0 5.200033181829156e-10
to O 0 2.0841772752078214e-09
Hex B-Disease 0 4.347151389083592e-06
A I-Disease 0 5.918232091062237e-07
deficiency I-Disease 0 1.0726061191235203e-05
in O 0 9.891938379524845e-10
this O 0 1.744693278737941e-09
proband O 0 1.1992168538199621e-06
. O 0 9.334294226448492e-09
. O 0 3.6470073183636487e-08

Two O 0 4.6399162556554074e-07
frequent O 0 7.949591235956177e-06
missense O 0 0.002790321595966816
mutations O 0 0.45289188623428345
in O 0 0.02525784634053707
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.1127835023216903e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.498518253763905e-06
an O 0 7.495307363569736e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.6555334329605103
by O 0 5.932584485890402e-07
early O 1 0.8819180727005005
childhood O 1 0.9999996423721313
deafness B-Disease 1 1.0
and O 1 0.7830491065979004
goiter B-Disease 1 1.0
. O 0 3.7590564261336112e-06

A O 0 5.841845336362894e-07
century O 0 1.5118182261630864e-07
after O 0 9.9789998486699e-09
its O 0 2.8203166468898644e-09
recognition O 0 1.4731187381045174e-09
as O 0 1.0564050745287545e-09
a O 0 1.273709955285085e-07
syndrome O 0 0.3133147656917572
by O 0 4.712109813453935e-09
Vaughan O 0 2.0360555481602205e-06
Pendred O 0 7.864824169701023e-07
, O 0 7.615112984638017e-10
the O 0 1.2619307376837696e-08
disease O 0 1.4313691281131469e-05
gene O 0 4.332574462750927e-06
( O 0 7.009798963508729e-08
PDS O 0 6.57549753668718e-06
) O 0 5.259546576041885e-09
was O 0 2.8691719222706524e-08
mapped O 0 2.0108602427626465e-07
to O 0 1.66425273562254e-08
chromosome O 0 4.96372831548797e-06
7q22 O 0 1.0880350600928068e-05
- O 0 1.60558211064199e-05
q31 O 0 2.0320409021223895e-05
. O 0 3.623184454681905e-07

1 O 0 1.3078672509436728e-06
and O 0 7.319629791169291e-09
, O 0 8.203082102475889e-10
recently O 0 7.862842821282356e-09
, O 0 1.7646860361875127e-10
found O 0 3.178765306532938e-10
to O 0 3.2630850799186817e-10
encode O 0 3.1897187113827385e-08
a O 0 1.3415924371429355e-08
putative O 0 1.162748844762973e-06
sulfate O 0 2.112358515660162e-06
transporter O 0 1.0740698598965537e-05
. O 0 3.268190198468801e-07

We O 0 5.324233143255697e-07
performed O 0 3.3773920904422994e-07
mutation O 0 1.7300152421739767e-07
analysis O 0 3.803477532926536e-09
of O 0 2.423679867913364e-10
the O 0 3.2023785845325392e-09
PDS B-Disease 0 1.670134565756598e-06
gene O 0 1.4293732419901062e-07
in O 0 7.366197873892588e-09
patients O 0 1.2954911809970326e-08
from O 0 2.7450288708763537e-09
14 O 0 1.0430909469505423e-08
Pendred B-Disease 0 2.0470119466153847e-07
families O 0 5.92923043996052e-10
originating O 0 8.4062712346622e-09
from O 0 7.902320464658885e-10
seven O 0 4.892886651397532e-10
countries O 0 1.4112735979843194e-10
and O 0 3.782488211534485e-10
identified O 0 2.4807120801995097e-09
all O 0 9.751477403341369e-10
mutations O 0 7.782750799378846e-07
. O 0 6.908116034765044e-08

The O 0 4.245856644047308e-07
mutations O 0 2.823676823027199e-06
include O 0 7.154859371638622e-09
three O 0 1.4710465068290546e-09
single O 0 1.3611296978410792e-08
base O 0 3.734540499067407e-08
deletions O 0 2.308485562707574e-07
, O 0 8.998881639854517e-10
one O 0 1.5471727232707622e-09
splice O 0 1.017586691887118e-05
site O 0 4.3256369508526404e-07
mutation O 0 1.0539491768213338e-06
and O 0 1.640821523096747e-08
10 O 0 4.8821807041576903e-08
missense O 0 6.174968439154327e-05
mutations O 0 2.0401748770382255e-05
. O 0 5.166775736142881e-07

One O 0 3.049624183404376e-06
missense O 0 0.0007848013192415237
mutation O 0 9.605404193280265e-05
( O 0 3.8029429560992867e-07
L236P O 0 1.7909009102368145e-06
) O 0 9.743431839126515e-09
was O 0 9.56473122926127e-09
found O 0 7.246115929504526e-10
in O 0 5.04820407698503e-10
a O 0 1.712936459341563e-09
homozygous O 0 6.187330114926226e-08
state O 0 4.0384745547683565e-10
in O 0 6.179528555527725e-10
two O 0 6.808225649912458e-10
consanguineous O 0 3.2731654187045933e-07
families O 0 6.534356389309437e-10
and O 0 1.3368145479475402e-10
in O 0 3.679787863308803e-10
a O 0 5.122014812286579e-09
heterozygous O 0 1.1206649475070662e-07
state O 0 4.1716075038777944e-10
in O 0 1.1604154304123426e-09
five O 0 5.705479977358152e-10
additional O 0 1.1211899186847063e-09
non O 0 1.5205278813823497e-08
- O 0 4.697508302342612e-06
consanguineous O 0 1.7154281522380188e-05
families O 0 1.2377380187444942e-07
. O 0 1.509367848484544e-07

Another O 0 1.0167398613702971e-05
missense O 0 0.0008960901759564877
mutation O 0 0.00019854999845847487
( O 0 7.66868424761924e-07
T416P O 0 2.5700855985633098e-06
) O 0 1.0771633363049204e-08
was O 0 1.341055178016859e-08
found O 0 3.463070663567436e-10
in O 0 1.560005596923375e-10
a O 0 5.267434821654149e-10
homozygous O 0 1.2787069181285915e-08
state O 0 3.6003230952097454e-10
in O 0 8.502372694785265e-10
one O 0 5.550609971649578e-10
family O 0 3.3303408919493904e-09
and O 0 1.0882952872215412e-10
in O 0 4.4119150000021534e-10
a O 0 2.8493305492816035e-09
heterozygous O 0 7.970187709815946e-08
state O 0 4.120317975697674e-10
in O 0 1.069504151907097e-09
four O 0 1.3724587022423407e-09
families O 0 5.7127782504551305e-09
. O 0 2.5639939948973733e-08

Pendred B-Disease 0 0.001498015015386045
patients O 0 4.475602509046439e-06
in O 0 3.9121154316035245e-08
three O 0 2.372889218449359e-09
non O 0 1.6609229547270843e-08
- O 0 5.536098228731134e-07
consanguineous O 0 2.8972428935958305e-06
families O 0 1.7954604469849755e-09
were O 0 9.335821005151956e-10
shown O 0 1.2034119256654208e-09
to O 0 3.3080546635311237e-10
be O 0 3.492069966526401e-10
compound O 0 2.1412841277879124e-08
heterozygotes O 0 1.5213844051231717e-07
for O 0 1.2254910419784437e-09
L236P O 0 3.779903181566624e-07
and O 0 1.2304993468603698e-08
T416P O 0 2.5218089376721764e-06
. O 0 1.3411785459993553e-07

In O 0 1.5321356272579578e-07
total O 0 5.701479288688915e-09
, O 0 6.096071425432115e-10
one O 0 2.690891676149221e-10
or O 0 4.905783002051578e-10
both O 0 8.664077788544944e-11
of O 0 5.954250981154985e-11
these O 0 2.5732510566811584e-10
mutations O 0 2.1626274104846743e-08
were O 0 1.3980179236483536e-09
found O 0 1.2022052242599557e-09
in O 0 5.914772560622339e-10
nine O 0 2.644523489081507e-10
of O 0 6.762562732021138e-11
the O 0 1.7591990086884834e-09
14 O 0 1.1872799632328679e-08
families O 0 2.620553996024455e-09
analyzed O 0 1.3605149717932363e-07
. O 0 1.437582426433437e-07

The O 0 1.298167973118325e-07
identification O 0 6.012725606296954e-08
of O 0 7.631892895432202e-10
two O 0 1.8199471929492006e-09
frequent O 0 2.8553878905768215e-07
PDS B-Disease 0 9.349860192742199e-05
mutations O 0 1.7279950270676636e-06
will O 0 1.4036288797925067e-09
facilitate O 0 2.4599240422418234e-09
the O 0 3.067292864145088e-09
molecular O 0 1.9513058759912383e-06
diagnosis O 0 0.0006286737625487149
of O 0 2.5076067231566412e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.4708735963940853e-06

Insertional O 0 0.0004010325646959245
mutation O 0 3.1629486329620704e-05
by O 0 6.645471728461416e-08
transposable O 0 5.947726549493382e-06
element O 0 1.2095270562895166e-07
, O 0 4.467782144246257e-09
L1 O 0 8.040506145334803e-06
, O 0 1.1638179309159113e-09
in O 0 2.099686646772625e-09
the O 0 1.960800766198645e-08
DMD B-Disease 1 0.9999998807907104
gene O 0 2.631209099490661e-06
results O 0 2.648595511800522e-07
in O 0 9.060011763040166e-08
X B-Disease 1 0.9999775886535645
- I-Disease 1 0.9998279809951782
linked I-Disease 1 0.998933732509613
dilated I-Disease 1 0.9972532391548157
cardiomyopathy I-Disease 1 1.0
. O 0 3.002728362844209e-06

X B-Disease 1 0.9999897480010986
- I-Disease 1 0.9999896287918091
linked I-Disease 1 0.9999599456787109
dilated I-Disease 1 0.9999978542327881
cardiomyopathy I-Disease 1 1.0
( O 0 6.106846285547363e-06
XLDCM B-Disease 0 0.00022650498431175947
) O 0 1.1744552885772919e-08
is O 0 6.924705253652519e-10
a O 0 3.189394748304153e-09
clinical O 0 1.3027641898588627e-07
phenotype O 0 2.1376538370532217e-06
of O 0 1.445149666601253e-09
dystrophinopathy B-Disease 0 2.198986658186186e-05
which O 0 3.860846753411806e-09
is O 0 3.959471917003299e-10
characterized O 0 1.1158738821848146e-08
by O 0 1.7212256064880194e-09
preferential O 0 1.697150793233959e-07
myocardial B-Disease 0 3.6740100313181756e-06
involvement I-Disease 0 4.5678500981694015e-08
without O 0 5.2669548722406034e-09
any O 0 5.087945620374512e-09
overt O 0 5.597319159278413e-07
clinical O 0 1.1346357950969832e-06
signs O 0 4.194004577584565e-05
of O 0 1.733147428240045e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 3.7008441722719e-05

To O 0 1.827080495786504e-07
date O 0 4.63020022323235e-08
, O 0 4.75279871015033e-10
several O 0 3.34643618371544e-10
mutations O 0 9.832354663785736e-08
in O 0 9.025667324635833e-09
the O 0 1.7024417502398137e-06
Duchenne B-Disease 1 0.9999998807907104
muscular I-Disease 1 0.999998927116394
dystrophy I-Disease 1 0.9999980926513672
gene O 0 0.0058708712458610535
, O 0 6.627914217460784e-07
DMD O 1 1.0
, O 0 3.033433415566833e-08
have O 0 1.020158180153885e-09
been O 0 5.777206490975573e-10
identified O 0 1.820211092962154e-09
in O 0 2.0959054491953566e-09
patients O 0 3.308308738070309e-09
with O 0 2.112440444790309e-09
XLDCM B-Disease 0 4.633181379176676e-05
, O 0 6.842829081143975e-10
but O 0 3.401722514784211e-10
a O 0 1.1965045620954129e-09
pathogenic O 0 1.3000213527902815e-07
correlation O 0 1.8471984830625843e-08
of O 0 5.485253362635945e-10
these O 0 2.676269428292244e-09
cardiospecific O 0 5.662737748934887e-06
mutations O 0 1.294901494475198e-06
in O 0 5.1956867253011296e-08
DMD O 1 0.9999998807907104
with O 0 1.0257311444661354e-08
the O 0 7.727328465989558e-08
XLDCM B-Disease 0 0.001222719089128077
phenotype O 0 1.9339086065883748e-05
has O 0 2.0264840472350443e-08
remained O 0 6.606823887977953e-08
to O 0 3.101194634425042e-09
be O 0 6.0510463306684414e-09
elucidated O 0 2.2433139292843407e-06
. O 0 5.741390296520876e-08

We O 0 4.5293731432138884e-07
report O 0 4.329441338768447e-08
here O 0 1.3323249170582585e-09
the O 0 3.1609415085398496e-10
identification O 0 1.145272099378758e-09
of O 0 5.503422023656057e-11
a O 0 1.1232790253501435e-09
unique O 0 4.372192830004451e-09
de O 0 4.390044523461256e-07
novo O 0 2.480607918187161e-06
L1 O 0 6.8662961894006e-06
insertion O 0 2.9999810635672475e-07
in O 0 8.112405858184957e-09
the O 0 1.0294530561338888e-08
muscle O 0 6.485728135885438e-06
exon O 0 1.47388607274479e-06
1 O 0 6.45392503884068e-08
in O 0 6.638453697860314e-08
DMD O 1 1.0
in O 0 4.850354073937524e-08
three O 0 6.035393518288856e-09
XLDCM B-Disease 0 1.910714854602702e-05
patients O 0 1.5362111582817306e-08
from O 0 1.0779601655741544e-09
two O 0 5.757208043633e-10
unrelated O 0 1.4272245607571676e-08
Japanese O 0 6.383955764022176e-08
families O 0 2.7368015409479085e-08
. O 0 5.546509385112586e-08

The O 0 4.625777876299253e-07
insertion O 0 2.7657424652716145e-06
was O 0 1.5983340517777833e-07
a O 0 1.6578782791043523e-08
5 O 0 4.650512863690892e-08
- O 0 8.950206620284007e-08
truncated O 0 2.066043833792719e-07
form O 0 5.929889912437147e-09
of O 0 3.7845085398835465e-10
human O 0 5.1695576708254976e-09
L1 O 0 4.985837222193368e-06
inversely O 0 9.129125828621909e-07
integrated O 0 3.330107389842851e-08
in O 0 1.9712957932682684e-09
the O 0 7.122589629204867e-09
5 O 0 5.167569128161631e-08
- O 0 2.3708236085440149e-07
untranslated O 0 6.620978183491388e-07
region O 0 1.6243024703044284e-08
in O 0 3.1135878320043275e-09
the O 0 5.549247283909153e-09
muscle O 0 2.9274108328536386e-06
exon O 0 2.328562374032117e-07
1 O 0 8.614390090144752e-09
, O 0 1.4543236059871845e-10
which O 0 1.3622711292349265e-10
affected O 0 6.363830018507599e-10
the O 0 4.087941651853555e-10
transcription O 0 6.05451191404427e-08
or O 0 2.745259131131661e-09
the O 0 3.0325699729161215e-09
stability O 0 6.309301525675437e-09
of O 0 5.3031690150362465e-11
the O 0 1.6102079669622071e-09
muscle O 0 2.445636084758007e-07
form O 0 2.5830082517330766e-09
of O 0 4.478923065764917e-10
dystrophin O 0 1.7052267367034801e-06
transcripts O 0 1.4135547132809734e-07
but O 0 5.423085314149034e-10
not O 0 8.946064722348268e-11
that O 0 1.3571509367704682e-11
of O 0 1.419192714735562e-11
the O 0 2.1319179754897277e-09
brain O 0 1.7619386198930442e-06
or O 0 1.1414475586946082e-08
Purkinje O 0 3.764018003948877e-07
cell O 0 1.1601509442016322e-07
form O 0 6.018414211439449e-09
, O 0 4.832618749617268e-10
probably O 0 7.451208539066556e-09
due O 0 4.650732243760558e-09
to O 0 3.2231689539585773e-10
its O 0 2.211341332269967e-09
unique O 0 4.4576764501869093e-10
site O 0 4.691680377533203e-09
of O 0 4.1017345075999856e-10
integration O 0 1.5923966145692248e-08
. O 0 3.948111171325763e-08

We O 0 2.1247667802981596e-07
speculate O 0 1.0778028780578097e-07
that O 0 4.141410547831015e-10
this O 0 1.3017936728587642e-10
insertion O 0 6.095783877668737e-09
of O 0 1.5279134901735603e-10
an O 0 9.918690313526213e-10
L1 O 0 1.1891826943610795e-05
sequence O 0 1.955054074187501e-07
in O 0 4.3695820295397425e-07
DMD O 1 1.0
is O 0 8.96602525557455e-09
responsible O 0 1.6267572844341771e-09
for O 0 4.3593729320834385e-11
some O 0 3.308425061687714e-11
of O 0 2.333702675549887e-11
the O 0 5.399573566045035e-10
population O 0 5.523233606585798e-11
of O 0 4.3688955231324655e-11
Japanese O 0 3.1248159615415716e-08
patients O 0 1.187839426819437e-08
with O 0 5.2040545206466504e-09
XLDCM B-Disease 0 1.0874012332351413e-05
. O 0 1.7172981259250264e-08
. O 0 5.707412142896828e-08

Severe O 0 0.003810994792729616
early O 0 0.0019469757098704576
- O 1 0.9999574422836304
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0014585782773792744
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.4926308128669916e-07
red O 0 0.0020654064137488604
hair O 1 0.9999974966049194
pigmentation O 1 0.8167083859443665
caused O 0 2.4124026367644547e-06
by O 0 7.321769146528823e-08
POMC O 0 0.000548201147466898
mutations O 0 3.2555342386331176e-06
in O 0 2.047842961871993e-08
humans O 0 1.8689249259296048e-07
. O 0 1.644533540456905e-07

Sequential O 0 0.00011523119610501453
cleavage O 0 6.129196844995022e-05
of O 0 1.752772682550585e-08
the O 0 1.5781131068592913e-08
precursor O 0 4.3827532181239803e-07
protein O 0 8.661114065944275e-07
pre O 0 8.962573338067159e-05
- O 0 0.0001551214954815805
pro O 0 4.3032057874370366e-05
- O 0 9.697001951280981e-05
opiomelanocortin O 0 4.586556678987108e-05
( O 0 4.835555955651216e-08
POMC O 0 8.958394573710393e-06
) O 0 4.939341380350015e-09
generates O 0 2.3386789393953222e-08
the O 0 1.208560540533199e-08
melanocortin O 0 2.7398800739319995e-05
peptides O 0 2.2072101728554117e-06
adrenocorticotrophin O 0 8.131174581649248e-06
( O 0 1.6963790017143765e-07
ACTH O 0 9.805881745705847e-06
) O 0 1.3604262605326767e-08
, O 0 5.307879913374336e-09
melanocyte O 0 1.7229960576514713e-05
- O 0 3.2772357371868566e-05
stimulating O 0 6.62351840219344e-06
hormones O 0 8.831755621940829e-06
( O 0 4.696311961538413e-08
MSH O 0 5.070344286650652e-06
) O 0 2.435182056004237e-09
alpha O 0 3.434248663225503e-09
, O 0 1.6310688910614601e-10
beta O 0 1.8721755257189443e-09
and O 0 1.9099885562035013e-10
gamma O 0 3.0662516969925946e-09
as O 0 4.1599912403711414e-10
well O 0 1.2483936107088311e-10
as O 0 1.5410665799020506e-10
the O 0 4.6182532797978126e-10
opioid O 0 3.594206532397948e-08
- O 0 6.493697668474852e-08
receptor O 0 1.0154069229884044e-07
ligand O 0 1.4813362270160724e-07
beta O 0 9.731090813147603e-07
- O 0 2.445899008307606e-05
endorphin O 0 0.00039804287371225655
. O 0 9.235565698872961e-07

While O 0 8.375929638759771e-08
a O 0 6.934251395307456e-09
few O 0 2.4059298997514134e-09
cases O 0 1.1045635517348273e-09
of O 0 2.297480206081559e-09
isolated O 0 0.0003632273292168975
ACTH B-Disease 1 0.9999264478683472
deficiency I-Disease 0 0.0485917292535305
have O 0 6.449948131148631e-09
been O 0 2.1734283706109636e-08
reported O 0 1.6049187934186193e-06
( O 0 9.26521011024306e-08
OMIM O 0 4.186244768789038e-05
201400 O 0 1.0044174132417538e-06
) O 0 3.900252565358642e-09
, O 0 5.373826383880953e-10
an O 0 4.214605109353897e-09
inherited O 0 0.1649441421031952
POMC O 1 0.8844345808029175
defect O 0 0.0005539614357985556
has O 0 3.2188040677283425e-08
not O 0 1.2719488795553957e-09
been O 0 1.7947654473715602e-09
described O 0 9.810602108473176e-09
so O 0 5.1693209712766475e-09
far O 0 3.16758388407834e-08
. O 0 5.8751336240447927e-08

Recent O 0 3.71407941202051e-06
studies O 0 2.9003510348957207e-07
in O 0 1.4068889164775555e-08
animal O 0 8.811313279011301e-08
models O 0 1.7400455476490606e-07
elucidated O 0 1.915958591780509e-07
a O 0 5.808367120607727e-09
central O 0 1.6988130013828595e-08
role O 0 1.5841377098979592e-09
of O 0 6.176299471860602e-10
alpha O 0 1.1334274319096949e-07
- O 0 2.78118363894464e-06
MSH O 0 2.1831980120623484e-05
in O 0 4.338458037267401e-09
the O 0 1.2731430354406825e-09
regulation O 0 2.3280600558450715e-08
of O 0 1.3246818919565584e-10
food O 0 1.8242010124680519e-09
intake O 0 8.371485726854644e-09
by O 0 1.0365668046130594e-10
activation O 0 4.709809875436122e-09
of O 0 2.331577153569242e-10
the O 0 1.4481468468829917e-08
brain O 0 1.3209463759267237e-05
melanocortin O 0 2.5677642042865045e-05
- O 0 7.190265023382381e-06
4 O 0 1.454503291142828e-07
- O 0 6.627788025070913e-07
receptor O 0 5.959520308351784e-07
( O 0 4.074883364069137e-08
MC4 O 0 6.347375165205449e-05
- O 0 6.427031166822417e-06
R O 0 9.55564701143885e-06
; O 0 1.843615216046146e-08
refs O 0 2.8760703116859077e-06
3 O 0 3.4399015191866056e-08
- O 0 4.3003731775570486e-07
5 O 0 7.742181118430835e-09
) O 0 3.1756988705389233e-10
and O 0 6.449842743228018e-11
the O 0 1.1422653101167413e-10
linkage O 0 5.822953230705252e-09
of O 0 1.1250280568253501e-10
human O 0 1.3583338898115471e-08
obesity B-Disease 1 0.9999959468841553
to O 0 8.68728644576322e-09
chromosome O 0 5.180003199711791e-07
2 O 0 6.114182049543615e-09
in O 0 1.0265565064671023e-09
close O 0 1.3209239924094618e-08
proximity O 0 1.1298590507635708e-08
to O 0 2.6655255780383413e-09
the O 0 1.2450848352330013e-08
POMC O 0 1.0547934834903572e-05
locus O 0 1.2742992794301244e-07
, O 0 2.0781268372793704e-10
led O 0 5.532599378632597e-10
to O 0 3.1848948478518935e-10
the O 0 5.264441660379759e-10
proposal O 0 1.256238557623135e-09
of O 0 3.345962049094986e-11
an O 0 2.542515087355923e-10
association O 0 2.627771555907543e-09
of O 0 4.699380329320491e-10
POMC O 0 1.870771848189179e-05
with O 0 1.496409041124025e-08
human O 0 1.036935486808943e-06
obesity B-Disease 1 0.9999998807907104
. O 0 4.2386230347801757e-07

The O 0 3.5637279438560654e-07
dual O 0 5.78892070279835e-07
role O 0 1.2552906270002495e-08
of O 0 1.3004441967723324e-09
alpha O 0 1.25322657140714e-07
- O 0 3.148203632008517e-06
MSH O 0 3.1339564884547144e-05
in O 0 1.3076681071311214e-08
regulating O 0 5.371258566810866e-07
food O 0 5.095134625321407e-08
intake O 0 2.4844905510690296e-07
and O 0 3.089723366045405e-09
influencing O 0 8.03439775154402e-07
hair O 1 0.9837952852249146
pigmentation O 0 0.001696872292086482
predicts O 0 3.5501221873346367e-07
that O 0 6.75173972286558e-10
the O 0 2.498633522307614e-09
phenotype O 0 4.5289499439604697e-07
associated O 0 4.986177248866852e-09
with O 0 7.951397318350928e-10
a O 0 6.700430077444253e-08
defect O 0 1.750546061884961e-06
in O 0 9.255756161508089e-09
POMC O 0 1.3356633644434623e-05
function O 0 4.6930612285223106e-08
would O 0 7.138678981277735e-09
include O 0 6.782746808653428e-09
obesity B-Disease 1 0.9999759197235107
, O 0 1.6067596142477214e-09
alteration O 0 1.8655431688330282e-07
in O 0 5.703690320046917e-08
pigmentation O 1 0.832289457321167
and O 0 2.002062501560431e-05
ACTH B-Disease 1 0.9924823641777039
deficiency I-Disease 0 0.0021716528572142124
. O 0 1.7737863799993647e-07

The O 0 1.2400845150750683e-07
observation O 0 1.7984814348892542e-07
of O 0 2.006093069439885e-09
these O 0 8.069227064311235e-09
symptoms O 0 7.652562999282964e-06
in O 0 6.43685904577751e-09
two O 0 2.7410107517056304e-09
probands O 0 6.92090111442667e-07
prompted O 0 3.010389804103397e-08
us O 0 1.6222211352001636e-09
to O 0 2.8367916349303357e-10
search O 0 3.159930539453626e-09
for O 0 6.509452421532558e-10
mutations O 0 5.517840406810137e-08
within O 0 2.5876485398868e-09
their O 0 4.456779478800854e-08
POMC O 0 0.00012766748841386288
genes O 0 2.925786475316272e-06
. O 0 2.3902316570456605e-07

Patient O 0 0.0006960750324651599
1 O 0 1.0307409183951677e-06
was O 0 5.198829100550029e-08
found O 0 2.004173271785703e-09
to O 0 3.858989516825062e-10
be O 0 9.41330971504506e-11
a O 0 5.219489840335712e-10
compound O 0 8.676374285698785e-09
heterozygote O 0 2.1001643091267397e-08
for O 0 2.017450095870288e-10
two O 0 3.642415258298115e-10
mutations O 0 5.210085873841308e-08
in O 0 7.561189896421183e-09
exon O 0 1.3764844197794446e-06
3 O 0 8.567464249154e-08
( O 0 1.1106165764829257e-08
G7013T O 0 1.7896631732128299e-07
, O 0 9.52649292784713e-10
C7133delta O 0 2.3399110204991302e-07
) O 0 8.61474613866875e-10
which O 0 6.254100570757259e-10
interfere O 0 5.791816803935035e-09
with O 0 1.773520080794455e-10
appropriate O 0 1.6269653402289919e-09
synthesis O 0 1.2294155027348097e-08
of O 0 1.0921906712368923e-09
ACTH O 0 3.0343765047291527e-06
and O 0 1.512616520926713e-08
alpha O 0 6.013305551277881e-07
- O 0 4.30556210631039e-05
MSH O 0 0.000966892926953733
. O 0 6.590751127077965e-07

Patient O 0 0.00046342163113877177
2 O 0 9.143885790763306e-07
was O 0 5.353861354251421e-08
homozygous O 0 1.6862719576238305e-07
for O 0 4.92701268672846e-10
a O 0 3.3808509325439218e-09
mutation O 0 1.1043433545410153e-07
in O 0 1.33703004223662e-08
exon O 0 2.493827196303755e-06
2 O 0 1.4890810007273103e-07
( O 0 2.3118381875519844e-08
C3804A O 0 1.3187548120185966e-06
) O 0 1.1792859133663569e-08
which O 0 2.7373234345873243e-08
abolishes O 0 3.999756881967187e-05
POMC O 0 5.4002121032681316e-05
translation O 0 1.3293959000293398e-06
. O 0 2.8106583727094403e-07

These O 0 7.775719268465764e-08
findings O 0 5.207592224110158e-08
represent O 0 1.1063410187972522e-09
the O 0 4.1948258755475365e-10
first O 0 4.0165043513340493e-10
examples O 0 5.027449012651175e-10
of O 0 1.6875470465471665e-10
a O 0 1.2422673023593234e-07
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.999994158744812
within O 0 1.8285703617948457e-08
the O 0 4.058996694311645e-08
POMC O 0 4.230333070154302e-05
gene O 0 2.4990930569401826e-07
and O 0 1.1545584488459326e-09
define O 0 1.6843586081449757e-08
a O 0 3.391768288452113e-08
new O 0 3.857518095173873e-06
monogenic B-Disease 1 0.9952752590179443
endocrine I-Disease 1 0.9889820218086243
disorder I-Disease 0 0.00023592043726239353
resulting O 0 7.214210739903137e-08
in O 0 2.638822493850057e-08
early O 0 0.00046011072117835283
- O 1 0.9999587535858154
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0005220453604124486
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.384956078709365e-07
red O 0 5.271055124467239e-05
hair O 1 0.9983389377593994
pigmentation O 0 0.00427355756983161
. O 0 4.289649879751778e-08
. O 0 1.3121432118623488e-07

A O 0 1.4458280475082574e-06
European O 0 1.509030994384375e-06
multicenter O 0 7.851256668800488e-05
study O 0 5.080161713522102e-07
of O 0 7.103258781171462e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.4605443254822603e-07
classification O 0 1.7401718821474788e-07
of O 0 1.8447257055242972e-09
105 O 0 4.904782144876663e-07
mutations O 0 4.353631538833724e-06
and O 0 2.329595627514891e-09
a O 0 3.687293359533328e-09
general O 0 1.4548348081788731e-09
system O 0 4.242772178031373e-08
for O 0 9.153503510717087e-10
genotype O 0 1.781164883141173e-06
- O 0 7.465550311280822e-07
based O 0 2.098738605127437e-08
prediction O 0 5.050279696661164e-07
of O 0 7.0470242974352004e-09
metabolic O 0 0.00034965737722814083
phenotype O 0 4.102680759388022e-05
. O 0 3.1394171173815266e-07

Phenylketonuria B-Disease 1 0.9996999502182007
( O 0 0.00011319550685584545
PKU B-Disease 0 0.04115242511034012
) O 0 5.399443807618809e-07
and O 0 2.2189523463111982e-07
mild B-Disease 1 0.9999949932098389
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.800045907497406
MHP B-Disease 1 1.0
) O 0 2.4641099116706755e-07
are O 0 2.1226032487220436e-08
allelic B-Disease 0 0.17538763582706451
disorders I-Disease 1 0.9997221827507019
caused O 0 1.6197042214116664e-06
by O 0 3.224937117352056e-08
mutations O 0 1.4644791690443526e-06
in O 0 9.10697739442412e-09
the O 0 1.1810416644664201e-08
gene O 0 5.452501682157163e-06
encoding O 0 1.2447743756638374e-05
phenylalanine O 0 0.030736664310097694
hydroxylase O 0 0.00737189082428813
( O 0 1.770434664649656e-06
PAH O 0 0.00019851516117341816
) O 0 2.9641287824233586e-07
. O 0 3.088046298671543e-07

Previous O 0 4.141772478760686e-06
studies O 0 8.73600924933271e-08
have O 0 1.7565469079272589e-09
suggested O 0 4.317844304324581e-09
that O 0 1.19154824895773e-10
the O 0 9.477052476114523e-10
highly O 0 1.7640482852243622e-08
variable O 0 5.11198777530808e-06
metabolic O 0 0.0017223022878170013
phenotypes O 0 1.505690670455806e-05
of O 0 1.9145538487919112e-07
PAH B-Disease 1 0.9998773336410522
deficiency I-Disease 0 0.35564562678337097
correlate O 0 6.882442903588526e-06
with O 0 4.981379788659979e-07
PAH O 0 0.021953051909804344
genotypes O 0 0.000264626374701038
. O 0 1.0653116078174207e-06

We O 0 1.716143032126638e-07
identified O 0 3.858934505274192e-08
both O 0 5.651911827442291e-09
causative O 0 6.515210202451271e-07
mutations O 0 1.0215858310402837e-06
in O 0 2.826845246772791e-08
686 O 0 1.384381903335452e-06
patients O 0 5.32620845206111e-08
from O 0 7.784649369568797e-09
seven O 0 1.4566459149989441e-08
European O 0 1.0639384129262908e-07
centers O 0 1.6472598929340165e-07
. O 0 7.207911778550624e-08

On O 0 2.4821480337777757e-07
the O 0 3.2535409921763403e-09
basis O 0 6.143262565316832e-10
of O 0 6.856151063550087e-11
the O 0 7.505178145628122e-10
phenotypic O 0 7.659811984694898e-08
characteristics O 0 1.0739814371163448e-08
of O 0 1.072153255066155e-09
297 O 0 6.345509859784215e-07
functionally O 0 2.9664324756595306e-06
hemizygous O 0 3.5952860343968496e-05
patients O 0 1.9407147533456737e-07
, O 0 7.691897119244118e-10
105 O 0 1.0293215169099312e-08
of O 0 1.2559718542970444e-10
the O 0 1.9888231062026307e-09
mutations O 0 5.6483582255850706e-08
were O 0 7.17516324133527e-10
assigned O 0 4.0540197865368555e-09
to O 0 5.321501572730369e-10
one O 0 2.5103980005880544e-10
of O 0 8.700758863389169e-11
four O 0 1.1945116007439083e-09
arbitrary O 0 6.762236637314345e-08
phenotype O 0 3.1521783512289403e-06
categories O 0 1.7724842393818108e-07
. O 0 1.3658790010140365e-07

We O 0 3.980538565429015e-07
proposed O 0 7.966007586901469e-08
and O 0 3.902469902783423e-09
tested O 0 6.026641585776815e-08
a O 0 3.429104111773995e-09
simple O 0 3.3577287616992635e-09
model O 0 7.05123248678774e-09
for O 0 1.7647568129053326e-10
correlation O 0 1.2534340676495503e-08
between O 0 6.8435372924113835e-09
genotype O 0 7.486369213438593e-07
and O 0 1.1165297131299212e-08
phenotypic O 0 7.701754043409892e-07
outcome O 0 5.447535613711807e-07
. O 0 2.8549794706123066e-07

The O 0 5.655688255501445e-07
observed O 0 2.3106581465981435e-06
phenotype O 0 1.1746000382117927e-05
matched O 0 6.561588747899805e-07
the O 0 1.400244364901937e-08
predicted O 0 8.415400429839792e-07
phenotype O 0 2.0300412870710716e-06
in O 0 9.231443165447217e-09
79 O 0 6.236393090830461e-08
% O 0 2.698688772451163e-10
of O 0 1.8687700692465725e-11
the O 0 6.303512711802739e-10
cases O 0 5.522562407378473e-10
, O 0 1.523693671234838e-10
and O 0 1.252605796864259e-10
in O 0 1.8842759297310607e-10
only O 0 2.5278731885514105e-10
5 O 0 1.0795589977519171e-09
of O 0 8.490829567220359e-11
184 O 0 1.2890063239012761e-08
patients O 0 5.470930819484465e-09
was O 0 1.1852526071720604e-08
the O 0 2.330591275523375e-09
observed O 0 3.9553018638116555e-08
phenotype O 0 7.224331710631304e-08
more O 0 1.5404023889775686e-10
than O 0 1.5967076272271896e-10
one O 0 2.1905227631791035e-10
category O 0 1.1979933711714352e-09
away O 0 1.1085166118363077e-09
from O 0 5.495662258603318e-10
that O 0 2.6768298688750747e-10
expected O 0 2.25636416217867e-08
. O 0 3.817688565277422e-08

Among O 0 9.509454201861445e-08
the O 0 1.0830779828552295e-08
seven O 0 2.485201600066489e-09
contributing O 0 5.203449227053625e-09
centers O 0 9.547229673501079e-10
, O 0 9.369352516053198e-11
the O 0 4.272457110321426e-10
proportion O 0 8.267577733533926e-10
of O 0 1.398129251262148e-10
patients O 0 1.2808518690121673e-09
for O 0 1.1470641797517445e-10
whom O 0 1.1003538080700537e-09
the O 0 1.5032681766058431e-09
observed O 0 1.3889692240809381e-07
phenotype O 0 4.2369578068246483e-07
did O 0 1.166881347103299e-08
not O 0 7.36080085772528e-10
match O 0 7.057650019959283e-09
the O 0 8.261811679233233e-09
predicted O 0 6.671220944554079e-07
phenotype O 0 6.695894398944802e-07
was O 0 2.1489515944494997e-08
4 O 0 8.601353407300394e-09
% O 0 9.35607147312112e-10
- O 0 7.588513994960522e-08
23 O 0 4.9159037729396005e-08
% O 0 2.0807533473998774e-09
( O 0 1.01570085675462e-08
P O 0 2.792373015836347e-05
< O 0 3.3359057738380216e-07
. O 0 3.46066242329357e-09
0001 O 0 5.726620202040067e-06
) O 0 1.207184463503097e-09
, O 0 1.371215224699185e-10
suggesting O 0 5.3272724009900685e-09
that O 0 1.470209926024424e-10
differences O 0 1.0003616823794914e-09
in O 0 5.756000120982208e-10
methods O 0 1.4558563243838307e-09
used O 0 1.0644164438744497e-09
for O 0 2.6623331317310317e-10
mutation O 0 6.04283627581026e-08
detection O 0 1.4842788687019492e-07
or O 0 6.10802999290172e-07
phenotype O 0 7.096673652995378e-05
classification O 0 4.053282737004338e-06
may O 0 3.0111826276879583e-07
account O 0 3.268904924524918e-09
for O 0 9.032099373973423e-11
a O 0 7.31001315035229e-10
considerable O 0 2.1809436479003352e-09
proportion O 0 6.112736095076343e-09
of O 0 4.9761830211991764e-09
genotype O 0 0.0003502567415125668
- O 0 0.021341580897569656
phenotype O 0 0.0004084765096195042
inconsistencies O 0 1.2057962521794252e-05
. O 0 6.992385692683456e-07

Our O 0 4.556355577278737e-07
data O 0 3.932457275368506e-07
indicate O 0 1.0123417837348825e-07
that O 0 8.217175828661993e-10
the O 0 2.2025909984790815e-08
PAH O 0 3.2655087125021964e-05
- O 0 3.134922280878527e-06
mutation O 0 1.6405512042183545e-06
genotype O 0 7.681083502575348e-07
is O 0 5.599374852671701e-10
the O 0 5.377045475540854e-10
main O 0 5.658944868258686e-09
determinant O 0 3.060912590058251e-08
of O 0 5.62475399590312e-10
metabolic O 0 1.855783375503961e-05
phenotype O 0 9.261283935302345e-07
in O 0 2.805375043379854e-09
most O 0 3.5742766524293756e-09
patients O 0 1.547444128391362e-07
with O 0 2.5477761482761707e-06
PAH B-Disease 1 0.9999188184738159
deficiency I-Disease 1 0.6175280809402466
. O 0 3.0563683139916975e-07

In O 0 2.2633258822679636e-07
the O 0 1.4297039996336025e-08
present O 0 4.3484407186156204e-09
study O 0 1.808928229429796e-09
, O 0 2.0875859374491768e-10
the O 0 7.210256280920646e-10
classification O 0 1.1799293986314296e-08
of O 0 5.410067949185304e-10
105 O 0 8.961307571553334e-07
PAH O 0 5.915786459809169e-05
mutations O 0 4.736423761642072e-06
may O 0 2.887993133526834e-08
allow O 0 8.939893825221645e-10
the O 0 2.0321226923414315e-09
prediction O 0 3.589280694882291e-08
of O 0 1.2383952197048131e-10
the O 0 3.21192761276734e-09
biochemical O 0 4.311518182475993e-07
phenotype O 0 6.468318929364614e-07
in O 0 1.3665768960891e-08
> O 0 1.4405715376142325e-07
10 O 0 9.453984262108861e-09
, O 0 6.28985696859985e-10
000 O 0 3.454996955198908e-09
genotypes O 0 5.2825928520405796e-08
, O 0 6.545258779411256e-10
which O 0 9.839667747257863e-09
may O 0 3.4684418892538815e-08
be O 0 1.0843833470053355e-10
useful O 0 1.0256870353053671e-10
for O 0 8.281873103976878e-11
the O 0 1.9025905295677603e-09
management O 0 8.661112715913077e-09
of O 0 6.714817035735621e-10
hyperphenylalaninemia B-Disease 1 0.9999998807907104
in O 0 4.958350245942711e-07
newborns O 0 1.0589843441266567e-05
. O 0 9.835486736164967e-08

Somatic O 0 0.00016911780403461307
instability O 0 2.6385256205685437e-05
of O 0 1.5389620244832258e-08
the O 0 5.1562469849386616e-08
CTG O 0 1.2626824172912166e-05
repeat O 0 1.25843791920488e-06
in O 0 1.6696960258855142e-08
mice O 0 3.501438072817109e-07
transgenic O 0 1.1167409752488311e-07
for O 0 1.978411212633091e-09
the O 0 2.782797139389004e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 2.7120051981910365e-07
is O 0 8.918303429084062e-09
age O 0 3.542580895299352e-09
dependent O 0 1.4475000087443846e-09
but O 0 4.428270250489419e-10
not O 0 1.6349060993903208e-10
correlated O 0 3.5795644226510603e-09
to O 0 3.467141851398736e-10
the O 0 7.721707717678328e-10
relative O 0 1.608584909718047e-08
intertissue O 0 5.782503080808965e-07
transcription O 0 2.74321223514562e-07
levels O 0 1.9322068567362294e-07
and O 0 2.0928704103084783e-08
proliferative O 0 5.744322334066965e-05
capacities O 0 2.0649301859521074e-06
. O 0 2.480893783740612e-07

A O 0 1.6843716366565786e-05
( O 0 1.1968312492172117e-06
CTG O 0 2.3630011128261685e-05
) O 0 3.1016163859476364e-08
nexpansion O 0 1.506891067037941e-06
in O 0 4.5876853427273545e-09
the O 0 4.9659614198560575e-09
3 O 0 1.1405796840335825e-07
- O 0 2.4238454443548108e-06
untranslated O 0 4.452006578503642e-06
region O 0 1.8322261041703314e-07
( O 0 1.9073912227440815e-08
UTR O 0 7.908990937721683e-07
) O 0 2.1117838588935456e-09
of O 0 5.174112804873232e-10
the O 0 8.397861250841743e-08
DM O 1 1.0
protein O 0 5.313835572451353e-06
kinase O 0 2.4287495762109756e-05
gene O 0 3.554601107680355e-06
( O 0 3.8867089102723185e-08
DMPK O 0 5.407852313510375e-06
) O 0 1.98620364599833e-09
is O 0 5.05392672156546e-10
responsible O 0 7.515624567133727e-09
for O 0 1.4031370731970583e-08
causing O 1 0.5104892253875732
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.16274744272232056
DM B-Disease 1 1.0
) O 0 9.439588666282361e-07
. O 0 4.04754786131889e-07

Major O 0 4.680743586504832e-06
instability O 0 6.840147761977278e-06
, O 0 3.72500608136761e-09
with O 0 8.020458741597736e-10
very O 0 2.021387501827121e-09
large O 0 1.3717940117174976e-09
expansions O 0 1.0542924400169795e-07
between O 0 4.178474011240496e-09
generations O 0 6.760016102447253e-09
and O 0 1.7862413770330932e-09
high O 0 1.4727373987000192e-08
levels O 0 9.396456945864884e-09
of O 0 7.194403406352023e-10
somatic O 0 5.126484552420152e-07
mosaicism O 0 1.444838289899053e-06
, O 0 2.0908266229469064e-09
is O 0 6.283119025063399e-10
observed O 0 1.347197819967505e-08
in O 0 2.7186128903622375e-08
patients O 0 1.7764305937362224e-07
. O 0 1.1185593962181883e-07

There O 0 1.8800386669681757e-07
is O 0 7.757702924493515e-09
a O 0 3.477183652123017e-09
good O 0 2.1158477192528835e-09
correlation O 0 1.0494469293576003e-08
between O 0 3.639056167514809e-09
repeat O 0 8.74797876804223e-07
size O 0 1.2578747998759354e-07
( O 0 5.758990173632128e-09
at O 0 5.571774153168008e-09
least O 0 1.5210549486610603e-09
in O 0 4.251989427217495e-09
leucocytes O 0 6.191226020746399e-07
) O 0 5.266068137110835e-10
, O 0 1.9064944067892498e-10
clinical O 0 8.164904308216592e-09
severity O 0 6.43531507193984e-07
and O 0 1.2403797100546399e-08
age O 0 2.164278001259845e-08
of O 0 2.156233858130463e-09
onset O 0 8.328061812790111e-05
. O 0 4.0010638713283697e-07

The O 0 5.2205582505848724e-06
trinucleotide O 0 0.0011785688111558557
repeat O 0 0.00010790859960252419
instability O 0 6.633620614593383e-06
mechanisms O 0 3.806172230724769e-07
involved O 0 2.2052896397894983e-08
in O 0 3.9427311548934085e-07
DM B-Disease 1 1.0
and O 0 5.851176432258853e-09
other O 0 1.05832909103043e-09
human O 0 4.46179768687216e-08
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 3.2293918650339037e-09
unknown O 0 8.252334993130717e-08
. O 0 9.191300875954767e-08

We O 0 6.624539992117207e-07
studied O 0 3.9665366102781263e-07
somatic O 0 2.0273366772016743e-06
instability O 0 2.0542020138236694e-06
by O 0 1.3518747898899619e-08
measuring O 0 6.900279458932346e-07
the O 0 6.730170554192227e-08
CTG O 0 1.9384191546123475e-05
repeat O 0 6.637345677518169e-07
length O 0 3.375916790560041e-08
at O 0 2.0762666252949202e-08
several O 0 2.781394004003346e-09
ages O 0 1.0378061965354846e-08
in O 0 5.414754755683759e-10
various O 0 6.793593465559411e-10
tissues O 0 2.872303994649883e-08
of O 0 2.4000804121904196e-10
transgenic O 0 1.4301299700036907e-07
mice O 0 3.9308375221480674e-07
carrying O 0 1.2598601273339227e-08
a O 0 2.625358064278771e-08
( O 0 2.525061759683922e-08
CTG O 0 1.3498621456164983e-06
) O 0 4.802848785345759e-09
55expansion O 0 1.365264381547604e-07
surrounded O 0 4.19140500085291e-09
by O 0 9.46213329910961e-10
45 O 0 4.75782568898353e-09
kb O 0 4.2360204588476336e-07
of O 0 3.555745697880752e-10
the O 0 1.0266118621871101e-08
human O 0 5.5244534280518565e-08
DM B-Disease 1 1.0
region O 0 4.05522015967108e-08
, O 0 5.30450683378092e-10
using O 0 5.815827819333208e-09
small O 0 1.697310381132411e-08
- O 0 7.88058514444856e-06
pool O 0 1.0839738706636126e-06
PCR O 0 5.079693437437527e-05
. O 0 3.765518670206802e-07

These O 0 2.3095954304608313e-07
mice O 0 4.8364640861109365e-06
have O 0 2.7732149909809323e-09
been O 0 4.87333728926842e-10
shown O 0 2.0299879555096823e-09
to O 0 8.763570424896727e-10
reproduce O 0 2.576289261924103e-07
the O 0 1.5228315275450655e-09
intergenerational O 0 2.637101914615414e-08
and O 0 1.3447326585591668e-09
somatic O 0 1.614746025779823e-07
instability O 0 1.1150893186595567e-07
of O 0 4.984862522761091e-10
the O 0 6.9663319557378145e-09
55 O 0 1.5319719182116387e-07
CTG O 0 2.398166770944954e-06
repeat O 0 3.2085438306239666e-07
suggesting O 0 7.64352563464854e-08
that O 0 5.561398008779861e-10
surrounding O 0 1.8338084384339481e-09
sequences O 0 1.8339562757319072e-08
and O 0 8.491060632387359e-10
the O 0 1.294265472573386e-09
chromatin O 0 2.743523452863883e-07
environment O 0 9.634344877440526e-09
are O 0 1.1655990062031663e-10
involved O 0 5.306298178631152e-10
in O 0 7.585978067936594e-09
instability O 0 6.462030341936043e-07
mechanisms O 0 5.882724849470833e-07
. O 0 1.2112793967844482e-07

As O 0 1.7648703476424998e-07
observed O 0 3.114866586884091e-08
in O 0 7.255090972435596e-10
some O 0 7.133649226886973e-11
of O 0 3.5874480469599845e-11
the O 0 1.9267991646643168e-09
tissues O 0 1.9406440969760297e-06
of O 0 3.229356337897116e-08
DM B-Disease 1 1.0
patients O 0 8.096222927633789e-07
, O 0 8.185233602020503e-10
there O 0 2.2985573167044748e-10
is O 0 1.4829623640189027e-10
a O 0 1.0883373091630233e-09
tendency O 0 2.26143530568379e-08
for O 0 6.767842952726255e-10
repeat O 0 1.4766364131446608e-07
length O 0 1.1048295611715275e-08
and O 0 1.5218617477330554e-09
somatic O 0 6.24329601350837e-08
mosaicism O 0 1.828679074833417e-07
to O 0 8.439264287396497e-10
increase O 0 8.948629059979396e-10
with O 0 3.4648017788185825e-10
the O 0 5.168729444449127e-09
age O 0 1.902416224552894e-09
of O 0 4.9970642207464167e-11
the O 0 4.6723909186141555e-09
mouse O 0 1.0272767212882172e-05
. O 0 1.2378018254821654e-07

Furthermore O 0 7.68713198340265e-06
, O 0 5.187359164438021e-08
we O 0 2.863888903803513e-09
observed O 0 1.4131713577114624e-08
no O 0 8.142351237694356e-10
correlation O 0 9.270119782911479e-09
between O 0 6.892973414274195e-10
the O 0 4.471644388104323e-09
somatic O 0 5.059815748609253e-07
mutation O 0 6.412280413314875e-07
rate O 0 1.989964175663772e-06
and O 0 1.322027909367307e-08
tissue O 0 2.843425363607821e-06
proliferation O 0 6.841758022346767e-07
capacity O 0 8.659399242105792e-08
. O 0 5.064556418687971e-08

The O 0 3.8368730770343973e-07
somatic O 0 1.1674939742079005e-05
mutation O 0 1.3357168427319266e-05
rates O 0 1.4258485862228554e-05
in O 0 4.216229143594319e-09
different O 0 2.69593258828138e-09
tissues O 0 6.949811108825088e-07
were O 0 3.876637677535655e-09
also O 0 5.73526615088582e-10
not O 0 2.2435392432740286e-10
correlated O 0 7.926024281346145e-09
to O 0 3.491297251301262e-10
the O 0 1.0025927865697781e-09
relative O 0 1.7570805255218147e-08
inter O 0 1.988896656257566e-07
- O 0 1.842082929215394e-05
tissue O 0 2.0663505893026013e-06
difference O 0 5.541156422594895e-09
in O 0 1.4753851473869872e-09
transcriptional O 0 1.1069709415778561e-07
levels O 0 1.1848932501834497e-08
of O 0 3.7761137966496605e-11
the O 0 1.5328817382087578e-10
three O 0 4.5103767942755724e-10
genes O 0 1.1427894186510912e-08
( O 0 3.5811897891591116e-09
DMAHP O 0 1.3803294223180274e-06
, O 0 1.4691174943237684e-09
DMPK O 0 1.215265911014285e-06
and O 0 3.507243828693163e-09
59 O 0 9.532677758272712e-09
) O 0 2.8360666592952555e-10
surrounding O 0 2.527932307927472e-09
the O 0 8.843771936994926e-09
repeat O 0 9.053478606801946e-07
. O 0 1.6795144830439312e-08
. O 0 3.388024438777393e-08

A O 0 3.2453790481667966e-06
novel O 0 2.467416834406322e-06
missense O 0 4.409544271766208e-05
mutation O 0 3.3547173643455608e-06
in O 0 3.585456198607062e-08
patients O 0 3.574571749709321e-08
from O 0 6.459440093919966e-09
a O 0 4.3015873529839155e-08
retinoblastoma B-Disease 0 0.00015859038103371859
pedigree O 0 3.535382347763516e-05
showing O 0 9.098001100937836e-06
only O 0 2.158407674812679e-08
mild O 0 7.5052516876894515e-06
expression O 0 1.9360909320198516e-08
of O 0 8.151332386852062e-10
the O 0 4.931116848183592e-08
tumor B-Disease 0 2.947217581095174e-05
phenotype O 0 2.437009425193537e-05
. O 0 3.4928402214973175e-07

We O 0 3.0180510179889097e-07
have O 0 3.573118023680877e-09
used O 0 4.893915939163662e-09
single O 0 9.421366797823794e-09
strand O 0 2.389901112564985e-07
conformation O 0 8.340878707713273e-07
polymorphism O 0 3.410357294342248e-07
analysis O 0 7.52447437690762e-09
to O 0 1.4447527618699496e-09
study O 0 1.4272564241579744e-09
the O 0 2.9840343529485835e-09
27 O 0 2.216934014143135e-08
exons O 0 6.183648793012253e-08
of O 0 3.338492537974247e-10
the O 0 6.310817646237865e-09
RB1 O 0 3.4655963645491283e-06
gene O 0 6.221672776973719e-08
in O 0 1.303342100911209e-09
individuals O 0 1.472488658782467e-10
from O 0 4.0694889125170164e-10
a O 0 9.519921739808979e-09
family O 0 1.167523038247964e-07
showing O 0 1.8084707562593394e-06
mild O 0 2.900854087783955e-05
expression O 0 2.60862655920846e-08
of O 0 1.0033504027617823e-09
the O 0 6.864993906674499e-08
retinoblastoma B-Disease 0 0.00013052861322648823
phenotype O 0 8.071655611274764e-05
. O 0 3.654468798686139e-07

In O 0 1.4484983523743722e-07
this O 0 1.1616850592588435e-08
family O 0 1.9723197297594197e-08
affected O 0 1.4916444968093856e-08
individuals O 0 8.864539657871262e-10
developed O 0 2.6623010285220516e-07
unilateral B-Disease 0 0.24313129484653473
tumors I-Disease 1 1.0
and O 0 2.3744574662032392e-07
, O 0 4.941524966994848e-10
as O 0 4.926956620465717e-10
a O 0 1.4244769808158253e-09
result O 0 7.019225756188519e-10
of O 0 6.747088998615425e-11
linkage O 0 3.5681960497413456e-08
analysis O 0 2.8853928135674778e-09
, O 0 7.478200281241243e-10
unaffected O 0 2.231596312185502e-07
mutation O 0 8.463015888082737e-08
carriers O 0 1.6890718157469564e-08
were O 0 2.6247259921063915e-09
also O 0 1.7964745246956682e-09
identified O 0 2.8522830763932916e-09
within O 0 2.418462763387197e-09
the O 0 2.7414301939643337e-08
pedigree O 0 1.5859601262491196e-05
. O 0 2.1972249442114844e-07

A O 0 2.4494665922247805e-06
single O 0 1.8145726699003717e-07
band O 0 2.1669674765689706e-07
shift O 0 7.382756450624584e-08
using O 0 8.963238151693531e-09
SSCP O 0 1.5177222394413548e-06
was O 0 5.619899212661039e-09
identified O 0 2.0160315639117243e-09
in O 0 1.8139759694335567e-09
exon O 0 3.665942642783193e-07
21 O 0 3.868013109808999e-08
which O 0 4.422396060466127e-10
resulted O 0 3.1153819524121218e-09
in O 0 2.1177173348263523e-09
a O 0 2.242121155404675e-08
missense O 0 1.3539022802433465e-05
mutation O 0 8.07620381237939e-07
converting O 0 2.0574788095473195e-07
a O 0 3.2222169465967454e-07
cys O 0 0.16618654131889343
- O 0 8.721342601347715e-05
- O 0 1.7977910829358734e-05
> O 0 2.3994891762413317e-06
arg O 0 9.362913147015206e-07
at O 0 3.5834325728956173e-08
nucleotide O 0 1.8444457339228393e-07
position O 0 6.908708627406668e-08
28 O 0 1.833033103082471e-08
in O 0 1.6040710981712891e-09
the O 0 1.2678897931550637e-08
exon O 0 6.036459126335103e-06
. O 0 2.1902916103044845e-07

The O 0 6.997963168942078e-07
mutation O 0 3.748138851733529e-06
destroyed O 0 7.440531248903426e-07
an O 0 2.30719514604516e-08
NdeI O 0 5.490195690072142e-06
restriction O 0 6.818549422860087e-07
enzyme O 0 6.557797860295977e-07
site O 0 4.776987339027983e-07
. O 0 1.6266859859115357e-07

Analysis O 0 3.737041822660103e-07
of O 0 3.0265894235270707e-09
all O 0 6.68786026558621e-10
family O 0 2.373463869886905e-09
members O 0 2.1595254751094473e-10
demonstrated O 0 6.638296023986356e-10
that O 0 1.0088072738279052e-10
the O 0 2.797029274859142e-09
missense O 0 1.4580697097699158e-05
mutation O 0 3.364665872140904e-06
co O 0 1.0949403304039151e-06
- O 0 2.565873501225724e-06
segregated O 0 3.549062341789977e-07
with O 0 3.675609150377568e-09
patients O 0 9.77530305590335e-08
with O 0 4.4730029458150966e-07
tumors B-Disease 1 1.0
or O 0 0.00020630461222026497
who O 0 9.724884009187917e-09
, O 0 7.921133887700549e-11
as O 0 8.923705524521708e-11
a O 0 5.590698459734256e-10
result O 0 3.8057682005820936e-10
of O 0 5.585654161421871e-11
linkage O 0 5.359828136874967e-08
analysis O 0 1.0117449100732756e-08
had O 0 1.5866847391521333e-08
been O 0 9.688295721232976e-10
predicted O 0 1.0938152605888263e-08
to O 0 3.998648634429003e-10
carry O 0 2.2878774430523663e-09
the O 0 8.204995793903436e-09
predisposing O 0 1.1341610388626577e-06
mutation O 0 1.9593728666222887e-06
. O 0 1.9817476015759894e-07

These O 0 1.4310113272131275e-07
observations O 0 1.0657561944071858e-07
point O 0 8.52563086795044e-09
to O 0 7.283625369503e-10
another O 0 6.386495776666834e-10
region O 0 2.770085494319119e-09
of O 0 3.1245922516021096e-10
the O 0 6.798029694721208e-09
RB1 O 0 4.492708285397384e-06
gene O 0 9.317648164142156e-08
where O 0 3.3139673227822186e-09
mutations O 0 9.479790463728932e-08
only O 0 1.1420131507122733e-09
modify O 0 2.7481715392241313e-07
the O 0 2.592410730528627e-09
function O 0 2.2467776528145578e-09
of O 0 4.489963262299668e-11
the O 0 4.048075763485315e-10
gene O 0 1.2171335939115124e-08
and O 0 3.487111155386913e-10
raise O 0 2.948538080360663e-09
important O 0 2.0896813446302787e-10
questions O 0 6.992020296081591e-10
for O 0 1.6245797762604042e-10
genetic O 0 1.1902820062914543e-08
counseling O 0 3.3041966940317025e-09
in O 0 1.030307061888891e-09
families O 0 7.199620344344737e-10
with O 0 4.091631755631653e-10
these O 0 2.2982165059914905e-09
distinctive O 0 4.244158390065422e-06
phenotypes O 0 1.9082738162978785e-06
. O 0 1.1604006644461151e-08
. O 0 6.367052662881179e-08

Maternal B-Disease 0 0.008459286764264107
disomy I-Disease 0 0.14954514801502228
and O 0 0.012992258183658123
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 4.383360646897927e-06
with O 0 1.70434990565127e-08
gamete O 0 2.5842127797659487e-06
complementation O 0 1.1819332939921878e-05
in O 0 5.125444957343461e-09
a O 0 4.991182578351072e-09
case O 0 5.895786081566712e-09
of O 0 1.718568509723184e-09
familial O 0 4.360246293799719e-06
translocation O 0 5.049806532042567e-06
( O 0 4.951965593136265e-08
3 O 0 4.549451659840997e-08
; O 0 6.401145835610578e-09
15 O 0 1.0076659506808028e-08
) O 0 1.8023191827865048e-09
( O 0 4.294272937244159e-09
p25 O 0 3.154786725190206e-07
; O 0 3.430647987912039e-09
q11 O 0 1.6321480700298707e-07
. O 0 2.0065675787606096e-09
2 O 0 1.3221566064203216e-08
) O 0 9.379589549496359e-09
. O 0 4.116379415108895e-08

Maternal B-Disease 0 0.060809940099716187
uniparental I-Disease 1 0.933910071849823
disomy I-Disease 1 0.9452159404754639
( I-Disease 0 0.00018958088185172528
UPD I-Disease 1 1.0
) I-Disease 0 7.307956906288382e-08
for I-Disease 0 3.4676859161919538e-09
chromosome I-Disease 0 2.4418588964181254e-06
15 I-Disease 0 1.4714458096420913e-08
is O 0 2.8232430282493226e-10
responsible O 0 3.1499339248064473e-10
for O 0 1.982023746516237e-11
an O 0 4.140468176649925e-11
estimated O 0 2.323789771718765e-10
30 O 0 7.955402447912263e-10
% O 0 4.225628180698493e-11
of O 0 1.759287854286029e-11
cases O 0 2.174078250760658e-09
of O 0 3.851236272112146e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.921537270594854e-05
PWS B-Disease 1 1.0
) O 0 4.371286479454284e-07
. O 0 1.1113671405382775e-07

We O 0 3.470209151146264e-07
report O 0 5.4481596123423515e-08
on O 0 3.491712030623262e-09
an O 0 1.696690427044345e-10
unusual O 0 2.2849031555693955e-09
case O 0 9.892880958872752e-10
of O 0 6.342309455398265e-10
maternal B-Disease 0 7.372518666670658e-07
disomy I-Disease 0 2.290408019689494e-06
15 I-Disease 0 3.6234883538099893e-08
in O 0 6.895241000393071e-08
PWS B-Disease 1 1.0
that O 0 5.857675233755799e-09
is O 0 5.986092177501234e-10
most O 0 1.620065193108644e-10
consistent O 0 3.1754279206097635e-09
with O 0 3.44065914648084e-10
adjacent O 0 7.548685232450225e-08
- O 0 1.408890170750965e-06
1 O 0 1.933714166568734e-08
segregation O 0 1.4488485966523967e-08
of O 0 1.0763017560533328e-10
a O 0 1.2184900199940785e-08
paternal O 0 2.287685674673412e-05
t O 0 6.393673538696021e-05
( O 0 1.9561426256586856e-08
3 O 0 2.496024364972982e-08
; O 0 5.147665405047519e-09
15 O 0 3.311667384764405e-09
) O 0 7.174821292643685e-10
( O 0 1.7491048609485915e-09
p25 O 0 2.047131033577898e-07
; O 0 2.164615375832568e-09
q11 O 0 4.964865141232622e-08
. O 0 4.404079323450105e-10
2 O 0 1.5544877607354124e-09
) O 0 2.3467017218337105e-10
with O 0 3.7644587447260847e-10
simultaneous O 0 1.5609067816058086e-07
maternal O 0 4.333264314482221e-06
meiotic O 0 1.2563163181766868e-05
nondisjunction O 0 6.928066341060912e-06
for O 0 3.349427757370904e-08
chromosome O 0 6.279257831920404e-06
15 O 0 2.087660249117107e-07
. O 0 1.0980129161453078e-07

The O 0 1.348989599136985e-06
patient O 0 1.4190037290973123e-05
( O 0 1.1537427724306326e-07
J O 0 0.0009068369399756193
. O 0 5.610014230938987e-09
B O 0 5.205278696962523e-08
. O 0 1.2066750376682478e-10
) O 0 1.180887332363767e-10
, O 0 4.003209916336736e-11
a O 0 1.3833181267131067e-09
17 O 0 2.1116841608659342e-08
- O 0 1.9870464029736468e-07
year O 0 2.045964997421379e-08
- O 0 4.116348293337069e-07
old O 0 1.1118415841337992e-06
white O 0 5.327234475771547e-08
male O 0 1.1265366417489986e-08
with O 0 5.189087826096284e-09
PWS B-Disease 1 1.0
, O 0 1.8961454628652064e-09
was O 0 7.011909719523146e-09
found O 0 3.6330483066393526e-10
to O 0 2.8777519256451e-10
have O 0 3.431261386133144e-10
47 O 0 8.337321943940879e-09
chromosomes O 0 5.506745726080453e-09
with O 0 4.972915967904612e-10
a O 0 1.1500687513432695e-08
supernumerary O 0 2.207071247539716e-06
, O 0 7.262792589557421e-09
paternal O 0 3.257428397773765e-05
der O 1 0.57292640209198
( O 0 3.452679919746515e-08
15 O 0 7.401194768164032e-09
) O 0 2.570705037729937e-10
consisting O 0 1.8776531718334155e-10
of O 0 1.1912255903911984e-10
the O 0 1.3993686209801126e-08
short O 0 2.796071157717961e-06
arm O 0 0.0019972659647464752
and O 0 1.611200284301617e-09
the O 0 5.760352639327948e-09
proximal O 0 3.1281726933229947e-06
long O 0 1.4489930322270084e-07
arm O 0 1.896753383334726e-05
of O 0 1.7068019220189967e-09
chromosome O 0 8.356810212717392e-07
15 O 0 1.112881253817477e-08
, O 0 4.875866377318516e-10
and O 0 3.747482324456541e-09
distal O 0 0.00026521034305915236
chromosome O 0 0.014454936608672142
arm O 1 0.9660765528678894
3p O 0 0.00339419674128294
. O 0 1.3641284795085085e-06

The O 0 3.398138005650253e-06
t O 0 0.0002878321101889014
( O 0 7.052042150235138e-08
3 O 0 1.7305259447653043e-08
; O 0 2.485571526378294e-09
15 O 0 4.512581863735932e-09
) O 0 3.4050656738671137e-10
was O 0 5.718163720302982e-09
present O 0 1.6575003869423455e-10
in O 0 2.2720904324646796e-10
the O 0 5.947874970324563e-10
balanced O 0 2.9732172279750557e-09
state O 0 3.5567904177469245e-10
in O 0 5.424699578426839e-10
the O 0 1.6449444029120741e-09
patients O 0 4.509157491838778e-09
father O 0 1.0596405530804986e-08
and O 0 4.783081708481518e-10
a O 0 1.457407439175995e-08
sister O 0 1.8489276044419967e-05
. O 0 7.780748489949474e-08

Fluorescent O 0 8.489673200529069e-05
in O 0 1.592581071463428e-07
situ O 0 1.164408899967384e-06
hybridization O 0 1.0113807036304934e-07
analysis O 0 1.8981763716396927e-08
demonstrated O 0 9.69499147629449e-09
that O 0 9.129145772668323e-10
the O 0 4.350616578108202e-08
PWS B-Disease 1 0.9999998807907104
critical O 0 7.185523287489559e-08
region O 0 3.041602525399867e-08
resided O 0 9.022710401040968e-08
on O 0 7.402620294527651e-09
the O 0 1.0940128802872096e-09
derivative O 0 5.3168498936884134e-08
chromosome O 0 2.9512636956496863e-07
3 O 0 9.588916327629704e-09
and O 0 3.223341038527394e-10
that O 0 1.4222664712626454e-10
there O 0 3.3837327384489413e-10
was O 0 4.906178130426042e-09
no O 0 3.4906180723659475e-10
deletion O 0 1.2957728223739196e-08
of O 0 4.969047395775306e-10
the O 0 9.596640637710152e-08
PWS B-Disease 1 1.0
region O 0 5.4386287473562334e-08
on O 0 7.442206850782895e-08
the O 0 4.30309521348704e-09
normal O 0 4.135738862487415e-08
pair O 0 1.7625517045871675e-08
of O 0 7.223250331200859e-10
15s O 0 1.442223833691969e-07
present O 0 5.178696138585792e-09
in O 0 3.656019487152662e-08
J O 0 0.0012294702464714646
. O 0 1.5835229305594112e-07

B O 0 0.0008925236761569977
. O 0 7.023930720606586e-06

Methylation O 0 0.00012118255835957825
analysis O 0 1.250277250619547e-06
at O 0 2.1813426087646803e-07
exon O 0 1.4715602674186812e-06
alpha O 0 5.378507594855364e-08
of O 0 6.219804116192051e-10
the O 0 2.2440838076676073e-09
small O 0 4.076956994225611e-09
nuclear O 0 1.7312135014435626e-07
ribonucleoprotein O 0 3.757189006137196e-06
- O 0 2.160608801204944e-06
associated O 0 4.4224935891179484e-07
polypeptide O 0 4.5226070142234676e-06
N O 0 2.937111730716424e-06
( O 0 2.3844412666562675e-08
SNRPN O 0 7.279728606590652e-07
) O 0 1.2563488027694802e-09
gene O 0 5.507084210876201e-08
showed O 0 4.355016613999396e-08
a O 0 3.3562943535514478e-09
pattern O 0 6.443261781896581e-07
characteristic O 0 3.16377963827108e-08
of O 0 1.5419544807659946e-10
only O 0 2.3016986927526517e-10
the O 0 2.2822550516110596e-09
maternal O 0 9.69658344729396e-07
chromosome O 0 8.601452918810537e-07
15 O 0 3.3690721323864636e-08
in O 0 2.996469561367121e-08
J O 0 0.02111804485321045
. O 0 3.898890099662822e-07

B O 0 0.0007159067899920046
. O 0 5.953901563771069e-06

Maternal B-Disease 0 0.003957374952733517
disomy I-Disease 0 0.001154633122496307
was O 0 7.583701631119766e-07
confirmed O 0 9.338286588445044e-08
by O 0 4.6985850765679515e-09
polymerase O 0 1.4450766911977553e-06
chain O 0 5.055473138781963e-06
reaction O 0 1.9382419225166814e-07
analysis O 0 2.9587024386046323e-08
of O 0 2.475862181938737e-09
microsatellite O 0 5.831186172144953e-06
repeats O 0 1.2044539289490785e-05
at O 0 3.197814635313989e-08
the O 0 1.1825068035875574e-08
gamma O 0 7.748476491542533e-07
- O 0 2.477978796378011e-06
aminobutyric O 0 7.643854587513488e-06
acid O 0 1.284167979065387e-06
receptor O 0 1.0041472933153273e-06
beta3 O 0 3.893909706675913e-06
subunit O 0 1.885940832835331e-06
( O 0 1.251160597348644e-07
GABRB3 O 0 1.3157137800590135e-05
) O 0 9.698565150983995e-08
locus O 0 4.755714144266676e-06
. O 0 1.8787875433190493e-07

A O 0 9.556804798194207e-06
niece O 0 0.0004980048979632556
( O 0 4.146315291109204e-07
B O 0 8.251656140600971e-07
. O 0 2.7218387543825884e-09
B O 0 3.244247537281808e-08
. O 0 2.984943681116903e-10
) O 0 1.9175225296486076e-10
with O 0 1.4998993713710718e-10
45 O 0 2.7979312200443474e-09
chromosomes O 0 1.543745220544679e-08
and O 0 5.468215324988535e-10
the O 0 1.2469997257014143e-09
derivative O 0 2.221293549098391e-08
3 O 0 5.863007412898469e-09
but O 0 2.484356886878203e-10
without O 0 3.755315225451028e-10
the O 0 7.126843115656811e-09
der O 0 0.0008053730125539005
( O 0 2.3639221691240664e-09
15 O 0 1.061958743164837e-09
) O 0 2.401893961501145e-10
demonstrated O 0 2.0653878607390652e-09
a O 0 6.827683307619736e-09
phenotype O 0 1.2233033430675277e-06
consistent O 0 1.2498673207517186e-08
with O 0 3.48371387293156e-10
that O 0 4.266073050374075e-10
reported O 0 7.641091315235826e-08
for O 0 9.426898150977081e-10
haploinsufficiency O 0 4.1444732801210193e-07
of O 0 2.5426083460899918e-09
distal O 0 1.7616093828110024e-05
3 O 0 1.4237709820008604e-06
p O 0 0.0001222480059368536
. O 0 1.491682155574381e-07

Uniparental B-Disease 1 0.9999996423721313
disomy I-Disease 1 0.9999992847442627
associated O 0 2.6348190658609383e-05
with O 0 1.1515925280036754e-07
unbalanced O 0 8.887465810403228e-05
segregation O 0 1.6882719364730292e-06
of O 0 2.2973489777200484e-09
non O 0 5.875458697346403e-08
- O 0 2.34796107179136e-06
Robertsonian O 0 6.813675099692773e-06
translocations O 0 5.550452897296054e-06
has O 0 1.0436779440681221e-08
been O 0 1.002634753000109e-09
reported O 0 1.7309847777369214e-08
previously O 0 2.92138779833806e-09
but O 0 2.896629325288558e-10
has O 0 2.832034329269817e-10
not O 0 1.3037815271843556e-10
, O 0 2.537659318790908e-11
to O 0 1.2501760737748668e-10
our O 0 1.6533388547124162e-10
knowledge O 0 7.522113487645754e-11
, O 0 3.3404525673352836e-11
been O 0 9.052760624461698e-11
observed O 0 4.953821797215596e-10
in O 0 1.8574988769337608e-10
a O 0 1.3132261944548418e-09
case O 0 4.2374161957070555e-09
of O 0 7.732942286509115e-09
PWS B-Disease 1 0.9999998807907104
. O 0 4.311461054840038e-07

Furthermore O 0 2.320013891221606e-06
, O 0 1.865147858381988e-08
our O 0 6.932267204717846e-09
findings O 0 1.5129426600424267e-08
are O 0 3.4392552694662015e-10
best O 0 7.90648158055518e-10
interpreted O 0 3.843668050507176e-09
as O 0 5.83234294193602e-10
true O 0 2.152617861739259e-09
gamete O 0 1.8826474956767925e-07
complementation O 0 4.206512187465705e-07
resulting O 0 5.554883841796254e-08
in O 0 1.9674641293931927e-07
maternal B-Disease 0 0.012813443318009377
UPD I-Disease 1 1.0
15 I-Disease 0 2.0916246285196394e-05
and O 0 3.0728012916370062e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9981862902641296
- I-Disease 1 0.9999817609786987
Jampel I-Disease 1 0.9999613761901855
syndrome I-Disease 1 0.9999998807907104
type I-Disease 0 6.505899364128709e-05
2 I-Disease 0 1.6570918148772762e-07
and O 0 2.9007125590396754e-08
Stuve B-Disease 1 0.9956694841384888
- I-Disease 1 0.9999990463256836
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 9.877726192542013e-09
a O 0 5.0671138396296556e-09
case O 0 3.3823732703552878e-09
for O 0 3.3745869987278354e-10
" O 0 2.722586378567371e-09
lumping O 0 1.265677269657317e-07
" O 0 1.0973175257333878e-08
. O 0 2.340151361579501e-08

Recent O 0 2.263495161969331e-06
studies O 0 7.294421067172152e-08
demonstrated O 0 1.3732135428767833e-08
the O 0 1.1803407140575928e-09
existence O 0 1.5337188186137496e-09
of O 0 1.1125109167231528e-10
a O 0 3.553320526705761e-09
genetically O 0 2.2614395689402045e-08
distinct O 0 8.426561670660249e-09
, O 0 1.0835485841909076e-09
usually O 0 3.3104041730069866e-09
lethal O 0 6.7458474362069865e-09
form O 0 1.5662733332533207e-09
of O 0 2.334447080087898e-10
the O 0 4.260677854972528e-08
Schwartz B-Disease 1 0.6219657063484192
- I-Disease 1 0.9977810978889465
Jampel I-Disease 1 0.9999874830245972
syndrome I-Disease 1 0.9999998807907104
( O 0 6.514601409435272e-07
SJS B-Disease 1 0.9934899806976318
) O 0 1.4172634621445468e-08
of O 0 6.139235786406516e-09
myotonia B-Disease 1 0.8688369989395142
and O 0 7.041558092168998e-07
skeletal B-Disease 1 0.9995279312133789
dysplasia I-Disease 1 0.9999792575836182
, O 0 1.2872914290085191e-08
which O 0 2.5362597355638172e-08
we O 0 1.0901058722367907e-08
called O 0 2.5518711481709033e-06
SJS B-Disease 1 0.9988412261009216
type I-Disease 0 3.406913674552925e-05
2 I-Disease 0 3.3550421107975126e-07
. O 0 1.2272207072783203e-07

This O 0 1.4535075024468824e-05
disorder O 1 0.5638227462768555
is O 0 1.538342786489011e-08
reminiscent O 0 5.869790697943245e-07
of O 0 4.911044348965277e-10
another O 0 1.7768729820843987e-09
rare O 0 1.2320634290574617e-08
condition O 0 1.6996500562527217e-07
, O 0 9.997837002728716e-10
the O 0 4.343469228729191e-08
Stuve B-Disease 1 0.9967926144599915
- I-Disease 1 0.9999995231628418
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 5.518544980986917e-07
SWS B-Disease 1 0.9978448152542114
) O 0 1.2201460286576093e-08
, O 0 4.469067060863807e-10
which O 0 2.758737127628308e-10
comprises O 0 1.2128157367286008e-09
campomelia B-Disease 0 2.565070928994828e-07
at O 0 3.34641363508581e-08
birth O 0 7.382565740954306e-07
with O 0 2.4561744638162963e-08
skeletal B-Disease 1 0.9998065829277039
dysplasia I-Disease 1 0.9999449253082275
, O 0 2.0835543068642437e-08
contractures B-Disease 0 0.00012495291593950242
, O 0 5.024959115473848e-09
and O 0 3.053866493019086e-09
early B-Disease 0 1.196158109451062e-06
death I-Disease 0 1.691066131570551e-06
. O 0 9.362506148136163e-08

To O 0 5.951857815489348e-07
test O 0 1.0685712226177202e-07
for O 0 7.232832111014886e-10
possible O 0 5.691353166525914e-09
nosologic O 0 1.0092471711686812e-06
identity O 0 3.206732301919146e-08
between O 0 5.908145972455259e-09
these O 0 7.305727223183567e-08
disorders O 0 0.0003951321414206177
, O 0 1.6696635185553532e-09
we O 0 1.1974725655505836e-09
reviewed O 0 6.403917840458462e-09
the O 0 7.559946002544393e-10
literature O 0 3.534972314866991e-10
and O 0 5.1808050904877945e-11
obtained O 0 3.3888547523730495e-10
a O 0 1.2363023937922435e-09
follow O 0 3.013204619151111e-08
- O 0 4.804189188689634e-07
up O 0 8.961529296414028e-09
of O 0 3.8197001117623586e-11
the O 0 1.221779483140395e-10
only O 0 5.740166328371821e-11
two O 0 1.045669523191961e-10
surviving O 0 5.1668567202511895e-09
patients O 0 7.980752170233529e-10
, O 0 7.084981906713139e-11
one O 0 5.274019554413201e-10
with O 0 5.776437550508717e-09
SJS B-Disease 1 0.992348313331604
type I-Disease 0 7.532528798037674e-06
2 I-Disease 0 3.9507025206830804e-08
at O 0 1.6624800025510922e-07
age O 0 1.0692314589277885e-08
10 O 0 6.699210075566953e-10
years O 0 1.823831363712003e-10
and O 0 7.941996366112036e-11
another O 0 5.383110068812869e-10
with O 0 3.800032732925729e-09
SWS B-Disease 1 0.6587154269218445
at O 0 1.237732590197993e-06
age O 0 3.306581675133202e-08
7 O 0 2.3386700576111252e-08
years O 0 1.0536910011182954e-08
. O 0 4.6247102147845e-08

Patients O 0 8.740359044168144e-05
reported O 0 8.168105523509439e-06
as O 0 2.1352724033363302e-08
having O 0 4.1189551325260254e-08
either O 0 1.4513359474221943e-06
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 2.7866084565175697e-05
SWS B-Disease 1 0.998809814453125
presented O 0 1.4063791908824896e-08
a O 0 2.7956799097950125e-09
combination O 0 8.189454447915523e-09
of O 0 3.592174335764753e-10
a O 0 7.533219381627987e-09
severe O 0 7.356761216215091e-06
, O 0 3.3605751070808765e-08
prenatal O 0 0.020560771226882935
- O 1 0.9961203932762146
onset O 1 0.9999998807907104
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 6.799652396694e-07
with O 0 7.034268492134288e-07
congenital B-Disease 1 1.0
joint I-Disease 0 0.0001297880371566862
contractures I-Disease 1 0.9999872446060181
, O 0 5.907827016926603e-06
respiratory O 1 0.9999896287918091
and O 0 3.137881492421002e-07
feeding O 0 1.323687911281013e-06
difficulties O 0 8.055110356508521e-09
, O 0 4.820411847461514e-10
tendency O 0 1.1162298818589989e-07
to O 0 2.8861871115282156e-08
hyperthermia B-Disease 0 8.423523104283959e-05
, O 0 8.272988405444437e-10
and O 0 6.490496473610108e-10
frequent O 0 3.503955881001275e-08
death O 0 8.291603421639593e-07
in O 0 7.015256642262102e-08
infancy O 0 1.3210105862526689e-05
) O 0 3.5341901627461425e-10
with O 0 1.106785774140917e-10
a O 0 3.865643360967397e-09
distinct O 0 1.2720614961381216e-07
campomelic B-Disease 0 0.08429154008626938
- I-Disease 0 0.28505071997642517
metaphyseal I-Disease 0 0.33170855045318604
skeletal I-Disease 1 0.9987333416938782
dysplasia I-Disease 1 0.9998438358306885
. O 0 2.0823920294787968e-06

The O 0 1.293652047706928e-07
similarity O 0 7.317636629977642e-08
of O 0 8.241756721538707e-10
the O 0 3.2585218967540186e-09
clinical O 0 1.9486277480496028e-08
and O 0 9.164269343386877e-09
radiographic O 0 6.120746547821909e-06
findings O 0 8.83320510070007e-08
is O 0 5.496689770012608e-10
so O 0 3.6531158653652085e-10
extensive O 0 1.422999718059259e-09
that O 0 1.813038719156168e-09
these O 0 2.5594403041395708e-08
disorders O 0 2.420605960651301e-05
appear O 0 5.5091646800065064e-08
to O 0 1.6109452660728607e-09
be O 0 5.626546450976377e-10
a O 0 2.031374846112044e-09
single O 0 1.91196232179891e-08
entity O 0 2.2994417747668194e-07
. O 0 8.954408059480556e-08

The O 0 3.1284125157071685e-07
follow O 0 5.594170033873525e-07
- O 0 2.6862157938012388e-06
up O 0 1.5715230006208003e-08
observation O 0 1.4942356685310187e-08
of O 0 4.9469549984193506e-11
an O 0 2.4985655211473556e-10
identical O 0 3.0918505444788025e-07
and O 0 7.200430252041201e-10
unique O 0 2.2621891027085894e-09
pattern O 0 2.6930435979011236e-06
of O 0 2.8692581643952053e-09
progressive O 0 0.06031113490462303
bone B-Disease 1 0.9999767541885376
dysplasia I-Disease 1 0.999930739402771
in O 0 1.0211130074821995e-07
the O 0 2.986370617463763e-08
two O 0 1.9190245836853137e-08
patients O 0 6.292502519045229e-08
( O 0 3.290398620237056e-09
one O 0 2.256862252636438e-09
with O 0 1.9455750788210935e-08
SJS B-Disease 1 0.9999828338623047
type I-Disease 0 6.405719614122063e-05
2 I-Disease 0 2.8683786013061763e-08
, O 0 4.4973452739682784e-10
one O 0 5.741307429474318e-10
with O 0 4.545928078414363e-09
SWS B-Disease 0 0.19205570220947266
) O 0 4.2636996155920315e-09
surviving O 0 2.6528569563311066e-08
beyond O 0 3.0206276591115966e-08
infancy O 0 4.405950676300563e-06
adds O 0 1.9576802401388704e-08
to O 0 5.261570623638079e-10
the O 0 3.2698138641151786e-10
evidence O 0 2.618424366218619e-10
in O 0 3.968121109476641e-10
favor O 0 6.937144747531931e-10
of O 0 2.614850835858107e-10
identity O 0 3.271102144708493e-08
. O 0 5.1835016279255797e-08

The O 0 4.424450708029326e-07
hypothesis O 0 7.388383096440521e-07
that O 0 2.5028226602330506e-08
SWS B-Disease 0 0.34950554370880127
and O 0 3.4746469168567273e-07
SJS B-Disease 1 0.997877836227417
type I-Disease 0 9.749206583364867e-06
2 I-Disease 0 1.38255904502671e-08
are O 0 7.482818531467927e-11
the O 0 2.3380533065164855e-09
same O 0 9.630533668314456e-07
disorder O 0 3.33227617375087e-05
should O 0 1.6727776941394268e-09
be O 0 3.240854806740856e-10
testable O 0 8.73150707292325e-09
by O 0 4.424336452757416e-10
molecular O 0 1.98863823186457e-08
methods O 0 4.811589704445396e-08
. O 0 6.295717724924543e-09
. O 0 3.412826288240467e-08

A O 0 3.7183961012488e-06
mouse O 0 6.512981781270355e-05
model O 0 1.1667899570966256e-06
of O 0 3.673648407698238e-08
severe O 1 0.9997323155403137
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.44662395119667053
defects O 1 0.9999990463256836
in O 0 1.542323047942773e-06
hemostasis O 1 0.5568774342536926
and O 0 2.257857431686716e-06
thrombosis B-Disease 0 0.0019190966850146651
. O 0 9.796466429179418e-07

von B-Disease 1 0.9694736003875732
Willebrand I-Disease 1 0.8124781847000122
factor I-Disease 0 0.0001291411608690396
( I-Disease 0 8.088172762654722e-06
vWf I-Disease 0 0.0005806669942103326
) I-Disease 0 9.251618757843971e-05
deficiency I-Disease 1 0.9993776679039001
causes O 0 0.00025361296138726175
severe O 1 0.9999997615814209
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 2.6553167117526755e-05
humans O 0 2.8599604320334038e-06
. O 0 4.78393076264183e-07

We O 0 4.785714935451324e-08
generated O 0 1.6842879091427676e-08
a O 0 7.434004078987755e-09
mouse O 0 1.780071215762291e-06
model O 0 7.500591436837567e-08
for O 0 3.551841598614658e-10
this O 0 8.183095312475075e-10
disease O 0 4.691736421591486e-08
by O 0 7.981665328671284e-10
using O 0 2.115158892479485e-08
gene O 0 5.830635814163543e-07
targeting O 0 4.1478620005364064e-07
. O 0 1.1582252312791752e-07

vWf B-Disease 0 0.009914067573845387
- I-Disease 1 0.9092791080474854
deficient I-Disease 0 0.3943819999694824
mice O 0 0.0004161905962973833
appeared O 0 1.7749687231116695e-06
normal O 0 5.871571033821965e-07
at O 0 2.940514889360202e-07
birth O 0 4.442326826392673e-07
; O 0 1.046077002797574e-09
they O 0 2.2766540042074013e-10
were O 0 4.245390428092577e-10
viable O 0 6.880656044927491e-09
and O 0 2.664442666500122e-09
fertile O 0 1.7524860140838427e-07
. O 0 1.2267223326034582e-07

Neither O 0 4.5783854147884995e-05
vWf O 0 0.0006680074147880077
nor O 0 2.8057809686288238e-05
vWf O 0 0.00032268837094306946
propolypeptide O 0 0.00019872728444170207
( O 0 1.5574080407532165e-06
von B-Disease 0 0.012619801796972752
Willebrand I-Disease 0 0.005964596290141344
antigen O 0 2.542721267673187e-05
II O 0 4.267643453204073e-05
) O 0 1.0132628958103851e-08
were O 0 2.1739581246293938e-09
detectable O 0 1.8471072849024495e-07
in O 0 2.3458124331909858e-09
plasma O 0 9.625073005281592e-08
, O 0 1.649116287971708e-09
platelets O 0 1.0568272301725301e-07
, O 0 5.205491593329725e-10
or O 0 2.6111541817641637e-09
endothelial O 0 1.969199914242381e-08
cells O 0 5.712756490083848e-09
of O 0 2.1314860987331485e-10
the O 0 4.921596019613617e-09
homozygous O 0 1.6368991282433853e-06
mutant O 0 1.7762861261871876e-06
mice O 0 9.170178600470535e-06
. O 0 2.0104958764477487e-07

The O 0 7.819875804671028e-07
mutant O 0 1.0859752364922315e-05
mice O 0 0.0012150104157626629
exhibited O 0 0.0026996301021426916
defects O 1 0.8338086009025574
in O 0 6.603347202371879e-08
hemostasis O 0 2.7448177206679247e-05
with O 0 4.866884228960089e-09
a O 0 9.9895352434487e-08
highly O 0 7.595332931487064e-07
prolonged O 0 0.2099655121564865
bleeding O 1 0.9925328493118286
time O 0 7.178262535489921e-07
and O 0 1.73703735839581e-08
spontaneous O 0 1.6721459417112783e-07
bleeding O 0 1.0200068572885357e-05
events O 0 5.154886739688891e-09
in O 0 1.613959299540113e-09
approximately O 0 2.5301223338658474e-09
10 O 0 3.910994195166495e-09
% O 0 6.929209983574935e-10
of O 0 2.0645136711294754e-09
neonates O 0 7.769796866341494e-06
. O 0 1.5739114189727843e-07

As O 0 5.6017306349076534e-08
in O 0 6.4740932614881785e-09
the O 0 4.630992922471933e-09
human O 0 6.068961333483003e-09
disease O 0 1.7235795723991032e-07
, O 0 2.4671870102466187e-10
the O 0 9.290807567730042e-10
factor O 0 3.1979352499433844e-09
VIII O 0 1.546584087463998e-07
level O 0 2.9928581835036994e-09
in O 0 1.8042763949566165e-09
these O 0 1.3280372357371562e-09
mice O 0 1.839326955632714e-06
was O 0 4.818853938104439e-08
reduced O 0 9.127218980609086e-09
strongly O 0 8.662417450011617e-09
as O 0 2.0554206947576148e-10
a O 0 2.492282769051002e-10
result O 0 2.394136833228089e-10
of O 0 3.0686241742072795e-11
the O 0 4.679381326866405e-10
lack O 0 6.791131546002305e-10
of O 0 9.745781959225042e-11
protection O 0 1.7168386712285155e-09
provided O 0 3.562590666916776e-09
by O 0 1.1617913742156816e-08
vWf O 0 9.731640602694824e-06
. O 0 2.124357649790909e-07

Defective O 0 0.3231610059738159
thrombosis B-Disease 0 0.043189194053411484
in O 0 7.715471497249382e-07
mutant O 0 7.328137144213542e-06
mice O 0 0.000721682037692517
was O 0 4.6557312316508614e-07
also O 0 9.913810883332985e-10
evident O 0 1.6735882679697056e-09
in O 0 2.1946715278442497e-10
an O 0 9.425131508589146e-11
in O 0 1.5240084749734706e-09
vivo O 0 2.223180217697518e-07
model O 0 3.2157235096974546e-08
of O 0 5.207281716934631e-09
vascular B-Disease 0 0.0018615651642903686
injury I-Disease 0 0.00010506906255614012
. O 0 4.515382556746772e-07

In O 0 1.3431035483790765e-07
this O 0 4.569974620949324e-09
model O 0 3.482866972603915e-08
, O 0 4.848351164987719e-10
the O 0 2.0091486252482582e-09
exteriorized O 0 2.1150274278625147e-06
mesentery O 0 1.1917189112864435e-05
was O 0 1.5315512769120687e-07
superfused O 0 7.267589126058738e-07
with O 0 9.470624284801943e-09
ferric O 0 1.9051898334510042e-06
chloride O 0 1.3838470636073907e-07
and O 0 2.390177389344217e-09
the O 0 5.276930448161465e-09
accumulation O 0 7.405024149420569e-08
of O 0 2.3730881704153717e-09
fluorescently O 0 2.6802437787409872e-05
labeled O 0 4.62819707536255e-06
platelets O 0 2.591868906165473e-06
was O 0 5.917791767728886e-08
observed O 0 2.6867608582392677e-08
by O 0 8.633338488550635e-09
intravital O 0 7.627411378052784e-06
microscopy O 0 7.442302376148291e-06
. O 0 2.4895160777305136e-07

We O 0 1.6327956586792425e-07
conclude O 0 9.73269962400991e-08
that O 0 1.761021994894918e-09
these O 0 1.4660159752821755e-09
mice O 0 7.110755291250825e-07
very O 0 1.1385708376110415e-08
closely O 0 4.867388270213269e-07
mimic O 0 0.00019431576947681606
severe O 0 0.0011831208830699325
human O 0 1.557946961838752e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.0005769745330326259
will O 0 8.219064540071486e-08
be O 0 6.61468657625619e-10
very O 0 5.16599651945171e-10
useful O 0 2.904740059594957e-10
for O 0 6.34020128065238e-11
investigating O 0 2.5294371042150487e-09
the O 0 6.59858223617249e-10
role O 0 1.0070890787972075e-09
of O 0 1.3188231062777334e-10
vWf O 0 8.660984462949273e-08
in O 0 2.8191764478435744e-09
normal O 0 2.1282873774453037e-07
physiology O 0 8.481372759661099e-08
and O 0 2.1579413811423365e-09
in O 0 1.1630107543680879e-08
disease O 0 2.215422227891395e-06
models O 0 6.088616544275283e-08
. O 0 2.561314049742691e-09
. O 0 3.693714845098839e-08

Oral O 0 0.00019963907834608108
contraceptives O 0 0.0005391499144025147
and O 0 1.7897855641990645e-08
the O 0 1.4139370563270859e-08
risk O 0 3.135473605198058e-07
of O 0 2.7637625521492737e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.9156548205501167e-06

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.8194472193717957
Clinical O 0 1.0197471056017093e-05
Study O 0 2.2326308624087687e-07
Group O 0 4.5041531393508194e-07
. O 0 1.293269633606542e-07

BACKGROUND O 0 4.7479188651777804e-05
Women O 0 1.193902221530152e-07
with O 0 5.179999984505912e-09
mutations O 0 5.714208555218647e-07
in O 0 3.2967748531120833e-09
either O 0 3.0992788335737487e-09
the O 0 7.72969865892037e-09
BRCA1 O 0 1.533038926027075e-06
or O 0 8.642548010584505e-09
the O 0 4.822971355622485e-09
BRCA2 O 0 1.9385427094675833e-06
gene O 0 4.655136365272483e-08
have O 0 9.424758751208628e-10
a O 0 3.3974965063521267e-09
high O 0 7.263834334025887e-08
lifetime O 0 9.097882269770707e-08
risk O 0 8.426305839748238e-07
of O 0 2.5444169295951724e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.2797727322322316e-06

Oral O 0 0.00019597364007495344
contraceptives O 0 0.008588091470301151
protect O 0 6.888442294439301e-05
against O 1 0.9969971179962158
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.214668709006219e-08
general O 0 2.291580702973306e-09
, O 0 4.240753304074474e-10
but O 0 2.290946043981279e-10
it O 0 4.674349796118804e-10
is O 0 9.258713240534178e-11
not O 0 5.456200768971797e-11
known O 0 1.565944041104217e-10
whether O 0 1.0067274791580871e-10
they O 0 1.2559647766252624e-10
also O 0 1.1678599753928154e-10
protect O 0 3.622006028436431e-10
against O 0 1.0086423918309606e-09
hereditary B-Disease 0 7.710066711297259e-06
forms I-Disease 0 1.1391664855864292e-07
of I-Disease 0 5.6661527196411043e-05
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 4.52064341516234e-07

METHODS O 0 2.7854837298946222e-06
We O 0 3.0767868253178676e-08
enrolled O 0 3.4823688821461474e-08
207 O 0 3.2641037250868976e-07
women O 0 1.6870433938720453e-08
with O 0 1.0259217333441484e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.6925483237173466e-08
161 O 0 1.9132208706196252e-08
of O 0 2.783250019344763e-10
their O 0 1.1050128811973536e-08
sisters O 0 6.979328759371128e-08
as O 0 6.479945469095583e-10
controls O 0 6.078719252400333e-07
in O 0 1.0581656662012051e-09
a O 0 3.675412640902209e-09
case O 0 1.7497262305710137e-08
- O 0 1.1398233255022205e-06
control O 0 8.967804774329124e-07
study O 0 4.6847976165054206e-08
. O 0 4.83310351739874e-08

All O 0 2.9999064565799927e-08
the O 0 8.824175168342663e-09
patients O 0 7.825350145651555e-09
carried O 0 1.1859445869788487e-08
a O 0 4.490515514987692e-09
pathogenic O 0 8.701093179297459e-07
mutation O 0 5.229908879300638e-07
in O 0 1.5065815262005344e-08
either O 0 6.302484223397187e-08
BRCA1 O 0 4.516219178185565e-06
( O 0 1.7725275469615553e-08
179 O 0 5.770769462287717e-08
women O 0 2.5034421202718704e-09
) O 0 2.8826423470462714e-09
or O 0 6.301991817281305e-08
BRCA2 O 0 1.12724455902935e-05
( O 0 3.6037206996297755e-08
28 O 0 8.910384252658332e-08
women O 0 7.080896313738094e-09
) O 0 1.0643195658133209e-08
. O 0 5.547154913188024e-08

The O 0 4.835638947042753e-07
control O 0 2.6085504032380413e-06
women O 0 1.8160505987907527e-08
were O 0 6.929408713496343e-10
enrolled O 0 2.125300380129147e-09
regardless O 0 5.354570675741854e-10
of O 0 4.946464071675649e-11
whether O 0 8.325860001434648e-10
or O 0 4.773150319437036e-09
not O 0 7.555333025877076e-10
they O 0 2.0990288673861102e-10
had O 0 4.489762339687786e-09
either O 0 6.826745391208533e-09
mutation O 0 6.396400635821919e-07
. O 0 4.7170402694973745e-08

Lifetime O 0 1.2719085134449415e-05
histories O 0 3.3417722988815513e-06
of O 0 1.547784478361791e-08
oral O 0 2.7985415727016516e-06
- O 0 8.491847438563127e-06
contraceptive O 0 2.5926997295755427e-06
use O 0 1.3926427122612495e-08
were O 0 1.1458970439193195e-09
obtained O 0 1.1944387701134929e-09
by O 0 3.1886510098999565e-10
interview O 0 8.2043413840438e-08
or O 0 2.9224467290589473e-09
by O 0 3.9081737845947373e-10
written O 0 1.5706770328804964e-09
questionnaire O 0 4.246477836034046e-09
and O 0 2.3156840334159767e-10
were O 0 3.518639546395974e-10
compared O 0 3.0217326418835455e-09
between O 0 3.4289666661635465e-09
patients O 0 7.184520534053718e-09
and O 0 2.5619493193573817e-09
control O 0 2.699222250157618e-06
women O 0 1.4805269232809337e-09
, O 0 1.1931243493190635e-10
after O 0 1.606621724548063e-09
adjustment O 0 6.968139398821904e-09
for O 0 9.663966155093462e-11
year O 0 2.830360112948682e-10
of O 0 1.1993440962587698e-10
birth O 0 1.7280595443480706e-07
and O 0 3.1466986794015384e-09
parity O 0 6.215990993041487e-07
. O 0 4.7985203366351925e-08

RESULTS O 0 5.909269475523615e-06
The O 0 1.2417721961810457e-07
adjusted O 0 1.273148700420279e-05
odds O 0 9.458635759074241e-06
ratio O 0 3.878207644447684e-05
for O 0 0.004570378921926022
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.9582299159992544e-07
with O 0 1.2231954338304263e-09
any O 0 7.999253481827395e-10
past O 0 6.480430858601949e-09
use O 0 2.7898416909977186e-09
of O 0 4.913808249185081e-10
oral O 0 4.980581707059173e-07
contraceptives O 0 0.00017318014579359442
was O 0 5.902448947381345e-07
0 O 0 1.1675497546548286e-07
. O 0 3.53676981035278e-08

5 O 0 2.1432756511785556e-06
( O 0 5.8229232990925084e-08
95 O 0 1.619159206711629e-07
percent O 0 4.312069563638943e-07
confidence O 0 3.631189144925884e-07
interval O 0 1.6135591351940093e-07
, O 0 6.988313261402368e-10
0 O 0 1.4000993697749209e-09
. O 0 1.271506649969112e-10
3 O 0 2.491024719830648e-09
to O 0 2.4394541942029946e-09
0 O 0 5.97516791600583e-09
. O 0 8.761866232553928e-10
8 O 0 3.650876934102598e-08
) O 0 7.327018991531986e-09
. O 0 2.855637681875578e-08

The O 0 1.7312246427536593e-06
risk O 0 1.9059493752138223e-06
decreased O 0 3.1432637115358375e-07
with O 0 1.0690636154109256e-09
increasing O 0 5.3174864511618125e-09
duration O 0 2.29362413506351e-08
of O 0 2.2761591222941746e-10
use O 0 7.756903563915785e-09
( O 0 6.5014904571114585e-09
P O 0 1.9608905859058723e-06
for O 0 5.160826765937543e-10
trend O 0 3.275235016531042e-08
, O 0 7.213942776473914e-10
< O 0 1.5877262171670736e-08
0 O 0 3.0991902377763836e-09
. O 0 5.540836678363803e-10
001 O 0 2.3332253462626795e-08
) O 0 2.3253726721961243e-10
; O 0 1.1156792156796769e-10
use O 0 2.133120902136909e-10
for O 0 6.675061892114087e-11
six O 0 1.6972891148103741e-10
or O 0 4.303215839218666e-10
more O 0 9.058546968088166e-11
years O 0 4.760991600960551e-10
was O 0 8.621255931373639e-10
associated O 0 6.802977625675055e-11
with O 0 3.276898544180007e-11
a O 0 8.96417495788171e-10
60 O 0 5.597968311121804e-09
percent O 0 1.992586895482873e-08
reduction O 0 6.710378031016262e-09
in O 0 1.4351244637111904e-08
risk O 0 2.1456406784636783e-07
. O 0 6.48750742016091e-08

Oral O 0 9.584771032677963e-05
- O 0 3.135735460091382e-05
contraceptive O 0 1.8044385797111318e-05
use O 0 2.2099727914337564e-07
protected O 0 3.981130248575937e-06
against O 1 0.9979302883148193
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 1.9373829207580684e-09
for O 0 1.4958138894183293e-10
carriers O 0 7.024207882011524e-10
of O 0 1.7717077804846326e-10
the O 0 4.162788869166434e-08
BRCA1 O 0 9.194346785079688e-05
mutation O 0 1.7529250726511236e-06
( O 0 2.2665611609795633e-08
odds O 0 6.377019303727138e-07
ratio O 0 1.2056347031830228e-07
, O 0 1.1849400349817074e-09
0 O 0 3.491552158507716e-09
. O 0 1.8374697596801326e-10
5 O 0 2.1222135160314792e-09
; O 0 6.792142404066226e-10
95 O 0 3.3918844621894095e-08
percent O 0 2.5466630404480384e-07
confidence O 0 1.8966099446515727e-07
interval O 0 3.9399719042876313e-08
, O 0 3.6911756984281396e-10
0 O 0 1.708586938597989e-09
. O 0 1.1555844475763521e-10
3 O 0 8.669388540383238e-10
to O 0 7.234970955671827e-10
0 O 0 7.16923009846937e-09
. O 0 5.17401399502404e-10
9 O 0 2.280346045324677e-08
) O 0 1.527852427907206e-10
and O 0 1.4113139823468401e-10
for O 0 8.04891292505161e-11
carriers O 0 8.020856756552064e-10
of O 0 1.1779291431146532e-10
the O 0 3.058496744756667e-08
BRCA2 O 0 2.4744795155129395e-05
mutation O 0 8.168691465471056e-07
( O 0 2.1222390955699666e-08
odds O 0 5.429051839200838e-07
ratio O 0 1.5764337035761855e-07
, O 0 1.0112254367200535e-09
0 O 0 5.87609427782354e-09
. O 0 2.3216632782929736e-10
4 O 0 2.7953068748587384e-09
; O 0 8.566017895006439e-10
95 O 0 4.612562420902577e-08
percent O 0 2.7054642259827233e-07
confidence O 0 4.7047484486029134e-07
interval O 0 1.1427114543494099e-07
, O 0 4.462840097474441e-10
0 O 0 2.634898299547217e-09
. O 0 8.723075733962915e-11
2 O 0 1.3496430639747814e-09
to O 0 1.4547071325310412e-09
1 O 0 4.523784902232819e-09
. O 0 3.461683995009679e-10
1 O 0 5.190602614391082e-09
) O 0 4.45142500637985e-09
. O 0 1.1934464083651619e-08

CONCLUSIONS O 0 2.6638133931555785e-05
Oral O 0 1.858674113464076e-05
- O 0 2.0447365386644378e-05
contraceptive O 0 8.724403414817061e-06
use O 0 1.0338828104750064e-07
may O 0 5.2569113506706344e-08
reduce O 0 1.1851396308770745e-08
the O 0 5.7490576743646216e-09
risk O 0 3.984834222592326e-07
of O 0 3.3403607631043997e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.836682438418393e-08
women O 0 1.8551700176061559e-09
with O 0 6.62569721310291e-10
pathogenic O 0 9.419875937055622e-07
mutations O 0 3.5617912885754777e-07
in O 0 5.3633946173192726e-09
the O 0 3.6542349590718004e-08
BRCA1 O 0 3.813480361714028e-05
or O 0 8.828520208226109e-07
BRCA2 O 0 0.0002637369907461107
gene O 0 0.00011898295633727685

A O 0 9.072788316188962e-07
Japanese O 0 3.226291198643594e-07
family O 0 2.445969471409626e-07
with O 0 5.5650751562552614e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 3.544144178135866e-08
a O 0 8.149567776172262e-08
codon O 0 8.718015124031808e-06
291 O 0 4.316315482810751e-07
deletion O 0 9.707574690764886e-07
: O 0 3.6288811955387246e-09
a O 0 3.185455232923573e-09
clinical O 0 3.522940872358049e-08
, O 0 8.336427104183031e-10
biochemical O 0 6.412549424794634e-08
, O 0 4.436217226899686e-10
pathological O 0 2.474749294378853e-08
, O 0 1.5423788912727332e-09
and O 0 6.0335860752047665e-09
genetic O 0 4.0917299770626414e-07
report O 0 2.979145961035101e-07
. O 0 1.229523860502013e-07

We O 0 3.4301859841434634e-07
report O 0 7.048451777791342e-08
a O 0 4.403392761531677e-09
Japanese O 0 4.768239136865304e-08
family O 0 2.0902500352804054e-07
with O 0 3.0910157988728315e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.00588433351367712
ALD B-Disease 1 1.0
) O 0 9.498229758264642e-09
with O 0 3.137096971084219e-10
a O 0 4.4166661439248855e-09
three O 0 2.2579473846207065e-09
base O 0 5.733030050691923e-08
pair O 0 1.1710099556694331e-07
deletion O 0 9.555360520607792e-07
( O 0 4.1970231734467234e-08
delGAG O 0 7.886259822953434e-07
291 O 0 1.8310541349819687e-07
) O 0 2.6707265288195003e-09
in O 0 6.777160166393514e-09
the O 0 4.7492329713350045e-07
ALD B-Disease 1 1.0
gene O 0 3.386312891962007e-05
. O 0 5.384382575357449e-07

A O 0 6.146831310616108e-07
variety O 0 4.280487786445519e-08
of O 0 1.7809377306221563e-09
phenotypes O 0 3.770945227188349e-07
were O 0 3.054029473759101e-09
observed O 0 9.881043538939593e-09
within O 0 3.091043421221684e-09
this O 0 2.930618858698608e-09
family O 0 9.743007467477582e-08
. O 0 6.590336454337375e-08

While O 0 4.0096963971336663e-07
the O 0 1.0496815150418115e-07
proband O 0 2.213001425843686e-05
( O 0 7.98689683279008e-08
patient O 0 3.085444006956095e-07
1 O 0 2.6207603198713514e-08
) O 0 1.590313658539344e-09
was O 0 8.318117750150122e-09
classified O 0 2.2631816420926043e-09
as O 0 9.534708578229356e-10
having O 0 4.653409602095593e-10
a O 0 8.150399799511376e-10
rare O 0 4.715544399402916e-09
intermediate O 0 2.8403354335182485e-08
type O 0 1.9767719550145557e-07
of O 0 1.3344816363058953e-09
adult O 0 2.4837327146087773e-06
cerebral O 0 5.1478917157510296e-05
and O 0 6.985707301510047e-08
cerebello O 0 0.351754754781723
- O 0 0.16375732421875
brain O 0 0.0010875043226405978
stem O 0 4.939061568620673e-07
forms O 0 1.9369256420986858e-08
, O 0 1.0752967405380787e-09
his O 0 3.306190521357166e-08
younger O 0 2.570414210367744e-07
brother O 0 5.930638735662797e-07
( O 0 8.228377978980461e-09
patient O 0 9.75364287114644e-08
2 O 0 2.075997329598067e-08
) O 0 1.7211632119540354e-09
and O 0 7.241656163614607e-09
nephew O 0 2.298571780556813e-05
( O 0 1.9955079366695827e-08
patient O 0 2.6059069568873383e-07
3 O 0 4.729806590830776e-08
) O 0 3.1995459615075106e-09
had O 0 3.06768654922962e-08
a O 0 1.9348364332927304e-07
childhood O 0 0.007179342210292816
ALD B-Disease 1 1.0
type O 0 0.010940083302557468
. O 0 5.199146357881546e-07

Another O 0 6.57932423564489e-06
nephew O 0 0.0004908861592411995
( O 0 1.0981381137753488e-06
patient O 0 1.6477798681080458e-06
4 O 0 5.05235142611582e-08
) O 0 1.8509570542946108e-09
of O 0 4.300016176461696e-10
patient O 0 3.015576623965899e-07
1 O 0 9.06028745362164e-08
was O 0 1.5499327332690882e-07
classified O 0 8.358913561323789e-09
as O 0 1.395535020876082e-09
having O 0 2.5033559669651595e-09
an O 0 2.002736421147233e-09
adolescent O 0 7.30304407170479e-07
form O 0 1.8825038239356218e-07
. O 0 3.0084129321039654e-07

The O 0 4.37014449516937e-07
tau O 0 4.6543195253434533e-07
level O 0 3.80413958112058e-08
in O 0 7.761935094663386e-09
the O 0 2.8382773464841193e-08
cerebrospinal O 0 0.0077811176888644695
fluid O 0 5.696117295883596e-05
( O 0 6.979341264923278e-07
CSF O 0 0.32019901275634766
) O 0 3.873976694990233e-09
in O 0 6.6757053218680085e-09
patient O 0 1.769805351159448e-07
1 O 0 4.7573927020039264e-08
was O 0 1.1695523483012948e-07
as O 0 1.5706591582898e-09
high O 0 1.2964923357117186e-08
as O 0 1.9691451247361158e-10
that O 0 5.885644749348273e-11
of O 0 2.6936183838977e-10
patients O 0 3.162211470453258e-08
with O 0 1.610121671546949e-06
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.833733320236206
( O 0 6.273436525816578e-08
AD B-Disease 0 3.098279194091447e-05
) O 0 8.919055716205548e-08
. O 0 1.1343519901174659e-07

His O 0 6.685278549412033e-06
brain O 0 0.000412097288062796
magnetic O 0 1.9640534446807578e-05
resonance O 0 8.971072384156287e-05
image O 0 0.0005391401355154812
( O 0 2.0280276658013463e-07
MRI O 0 0.000772337254602462
) O 0 1.8548455216205184e-08
showed O 0 7.638804163434543e-06
abnormalities B-Disease 0 0.01350443810224533
in I-Disease 0 3.2250768722263956e-09
the I-Disease 0 4.175749079848856e-09
bilateral I-Disease 0 5.4606438482096564e-08
cerebellar I-Disease 0 9.236385812982917e-05
hemispheres I-Disease 0 1.1176076441188343e-05
and O 0 8.29563830961888e-08
brain O 0 4.462771539692767e-05
stem O 0 3.0812771001365036e-07
, O 0 3.668533532508178e-10
but O 0 3.038781171138538e-10
not O 0 2.0057094873848769e-10
in O 0 8.979713084222851e-10
the O 0 2.7687239168017186e-08
cerebral O 0 9.575443982612342e-06
white O 0 1.565129537084431e-07
matter O 0 1.6583519002466574e-09
, O 0 1.0517262061249255e-10
where O 0 1.9905298243028113e-10
marked O 0 3.2775582248234514e-09
reductions O 0 9.085705521272303e-09
of O 0 8.786328609122762e-11
the O 0 4.421588428726864e-09
cerebral O 0 1.1180553656231496e-06
blood O 0 8.411583252154742e-08
flow O 0 3.595708264469977e-08
and O 0 6.255260753817993e-09
oxygen O 0 2.675577377431182e-07
metabolism O 0 1.2601960861502448e-06
were O 0 5.358701038460367e-09
clearly O 0 5.286177717778173e-09
demonstrated O 0 2.0027821623358477e-09
by O 0 2.1868333810459717e-09
positron O 0 6.292668331298046e-06
emission O 0 2.7125481210532598e-05
tomography O 0 0.001137264771386981
( O 0 2.253220969805625e-07
PET O 0 1.3931169632996898e-05
) O 0 5.057229657268181e-08
. O 0 1.0876183154095997e-07

In O 0 2.388074790360406e-06
patients O 0 1.2030496918669087e-06
2 O 0 8.270739471072375e-08
and O 0 3.5942873122252195e-09
3 O 0 6.321299039768746e-09
, O 0 1.55716953220697e-10
the O 0 6.105146943546913e-10
autopsy O 0 3.5806180676445365e-05
findings O 0 9.680010748525092e-08
showed O 0 1.356748839498323e-06
massive O 0 1.0032055115516414e-06
demyelination B-Disease 1 1.0
of I-Disease 0 8.971260179180263e-09
the I-Disease 0 2.1067323530132853e-07
cerebral I-Disease 0 0.00021861236018594354
white I-Disease 0 5.199216275286744e-07
matter I-Disease 0 1.7105955540941409e-09
with O 0 3.693563233042596e-10
sparing O 0 3.748190202657042e-09
of O 0 1.6712173311894674e-10
the O 0 5.395808244657019e-09
U O 0 3.4912789033114677e-06
- O 0 9.796067388379015e-06
fibers O 0 1.969092636500136e-06
, O 0 4.4294362622210315e-10
compatible O 0 8.913406013277836e-09
with O 0 2.388198527825125e-10
the O 0 1.4389418545590615e-09
findings O 0 3.26603988298757e-08
of O 0 1.0928893345862889e-08
childhood O 0 0.0013441521441563964
ALD B-Disease 1 0.9999998807907104
. O 0 1.5776969348735292e-06

Oleic O 0 0.17353346943855286
and O 0 4.093129973625764e-06
erucic O 0 0.0007020850898697972
acids O 0 5.048025286669144e-06
( O 0 6.836077659500006e-08
Lorenzos O 0 1.0995917136824573e-06
Oil O 0 4.351379701006408e-08
) O 0 9.366356579221247e-10
were O 0 3.73578362689031e-10
administered O 0 2.4306343604507674e-09
to O 0 2.3628086154303674e-09
patients O 0 4.66218930128548e-09
1 O 0 2.75314038233887e-09
and O 0 9.8612695786926e-10
4 O 0 2.8478199798342985e-09
, O 0 5.487270013371237e-11
but O 0 1.2652071057495107e-10
sufficient O 0 8.487692215730647e-10
effectiveness O 0 1.0241319792214654e-08
was O 0 2.785324149101598e-08
not O 0 6.55869247800922e-10
obtained O 0 1.2828182072155414e-08
. O 0 2.299085899437614e-08

The O 0 1.221580845367498e-07
findings O 0 2.2282958411778964e-07
in O 0 5.743216124898254e-09
this O 0 4.090406624523979e-10
family O 0 8.043718580097448e-09
suggest O 0 2.570220924980049e-09
that O 0 4.113031581987059e-10
delGAG291 O 0 9.512048393389705e-08
is O 0 1.2272728666662402e-10
part O 0 9.321475535895019e-11
of O 0 3.15009476836714e-11
the O 0 1.0065878131015893e-09
cause O 0 6.26998941655188e-09
of O 0 7.052641248783686e-10
Japanese O 0 3.5123987345286878e-06
ALD B-Disease 1 0.9999998807907104
with O 0 2.5249171642371948e-08
phenotypic O 0 4.36429445471731e-06
variations O 0 7.692910003243014e-06
. O 0 4.1326566702082346e-07

Moreover O 0 4.0860472836357076e-06
, O 0 1.343492428418358e-08
although O 0 3.977731477533553e-09
the O 0 7.486762876318664e-10
scale O 0 3.3773188690133793e-09
of O 0 6.872595548212956e-11
the O 0 1.0338661038389318e-09
study O 0 6.281344888670048e-10
is O 0 2.2766540042074013e-10
limited O 0 8.844559529208595e-10
, O 0 1.309388847348103e-10
there O 0 4.218815227718942e-11
is O 0 5.4233308816042936e-11
a O 0 1.4831236239132295e-10
possibility O 0 7.096969123487895e-10
that O 0 9.197518302528351e-10
PET O 0 5.2586170795621e-07
can O 0 2.1785488968362188e-09
detect O 0 9.927042583512957e-07
an O 0 5.784696277544299e-09
insidious B-Disease 0 6.735353963449597e-05
lesion I-Disease 0 0.1055082380771637
which O 0 9.786959687119179e-09
is O 0 1.6558960869161865e-09
undetectable O 0 1.7009084274377528e-07
by O 0 3.759201394615275e-09
computed O 0 8.291096946777543e-07
tomogram O 0 4.885655016551027e-06
( O 0 4.799078467954132e-08
CT O 0 0.3667752146720886
) O 0 1.098125679277473e-08
or O 0 1.903945445747013e-08
MRI O 0 4.932706815452548e-06
analysis O 0 4.190678026816386e-09
, O 0 9.14079784086752e-11
and O 0 1.1094002105860312e-10
that O 0 2.3816787084185442e-11
the O 0 7.674048618788731e-10
higher O 0 1.858492915118859e-08
level O 0 1.8783561372970325e-09
of O 0 1.2297003693095832e-10
tau O 0 4.549119747565555e-09
reflects O 0 1.2863237142113348e-09
the O 0 2.6595875501911337e-10
process O 0 2.8599025925224453e-10
of O 0 3.60950935807125e-10
neuronal B-Disease 0 1.6714730008970946e-06
degeneration I-Disease 0 5.3683317673858255e-05
in O 0 2.420902092126198e-06
ALD B-Disease 1 1.0
. O 0 9.73678083937557e-07

Lorenzos O 0 0.00014374166494235396
Oil O 0 1.4848255887045525e-06
should O 0 6.925712447980459e-09
be O 0 9.772810338759541e-11
given O 0 4.417689131175351e-11
in O 0 1.4635034850662976e-10
the O 0 4.75328831850419e-10
early O 0 2.851615477084124e-08
stage O 0 4.1084724955453567e-08
. O 0 3.3105682639700262e-09
. O 0 2.505081475590032e-08

Nonsense O 0 0.00035248915082775056
mutation O 0 3.0433195206569508e-05
in O 0 1.2811365479592496e-07
exon O 0 4.81682354802615e-06
4 O 0 4.6580673540574935e-08
of O 0 4.602846159773577e-10
human O 0 4.619920890291951e-09
complement O 0 5.5677404020570975e-08
C9 O 0 3.154987325615366e-06
gene O 0 3.765094902519195e-07
is O 0 9.516831767086842e-10
the O 0 7.25713933391603e-10
major O 0 1.7300728627489548e-09
cause O 0 6.080362879856693e-09
of O 0 6.628781412665319e-10
Japanese O 0 9.56059238887974e-07
complement B-Disease 0 1.1562090548977721e-05
C9 I-Disease 0 0.29489031434059143
deficiency I-Disease 0 0.026002442464232445
. O 0 2.8134095941823034e-07

Deficiency B-Disease 1 0.9996480941772461
of I-Disease 0 2.438846102847947e-08
the I-Disease 0 8.184956712398161e-09
ninth I-Disease 0 7.922006517446789e-08
component I-Disease 0 1.4531051029109676e-08
of I-Disease 0 1.6728758656103793e-10
human I-Disease 0 1.8183720085218624e-09
complement I-Disease 0 4.064435188411153e-08
( O 0 1.5982266177161364e-08
C9 O 0 1.4082253301239689e-06
) O 0 1.5018238874731082e-09
is O 0 1.2851998631990824e-10
the O 0 4.608644299519682e-10
most O 0 1.206146515997375e-09
common O 0 9.719135505292797e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.4893019201499555e-08
Japan O 0 3.664956977900147e-07
but O 0 2.352887884526922e-09
is O 0 1.2401395188543773e-10
rare O 0 2.2357474205314531e-10
in O 0 2.7739543995153326e-10
other O 0 1.215040151825164e-10
countries O 0 1.2731040666125182e-09
. O 0 1.6805206115577676e-08

We O 0 9.454547011955583e-08
studied O 0 8.6311322533561e-09
the O 0 7.303309623729604e-10
molecular O 0 1.3280708088814208e-08
basis O 0 5.364939603680341e-09
of O 0 2.3104131940954176e-09
C9 B-Disease 0 0.1248360127210617
deficiency I-Disease 0 0.00020339204638730735
in O 0 3.0073237233807504e-09
four O 0 4.207568959913033e-09
Japanese O 0 4.686343686444161e-07
C9 B-Disease 0 0.023821208626031876
- I-Disease 1 0.8720929622650146
deficient I-Disease 0 0.3371685743331909
patients O 0 7.453044190697256e-07
who O 0 3.49709914360119e-08
had O 0 4.823387484975683e-07
suffered O 0 0.09380731731653214
from O 0 5.465730737341801e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 3.2123880373546854e-06

Direct O 0 2.4834603209455963e-06
sequencing O 0 3.980253040936077e-06
of O 0 5.4908692703747874e-08
amplified O 0 1.3045042578596622e-05
C9 O 0 2.152395245502703e-05
cDNA O 0 2.2835681647848105e-06
and O 0 1.3653991715045777e-08
DNA O 0 1.8557661007889692e-07
revealed O 0 2.1324973431546823e-07
a O 0 3.536850812224657e-08
nonsense O 0 7.300906759155623e-07
substitution O 0 1.2567093676807417e-07
( O 0 3.8398521695626187e-08
CGA O 0 5.69244111829903e-05
- O 0 0.00022943801013752818
- O 0 2.0027689970447682e-05
> O 0 1.4971020618759212e-06
TGA O 0 7.374406322924187e-06
) O 0 8.851467114823208e-09
at O 0 2.2365599150475646e-08
codon O 0 3.1754723295307485e-07
95 O 0 3.474844945117184e-08
in O 0 6.556770237864384e-09
exon O 0 4.895085794487386e-07
4 O 0 1.528757564983607e-08
in O 0 2.381940200635313e-09
the O 0 4.740045245199553e-09
four O 0 2.0703902592345003e-08
C9 B-Disease 0 0.00016097992192953825
- I-Disease 0 0.00037338960100896657
deficient I-Disease 0 0.00015636192983947694
individuals O 0 4.75727475190979e-08
. O 0 8.12628542234961e-08

An O 0 5.846761155225977e-07
allele O 0 2.5826266210060567e-05
- O 0 1.6392313000324066e-06
specific O 0 2.2529796694925608e-08
polymerase O 0 2.061824943666579e-06
chain O 0 2.115984716510866e-05
reaction O 0 5.310434971761424e-07
system O 0 1.28405406485399e-06
designed O 0 1.462056502532505e-06
to O 0 4.575277046114934e-09
detect O 0 3.3385410347364086e-07
exclusively O 0 2.00699634689272e-09
only O 0 1.1956667600454551e-10
one O 0 3.580680543735504e-11
of O 0 1.6591792176279263e-11
the O 0 2.983116809129882e-10
normal O 0 5.369669153765244e-09
and O 0 4.110239926191639e-10
mutant O 0 4.1440294751282636e-08
alleles O 0 2.3931256976084114e-08
indicated O 0 1.3923028063800302e-08
that O 0 1.573609020866229e-10
all O 0 3.5366567313621644e-11
the O 0 2.2040091973707376e-10
four O 0 5.79302938952253e-10
patients O 0 6.335466040674476e-10
were O 0 3.149783767142367e-10
homozygous O 0 1.6409122949312405e-08
for O 0 9.316249854895986e-11
the O 0 9.280800572497583e-10
mutation O 0 3.7911302541715486e-08
in O 0 3.4060156917092854e-09
exon O 0 3.8687443293383694e-07
4 O 0 3.591403796576742e-08
and O 0 1.4090606459404853e-09
that O 0 1.593774556774008e-10
the O 0 1.6348851161751554e-09
parents O 0 4.4966355083886356e-09
of O 0 2.2085371031987933e-10
patient O 0 3.077162702425085e-08
2 O 0 1.2327263654299259e-08
were O 0 1.4287061311790694e-08
heterozygous O 0 1.2280770533834584e-06
. O 0 1.1390622489670932e-07

The O 0 3.555963985490962e-07
common O 0 2.08659926670407e-07
mutation O 0 2.6669463295547757e-06
at O 0 1.8752325559034944e-07
codon O 0 2.4727121399337193e-06
95 O 0 1.2914874503167084e-07
in O 0 1.2871784527135333e-08
exon O 0 1.1522465683810879e-06
4 O 0 1.0474536082938357e-07
might O 0 1.552153960915348e-08
be O 0 4.874703973811734e-10
responsible O 0 2.2011283906664403e-09
for O 0 1.8094138687363426e-10
most O 0 1.5098889916131952e-09
Japanese O 0 1.7352924714941764e-06
C9 B-Disease 0 0.048488739877939224
deficiency I-Disease 0 0.00014323978393804282
. O 0 1.102141844455673e-08
. O 0 6.809803210217069e-08

BRCA1 O 0 0.00046894745901227
required O 0 3.5786791841019294e-07
for O 0 1.5598434544017437e-08
transcription O 0 9.489100193604827e-06
- O 0 0.0018014360684901476
coupled O 0 7.086522236932069e-05
repair O 0 5.0931925215991214e-05
of O 0 1.8457534389781927e-09
oxidative O 0 1.13592432171572e-06
DNA O 0 2.1107757675054017e-06
damage O 0 9.61418390943436e-06
. O 0 3.4399022297293413e-07

The O 0 1.2430235983629245e-05
breast B-Disease 1 0.9999990463256836
and I-Disease 1 0.9997400641441345
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.0007010828703641891
gene O 0 0.0001061854709405452
BRCA1 O 0 0.00015154773427639157
encodes O 0 2.621091198307113e-06
a O 0 1.1909380646102363e-06
zinc O 0 0.0478508360683918
finger O 0 0.00020123504509683698
protein O 0 1.6796435886590189e-07
of O 0 5.977306982707375e-10
unknown O 0 1.1445127512388353e-08
function O 0 5.30287387334738e-08
. O 0 5.9265456542334505e-08

Association O 0 1.0333362752135145e-06
of O 0 3.125940839510122e-09
the O 0 9.491945895945264e-09
BRCA1 O 0 1.0553794709267095e-06
protein O 0 2.8819073349950486e-08
with O 0 6.82632506077141e-10
the O 0 3.2847113917711113e-09
DNA O 0 6.829424137322349e-07
repair O 0 0.0001621726987650618
protein O 0 6.115794235483918e-07
Rad51 O 0 8.362316293641925e-06
and O 0 3.779468293885202e-09
changes O 0 5.2462811872544535e-09
in O 0 6.013718412134494e-10
the O 0 4.2461517635317136e-10
phosphorylation O 0 1.9962463682077214e-08
and O 0 6.748829828318037e-10
cellular O 0 2.2661460263861954e-08
localization O 0 2.045621627644323e-08
of O 0 1.1571614499938931e-10
the O 0 6.020328680023113e-10
protein O 0 7.1630243958509254e-09
after O 0 2.9794617883993624e-09
exposure O 0 2.8494731907358073e-08
to O 0 1.6960602922111434e-09
DNA O 0 1.2776749258591735e-07
- O 0 2.075704287562985e-06
damaging O 0 9.395230335940141e-07
agents O 0 3.07826617529372e-08
are O 0 3.089886402296571e-10
consistent O 0 3.0068132428340277e-09
with O 0 1.236205166010862e-10
a O 0 1.2943518479247018e-09
role O 0 1.019457962492254e-09
for O 0 5.517382106745572e-10
BRCA1 O 0 2.3462928311346332e-07
in O 0 5.749189124770737e-09
DNA O 0 1.7088963204514585e-06
repair O 0 0.00044256047112867236
. O 0 2.872754123472987e-07

Here O 0 4.951588152835029e-07
, O 0 2.792375886073728e-09
it O 0 3.7408032227403964e-10
is O 0 7.204699337126641e-11
shown O 0 5.610599762562174e-10
that O 0 1.9487894631353697e-10
mouse O 0 9.297744441028044e-07
embryonic O 0 3.038002489574865e-07
stem O 0 6.086561938900559e-07
cells O 0 3.50904997503676e-07
deficient B-Disease 0 2.1356509023462422e-06
in I-Disease 0 1.3417587929609454e-08
BRCA1 I-Disease 0 3.6548560728988377e-06
are O 0 8.676617757608085e-10
defective O 0 8.126127681862272e-07
in O 0 2.180194913492528e-09
the O 0 6.435407207128208e-10
ability O 0 2.552710709480266e-09
to O 0 2.851862634933866e-10
carry O 0 3.0161586561661125e-09
out O 0 1.7818211350828506e-09
transcription O 0 4.558980890578823e-07
- O 0 4.849756805924699e-06
coupled O 0 3.1422794108948437e-06
repair O 0 2.859796495613409e-06
of O 0 6.040549171970611e-10
oxidative O 0 1.4954824223423202e-07
DNA O 0 2.8782221761503024e-07
damage O 0 4.153868758294266e-06
, O 0 4.0480161445088925e-09
and O 0 2.8146096564540812e-09
are O 0 1.1806492450361361e-09
hypersensitive O 0 2.0896390196867287e-05
to O 0 2.8450200417751148e-08
ionizing O 0 3.7815291307197185e-06
radiation O 0 3.4729382605291903e-06
and O 0 1.2370319879551062e-08
hydrogen O 0 3.2589184684184147e-07
peroxide O 0 1.6374646293115802e-05
. O 0 1.5652116758246848e-07

These O 0 9.429118819070936e-08
results O 0 2.0351031082554982e-07
suggest O 0 8.115102190231482e-08
that O 0 4.883360826823946e-09
BRCA1 O 0 2.2696426640322898e-06
participates O 0 5.146833714775312e-08
, O 0 7.950335945139386e-10
directly O 0 7.557685144377047e-09
or O 0 4.966529854044666e-09
indirectly O 0 8.590826716670108e-09
, O 0 3.005991844329259e-10
in O 0 1.8550356806201762e-09
transcription O 0 2.0066161141585326e-06
- O 0 9.59054013947025e-05
coupled O 0 2.402458449068945e-05
repair O 0 9.830975614022464e-06
of O 0 1.579051667199849e-09
oxidative O 0 7.138027626751864e-07
DNA O 0 5.223598691372899e-07
damage O 0 2.096399839501828e-06
. O 0 2.3584695085787644e-08
. O 0 1.6877747555099631e-07

Truncation O 0 0.00039332726737484336
mutations O 0 0.00012923884787596762
in O 0 1.0696601293602725e-07
the O 0 1.584555597844428e-08
transactivation O 0 4.230661488691112e-06
region O 0 2.1508295589001136e-08
of O 0 2.190498671339469e-09
PAX6 O 0 6.4614537222951185e-06
result O 0 2.8656826245310185e-08
in O 0 1.7013000785937038e-08
dominant O 0 8.419074583798647e-05
- O 0 9.570304246153682e-05
negative O 0 8.439208613708615e-06
mutants O 0 5.663532192556886e-06
. O 0 3.0633660230705573e-07

PAX6 O 0 0.0012070263037458062
is O 0 1.8314784711037646e-07
a O 0 1.4789302227313783e-08
transcription O 0 1.768371333810137e-07
factor O 0 1.5636556494058595e-09
with O 0 7.362088716433846e-11
two O 0 4.920964746801815e-10
DNA O 0 9.754293728292396e-08
- O 0 6.904031693011348e-07
binding O 0 6.080087473492313e-07
domains O 0 2.410327510915522e-07
( O 0 1.3543291821349612e-08
paired O 0 3.325899342598859e-07
box O 0 7.210041076177731e-06
and O 0 9.139726309115304e-09
homeobox O 0 2.7055625650973525e-07
) O 0 2.594057635363356e-09
and O 0 1.1477124806091865e-09
a O 0 1.8875079277336226e-08
proline O 0 0.00011289971735095605
- O 0 8.826855264487676e-06
serine O 0 4.239023110130802e-05
- O 0 3.122173802694306e-05
threonine O 0 0.0001293570821871981
( O 0 7.175827221317377e-08
PST O 0 2.379150282649789e-05
) O 0 2.9648148824890086e-08
- O 0 6.604732334380969e-07
rich O 0 7.213577646325575e-08
transactivation O 0 8.596191946708132e-06
domain O 0 1.0842519486686797e-06
. O 0 1.9839978904201416e-07

PAX6 O 0 0.015790428966283798
regulates O 0 0.000665197498165071
eye O 0 0.00021241087233647704
development O 0 3.514310265018139e-08
in O 0 1.0690478724484365e-08
animals O 0 5.9861644530201374e-09
ranging O 0 6.611486025320801e-09
from O 0 2.3189248299360088e-09
jellyfish O 0 2.492437545242865e-08
to O 0 1.094221602215839e-09
Drosophila O 0 1.57940789335953e-08
to O 0 2.1533734795298187e-09
humans O 0 2.645166929937659e-08
. O 0 3.487939181923139e-08

Heterozygous O 0 0.000887551112100482
mutations O 0 6.915796984685585e-05
in O 0 6.970135757455864e-08
the O 0 6.1184279864789914e-09
human O 0 1.190434062436907e-08
PAX6 O 0 6.121423666627379e-06
gene O 0 3.3353964568050287e-07
result O 0 5.5804525445068975e-09
in O 0 7.794287437690173e-10
various O 0 6.488020676265194e-10
phenotypes O 0 8.834165043936082e-08
, O 0 6.37269736980528e-10
including O 0 2.466393311806314e-09
aniridia B-Disease 1 1.0
, O 0 1.5811129969733884e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999998807907104
, O 0 1.2632918355848233e-07
autosomal B-Disease 0 0.3385371267795563
dominant I-Disease 0 0.04338088259100914
keratitis I-Disease 1 0.6776203513145447
, O 0 1.8204625007456343e-07
and O 0 2.9594684747280553e-07
familial B-Disease 1 0.7573644518852234
foveal I-Disease 1 0.9999351501464844
dysplasia I-Disease 1 0.9999990463256836
. O 0 7.158784683269914e-06

It O 0 1.2854859221533843e-07
is O 0 1.6582696327205326e-09
believed O 0 1.1141167988171219e-09
that O 0 5.352668655533854e-11
the O 0 7.183570960300756e-10
mutated O 0 2.1824517659752019e-07
allele O 0 1.7605736957193585e-07
of O 0 8.158378417277845e-10
PAX6 O 0 2.0681327441707253e-06
produces O 0 4.402504671929819e-08
an O 0 7.314225336507718e-10
inactive O 0 6.039529409918032e-08
protein O 0 6.80732270552653e-08
and O 0 4.2745970318947e-08
aniridia B-Disease 1 1.0
is O 0 9.477274076630238e-09
caused O 0 4.601095326961513e-08
due O 0 1.4344293752799331e-08
to O 0 6.155651099959414e-09
genetic O 0 6.494242370536085e-07
haploinsufficiency O 0 4.077428820892237e-05
. O 0 1.9192813738300174e-07

However O 0 3.1351504503618344e-07
, O 0 5.5552624722565724e-09
several O 0 2.0095205499615076e-09
truncation O 0 3.9717597246635705e-06
mutations O 0 3.962562459491892e-06
have O 0 4.4225161310862404e-09
been O 0 1.1880857408996803e-09
found O 0 2.4338446813487735e-09
to O 0 1.3813352683911262e-09
occur O 0 2.1802282201832668e-09
in O 0 1.2084629963382554e-09
the O 0 1.2541347516048518e-08
C O 0 0.00024873853544704616
- O 0 4.415036073623924e-06
terminal O 0 4.4376477603691455e-07
half O 0 4.426364164089591e-09
of O 0 3.3845656832731663e-10
PAX6 O 0 1.1878731811520993e-06
in O 0 5.4878510624689625e-09
patients O 0 1.3204856763593398e-08
with O 0 4.686368182404976e-09
Aniridia B-Disease 1 0.9999998807907104
resulting O 0 5.009869141758827e-08
in O 0 1.8135954960030176e-09
mutant O 0 4.1398742212095385e-08
proteins O 0 4.196964997760233e-09
that O 0 1.3051898450910926e-10
retain O 0 5.551946902215832e-09
the O 0 7.842932969737149e-10
DNA O 0 3.8026012560976596e-08
- O 0 6.594637369516931e-08
binding O 0 3.933266867761631e-08
domains O 0 2.941765053776635e-08
but O 0 1.622471823559124e-09
have O 0 5.495326971249881e-10
lost O 0 4.7307509021266014e-09
most O 0 1.0541421902043879e-10
of O 0 1.4601271580705344e-10
the O 0 5.146575610126547e-09
transactivation O 0 5.862612852070015e-06
domain O 0 6.39110794509179e-07
. O 0 1.2011886951768247e-07

It O 0 2.3910456548037473e-07
is O 0 3.540318038730561e-09
not O 0 1.7878254432446283e-10
clear O 0 6.898971394164732e-10
whether O 0 4.699792777174139e-10
such O 0 2.6367469319055203e-10
mutants O 0 1.3227801787252247e-07
really O 0 3.4364127543540235e-08
behave O 0 1.9912040016834e-08
as O 0 1.4834778960803874e-09
loss O 0 1.8961825887231498e-08
- O 0 4.741232118021799e-08
of O 0 7.8786921431373e-10
- O 0 3.05463771610448e-07
function O 0 2.430709855616442e-08
mutants O 0 7.6932984427458e-08
as O 0 1.5309190581902499e-09
predicted O 0 5.336020691970589e-08
by O 0 3.1508307074545883e-09
haploinsufficiency O 0 6.497044068964897e-06
. O 0 1.377080280917653e-07

Contrary O 0 1.1351445436957874e-06
to O 0 1.5349547410892228e-08
this O 0 2.8535276919150476e-10
theory O 0 6.26392548941368e-10
, O 0 8.767010034604894e-11
our O 0 2.2711935110386605e-10
data O 0 9.398931410942168e-09
showed O 0 1.110947156490738e-08
that O 0 9.367565750872942e-11
these O 0 1.6080525799821999e-10
mutants O 0 7.0051586753550055e-09
are O 0 1.1928262544369517e-10
dominant O 0 1.1032148705680811e-07
- O 0 4.409879750255641e-07
negative O 0 1.8330335649352492e-07
in O 0 9.149022872634305e-09
transient O 0 1.8704315607465105e-07
transfection O 0 2.1504170035768766e-06
assays O 0 9.827992926148e-07
when O 0 1.865361376474084e-08
they O 0 5.326944441108594e-10
are O 0 1.2721591835518353e-10
coexpressed O 0 4.063629077677433e-08
with O 0 8.070300538953745e-10
wild O 0 2.8638365279221034e-07
- O 0 0.0001747446513036266
type O 0 0.00013557326747104526
PAX6 O 0 0.0003086721699219197
. O 0 5.549069896915171e-07

We O 0 1.7072105151783035e-07
found O 0 1.589253173506222e-08
that O 0 6.599714663657608e-10
the O 0 5.107693379358125e-09
dominant O 0 2.669312834768789e-06
- O 0 2.707937028390006e-06
negative O 0 5.453372864394623e-07
effects O 0 9.580017490407045e-08
result O 0 2.194551207423956e-09
from O 0 8.173424159707565e-10
the O 0 4.6408052400970234e-10
enhanced O 0 1.9083882918380368e-08
DNA O 0 3.017270699956498e-08
binding O 0 2.910322116633779e-08
ability O 0 7.680100111429056e-09
of O 0 3.2385807924306675e-10
these O 0 2.0131074585094666e-09
mutants O 0 2.3612359711933095e-07
. O 0 3.6175908491031805e-08

Kinetic O 0 5.92848346059327e-06
studies O 0 1.675451954952223e-07
of O 0 1.826004236704648e-09
binding O 0 1.2906366464449093e-07
and O 0 1.0269604722168424e-08
dissociation O 0 4.835869162889139e-07
revealed O 0 6.330205337690131e-08
that O 0 4.953264465257234e-10
various O 0 1.8074141072688121e-09
truncation O 0 6.964553449506639e-07
mutants O 0 1.9404835427394573e-07
have O 0 1.9010559793031234e-09
3 O 0 1.882574984790608e-08
- O 0 5.582839435192e-07
5 O 0 9.869933847994616e-08
- O 0 8.336527912433667e-07
fold O 0 3.679490419017384e-07
higher O 0 9.824608682151847e-09
affinity O 0 3.417071070543898e-09
to O 0 2.26345692189156e-10
various O 0 2.251847597278811e-10
DNA O 0 1.498345447714655e-08
- O 0 3.201574116928896e-08
binding O 0 1.1370495656137791e-08
sites O 0 7.1778778476527805e-09
when O 0 1.3467450488136024e-09
compared O 0 2.9599429574034275e-09
with O 0 1.4087374322624413e-10
the O 0 1.6084124032644809e-09
wild O 0 7.774399080062722e-08
- O 0 1.4005101547809318e-05
type O 0 2.3858710846980102e-05
PAX6 O 0 0.00014349515549838543
. O 0 4.334225707225414e-07

These O 0 1.4431677186621528e-07
results O 0 3.7753707715637574e-08
provide O 0 1.891846457269253e-09
a O 0 5.1496393815853025e-09
new O 0 1.8247796162995655e-08
insight O 0 7.062471052421415e-09
into O 0 4.0454822824997905e-10
the O 0 4.3928208293131377e-10
role O 0 6.202200419913595e-10
of O 0 1.8089962861012054e-10
mutant O 0 1.1611925998522565e-07
PAX6 O 0 4.2524802665866446e-06
in O 0 3.268439030534864e-08
causing O 0 2.9489610824384727e-06
aniridia B-Disease 1 0.9999998807907104
. O 0 1.1432869939653756e-07
. O 0 1.4100756118295976e-07

Reversal O 0 0.00013366565690375865
of O 0 9.043451996149088e-07
severe O 1 0.9961786270141602
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
and O 0 8.203453944588546e-06
excellent O 0 1.8319935861654812e-06
neuropsychologic O 0 0.0001454205485060811
outcome O 0 2.1821894335971592e-07
in O 0 2.586875247345688e-08
very B-Disease 0 3.1352402629636344e-07
- I-Disease 0 6.44606479909271e-05
long I-Disease 0 1.4991651369200554e-06
- I-Disease 0 4.070365321240388e-06
chain I-Disease 0 1.2578434507304337e-05
acyl I-Disease 0 3.430575816310011e-06
- I-Disease 0 1.0922577757810359e-06
coenzyme I-Disease 0 1.2747213986585848e-06
A I-Disease 0 8.569292049287469e-07
dehydrogenase I-Disease 0 0.0026927024591714144
deficiency I-Disease 0 0.007182874716818333
. O 0 2.991079384173645e-07

Very B-Disease 0 1.1516004633449484e-05
- I-Disease 0 0.00020861955999862403
long I-Disease 0 2.935428483397118e-06
- I-Disease 0 1.3296646102389786e-05
chain I-Disease 0 1.837314630392939e-05
acyl I-Disease 0 4.0773238652036525e-06
- I-Disease 0 1.0825698382177507e-06
coenzyme I-Disease 0 4.778568154506502e-07
A I-Disease 0 9.902479547463372e-08
dehydrogenase I-Disease 0 6.842685252195224e-06
( I-Disease 0 5.9476541025560437e-08
VLCAD I-Disease 0 0.00016420643078163266
) I-Disease 0 1.9407241325097857e-07
deficiency I-Disease 0 1.6840325770317577e-05
is O 0 9.363355646385685e-10
a O 0 6.364648896806102e-08
disorder O 0 7.237460522446781e-05
of O 0 2.5482693732925554e-09
fatty O 0 3.4624911222636e-06
acid O 0 4.673364912832767e-07
beta O 0 4.0768345144215345e-08
oxidation O 0 9.148834578809328e-08
that O 0 1.5398509134456617e-09
reportedly O 0 7.306311999855097e-08
has O 0 5.1926818400716e-09
high O 0 1.162419067668452e-07
rates O 0 5.137259904586244e-06
of O 0 6.751291969919748e-09
morbidity O 0 0.004241802729666233
and O 0 1.0165094721514834e-07
mortality O 0 3.6325025121186627e-06
. O 0 1.502378239592872e-07

We O 0 2.1901662705658964e-07
describe O 0 4.0672116341511355e-08
the O 0 2.0914368015212403e-09
outcome O 0 3.5115814700503734e-09
of O 0 2.2603161009548955e-10
a O 0 7.0309265076673455e-09
5 O 0 3.4040692042935916e-08
- O 0 2.1681375983462203e-07
year O 0 1.480471123471716e-08
- O 0 1.0319772627553903e-06
old O 0 4.223014457238605e-06
girl O 0 1.4509591892419849e-05
with O 0 1.9195853440123756e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 6.396154272891863e-09
was O 0 1.0664451544073472e-08
first O 0 1.4746226462136747e-09
seen O 0 1.4477713250471425e-08
at O 0 1.922328962677966e-08
5 O 0 2.77286593686199e-09
months O 0 1.2832434004295123e-09
of O 0 1.106258140648464e-10
age O 0 5.278933290497889e-09
with O 0 1.1477043315721858e-08
severe O 1 0.5453723669052124
hypertrophic B-Disease 1 0.9999990463256836
cardiomyopathy I-Disease 1 1.0
, O 0 0.0005969406920485198
hepatomegaly B-Disease 1 1.0
, O 0 6.783568824175745e-05
encephalopathy B-Disease 1 0.9999642372131348
, O 0 4.5856058505933106e-08
and O 0 1.4869834785713465e-07
hypotonia B-Disease 1 0.9923692941665649
. O 0 6.456252208408841e-07

Biochemical O 0 0.00024832121562212706
studies O 0 1.5608306057401933e-05
indicated O 1 0.996075451374054
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 4.619787432602607e-06
by O 0 8.710016707880186e-09
a O 0 9.397106026654001e-08
stable O 0 1.0666327398212161e-05
yet O 0 7.110362076900856e-08
inactive O 0 1.5211072650345159e-06
enzyme O 0 1.658013388805557e-06
. O 0 2.0608918305242696e-07

Molecular O 0 2.117559233738575e-05
genetic O 0 4.118930519325659e-06
analysis O 0 1.5961587962465273e-07
of O 0 4.101377015786056e-09
her O 0 3.185961929830228e-07
VLCAD O 0 7.673039362998679e-05
gene O 0 3.5865825793734984e-06
revealed O 0 3.635156531345274e-07
a O 0 4.238000528289376e-08
T1372C O 0 2.158168399546412e-06
( O 0 2.5931885971886004e-08
F458L O 0 1.2457533102860907e-06
) O 0 2.14601882930765e-08
missense O 0 9.501650310994592e-06
mutation O 0 3.2062541777122533e-06
and O 0 3.8866346585564315e-08
a O 0 9.870797157418565e-07
1668 O 0 0.4233773350715637
ACAG O 0 0.0016773559618741274
1669 O 0 0.00021366332657635212
splice O 0 0.00031585764372721314
site O 0 9.704024705570191e-06
mutation O 0 4.1715873521752656e-05
. O 0 7.588736821162456e-07

After O 0 5.388076260715025e-07
initial O 0 3.108516466454603e-07
treatment O 0 6.539710994957204e-08
with O 0 7.845256000393874e-09
intravenous O 0 3.1250449410435976e-06
glucose O 0 7.37923983251676e-05
and O 0 1.7554292242039082e-08
carnitine O 0 6.264862690841255e-07
, O 0 6.82637779636508e-10
the O 0 2.409769495059777e-09
patient O 0 1.3191997538797295e-07
has O 0 3.951303728655375e-09
thrived O 0 8.257971728653501e-08
on O 0 1.0324400001593403e-08
a O 0 2.3742845911556287e-08
low O 0 8.299102773889899e-05
- O 0 4.602839544531889e-05
fat O 0 5.540892016142607e-05
diet O 0 4.4218353423275403e-07
supplemented O 0 3.6705806394365936e-08
with O 0 1.89324711463712e-09
medium O 0 3.791416247622692e-07
- O 0 1.259050122826011e-06
chain O 0 5.069357939646579e-06
triglyceride O 0 2.2880763026478235e-06
oil O 0 7.329412454737394e-08
and O 0 1.7222765436031295e-09
carnitine O 0 4.166865323895763e-07
and O 0 1.935953397591561e-09
avoidance O 0 1.0952833662258854e-07
of O 0 4.707394030134537e-09
fasting O 0 2.258357562823221e-05
. O 0 1.4360094269250112e-07

Her O 0 6.03429289185442e-05
ventricular O 1 0.5803762078285217
hypertrophy O 0 0.0016880767652764916
resolved O 0 1.1040565368602984e-06
significantly O 0 4.05149478410749e-07
over O 0 5.988996409911351e-09
1 O 0 6.202605540295281e-09
year O 0 1.1105736330563332e-09
, O 0 2.1916930770249365e-10
and O 0 1.8549577429638475e-09
cognitively O 0 1.3658637953994912e-06
, O 0 5.818132087220818e-10
she O 0 1.130690652217936e-09
is O 0 9.751509322253327e-11
in O 0 4.977907530623327e-10
the O 0 1.131862270575823e-09
superior O 0 1.2030109353133867e-08
range O 0 1.753297595996628e-08
for O 0 3.912098645031392e-09
age O 0 4.9117421241362536e-08
. O 0 2.6794989338441155e-08

Clinical O 0 1.93052546819672e-05
recognition O 0 1.4914273833710467e-06
of O 0 7.746423307253281e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 7.920432310015713e-09
important O 0 3.3365063489831925e-10
because O 0 5.019888393853478e-10
it O 0 6.0342503216404e-10
is O 0 6.506296196251427e-11
one O 0 1.865806814604909e-11
of O 0 7.92023911733164e-12
the O 0 4.2701597813277203e-10
few O 0 2.9407536406012014e-09
directly O 0 8.290956543532957e-08
treatable O 0 2.709874479478458e-06
causes O 0 3.888013466735174e-08
of O 0 1.3609635196587533e-08
cardiomyopathy B-Disease 1 1.0
in O 0 5.337761876944569e-07
children O 0 2.655474240498279e-08
. O 0 5.492322152633733e-09
. O 0 7.259596657149814e-08

Cloning O 0 5.257581051409943e-06
of O 0 9.18875553423959e-09
a O 0 2.0481280671447166e-08
novel O 0 3.4849335861508735e-08
member O 0 2.868141946166247e-09
of O 0 2.5670887637829765e-10
the O 0 7.814699998220931e-09
low O 0 1.3868629139324185e-05
- O 0 3.893360371876042e-06
density O 0 2.584809237760055e-07
lipoprotein O 0 5.664974742103368e-05
receptor O 0 4.368288045952795e-06
family O 0 1.138668267230969e-06
. O 0 3.3872561289172154e-07

A O 0 1.470723987040401e-06
gene O 0 4.69066389996442e-06
encoding O 0 4.0265996403832105e-07
a O 0 4.8123879992090224e-08
novel O 0 1.3411657562301116e-07
transmembrane O 0 2.621768260269164e-07
protein O 0 1.0262070304634108e-07
was O 0 1.7021474008060977e-08
identified O 0 1.4525667335618664e-09
by O 0 3.722908648029488e-10
DNA O 0 1.2026323936709105e-08
sequence O 0 9.321804661510669e-09
analysis O 0 3.699537121093499e-09
within O 0 8.75718830783967e-10
the O 0 9.16287046237585e-09
insulin B-Disease 1 0.939524233341217
- I-Disease 1 0.9998233914375305
dependent I-Disease 1 0.9975836277008057
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 6.551821911671141e-07
IDDM B-Disease 0 3.304516940261237e-05
) O 0 3.801006087655878e-08
locus O 0 1.1665397323668003e-06
IDDM4 O 0 8.072236596490256e-06
on O 0 1.1822771739389282e-07
chromosome O 0 8.448671906080563e-06
11q13 O 0 1.4398711755347904e-05
. O 0 3.245043274091586e-07

Based O 0 2.754219394773827e-07
on O 0 3.8078415087738904e-08
its O 0 2.4524297259631567e-08
chromosomal O 0 2.2325624740915373e-05
position O 0 9.598599604032643e-08
, O 0 1.5978286749263049e-10
this O 0 1.2186747444520307e-10
gene O 0 1.3968513457029985e-08
is O 0 2.9880137253357475e-10
a O 0 7.898267595507491e-10
candidate O 0 4.869836978116382e-09
for O 0 3.482890087447288e-10
conferring O 0 3.7587870593824846e-08
susceptibility O 0 1.19959668154479e-06
to O 0 3.329047331135371e-07
diabetes B-Disease 0 0.000651845708489418
. O 0 2.4661412112436665e-07

The O 0 4.778851234732429e-07
gene O 0 4.8479951146873645e-06
, O 0 2.545530897180015e-08
termed O 0 1.3535398011299549e-06
low O 0 0.0001621161209186539
- O 0 1.971524216060061e-05
density O 0 7.660863161618181e-07
lipoprotein O 0 3.735247446456924e-05
receptor O 0 9.112380894293892e-07
related O 0 1.343285447319431e-07
protein O 0 7.635786687387736e-07
5 O 0 1.9930017458591465e-07
( O 0 2.5234244915850468e-08
LRP5 O 0 3.278408712503733e-06
) O 0 1.0618836920883723e-09
, O 0 1.5766402072792118e-10
encodes O 0 5.1383755028666656e-09
a O 0 5.429546146018538e-09
protein O 0 4.807635534120891e-08
of O 0 1.972860541599175e-09
1615 O 0 6.800771370762959e-05
amino O 0 6.947267650048161e-08
acids O 0 1.4320947983037513e-08
that O 0 1.6974704974970223e-10
contains O 0 1.0748231193957736e-09
conserved O 0 2.9960123271166594e-08
modules O 0 1.8155379422069018e-08
which O 0 1.0058566202175712e-09
are O 0 4.6244209850332396e-11
characteristic O 0 1.8080243968654486e-09
of O 0 2.0666481026498928e-10
the O 0 7.52355600042165e-09
low O 0 0.0005155833205208182
- O 0 0.00010599922825349495
density O 0 9.7937379450741e-07
lipoprotein O 0 0.000343399791745469
( O 0 1.7829752607667615e-07
LDL O 0 7.07376966602169e-05
) O 0 3.981764606919569e-08
receptor O 0 1.0741432561189868e-06
family O 0 5.090967647447542e-07
. O 0 1.4658132840850158e-07

These O 0 2.7678061087499373e-07
modules O 0 2.3671319127060997e-07
include O 0 3.5706042567085206e-09
a O 0 6.14085227113037e-09
putative O 0 3.281100475760468e-07
signal O 0 8.499914088133664e-07
peptide O 0 3.088994446898141e-07
for O 0 9.151513435945446e-10
protein O 0 1.1784045739204885e-08
export O 0 3.847453022842728e-09
, O 0 1.3020517997119896e-10
four O 0 5.47700440556298e-10
epidermal O 0 1.3626575423586473e-07
growth O 0 7.279562908024673e-08
factor O 0 3.7975279809643325e-08
( O 0 2.298511603271436e-08
EGF O 0 1.1848241001644055e-06
) O 0 3.215488764141128e-09
repeats O 0 3.911026738023793e-07
with O 0 2.6095259286762484e-09
associated O 0 7.38808125788637e-08
spacer O 0 4.499822352954652e-06
domains O 0 1.6066447017237806e-07
, O 0 2.02792160841625e-09
three O 0 5.432653882309069e-09
LDL O 0 0.000302579952403903
- O 0 2.2039326722733676e-05
receptor O 0 1.6795165720395744e-06
( O 0 4.505385930997363e-08
LDLR O 0 9.373328794026747e-06
) O 0 9.808974077429866e-09
repeats O 0 6.178250373523042e-07
, O 0 7.42137740150639e-10
a O 0 2.3951061134397378e-09
single O 0 4.28732676027721e-08
transmembrane O 0 8.293898190459004e-08
spanning O 0 3.404302972853657e-08
domain O 0 5.581988560265927e-08
, O 0 4.427307687127069e-10
and O 0 3.3012345634908513e-10
a O 0 5.280031523113848e-09
cytoplasmic O 0 6.194804882397875e-07
domain O 0 5.003366254641151e-07
. O 0 1.8096854148552666e-07

The O 0 1.618303997474868e-07
encoded O 0 5.178077344680787e-07
protein O 0 3.6425410598894814e-07
has O 0 3.551653637856589e-09
a O 0 1.7483443581767233e-09
unique O 0 5.9386928707994e-10
organization O 0 1.4477070653384772e-09
of O 0 7.469390661540842e-10
EGF O 0 1.7896443296194775e-06
and O 0 1.040378716510304e-08
LDLR O 0 1.7171369108837098e-05
repeats O 0 4.763281140185427e-06
; O 0 5.1024939828892e-09
therefore O 0 1.1798657606476581e-09
, O 0 5.022579574465169e-10
LRP5 O 0 1.6027315723476931e-06
likely O 0 1.1460461912804476e-08
represents O 0 1.0803870020836825e-09
a O 0 1.3639669393938902e-09
new O 0 6.606620139848474e-09
category O 0 5.814995152064739e-09
of O 0 1.185934406233713e-10
the O 0 6.207458103091312e-09
LDLR O 0 1.472939857194433e-05
family O 0 1.3831729006597016e-07
. O 0 6.109195282988367e-08

Both O 0 3.196150544226839e-07
human O 0 1.0398157712643297e-07
and O 0 3.9522248584944464e-08
mouse O 0 2.6209329007542692e-05
LRP5 O 0 9.039323776960373e-05
cDNAs O 0 1.320636442869727e-06
have O 0 2.787533315284918e-09
been O 0 1.0360533542197459e-09
isolated O 0 1.5599237457308845e-08
and O 0 4.6412834686648807e-10
the O 0 8.19166845467123e-10
encoded O 0 3.1930241561894945e-08
mature O 0 1.270465599390036e-08
proteins O 0 2.511117536130314e-09
are O 0 6.887266451593987e-11
95 O 0 5.3593964821629925e-09
% O 0 3.1544009071460266e-10
identical O 0 1.555520690033063e-08
, O 0 2.7604216135124204e-10
indicating O 0 1.686377437692954e-08
a O 0 5.694588800508882e-09
high O 0 5.0720480260224576e-08
degree O 0 3.6028944272459285e-09
of O 0 3.0024735475642217e-10
evolutionary O 0 1.3100246221142697e-08
conservation O 0 4.460212643664363e-09
. O 0 1.8578506510991133e-09
. O 0 3.560798589319347e-08

The O 0 1.2343354001131956e-06
APC B-Disease 0 4.737178187497193e-06
variants O 0 5.309340735948354e-07
I1307K O 0 1.0395673371021985e-06
and O 0 3.4655833758279186e-09
E1317Q O 0 2.9330706752261904e-07
are O 0 1.3156354894405808e-09
associated O 0 8.412656029577192e-07
with O 1 0.9999520778656006
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.1068589123606216e-06
but O 0 7.509134647420979e-09
not O 0 1.2225983558877829e-09
always O 0 5.207864695044861e-10
with O 0 9.572661413548289e-11
a O 0 5.4452273801075535e-09
family O 0 2.105281815545368e-08
history O 0 2.745475313759016e-08
. O 0 7.915119226709066e-08

Classical O 0 0.0743851363658905
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.23299983143806458
FAP B-Disease 0 0.00021736568305641413
) O 0 6.168017563368267e-08
is O 0 1.4525501912387995e-09
a O 0 1.2397340931613599e-08
high O 0 3.983822534792125e-05
- O 1 0.9957692623138428
penetrance O 1 0.9997164607048035
autosomal B-Disease 1 0.9999991655349731
dominant I-Disease 1 0.9999779462814331
disease I-Disease 1 0.9772366285324097
that O 0 3.3594647064205674e-09
predisposes O 0 1.9769001369240868e-07
to O 0 8.329179568278278e-10
hundreds O 0 5.503571487430747e-10
or O 0 1.015338146892475e-09
thousands O 0 1.4319136987239744e-09
of O 0 7.2265498829438e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.4470691680908203
carcinoma I-Disease 1 1.0
and O 0 2.8355394476875517e-08
that O 0 1.0697285279803737e-09
results O 0 5.77236605181497e-08
from O 0 9.561120783985189e-09
truncating O 0 2.3378192963718902e-06
mutations O 0 4.6843510403959954e-07
in O 0 4.953682353203703e-09
the O 0 7.946034941141988e-09
APC B-Disease 0 1.6359018673028913e-06
gene O 0 1.9741787582461257e-06
. O 0 2.5944706294467323e-07

A O 0 2.3861373392719543e-06
variant O 0 3.908962753484957e-05
of O 0 5.41399600706427e-08
FAP B-Disease 0 4.377810182631947e-05
is O 0 5.078408094050246e-07
attenuated B-Disease 1 0.9993957281112671
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
, O 0 1.78944461026731e-07
which O 0 6.175349120951523e-09
results O 0 3.956448679787172e-08
from O 0 6.573361410744383e-09
germ O 0 0.00012778221571352333
- O 0 0.00031792130903340876
line O 0 0.0003973022976424545
mutations O 0 8.985663271232625e-07
in O 0 7.321933725989993e-09
the O 0 3.755804112159922e-09
5 O 0 9.499135700252737e-09
and O 0 2.3112185776330563e-10
3 O 0 7.163349358130233e-10
regions O 0 4.84572548753448e-10
of O 0 1.77914419308145e-10
the O 0 1.7617349357124112e-08
APC B-Disease 0 1.6389782331316383e-06
gene O 0 1.987585847018636e-06
. O 0 1.860178144852398e-07

Attenuated B-Disease 1 0.9999983310699463
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.9995137453079224
have O 0 6.720665624015965e-07
" O 0 6.668351915095627e-08
multiple O 0 1.0951670446956996e-05
" O 1 0.9560813307762146
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 3.897354474702297e-07
typically O 0 3.349159527488155e-08
fewer O 0 6.9771961541675864e-09
than O 0 1.7720263034703976e-09
100 O 0 3.9715684074792534e-09
) O 0 4.188685509554091e-10
without O 0 7.728249706850931e-10
the O 0 7.516499422877132e-09
florid O 0 5.3395822760649025e-05
phenotype O 0 2.467870899636182e-06
of O 0 4.344063775363338e-09
classical O 0 4.508308677486639e-07
FAP B-Disease 0 1.1811939657491166e-05
. O 0 2.2208917016541818e-07

Another O 0 2.7333516072758357e-07
group O 0 1.4701161177299582e-08
of O 0 5.181460260850201e-10
patients O 0 4.171108347605923e-09
with O 0 1.7593567713802827e-09
multiple O 0 4.226178589306073e-07
adenomas B-Disease 0 7.702012226218358e-06
has O 0 1.3462063463975937e-08
no O 0 5.092965160713447e-09
mutations O 0 1.0495173796698509e-07
in O 0 2.512871244420012e-09
the O 0 7.991449280098095e-09
APC B-Disease 0 1.8808994184382755e-07
gene O 0 4.586865642863813e-08
, O 0 3.206765686325497e-10
and O 0 3.262064507403295e-10
their O 0 6.031572574727306e-09
phenotype O 0 1.5006041849119356e-06
probably O 0 2.776900487333478e-08
results O 0 1.4089297728503425e-08
from O 0 6.815006892146869e-10
variation O 0 1.5121663921036088e-08
at O 0 5.156364935032798e-08
a O 0 1.1977153491216086e-08
locus O 0 8.555363706364005e-08
, O 0 9.045999505019608e-10
or O 0 1.874948640789853e-09
loci O 0 8.009333640757177e-09
, O 0 2.9660052192070907e-10
elsewhere O 0 2.645534014078521e-09
in O 0 7.576690941313302e-10
the O 0 3.892909550273771e-09
genome O 0 2.0563489044889138e-07
. O 0 5.339319386621355e-08

Recently O 0 6.586154540855205e-06
, O 0 9.529587785550575e-09
however O 0 2.047822356132656e-09
, O 0 1.972152302576191e-10
a O 0 1.3833285628095382e-09
missense O 0 1.4237016330298502e-06
variant O 0 4.889948286290746e-06
of O 0 2.2393773946305373e-08
APC B-Disease 0 3.931807441404089e-06
( O 0 1.8871912033091576e-08
I1307K O 0 3.3405348176529515e-07
) O 0 1.7384947925691563e-09
was O 0 7.589943784580555e-09
described O 0 1.4826745386997686e-09
that O 0 3.6255842078558587e-11
confers O 0 1.2797505277717391e-09
an O 0 1.788350578735276e-10
increased O 0 5.6164303430250584e-08
risk O 0 1.0026374184235465e-06
of O 0 0.0750911757349968
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.8538299662604913e-08
including O 0 1.1882262951345979e-09
multiple O 0 2.503797418285103e-07
adenomas B-Disease 0 8.641743988846429e-06
, O 0 1.0895550239808927e-08
in O 0 7.956017356036682e-08
Ashkenazim O 0 0.0001720817235764116
. O 0 3.4362136602794635e-07

We O 0 2.1257761773085804e-07
have O 0 3.05349967533175e-09
studied O 0 5.452190254828793e-09
a O 0 2.119475039918939e-09
set O 0 1.635527602239506e-09
of O 0 1.538916494236986e-10
164 O 0 4.8011479236720334e-08
patients O 0 1.5195624314401357e-08
with O 0 2.9292342773601376e-08
multiple O 1 0.9999983310699463
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.0047774347476661205
/ I-Disease 1 0.9999644756317139
or I-Disease 1 0.6076028943061829
carcinoma I-Disease 1 1.0
and O 0 1.5513361972807616e-07
analyzed O 0 1.5200949974314426e-06
codons O 0 2.0269506421755068e-05
1263 O 0 0.00017823510279413313
- O 0 4.521907612797804e-05
1377 O 0 0.00012735597556456923
( O 0 3.16955436119315e-07
exon O 0 5.1040910875599366e-06
15G O 0 4.463868208404165e-06
) O 0 2.123144771104535e-09
of O 0 1.745231598127006e-10
the O 0 1.7187520295891545e-09
APC B-Disease 0 1.9970258335888502e-07
gene O 0 9.080962115604052e-08
for O 0 3.802730130786358e-09
germ O 0 7.406446911772946e-06
- O 0 2.0190889699733816e-05
line O 0 1.165090361610055e-05
variants O 0 5.089810656500049e-06
. O 0 1.6997019258724322e-07

Three O 0 7.505313419642334e-07
patients O 0 2.3004727722764073e-07
with O 0 3.3609068861295555e-09
the O 0 5.3303823577266485e-09
I1307K O 0 6.512116215162678e-07
allele O 0 4.541666100976727e-07
were O 0 4.8361621374226615e-09
detected O 0 8.502964021772641e-08
, O 0 3.340932530626617e-10
each O 0 3.9258127304542256e-10
of O 0 1.7067368629497537e-09
Ashkenazi O 0 7.274223207787145e-06
descent O 0 1.0458699080118095e-06
. O 0 1.6779688394308323e-07

Four O 0 5.483929612637439e-07
patients O 0 1.3262031473004754e-07
had O 0 3.124643299656782e-08
a O 0 3.228014122669265e-08
germ O 0 0.0004813720006495714
- O 0 0.00018989804084412754
line O 0 5.0299706344958395e-05
E1317Q O 0 6.478854174929438e-06
missense O 0 7.173429821705213e-06
variant O 0 1.9351514310983475e-06
of O 0 3.3500777707473617e-09
APC O 0 2.8359514203657454e-07
that O 0 1.0249130433237497e-09
was O 0 7.742003482746895e-09
not O 0 1.6715234751885077e-10
present O 0 7.16225634356249e-10
in O 0 4.340022563553703e-09
controls O 0 0.0015136501751840115
; O 0 1.1624469165028017e-09
one O 0 5.682040948862266e-11
of O 0 1.2044670816280245e-11
these O 0 6.978506661425854e-11
individuals O 0 1.536633841003887e-11
had O 0 6.609162106485655e-10
an O 0 7.134329238489556e-11
unusually O 0 1.0418044205096066e-08
large O 0 3.8078667996543913e-10
number O 0 4.4030210033518813e-10
of O 0 9.148442003947821e-10
metaplastic B-Disease 0 6.289177690632641e-05
polyps I-Disease 0 1.21979439882125e-06
of I-Disease 0 1.1287858425745867e-09
the I-Disease 0 2.3101014434701028e-08
colorectum I-Disease 0 3.3798536605900154e-05
. O 0 3.765590577131661e-07

There O 0 5.283640547304458e-08
is O 0 9.806051526339843e-10
increasing O 0 5.309213624293818e-10
evidence O 0 3.2968799912325153e-10
that O 0 3.303779194663292e-10
there O 0 3.85857734652717e-10
exist O 0 4.188096536239527e-09
germ O 0 2.6401828563393792e-06
- O 0 2.5793501663429197e-06
line O 0 6.175793600959878e-07
variants O 0 2.7745919339849934e-08
of O 0 1.2304605945256952e-10
the O 0 1.929851833892826e-09
APC B-Disease 0 7.653956402009499e-08
gene O 0 2.606239668523358e-08
that O 0 3.361962930270579e-10
predispose O 0 7.921731715043734e-09
to O 0 1.5582450607620757e-10
the O 0 3.8692193893297144e-10
development O 0 4.683300969254844e-10
of O 0 2.565778256524709e-09
multiple O 1 0.999754011631012
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9843569397926331
carcinoma I-Disease 1 1.0
, O 0 1.800633064874546e-08
but O 0 3.8579019978612905e-09
without O 0 3.0832592035068274e-09
the O 0 1.0226933078172351e-08
florid O 0 0.000318489212077111
phenotype O 0 4.077634912391659e-06
of O 0 1.7290965326210994e-09
classical O 0 4.314076562650371e-08
FAP B-Disease 0 2.2896514906278753e-07
, O 0 3.5982225532471546e-10
and O 0 1.0739475281296151e-10
possibly O 0 2.960280076624855e-10
with O 0 2.017265382514566e-10
importance O 0 2.2302979019173108e-08
for O 1 0.927028238773346
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 2.2162116408708243e-07
in O 0 1.216406531057146e-09
the O 0 7.684169411881214e-10
general O 0 6.83255174660502e-10
population O 0 8.62146964930588e-10
. O 0 1.1755955098280424e-09
. O 0 2.059959669509226e-08

Genomic O 0 4.515546606853604e-05
structure O 0 1.1604844303292339e-06
of O 0 5.708301831219842e-09
the O 0 5.837312500034386e-08
human O 0 3.2896004995564e-05
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 3.7406796764116734e-05
CLD B-Disease 0 0.419080525636673
) O 0 4.076547384102014e-07
gene O 0 2.1141415345482528e-05
. O 0 5.166839969206194e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.37901750206947327
CLD B-Disease 1 0.9999469518661499
) O 0 5.597361791842559e-07
is O 0 7.1048420480224195e-09
caused O 0 4.2513669029631274e-08
by O 0 2.8938254015287157e-09
mutations O 0 9.0412633824144e-08
in O 0 1.2788428094268056e-09
a O 0 2.8387634465332212e-09
gene O 0 1.1629823859493627e-07
which O 0 1.793844850439541e-09
encodes O 0 7.710765004276254e-08
an O 0 1.6133260061224064e-08
intestinal O 0 0.00019938737386837602
anion O 0 7.309089596674312e-06
transporter O 0 3.358468529768288e-05
. O 0 4.53329704441785e-07

We O 0 3.424152339448483e-07
report O 0 8.747630886318802e-08
here O 0 6.765997762059328e-10
the O 0 4.398907627045645e-10
complete O 0 2.969759993476373e-09
genomic O 0 5.989729601196814e-08
organization O 0 9.083344632010437e-10
of O 0 1.0529867255915093e-10
the O 0 3.7506215910809715e-09
human O 0 1.956381368017901e-08
CLD B-Disease 0 5.920543480897322e-05
gene O 0 1.0697372090362478e-06
which O 0 1.0577424269797575e-08
spans O 0 5.466083763394636e-08
approximately O 0 1.2044251818110752e-08
39kb O 0 1.257871531379351e-06
, O 0 1.3282145383541888e-09
and O 0 2.45983011737394e-09
comprises O 0 1.2384790970543236e-08
21 O 0 7.492656095564598e-08
exons O 0 3.750416453840444e-06
. O 0 2.5529320168971026e-07

All O 0 7.769668286528031e-07
exon O 0 0.00010065889364341274
/ O 0 3.0495188184431754e-05
intron O 0 6.474983820226043e-05
boundaries O 0 4.974610305907845e-07
conform O 0 1.8390130662737647e-06
to O 0 1.3743244764441442e-08
the O 0 5.0460432277077416e-08
GT O 0 4.612066186382435e-05
/ O 0 0.0011411617742851377
AG O 1 0.5039596557617188
rule O 0 2.486856601535692e-06
. O 0 2.8354483561088273e-07

An O 0 1.0942872563646233e-07
analysis O 0 5.617287612835753e-08
of O 0 6.839618871268272e-10
the O 0 4.2034620229003394e-09
putative O 0 5.010538757233007e-07
promoter O 0 3.83332917408552e-07
region O 0 1.8574937143966963e-08
sequence O 0 4.516993001857372e-08
shows O 0 7.257546741357146e-08
a O 0 3.457985187083068e-08
putative O 0 3.857142928609392e-06
TATA O 0 3.9966803342395e-06
box O 0 2.1045345874881605e-06
and O 0 1.0331924649165103e-08
predicts O 0 2.969592287627165e-07
multiple O 0 6.003935482112865e-08
transcription O 0 5.960202429378114e-07
factor O 0 3.866714592959397e-08
binding O 0 1.7415895570138673e-07
sites O 0 2.5424844807275804e-07
. O 0 1.4697718597744824e-07

The O 0 4.3192804355385306e-07
genomic O 0 4.350560629973188e-06
structure O 0 1.4089990827415022e-06
was O 0 4.412744303294858e-08
determined O 0 4.373719164618706e-09
using O 0 2.7203388430763198e-09
DNA O 0 6.908428940022304e-09
from O 0 5.688876036913371e-10
several O 0 9.887896057492185e-11
sources O 0 3.8541347890941324e-10
including O 0 6.895889415048373e-11
multiple O 0 5.4159969842260125e-09
large O 0 2.1944224215530994e-08
- O 0 0.005174201913177967
insert O 0 0.013180356472730637
libaries O 0 7.694861778873019e-06
and O 0 2.8896447457071872e-09
genomic O 0 1.597828145349922e-07
DNA O 0 2.5304478867838043e-07
from O 0 7.099995258386116e-08
Finnish O 0 0.00041607380262576044
CLD B-Disease 0 0.3541924059391022
patients O 0 3.782308112931787e-06
and O 0 6.823871245842383e-08
controls O 0 0.00016489178233314306
. O 0 2.239997343167488e-07

Exon O 0 0.0002467113081365824
- O 0 2.0043969925609417e-05
specific O 0 1.8696789538807934e-07
primers O 0 9.901939847622998e-06
developed O 0 1.1542490341298617e-07
in O 0 1.9235715242871265e-09
this O 0 2.187767189631984e-10
study O 0 4.818316301502534e-10
will O 0 4.424319244300534e-10
facilitate O 0 2.885371053196195e-09
mutation O 0 6.978436317695014e-08
screening O 0 1.960243523058125e-08
studies O 0 2.354028083573212e-09
of O 0 2.3648635827377973e-10
patients O 0 3.5235372397579567e-09
with O 0 1.6577890171731724e-09
the O 0 4.980458356840245e-07
disease O 0 8.669973612995818e-05
. O 0 9.626008790064589e-08

Genomic O 0 2.502584902686067e-05
sequencing O 0 1.4711616813656292e-06
of O 0 1.705445740185496e-08
a O 0 2.212064487139287e-07
BAC O 0 0.1397620141506195
clone O 0 0.00040914909914135933
H O 1 1.0
_ O 0 6.274824215779518e-08
RG364P16 O 0 2.830731204994663e-07
revealed O 0 1.6574293937310358e-08
the O 0 4.253155050371049e-10
presence O 0 6.530830320983227e-10
of O 0 7.435017185253301e-11
another O 0 9.898128983110155e-10
, O 0 2.2167666313688272e-10
highly O 0 3.319034380666608e-09
homologous O 0 7.50422586293098e-08
gene O 0 2.4076740601230995e-07
3 O 0 2.0394972821691226e-08
of O 0 7.497966691971669e-10
the O 0 2.0196658567783743e-08
CLD B-Disease 0 0.00012114489072700962
gene O 0 2.4231189854617696e-07
, O 0 3.710757534580722e-10
with O 0 1.3737046222761506e-10
a O 0 3.0307254483830093e-09
similar O 0 2.3633056400740315e-08
genomic O 0 3.459140316408593e-07
structure O 0 1.2906207302876282e-07
, O 0 6.16457773716661e-10
recently O 0 1.052726794625869e-08
identified O 0 4.968330191701398e-09
as O 0 3.5441016787984836e-09
the O 0 9.097922884393483e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.00021665429812856019
( O 0 2.4232068085439096e-07
PDS B-Disease 0 1.4311835911939852e-05
) O 0 2.0859561189467968e-08
. O 0 6.948616348978476e-09
. O 0 6.142787611906897e-08

The O 0 1.7282554836128838e-06
APCI1307K O 0 0.00040564261144027114
allele O 0 0.00014594773529097438
and O 0 3.4690512507040694e-07
cancer B-Disease 0 7.636269401700702e-06
risk O 0 2.100797225068618e-08
in O 0 2.8042033139996647e-09
a O 0 1.0006827366737525e-08
community O 0 4.233958073029953e-09
- O 0 9.908034570571544e-08
based O 0 3.7220513338098726e-09
study O 0 5.635417688054645e-10
of O 0 6.807965302613184e-10
Ashkenazi O 0 9.053357530319772e-07
Jews O 0 2.73078413215444e-08
. O 0 7.152488024075865e-08

Mutations O 0 0.0017602862790226936
in O 0 1.4120660125627182e-06
APC O 0 1.8969054508488625e-05
are O 0 2.3226844447776784e-08
classically O 0 1.341270672128303e-05
associated O 0 1.5326397715398343e-06
with O 0 1.5507413991144858e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0010675813537091017
FAP B-Disease 0 4.667301254812628e-05
) O 0 1.543821781524457e-08
, O 0 9.025593605826998e-10
a O 0 1.1429812651897464e-08
highly O 0 4.0401628211839125e-05
penetrant O 1 0.9999997615814209
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.00559970922768116
by O 0 4.991275659449457e-07
multiple O 0 0.0027878519613295794
intestinal O 1 0.9999934434890747
polyps B-Disease 0 0.22126740217208862
and O 0 1.4817340243666877e-08
, O 0 7.722856798508815e-10
without O 0 1.630668489127629e-09
surgical O 0 1.8935340051484673e-07
intervention O 0 2.826899248020709e-08
, O 0 2.421849942813026e-10
the O 0 9.67236069016053e-10
development O 0 5.748038489628016e-09
of O 0 2.648720874276478e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.3567902215072536e-06
CRC B-Disease 0 0.00016431763651780784
) O 0 8.355282687944054e-08
. O 0 2.0292695523949078e-07

APC B-Disease 0 0.00014372794248629361
is O 0 2.2088812556830817e-07
a O 0 7.158765242820664e-07
tumour O 1 1.0
- O 0 0.00012540805619210005
suppressor O 0 6.234997999854386e-05
gene O 0 1.7994267409449094e-06
, O 0 1.9530770334341696e-09
and O 0 1.901143020788254e-09
somatic O 0 3.73453360680287e-07
loss O 0 4.174823970970465e-07
occurs O 0 2.7949678838012915e-07
in O 0 2.2746894501324277e-06
tumours B-Disease 1 1.0
. O 0 8.716549473319901e-07

The O 0 2.3505263015977107e-06
germline O 0 0.0002647595829330385
T O 0 0.308081716299057
- O 0 3.1910763937048614e-05
to O 0 5.581467021897879e-08
- O 0 5.917588623560732e-07
A O 0 3.433516937434433e-08
transversion O 0 4.2848824932661955e-07
responsible O 0 6.639059080271181e-09
for O 0 2.3565155382598846e-10
the O 0 1.5498929917256987e-09
APC O 0 2.177601317043809e-07
I1307K O 0 3.3623101103330555e-07
allele O 0 3.344136416671972e-07
converts O 0 2.0999600280902087e-08
the O 0 1.4692967953422453e-09
wild O 0 2.0377866505327802e-08
- O 0 3.765712790482212e-07
type O 0 1.4417507543385e-07
sequence O 0 2.7906949640055245e-08
to O 0 4.3521248827005365e-09
a O 0 8.003503637610265e-08
homopolymer O 0 0.04343700781464577
tract O 0 0.01690809428691864
( O 0 6.68390001123953e-08
A8 O 0 2.6173585865763016e-05
) O 0 2.7387949685930835e-09
that O 0 4.994932245594441e-10
is O 0 1.189927267830626e-09
genetically O 0 7.323291129068821e-08
unstable O 0 5.815368058392778e-05
and O 0 2.5441087458943912e-08
prone O 0 1.065210994966037e-06
to O 0 3.085743216502124e-08
somatic O 0 6.6430907281755935e-06
mutation O 0 1.3819410014548339e-05
. O 0 3.4567463558232703e-07

The O 0 4.1689560248414637e-07
I1307K O 0 1.2317177606746554e-05
allele O 0 8.327395335072652e-06
was O 0 1.0554453666600239e-07
found O 0 8.467242906817773e-09
in O 0 1.055895992863043e-08
6 O 0 1.6295258831178216e-07
. O 0 6.759309201243013e-08

1 O 0 9.739085271576187e-07
% O 0 2.695610135106108e-08
of O 0 1.8038083249294345e-09
unselected O 0 3.7591926229652017e-06
Ashkenazi O 0 2.7187688829144463e-06
Jews O 0 1.6972455441077727e-08
and O 0 1.933344373483692e-09
higher O 0 2.9448132821130457e-08
proportions O 0 2.132346210714786e-08
of O 0 5.522414747716198e-10
Ashkenazim O 0 1.0248099897580687e-06
with O 0 3.930212599811966e-09
family O 0 7.6129850867801e-08
or O 0 1.3171627344377157e-08
personal O 0 3.481087418322204e-08
histories O 0 4.375465891826025e-07
of O 0 2.025193701626904e-08
CRC B-Disease 0 0.0004049791896250099
( O 0 1.3954324629139592e-07
ref O 0 5.845161012985045e-06
. O 0 2.2059281068464998e-09
2 O 0 2.0413537527019798e-08
) O 0 1.263534699091906e-08
. O 0 3.7974988487121664e-08

To O 0 2.4798200115583313e-07
evaluate O 0 1.4583478957774787e-07
the O 0 3.93728072367594e-09
role O 0 2.196230308726399e-09
of O 0 2.1989621235007917e-10
I1307K O 0 1.3183671399019659e-07
in O 0 1.381720782234197e-08
cancer B-Disease 0 2.8587857059392263e-07
, O 0 7.020377057465055e-10
we O 0 1.3902853313041419e-09
genotyped O 0 1.0256379709971952e-06
5 O 0 2.7532625068715788e-08
, O 0 4.598653902121441e-09
081 O 0 7.007191470620455e-06
Ashkenazi O 0 9.72697989709559e-07
volunteers O 0 4.735662528787543e-09
in O 0 1.4562367978143698e-09
a O 0 1.4544860427179174e-08
community O 0 3.701754991425332e-08
survey O 0 4.773490331899666e-07
. O 0 1.3584069336047833e-07

Risk O 0 1.3462262359098531e-05
of O 0 1.212095241953648e-07
developing O 0 1.9352333765709773e-05
colorectal B-Disease 1 1.0
, I-Disease 0 3.0161370432324475e-06
breast I-Disease 0 0.0420464463531971
and I-Disease 0 3.006797655302762e-08
other I-Disease 0 5.183459439450644e-09
cancers I-Disease 0 1.4791363355470821e-05
were O 0 4.22046086967498e-09
compared O 0 1.539646099502079e-08
between O 0 7.233291299257871e-09
genotyped O 0 2.2708982214680873e-06
I1307K O 0 4.968740654476278e-07
carriers O 0 2.918081598579647e-08
and O 0 1.8011061531097994e-09
non O 0 5.886156451140323e-09
- O 0 3.058846971271123e-07
carriers O 0 1.647909719793006e-08
and O 0 4.624370608663497e-10
their O 0 8.523318162367843e-10
first O 0 2.855314873428938e-09
- O 0 5.6963845196378315e-08
degree O 0 1.4532381520382387e-08
relatives O 0 3.872323972586855e-08
. O 0 3.6779532308628404e-08

Sperm O 0 1.1858362995553762e-05
DNA O 0 1.3607153732664301e-06
analysis O 0 1.2903056756385922e-07
in O 0 3.571246054434596e-08
a O 0 4.19562269371454e-07
Friedreich B-Disease 1 0.9999866485595703
ataxia I-Disease 1 0.9999992847442627
premutation O 0 0.044600289314985275
carrier O 0 1.0428768291603774e-05
suggests O 0 8.244798266332509e-08
both O 0 3.3635489948835584e-09
meiotic O 0 1.1164912621097756e-06
and O 0 2.4247073238115036e-09
mitotic O 0 5.026773237659654e-07
expansion O 0 2.3443195829031538e-08
in O 0 6.288876974736013e-09
the O 0 1.2391667247868554e-08
FRDA B-Disease 0 2.1941601517028175e-05
gene O 0 5.900642463529948e-06
. O 0 1.5906761063888553e-07

Friedreich B-Disease 1 0.9999994039535522
ataxia I-Disease 1 1.0
is O 0 0.00012679373321589082
usually O 0 1.8869915265895543e-06
caused O 0 8.985306010345084e-08
by O 0 1.1641287933628064e-09
an O 0 3.772660517320503e-10
expansion O 0 9.09812225557971e-09
of O 0 1.0604528366542354e-09
a O 0 1.1159701784890785e-07
GAA O 0 0.0016050608828663826
trinucleotide O 0 6.581686466233805e-05
repeat O 0 5.4017186812416185e-06
in O 0 5.6198597775392045e-08
intron O 0 5.704294380848296e-06
1 O 0 1.5814094922461663e-08
of O 0 4.930585384421704e-10
the O 0 1.627242163237952e-08
FRDA B-Disease 0 2.295102058269549e-05
gene O 0 4.100877504242817e-06
. O 0 2.0448344173473743e-07

Occasionally O 0 5.137171683600172e-06
, O 0 1.168433705345251e-08
a O 0 5.984177597895268e-09
fully O 0 6.9694952031795765e-09
expanded O 0 2.4164169332152596e-08
allele O 0 2.330019555074614e-07
has O 0 6.46535269765991e-10
been O 0 2.569454926604209e-10
found O 0 3.4375630120209166e-10
to O 0 4.0730921413434373e-10
arise O 0 4.4690159906046745e-10
from O 0 1.766558427318543e-10
a O 0 1.6806546154768398e-09
premutation O 0 1.414717303305224e-07
of O 0 2.451398251057668e-10
100 O 0 2.9094047171440707e-09
or O 0 9.005616696811103e-09
less O 0 9.55516199496742e-08
triplet O 0 0.00022255232033785433
repeats O 0 6.446409679483622e-05
. O 0 4.807525897376763e-07

We O 0 3.429692014833563e-07
have O 0 3.1780513776169528e-09
examined O 0 1.597525667307309e-08
the O 0 8.850989385855712e-10
sperm O 0 1.7641157867842594e-08
DNA O 0 9.793906130539654e-09
of O 0 3.5321956470824034e-10
a O 0 1.429480356307522e-08
premutation O 0 1.3738203051616438e-05
carrier O 0 5.622712706099264e-06
. O 0 1.1248451414758165e-07

This O 0 3.6006431969326513e-07
mans O 0 5.319321644492447e-06
leucocyte O 0 2.9905254450568464e-06
DNA O 0 3.3357085271745746e-07
showed O 0 2.3141284088978864e-07
one O 0 1.8168186954881094e-09
normal O 0 4.073702086770936e-08
allele O 0 3.623585485001968e-07
and O 0 6.182546141708656e-10
one O 0 6.870227164945675e-10
allele O 0 8.684009600301579e-08
of O 0 3.1898250707484976e-10
approximately O 0 7.596171691659492e-09
100 O 0 6.935523089168782e-08
repeats O 0 8.88989325176226e-06
. O 0 1.8691939374093636e-07

His O 0 4.6518613316948176e-07
sperm O 0 4.913626412417216e-07
showed O 0 7.807432922390944e-08
an O 0 9.993509353378727e-10
expanded O 0 2.1961644947054992e-08
allele O 0 1.5322672197726206e-07
in O 0 3.2525422355433875e-09
a O 0 1.2131193827258357e-08
tight O 0 2.355600918235723e-05
range O 0 1.6749150688610825e-07
centering O 0 8.389199734892827e-08
on O 0 1.2087034484409287e-08
a O 0 4.525562591339849e-09
size O 0 8.63465565714705e-09
of O 0 6.53201437383899e-10
approximately O 0 3.015987459775715e-08
320 O 0 9.805860372580355e-07
trinucleotide O 0 0.00013348045467864722
repeats O 0 8.218544098781422e-05
. O 0 7.433027917613799e-07

His O 0 5.998321285005659e-06
affected O 0 4.2702640712377615e-06
son O 0 1.983298898267094e-05
has O 0 3.380426960575278e-08
repeat O 0 8.456503337583854e-07
sizes O 0 3.278516942373244e-07
of O 0 2.588551817339635e-09
1040 O 0 2.812432512655505e-06
and O 0 1.4761402766794163e-08
540 O 0 1.2355437775113387e-06
. O 0 1.5039952927509148e-07

These O 0 6.603762869872298e-08
data O 0 8.917508154127063e-08
suggest O 0 2.1824094531552873e-08
that O 0 6.877936553628672e-10
expansion O 0 8.514320803953979e-09
occurs O 0 4.595760660919268e-09
in O 0 7.075627861397038e-10
two O 0 3.53269413722046e-10
stages O 0 3.858277253243614e-09
, O 0 1.1150600581766312e-10
the O 0 2.2030301194408963e-10
first O 0 8.202017953706786e-10
during O 0 2.869531723348473e-09
meiosis O 0 9.621325069986142e-09
followed O 0 1.855067321976378e-09
by O 0 3.237098644692793e-10
a O 0 2.031351531428527e-09
second O 0 2.100480678279837e-08
mitotic O 0 3.114194896625122e-06
expansion O 0 1.0120973001903621e-06
. O 0 4.38248179079892e-07

We O 0 1.038501693528815e-07
also O 0 4.79935113872898e-09
show O 0 6.400290963881616e-09
that O 0 8.97315000081278e-11
in O 0 2.2258506149341883e-10
all O 0 1.9097845527227264e-10
informative O 0 1.2304618657310584e-08
carrier O 0 2.2891445183859105e-08
father O 0 1.3961427569597618e-08
to O 0 7.035819704626078e-10
affected O 0 1.0520362359045521e-08
child O 0 4.2409112666064175e-08
transmissions O 0 5.667703135259217e-06
, O 0 1.310648117813784e-10
with O 0 8.20675610802013e-11
the O 0 5.995747787146399e-10
notable O 0 6.817945652493052e-10
exception O 0 9.603298156690698e-10
of O 0 7.857378636622059e-11
the O 0 2.5744599785326727e-09
premutation O 0 8.170873684321123e-07
carrier O 0 2.7598979102094745e-08
, O 0 2.4749310933991353e-10
the O 0 5.917176193470652e-10
expansion O 0 1.3584790181653261e-08
size O 0 4.093345040701024e-08
decreases O 0 7.790251999040265e-08
. O 0 5.94294480293911e-09
. O 0 4.2319904025589494e-08

The O 0 5.402472993409901e-07
R496H O 0 1.1203394933545496e-05
mutation O 0 2.3185607460618485e-06
of O 0 2.4486237482079787e-09
arylsulfatase O 0 2.0681445676018484e-06
A O 0 9.190003424919269e-08
does O 0 5.308601558340342e-08
not O 0 4.3384350334463306e-08
cause O 0 1.6780337318778038e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999998807907104
. O 0 2.666630962266936e-06

Deficiency B-Disease 1 0.9992631077766418
of I-Disease 0 1.32500986183004e-07
arylsulfatase I-Disease 0 6.018787462380715e-05
A I-Disease 0 1.141702114182408e-06
( O 0 3.9322546285802673e-07
ARSA O 0 0.0005557608674280345
) O 0 9.431330738607357e-08
enzyme O 0 2.6430495836393675e-06
activity O 0 8.635105587018188e-06
causes O 0 0.00025349261704832315
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.00011171613732585683
MLD B-Disease 1 0.9999998807907104
) O 0 5.29836484020052e-07
. O 0 2.173056117271699e-07

A O 0 1.094970571102749e-06
number O 0 2.2335205684953507e-08
of O 0 1.041101338472572e-08
ARSA O 0 0.0016142611857503653
gene O 0 1.9274953956482932e-05
mutations O 0 1.3589562513516285e-05
responsible O 0 4.1063464095714153e-07
for O 0 3.6609460352110546e-08
MLD B-Disease 1 1.0
have O 0 1.7404099494910952e-08
been O 0 5.4399951210371e-09
identified O 0 5.817794246354424e-08
. O 0 6.676319230791705e-08

Recently O 0 6.538765774166677e-06
, O 0 1.2743438304596566e-08
the O 0 5.757606391654235e-09
R496H O 0 3.92536406934596e-07
mutation O 0 1.3165278289761773e-07
of O 0 1.6691317217265578e-09
ARSA O 0 0.00019170621817465872
was O 0 4.718362944799992e-08
proposed O 0 1.5677259490587403e-09
to O 0 3.3319846881596504e-10
be O 0 3.605848675203305e-10
a O 0 2.235296614472304e-09
cause O 0 2.734662096770535e-08
of O 0 1.1267944799442375e-08
MLD B-Disease 1 0.9999998807907104
( O 0 7.598275431064394e-08
Draghia O 0 3.51089170180785e-06
et O 0 4.1887381030392135e-07
al O 0 1.3042608770774677e-07
. O 0 1.5129274499869894e-09
, O 0 1.3760549366637065e-09
1997 O 0 1.6346927367294484e-08
) O 0 1.0797448268817789e-08
. O 0 2.597049508779037e-08

We O 0 3.329390381168196e-07
have O 0 5.205195829915965e-09
investigated O 0 2.1607554856473143e-08
the O 0 3.6966874006338912e-09
R496H O 0 4.395498933718045e-07
mutation O 0 9.858645455551596e-08
and O 0 5.637481592657423e-10
found O 0 1.1931567955869582e-09
this O 0 4.794407648667232e-10
mutation O 0 5.2267978389863856e-08
at O 0 1.2355887868409354e-08
a O 0 9.339316875411896e-09
relatively O 0 4.054957614130217e-08
high O 0 1.9424830099978863e-07
frequency O 0 1.374434191347973e-06
in O 0 1.238428803951308e-09
an O 0 1.9651455462899037e-10
African O 0 3.151670591172717e-10
American O 0 6.553590448099555e-10
population O 0 7.032894822067703e-10
( O 0 4.579808088323034e-09
f O 0 6.845771736152528e-07
= O 0 2.527307572108839e-07
0 O 0 5.4986351472052775e-08
. O 0 4.57407312026703e-09
09 O 0 3.498647629385232e-07
, O 0 3.1795308608195683e-09
n O 0 7.642772743565729e-07
= O 0 1.2294646012378507e-06
61 O 0 2.5748352072696434e-07
subjects O 0 1.925132835367549e-07
) O 0 3.262341508047939e-08
. O 0 1.1453932557969893e-07

The O 0 3.2250836738967337e-06
ARSA O 0 0.0008712165872566402
enzyme O 0 6.365660738083534e-06
activity O 0 6.736579507560236e-07
in O 0 1.2774003188553706e-08
subjects O 0 7.797458678737712e-09
with O 0 4.2342149231267e-10
and O 0 7.336860008422263e-10
without O 0 3.520787827948624e-10
the O 0 1.0990806043054135e-09
R496H O 0 2.720833833791403e-07
mutation O 0 1.1241738206990703e-07
was O 0 2.146112976220138e-08
determined O 0 7.934796819597523e-09
and O 0 4.3483391887200185e-10
found O 0 1.2091501133681959e-09
to O 0 7.959348180541781e-10
be O 0 1.3008957244764474e-09
normal O 0 2.555246112478926e-07
. O 0 9.847894943959545e-08

It O 0 6.565394414792536e-07
is O 0 9.307059123386807e-09
therefore O 0 1.593754128670355e-09
concluded O 0 3.0288413999102204e-09
that O 0 1.0736034977698594e-10
the O 0 1.1359218010653649e-09
R496H O 0 3.2676416594767943e-07
mutation O 0 1.0401330996501201e-07
of O 0 2.547477340186788e-09
ARSA O 0 9.208937990479171e-05
does O 0 3.163930983873797e-08
not O 0 6.734993118762134e-10
negatively O 0 7.571320459476283e-09
influence O 0 2.556472367132301e-09
the O 0 1.2041651009653265e-09
activity O 0 1.917027248055092e-08
of O 0 9.688905233673495e-10
ARSA O 0 8.875938510755077e-05
and O 0 2.3670938542608155e-09
is O 0 2.2182893022471006e-10
not O 0 1.4163162309621669e-10
a O 0 2.2343502603661136e-09
cause O 0 7.332194229547895e-08
of O 0 8.490032143981807e-08
MLD B-Disease 1 0.9999998807907104

Down O 0 0.00018126695067621768
- O 0 7.740080036455765e-06
regulation O 0 2.1788673620903865e-06
of O 0 1.3541690435658893e-08
transmembrane O 0 1.3999233487993479e-06
carbonic O 0 3.817013566731475e-05
anhydrases O 0 8.032441110117361e-05
in O 0 2.250496891065268e-06
renal B-Disease 1 0.9999884366989136
cell I-Disease 1 0.9999995231628418
carcinoma I-Disease 1 1.0
cell O 0 0.20158417522907257
lines O 0 1.8658576664165594e-05
by O 0 1.3364130246884542e-08
wild O 0 2.943634740404377e-07
- O 0 0.00018147449009120464
type O 0 0.04590604826807976
von B-Disease 1 0.9999638795852661
Hippel I-Disease 1 0.999643087387085
- I-Disease 1 0.7476776242256165
Lindau I-Disease 0 0.4880126714706421
transgenes O 0 0.000698468298651278
. O 0 2.818038410623558e-06

To O 0 6.031655743754527e-07
discover O 0 1.0101850875798846e-06
genes O 0 1.6727409501982038e-07
involved O 0 1.0237648062627613e-08
in O 0 4.02518232078819e-08
von B-Disease 1 0.9999356269836426
Hippel I-Disease 1 0.9999845027923584
- I-Disease 1 0.9999791383743286
Lindau I-Disease 1 0.9999504089355469
( O 0 1.559420297780889e-06
VHL B-Disease 0 0.0009003334562294185
) O 0 9.131627365377426e-08
- O 0 1.2983799706489663e-06
mediated O 0 2.2003000594850164e-06
carcinogenesis O 0 1.2830604646296706e-05
, O 0 3.1645990272721747e-09
we O 0 1.371375457637214e-09
used O 0 5.815136887576955e-07
renal B-Disease 1 0.9463911056518555
cell I-Disease 1 0.9999469518661499
carcinoma I-Disease 1 1.0
cell O 0 0.40886402130126953
lines O 0 0.0008496993104927242
stably O 0 8.674215496284887e-05
transfected O 0 8.969858754426241e-06
with O 0 7.446335992256081e-09
wild O 0 5.218818728280894e-07
- O 0 0.004321461543440819
type O 0 0.02822028286755085
VHL O 1 0.8541054129600525
- O 0 0.000738820293918252
expressing O 0 1.4098485507929581e-06
transgenes O 0 3.119301618426107e-05
. O 0 5.884048164261912e-07

Large O 0 1.9436818092799513e-06
- O 0 3.1599493013345636e-06
scale O 0 3.298261503914546e-07
RNA O 0 2.4945645691332174e-06
differential O 0 3.438668727540062e-07
display O 0 4.1132091155304806e-07
technology O 0 2.8254278916506337e-08
applied O 0 2.794789732973868e-09
to O 0 4.734178604692829e-10
these O 0 2.9083213615166414e-10
cell O 0 4.421253407826953e-08
lines O 0 1.2758204093188397e-07
identified O 0 4.465984471124784e-09
several O 0 9.358391839242586e-10
differentially O 0 2.0007297507618205e-07
expressed O 0 1.302708385608753e-09
genes O 0 8.60266613500471e-09
, O 0 1.6504622668556124e-10
including O 0 1.4549784987938352e-10
an O 0 1.5972019262733284e-09
alpha O 0 2.895092165999813e-07
carbonic O 0 9.49142577155726e-06
anhydrase O 0 1.7812764781410806e-05
gene O 0 3.157214678140008e-06
, O 0 2.4816314336817413e-08
termed O 0 2.0015743302792544e-06
CA12 O 0 0.0001814942224882543
. O 0 8.021749522413302e-07

The O 0 4.719929052043881e-07
deduced O 0 1.0428024097564048e-06
protein O 0 2.185421692502132e-07
sequence O 0 1.1533620636328124e-07
was O 0 3.7115754025762726e-08
classified O 0 9.070831197277585e-09
as O 0 9.228287578544325e-10
a O 0 1.450473741115843e-09
one O 0 4.2008170275664725e-09
- O 0 6.019776719767833e-06
pass O 0 6.442929816330434e-07
transmembrane O 0 4.852287815992895e-07
CA O 0 6.049820058251498e-07
possessing O 0 5.9424123399764994e-09
an O 0 6.371627114809542e-10
apparently O 0 3.6281701198959126e-08
intact O 0 1.1078454775770297e-07
catalytic O 0 2.8593063916559913e-07
domain O 0 2.9734227524613743e-08
in O 0 4.8676080943721445e-09
the O 0 1.576260011404429e-08
extracellular O 0 9.03395232398907e-07
CA O 0 2.163260433007963e-05
module O 0 2.7806852358480683e-06
. O 0 1.2220306189192343e-07

Reintroduced O 0 0.00021293848112691194
wild O 0 1.5594676369801164e-05
- O 0 0.00040278193773701787
type O 0 0.00014803215162828565
VHL B-Disease 0 0.003300153650343418
strongly O 0 2.007448983931681e-06
inhibited O 0 6.969750074858894e-07
the O 0 5.528045132763282e-09
overexpression O 0 9.754219831847877e-08
of O 0 2.9315005978247655e-10
the O 0 1.5714022305601816e-09
CA12 O 0 6.226854907254165e-07
gene O 0 4.114605189897702e-08
in O 0 1.139510930059373e-09
the O 0 1.600703924964364e-08
parental O 0 0.14119242131710052
renal B-Disease 1 0.9982507824897766
cell I-Disease 1 0.9999889135360718
carcinoma I-Disease 1 1.0
cell O 1 0.9732017517089844
lines O 0 0.027112562209367752
. O 0 1.7380534700350836e-06

Similar O 0 3.2923703656706493e-06
results O 0 7.757467415103747e-07
were O 0 1.3102545715071301e-08
obtained O 0 8.036479925976892e-09
with O 0 2.211084204617464e-09
CA9 O 0 1.815679388528224e-05
, O 0 3.5225493633106453e-09
encoding O 0 1.412775674225486e-07
another O 0 8.450047772612379e-08
transmembrane O 0 1.2715572665911168e-06
CA O 0 4.6859959184075706e-06
with O 0 1.1294103430259383e-09
an O 0 2.4826907196739967e-09
intact O 0 1.480515720686526e-06
catalytic O 0 2.2638791961071547e-06
domain O 0 6.898634978824703e-07
. O 0 1.716457234124391e-07

Although O 0 2.695986154321872e-07
both O 0 1.2606508725809817e-08
domains O 0 1.8035134274896336e-08
of O 0 1.9660566230594867e-10
the O 0 2.9365443410256376e-09
VHL B-Disease 0 6.398922323569423e-06
protein O 0 6.946724084855305e-08
contribute O 0 2.522422271056257e-09
to O 0 1.689154704997975e-09
regulation O 0 6.891428228072982e-08
of O 0 9.207927198495724e-10
CA12 O 0 2.441342076053843e-06
expression O 0 1.7363415594218168e-08
, O 0 3.946368232199404e-10
the O 0 1.8472255947088456e-09
elongin O 0 6.489586326097196e-07
binding O 0 1.1205879957287834e-07
domain O 0 5.691193294410368e-08
alone O 0 1.3224718209414732e-08
could O 0 1.1406183553219762e-08
effectively O 0 1.131079869765017e-07
regulate O 0 2.2694564449921018e-06
CA9 O 0 0.00012725083797704428
expression O 0 1.1208193200218375e-06
. O 0 1.9932870998218277e-07

We O 0 3.246245796617586e-06
mapped O 0 3.702400499605574e-05
CA12 O 0 0.00011411651212256402
and O 0 2.7432332672105986e-07
CA9 O 0 0.000198568741325289
loci O 0 2.365298087170231e-06
to O 0 3.895882727533717e-08
chromosome O 0 3.85805515179527e-06
bands O 0 9.386409374201321e-07
15q22 O 0 3.80779488295957e-06
and O 0 4.899644068245834e-08
17q21 O 0 1.295638139708899e-05
. O 0 5.710297159566835e-07

2 O 0 3.5549674066714942e-06
respectively O 0 2.1231585378700402e-07
, O 0 8.464997591772772e-09
regions O 0 6.347361392045059e-08
prone O 0 2.923814463429153e-06
to O 0 1.330913423913671e-08
amplification O 0 8.608756729699962e-07
in O 0 5.22230036992255e-09
some O 0 1.626530909959456e-09
human O 0 3.287013328190369e-08
cancers B-Disease 0 3.977987580583431e-05
. O 0 2.351001171518874e-07

Additional O 0 1.62358460897849e-07
experiments O 0 1.5825446553208167e-07
are O 0 5.34905841842459e-10
needed O 0 8.417449515185638e-10
to O 0 4.964652022820815e-10
define O 0 2.7604227792465963e-09
the O 0 3.392903458188101e-10
role O 0 7.347979447125397e-10
of O 0 4.3677483851922716e-10
CA O 0 6.68006532578147e-06
IX O 0 1.6495816907990957e-06
and O 0 4.7900435617975745e-08
CA O 0 3.4499660159781342e-06
XII O 0 1.045504973262723e-06
enzymes O 0 3.2689566609178655e-08
in O 0 1.5232266559195295e-09
the O 0 1.6067474017944505e-09
regulation O 0 7.923064515580336e-08
of O 0 9.255116117934392e-10
pH O 0 3.873809646393056e-07
in O 0 9.888315721795493e-10
the O 0 4.280730436789781e-09
extracellular O 0 7.920404954120386e-08
microenvironment O 0 6.104053227318218e-07
and O 0 7.404029056523598e-10
its O 0 1.5226020444458754e-09
potential O 0 1.5106955686405854e-09
impact O 0 7.872537288733383e-09
on O 0 3.753056887489947e-07
cancer B-Disease 0 3.239365014451323e-06
cell O 0 9.370560292154551e-07
growth O 0 5.519002570508746e-07
. O 0 6.132064811481541e-08

A O 0 2.892519432862173e-06
gene O 0 6.465595561166992e-06
encoding O 0 1.8704081412579399e-06
a O 0 6.50647962174844e-08
transmembrane O 0 4.6229644112827373e-07
protein O 0 1.5426627442138852e-07
is O 0 1.1823370060781713e-09
mutated O 0 1.3432624257347925e-07
in O 0 1.1971215130301971e-08
patients O 0 3.1304895742323424e-07
with O 0 0.004456487949937582
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.3441805839538574
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999998807907104
( O 0 0.4476207196712494
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 6.950341457923059e-07
. O 0 4.868437031291251e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0005965982563793659
WFS B-Disease 0 0.288855642080307
; O 0 5.832365332025802e-06
OMIM O 0 0.0015902898740023375
222300 O 0 1.6635292922728695e-05
) O 0 4.0137596357681105e-08
is O 0 5.5824753708577646e-09
an O 0 6.49586482381892e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
defined O 0 2.237376293123816e-06
by O 0 5.214887721649575e-08
young O 0 1.4677883086733345e-07
- O 0 7.509403985750396e-06
onset O 0 0.0015723565593361855
non O 0 1.1328669415888726e-06
- O 0 0.0040587689727544785
immune O 1 0.5709388256072998
insulin B-Disease 1 0.9999889135360718
- I-Disease 1 0.9999914169311523
dependent I-Disease 1 0.999294638633728
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 1.4402777196664829e-05
progressive O 0 0.16050443053245544
optic B-Disease 1 0.9999977350234985
atrophy I-Disease 1 0.9003547430038452
. O 0 2.465581928845495e-06

Linkage O 0 3.7207351851975545e-05
to O 0 2.175150228822531e-07
markers O 0 6.583194362974609e-07
on O 0 1.5064584601987008e-07
chromosome O 0 5.6638997193658724e-05
4p O 0 0.0003818994155153632
was O 0 3.8863085194407176e-08
confirmed O 0 1.8557194891855033e-08
in O 0 3.370921985990094e-09
five O 0 2.101309126700812e-09
families O 0 5.779678069472993e-09
. O 0 2.6302698685753967e-08

On O 0 3.2083173095998063e-07
the O 0 4.829405764184003e-09
basis O 0 3.1857347870811736e-09
of O 0 6.202602320648509e-10
meiotic O 0 2.2274882212514058e-05
recombinants O 0 0.00012701227387879044
and O 0 4.025620512493333e-07
disease O 0 0.00032892776653170586
- O 0 2.946596396213863e-05
associated O 0 5.920963985772687e-07
haplotypes O 0 2.3158424937719246e-06
, O 0 2.1426229679377684e-09
the O 0 9.490696228908746e-09
WFS B-Disease 0 1.4389404896064661e-05
gene O 0 3.6827833582719904e-07
was O 0 1.0275090112088492e-08
localized O 0 9.548548973725701e-08
to O 0 8.574048138143553e-09
a O 0 1.6823399562326813e-07
BAC O 0 0.10367616266012192
/ O 0 2.791952465486247e-05
P1 O 0 9.99674648483051e-06
contig O 0 1.3465140682455967e-06
of O 0 1.1522968135224687e-09
less O 0 6.838500876682474e-09
than O 0 1.846640729219473e-09
250 O 0 6.136955477131778e-08
kb O 0 4.0475668356521055e-05
. O 0 1.7571987598330452e-07

Mutations O 0 0.0001819232275011018
in O 0 1.881938374026504e-07
a O 0 7.48901243241562e-08
novel O 0 1.8197438578226866e-07
gene O 0 1.4065502682569786e-06
( O 0 2.496862627765495e-08
WFS1 O 0 1.3541196040023351e-06
) O 0 2.2689388146091005e-09
encoding O 0 2.5135291181754837e-08
a O 0 4.599127745308351e-09
putative O 0 3.670273258649104e-07
transmembrane O 0 1.387894172921733e-07
protein O 0 6.818926578944229e-08
were O 0 3.307879525848989e-09
found O 0 1.5968303346269863e-09
in O 0 5.577566186687477e-10
all O 0 1.5144828446889136e-10
affected O 0 5.143765968718128e-10
individuals O 0 4.9673300195340886e-11
in O 0 8.638703641317136e-10
six O 0 5.3925570675517065e-09
WFS B-Disease 0 3.8616735764662735e-06
families O 0 2.0697890068532843e-09
, O 0 2.3510204893995024e-10
and O 0 2.307778274035499e-10
these O 0 2.0371783426842427e-10
mutations O 0 2.866163661963128e-08
were O 0 6.562810295207555e-10
associated O 0 2.132438670088277e-09
with O 0 1.4353892519025635e-09
the O 0 2.9615830499096774e-07
disease O 0 0.0002188974613090977
phenotype O 0 3.0497980333166197e-05
. O 0 2.7834818183691823e-07

WFS1 O 0 0.00043533043935894966
appears O 0 1.1631969982772716e-06
to O 0 1.307503438852109e-08
function O 0 7.44109662775827e-09
in O 0 1.1273377786835681e-09
survival O 0 1.0492207103141027e-08
of O 0 2.849725733167219e-10
islet O 0 1.985406044013871e-07
beta O 0 2.020834131144511e-07
- O 0 2.369296225879225e-06
cells O 0 8.772408932600229e-08
and O 0 3.297856654427278e-09
neurons O 0 1.4495651612378424e-07
. O 0 4.913079720836322e-09
. O 0 2.6078904369342126e-08

Stable O 0 9.29621728573693e-06
interaction O 0 6.950209296974208e-08
between O 0 6.4299876534335e-09
the O 0 2.5466466713197633e-09
products O 0 4.145798371268938e-09
of O 0 9.760087182897337e-11
the O 0 2.9047193539355476e-09
BRCA1 O 0 3.348452310092398e-06
and O 0 2.5216445820319677e-08
BRCA2 O 0 2.02692153834505e-05
tumor B-Disease 0 1.8413400084682507e-06
suppressor O 0 2.0573113488353556e-06
genes O 0 2.4660468511683575e-07
in O 0 3.107063761831341e-08
mitotic O 0 6.937091711733956e-06
and O 0 5.969485528112273e-08
meiotic O 0 7.16821159585379e-05
cells O 0 1.0209419997408986e-05
. O 0 4.0543085333411e-07

BRCA1 O 0 0.009173145517706871
and O 0 9.648579180066008e-07
BRCA2 O 0 2.485028926457744e-05
account O 0 2.679503907643266e-08
for O 0 2.3584670327814194e-10
most O 0 1.4673132153752988e-10
cases O 0 2.3514240554689536e-10
of O 0 2.860993941755652e-10
familial O 0 7.207980274870351e-07
, O 0 2.6362352301134706e-09
early O 0 1.0797282357088989e-06
onset O 1 0.6081874370574951
breast B-Disease 1 0.7371808290481567
and I-Disease 0 5.409731966210529e-05
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.507048399053474e-09
encode O 0 5.745564379822099e-08
products O 0 1.0598996880162304e-07
that O 0 3.641942858401137e-10
each O 0 1.783326403215213e-10
interact O 0 2.691693756773361e-09
with O 0 3.0007001328158367e-09
hRAD51 O 0 3.005367034347728e-06
. O 0 6.299611499116509e-08

Results O 0 3.804466132351081e-06
presented O 0 8.091284087186068e-08
here O 0 5.286682203120563e-09
show O 0 2.1987462517358836e-08
that O 0 1.644342106921215e-09
BRCA1 O 0 1.3603765864900197e-06
and O 0 5.313248507832213e-09
BRCA2 O 0 9.219241405844514e-07
coexist O 0 1.508122515758714e-08
in O 0 9.562848291011505e-10
a O 0 4.4318722025593615e-09
biochemical O 0 8.872446954910629e-08
complex O 0 1.9007451612651494e-08
and O 0 5.833469707283712e-09
colocalize O 0 1.5794146293046651e-06
in O 0 8.924956773626036e-09
subnuclear O 0 1.6548665371374227e-06
foci O 0 4.254758039223816e-07
in O 0 2.955193201259476e-09
somatic O 0 2.7479174491418235e-07
cells O 0 9.30700920775962e-08
and O 0 2.3642512392285653e-09
on O 0 3.295046235862742e-09
the O 0 4.914905149533411e-10
axial O 0 5.216586274059409e-09
elements O 0 8.68837612966189e-10
of O 0 3.1302710423730673e-10
developing O 0 1.6910671973846547e-08
synaptonemal O 0 3.4113113542844076e-06
complexes O 0 1.0622710533425561e-06
. O 0 1.58729378085809e-07

Like O 0 4.422297024575528e-06
BRCA1 O 0 0.000172893371200189
and O 0 1.8077362540225295e-07
RAD51 O 0 0.000457068148534745
, O 0 1.0825331742125854e-07
BRCA2 O 0 1.757505197019782e-05
relocates O 0 3.2676371120032854e-06
to O 0 7.968257165202886e-08
PCNA O 0 1.9868237359332852e-05
+ O 0 3.533297956437309e-07
replication O 0 3.014213802998711e-07
sites O 0 2.8687123787562996e-08
following O 0 1.8432706028193024e-08
exposure O 0 1.5722072532753373e-07
of O 0 1.9735757472716386e-09
S O 0 7.446274139510933e-07
phase O 0 2.0011144741260978e-08
cells O 0 5.333863128953453e-08
to O 0 8.70828920085387e-09
hydroxyurea O 0 4.781545612786431e-06
or O 0 8.514064830933421e-08
UV O 0 2.5703020583023317e-05
irradiation O 0 4.429421551321866e-06
. O 0 1.235718798398011e-07

Thus O 0 1.5442834637724445e-06
, O 0 7.740928964494742e-08
BRCA1 O 0 4.679689936892828e-06
and O 0 2.1393734783714535e-08
BRCA2 O 0 2.085357209580252e-06
participate O 0 5.029254346311518e-09
, O 0 7.083080788561347e-10
together O 0 1.0483840462427452e-09
, O 0 1.7043222388934964e-10
in O 0 5.613254860925565e-10
a O 0 6.312190325985512e-09
pathway O 0 2.169973889465382e-08
( O 0 8.845526089373834e-09
s O 0 9.825715778788435e-07
) O 0 1.6828036741856067e-09
associated O 0 1.9672992124242228e-09
with O 0 1.5486392723751408e-10
the O 0 8.45727987641709e-10
activation O 0 2.552200939476279e-08
of O 0 5.010351578071948e-10
double O 0 1.0804208727677178e-07
- O 0 2.378920953560737e-06
strand O 0 2.4660664621478645e-06
break O 0 1.640033588046208e-05
repair O 0 0.00734670227393508
and O 0 3.1275408929332116e-08
/ O 0 3.3045816962840036e-06
or O 0 3.037648355075362e-08
homologous O 0 7.660987648705486e-07
recombination O 0 2.2300355340121314e-06
. O 0 2.665014164904278e-07

Dysfunction O 0 0.0002064258005702868
of O 0 7.875751606434278e-09
this O 0 3.811109650087019e-09
pathway O 0 3.6562987304478156e-08
may O 0 3.077503052395514e-08
be O 0 1.0549809636994922e-10
a O 0 3.32256056001512e-10
general O 0 3.5334421499833013e-10
phenomenon O 0 3.4184073349763366e-09
in O 0 4.826060662210807e-10
the O 0 3.733881259737615e-10
majority O 0 1.689054035525217e-10
of O 0 2.0672581702019244e-11
cases O 0 1.0222145352400958e-10
of O 0 2.930008180523913e-10
hereditary B-Disease 1 0.9275079369544983
breast I-Disease 0 0.01650056801736355
and I-Disease 0 3.0552422686014324e-05
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.9278265729954e-08
. O 0 1.3542471322125493e-07

A O 0 4.681671725847991e-06
novel O 0 3.919595201296033e-06
Arg362Ser O 0 1.5022384104668163e-05
mutation O 0 1.5903530083960504e-06
in O 0 1.618226086463892e-08
the O 0 1.520153780631972e-08
sterol O 0 2.3773542125127278e-05
27 O 0 6.044322162779281e-06
- O 0 8.128258741635364e-06
hydroxylase O 0 0.00014069057942833751
gene O 0 7.51791685615899e-06
( O 0 7.036590687903299e-08
CYP27 O 0 1.3361398487177212e-05
) O 0 5.811447767456457e-09
: O 0 2.7261393142907764e-10
its O 0 3.078687305091421e-09
effects O 0 9.376892506907097e-08
on O 0 6.372921035335821e-08
pre O 0 9.169069699055399e-07
- O 0 1.4301953399353806e-07
mRNA O 0 7.588673156533332e-08
splicing O 0 1.9195925915482803e-07
and O 0 1.6025665239283171e-09
enzyme O 0 4.568407874216973e-08
activity O 0 1.0560977869999988e-07
. O 0 6.595253410068835e-08

A O 0 1.150827756646322e-06
novel O 0 4.1617261103965575e-07
C O 0 1.313426878368773e-06
to O 0 3.101295442675678e-09
A O 0 7.231304888222212e-09
mutation O 0 9.248877574918879e-08
in O 0 2.7476005914905954e-09
the O 0 1.444819641704953e-08
sterol O 0 9.841847713687457e-06
27 O 0 1.41378541229642e-06
- O 0 5.466309175972128e-06
hydroxylase O 0 0.00011050469765905291
gene O 0 6.10200231676572e-06
( O 0 5.107930078906975e-08
CYP27 O 0 8.336708560818806e-06
) O 0 5.590349516637616e-09
was O 0 3.638778611758653e-09
identified O 0 1.92089499861936e-09
by O 0 5.437502670346817e-10
sequencing O 0 4.479935711287908e-08
amplified O 0 1.56852763666393e-06
CYP27 O 0 1.2707487258012407e-06
gene O 0 1.765011745646916e-07
products O 0 1.6838447081113372e-08
from O 0 5.093467869698998e-10
a O 0 6.632667304273809e-09
patient O 0 5.206202331464738e-07
with O 0 3.8178200156835373e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 9.279460186917277e-07
CTX B-Disease 0 0.0001511783921159804
) O 0 1.1309051473062937e-07
. O 0 1.0794364158073222e-07

The O 0 1.2247741096871323e-06
mutation O 0 1.6469361071358435e-05
changed O 0 1.0738513083197176e-06
the O 0 2.2158305412744994e-08
adrenodoxin O 0 2.302567509104847e-06
cofactor O 0 8.066219834290678e-07
binding O 0 1.2783659997239738e-07
residue O 0 7.073919050526456e-07
362Arg O 0 1.8618193280417472e-06
to O 0 3.357525812930362e-08
362Ser O 0 7.430826826748671e-06
( O 0 5.567665795069843e-08
CGT O 0 1.3441300325212069e-05
362Arg O 0 6.114224106568145e-06
to O 0 7.541561330981494e-08
AGT O 0 2.4750293960096315e-05
362Ser O 0 2.452514991091448e-06
) O 0 4.629367555963881e-09
, O 0 2.437290369528e-10
and O 0 2.19498128006812e-10
was O 0 2.90483037623801e-09
responsible O 0 4.454856483704361e-09
for O 0 4.154965704827873e-09
deficiency O 0 1.6358768561985926e-06
in O 0 2.261265841241311e-09
the O 0 1.6541006786496837e-08
sterol O 0 1.4684965208289213e-05
27 O 0 1.185722794616595e-06
- O 0 5.662661237693101e-07
hydroxylase O 0 6.974077678023605e-06
activity O 0 2.0905370945456525e-07
, O 0 5.173175221528936e-10
as O 0 2.713254065866977e-10
confirmed O 0 1.5758804261523096e-09
by O 0 3.641262291687042e-10
expression O 0 2.732257087245671e-09
of O 0 2.2785351383447505e-10
mutant O 0 5.179608209004982e-08
cDNA O 0 1.331645194113662e-07
into O 0 4.939042597129628e-08
COS O 0 3.6562538298312575e-05
- O 0 1.1701821449605632e-06
1 O 0 5.919293144529547e-08
cells O 0 2.226146307293675e-07
. O 0 7.292654657931052e-08

Quantitative O 0 7.129915957193589e-06
analysis O 0 2.019473868131172e-07
showed O 0 3.0010113505340996e-07
that O 0 5.192184460156568e-10
the O 0 8.273603469000079e-10
expression O 0 4.235816142283966e-09
of O 0 4.6159195910000506e-10
CYP27 O 0 7.673644972783222e-07
gene O 0 4.360485661436542e-08
mRNA O 0 3.650306013014415e-08
in O 0 2.1397887906005053e-09
the O 0 3.5322984537344837e-09
patient O 0 1.1345953510044637e-07
represented O 0 4.664681796384684e-08
52 O 0 3.72647207314003e-07
. O 0 7.000593171824221e-08

5 O 0 2.0557934021780966e-06
% O 0 1.4256792191247314e-08
of O 0 3.301159068325177e-10
the O 0 2.656359576747036e-09
normal O 0 3.2233725733021856e-07
level O 0 4.238372639520094e-07
. O 0 1.6232719701747556e-07

As O 0 1.1126376620040901e-07
the O 0 1.9703156439732084e-08
mutation O 0 3.5989475577480334e-07
occurred O 0 9.46918277122677e-08
at O 0 9.412458368274201e-09
the O 0 1.7580150668550232e-09
penultimate O 0 2.440400805880927e-07
nucleotide O 0 7.886878705676281e-08
of O 0 1.8814756419516243e-09
exon O 0 1.8287206557943136e-06
6 O 0 2.440933997149841e-07
( O 0 2.8864842960274473e-08
- O 0 1.4910377785781748e-06
2 O 0 2.2814074185362188e-08
position O 0 1.2568718510408416e-08
of O 0 2.227345391458968e-10
exon O 0 4.5999723852219176e-07
6 O 0 2.9729531547673105e-07
- O 0 6.7900700742029585e-06
intron O 0 1.571362736285664e-05
6 O 0 1.771997517607815e-07
splice O 0 3.306132612124202e-06
site O 0 4.3377070824135444e-08
) O 0 1.5661889840590248e-10
of O 0 2.8019229297848725e-11
the O 0 5.503550948304792e-10
gene O 0 4.637854544853326e-08
, O 0 2.7161947691034527e-10
we O 0 1.599023968790192e-10
hypothesized O 0 2.3209074662133844e-09
that O 0 9.100959569297018e-11
the O 0 5.118323542774306e-09
mutation O 0 6.126570042397361e-07
may O 0 1.2598269449881627e-07
partially O 0 5.463414964879121e-08
affect O 0 3.4158396111649836e-09
the O 0 1.131540638965589e-09
normal O 0 1.518003855949246e-08
splicing O 0 1.2076300492935843e-07
efficiency O 0 2.1882490486291317e-08
in O 0 4.525303687330506e-09
exon O 0 5.996440108901879e-07
6 O 0 2.6217852777676853e-08
and O 0 8.177337695869369e-10
cause O 0 5.134848546362036e-09
alternative O 0 8.581116262007527e-09
splicing O 0 1.4337159370825248e-07
elsewhere O 0 2.561110257204291e-08
, O 0 2.724252490260426e-10
which O 0 2.2954292633325935e-10
resulted O 0 1.4972448836303442e-09
in O 0 2.001090626535529e-09
decreased O 0 4.805985298617088e-08
transcript O 0 4.792876779902144e-07
in O 0 4.6538199960366455e-09
the O 0 1.221459200451136e-08
patient O 0 1.1397330581530696e-06
. O 0 1.0650978055082305e-07

Transfection O 0 0.00018661984358914196
of O 0 6.005906527661864e-08
constructed O 0 1.025484493766271e-06
minigenes O 0 3.4423806027916726e-06
, O 0 1.7408108288208268e-09
with O 0 3.0222266356183525e-10
or O 0 2.011921296229957e-09
without O 0 2.303929963476392e-10
the O 0 6.287566578500048e-10
mutation O 0 1.548504968695852e-08
, O 0 2.2436932867186954e-10
into O 0 3.2570615093874267e-09
COS O 0 2.3192209482658654e-05
- O 0 2.2694534607126116e-07
1 O 0 3.803890979980906e-09
cells O 0 4.031004419147166e-09
confirmed O 0 2.6960149668298072e-09
that O 0 6.263205926115845e-11
the O 0 4.3429515539372687e-10
mutant O 0 3.2065301525108225e-08
minigene O 0 1.918560315061768e-07
was O 0 5.742317732426727e-09
responsible O 0 1.0959447793723598e-09
for O 0 4.9294922310760825e-11
a O 0 3.2537875171989583e-10
mRNA O 0 1.3302891233024638e-08
species O 0 6.421870257788953e-10
alternatively O 0 1.867846322056721e-08
spliced O 0 2.8548370210046414e-06
at O 0 1.2128097637287283e-07
an O 0 3.1181819348802264e-09
activated O 0 7.656914021936245e-06
cryptic O 0 7.363713621089119e-07
5 O 0 2.0978982107067168e-08
splice O 0 3.173242703269352e-06
site O 0 1.1997140347830282e-07
88 O 0 1.253728640904228e-07
bp O 0 1.3023543488088762e-07
upstream O 0 1.5465863256736156e-08
from O 0 1.221719614363792e-09
the O 0 1.7400871854533762e-09
3 O 0 7.642151800268948e-09
end O 0 8.010494489951725e-09
of O 0 5.152132054320191e-10
exon O 0 1.3535927791963331e-06
6 O 0 3.993896768861305e-07
. O 0 9.136418555044656e-08

Our O 0 2.638465730342432e-07
data O 0 1.0236577452360507e-07
suggest O 0 8.124483308336039e-09
that O 0 2.2141384559137833e-10
the O 0 6.036783295471082e-10
C O 0 8.219095803951859e-08
to O 0 3.8181796613301344e-10
A O 0 4.5243200297306885e-09
mutation O 0 7.160473103340337e-08
at O 0 1.1709883729338344e-08
the O 0 1.249766623523385e-09
penultimate O 0 1.3021258382650558e-07
nucleotide O 0 2.062625448218114e-08
of O 0 5.086012166977127e-10
exon O 0 2.800744596243021e-07
6 O 0 6.4437140068207555e-09
of O 0 7.399902912652578e-11
the O 0 1.425031426194323e-09
CYP27 O 0 1.7138447674369672e-06
gene O 0 8.02135389221803e-08
not O 0 7.986660777170584e-10
only O 0 5.619231746578635e-10
causes O 0 1.2708145646911362e-08
the O 0 6.43299529201613e-08
deficiency B-Disease 0 6.519599537568865e-06
in I-Disease 0 2.5268813708123616e-09
the I-Disease 0 1.3060653003549305e-08
sterol I-Disease 0 1.4701641703140922e-05
27 I-Disease 0 1.0433356010253192e-06
- I-Disease 0 4.165355278473726e-07
hydroxylase I-Disease 0 3.838984866888495e-06
activity I-Disease 0 2.603770781206549e-07
, O 0 9.116461474611981e-10
but O 0 4.817525822709001e-10
also O 0 2.1153716556199242e-09
partially O 0 3.969850936869079e-08
leads O 0 3.181059415879872e-09
to O 0 1.4385054258880814e-09
alternative O 0 1.1219584372668123e-08
pre O 0 3.1470131034438964e-07
- O 0 6.209651104427394e-08
mRNA O 0 4.959479937838296e-08
splicing O 0 6.086177961606154e-08
of O 0 1.686954881341407e-10
the O 0 1.8407119162233698e-09
gene O 0 1.228653445650707e-06
. O 0 1.3299229806307267e-07

To O 0 1.9499036341130704e-07
our O 0 1.0972777353401852e-08
knowledge O 0 1.090165624439976e-09
, O 0 9.152102686815766e-11
this O 0 5.886172799174361e-11
is O 0 6.502103022665295e-11
the O 0 2.542844823594237e-10
first O 0 1.5974152001163588e-09
report O 0 7.053317485627986e-09
regarding O 0 1.870198218512087e-09
effects O 0 2.4875550508340893e-08
on O 0 4.0913622711968856e-08
pre O 0 1.120494403039629e-06
- O 0 9.449949800455215e-08
mRNA O 0 4.93186966821213e-08
splicing O 0 6.694924081784848e-08
of O 0 2.2218887840708135e-10
a O 0 1.8950281344132236e-09
mutation O 0 3.7203282232667334e-08
at O 0 1.946079741799167e-08
the O 0 1.2207558519605755e-08
- O 0 2.0181696527288295e-06
2 O 0 1.082883915870525e-08
position O 0 8.505328885632935e-09
of O 0 1.3159635880999332e-10
a O 0 5.051230544950158e-09
5 O 0 2.1740131472824942e-08
splice O 0 7.4757203947228845e-06
site O 0 6.126944072093465e-07
. O 0 1.3045793423316354e-07

ATM O 0 0.003331413259729743
germline O 0 0.004149501211941242
mutations O 0 0.0019870763644576073
in O 0 3.3522067042213166e-06
classical O 1 0.8729401230812073
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.4754519760608673
in O 0 4.3423096229844305e-08
the O 0 1.5802063657588405e-08
Dutch O 0 2.6678619633457856e-06
population O 0 1.563331331055906e-08
. O 0 5.7493242167083736e-08

Germline O 0 0.004530478734523058
mutations O 0 0.0007040046039037406
in O 0 2.598997639324807e-07
the O 0 1.5059034907949354e-08
ATM O 0 7.0684159254597034e-06
gene O 0 3.3202709914803563e-07
are O 0 1.638761903954844e-10
responsible O 0 2.2647621555904607e-09
for O 0 2.1305686104255983e-09
the O 0 0.001727085211314261
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.5118284821510315
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.3483937045275525e-07
. O 0 1.2058727349995024e-07

In O 0 3.827444174930861e-07
our O 0 2.3193198472881704e-08
study O 0 3.4168821105851066e-09
, O 0 6.301408839171074e-10
we O 0 3.7873393310405845e-10
have O 0 1.2247777791962733e-10
determined O 0 1.5176730983057496e-09
the O 0 1.994411080730174e-09
ATM O 0 8.00652469479246e-06
mutation O 0 3.8871095853210136e-07
spectrum O 0 1.1461067828122395e-07
in O 0 6.3598291077937574e-09
19 O 0 3.326165298744854e-08
classical O 0 9.241682619176572e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.0284912832503323e-06
, O 0 2.8699514986740837e-10
including O 0 5.90604440353637e-11
some O 0 1.1555227608095464e-10
immigrant O 0 3.825522565392703e-09
populations O 0 7.572096838437403e-10
, O 0 1.0652039666991797e-10
as O 0 1.9527258976470563e-10
well O 0 4.454650259777537e-10
as O 0 5.725233065412283e-10
12 O 0 1.448991704400271e-09
of O 0 6.933715407386742e-11
Dutch O 0 8.666719253369592e-08
ethnic O 0 2.6416413501095803e-09
origin O 0 1.3727631476001534e-08
. O 0 2.6742091208120655e-08

Both O 0 2.549097928294941e-07
the O 0 8.358278336118019e-08
protein O 0 5.385255690271151e-07
truncation O 0 6.9131174313952215e-06
test O 0 1.4731974715687102e-06
( O 0 4.5980073082318995e-08
PTT O 0 1.4559717556039686e-06
) O 0 1.0913034920179143e-09
and O 0 2.3607263366365316e-10
the O 0 1.5271188757992604e-09
restriction O 0 7.979755878295691e-08
endonuclease O 0 2.3107770630304003e-06
fingerprinting O 0 3.745880121641676e-07
( O 0 2.832274681452418e-08
REF O 0 1.1812296634161612e-06
) O 0 4.701639633175603e-10
method O 0 7.533776935630954e-10
were O 0 1.9548500318489204e-10
used O 0 1.8091006470655202e-09
and O 0 2.8984420419320145e-10
compared O 0 1.5216440329979264e-09
for O 0 5.1317689681029677e-11
their O 0 6.13499528956396e-10
detection O 0 1.4237172329956138e-08
efficiency O 0 1.1710642233708768e-08
, O 0 1.7089150927684926e-10
identifying O 0 1.407755245708131e-09
76 O 0 6.837300503548249e-09
% O 0 1.895757578695978e-10
and O 0 1.3498560602620557e-10
60 O 0 1.4143894944140811e-09
% O 0 1.1258609322606361e-10
of O 0 4.749479282084579e-11
the O 0 3.946257542963849e-09
mutations O 0 2.736687463311682e-07
, O 0 2.2760258122644927e-09
respectively O 0 3.784396795936118e-08
. O 0 8.39340899005947e-08

Most O 0 1.8278559821283125e-07
patients O 0 8.467811341006382e-08
were O 0 3.1718503379352114e-09
found O 0 2.8624254078124522e-09
to O 0 1.5471284253720796e-09
be O 0 1.0892967639009044e-09
compound O 0 9.404852363559257e-08
heterozygote O 0 6.755984031769913e-06
. O 0 1.8996583150965307e-07

Seventeen O 0 5.843846338393632e-06
mutations O 0 1.615210021554958e-05
were O 0 4.387012086937148e-09
distinct O 0 4.4710217750321135e-09
, O 0 2.9525040745603803e-10
of O 0 1.0756408957979247e-10
which O 0 1.0081960821750613e-09
10 O 0 1.0756948665147092e-09
were O 0 5.73716962826154e-10
not O 0 5.524353197117193e-10
reported O 0 1.8854251493394258e-07
previously O 0 1.2187602749236248e-07
. O 0 8.827057484950274e-08

Mutations O 0 0.000749883649405092
are O 0 3.4139912230557456e-08
small O 0 1.878805022670349e-08
deletions O 0 8.58776820678031e-06
or O 0 4.3315563402757107e-07
point O 0 1.1310324055102683e-07
mutations O 0 2.758977416306152e-06
frequently O 0 3.002224957526778e-07
affecting O 0 3.4519760561124713e-07
splice O 0 3.7698231608374044e-05
sites O 0 1.0037394986284198e-06
. O 0 3.437737916556216e-07

Moreover O 0 2.142584889952559e-06
, O 0 1.8545483371212867e-08
a O 0 5.816662707047726e-08
16 O 0 1.9411794482948608e-07
. O 0 8.850052779507678e-08

7 O 0 7.921633368823677e-05
- O 0 3.776883386308327e-05
kb O 0 4.283896487322636e-05
genomic O 0 2.0776944893441396e-06
deletion O 0 1.4191293757903622e-06
of O 0 2.8388718043004246e-09
the O 0 5.6115876390094854e-09
3 O 0 9.657471267132678e-09
end O 0 7.1919377120366335e-09
of O 0 8.714028804091001e-11
the O 0 6.816359143790862e-10
gene O 0 2.3386387937307518e-08
, O 0 1.5835206756964482e-10
most O 0 1.450611297748594e-10
likely O 0 1.6636363397992682e-09
a O 0 9.861231831109762e-10
result O 0 1.4927196145819721e-09
of O 0 1.8004252255732212e-10
recombination O 0 1.7185037393119273e-08
between O 0 2.305377222455718e-09
two O 0 4.191213154314255e-09
LINE O 0 6.884898539283313e-06
elements O 0 8.232899695315155e-09
, O 0 1.034809238298351e-09
was O 0 2.0179445670009954e-08
identified O 0 4.15539567200085e-08
. O 0 5.848680117992444e-08

The O 0 7.363910725644018e-08
most O 0 3.4659801695369197e-09
frequently O 0 1.852844100369566e-08
found O 0 1.0143863526934638e-08
mutation O 0 7.230342191633099e-08
, O 0 4.189468771897964e-10
identified O 0 1.1157371693215623e-09
in O 0 5.202116515334865e-10
three O 0 3.1748628726013806e-10
unrelated O 0 9.676591972151982e-09
Turkish O 0 1.075925553095658e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
individuals O 0 2.9959650316158104e-09
, O 0 6.074448166693003e-10
was O 0 5.931360291810961e-09
previously O 0 8.910120974370273e-10
described O 0 1.9455073108076704e-09
to O 0 6.650512918149332e-10
be O 0 2.5760255040196967e-10
a O 0 1.7347254743782514e-09
Turkish O 0 8.570177101319132e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
founder O 0 8.973494914243929e-06
mutation O 0 5.758417501056101e-06
. O 0 1.309842758701052e-07

The O 0 1.6550259829273273e-07
presence O 0 1.8804145796025296e-08
of O 0 4.3147552197808636e-10
a O 0 3.634492040660575e-09
founder O 0 1.0233825520344908e-07
mutation O 0 8.642419402349333e-08
among O 0 4.374459960931887e-10
relatively O 0 1.1172278657767265e-09
small O 0 3.961171668454e-10
ethnic O 0 2.269985172054234e-10
population O 0 6.450445039218877e-11
groups O 0 2.7212856967828714e-11
in O 0 1.717315872840075e-10
Western O 0 4.461097713459594e-09
Europe O 0 1.8650202093795087e-07
could O 0 4.417845644866247e-09
indicate O 0 2.936460186120371e-09
a O 0 1.9701078546319195e-09
high O 0 4.512308748871874e-08
carrier O 0 6.58969554478972e-08
frequency O 0 3.356277602506452e-07
in O 0 2.201523185973997e-09
such O 0 5.464285135481362e-10
communities O 0 9.316756255373093e-09
. O 0 3.358076483550576e-08

In O 0 6.053542165318504e-07
patients O 0 1.4984404117512895e-07
of O 0 8.765392855991649e-10
Dutch O 0 2.01168887770109e-07
ethnic O 0 1.1073797434590915e-09
origin O 0 7.904566445837702e-10
, O 0 2.2714403968837615e-10
however O 0 3.616138499751287e-10
, O 0 8.03944619209851e-11
no O 0 1.0090266816531468e-10
significant O 0 2.2184840076100443e-10
founder O 0 1.2540414928707833e-08
effect O 0 6.5625127554369556e-09
could O 0 3.5948768406512954e-09
be O 0 7.758675368840784e-10
identified O 0 1.462146315134305e-08
. O 0 1.7860481094089664e-08

The O 0 4.771314365825674e-07
observed O 0 5.875569968338823e-07
genetic O 0 1.7348990866139502e-07
heterogeneity O 0 1.9732215150725096e-07
including O 0 1.8986716643354384e-09
the O 0 2.907756924130922e-09
relative O 0 6.013035402929745e-08
high O 0 2.5431538119846664e-07
percentage O 0 3.1768291108846824e-08
of O 0 9.019742730487224e-10
splice O 0 0.0007081428193487227
- O 0 0.0001529425207991153
site O 0 4.366022039903328e-06
mutations O 0 6.952217972866492e-06
had O 0 4.075831583350009e-08
no O 0 1.8435790671844643e-09
reflection O 0 6.584943701426482e-09
on O 0 8.708587628802889e-09
the O 0 1.4521297941882949e-08
phenotype O 0 4.49519393441733e-06
. O 0 6.596398094416145e-08

All O 0 5.934644491389918e-07
patients O 0 8.03780778824148e-07
manifested O 0 6.019380975885724e-07
classical O 0 4.667539315050817e-07
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.999967098236084
T I-Disease 1 1.0
and O 0 1.7141042363277847e-08
increased O 0 4.204891723702531e-08
cellular O 0 4.143042815485387e-07
radioresistant O 0 1.4031471664566197e-06
DNA O 0 2.451649265822198e-07
synthesis O 0 9.140084102909896e-07
. O 0 2.0560077018672018e-07

Determination O 0 9.099902058551379e-07
of O 0 4.537403786031291e-09
the O 0 3.683511495822245e-09
genomic O 0 9.267100153920182e-08
structure O 0 1.2101914137474523e-08
of O 0 1.4022152883264027e-10
the O 0 1.9465280498565107e-09
COL4A4 O 0 1.8806712205332587e-06
gene O 0 6.393302243168364e-08
and O 0 4.1096831493447894e-10
of O 0 3.1461211413841284e-10
novel O 0 3.5693059885488765e-07
mutations O 0 0.00013188344018999487
causing O 0 0.00046446730266325176
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.051968294836115e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.2364746402890887e-06
a O 0 3.4354475246800575e-06
progressive O 0 0.16129212081432343
hematuric B-Disease 1 0.9997132420539856
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.0002229086821898818
by O 0 4.410295844081702e-07
glomerular B-Disease 1 0.996552586555481
basement I-Disease 1 0.9999977350234985
membrane I-Disease 1 0.9695537090301514
abnormalities I-Disease 1 0.999992847442627
and O 0 2.1860257604089384e-08
associated O 0 2.9368875331670097e-08
with O 0 3.741904119891615e-09
mutations O 0 1.5213944379866007e-06
in O 0 1.0513421244695564e-08
either O 0 1.0160555063976062e-08
the O 0 2.1480991208022715e-08
COL4A3 O 0 5.039463758294005e-06
or O 0 3.1138849276857172e-09
the O 0 1.7782291195089783e-09
COL4A4 O 0 7.042229412945744e-07
gene O 0 4.6938847475530565e-08
, O 0 2.248654457082111e-10
which O 0 2.1663076887890043e-10
encode O 0 1.3905033569017178e-08
the O 0 5.1236761500206285e-09
alpha3 O 0 1.3370564602155355e-06
and O 0 4.373911455246571e-09
alpha4 O 0 3.1403981211042264e-06
type O 0 2.9494754926417954e-05
IV O 0 0.0005872722831554711
collagen O 0 2.2647456717095338e-05
chains O 0 6.292573380051181e-05
, O 0 1.3668010723222324e-08
respectively O 0 1.4105758339155727e-07
. O 0 1.0604213684928254e-07

To O 0 2.1508095926492388e-07
date O 0 1.2198229626392276e-07
, O 0 3.088203026635483e-09
mutation O 0 4.269357845032573e-08
screening O 0 3.0902313596925524e-08
in O 0 1.5127947783355467e-09
the O 0 7.484007857883057e-10
two O 0 6.273861430372563e-10
genes O 0 2.0797308764031186e-08
has O 0 2.7857156581490017e-09
been O 0 1.2239866897800766e-09
hampered O 0 3.147600580177823e-08
by O 0 4.366573769232218e-10
the O 0 5.508213329896705e-10
lack O 0 6.494248472321829e-10
of O 0 1.5493187288662114e-10
genomic O 0 8.489416813972639e-08
structure O 0 8.931210970786196e-08
information O 0 3.344244348113534e-08
. O 0 7.345408192804825e-08

We O 0 3.179090413141239e-07
report O 0 5.323425611436505e-08
here O 0 1.2249348202431065e-09
the O 0 5.742862851931818e-10
complete O 0 2.9051958616577167e-09
characterization O 0 1.5839210831813944e-08
of O 0 1.696654761129679e-10
the O 0 1.5534028507957487e-09
48 O 0 1.0478547807224459e-08
exons O 0 3.1821716817148626e-08
of O 0 1.8659394862563516e-10
the O 0 4.477618276155226e-09
COL4A4 O 0 2.8838842354161898e-06
gene O 0 7.55861222501153e-08
, O 0 3.220378963497694e-10
a O 0 8.556220731925634e-10
comprehensive O 0 1.0432083641376266e-08
gene O 0 2.665275928848132e-07
screen O 0 5.014046109863557e-06
, O 0 6.955812592579491e-10
and O 0 8.935934631137954e-11
the O 0 2.1475397848913502e-10
subsequent O 0 8.621650615658893e-10
detection O 0 5.066205677195512e-09
of O 0 2.826314182691192e-10
10 O 0 2.739761528758322e-09
novel O 0 8.760115299821791e-09
mutations O 0 1.1380676312455762e-07
in O 0 2.757749362203299e-09
eight O 0 3.4336345322572015e-08
patients O 0 1.5863721500863903e-06
diagnosed O 0 0.00016439444152638316
with O 0 1.7622630821279017e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.3365961422096007e-05

Furthermore O 0 2.746816562648746e-06
, O 0 2.3313480923548013e-08
we O 0 2.549309874311234e-09
identified O 0 5.0997890355120035e-09
a O 0 2.0703576630864973e-09
glycine O 0 1.3574968988905312e-06
to O 0 8.644344795527559e-09
alanine O 0 5.168210464034928e-07
substitution O 0 1.552082906641772e-08
in O 0 1.848268649240481e-09
the O 0 2.777714724899738e-09
collagenous O 0 9.378901495438186e-07
domain O 0 2.1767391444882378e-08
that O 0 4.4702347379299567e-10
is O 0 2.3004698146422697e-10
apparently O 0 3.14855985728002e-09
silent O 0 4.263425523731712e-08
in O 0 1.0206914202726125e-09
the O 0 9.065327377655308e-10
heterozygous O 0 4.591767677197822e-08
carriers O 0 2.7892992360278868e-09
, O 0 3.370997370133466e-10
in O 0 2.5932809233353282e-09
11 O 0 4.305486100975031e-08
. O 0 2.455331404860317e-08

5 O 0 4.611876249782654e-07
% O 0 5.62815927196425e-09
of O 0 8.123669098525355e-11
all O 0 1.2609285837683615e-10
control O 0 2.6377909634334173e-08
individuals O 0 1.6116943890587265e-10
, O 0 7.039896443572502e-11
and O 0 2.114668856689761e-10
in O 0 6.070961511284167e-10
one O 0 6.565276100545248e-10
control O 0 2.7551115167057105e-08
individual O 0 4.871097969427751e-10
homozygous O 0 1.3144648036700346e-08
for O 0 1.1229143309643419e-10
this O 0 4.688958665788334e-10
glycine O 0 1.383608491778432e-06
substitution O 0 2.9334174200812413e-07
. O 0 1.5994578461686615e-07

There O 0 3.2766288882157824e-07
has O 0 9.002079082165437e-09
been O 0 1.729225096447351e-09
no O 0 1.6146295411800793e-10
previous O 0 1.4194676545287166e-09
finding O 0 1.2243363267661067e-10
of O 0 4.240791398602006e-11
a O 0 6.371894678558476e-10
glycine O 0 1.094239223675686e-07
substitution O 0 6.570929578231244e-09
that O 0 2.88953305727091e-10
is O 0 1.423851453408176e-10
not O 0 1.0798879152007501e-10
associated O 0 4.381006113440833e-10
with O 0 1.1089961587940067e-10
any O 0 1.5504930672705086e-09
obvious O 0 3.127272663050462e-08
phenotype O 0 7.654962246306241e-07
in O 0 9.930885447317905e-09
homozygous O 0 7.356470064223686e-07
individuals O 0 6.0596856421568646e-09
. O 0 5.310616657538958e-08

Founder O 0 0.00012629969569388777
BRCA1 O 0 0.000748658727388829
and O 0 5.343363795873302e-07
BRCA2 O 0 6.455316906794906e-05
mutations O 0 1.993887053686194e-06
in O 0 6.242974848191807e-08
French O 0 2.9633504254888976e-06
Canadian O 0 0.003367998404428363
breast B-Disease 1 0.9999996423721313
and I-Disease 1 0.9999953508377075
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.406225689810526e-07
. O 0 2.2878093375311437e-07

We O 0 5.128978841639764e-07
have O 0 7.4251045312223596e-09
identified O 0 1.1112352815700888e-08
four O 0 1.0694837238034438e-09
mutations O 0 4.523631957908947e-08
in O 0 2.9879057561466027e-10
each O 0 1.3484408034614148e-10
of O 0 2.475832872050887e-10
the O 0 5.873653776689025e-07
breast B-Disease 1 0.9977050423622131
cancer I-Disease 0 4.568302392726764e-05
- O 0 6.461256361944834e-06
susceptibility O 0 2.641693981786375e-06
genes O 0 3.7899380345152167e-07
, O 0 7.687310343840181e-09
BRCA1 O 0 1.7120347592936014e-06
and O 0 6.420820319874565e-09
BRCA2 O 0 3.201336653546605e-07
, O 0 3.785866065086907e-10
in O 0 1.0546152839907563e-09
French O 0 4.0828271608006617e-07
Canadian O 0 5.262120612314902e-05
breast B-Disease 1 0.9981903433799744
cancer I-Disease 0 0.0284567903727293
and O 0 0.34395334124565125
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.731211664780858e-08
from O 0 4.4744279392716635e-08
Quebec O 0 3.0996267014415935e-05
. O 0 2.0626556818115205e-07

To O 0 2.802842118398985e-07
identify O 0 3.2729934673625394e-07
founder O 0 2.612536036394886e-07
effects O 0 2.6125758267880883e-07
, O 0 1.870387400515483e-09
we O 0 6.278758069022672e-10
examined O 0 1.6322250218081535e-08
independently O 0 1.4678297688419661e-08
ascertained O 0 5.363847321859794e-08
French O 0 4.9539305990720095e-08
Canadian O 0 2.708066517698171e-07
cancer B-Disease 0 1.376350269310933e-07
families O 0 6.203711849783744e-11
for O 0 1.5656326929347486e-11
the O 0 1.3259307540813836e-10
distribution O 0 7.363384901815095e-10
of O 0 5.247777212780136e-11
these O 0 4.6332701564288925e-10
eight O 0 6.181995804155349e-09
mutations O 0 1.1845304470625706e-06
. O 0 1.1744692329784812e-07

Mutations O 0 0.000565826368983835
were O 0 1.1156829060610107e-07
found O 0 1.0045782872225573e-08
in O 0 3.49087292406125e-09
41 O 0 9.058711114562357e-09
of O 0 3.9076591962228235e-10
97 O 0 1.1592595683396212e-07
families O 0 1.8817924996028523e-08
. O 0 5.032557481854383e-08

Six O 0 3.1570229452881904e-07
of O 0 3.985531016326149e-09
eight O 0 1.1219242423976539e-08
mutations O 0 1.8820406921804533e-07
were O 0 2.883852490143113e-09
observed O 0 3.065995812789879e-08
at O 0 4.941285425275055e-08
least O 0 1.2517664238487214e-08
twice O 0 6.619449663958221e-07
. O 0 6.148390241378365e-08

The O 0 1.7623689245738205e-06
BRCA1 O 0 6.206019315868616e-05
C4446T O 0 9.332745321444236e-06
mutation O 0 7.291412657650653e-06
was O 0 5.364768185245339e-08
the O 0 1.0906251457498684e-09
most O 0 3.742487431068753e-10
common O 0 4.196909042519792e-09
mutation O 0 6.828427956406813e-08
found O 0 5.343248954403634e-09
, O 0 2.2687041134616948e-10
followed O 0 1.3451276759113284e-09
by O 0 1.193327436865843e-09
the O 0 5.2112191895048454e-08
BRCA2 O 0 5.050205436418764e-05
8765delAG O 0 1.1285448636044748e-05
mutation O 0 1.0597905202303082e-05
. O 0 2.621535770686023e-07

Together O 0 7.715854621892504e-07
, O 0 4.974578526883988e-09
these O 0 7.233066923184595e-10
mutations O 0 4.562034305877205e-08
were O 0 6.629742310693132e-10
found O 0 9.33963351101852e-10
in O 0 1.359468537742714e-09
28 O 0 4.153444255194927e-09
of O 0 4.471213330137225e-11
41 O 0 2.834386503280939e-09
families O 0 9.27686746865497e-11
identified O 0 7.554872283321856e-10
to O 0 4.071321058063404e-10
have O 0 3.015829252994706e-10
a O 0 1.2109140357097203e-08
mutation O 0 1.257989083569555e-06
. O 0 5.2146990725532305e-08

The O 0 3.5957981481260504e-07
odds O 0 9.840888424150762e-07
of O 0 1.2145171535138388e-09
detection O 0 1.9245669946599264e-08
of O 0 2.0119089727543837e-10
any O 0 1.5819751064682919e-10
of O 0 5.778459308269923e-11
the O 0 1.6036427741283887e-09
four O 0 9.72902114426688e-09
BRCA1 O 0 6.5332369558745995e-06
mutations O 0 7.125730121515517e-07
was O 0 4.3050758335994033e-07
18 O 0 1.0798152771940295e-07
. O 0 4.3374754454816866e-08

7x O 0 0.0003171823045704514
greater O 0 3.432816981785436e-07
if O 0 5.62371704759812e-09
one O 0 9.716573101670178e-10
or O 0 5.285146764677506e-10
more O 0 1.6643335321031572e-10
cases O 0 3.861163389018429e-09
of O 0 6.806453257013345e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 2.7917435474478225e-08
also O 0 1.7992555223500517e-09
present O 0 4.083710036795196e-10
in O 0 7.447170102814482e-10
the O 0 5.16815745754684e-09
family O 0 6.048601619568217e-08
. O 0 4.629670513622841e-08

The O 0 2.6211407089249406e-07
odds O 0 4.488981062422681e-07
of O 0 4.619037097253198e-10
detection O 0 1.0789666937682796e-08
of O 0 7.98531657464352e-11
any O 0 1.0166845143544379e-10
of O 0 2.876334587176288e-11
the O 0 8.579229548999479e-10
four O 0 1.0491986834892941e-08
BRCA2 O 0 1.014847839542199e-05
mutations O 0 9.789321211428614e-07
was O 0 2.4646175234011025e-07
5 O 0 1.3444952173813363e-07
. O 0 1.0797123195516178e-07

3x O 0 0.00018202749197371304
greater O 0 2.948894746168662e-07
if O 0 1.595369703011329e-08
there O 0 1.6174569461568922e-09
were O 0 5.015534099150898e-10
at O 0 1.3866782166971348e-09
least O 0 2.2522814169256833e-10
five O 0 1.5994693070009447e-10
cases O 0 3.545546634065033e-10
of O 0 4.476662152086419e-09
breast B-Disease 0 0.20115309953689575
cancer I-Disease 0 4.7539367642457364e-07
in O 0 5.069414665825889e-09
the O 0 3.169034457073394e-08
family O 0 2.7627743293123785e-07
. O 0 9.246161170040068e-08

Interestingly O 0 1.8630486010806635e-05
, O 0 2.7178662875826376e-08
the O 0 1.8442366522819498e-09
presence O 0 2.0571475634056924e-09
of O 0 3.8218811448942347e-10
a O 0 3.033786981632147e-07
breast B-Disease 1 0.8793688416481018
cancer I-Disease 0 2.2221595372684533e-06
case O 0 1.2220512601857081e-08
< O 0 9.300797643163605e-08
36 O 0 4.439131284783571e-09
years O 0 3.4706884588509013e-10
of O 0 2.414124733451928e-10
age O 0 9.728927885532812e-09
was O 0 1.6229430244152354e-08
strongly O 0 1.0317195098252796e-08
predictive O 0 1.506817071117439e-08
of O 0 3.691089447976914e-11
the O 0 1.6668592894841794e-10
presence O 0 2.9009197821672217e-10
of O 0 2.7618313885868773e-11
any O 0 9.240859466519424e-11
of O 0 6.091825655030192e-11
the O 0 9.890730456874053e-10
eight O 0 4.448895474240544e-09
mutations O 0 6.024550316396926e-07
screened O 0 9.36618278046808e-07
. O 0 1.1889256512631619e-07

Carriers O 0 1.5079461945788353e-06
of O 0 5.994515994700578e-09
the O 0 2.6627966498438127e-09
same O 0 4.835922773338552e-09
mutation O 0 3.1776046682807646e-08
, O 0 7.906779397881536e-11
from O 0 2.0480481199847134e-10
different O 0 1.5770161565509255e-10
families O 0 2.003262555838603e-10
, O 0 1.1446076031429442e-10
shared O 0 4.883675130962217e-10
similar O 0 5.60372592772751e-09
haplotypes O 0 1.3290366496221395e-07
, O 0 2.899680495715984e-10
indicating O 0 5.079383580408603e-09
that O 0 1.235276464450763e-10
the O 0 4.2071096606477454e-10
mutant O 0 3.652409219512265e-08
alleles O 0 1.0938152605888263e-08
were O 0 6.26779739221206e-10
likely O 0 1.2916143710128836e-09
to O 0 7.362598308802148e-10
be O 0 5.031650651687869e-10
identical O 0 1.4138076487313356e-08
by O 0 3.676848547851108e-10
descent O 0 3.2902229829545604e-09
for O 0 9.517044097240301e-11
a O 0 1.7660741757907772e-09
mutation O 0 5.369385291942308e-08
in O 0 1.396365800765409e-09
the O 0 4.347420645700595e-09
founder O 0 8.402923867834033e-08
population O 0 5.043894635292645e-09
. O 0 2.7965988635969552e-08

The O 0 9.026737757267256e-08
identification O 0 8.547095120547965e-08
of O 0 2.089080686218381e-09
common O 0 9.418225488388998e-08
BRCA1 O 0 2.1713171008741483e-05
and O 0 1.8224463360638765e-07
BRCA2 O 0 1.7592168660485186e-05
mutations O 0 6.292335115176684e-07
will O 0 3.728112041301301e-09
facilitate O 0 7.514750599568742e-09
carrier O 0 6.943372454770724e-08
detection O 0 3.5095613526436864e-08
in O 0 4.809100673242028e-09
French O 0 7.887447850407625e-07
Canadian O 0 5.795183824375272e-05
breast B-Disease 1 0.9994266033172607
cancer I-Disease 0 0.18531709909439087
and O 1 0.5473707318305969
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.77856997854542e-07
. O 0 2.418460098851938e-07

Are O 0 5.470108703775622e-07
Dp71 O 0 3.586331513361074e-05
and O 0 6.196140134306916e-08
Dp140 O 0 8.447261279798113e-06
brain O 0 6.103940540924668e-05
dystrophin O 0 6.18267513345927e-05
isoforms O 0 1.4175252545101102e-06
related O 0 9.241453824415657e-08
to O 0 3.193395770040297e-08
cognitive B-Disease 0 4.11713563153171e-06
impairment I-Disease 0 1.843956852098927e-05
in O 0 3.113010461675003e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
? O 0 0.0003022895834874362

Molecular O 0 2.1001535060349852e-05
study O 0 9.534533091937192e-07
and O 0 9.812963952526843e-08
neuropsychological O 0 2.3577015326736728e-06
analysis O 0 4.3403222349525095e-08
were O 0 3.960131333968775e-09
performed O 0 2.6046691914416442e-08
concurrently O 0 1.77635861575709e-08
on O 0 2.1650665260608548e-08
49 O 0 1.55685100367009e-07
patients O 0 6.234192539977812e-08
with O 0 5.610011157841654e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 4.979504956281744e-05
DMD B-Disease 1 1.0
) O 0 3.177822804900643e-08
in O 0 1.5087719962281199e-09
order O 0 4.959295751838511e-10
to O 0 2.1181362219735433e-10
find O 0 2.0350539309266225e-10
a O 0 2.4894797334695795e-10
molecular O 0 3.8184149175890525e-09
explanation O 0 9.515597199083459e-10
for O 0 1.221779483140395e-10
the O 0 6.291240417510835e-09
cognitive B-Disease 0 3.119022835562646e-07
impairment I-Disease 0 6.625842274843308e-08
observed O 0 4.73165613357196e-08
in O 0 2.4119410468870228e-08
most O 0 2.7518248657543154e-07
DMD B-Disease 1 1.0
patients O 0 2.160510302928742e-05
. O 0 2.873861149055301e-07

Complete O 0 1.0731080237746937e-06
analysis O 0 1.2106696090086189e-07
of O 0 1.7217182124440455e-09
the O 0 1.0091085300700797e-08
dystrophin O 0 1.3760154615738429e-05
gene O 0 1.2453957651814562e-06
was O 0 1.383841805591146e-07
performed O 0 9.567724390535659e-09
to O 0 3.9028250076178495e-10
define O 0 2.8266928797648916e-09
the O 0 1.8453170103072125e-09
localization O 0 4.0278397506199326e-08
of O 0 1.9173104770509042e-10
deletions O 0 1.2251253167505638e-07
and O 0 2.367897655730644e-09
duplications O 0 1.390551744862023e-07
in O 0 2.583983915727117e-09
relation O 0 6.923757567278699e-09
to O 0 2.316435931959404e-09
the O 0 1.0637513092603967e-08
different O 0 6.922255124663934e-08
DMD B-Disease 1 1.0
promoters O 0 1.4387373994395602e-05
. O 0 2.7008857728105795e-07

Qualitative O 0 1.0152922186534852e-05
analysis O 0 9.710893067449433e-08
of O 0 1.8253391020905951e-09
the O 0 5.094130894889304e-09
Dp71 O 0 1.8373756347500603e-06
transcript O 0 1.7606655546842376e-06
and O 0 3.0855300536813957e-09
testing O 0 4.962079636072758e-09
for O 0 5.3030375229967674e-11
the O 0 1.842896113490866e-10
specific O 0 2.795049469650479e-10
first O 0 1.1571487101846856e-09
exon O 0 5.2384351079126645e-08
of O 0 4.0886746766055637e-10
Dp140 O 0 2.604024018637574e-07
were O 0 5.768037603104403e-09
also O 0 2.736956661308909e-09
carried O 0 3.2274968475576316e-08
out O 0 2.2480348249587223e-08
. O 0 5.3073868855335604e-08

Neuropsychological O 0 0.0005557190743274987
analysis O 0 5.428023996500997e-06
assessed O 0 1.8249696722705266e-06
verbal O 0 4.8682509259379e-06
and O 0 1.3762991102339583e-07
visuospatial O 0 2.8350388674880378e-05
intelligence O 0 1.174593990072026e-06
, O 0 1.2019972572829829e-08
verbal O 0 8.041871524255839e-07
memory O 0 0.0011051606852561235
, O 0 1.36898217206749e-08
and O 0 1.0747108980524445e-08
reading O 0 9.476082141191e-07
skills O 0 4.2610358264028037e-07
. O 0 1.0610546041789348e-07

Comparison O 0 1.2213403124405886e-06
of O 0 7.2334565004439355e-09
molecular O 0 1.0180966825146243e-07
and O 0 4.5419930039258816e-09
psychometric O 0 1.2606204791154596e-06
findings O 0 5.714982975746352e-08
demonstrated O 0 3.047165364478133e-08
that O 0 1.6257244439543683e-09
deletions O 0 2.401933727469441e-07
and O 0 2.6089934657136382e-09
duplications O 0 1.0661201343964422e-07
that O 0 4.954568422199657e-10
were O 0 5.017945503560384e-10
localized O 0 3.575322082838284e-08
in O 0 5.8884355169652736e-09
the O 0 4.913313755849913e-09
distal O 0 3.329625144488091e-07
part O 0 1.0481860934774545e-09
of O 0 1.1008045863736271e-10
the O 0 1.1156308099558032e-09
gene O 0 9.120451949229391e-08
seemed O 0 2.8380933159155575e-08
to O 0 8.884681879095524e-10
be O 0 5.893893706421238e-10
preferentially O 0 1.8702134951809057e-08
associated O 0 4.792179542079111e-09
with O 0 4.2064294270005576e-09
cognitive B-Disease 0 2.0646546090574702e-06
impairment I-Disease 0 3.831421054201201e-06
. O 0 3.6943001191502844e-07

Two O 0 2.837157921931066e-07
altered O 0 1.0417635166959371e-05
Dp71 O 0 6.255374955799198e-06
transcripts O 0 3.3237307661693194e-07
and O 0 7.829496495581623e-10
two O 0 4.025685340636187e-10
deleted O 0 6.683938380547261e-08
Dp140 O 0 6.865700186153845e-08
DNA O 0 1.4941958781378162e-08
sequences O 0 7.672968926897283e-09
were O 0 1.0855386589625482e-09
found O 0 4.496410466181544e-10
in O 0 5.699563043748412e-10
four O 0 1.8955814695686968e-09
patients O 0 1.0705496045204654e-08
with O 0 5.5058766434967765e-08
severe O 1 0.9997920393943787
cerebral B-Disease 1 0.9999943971633911
dysfunction I-Disease 1 0.9299868941307068
. O 0 2.600331526991795e-06

These O 0 8.73707506343635e-08
findings O 0 1.388431627447062e-07
suggest O 0 2.417375633001484e-08
that O 0 2.775113194797285e-10
some O 0 1.2929891879398525e-10
sequences O 0 4.015732635309632e-09
located O 0 2.5813648107941845e-08
in O 0 2.0721433457993044e-09
the O 0 1.6656112045154714e-09
distal O 0 2.2762314699775743e-07
part O 0 1.2535912308209163e-09
of O 0 9.954884833129896e-11
the O 0 1.0483660606297462e-09
gene O 0 4.569418621258592e-08
and O 0 6.622083992269268e-10
, O 0 5.572831085487451e-11
in O 0 2.079395683418639e-10
particular O 0 9.304782500052511e-10
, O 0 3.240663015713352e-10
some O 0 1.7651177186550626e-09
DMD B-Disease 1 0.9999961853027344
isoforms O 0 1.3555469990933489e-07
expressed O 0 2.631975082323379e-09
in O 0 1.4705752171551012e-09
the O 0 1.622287015834445e-08
brain O 0 0.00012206676183268428
may O 0 1.6756915499627212e-07
be O 0 2.3547183647387726e-10
related O 0 5.535280567237066e-10
to O 0 3.0035160469843447e-10
the O 0 8.062796652552606e-09
cognitive B-Disease 0 4.3299127128193504e-07
impairment I-Disease 0 2.1402678385129548e-07
associated O 0 3.1640816189337784e-08
with O 0 9.482702978402813e-08
DMD B-Disease 1 1.0
. O 0 1.8579920890715584e-07
. O 0 2.906207043906761e-07

I1307K O 0 0.0002387849526712671
APC O 0 5.4067455494077876e-05
and O 0 1.4493107869384403e-07
hMLH1 O 0 7.5711445788329e-06
mutations O 0 2.7757730549637927e-06
in O 0 1.230208379610076e-08
a O 0 8.532268225280859e-09
non O 0 7.033730486938339e-09
- O 0 1.2045968844631716e-07
Jewish O 0 1.5223676541609166e-08
family O 0 4.384034024695893e-09
with O 0 1.5845154077709367e-09
hereditary B-Disease 0 0.15347081422805786
non I-Disease 0 0.0002204261691076681
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.697713196335826e-05

We O 0 1.2020436201964912e-07
describe O 0 3.1824328061702545e-08
a O 0 8.350625968489567e-09
French O 0 1.5879417958331032e-07
Canadian O 0 7.88557542819035e-07
hereditary B-Disease 0 0.3830006420612335
non I-Disease 0 0.014452117495238781
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.00021333518088795245
HNPCC B-Disease 1 0.9758988618850708
) O 0 1.0607956113517503e-07
kindred O 0 2.937142426162609e-06
which O 0 6.3137073347263595e-09
carries O 0 1.7525787043837227e-08
a O 0 5.311019624087976e-09
novel O 0 1.0652481563511174e-07
truncating O 0 4.4428411456465255e-06
mutation O 0 1.2297530247451505e-06
in O 0 8.12716862697016e-08
hMLH1 O 0 1.9005778085556813e-05
. O 0 4.2807002387235116e-07

Interestingly O 0 1.125469043472549e-05
, O 0 2.489368355895749e-08
the O 0 1.7626492265776506e-08
I1307K O 0 1.3007918369112303e-06
APC O 0 5.5045893532224e-07
polymorphism O 0 3.54441169747588e-07
, O 0 9.035583947714088e-10
associated O 0 1.0779458436971368e-09
with O 0 6.897007964745683e-11
an O 0 3.538324910845603e-10
increased O 0 5.6176947538233435e-08
risk O 0 8.997419627121417e-07
of O 0 0.0034358054399490356
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.0586870874694796e-08
is O 0 9.380837218131433e-10
also O 0 4.4072553939678016e-10
present O 0 1.1801262744803864e-10
in O 0 3.687530836238295e-10
this O 0 6.75490829937786e-10
family O 0 6.05704073564084e-08
. O 0 3.400694481570099e-08

The O 0 9.368844189339143e-07
I1307K O 0 7.0836599661561195e-06
polymorphism O 0 4.7381136027979665e-06
has O 0 1.7556098796944752e-08
previously O 0 4.867050762413783e-09
only O 0 2.8238786309309205e-10
been O 0 4.6544215703825387e-10
identified O 0 7.027115556113017e-10
in O 0 3.3484282013773736e-10
individuals O 0 9.935422623508217e-11
of O 0 2.514859986924023e-10
self O 0 6.88108400481724e-07
- O 0 1.966079253179487e-05
reported O 0 9.204639354720712e-06
Ashkenazi O 0 2.6954151053359965e-06
Jewish O 0 1.1330707394563433e-07
origins O 0 4.589552418110543e-07
. O 0 2.1166245289805374e-07

In O 0 1.1345618844416094e-07
addition O 0 7.651442146539011e-09
, O 0 3.1191380034378824e-10
in O 0 4.5532494441502536e-10
this O 0 5.79011283363684e-10
family O 0 4.560778865680959e-09
, O 0 8.426295772245851e-11
there O 0 5.847890921506504e-11
appears O 0 2.289483713724394e-09
to O 0 5.169535355342703e-10
be O 0 3.441676388327153e-10
no O 0 2.498632134528833e-10
relationship O 0 8.965747588796091e-10
between O 0 5.62006829962769e-10
the O 0 1.4754413246720333e-09
I1307K O 0 9.54844026068713e-08
polymorphism O 0 3.743619103602214e-08
and O 0 1.6993946527765758e-10
the O 0 1.1813378053560086e-10
presence O 0 1.1417561340820725e-09
or O 0 1.8583574679098547e-09
absence O 0 1.894200796215273e-09
of O 0 5.66490299114264e-10
cancer B-Disease 0 3.6237375411474204e-07
. O 0 4.2269223676782985e-09
. O 0 5.1945175272294364e-08

Identification O 0 8.613503723609028e-07
of O 0 1.0411052464576187e-08
a O 0 9.532186595606618e-09
novel O 0 3.903960532625206e-08
mutation O 0 7.266120860549563e-08
of O 0 3.5575503654072804e-10
the O 0 1.2308092323110031e-08
CPO O 0 2.3155134840635583e-06
gene O 0 5.296677230148816e-08
in O 0 8.494948633419597e-10
a O 0 4.648497142767383e-09
Japanese O 0 2.4559901135035034e-07
hereditary B-Disease 0 0.013492378406226635
coproporphyria I-Disease 0 6.077414218452759e-05
family O 0 8.304771768052888e-07
. O 0 2.3473290866604657e-07

Hereditary B-Disease 1 0.9997351765632629
coproporphyria I-Disease 1 0.9244617819786072
( O 0 2.1578580344794318e-05
HCP B-Disease 0 0.002038752194494009
) O 0 2.511075791744588e-08
is O 0 1.9381147797759013e-09
an O 0 7.56297779958004e-09
autosomal B-Disease 1 0.999984622001648
dominant I-Disease 1 0.9999982118606567
disease I-Disease 1 0.9972609281539917
characterized O 0 7.477421490875713e-07
by O 0 1.8865398132561495e-08
a O 0 5.908999355597189e-06
deficiency B-Disease 0 0.005068022757768631
of I-Disease 0 1.7756802694890439e-09
coproporphyrinogen I-Disease 0 5.348413469619118e-05
oxidase I-Disease 0 1.0864403520827182e-05
( O 0 6.632758697833196e-08
CPO O 0 8.590979632572271e-06
) O 0 1.7597930890289604e-09
caused O 0 4.358205352161804e-09
by O 0 4.472170689329147e-10
a O 0 3.9855541089650615e-09
mutation O 0 1.2655105763315078e-07
in O 0 6.325062251733016e-09
the O 0 2.239129592851441e-08
CPO O 0 1.693126068857964e-05
gene O 0 2.0112797756155487e-06
. O 0 1.392231609997907e-07

Only O 0 2.515328390018112e-07
11 O 0 6.805660746067588e-08
mutations O 0 8.853918842532948e-08
of O 0 2.0136595169084615e-10
the O 0 1.1655284515299513e-09
gene O 0 1.0858874333052881e-07
have O 0 1.2418681638592943e-09
been O 0 2.0918398124791793e-09
reported O 0 8.398885853466709e-08
in O 0 1.9769717596318515e-07
HCP B-Disease 0 0.14435304701328278
patients O 0 1.9467870515654795e-06
. O 0 2.0494536556725507e-07

We O 0 2.147554738485269e-07
report O 0 3.481578758623982e-08
another O 0 5.639538613877448e-09
mutation O 0 7.992398565193071e-08
in O 0 2.1886403800408516e-09
a O 0 6.4477951866592775e-09
Japanese O 0 1.1656317155939178e-07
family O 0 1.0709830178257107e-07
. O 0 7.125173340227775e-08

Polymerase O 0 0.00046716522774659097
chain O 0 0.0008306173840537667
reaction O 0 2.0307179511291906e-05
- O 0 8.129019079206046e-06
single O 0 1.302761774013561e-07
strand O 0 1.164444483947591e-06
conformational O 0 2.3985961661310284e-07
polymorphism O 0 5.13412203417829e-07
and O 0 2.578342206405182e-09
direct O 0 1.4300339579165211e-08
sequence O 0 5.44543823366439e-08
analyses O 0 4.515735341215077e-08
demonstrated O 0 1.8469728857439804e-08
a O 0 1.7324644829841418e-08
C O 0 1.8080378367812955e-06
to O 0 7.304469917812639e-09
T O 0 6.509061449833098e-07
substitution O 0 1.4784027335679184e-08
in O 0 3.594691877495393e-09
exon O 0 7.84964484523698e-08
1 O 0 1.3908370011250781e-09
of O 0 7.791384898370168e-11
the O 0 1.905906321653106e-09
CPO O 0 8.103514801405254e-07
gene O 0 5.578529282956879e-08
at O 0 5.6808437953748125e-09
nucleotide O 0 3.909996593165488e-08
position O 0 1.439005625769596e-08
85 O 0 5.252088097762453e-09
, O 0 9.411514623192119e-11
which O 0 3.0749300328203333e-10
lies O 0 1.050832421078951e-09
in O 0 6.947737940521392e-10
the O 0 1.891081735649891e-09
putative O 0 5.5609369553621946e-08
presequence O 0 7.457653339315584e-08
for O 0 3.311008689443895e-10
targeting O 0 8.754586389159158e-09
to O 0 3.7284819676131065e-09
mitochondria O 0 1.686958626123669e-06
. O 0 1.0510598968949125e-07

This O 0 1.9807913531622034e-07
mutation O 0 2.1801643015351146e-06
changes O 0 7.629047615864692e-08
the O 0 8.835510101334876e-09
codon O 0 7.108300792424416e-07
for O 0 8.7134843784753e-10
glutamine O 0 1.64565051363752e-07
to O 0 2.5118600532891833e-09
a O 0 2.370664731188299e-08
termination O 0 1.8751945844996953e-06
codon O 0 5.6653684623597655e-06
at O 0 1.6984316175694403e-07
amino O 0 1.9388076566428936e-07
acid O 0 5.757482313129003e-07
position O 0 4.5213374733066303e-07
29 O 0 6.312782829809294e-07
. O 0 5.053295737411645e-08

MaeI O 0 0.00029831973370164633
restriction O 0 2.3514412532676943e-06
analysis O 0 5.200019259632427e-08
showed O 0 5.107521161562545e-08
two O 0 4.273524867315359e-10
other O 0 1.5796955410429803e-10
carriers O 0 2.4098383288873038e-09
in O 0 8.839871057375603e-10
the O 0 4.988393698113214e-09
family O 0 6.587772816146753e-08
. O 0 3.4929659165072735e-08

The O 0 1.9580670596042182e-06
C O 0 0.06418699771165848
- O 0 0.015112875029444695
T O 0 0.0029318861197680235
mutation O 0 9.504746003585751e-07
is O 0 1.8589884076547492e-09
located O 0 6.080687064979884e-09
within O 0 9.575131798555958e-10
a O 0 2.1904527081062497e-09
recently O 0 2.311798397158782e-08
proposed O 0 5.240320621879846e-09
putative O 0 1.1934081101117044e-07
alternative O 0 2.669184873127506e-08
translation O 0 1.214067708588118e-07
initiation O 0 1.7858853595953406e-07
codon O 0 8.869882549333852e-06
( O 0 1.3444029889342346e-07
TIC O 0 4.8174075345741585e-05
- O 0 1.3586803106591105e-05
1 O 0 2.901697371271439e-08
) O 0 1.288415707456636e-09
, O 0 1.5609462333809887e-10
supporting O 0 8.38384917045687e-10
that O 0 1.1129719368341284e-09
TIC O 0 5.3183680392976385e-06
- O 0 3.2361072044295724e-06
1 O 0 2.2050585357646924e-08
is O 0 5.082928522526231e-10
the O 0 1.5065404479486233e-09
real O 0 2.4566618961330278e-08
TIC O 0 9.350322898171726e-07
rather O 0 5.183637075134584e-09
than O 0 4.253270624587913e-09
TIC O 0 5.199709448788781e-06
- O 0 1.0125443168362835e-06
2 O 0 1.9978005028065127e-08
. O 0 1.470880972576083e-09
. O 0 1.8722763783785012e-08

Human B-Disease 0 2.2620383788307663e-06
complement I-Disease 0 8.178457392205019e-06
factor I-Disease 0 2.085219784930814e-05
H I-Disease 1 1.0
deficiency I-Disease 1 0.9998985528945923
associated O 0 1.0185965038544964e-05
with O 0 0.00012014036474283785
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.85270977858454e-05

This O 0 6.118465734061829e-08
study O 0 6.089833526345956e-09
reports O 0 5.512756473535774e-09
on O 0 5.321239893163465e-09
six O 0 9.123593547322173e-10
cases O 0 3.7771241689910084e-10
of O 0 1.1719574199986482e-09
deficiency B-Disease 0 3.4948034226545133e-06
in I-Disease 0 7.191413020635196e-10
the I-Disease 0 8.260767625500876e-10
human I-Disease 0 1.7249000006103188e-09
complement I-Disease 0 2.5875758424831474e-08
regulatory I-Disease 0 2.738567275173409e-07
protein I-Disease 0 3.9523615669168066e-07
Factor I-Disease 0 2.8331618295851513e-07
H I-Disease 1 1.0
( O 0 4.885226871920167e-07
FH O 0 5.6797096476657316e-05
) O 0 1.2147024497366488e-09
in O 0 3.5949160315240647e-10
the O 0 2.612726979211999e-10
context O 0 1.6045117456897628e-09
of O 0 2.3068144616722464e-10
an O 0 5.175213502184306e-08
acute B-Disease 1 0.9997676014900208
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.258542038674932e-06

Five O 0 8.179841159972057e-08
of O 0 5.949894466006356e-10
the O 0 8.93859875006342e-10
cases O 0 4.4036929658375357e-10
were O 0 5.152583915091213e-10
observed O 0 3.562454553573957e-09
in O 0 1.0209602052668743e-09
children O 0 1.0884244616704564e-09
presenting O 0 3.3771787144587506e-08
with O 0 2.5231031486327993e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00031549434061162174
HUS B-Disease 1 0.9999977350234985
) O 0 1.6161307030415628e-06
. O 0 9.233152127308131e-07

Two O 0 3.222188738050136e-08
of O 0 1.3695926615042708e-09
the O 0 4.055319191564877e-09
children O 0 2.9687519109700133e-09
exhibited O 0 8.519555194652639e-08
a O 0 1.138389933430517e-07
homozygous O 0 0.07527966797351837
deficiency O 0 0.0009238779311999679
characterized O 0 7.355151865340304e-08
by O 0 4.825823740617352e-09
the O 0 1.0457503307748084e-08
absence O 0 1.252315673383464e-08
of O 0 1.246423658729512e-10
the O 0 1.815280925576701e-09
150 O 0 1.568641927462977e-08
- O 0 2.0954571766651497e-07
kD O 0 2.3200460930183908e-07
form O 0 3.482453436731703e-09
of O 0 6.488354853395606e-10
Factor O 0 1.7317477229994438e-08
H O 1 0.9999984502792358
and O 0 5.13917686184584e-10
the O 0 2.4647414664791256e-10
presence O 0 5.547741710465459e-10
, O 0 8.607892176826226e-11
upon O 0 2.6031662936354394e-10
immunoblotting O 0 2.6727304813789488e-08
, O 0 7.632384307898477e-11
of O 0 2.513755523181338e-11
the O 0 2.1204940026109398e-09
42 O 0 1.1466020310990643e-07
- O 0 4.3305485064593086e-07
kD O 0 2.7298212899040664e-06
Factor O 0 1.8522263189879595e-07
H O 1 0.9999935626983643
- O 0 1.0200262750004185e-06
like O 0 2.0873848427527264e-08
protein O 0 2.664338296654023e-07
1 O 0 8.749366031679529e-08
( O 0 3.057388298088881e-08
FHL O 0 1.82568564923713e-05
- O 0 2.955566515083774e-06
1 O 0 1.5751179915923785e-08
) O 0 3.4280558947052953e-10
and O 0 2.174346674932437e-10
other O 0 6.974119060032535e-10
FH O 0 2.094576666422654e-05
- O 0 1.5303658074117266e-07
related O 0 4.232652628388678e-08
protein O 0 2.591073382518516e-07
( O 0 2.133359089384612e-08
FHR O 0 3.5628279420052422e-06
) O 0 8.361847214644058e-09
bands O 0 2.009591213436579e-07
. O 0 6.7512438306494e-08

Southern O 0 1.2167631211923435e-05
blot O 0 0.0005479473038576543
and O 0 4.1686607943347553e-08
PCR O 0 2.952630666186451e-06
analysis O 0 1.0670840211446375e-08
of O 0 2.0093969543832912e-10
DNA O 0 7.704733739899439e-09
of O 0 1.6856875617587974e-10
one O 0 4.364017480718019e-10
patient O 0 3.927112146584477e-08
with O 0 3.7250789119980254e-08
homozygous O 1 0.6194595098495483
deficiency O 0 0.007904386147856712
ruled O 0 5.666248625857406e-08
out O 0 1.6723820106534504e-09
the O 0 3.4385730374175694e-10
presence O 0 6.987460610119456e-10
of O 0 5.3144388195702774e-11
a O 0 9.040824755501831e-10
large O 0 5.509957490268391e-10
deletion O 0 3.4088053268988006e-08
of O 0 2.359042960975444e-10
the O 0 9.341009743479844e-09
FH O 0 6.761875738447998e-06
gene O 0 5.417373571958706e-08
as O 0 9.68770397236085e-10
the O 0 2.013207378581683e-09
underlying O 0 4.606152970154653e-08
defect O 0 1.7642038585563569e-07
for O 0 1.146159278597736e-09
the O 0 2.5770265210667276e-07
deficiency O 0 0.0004553894395940006
. O 0 1.5696872424086905e-07

The O 0 9.570209869025348e-08
other O 0 1.5547516607483658e-09
four O 0 1.1455953963235288e-09
children O 0 5.774441480532744e-10
presented O 0 2.6356823390472073e-09
with O 0 1.8135306589783795e-08
heterozygous O 1 0.6243018507957458
deficiency O 0 0.0004052228759974241
and O 0 4.034788947393508e-09
exhibited O 0 2.4895447836570384e-07
a O 0 1.982578723414008e-08
normal O 0 2.043044332822319e-06
immunoblotting O 0 5.969081030343659e-06
pattern O 0 3.6872816622235405e-07
of O 0 3.309714169397182e-10
proteins O 0 5.382014389709866e-09
of O 0 7.126703116533406e-10
the O 0 6.446175149221745e-08
FH O 0 0.0003526236105244607
family O 0 2.3570062523958768e-07
. O 0 6.669650076673861e-08

Factor B-Disease 0 0.00828772597014904
H I-Disease 1 1.0
deficiency I-Disease 1 0.9903230667114258
is O 0 4.152018728831308e-09
the O 0 7.1414976154926535e-09
only O 0 7.055392359234247e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 6.885646826049197e-07
with O 0 2.2035959545974038e-07
HUS B-Disease 1 0.9999748468399048
. O 0 2.2461697426479077e-06

These O 0 1.4815552162872336e-07
observations O 0 3.6072765396966133e-07
suggest O 0 7.147782810079661e-08
a O 0 1.1290360646398767e-08
role O 0 1.0330880151343536e-08
for O 0 7.233994736566274e-09
FH O 0 0.00013080373173579574
and O 0 3.385989444382176e-08
/ O 0 3.223104067728855e-05
or O 0 4.2146757550654e-07
FH O 0 4.499887290876359e-05
receptors O 0 1.9360508929366915e-07
in O 0 4.2406744782397254e-09
the O 0 1.4415935112310763e-08
pathogenesis O 0 2.5759773052413948e-06
of O 0 1.4794098390780164e-08
idiopathic O 0 0.0019349423237144947
HUS B-Disease 1 0.9990904331207275
. O 0 1.8519595812449552e-07
. O 0 2.2826573342626943e-07

Further O 0 9.251294130763199e-08
evidence O 0 7.519108891074211e-09
for O 0 1.9561853525917883e-10
a O 0 4.938284225985967e-10
major O 0 8.659754024975541e-10
ancient O 0 1.879761946099734e-08
mutation O 0 0.00013370859960559756
underlying O 0 0.003892784472554922
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 9.329453405371169e-07
linkage O 0 2.7133190087624826e-05
disequilibrium O 0 1.3910883353673853e-05
studies O 0 4.8928548324056464e-08
in O 0 4.3558450180114505e-09
the O 0 1.8329832096597443e-09
Japanese O 0 6.257912588125691e-08
population O 0 1.691705975304103e-08
. O 0 3.0718378951632985e-08

The O 0 0.0004297134291846305
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9040385484695435
DM B-Disease 1 1.0
) O 0 4.045660659812711e-07
mutation O 0 1.7827011333793052e-06
is O 0 4.595672731255718e-09
an O 0 3.42898620608878e-09
unstable O 0 4.817315493710339e-05
( O 0 6.615676539922788e-08
CTG O 0 4.961428203387186e-06
) O 0 1.1029956503705307e-08
n O 0 1.3266003406897653e-07
repeat O 0 2.8519750117084186e-07
, O 0 3.7940631192334706e-10
present O 0 8.07325650775681e-10
at O 0 6.150147058292532e-09
a O 0 7.908065313699808e-10
copy O 0 1.0357243951375494e-07
number O 0 3.436468332118636e-10
of O 0 9.688548574526834e-11
5 O 0 2.83886212315565e-08
- O 0 4.6279490106826415e-07
37 O 0 7.936465351576771e-08
repeats O 0 5.311893573889392e-07
on O 0 2.7807908864474484e-08
normal O 0 9.381543719655383e-08
chromosomes O 0 4.462546954187019e-08
but O 0 7.793157785762617e-10
amplified O 0 1.4327783048884157e-07
to O 0 2.0659474131434763e-09
50 O 0 6.874739444384659e-09
- O 0 3.6691385929543685e-08
3000 O 0 3.065271059199404e-08
copies O 0 1.215908440599378e-08
on O 0 7.52622838717798e-07
DM B-Disease 1 1.0
chromosomes O 0 5.0830872169171926e-06
. O 0 1.37362150098852e-07

Previous O 0 3.2712075608287705e-06
findings O 0 5.367520543586579e-07
in O 0 1.5908694805943924e-08
Caucasian O 0 2.526541322822595e-07
populations O 0 9.721434324205802e-09
of O 0 5.531839430972241e-10
a O 0 8.566236147089512e-07
DM B-Disease 1 1.0
founder O 0 3.474703817119007e-06
chromosome O 0 3.769183194890502e-06
raise O 0 6.908497596214147e-08
a O 0 4.0848107119018096e-09
question O 0 1.1285532508509277e-09
about O 0 1.4592750618991346e-10
the O 0 3.0974983689091573e-10
molecular O 0 2.6080630988190023e-09
events O 0 6.195271518016909e-10
involved O 0 2.0573112657906734e-10
in O 0 1.0960409246862923e-09
the O 0 3.926196701087292e-09
expansion O 0 1.3579381175077287e-07
mutation O 0 9.73646592683508e-07
. O 0 1.1030697066871653e-07

To O 0 2.002520318455936e-07
investigate O 0 1.3229995943220274e-07
whether O 0 1.1359093221585681e-08
a O 0 7.386556255539745e-09
founder O 0 1.591043314874696e-07
chromosome O 0 4.5005674564890796e-07
for O 0 1.3725661718311244e-09
the O 0 1.2160295170815516e-07
DM B-Disease 1 1.0
mutation O 0 9.276487276110856e-07
exists O 0 2.2287318657276955e-09
in O 0 5.561143212595709e-10
the O 0 7.557639514210734e-10
Japanese O 0 9.736520922842828e-09
population O 0 4.415366405829957e-10
, O 0 2.9163205184090657e-10
we O 0 5.954356452342324e-10
genotyped O 0 2.1242603054361098e-07
families O 0 1.0978570275099742e-09
using O 0 9.70500035890609e-09
polymorphic O 0 1.663931243456318e-06
markers O 0 5.082972620584769e-07
near O 0 5.620963179353566e-07
the O 0 3.2229326762944766e-08
( O 0 3.0468282119500145e-08
CTG O 0 3.079587031606934e-06
) O 0 8.917997007529266e-09
n O 0 4.616655076006282e-07
repeat O 0 9.786344890017062e-07
region O 0 1.0604618694287637e-07
and O 0 1.8173741622717898e-08
constructed O 0 8.816724061944115e-07
haplotypes O 0 1.542084828543011e-05
. O 0 3.414617424368771e-07

Six O 0 2.437242301311926e-07
different O 0 1.2631637069659973e-08
haplotypes O 0 9.416921216143237e-07
were O 0 8.26247426033433e-09
found O 0 1.6491233267856842e-08
and O 0 2.289153826495749e-07
DM B-Disease 1 1.0
alleles O 0 3.3280043680861127e-06
were O 0 3.633426359783698e-08
always O 0 4.4553772227118316e-08
haplotype O 0 4.814059593627462e-06
A O 0 2.3352606604021275e-07
. O 0 1.9678786600252351e-07

To O 0 1.2354264811165194e-07
find O 0 8.721869448891084e-09
an O 0 2.978823854249413e-10
origin O 0 6.976540456449243e-10
of O 0 1.1597511145877704e-10
the O 0 6.842075794821767e-09
( O 0 1.4425341809953807e-08
CTG O 0 1.855010054896411e-06
) O 0 5.745495190723204e-09
n O 0 1.0362144564624032e-07
repeat O 0 4.94277912821417e-07
mutation O 0 1.9531029238351039e-07
and O 0 2.769113383038757e-09
to O 0 4.916067553040193e-10
investigate O 0 1.7911200300702035e-09
the O 0 1.0386927984384897e-09
mechanism O 0 5.705678596257258e-09
of O 0 4.552101057209157e-11
the O 0 1.4687384641831613e-10
expansion O 0 3.6720495533160147e-09
mutation O 0 9.588696947560038e-09
in O 0 3.8090799958645505e-10
the O 0 4.290013622121336e-10
Japanese O 0 4.537611619781501e-09
population O 0 2.0934712297027147e-10
we O 0 1.817164474449129e-10
have O 0 1.779137254187546e-10
studied O 0 2.8511135674591515e-09
90 O 0 8.03304800456317e-09
Japanese O 0 3.5396183761804423e-07
DM B-Disease 1 1.0
families O 0 7.993919304283281e-09
comprising O 0 2.8761726333925708e-09
190 O 0 3.250577762514695e-08
affected O 0 1.5131186970052113e-08
and O 0 3.78065800887839e-09
130 O 0 5.3579476855247776e-08
unaffected O 0 9.731026011650101e-07
members O 0 1.3505887963560781e-08
. O 0 6.968367927129293e-08

The O 0 2.704953487864259e-07
results O 0 1.4235155276765e-07
suggest O 0 2.348486205505651e-08
that O 0 2.542699384378011e-10
a O 0 1.5136664144321799e-09
few O 0 8.260626627176748e-10
common O 0 2.71420774744513e-09
ancestral O 0 4.329441338768447e-08
mutations O 0 6.275626418528191e-08
in O 0 1.4872062470416836e-09
both O 0 1.357499224141634e-09
Caucasian O 0 5.3692417623096844e-08
and O 0 1.328716248139017e-09
Japanese O 0 9.983779136746307e-09
populations O 0 2.3900770251827907e-09
have O 0 2.602957849262566e-10
originated O 0 1.7330321622210931e-09
by O 0 1.5314322032722316e-10
expansion O 0 1.3402260412576084e-09
of O 0 1.0559754459738002e-10
an O 0 4.243609630361078e-10
ancestral O 0 1.622491794250891e-07
n O 0 2.6179381507063226e-07
= O 0 1.670936029540826e-07
5 O 0 3.326317710161675e-08
repeat O 0 2.7894611775991507e-07
to O 0 1.769001478635346e-08
n O 0 7.222946010188025e-07
= O 0 4.172304954863648e-07
19 O 0 8.461579881213765e-08
- O 0 2.527765730064857e-07
37 O 0 9.534736022942525e-08
copies O 0 1.0054854016061654e-07
. O 0 5.973950578663789e-08

These O 0 1.7968186227790284e-07
data O 0 1.2469818955196388e-07
support O 0 8.774981630210732e-09
multistep O 0 5.120890023135871e-07
models O 0 1.6383219758608902e-07
of O 0 1.5004838482823857e-09
triplet O 0 1.115421673603123e-05
repeat O 0 3.985297780673136e-07
expansion O 0 1.0537874572946748e-08
that O 0 3.702923800918967e-10
have O 0 1.2436736362975154e-10
been O 0 2.09032319231639e-10
proposed O 0 9.430062286597263e-10
for O 0 3.7946279451972487e-10
both O 0 3.227694023166805e-08
DM B-Disease 1 1.0
and O 0 3.443814762249531e-07
Friedreichs B-Disease 0 0.0006076385034248233
ataxia I-Disease 1 0.9324595928192139
. O 0 6.116470530059814e-08
. O 0 1.456415930078947e-07

The O 0 1.7805996321840212e-07
molecular O 0 9.517017929283611e-07
basis O 0 1.8459995487773995e-07
of O 0 6.430682901736873e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.2152136125441757e-08
the O 0 3.173048490623387e-09
western O 0 1.5999651381548574e-08
Cape O 0 4.701187208411284e-07
, O 0 8.969989750973184e-10
South O 0 5.3467967831011265e-09
Africa O 0 2.8576263133572866e-08
. O 0 5.507189371201093e-08

Deficiency B-Disease 1 0.9997215867042542
of I-Disease 0 2.24476561783149e-08
the I-Disease 0 2.3237566537659404e-08
sixth I-Disease 0 9.578300108614712e-08
component I-Disease 0 1.3847548885337346e-08
of I-Disease 0 2.2636381658003302e-10
human I-Disease 0 1.90367210883835e-09
complement I-Disease 0 7.143258073938341e-08
( O 0 6.009538111584334e-08
C6 O 0 3.055609340663068e-05
) O 0 1.741710997649193e-09
has O 0 1.975428709499738e-09
been O 0 1.055853071640911e-09
reported O 0 3.1191291327559156e-08
in O 0 4.1997896826906356e-10
a O 0 4.5128722980791736e-10
number O 0 2.590653559730871e-11
of O 0 1.1634505858726385e-11
families O 0 6.481400832702988e-11
from O 0 1.1299872149095336e-10
the O 0 3.633394973778792e-10
western O 0 1.1226691576382564e-08
Cape O 0 2.0830026414841996e-07
, O 0 6.91079748982304e-10
South O 0 4.367808781324811e-09
Africa O 0 1.5146691012546398e-08
. O 0 2.1658058457774132e-08

Meningococcal B-Disease 1 0.9999210834503174
disease I-Disease 1 0.9995915293693542
is O 0 7.125513690198204e-08
endemic O 0 8.507117854605895e-08
in O 0 6.0847131777563845e-09
the O 0 9.921495625064836e-09
Cape O 0 1.4349733419294353e-06
and O 0 3.305191120794859e-10
almost O 0 4.1046771537267546e-10
all O 0 9.421752267257943e-11
pedigrees O 0 5.0027267661789665e-08
of O 0 1.5313628143331925e-09
total O 0 2.6957466161547927e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 9.051823468553266e-08
C6Q0 O 0 4.27161758125294e-05
) O 0 4.377249673837014e-09
have O 0 7.751959074653314e-10
been O 0 1.7769304916370743e-09
ascertained O 0 1.4888305699400917e-08
because O 0 7.082432418314966e-10
of O 0 2.7592015339195086e-09
recurrent O 0 0.0005817372002638876
disease O 0 0.0012402848806232214
. O 0 4.527732357928471e-07

We O 0 4.008388998499868e-07
have O 0 6.6021481615052835e-09
sequenced O 0 9.438582537768525e-08
the O 0 1.6013871340092578e-09
expressed O 0 2.254035846860347e-09
exons O 0 4.1204717859955053e-08
of O 0 2.726659176222057e-10
the O 0 5.7399089925525004e-09
C6 O 0 5.719077762478264e-06
gene O 0 9.578482718097803e-08
from O 0 3.1479592266236978e-09
selected O 0 2.1140609263170518e-09
cases O 0 2.32440608427531e-10
and O 0 3.7904757110851506e-10
have O 0 5.1434790454552015e-11
found O 0 3.2748320721864843e-10
three O 0 2.8674948526763444e-10
molecular O 0 3.869113243126776e-07
defects O 0 5.682987466570921e-05
leading O 0 7.222785480820448e-09
to O 0 1.0489626944831798e-08
total O 0 8.333080359079759e-08
deficiency O 0 7.488192932214588e-05
879delG O 0 4.485202396153909e-07
, O 0 7.242937916096537e-10
which O 0 2.7185687034858574e-10
is O 0 1.1662705523551864e-10
the O 0 4.2214573503507324e-10
common O 0 1.5269886688429324e-08
defect O 0 1.0076912815293326e-07
in O 0 1.6606371833205458e-09
the O 0 8.801634088229093e-09
Cape O 0 2.901485061101994e-07
and O 0 1.1459100335287076e-09
hitherto O 0 6.579633282655095e-09
unreported O 0 1.5956398424776808e-09
, O 0 2.1393264937330514e-10
and O 0 4.0429215530934925e-10
1195delC O 0 8.220460046004519e-08
and O 0 1.321676879051381e-09
1936delG O 0 1.0165773289827484e-07
, O 0 4.036934120321689e-10
which O 0 4.010556609035376e-10
have O 0 1.0133275468726666e-10
been O 0 1.4275824966603068e-10
previously O 0 7.588955575066336e-10
reported O 0 6.60301724408896e-09
in O 0 1.6301522354211784e-09
African O 0 7.251995448598336e-09
- O 0 5.916058967159188e-07
Americans O 0 2.0109748533059246e-08
. O 0 5.922093393451178e-08

We O 0 1.6223401644310798e-07
also O 0 6.167827582004293e-09
show O 0 1.07321973530361e-08
that O 0 1.0300314767786034e-10
the O 0 1.124972892618814e-09
879delG O 0 3.6008424331157585e-07
and O 0 9.483006380150982e-09
1195delC O 0 0.00011092265049228445
defects O 0 0.0014993379591032863
are O 0 4.247285856351368e-10
associated O 0 7.734122675628896e-09
with O 0 1.1367458974120837e-08
characteristic O 0 0.014114595018327236
C6 O 1 0.998675525188446
/ O 0 0.008785514160990715
C7 O 0 8.030503522604704e-05
region O 0 2.3734567378141946e-07
DNA O 0 1.8993534922628896e-06
marker O 0 1.963272779903491e-06
haplotypes O 0 1.2254728289917693e-06
, O 0 1.2089195200459812e-09
although O 0 9.36862587508358e-10
small O 0 1.2940752913692677e-09
variations O 0 1.421495454678734e-07
were O 0 1.845902275476874e-08
observed O 0 1.4840311735042633e-07
. O 0 1.0170001019105257e-07

The O 0 1.2920335166199948e-06
1936delG O 0 5.066925223218277e-05
defect O 0 1.6293486623908393e-05
was O 0 7.760695552860852e-08
observed O 0 1.0746740386480269e-08
only O 0 3.991204033937379e-10
once O 0 1.049070053049661e-09
in O 0 3.9961933762100443e-10
the O 0 1.3806978893526889e-09
Cape O 0 3.4313892172121996e-08
, O 0 1.0035259428997634e-10
but O 0 7.917161370940562e-11
its O 0 1.6440849792687118e-09
associated O 0 1.3736274340203636e-08
haplotype O 0 9.258563977709855e-07
could O 0 1.1369822416895659e-08
be O 0 4.540815279341359e-09
deduced O 0 2.5324709440610604e-07
. O 0 5.154477022983883e-08

The O 0 1.7118146899974818e-07
data O 0 1.853442057608845e-07
from O 0 1.9442867316143975e-09
the O 0 7.355649978002532e-10
haplotypes O 0 6.187683965208635e-08
indicate O 0 6.7600542941193e-09
that O 0 9.068228112862897e-11
these O 0 6.580128802946561e-11
three O 0 5.849633555321532e-10
molecular O 0 3.9500102388956293e-07
defects O 0 4.003489084425382e-05
account O 0 4.866865577213275e-09
for O 0 9.222533847719205e-10
the O 0 5.870562631571374e-07
defects O 0 0.10165352374315262
in O 0 2.164293411155427e-09
all O 0 6.457634427192716e-11
the O 0 9.075863394159001e-10
38 O 0 1.3374228835516533e-08
unrelated O 0 1.50770258500188e-08
C6Q0 O 0 1.394923060615838e-06
individuals O 0 7.372968902075172e-10
we O 0 2.0666597599916514e-10
have O 0 8.626843683856578e-11
studied O 0 1.4085367316951647e-09
from O 0 3.9783898397871553e-10
the O 0 3.971144302283847e-09
Cape O 0 1.150353682533023e-06
. O 0 6.272551189567821e-08

We O 0 1.1265176880215222e-07
have O 0 2.1166186581211832e-09
also O 0 1.940067662076217e-09
observed O 0 6.428785503942436e-09
the O 0 3.7060345903228153e-09
879delG O 0 1.673757310527435e-06
defect O 0 2.450651095387002e-07
in O 0 2.5542012949131276e-09
two O 0 9.897151542759275e-09
Dutch O 1 0.9958147406578064
C6 B-Disease 1 1.0
- I-Disease 1 0.9999982118606567
deficient I-Disease 1 1.0
kindreds O 0 5.378940841183066e-06
, O 0 7.814129898697786e-10
but O 0 3.940809623070862e-10
the O 0 2.462374304457171e-09
879delG O 0 6.30540057500184e-07
defect O 0 1.2136510463278682e-07
in O 0 1.2328714715792444e-09
the O 0 1.6694405857720085e-09
Cape O 0 1.7327859325177997e-07
probably O 0 1.4354310629016709e-08
did O 0 2.4499691164692194e-09
not O 0 1.0253270454896324e-10
come O 0 1.845449765225382e-10
from O 0 2.0846374626515285e-10
The O 0 8.033655962691455e-10
Netherlands O 0 4.673944431488053e-08
. O 0 1.5600896130507635e-09
. O 0 9.193892758219135e-09

Complement B-Disease 1 0.9998012185096741
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 9.506788245516873e-08
seven O 0 8.174066756794218e-09
further O 0 1.6176706196802115e-08
molecular O 0 2.4973471226985566e-05
defects O 1 0.9838963747024536
and O 0 9.60898205448757e-09
their O 0 1.8050826611215598e-08
associated O 0 4.132341189233557e-07
marker O 0 6.169927928567631e-06
haplotypes O 0 1.2012763363600243e-05
. O 0 2.5671755565781496e-07

Seven O 0 4.04974088041854e-07
further O 0 4.572243383904606e-08
molecular O 0 2.5482810883659113e-07
bases O 0 1.645303768782469e-07
of O 0 1.1121375109723886e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.5889440874161664e-08
described O 0 4.525349481809826e-07
. O 0 9.17921241239128e-08

All O 0 6.219620019010108e-08
these O 0 1.92936600029725e-09
new O 0 2.6591337132231274e-08
molecular O 0 2.0176673842797754e-06
defects O 0 7.773822289891541e-05
involve O 0 5.23145260444835e-09
single O 0 8.831790410113172e-08
- O 0 7.054799198158435e-07
nucleotide O 0 1.4261230774081923e-07
events O 0 9.949199686332122e-09
, O 0 1.082602452129322e-09
deletions O 0 1.8181445682330377e-07
and O 0 2.5402575598576504e-09
substitutions O 0 1.7714492983600394e-08
, O 0 1.7355254733342207e-10
some O 0 5.4828239171023085e-11
of O 0 1.0063992000874933e-10
which O 0 2.6740754055509797e-09
alter O 0 6.464335342570848e-07
splice O 0 1.9720466752914945e-06
sites O 0 2.8229496962239864e-08
, O 0 6.775295324779051e-10
and O 0 7.516294253662181e-10
others O 0 5.553281390291431e-09
codons O 0 7.958503829286201e-07
. O 0 5.932890800863788e-08

They O 0 9.978470671967443e-08
are O 0 1.1594751825327876e-09
distributed O 0 2.85062973226502e-09
along O 0 2.9665330192329975e-09
the O 0 1.1184992487756062e-08
C7 O 0 6.313195626717061e-06
gene O 0 2.237055554132894e-07
, O 0 3.932542624873747e-10
but O 0 1.1750726780501708e-10
predominantly O 0 7.746756569559921e-10
towards O 0 5.696856875125889e-10
the O 0 1.6944565750520724e-09
3 O 0 2.3625171152730218e-08
end O 0 1.882073092929204e-07
. O 0 4.428663302746827e-08

All O 0 7.899841136804753e-08
were O 0 3.4189031605791342e-09
found O 0 2.5526913915996374e-09
in O 0 3.0318587640465466e-09
compound O 0 1.4748097498795687e-07
heterozygous O 0 1.8001578609982971e-06
individuals O 0 8.831297471090238e-09
. O 0 4.8775920191701516e-08

The O 0 7.221624400699511e-05
C6 O 1 0.99354088306427
/ O 0 0.25648966431617737
C7 O 0 0.0012888881610706449
marker O 0 2.282869172631763e-05
haplotypes O 0 1.2481038538680878e-05
associated O 0 4.542926603789965e-07
with O 0 3.987555530216014e-08
most O 0 1.2395518069752143e-06
C7 B-Disease 1 0.9999991655349731
defects I-Disease 1 0.9999927282333374
are O 0 1.5456425472848423e-08
tabulated O 0 7.055647301967838e-07
. O 0 9.741535578200455e-09
. O 0 5.001716019137348e-08

A O 0 1.944089490280021e-06
genome O 0 2.4705059331608936e-06
- O 0 1.0696800245568738e-06
wide O 0 6.680127739855379e-08
search O 0 2.827266065708045e-08
for O 0 5.708661099390611e-09
chromosomal O 0 2.0851162844337523e-05
loci O 0 1.2119846815039637e-06
linked O 0 9.546957699058112e-06
to O 0 2.2430714352594805e-07
mental O 0 9.391152161697391e-06
health O 0 1.9064533773871517e-07
wellness O 0 2.2402537069865502e-07
in O 0 3.6575102946301286e-09
relatives O 0 1.645993563670345e-08
at O 0 5.446507600481709e-08
high O 0 4.68036745360223e-07
risk O 0 4.04797248165778e-07
for O 0 1.5550882892512163e-07
bipolar B-Disease 1 0.9999957084655762
affective I-Disease 1 0.8315014243125916
disorder I-Disease 0 0.3460131287574768
among O 0 7.346694363974393e-09
the O 0 3.6179496731847394e-08
Old O 0 3.8773823689552955e-06
Order O 0 6.101218019693988e-08
Amish O 0 8.144382263708394e-06
. O 0 9.820546864602875e-08

Bipolar B-Disease 1 0.9999998807907104
affective I-Disease 1 0.9999922513961792
disorder I-Disease 1 0.9999994039535522
( O 0 0.00021860943525098264
BPAD B-Disease 1 1.0
; O 0 0.02829792909324169
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 0.9999890327453613
) O 0 4.2924000354105374e-08
is O 0 1.6973094041361492e-09
characterized O 0 2.408024712963197e-08
by O 0 2.6152511267696354e-09
episodes O 0 1.2347410915936052e-07
of O 0 6.280126640945127e-09
mania B-Disease 0 0.00026603593141771853
and O 0 1.9858909183767537e-07
/ O 0 0.0002750241255853325
or O 0 5.362650767892774e-07
hypomania B-Disease 0 0.0004236920503899455
interspersed O 0 1.1252866443101084e-06
with O 0 6.879684821825549e-09
periods O 0 1.6761119070451969e-07
of O 0 9.680320545157883e-09
depression B-Disease 0 2.3673272153246216e-05
. O 0 2.1316920140179718e-07

Compelling O 0 2.2884298687131377e-06
evidence O 0 7.445927252547335e-08
supports O 0 2.9961839231873455e-08
a O 0 4.755847715642858e-09
significant O 0 3.2391200832648792e-09
genetic O 0 3.26277707074496e-08
component O 0 6.139329933319004e-09
in O 0 2.0284940394077466e-09
the O 0 6.0067284479714544e-09
susceptibility O 0 4.782138489645149e-07
to O 0 4.522527419226208e-08
develop O 0 3.5380460303713335e-06
BPAD B-Disease 1 1.0
. O 0 1.2604941730387509e-06

To O 0 1.766123034485645e-07
date O 0 5.855365969864579e-08
, O 0 5.428797966722243e-10
however O 0 8.064822143438732e-10
, O 0 2.214358002516903e-10
linkage O 0 1.6585772755206563e-08
studies O 0 5.762063604031198e-10
have O 0 1.667091464874204e-10
attempted O 0 2.537226206911214e-09
only O 0 1.206589966828986e-10
to O 0 1.0059717503452248e-09
identify O 0 4.058640712401029e-08
chromosomal O 0 5.248989054962294e-06
loci O 0 6.115793382832635e-08
that O 0 5.917514811493163e-10
cause O 0 1.639835822686564e-08
or O 0 3.855827657162081e-09
increase O 0 1.6872711006143959e-09
the O 0 3.0619036195389526e-09
risk O 0 2.3447800145959263e-08
of O 0 1.1830024737591316e-09
developing O 0 3.6751592347172846e-07
BPAD B-Disease 1 1.0
. O 0 7.434076678691781e-07

To O 0 1.2443446451015916e-07
determine O 0 1.989731046592169e-08
whether O 0 3.748190202657042e-09
there O 0 4.262396824383785e-10
could O 0 1.739871580141994e-09
be O 0 3.7348998893627083e-10
protective O 0 2.8665683160511435e-08
alleles O 0 1.6592512253055247e-08
that O 0 2.0920301602167513e-10
prevent O 0 9.128088507281973e-09
or O 0 5.889491561106297e-09
reduce O 0 1.6842429673147308e-08
the O 0 2.8699915777252727e-09
risk O 0 4.906196782172856e-09
of O 0 3.494501632506086e-10
developing O 0 3.195187048277148e-08
BPAD B-Disease 1 1.0
, O 0 7.981056926453789e-10
similar O 0 2.619054972896606e-09
to O 0 6.709759969858453e-10
what O 0 1.274634148229481e-10
is O 0 4.088875765750899e-11
observed O 0 3.6910632883468963e-10
in O 0 4.822435228923894e-10
other O 0 6.1055347444494146e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.784031893909855e-09
we O 0 1.1912989483775505e-09
used O 0 3.4131716120100464e-07
mental O 0 3.846985691779992e-06
health O 0 2.1726623344875406e-07
wellness O 0 5.595322818408022e-07
( O 0 2.826412659473476e-09
absence O 0 4.260285901835914e-09
of O 0 4.675830278522142e-10
any O 0 2.359865050038934e-07
psychiatric B-Disease 1 0.5981863141059875
disorder I-Disease 0 0.0004368577210698277
) O 0 1.1755977302740916e-09
as O 0 1.2771657065258069e-09
the O 0 4.290752197988468e-09
phenotype O 0 3.688322749439976e-07
in O 0 2.651449282353724e-09
our O 0 5.722964768750671e-09
genome O 0 1.3016168054491573e-07
- O 0 2.9473978884198004e-06
wide O 0 2.1556311935455597e-07
linkage O 0 2.3308739400818013e-06
scan O 0 3.5838565963786095e-05
of O 0 5.000603819915739e-10
several O 0 8.016298735924465e-10
large O 0 3.590710395684482e-09
multigeneration O 0 3.446335540502332e-06
Old O 0 2.577011741777824e-07
Order O 0 9.058159555763723e-09
Amish O 0 1.0931019005511189e-06
pedigrees O 0 6.732327619829448e-07
exhibiting O 0 1.2112285219245678e-07
an O 0 3.962548955627199e-09
extremely O 0 7.028776849438145e-07
high O 0 2.3476084606954828e-05
incidence O 0 0.00011483434354886413
of O 0 1.161348706091303e-07
BPAD B-Disease 1 1.0
. O 0 1.2306776397963404e-06

We O 0 2.2211669659100153e-07
have O 0 2.112150232491672e-09
found O 0 9.710755533021143e-10
strong O 0 1.5338212921989225e-09
evidence O 0 4.432106626151011e-10
for O 0 2.280208799554373e-10
a O 0 2.6226090188430362e-09
locus O 0 1.1573882119364498e-07
on O 0 3.902025014212995e-08
chromosome O 0 9.994515494327061e-06
4p O 0 3.4533364669186994e-05
at O 0 1.0054623800215268e-07
D4S2949 O 0 9.118440402744454e-07
( O 0 2.317754344005607e-08
maximum O 0 1.2622562906017265e-07
GENEHUNTER O 0 3.8681351725244895e-05
- O 0 5.0345347517577466e-06
PLUS O 0 3.521450082644151e-07
nonparametric O 0 2.9454085961333476e-06
linkage O 0 1.2031575806759065e-06
score O 0 4.321851463373605e-07
= O 0 4.65094757373663e-07
4 O 0 4.737001901844451e-08
. O 0 3.3469866878022003e-09
05 O 0 1.382384539283521e-06
, O 0 4.942988685030514e-09
P O 0 7.680786438868381e-06
= O 0 2.14209734394899e-07
5 O 0 1.5131128350276413e-08
. O 0 1.1024818835636552e-09
22 O 0 2.5389896407546075e-08
x O 0 1.7205098856720724e-06
10 O 0 4.128330388653012e-08
( O 0 3.296556627674363e-08
- O 0 3.19166565532214e-06
4 O 0 4.6088775462749254e-08
) O 0 2.1492045920723513e-09
; O 0 2.7494198029387462e-09
SIBPAL O 0 1.0765891147457296e-06
Pempirical O 0 4.5976565843375283e-07
value O 0 1.672673377584033e-08
< O 0 4.919711926731907e-08
3 O 0 5.787753387664907e-09
x O 0 1.2644915159398806e-06
10 O 0 2.4624977612575094e-08
( O 0 2.0447009418944617e-08
- O 0 3.876990376738831e-06
5 O 0 2.2400692856194837e-08
) O 0 6.185330025942903e-10
) O 0 2.4283811073111394e-10
and O 0 3.7653852258401344e-10
suggestive O 0 6.233277360934153e-08
evidence O 0 4.504238648728176e-10
for O 0 2.5678187354216675e-10
a O 0 3.1206393025229318e-09
locus O 0 3.2789549209155666e-07
on O 0 3.4554312833279255e-07
chromosome O 0 0.00013303128071129322
4q O 0 0.004435344133526087
at O 0 4.80891969800723e-07
D4S397 O 0 2.590618578324211e-06
( O 0 2.0009732537573655e-08
maximum O 0 1.9001547002517327e-07
GENEHUNTER O 0 5.4278185416478664e-05
- O 0 6.355687673931243e-06
PLUS O 0 6.824560045970429e-07
nonparametric O 0 4.089723461220274e-06
linkage O 0 1.3615680245493422e-06
score O 0 2.913205605636904e-07
= O 0 3.5857539160133456e-07
3 O 0 2.282739508530085e-08
. O 0 1.6040129224847988e-09
29 O 0 5.6704003270624526e-08
, O 0 2.64940180905171e-09
P O 0 2.7110691007692367e-05
= O 0 1.9344821566846804e-07
2 O 0 1.1010870437644371e-08
. O 0 7.994769291030934e-10
57 O 0 4.366145134326871e-08
x O 0 1.841203129515634e-06
10 O 0 4.741024284271589e-08
( O 0 2.0352850071958528e-08
- O 0 2.6233867629343877e-06
3 O 0 5.518829837569683e-08
) O 0 2.5797293190521486e-09
; O 0 1.7005012953319465e-09
SIBPAL O 0 1.0970119319608784e-06
Pempirical O 0 3.094747285103949e-07
value O 0 7.848249161668264e-09
< O 0 6.105350536245169e-08
1 O 0 8.321466182792392e-09
x O 0 1.2929284594065393e-06
10 O 0 2.925694175814897e-08
( O 0 2.0083453122765604e-08
- O 0 4.319290383136831e-06
3 O 0 1.5013005949526814e-08
) O 0 2.5268320769100683e-10
) O 0 1.0696994678927041e-10
that O 0 3.8730199602987625e-11
are O 0 7.568656118506212e-11
linked O 0 5.855823914657776e-08
to O 0 2.509313823395587e-08
mental O 0 4.143945716350572e-06
health O 0 9.570763950250694e-07
wellness O 0 6.774410849175183e-06
. O 0 3.8837970350869e-07

These O 0 9.354366170555295e-08
findings O 0 1.1366943653001726e-07
are O 0 1.315612951913181e-09
consistent O 0 4.978147671863553e-09
with O 0 1.6228608734625283e-10
the O 0 7.003551627526861e-10
hypothesis O 0 3.0592242072913223e-09
that O 0 7.5956997636073e-11
certain O 0 3.5517061514056536e-10
alleles O 0 1.4588090735401238e-08
could O 0 3.0696516439832067e-09
prevent O 0 1.5942655195999578e-08
or O 0 1.9554859065351593e-08
modify O 0 9.664925073593622e-07
the O 0 1.0519078053050634e-08
clinical O 0 6.673581509630822e-08
manifestations O 0 1.0919812609699875e-07
of O 0 5.410854875265159e-09
BPAD B-Disease 1 1.0
and O 0 5.191968632800581e-09
perhaps O 0 1.9207813117816386e-09
other O 0 1.1581048342534928e-09
related O 0 4.5401591819427267e-07
affective B-Disease 0 0.0012124560307711363
disorders I-Disease 0 0.2908380925655365
. O 0 1.0788400004457799e-06

Segregation O 0 0.002347825560718775
distortion O 0 0.16205310821533203
in O 0 0.0004758813010994345
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 4.2904091969830915e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9996067881584167
DM B-Disease 1 1.0
) O 0 2.694143290682405e-07
is O 0 9.463221317673742e-09
an O 0 9.310610060708768e-09
autosomal B-Disease 1 0.9994801878929138
dominant I-Disease 1 0.9999806880950928
disease I-Disease 1 0.9970256686210632
which O 0 1.295780371890487e-08
, O 0 1.492593548757526e-10
in O 0 1.5556050891873952e-10
the O 0 1.0507201775311614e-09
typical O 0 8.618501823320912e-08
pedigree O 0 5.108646519147442e-07
, O 0 2.9549321323152355e-10
shows O 0 3.4262275239171913e-09
a O 0 2.725308645423752e-09
three O 0 2.068115900755174e-09
generation O 0 4.056195024304543e-08
anticipation O 0 1.7713556133003294e-07
cascade O 0 5.842441623826744e-06
. O 0 3.370680019543215e-07

This O 0 2.0871664219157537e-07
results O 0 9.250638299818092e-07
in O 0 1.1847620271510095e-06
infertility B-Disease 1 0.9651824235916138
and O 0 0.21445372700691223
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.094150815741159e-05
CDM B-Disease 0 2.1496998670045286e-05
) O 0 3.3932676668513295e-09
with O 0 2.051535469282939e-10
the O 0 1.8186909755968372e-09
disappearance O 0 8.106701443466591e-08
of O 0 1.0497132052478264e-08
DM B-Disease 1 1.0
in O 0 4.411187504160807e-08
that O 0 1.4319854635402862e-08
pedigree O 0 3.827735781669617e-06
. O 0 1.4978147078181792e-07

The O 0 8.391952377451162e-08
concept O 0 2.9078915275704276e-08
of O 0 1.3822788469397551e-09
segregation O 0 2.2260655896388926e-07
distortion O 0 4.0669056033948436e-07
, O 0 3.0016719665404423e-10
where O 0 1.679064387527518e-10
there O 0 7.702522647479171e-11
is O 0 1.7346882263957752e-10
preferential O 0 8.624187586292464e-09
transmission O 0 1.6434859162473003e-06
of O 0 7.842256705137274e-11
the O 0 1.1503358265940733e-09
larger O 0 8.601714007738792e-09
allele O 0 1.6706971450730634e-07
at O 0 3.888295552201271e-08
the O 0 1.3009093891014345e-07
DM B-Disease 1 1.0
locus O 0 1.2870848422608105e-06
, O 0 1.4687140392766196e-09
has O 0 1.2147882699764523e-09
been O 0 1.096429946834121e-09
put O 0 5.208036224502166e-09
forward O 0 5.47630740754812e-09
to O 0 3.6730161134812533e-09
explain O 0 1.6853451967335786e-08
partially O 0 6.55162182283675e-08
the O 0 3.014433369585845e-09
maintenance O 0 2.7438680660907266e-08
of O 0 1.4704994999448218e-09
DM B-Disease 1 1.0
in O 0 1.2256319514847291e-08
the O 0 9.630670483318227e-09
population O 0 7.3338979333925636e-09
. O 0 2.8548750918844235e-08

In O 0 7.577975225103728e-07
a O 0 1.1413020928330297e-07
survey O 0 3.683169893520244e-07
of O 0 7.788288236554308e-09
DM B-Disease 1 1.0
in O 0 5.4687738781922235e-08
Northern O 0 9.03826347098402e-08
Ireland O 0 4.9570684268474e-07
, O 0 1.1180464332127826e-09
59 O 0 2.019504030670305e-08
pedigrees O 0 2.1087645052375592e-07
were O 0 2.0711484083335563e-08
ascertained O 0 7.618169206580205e-07
. O 0 1.5091821126134164e-07

Sibships O 0 7.824275962775573e-05
where O 0 7.35732612611173e-08
the O 0 4.3480259392936205e-09
status O 0 1.0568201869176619e-09
of O 0 5.805193131758202e-11
all O 0 3.2686398726555765e-11
the O 0 1.034161506430209e-10
members O 0 1.0759938079418774e-10
had O 0 8.648430305235877e-10
been O 0 3.1981164938521545e-10
identified O 0 4.2232936592334624e-10
were O 0 2.9939525858502236e-10
examined O 0 2.869646520409219e-09
to O 0 3.5467845327374903e-10
determine O 0 1.1901860608176662e-09
the O 0 2.1936932270705256e-09
transmission O 0 1.2300931757636135e-06
of O 0 1.2452212871938428e-10
the O 0 1.1868497296063651e-08
DM B-Disease 1 1.0
expansion O 0 3.136280568583061e-08
from O 0 2.561323819705308e-09
affected O 0 3.7248921724852835e-09
parents O 0 3.8550114211943765e-09
to O 0 5.13751097219739e-10
their O 0 7.924814582338513e-09
offspring O 0 1.303432810573213e-07
. O 0 2.7910568078937104e-08

Where O 0 3.716786238783243e-07
the O 0 9.709577852845541e-08
transmitting O 0 2.398841388639994e-05
parent O 0 3.0390333449759055e-06
was O 0 4.8358330673181626e-08
male O 0 9.25296728127023e-09
, O 0 1.2449892228261206e-09
58 O 0 7.445940752859315e-08
. O 0 3.577347484906568e-08

3 O 0 5.808690843878139e-07
% O 0 3.8228162857478765e-09
of O 0 1.4907100553962493e-10
the O 0 7.680550639932449e-10
offspring O 0 1.7835832366586146e-08
were O 0 2.0019497171119838e-09
affected O 0 3.3177620650803874e-09
, O 0 1.5741943859559626e-10
and O 0 2.7083676967798453e-10
in O 0 2.6898805405295434e-10
the O 0 2.4668014853013176e-10
case O 0 1.4749117205337114e-10
of O 0 3.4722093256167597e-11
a O 0 2.2138608724020514e-09
female O 0 1.610439070987013e-08
transmitting O 0 3.222743998776423e-06
parent O 0 5.115154522172816e-07
, O 0 4.379888451921943e-09
68 O 0 4.094251551123307e-07
. O 0 8.349817903763324e-08

7 O 0 6.87055398884695e-06
% O 0 6.729477775024861e-08
were O 0 1.85715709477563e-08
affected O 0 1.923341841347792e-07
. O 0 1.8071570195843378e-07

Studies O 0 4.235497272020439e-06
on O 0 2.600653772333317e-07
meiotic O 0 1.3616404430649709e-05
drive O 0 5.107757715450134e-06
in O 0 8.339613373209431e-07
DM B-Disease 1 1.0
have O 0 5.972478511750978e-09
shown O 0 1.2806301796786101e-08
increased O 0 7.0110672822920606e-09
transmission O 0 4.468620034003834e-07
of O 0 3.749637753069912e-11
the O 0 2.9614322105686597e-10
larger O 0 2.7478574970984937e-09
allele O 0 1.6864844099018228e-07
at O 0 3.646916724164839e-08
the O 0 7.147959735220866e-08
DM B-Disease 1 1.0
locus O 0 9.27020892049768e-07
in O 0 5.541381042917237e-08
non O 0 3.742727301414561e-07
- O 0 0.13196834921836853
DM O 1 1.0
heterozygotes O 0 2.3529899408458732e-05
for O 0 5.801670965865924e-08
CTGn O 0 2.5113660740316845e-05
. O 0 2.8390689976731665e-07

This O 0 6.71187834200282e-08
study O 0 5.580314432762634e-09
provides O 0 1.053346854185122e-09
further O 0 3.170082807368857e-10
evidence O 0 3.9043662747317853e-10
that O 0 2.9514513055772795e-10
the O 0 3.735494757961533e-08
DM B-Disease 1 1.0
expansion O 0 9.760081809417898e-08
tends O 0 1.873670214536105e-07
to O 0 5.806340297453971e-09
be O 0 4.863580205238804e-09
transmitted O 0 4.3495733734744135e-06
preferentially O 0 7.486683557544893e-07
. O 0 6.630759941117503e-08

Diagnosis O 1 0.9420561790466309
of O 0 5.419856734079076e-06
hemochromatosis B-Disease 1 1.0
. O 0 1.0244005352433305e-05

If O 0 3.4379056614852743e-06
untreated O 0 0.00023764569777995348
, O 0 9.847046840150142e-07
hemochromatosis B-Disease 1 1.0
can O 0 2.4254955860669725e-05
cause O 0 1.5009623894002289e-05
serious O 0 1.5840192645555362e-05
illness O 0 0.017884166911244392
and O 0 1.8899216414069997e-08
early B-Disease 0 6.775935617042705e-06
death I-Disease 0 1.623568891773175e-06
, O 0 2.9927765821113894e-10
but O 0 4.122825969510302e-10
the O 0 1.0937108996245115e-08
disease O 0 2.3956729364726925e-06
is O 0 1.0105699610463148e-09
still O 0 3.527457437257908e-09
substantially O 0 5.663395654664782e-07
under O 0 5.523989443645405e-07
- O 1 0.9667043685913086
diagnosed O 0 0.005031113047152758
. O 0 1.2710417252037587e-07

The O 0 2.1604799371743866e-07
cornerstone O 0 2.856351954960701e-07
of O 0 7.50178585917638e-10
screening O 0 2.4813948229507332e-08
and O 0 6.973294719436751e-10
case O 0 5.033455319214397e-10
detection O 0 8.961529296414028e-09
is O 0 2.5249674573402103e-10
the O 0 4.653276375332638e-10
measurement O 0 1.4131443570875035e-08
of O 0 7.011116687216656e-10
serum O 0 2.0971025094240758e-07
transferrin O 0 2.6165153599322366e-07
saturation O 0 1.7933774643097422e-07
and O 0 3.5037737156073945e-09
the O 0 1.3650997665592968e-08
serum O 0 2.1787925561511656e-06
ferritin O 0 2.2705804440192878e-05
level O 0 4.6854140123286925e-07
. O 0 2.601060486995266e-07

Once O 0 2.352959654672304e-06
the O 0 4.9370836308071375e-08
diagnosis O 0 1.270032225875184e-05
is O 0 4.049066415490188e-09
suspected O 0 1.7079678116260766e-07
, O 0 2.232033002869116e-09
physicians O 0 2.1772207148273992e-08
must O 0 5.006189685019535e-09
use O 0 5.38038520403461e-08
serum O 0 5.9499507187865674e-06
ferritin O 0 3.256018317188136e-05
levels O 0 1.852948571468005e-06
and O 0 2.8185541012248905e-08
hepatic O 0 6.44445390207693e-05
iron O 0 5.2910534577677026e-05
stores O 0 1.1245034329476766e-05
on O 0 6.328044719339232e-07
liver O 0 0.00010479950287844986
biopsy O 0 0.0001989388547372073
specimens O 0 2.3086567324526186e-08
to O 0 5.308406603177218e-09
assess O 0 7.449208538901075e-08
patients O 0 1.431559404352356e-08
for O 0 1.7636898885786678e-10
the O 0 9.969293168765603e-10
presence O 0 5.401719072040123e-09
of O 0 1.9694468278430577e-09
iron B-Disease 0 0.0018446213798597455
overload I-Disease 0 8.538573638361413e-06
. O 0 8.634346215785627e-08

Liver O 1 0.9998552799224854
biopsy O 1 0.9997503161430359
is O 0 2.841272639386716e-08
also O 0 2.616034500135811e-09
used O 0 1.3905080420428817e-09
to O 0 3.6237335354627476e-10
establish O 0 7.158759696146433e-10
the O 0 3.6991049112700125e-10
presence O 0 1.5780520223884764e-09
or O 0 2.6075208658937754e-09
absence O 0 2.244567420817134e-09
of O 0 4.2684494827582853e-10
cirrhosis B-Disease 0 1.2502653135015862e-06
, O 0 6.49090503568317e-10
which O 0 3.022758710002904e-09
can O 0 7.462886308928773e-09
affect O 0 1.2926334136409423e-07
prognosis O 0 2.6473530851944815e-06
and O 0 2.363819717743354e-08
management O 0 5.068649215900223e-07
. O 0 1.5602488190324948e-07

A O 0 8.219266192099894e-07
DNA O 0 1.2871191756858025e-06
- O 0 1.0417130624773563e-06
based O 0 1.062903542958793e-08
test O 0 1.549941153200507e-08
for O 0 2.0732413008595074e-10
the O 0 1.0764212854397215e-09
HFE O 0 3.0378539577213814e-06
gene O 0 5.0600856837945685e-08
is O 0 4.2207490280610216e-10
commercially O 0 1.390996096084507e-09
available O 0 7.790586509237585e-10
, O 0 3.395426648178379e-11
but O 0 5.0862234562965014e-11
its O 0 6.636574623186675e-10
place O 0 5.796488844467262e-10
in O 0 2.817368838226031e-10
the O 0 2.1319341847458873e-09
diagnosis O 0 9.640871212468483e-07
of O 0 6.416522868590846e-09
hemochromatosis B-Disease 1 1.0
is O 0 3.987205587918652e-08
still O 0 1.1965690660531436e-08
being O 0 2.079738692373212e-08
evaluated O 0 1.999817840214746e-07
. O 0 5.151518678303546e-08

Currently O 0 1.5755453830479382e-07
, O 0 1.6224626087080196e-09
the O 0 4.068448911098699e-10
most O 0 2.3620416733649563e-10
useful O 0 3.70251412862288e-10
role O 0 2.431495560450969e-10
for O 0 1.0045772547151444e-10
this O 0 2.5807317394210827e-10
test O 0 5.488563381561562e-09
is O 0 6.397501278732065e-11
in O 0 1.3369930162987487e-10
the O 0 5.524627422204276e-10
detection O 0 2.680531352439175e-08
of O 0 5.5891131722773935e-09
hemochromatosis B-Disease 1 1.0
in O 0 1.5240759765333678e-08
the O 0 4.408872378292017e-09
family O 0 2.0216266438666253e-09
members O 0 6.255708451252673e-11
of O 0 4.25366408762784e-11
patients O 0 5.189194629551253e-10
with O 0 9.843637016615503e-11
a O 0 9.902759501301261e-09
proven O 0 2.6513141904160875e-08
case O 0 1.1157371693215623e-09
of O 0 2.5757357358102695e-10
the O 0 5.975648775802256e-08
disease O 0 7.727394404355437e-06
. O 0 6.212862047050294e-08

It O 0 1.126069761880899e-07
is O 0 4.305278800131873e-09
crucial O 0 1.6932037993910853e-08
to O 0 9.076771334548539e-08
diagnose O 1 0.9999903440475464
hemochromatosis B-Disease 1 1.0
before O 0 0.010709811002016068
hepatic B-Disease 1 0.9999862909317017
cirrhosis I-Disease 1 0.9596158862113953
develops O 0 1.945137591974344e-05
because O 0 2.2020665824129537e-07
phlebotomy O 0 0.002244893228635192
therapy O 0 0.0001148218652815558
can O 0 3.97430653720221e-07
avert O 0 0.28223317861557007
serious O 1 0.9818164110183716
chronic O 1 1.0
disease O 1 0.9999984502792358
and O 0 5.347003479982959e-07
can O 0 2.4444345214647e-08
even O 0 6.390325157923371e-09
lead O 0 1.2247813430121823e-08
to O 0 2.4783850527398954e-09
normal O 0 1.7153443820916436e-07
life O 0 1.8812182034366742e-08
expectancy O 0 3.4820963890069834e-08
. O 0 1.016999262581919e-09
. O 0 1.550053418952757e-08

Prevalence O 0 5.341823271010071e-05
of O 0 2.903779261487216e-08
the O 0 3.8254437839668753e-08
I1307K O 0 3.1240049338521203e-06
APC B-Disease 0 8.866219332048786e-07
gene O 0 5.688392548108823e-07
variant O 0 4.780077347277256e-07
in O 0 6.805164876055869e-09
Israeli O 0 2.881621519179589e-08
Jews O 0 2.032770174409393e-09
of O 0 1.0847846232397984e-10
differing O 0 1.8407328994385352e-09
ethnic O 0 3.8246811273623393e-10
origin O 0 1.0076424139526807e-09
and O 0 6.311179134854683e-09
risk O 0 5.970317715764395e-07
for O 0 0.00014006815035827458
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.304495185650012e-06

BACKGROUND O 0 0.00023312408302444965
& O 0 1.0823575394169893e-05
AIMS O 0 1.9172397003330843e-07
Israeli O 0 4.646106432915076e-08
Jews O 0 7.1180399352499535e-09
of O 0 4.694937216775941e-10
European O 0 6.417260323132723e-08
birth O 0 5.2456111916399095e-06
, O 0 1.4299869066647375e-09
i O 0 3.1486320217766206e-09
. O 0 1.314022224363498e-10
e O 0 6.765691118459927e-09
. O 0 1.536517302280771e-10
, O 0 1.8730425543900253e-10
Ashkenazim O 0 1.0630682112378054e-07
, O 0 1.6535343927426283e-10
have O 0 1.2760985323989615e-10
the O 0 5.653014056861139e-08
highest O 1 0.9999178647994995
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 4.0915136196417734e-05
of O 0 3.013109761695887e-10
any O 0 7.51155082578947e-10
Israeli O 0 2.505688456722055e-08
ethnic O 0 5.120539992020667e-09
group O 0 1.538718485960544e-08
. O 0 2.6214852510975106e-08

The O 0 1.611395077816269e-06
I1307K O 0 3.725094938999973e-05
APC B-Disease 0 7.68673635320738e-06
gene O 0 3.176712880303967e-06
variant O 0 9.430586942471564e-06
was O 0 6.404824262062903e-07
found O 0 1.2720270170518688e-08
in O 0 2.26760743515797e-08
6 O 0 3.384460001143452e-07
. O 0 7.365498788658442e-08

1 O 0 1.4339883591674152e-06
% O 0 8.704934550962662e-09
of O 0 2.2866809834543034e-10
American O 0 6.52022602576352e-10
Jews O 0 1.2061787124650891e-09
, O 0 2.0833376690454486e-10
28 O 0 1.5435972500199568e-09
% O 0 7.496776116555637e-11
of O 0 1.6209551756407592e-10
their O 0 0.0056831855326890945
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 3.9094268799999554e-07
, O 0 2.339695104325301e-09
but O 0 7.747672503555236e-10
not O 0 5.074093922807776e-10
in O 0 2.0103831932516414e-09
non O 0 8.152362340752006e-09
- O 0 2.748032841282111e-07
Jews O 0 7.311414407240591e-08
. O 0 5.01717529743928e-08

We O 0 4.4799017473451386e-07
assessed O 0 2.798181526486587e-07
the O 0 1.3189904279897746e-08
I1307K O 0 1.005469698611705e-06
prevalence O 0 2.124442772810653e-07
in O 0 3.294832406908199e-09
Israeli O 0 1.3422630118498091e-08
Jews O 0 1.5962547950110206e-09
of O 0 5.2919734566669874e-11
differing O 0 7.952277170097943e-10
ethnic O 0 2.779197150193369e-10
origin O 0 9.951890422854603e-10
and O 0 4.725556390638985e-09
risk O 0 7.857260015953216e-07
for O 0 0.0024956557899713516
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.2307151564527885e-06

METHODS O 0 3.8065384160290705e-06
DNA O 0 7.943974651425378e-07
samples O 0 8.92012792519381e-08
from O 0 3.0817894902668286e-09
500 O 0 2.9720719219028524e-09
unrelated O 0 7.993325112920502e-09
Jews O 0 1.7711883071314105e-09
of O 0 1.6713386230549077e-10
European O 0 1.5301198530437432e-08
or O 0 1.3361836970204877e-08
non O 0 5.419427573372104e-09
- O 0 2.3760243550441373e-08
European O 0 3.954447436171904e-09
origin O 0 5.418597792683499e-10
, O 0 6.504956295838582e-11
with O 0 7.968974785610428e-11
or O 0 7.608216279209046e-10
without O 0 1.6209737718764217e-10
a O 0 8.88137785537424e-10
personal O 0 7.900667675642126e-09
and O 0 1.2664204795953538e-08
/ O 0 2.7009680707124062e-05
or O 0 1.9891693625595508e-08
family O 0 6.537925312244397e-09
history O 0 1.8093767595317445e-09
of O 0 4.3547132566601476e-10
neoplasia B-Disease 0 1.730650728859473e-05
, O 0 1.2114724778911068e-09
were O 0 1.9975252563142476e-09
examined O 0 2.3368327717321336e-08
for O 0 1.9420953734083923e-10
the O 0 1.2182386210923823e-09
I1307K O 0 1.6601192953658028e-07
variant O 0 1.3083719352380285e-07
by O 0 1.4072371046225385e-09
the O 0 3.514858404329857e-09
allele O 0 9.416049806532101e-07
- O 0 2.818958364514401e-07
specific O 0 4.6412704790554926e-08
oligonucleotide O 0 2.9496442948584445e-05
( O 0 3.855977297462232e-07
ASO O 0 0.0004238055262248963
) O 0 4.145025656043799e-08
method O 0 3.517791640206269e-07
. O 0 1.4962056127387768e-07

RESULTS O 0 3.265422265030793e-06
In O 0 2.1230325941701267e-08
persons O 0 2.0632224817518363e-09
at O 0 1.231034651993923e-08
average O 0 3.556774288426823e-07
risk O 0 2.0803793177037733e-06
for O 1 0.5444068312644958
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.637844881940964e-08
I1307K O 0 5.844977408742125e-07
was O 0 5.456167073703e-08
found O 0 3.033362450111099e-09
in O 0 6.115721262744955e-09
5 O 0 8.45815861794108e-08
. O 0 6.298891008782448e-08

0 O 0 1.4299951089924434e-06
% O 0 1.8071634855232332e-08
of O 0 3.181652719064232e-10
120 O 0 7.335940299668664e-09
European O 0 3.235163958947851e-08
and O 0 5.39500533136561e-09
1 O 0 5.976948358465961e-08
. O 0 6.658807194526162e-08

6 O 0 4.008047653769609e-06
% O 0 1.5244744133724453e-08
of O 0 1.3007568355760668e-09
188 O 0 1.0437261721563118e-07
non O 0 5.407308378835296e-08
- O 0 7.104755468390067e-07
European O 0 1.626324461767581e-07
Jews O 0 4.030252398479206e-08
( O 0 1.874148658487229e-08
P O 0 1.1166487638547551e-05
= O 0 3.5373236073610315e-07
0 O 0 4.15828154132214e-08
. O 0 8.048967714557875e-09
08 O 0 6.416048563551158e-07
) O 0 2.0103227527101808e-08
. O 0 3.8137439872798495e-08

It O 0 3.2881737865864125e-07
occurred O 0 4.1948544549086364e-07
in O 0 2.8479680835857835e-08
15 O 0 7.727048512151669e-08
. O 0 6.339098490570905e-08

4 O 0 7.623009992130392e-07
% O 0 9.299393255446375e-09
of O 0 5.331213248638278e-10
52 O 0 6.541520036762449e-08
Ashkenazi O 0 1.0058600992124411e-06
Israelis O 0 8.84738611262037e-08
with O 0 8.64383764564991e-08
familial O 1 0.9273043870925903
cancer B-Disease 0 0.15906725823879242
( O 0 2.383837198749461e-07
P O 0 0.0004671135975513607
= O 0 1.6093144949991256e-06
0 O 0 1.1697342472416494e-07
. O 0 8.399827500227275e-09
02 O 0 6.967968602111796e-07
) O 0 1.160470719518969e-09
and O 0 7.996568962553852e-10
was O 0 5.89119952820738e-09
not O 0 5.683995496497118e-10
detected O 0 3.1581368631350415e-08
in O 0 4.817133358869796e-09
51 O 0 2.8840519306072565e-08
non O 0 2.92003976554156e-09
- O 0 2.9092340980696463e-08
European O 0 8.066979972909394e-09
Jews O 0 2.586276526272968e-09
at O 0 2.9229054732127224e-08
increased O 0 2.4585750679761986e-07
cancer B-Disease 0 3.438607336647692e-06
risk O 0 3.19665048209572e-07
. O 0 1.1586030268517788e-07

Colorectal B-Disease 1 0.9999923706054688
neoplasia I-Disease 1 0.9828914403915405
occurred O 0 0.00029868344427086413
personally O 0 2.992068857565755e-06
or O 0 4.8419796172538554e-08
in O 0 1.9816439600361946e-09
the O 0 5.454538487548177e-10
families O 0 1.8326676287649946e-10
of O 0 8.533854872760926e-11
13 O 0 1.5336427683365628e-09
of O 0 1.5929418895055392e-10
20 O 0 8.210099267103033e-09
Ashkenazi O 0 7.353706337198673e-07
I1307K O 0 2.581082299002446e-07
carriers O 0 2.0517056498192687e-08
, O 0 5.641687672586215e-10
8 O 0 6.621190706823654e-09
of O 0 1.2381448644127602e-10
whom O 0 1.7866876866889925e-09
also O 0 1.5001976327866373e-09
had O 0 2.0656796273499367e-09
a O 0 1.039122787815927e-09
personal O 0 2.6799229502216804e-08
or O 0 1.8352229957940835e-08
family O 0 1.5076766501920247e-08
history O 0 5.853766360530699e-09
of O 0 5.239481293273229e-09
noncolonic O 0 0.0002342269435757771
neoplasia B-Disease 0 0.0008808592101559043
. O 0 8.197988563551917e-07

CONCLUSIONS O 0 6.716975804010872e-06
The O 0 3.24428810927202e-07
I1307K O 0 9.62306421570247e-06
APC O 0 3.7752738535345998e-06
variant O 0 1.1441805327194743e-05
may O 0 1.6774025368704315e-07
represent O 0 2.052397585217136e-09
a O 0 4.241305529006922e-09
susceptibility O 0 6.355478490149835e-07
gene O 0 1.4099587133387104e-06
for O 0 1.803906002351141e-07
colorectal B-Disease 1 1.0
, I-Disease 0 8.187517330782157e-09
or I-Disease 0 6.216889669730108e-09
other I-Disease 0 1.025176943336703e-09
, I-Disease 0 5.131676417136077e-09
cancers I-Disease 0 1.5234968486765865e-06
in O 0 1.198910659638841e-08
Ashkenazi O 0 2.081065986203612e-06
Jews O 0 3.833578787748593e-09
, O 0 4.806328668394144e-10
and O 0 6.15361761546751e-10
partially O 0 7.44209387448791e-08
explains O 0 6.666684093659114e-09
the O 0 1.324601761609756e-09
higher O 0 3.064248232931277e-07
incidence O 0 9.169899567496032e-05
of O 0 0.00015287892892956734
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 8.224255054756213e-08
European O 0 2.1640556724378257e-07
Israelis O 0 3.1722760240882053e-07
. O 0 1.2849945107973326e-07

Systematic O 0 6.768276307411725e-06
analysis O 0 6.945133463887032e-07
of O 0 3.4063294407360445e-08
coproporphyrinogen O 0 0.0002005925343837589
oxidase O 0 0.0006263150717131793
gene O 0 0.2040156126022339
defects O 1 0.8913665413856506
in O 0 7.447589212006278e-08
hereditary B-Disease 0 0.3878506124019623
coproporphyria I-Disease 0 0.0003750211326405406
and O 0 1.0155540763889803e-07
mutation O 0 1.4338803339342121e-05
update O 0 2.0651625163736753e-05
. O 0 6.115064934419934e-07

Hereditary B-Disease 1 0.9998239874839783
coproporphyria I-Disease 1 0.7515519857406616
( O 0 6.140378445707029e-06
HC B-Disease 0 0.00033054384402930737
) O 0 4.2433548230746965e-08
is O 0 5.703371996901296e-09
an O 0 2.7050973017139768e-08
acute O 0 0.004743803292512894
hepatic B-Disease 1 0.9999867677688599
porphyria I-Disease 1 0.9999995231628418
with O 0 1.1321130841679405e-05
autosomal O 1 0.9999997615814209
dominant O 1 0.9998495578765869
inheritance O 0 0.00027816780493594706
caused O 0 2.5874926450342173e-06
by O 0 2.8119549355665185e-08
deficient B-Disease 0 1.3827096154273022e-05
activity I-Disease 0 2.6355488103035896e-07
of I-Disease 0 7.756548292547905e-09
coproporphyrinogen I-Disease 0 4.6679422666784376e-05
III I-Disease 0 1.748697650327813e-05
oxidase I-Disease 0 9.042450983542949e-06
( O 0 1.8954816027871857e-07
CPO O 0 1.3006532753934152e-05
) O 0 5.7746781578771333e-08
. O 0 8.906238946337908e-08

Clinical O 0 3.77556134480983e-05
manifestations O 0 3.0558603612007573e-06
of O 0 6.854013800960956e-09
the O 0 1.8239589394397626e-07
disease O 0 5.736396269639954e-05
are O 0 4.752045978939634e-10
characterized O 0 9.163485970020702e-08
by O 0 1.4741819320818195e-08
acute O 0 2.7786570626631146e-06
attacks O 0 3.121851841569878e-05
of O 0 5.17939099609066e-07
neurological B-Disease 1 0.9999996423721313
dysfunction I-Disease 0 0.05434240400791168
often O 0 1.322170959383584e-07
precipitated O 0 2.559933989232377e-07
by O 0 1.5002663555918616e-09
drugs O 0 1.1037154301618557e-08
, O 0 7.218223796456869e-10
fasting O 0 3.1098034014576115e-07
, O 0 2.449100033885543e-09
cyclical O 0 6.094500804465497e-06
hormonal O 0 8.358360901183914e-06
changes O 0 7.449947503346266e-08
, O 0 1.1160399715492986e-08
or O 0 1.98472548618156e-06
infectious B-Disease 0 0.0042282212525606155
diseases I-Disease 0 0.00044963782420381904
. O 0 4.1831890484900214e-07

Skin O 1 1.0
photosensitivity O 1 0.9999850988388062
may O 0 0.09375813603401184
also O 0 3.452811725423999e-08
be O 0 2.5164827999191175e-09
present O 0 2.5932182623478184e-08
. O 0 3.748506216538772e-08

The O 0 4.904431420982291e-07
seven O 0 6.229343085806249e-08
exons O 0 1.3063040569250006e-06
, O 0 2.596572512558737e-09
the O 0 1.227904000700164e-08
exon O 0 1.255232473340584e-05
/ O 0 2.1048030248493887e-05
intron O 0 1.876183523563668e-05
boundaries O 0 4.812645215679368e-07
and O 0 5.606003217195621e-09
part O 0 2.5692354910233917e-09
of O 0 1.0380155623934684e-09
3 O 0 1.1447966130617715e-08
noncoding O 0 1.102487061643842e-07
sequence O 0 8.752349067719933e-09
of O 0 3.2474634092949373e-10
the O 0 9.181800209034918e-09
CPO O 0 2.590025587778655e-06
gene O 0 7.429456871932416e-08
were O 0 1.359624079988464e-09
systematically O 0 2.3709269214577944e-08
analyzed O 0 6.653739337281195e-09
by O 0 4.557732802279446e-10
an O 0 7.439305282908037e-10
exon O 0 5.161905392014887e-07
- O 0 3.2678474326530704e-07
by O 0 4.547456455838983e-08
- O 0 5.620932824967895e-06
exon O 0 2.597996535769198e-05
denaturing O 0 0.0004237526445649564
gradient O 0 2.182794014515821e-05
gel O 0 0.00011893008922925219
electrophoresis O 0 9.976441106118727e-06
( O 0 1.0971923103397785e-07
DGGE O 0 6.39852578387945e-06
) O 0 9.618242202691363e-09
strategy O 0 1.5423207599951638e-08
followed O 0 1.4588890095978968e-09
by O 0 1.2798402615477045e-10
direct O 0 1.3192866799016656e-09
sequencing O 0 1.0922183157902055e-08
in O 0 1.457553966410785e-09
seven O 0 2.452718472767401e-09
unrelated O 0 1.2722483688776265e-07
heterozygous O 0 2.868975343517377e-06
HC B-Disease 0 4.6918634325265884e-05
patients O 0 2.79224252608401e-07
from O 0 5.705268080191672e-08
France O 0 2.896742898883531e-06
, O 0 3.777990809084031e-09
Holland O 0 1.5659970813430846e-06
, O 0 1.1773164665385139e-09
and O 0 6.716216027768951e-09
Czech O 0 4.373339834273793e-06
Republic O 0 8.607065637988853e-07
. O 0 1.765759378713483e-07

Seven O 0 1.616324993847229e-06
novel O 0 7.345183234974684e-07
mutations O 0 2.6169198008574313e-06
and O 0 4.5003765158924125e-09
two O 0 2.9177069649222176e-09
new O 0 5.888798426667563e-08
polymorphisms O 0 4.669071586249629e-06
were O 0 3.1937794631176075e-08
detected O 0 3.7877946397202322e-06
. O 0 1.435475383004814e-07

Among O 0 9.404512013588828e-08
these O 0 1.2019972572829829e-08
mutations O 0 3.5935389064434275e-07
two O 0 2.949246846739584e-09
are O 0 2.6843776090856863e-09
missense O 0 4.194449047645321e-06
( O 0 2.316711267269511e-08
G197W O 0 7.601347533636726e-07
, O 0 2.558077305536699e-09
W427R O 0 2.6897970428763074e-07
) O 0 7.981316163530039e-10
, O 0 1.562975027180613e-10
two O 0 3.3645161656714606e-10
are O 0 3.439950269079617e-10
nonsense O 0 6.364345495057933e-08
( O 0 6.0173466209789694e-09
Q306X O 0 1.3965986056518886e-07
, O 0 8.476044310867792e-10
Q385X O 0 8.09847975347111e-08
) O 0 4.818757615154823e-10
, O 0 8.016753927364562e-11
two O 0 1.764134116566396e-10
are O 0 1.6324101792530854e-10
small O 0 1.4144055926479382e-09
deletions O 0 3.5326581837580306e-07
( O 0 1.0830036423215006e-08
662de14bp O 0 3.7752269577140396e-07
; O 0 7.49159578816716e-09
1168del3bp O 0 6.761422923773353e-07
removing O 0 6.987680478687253e-08
a O 0 1.7243349859086265e-08
glycine O 0 4.78915808344027e-06
at O 0 2.866768511466944e-07
position O 0 7.772190002697243e-08
390 O 0 4.589333357785108e-08
) O 0 1.0849341425256398e-09
, O 0 1.8927841238802756e-10
and O 0 9.299561815057089e-11
one O 0 1.1922349218984607e-10
is O 0 2.0495953545474066e-10
a O 0 3.3867693094435936e-09
splicing O 0 1.884358766801597e-06
mutation O 0 1.263276431018312e-06
( O 0 4.27056328078379e-08
IVS1 O 0 1.8990160242537968e-05
- O 0 4.339894530858146e-06
15c O 0 2.585448237368837e-05
- O 0 5.797589437861461e-06
- O 0 3.4714646517386427e-06
> O 0 6.312313303169503e-07
g O 0 2.4641340132802725e-06
) O 0 2.1197215094304056e-09
which O 0 5.315181628162691e-10
creates O 0 2.001537380280638e-09
a O 0 1.5423847754547637e-09
new O 0 2.2239007080315787e-08
acceptor O 0 4.7540910941279435e-07
splice O 0 1.0731176189437974e-05
site O 0 9.897529480440426e-07
. O 0 1.447667017373533e-07

The O 0 2.0068313233423396e-07
pathological O 0 4.526251586867147e-07
significance O 0 2.4964341704958315e-08
of O 0 4.799238784158888e-10
the O 0 2.6529518581952516e-09
point O 0 1.0638609104773877e-08
mutations O 0 1.6103184918847546e-07
G197W O 0 1.0000439232271674e-07
, O 0 5.389448887171966e-10
W427R O 0 6.847835720691364e-08
, O 0 3.581795693374801e-10
and O 0 1.348986200522262e-10
the O 0 5.555831905645903e-10
in O 0 1.3856743308338082e-08
- O 0 2.5219101189577486e-06
frame O 0 3.8747875805711374e-05
deletion O 0 5.9314419331713e-07
390delGly O 0 2.665898648501752e-07
were O 0 1.906080848712577e-09
assessed O 0 3.51452311697642e-09
by O 0 4.2509326614315057e-10
their O 0 1.9205541601508003e-09
respective O 0 1.913553049348593e-08
expression O 0 1.2243562608205139e-08
in O 0 2.5487749688579697e-09
a O 0 2.309060720406819e-09
prokaryotic O 0 2.802905463283878e-08
system O 0 3.374783474896503e-08
using O 0 2.2329709636892403e-08
site O 0 5.612237146124244e-07
- O 0 4.0383866917181876e-07
directed O 0 6.498319038428235e-08
mutagenesis O 0 5.216069894231623e-06
. O 0 1.6089386178919085e-07

These O 0 4.694932442816935e-07
mutations O 0 8.630527190689463e-06
resulted O 0 9.32618249294137e-08
in O 0 9.904025155549334e-09
the O 0 9.104927478631453e-09
absence O 0 2.2098625152011664e-08
or O 0 2.8952831243600485e-09
a O 0 3.920913371757706e-09
dramatic O 0 3.561559580589346e-08
decrease O 0 7.367915344502762e-08
of O 0 4.699579836398016e-09
CPO O 0 1.7984308215091005e-05
activity O 0 5.133676381774421e-07
. O 0 1.0660326665856701e-07

The O 0 1.037858154973037e-07
two O 0 1.188322062972702e-08
polymorphisms O 0 1.5622306364093674e-06
were O 0 4.1370307179988686e-09
localized O 0 3.400497234906652e-07
in O 0 2.969919954409761e-08
noncoding O 0 1.1296122011117404e-06
part O 0 7.9099855554432e-09
of O 0 3.243662560770133e-10
the O 0 1.5082310955705225e-09
gene O 0 4.9618737563150717e-08
1 O 0 5.104265454747292e-09
) O 0 8.026519449089164e-10
a O 0 8.888330960132862e-09
C O 0 2.8110998755437322e-05
/ O 0 7.3202859312004875e-06
G O 0 3.083895535382908e-06
polymorphism O 0 6.719024554513453e-07
in O 0 1.0744527045858376e-08
the O 0 2.2811899924590762e-08
promotor O 0 4.154118414589902e-06
region O 0 5.008140036011355e-08
, O 0 3.1147047163671004e-09
142 O 0 4.074945536558516e-08
bp O 0 1.9432168585353793e-07
upstream O 0 4.163344868857166e-08
from O 0 2.5741113685029404e-09
the O 0 2.925101494355431e-09
transcriptional O 0 4.7188490270855254e-07
initiation O 0 3.023244232736033e-08
site O 0 1.768870561136282e-07
( O 0 3.691813432737945e-08
- O 0 1.0246731108054519e-06
142C O 0 7.573520178993931e-06
/ O 0 1.8182456187787466e-05
G O 0 6.104394742578734e-06
) O 0 3.2884726053339364e-09
, O 0 4.304324119352998e-10
and O 0 7.03101687982155e-10
2 O 0 3.5288838517999466e-09
) O 0 3.594998465583643e-10
a O 0 1.344342859255221e-09
6 O 0 1.2798756721110749e-08
bp O 0 1.4629655709086364e-07
deletion O 0 9.852912086216747e-08
polymorphism O 0 9.494502251072845e-08
in O 0 2.198753401572162e-09
the O 0 2.5647459711564125e-09
3 O 0 9.659663291472498e-09
noncoding O 0 6.583226053180624e-08
part O 0 1.1980939573774663e-09
of O 0 2.3951873817651403e-10
the O 0 5.691114246531015e-09
CPO O 0 1.4014889302416123e-06
gene O 0 5.4556675621597606e-08
, O 0 3.0962346575513777e-10
574 O 0 1.242541625146032e-08
bp O 0 2.3789356262682304e-08
downstream O 0 3.480554511270384e-09
of O 0 6.965900078981235e-11
the O 0 4.013035737049364e-10
last O 0 7.2464647615788635e-09
base O 0 8.67718064068157e-10
of O 0 6.855941508954189e-11
the O 0 2.4797375264284938e-09
normal O 0 3.3779269870137796e-07
termination O 0 6.164513592921139e-07
codon O 0 3.4847259939851938e-06
( O 0 6.170218114220916e-08
+ O 0 4.896673431176168e-07
574 O 0 1.0683149866963504e-06
delATTCTT O 0 2.804389851007727e-06
) O 0 5.991238083424832e-08
. O 0 6.702065746821972e-08

Five O 0 3.97949042962864e-06
intragenic O 0 4.7623841965105385e-05
dimorphisms O 0 1.7098896933021024e-05
are O 0 5.353021581555595e-09
now O 0 7.007083357990496e-09
well O 0 1.4405318049526272e-09
characterized O 0 5.339492048506145e-08
and O 0 1.7135572960569334e-09
the O 0 1.8018381231499347e-09
high O 0 2.209567462330142e-08
degree O 0 1.1165930402512458e-09
of O 0 5.574120609530553e-10
allelic O 0 8.517489504811238e-07
heterogeneity O 0 5.854818141415308e-07
in O 0 1.5881872172940348e-07
HC B-Disease 0 0.0017683944897726178
is O 0 1.2976946628384667e-08
demonstrated O 0 1.2248935199465905e-08
with O 0 5.651704104714383e-10
seven O 0 9.620457763759305e-10
new O 0 2.009815869286058e-09
different O 0 4.253868923775883e-10
mutations O 0 1.996410148308314e-08
making O 0 5.46647394017441e-10
a O 0 4.6735831871203e-10
total O 0 9.896386488073006e-11
of O 0 1.7880777414269744e-10
nineteen O 0 1.6986129480756063e-07
CPO O 0 0.006209246814250946
gene B-Disease 0 0.0008988616755232215
defects I-Disease 0 0.030377527698874474
reported O 0 3.2303611874340277e-07
so O 0 1.0064462152570286e-08
far O 0 1.1992880466493716e-08
. O 0 6.054463153049028e-09
. O 0 4.1175567844220495e-08

Coincidence O 0 7.696930879319552e-06
of O 0 2.057015180412236e-08
two O 0 1.0833590025072226e-08
novel O 0 9.716877258370005e-08
arylsulfatase O 0 1.362715238428791e-06
A O 0 3.36058789685012e-08
alleles O 0 4.429162174801604e-07
and O 0 1.4335815201604873e-08
mutation O 0 1.212872803080245e-06
459 O 0 1.234669753102935e-06
+ O 0 7.989904133864911e-07
1G O 0 2.825737465173006e-05
> O 0 2.8720526756842446e-07
A O 0 1.737729782291808e-08
within O 0 2.3694790574069202e-09
a O 0 1.6130092816979413e-08
family O 0 9.751931884238729e-08
with O 0 7.23314244055473e-08
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999996423721313
: O 0 8.915786331442632e-09
molecular O 0 3.9327417766799044e-08
basis O 0 1.131001781118357e-08
of O 0 3.4883569366428446e-09
phenotypic O 0 2.2907793209014926e-06
heterogeneity O 0 1.0848873898794409e-05
. O 0 7.965443842294917e-07

In O 0 3.133966686164058e-07
a O 0 2.803071197376994e-08
family O 0 1.813641326009474e-08
with O 0 9.925313904091126e-10
three O 0 1.6224595000835507e-09
siblings O 0 4.8466734625662866e-08
, O 0 1.236594299180993e-10
one O 0 3.3508879004884307e-10
developed O 0 3.997043762637986e-08
classical O 0 1.5956399010974565e-06
late O 1 0.9977030158042908
infantile O 1 1.0
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 7.210146577563137e-05
MLD B-Disease 1 0.9999998807907104
) O 0 4.213136151065555e-08
, O 0 3.0977482801120004e-09
fatal O 0 2.6899610929831397e-06
at O 0 3.125697730865795e-06
age O 0 7.230631382526553e-08
5 O 0 8.855604249902171e-09
years O 0 1.0576772790926725e-09
, O 0 2.859782688435786e-10
with O 0 2.5729773867055883e-09
deficient O 0 1.685374263615813e-05
arylsulfatase O 0 4.551875008473871e-06
A O 0 2.3568061635614868e-07
( O 0 5.39265236909614e-08
ARSA O 0 2.370901347603649e-05
) O 0 6.270383323681017e-09
activity O 0 4.9064617257954524e-08
and O 0 4.950281962123881e-09
increased O 0 9.775098419595452e-08
galactosylsulfatide O 0 3.210722570656799e-05
( O 0 5.217514740252227e-07
GS O 1 0.9999996423721313
) O 0 1.4518548141495558e-07
excretion O 0 3.1644487989979098e-06
. O 0 1.6933790902839974e-07

The O 0 8.917287175336241e-08
two O 0 3.685127758501494e-09
other O 0 1.675888205987519e-09
siblings O 0 9.724516303322162e-08
, O 0 9.620274576960242e-10
apparently O 0 7.236702970203623e-08
healthy O 0 1.420365407511781e-07
at O 0 1.2033028440328053e-07
12 O 0 1.7728046586285018e-08
( O 0 4.099265371593219e-09
1 O 0 2.651567143630018e-08
/ O 0 2.6427017019159393e-06
2 O 0 8.356138891940645e-09
) O 0 4.401543296506105e-10
and O 0 2.622762840243098e-10
15 O 0 9.5570862335137e-10
years O 0 2.649653274566788e-10
, O 0 5.3513922460002306e-11
respectively O 0 6.698213650402352e-10
, O 0 5.217118403955112e-11
and O 0 1.9474219459247877e-10
their O 0 2.465955661890007e-09
father O 0 6.420970066756126e-08
, O 0 2.0976999304256339e-10
apparently O 0 5.4492170775688464e-09
healthy O 0 4.171084366788591e-09
as O 0 5.117452017699975e-10
well O 0 6.828878018616535e-10
, O 0 4.808676234979714e-10
presented O 0 2.484131833568881e-08
ARSA O 0 0.00015548517694696784
and O 0 1.360556609597552e-07
GS O 1 0.999998927116394
values O 0 1.476526012567092e-08
within O 0 9.110655563304704e-10
the O 0 1.8385154509914514e-09
range O 0 4.053511304391577e-08
of O 0 2.4967720335666854e-08
MLD B-Disease 1 0.9999998807907104
patients O 0 1.2513544334069593e-06
. O 0 1.8829598502634326e-07

Mutation O 0 0.00021910315263085067
screening O 0 9.197365216095932e-06
and O 0 2.315183067480575e-08
sequence O 0 1.0622635926438306e-07
analysis O 0 3.148669591723774e-08
disclosed O 0 1.1847433967204779e-07
the O 0 4.977777745551748e-09
involvement O 0 7.667702917046881e-09
of O 0 2.9352603680976586e-10
three O 0 1.175093244931702e-09
different O 0 7.317018990704582e-09
ARSA O 0 0.002206748351454735
mutations O 0 7.179714316407626e-07
being O 0 2.114560970767343e-09
the O 0 1.1228291629805653e-09
molecular O 0 3.270453419190744e-08
basis O 0 7.963103065833366e-09
of O 0 2.747799987545818e-09
intrafamilial O 0 8.177825293387286e-06
phenotypic O 0 7.761273081996478e-06
heterogeneity O 0 2.1316409402061254e-05
. O 0 1.1763552265620092e-06

The O 0 5.278519097373646e-07
late O 0 0.00018541055032983422
infantile O 1 0.9998369216918945
patient O 0 0.0029907592106610537
inherited O 0 0.0035431194119155407
from O 0 3.734832532131804e-08
his O 0 1.4329040709526453e-07
mother O 0 1.8309614802092256e-07
the O 0 4.8360884186138264e-09
frequent O 0 3.9617503944100463e-07
0 O 0 3.7907474847997946e-07
- O 0 4.283659109205473e-06
type O 0 2.9145136068109423e-05
mutation O 0 8.061620064836461e-06
459 O 0 1.1784537718995125e-06
+ O 0 7.897850764493342e-07
1G O 0 2.0459418010432273e-05
> O 0 3.247560016461648e-07
A O 0 3.4934188875013206e-08
, O 0 5.400294655899529e-10
and O 0 4.806805509183221e-10
from O 0 9.295132996633981e-10
his O 0 1.4646025725539857e-08
father O 0 3.664089476274057e-08
a O 0 2.9060494011190485e-09
novel O 0 7.417036318457804e-09
, O 0 5.064570429702542e-10
single O 0 1.498997193039031e-08
basepair O 0 1.0336024161006208e-06
microdeletion O 0 5.41379392871022e-07
of O 0 1.4087301325460544e-09
guanine O 0 1.2475480559714924e-07
at O 0 2.2431391855093352e-08
nucleotide O 0 1.2119565440116276e-07
7 O 0 3.982463070428821e-08
in O 0 1.137331473444192e-08
exon O 0 2.1939304133411497e-06
1 O 0 1.5950023168898042e-07
( O 0 4.336772363444652e-08
7delG O 0 2.6483555757295107e-06
) O 0 3.913533319632734e-08
. O 0 5.2353286150719214e-08

The O 0 4.0769052134237427e-07
two O 0 5.3717410963827206e-08
clinically O 0 5.183104804018512e-06
unaffected O 0 1.6241299817920662e-05
siblings O 0 5.444907742457872e-07
carried O 0 5.402442582180811e-08
the O 0 1.996650134117317e-08
maternal O 0 2.8076358375983546e-06
mutation O 0 1.8938892480946379e-06
459 O 0 7.213577077891387e-07
+ O 0 5.063667458671262e-07
1G O 0 2.8837723220931366e-05
> O 0 6.61479873542703e-07
A O 0 4.950454624008671e-08
and O 0 2.047181979492052e-09
, O 0 1.3380950514285672e-10
on O 0 1.958575746030533e-09
their O 0 2.164574297580657e-09
paternal O 0 4.13384697139918e-07
allele O 0 2.086119792465979e-07
, O 0 5.435512040463664e-10
a O 0 1.1915648467919482e-09
novel O 0 1.4494512257101633e-08
cytosine O 0 2.6315805712329166e-07
to O 0 4.897287020355634e-09
thymidine O 0 1.015001771520474e-06
transition O 0 7.610938013158375e-08
at O 0 4.884518389758341e-08
nucleotide O 0 5.063972139396355e-07
2435 O 0 6.11621226198622e-06
in O 0 1.917915959381844e-08
exon O 0 6.899858817632776e-07
8 O 0 5.0786887584308715e-08
, O 0 3.2556932150207274e-10
resulting O 0 3.380773661021408e-09
in O 0 2.1935928629090995e-09
substitution O 0 2.256781606035929e-08
of O 0 1.384426684403195e-09
alanine O 0 3.172008291585371e-06
464 O 0 3.1206116091198055e-07
by O 0 4.8223483872789075e-08
valine O 0 0.00012145163054810837
( O 0 5.001228942091984e-08
A464V O 0 1.667585024733853e-06
) O 0 4.568390465919947e-08
. O 0 6.085586079507266e-08

The O 0 1.2644371736314497e-06
fathers O 0 3.8738016883144155e-06
genotype O 0 1.358084409730509e-05
thus O 0 2.0578909243340604e-07
was O 0 5.869991923646012e-07
7delG O 0 1.918088673846796e-05
/ O 0 1.8036196706816554e-05
A464V O 0 1.2853446605731733e-05
. O 0 4.737570975521521e-07

Mutation O 0 0.00018354045460000634
A464V O 0 2.9469814762705937e-05
was O 0 5.050135314377258e-07
not O 0 1.961955709006702e-09
found O 0 4.25724744346212e-09
in O 0 5.25055554589926e-09
18 O 0 6.345582193034716e-08
unrelated O 0 2.113176606144407e-06
MLD B-Disease 1 1.0
patients O 0 2.796599574139691e-07
and O 0 7.865827988950969e-09
50 O 0 2.3199127952011622e-08
controls O 0 7.128075958462432e-05
. O 0 1.3359905892684765e-07

A464V O 0 5.087464160169475e-05
, O 0 9.180420335042072e-08
although O 0 4.264125053055068e-08
clearly O 0 8.376057536452208e-08
modifying O 0 3.6873241242574295e-06
ARSA O 0 0.001994858728721738
and O 0 5.059593490841507e-07
GS O 1 1.0
levels O 0 9.113841201724426e-07
, O 0 2.1275146089294594e-09
apparently O 0 3.494018585570302e-08
bears O 0 8.36339779652917e-08
little O 0 9.02150265602586e-09
significance O 0 5.491473942242919e-09
for O 0 7.224491005430878e-10
clinical O 0 2.5468178677101605e-08
manifestation O 0 8.204607837569711e-08
of O 0 1.7165579180300483e-08
MLD B-Disease 1 0.9999998807907104
, O 0 1.0083888390965967e-08
mimicking O 0 1.4785234725422924e-06
the O 0 1.0116661997017218e-07
frequent O 0 1.0332740203011781e-05
ARSA O 0 0.1794058084487915
pseudodeficiency O 0 0.0008071904885582626
allele O 0 0.00019587724818848073
. O 0 1.4409744153454085e-06

Our O 0 6.702787800350052e-07
results O 0 1.478863254078533e-07
demonstrate O 0 9.496382347151666e-09
that O 0 2.3116329683769976e-10
in O 0 5.873290187530245e-10
certain O 0 1.6306621608563887e-09
genetic O 0 1.4317019747522863e-07
conditions O 0 2.1635469238390215e-06
MLD B-Disease 1 1.0
- O 0 7.75679072830826e-05
like O 0 2.214339787087738e-07
ARSA O 0 0.06217651441693306
and O 0 4.278630854059884e-07
GS O 1 1.0
values O 0 3.001548876113702e-08
need O 0 9.541240020283226e-10
not O 0 8.58937712622243e-11
be O 0 6.195221419202923e-11
paralleled O 0 1.5757731119947493e-08
by O 0 2.191292924891286e-09
clinical O 0 1.4561979355676158e-07
disease O 0 1.4179117897583637e-06
, O 0 1.5538170750062363e-10
a O 0 9.611048623625607e-10
finding O 0 9.482693519302643e-10
with O 0 1.5222013649562882e-09
serious O 0 8.444424537401574e-08
diagnostic O 0 2.904576831497252e-06
and O 0 7.355334474823394e-08
prognostic O 0 8.699858881300315e-06
implications O 0 9.171177453026758e-07
. O 0 2.851404019565962e-07

Moreover O 0 1.4838071365375072e-05
, O 0 1.7982378608394356e-07
further O 0 3.204158929293044e-07
ARSA O 0 0.0020764749497175217
alleles O 0 9.652936569182202e-06
functionally O 0 1.9139326923323097e-06
similar O 0 5.763696364624593e-08
to O 0 1.2327122433930526e-08
A464V O 0 6.322157446447818e-07
might O 0 1.2599297605220272e-08
exist O 0 1.532198479203828e-09
which O 0 7.068020058120794e-10
, O 0 4.9285048264735565e-11
together O 0 1.1345873546231289e-10
with O 0 1.7445060673804136e-10
0 O 0 4.249542939760431e-08
- O 0 4.205110599286854e-06
type O 0 0.0003026818158105016
mutations O 0 3.116761945420876e-06
, O 0 3.562318662275743e-09
may O 0 2.2115791864507628e-07
cause O 0 1.7721023937156133e-07
pathological O 0 2.329647259102785e-06
ARSA O 0 0.09217923879623413
and O 0 2.7739733923226595e-06
GS O 1 1.0
levels O 0 7.112450362001255e-07
, O 0 4.495758765266089e-10
but O 0 3.4954483751903354e-10
not O 0 7.099366094998061e-10
clinical O 0 1.0829355190367096e-08
outbreak O 0 1.0059035560061602e-07
of O 0 7.612353525310311e-10
the O 0 1.0909487002663809e-07
disease O 0 6.28088719167863e-06
. O 0 4.35181757296732e-09
. O 0 4.376700601937955e-08

Human O 0 0.00019761321891564876
MLH1 O 1 0.9999005794525146
deficiency O 1 0.9994311928749084
predisposes O 0 0.00015276731573976576
to O 0 1.1062434168707114e-06
hematological B-Disease 1 0.9803178310394287
malignancy I-Disease 1 0.8500126004219055
and O 0 3.1669212603446795e-06
neurofibromatosis B-Disease 1 0.9999825954437256
type I-Disease 0 0.180532768368721
1 I-Disease 0 4.019377684016945e-06
. O 0 5.027420684200479e-07

Heterozygous O 0 0.0027781599201261997
germ O 0 0.0474584698677063
- O 0 0.009600860066711903
line O 0 3.3797245123423636e-05
mutations O 0 2.3022819277684903e-06
in O 0 4.957349197809435e-09
the O 0 4.06090716609242e-09
DNA O 0 7.130291805879097e-07
mismatch O 0 7.331058895942988e-06
repair O 0 1.3444543583318591e-05
genes O 0 4.358149681138457e-07
lead O 0 1.7841250610217685e-07
to O 0 1.2335093515503104e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.317047220567474e-06

The O 0 3.4796119052771246e-06
disease O 0 0.0005891990149393678
susceptibility O 0 4.33431023338926e-06
of O 0 3.530863601497458e-09
individuals O 0 1.9413779472898796e-09
who O 0 1.9117072369567722e-08
constitutionally O 0 4.964411459695839e-07
lack O 0 1.0063867961207507e-08
both O 0 2.0952779511418385e-09
wild O 0 2.3855474751144357e-07
- O 0 0.00041347331716679037
type O 0 0.0003439132124185562
alleles O 0 9.604659680917393e-07
is O 0 6.676316832709972e-09
unknown O 0 8.613160673576203e-08
. O 0 9.704671555255118e-08

We O 0 1.1733048665973911e-07
have O 0 3.19195092579605e-09
identified O 0 2.5279178750281517e-09
three O 0 3.2391492266192756e-10
offspring O 0 5.392700952455698e-09
in O 0 2.4335893300531097e-09
a O 0 3.8277656244645186e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 2.394354851276148e-05
who O 0 9.159118263823984e-08
developed O 0 2.0027773643960245e-06
hematological B-Disease 0 0.009715726599097252
malignancy I-Disease 0 0.00016179845260921866
at O 0 2.1823559848144214e-07
a O 0 1.711751806965367e-08
very O 0 7.801594925638256e-09
early O 0 1.0971189112751745e-05
age O 0 3.3738501770130824e-08
, O 0 7.416151720507358e-11
and O 0 2.0205345729884527e-10
at O 0 3.3655447317926246e-09
least O 0 1.1951080403083125e-10
two O 0 7.71148978007119e-11
of O 0 4.2002280126185454e-11
them O 0 3.230634371131913e-10
displayed O 0 1.515184209210929e-07
signs O 0 1.4383778079718468e-07
of O 0 3.556839711649218e-09
neurofibromatosis B-Disease 1 0.938283383846283
type I-Disease 0 0.0001803950290195644
1 I-Disease 0 1.1491541727082222e-06
( O 0 1.7125951501384407e-07
NF1 B-Disease 0 3.131775520159863e-05
) O 0 8.735459289255232e-08
. O 0 1.2512441571743693e-07

DNA O 0 2.218658664787654e-05
sequence O 0 1.4394470326806186e-06
analysis O 0 1.3043553792613238e-07
and O 0 4.494611793859349e-09
allele O 0 9.492634376329079e-07
- O 0 1.8393586742604384e-07
specific O 0 4.605571035654066e-09
amplification O 0 3.7979845046720584e-07
in O 0 2.514079389115409e-09
two O 0 3.7738421276856116e-09
siblings O 0 1.6574267647229135e-07
revealed O 0 1.4426090899632982e-07
a O 0 9.835787295742193e-08
homozygous O 0 2.812491584336385e-05
MLH1 O 0 0.0016498222248628736
mutation O 0 1.584460369485896e-05
( O 0 1.6991477025385393e-07
C676T O 0 1.1775060556828976e-05
- O 0 7.225145236589015e-05
- O 0 3.17371086566709e-05
> O 0 3.933022526325658e-06
Arg226Stop O 0 1.726585287542548e-05
) O 0 8.617433167046329e-08
. O 0 9.201878725662027e-08

Thus O 0 6.483932111223112e-07
, O 0 2.0355178875774982e-08
a O 0 1.8331414608496743e-08
homozygous O 0 3.014112508026301e-06
germ O 0 0.0002526468597352505
- O 0 0.0014668144285678864
line O 0 0.00022679085668642074
MLH1 O 0 0.0022664929274469614
mutation O 0 7.114531399565749e-06
and O 0 3.2263088201034407e-08
consequent O 0 1.300174517382402e-05
mismatch O 1 0.6319900751113892
repair O 1 0.9999992847442627
deficiency O 1 0.9976130723953247
results O 0 2.196571244894585e-07
in O 0 3.381684621217573e-08
a O 0 3.348505401845614e-07
mutator O 0 0.1504615694284439
phenotype O 0 5.4730535339331254e-05
characterized O 0 1.322310026807827e-06
by O 0 1.5263589148162282e-07
leukemia B-Disease 1 0.9836753010749817
and O 0 7.460009328497108e-06
/ O 1 0.9999927282333374
or O 1 0.9956757426261902
lymphoma B-Disease 1 1.0
associated O 0 1.3618950106319971e-05
with O 0 5.909208198318083e-07
neurofibromatosis B-Disease 1 0.9999972581863403
type I-Disease 0 0.07162833958864212
1 I-Disease 0 5.30057832293096e-07
. O 0 1.7472984836786054e-08
. O 0 9.940895751014978e-08

Missense O 0 0.007149897050112486
mutations O 0 0.0010719513520598412
in O 0 1.0514668957739559e-07
the O 0 5.468875574621279e-09
most O 0 4.711496193188225e-10
ancient O 0 1.6158566706891975e-09
residues O 0 5.058937091462212e-08
of O 0 3.915283930400193e-10
the O 0 7.648057298581534e-09
PAX6 O 0 1.3667987332155462e-05
paired O 0 3.903160745721834e-07
domain O 0 2.1057522303635778e-07
underlie O 0 5.896052925891127e-07
a O 0 1.57058206440297e-08
spectrum O 0 6.727424306518515e-07
of O 0 3.757079536370611e-09
human O 0 3.68643441106542e-06
congenital B-Disease 1 0.9999998807907104
eye I-Disease 1 0.9998732805252075
malformations I-Disease 1 0.9992535710334778
. O 0 2.9053194339212496e-06

Mutations O 0 0.00010789017687784508
of O 0 2.9157670056179086e-08
the O 0 1.6528581170405232e-08
human O 0 1.1173609948400554e-07
PAX6 O 0 0.0005156147526577115
gene O 0 0.002144534606486559
underlie O 1 0.9888807535171509
aniridia B-Disease 1 1.0
( O 0 0.09129242599010468
congenital B-Disease 1 0.9999998807907104
absence I-Disease 0 2.8557226983139117e-07
of I-Disease 0 7.126852441530218e-10
the I-Disease 0 1.7759386850002556e-08
iris I-Disease 0 3.512667535687797e-05
) O 0 1.95879246156494e-09
, O 0 2.776203711363223e-10
a O 0 1.3390609732155667e-09
rare O 0 9.682374724206966e-08
dominant O 1 0.9708961844444275
malformation B-Disease 0 0.45598649978637695
of I-Disease 0 4.810237985708454e-09
the I-Disease 0 2.0039033188368194e-07
eye I-Disease 0 0.00047618625103496015
. O 0 5.930921815888723e-07

The O 0 4.264954895916162e-07
spectrum O 0 2.7025655526813352e-06
of O 0 3.790971092598738e-08
PAX6 O 0 0.0003026079502888024
mutations O 0 9.708559809951112e-05
in O 0 3.0425392196775647e-06
aniridia B-Disease 1 1.0
patients O 0 6.489824500022223e-06
is O 0 2.898421280761454e-09
highly O 0 2.0205982664833755e-08
biased O 0 2.3689544548233243e-07
, O 0 5.897087262951572e-10
with O 0 3.2055791354679286e-10
92 O 0 1.8671482138188367e-08
% O 0 1.236601376852775e-10
of O 0 2.5444252607642603e-11
all O 0 2.4780391627565734e-10
reported O 0 4.0307455151378235e-07
mutations O 0 3.370262220414588e-07
leading O 0 2.0537848754997867e-08
to O 0 1.2241320845873815e-08
premature O 0 1.200184783556324e-06
truncation O 0 1.4612520260470774e-07
of O 0 4.919312734941172e-10
the O 0 6.216344328180412e-09
protein O 0 8.28950135201012e-08
( O 0 7.512142907728503e-09
nonsense O 0 6.601697322139444e-08
, O 0 4.358984562191637e-10
splicing O 0 8.767040071688825e-08
, O 0 6.600533453138269e-10
insertions O 0 7.829459036656772e-08
and O 0 1.8456126626986702e-09
deletions O 0 1.1682826084324915e-07
) O 0 1.013063299915018e-09
and O 0 8.113346106064512e-10
just O 0 3.7063456748143153e-09
2 O 0 3.883935395521121e-09
% O 0 1.4718709584471412e-10
leading O 0 3.241893420380393e-10
to O 0 9.671526773891159e-11
substitution O 0 8.265464424006552e-10
of O 0 6.586532014241087e-11
one O 0 6.781643580033858e-10
amino O 0 7.332863205533613e-09
acid O 0 1.0529958238691961e-08
by O 0 1.691498718869866e-09
another O 0 1.6611954478662483e-08
( O 0 4.489627514203676e-08
missense O 0 8.521506970282644e-06
) O 0 7.946871960484714e-08
. O 0 1.2577044117279002e-07

The O 0 2.70891632681014e-07
extraordinary O 0 1.656368198155178e-07
conservation O 0 6.440125766005167e-09
of O 0 3.258234237968338e-10
the O 0 3.92815913130562e-09
PAX6 O 0 2.695232751648291e-06
protein O 0 5.062537411504309e-08
at O 0 2.5355875621357882e-08
the O 0 3.6369398603852687e-09
amino O 0 3.522618285956014e-08
acid O 0 4.130913922040236e-08
level O 0 1.4724790275977284e-08
amongst O 0 6.955246156792327e-09
vertebrates O 0 8.799472794862595e-08
predicts O 0 2.479666250110313e-07
that O 0 2.433185430916751e-09
pathological O 0 1.2045674111504923e-06
missense O 0 4.676604658016004e-05
mutations O 0 2.5775310859899037e-05
should O 0 1.0972609487680529e-08
in O 0 3.1414995049772187e-09
fact O 0 1.839076557708097e-09
be O 0 4.652948026873105e-10
common O 0 1.503537738756222e-09
even O 0 1.373561264728096e-09
though O 0 1.6083141485268015e-09
they O 0 4.794736829794033e-10
are O 0 7.438393651026942e-11
hardly O 0 6.0735825258007026e-09
ever O 0 3.951077687247562e-09
seen O 0 3.5803989106852896e-08
in O 0 8.863465694730621e-08
aniridia B-Disease 1 1.0
patients O 0 8.615376145826303e-07
. O 0 6.620877002205816e-08

This O 0 1.7180522604576254e-07
indicates O 0 4.293357847018342e-08
that O 0 6.422886666967997e-10
there O 0 1.730441762104462e-10
is O 0 1.6078441356093265e-10
a O 0 1.5121945917684343e-09
heavy O 0 7.522908617829671e-06
ascertainment O 0 8.103846630547196e-05
bias O 0 1.3315656133272569e-06
in O 0 3.724742958510774e-09
the O 0 1.2533140081316674e-09
selection O 0 1.0724783283677652e-09
of O 0 1.9069126833137773e-10
patients O 0 4.467126224483309e-09
for O 0 1.161256868442706e-09
PAX6 O 0 1.6993848475976847e-05
mutation O 0 4.843711849389365e-07
analysis O 0 1.0489986657091777e-08
and O 0 4.4424999789960395e-10
that O 0 1.487262257793276e-10
the O 0 3.442787832597105e-09
missing O 0 1.1446223169286895e-07
PAX6 O 0 0.00011948413157369941
missense O 0 5.7036897487705573e-05
mutations O 0 4.5067023165756837e-05
frequently O 0 6.179255706229014e-06
may O 0 9.04377975530224e-06
underlie O 0 2.233985287602991e-05
phenotypes O 0 6.074909833841957e-06
distinct O 0 2.1571283070898062e-07
from O 0 2.3223616096856858e-07
textbook O 0 0.0004172626358922571
aniridia B-Disease 1 1.0
. O 0 1.5121454453037586e-06

Here O 0 4.975659066985827e-07
we O 0 6.336750679736269e-09
present O 0 3.2655025350436517e-09
four O 0 2.22805174310281e-09
novel O 0 7.679986424591334e-08
PAX6 O 0 2.341953404538799e-05
missense O 0 2.472182131896261e-05
mutations O 0 6.1664218264922965e-06
, O 0 3.4117113578702174e-09
two O 0 1.8357647624256401e-09
in O 0 1.3818051591840685e-08
association O 0 3.617501320718475e-08
with O 0 1.0912417636177452e-08
atypical O 0 3.731622564373538e-05
phenotypes O 0 0.00011711013939930126
ectopia B-Disease 0 0.0006304023554548621
pupillae I-Disease 0 0.00023288658121600747
( O 0 6.728412671463957e-08
displaced B-Disease 0 2.5049908813912225e-08
pupils I-Disease 0 7.175566452133353e-08
) O 0 3.0773620096624654e-08
and O 0 2.4204107376135653e-06
congenital B-Disease 1 0.9999986886978149
nystagmus I-Disease 0 0.00016894214786589146
( O 0 4.705233180857249e-08
searching B-Disease 0 2.1310782472028222e-07
gaze I-Disease 0 2.7673844670061953e-05
) O 0 3.6373493106367505e-09
, O 0 1.7868367896411996e-10
and O 0 1.2840384311374464e-10
two O 0 3.2687411111176345e-10
in O 0 6.918174033643254e-09
association O 0 3.804558446063311e-09
with O 0 3.794497493991855e-10
more O 0 4.39834790810778e-09
recognizable O 0 9.024992323247716e-05
aniridia B-Disease 1 1.0
phenotypes O 0 2.9444729079841636e-05
. O 0 3.3196758408848837e-07

Strikingly O 0 0.00021190193365328014
, O 0 3.239171419977538e-08
all O 0 5.979234329878125e-10
four O 0 4.85920137460738e-10
mutations O 0 3.642919210733453e-08
are O 0 1.3292961176247786e-10
located O 0 5.1691433355927074e-09
within O 0 3.335006493188075e-09
the O 0 1.448569530992927e-08
PAX6 O 0 7.094171905919211e-06
paired O 0 1.677415184531128e-07
domain O 0 4.905787776010584e-08
and O 0 2.4664215114711396e-09
affect O 0 6.894028903303706e-09
amino O 0 1.7810812380503194e-08
acids O 0 1.4398293224360259e-08
which O 0 6.727149393093157e-10
are O 0 4.2727318211310816e-11
highly O 0 1.4167114148477822e-09
conserved O 0 1.221776191329127e-08
in O 0 3.0145024254579766e-09
all O 0 2.77261075209978e-10
known O 0 3.0161702024855686e-09
paired O 0 5.0427235720462704e-08
domain O 0 8.177251942242947e-08
proteins O 0 6.947082198394128e-08
. O 0 8.241072890768919e-08

Our O 0 4.105073685423122e-07
results O 0 5.358284838052896e-08
support O 0 1.676837779740481e-09
the O 0 8.266505258092138e-10
hypothesis O 0 3.5640312923135298e-09
that O 0 6.89352255833775e-11
the O 0 1.9528824390935284e-10
under O 0 1.1905743058093776e-09
- O 0 1.3567440504402839e-08
representation O 0 1.713220676435867e-09
of O 0 7.25033200144054e-10
missense O 0 8.706681910553016e-06
mutations O 0 1.3558460523199756e-06
is O 0 6.276701380869554e-09
caused O 0 7.537419577374749e-08
by O 0 7.157998638263052e-09
ascertainment O 0 6.395842501660809e-05
bias O 0 1.0256556379317772e-05
and O 0 3.476719356854119e-09
suggest O 0 5.472652997440264e-09
that O 0 8.850410682104126e-11
a O 0 7.586553052441047e-10
substantial O 0 3.5371390261218494e-09
burden O 0 3.484608157577895e-08
of O 0 1.4654847335648924e-09
PAX6 B-Disease 0 0.0008589026401750743
- I-Disease 0 0.11520605534315109
related I-Disease 0 5.434492777567357e-06
disease I-Disease 0 0.000459200149634853
remains O 0 3.274410431686192e-08
to O 0 1.1918057651882918e-09
be O 0 6.682925324241751e-10
uncovered O 0 6.803350771633632e-08
. O 0 2.500392781712435e-09
. O 0 2.4789349239995317e-08

The O 0 2.7729262797038245e-07
chromosomal O 0 2.0949504687450826e-05
order O 0 2.5235113554344935e-08
of O 0 7.785432298845762e-10
genes O 0 4.14744540933043e-08
controlling O 0 3.045649350497115e-07
the O 0 1.2720659192666517e-08
major O 0 2.0782714216238674e-08
histocompatibility O 0 1.6073006463557249e-06
complex O 0 6.645497307999904e-08
, O 0 2.708973489973232e-09
properdin O 0 8.994476843326993e-07
factor O 0 2.9835575787728885e-08
B O 0 2.224261947958439e-07
, O 0 1.0553155016523874e-09
and O 0 4.242335194248881e-08
deficiency B-Disease 0 1.5111451148186461e-06
of I-Disease 0 7.714755223542369e-11
the I-Disease 0 1.480295330757997e-09
second I-Disease 0 7.750720953936252e-09
component I-Disease 0 9.78837810805544e-09
of I-Disease 0 6.21164730763013e-10
complement I-Disease 0 5.5421736533389776e-08
. O 0 4.188897761991939e-08

The O 0 4.510398454726783e-08
relationship O 0 1.3092078532395135e-08
of O 0 2.0616873486201115e-10
the O 0 8.368192250252093e-10
genes O 0 2.3165434015481878e-08
coding O 0 4.24899212703167e-07
for O 0 5.839336125745831e-09
HLA O 0 7.723223802713619e-07
to O 0 1.5159025146260774e-09
those O 0 1.0166230079988736e-09
coding O 0 1.6568769467539823e-07
for O 0 7.709052285420626e-10
properdin O 0 4.5103726620254747e-07
Factor O 0 1.668168181367946e-08
B O 0 5.1329127614963e-08
allotypes O 0 1.2318265874000645e-07
and O 0 1.656843884312309e-09
for O 0 1.934048921015119e-09
deficiency B-Disease 0 5.911603579988878e-07
of I-Disease 0 4.5860714531498203e-11
the I-Disease 0 1.267180804731538e-09
second I-Disease 0 4.700547950875489e-09
component I-Disease 0 3.4855767161445783e-09
of I-Disease 0 2.1382616510745578e-10
complement I-Disease 0 4.155173627395925e-08
( O 0 3.493032352253067e-08
C2 O 0 7.191156782937469e-06
) O 0 1.0413351292370976e-09
was O 0 4.42476899564781e-09
studied O 0 8.638588178122575e-10
in O 0 2.677182087129637e-10
families O 0 2.3364740697751074e-10
of O 0 1.4824448613115493e-10
patients O 0 2.0790803745285302e-08
with O 0 1.6159505378254835e-07
connective O 1 0.999993085861206
tissue O 1 0.9999977350234985
disorders O 1 0.9973317384719849
. O 0 1.4601447446693783e-06

Patients O 0 1.701522160146851e-05
were O 0 4.477005788317001e-08
selected O 0 9.795419586566823e-09
because O 0 6.394637597217923e-10
they O 0 1.7631754389846321e-10
were O 0 9.384363286457642e-10
heterozygous O 0 9.408871903815452e-08
or O 0 1.2617141109672048e-08
homozygous O 0 4.084527972736396e-06
for O 0 2.093978082484682e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.1019275234502857e-06

12 O 0 1.969768845810904e-06
families O 0 1.4686335703117948e-08
with O 0 3.5790659325130036e-09
15 O 0 3.551479110797118e-08
matings O 0 1.6448468613816658e-06
informative O 0 6.9485126914514694e-06
for O 0 0.0021332642063498497
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 7.898545817397462e-08
found O 0 1.3985473401589843e-07
. O 0 1.504833022636376e-07

Of O 0 1.1522121212692582e-07
57 O 0 1.162990656666807e-06
informative O 0 7.613724619659479e-07
meioses O 0 3.4593488180689747e-06
, O 0 1.5181826906740525e-09
two O 0 5.411378567465874e-10
crossovers O 0 4.01998043741969e-08
were O 0 9.697983527345855e-10
noted O 0 1.4031096284838895e-09
between O 0 5.0943449458884515e-09
the O 0 0.0014667558716610074
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
gene O 0 2.686710161015071e-07
and O 0 1.688890693962719e-09
the O 0 9.438688053364785e-09
HLA O 0 1.4209212167770602e-05
- O 0 2.5303538677690085e-06
B O 0 3.2144180295290425e-07
gene O 0 4.756739357958395e-08
, O 0 1.4204609710688487e-10
with O 0 5.4110767949699934e-11
a O 0 7.355495657002109e-10
recombinant O 0 1.3988723068791842e-08
fraction O 0 5.665792279785364e-09
of O 0 1.4031256156954441e-09
0 O 0 1.255006338851672e-07
. O 0 5.7024831079388605e-08

035 O 0 0.0485336072742939
. O 0 7.335432019317523e-05

A O 0 9.070088708540425e-06
lod O 0 0.00075741350883618
score O 0 2.1923605686424708e-07
of O 0 2.1017820817093025e-09
13 O 0 1.2062852050576112e-08
was O 0 5.436634253896955e-09
calculated O 0 8.850149946226793e-09
for O 0 9.659382183002663e-10
linkage O 0 2.163489170925459e-06
between O 0 0.00016938215412665159
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.6249416034952446e-07
HLA O 0 3.179293707944453e-05
- O 0 3.200248556822771e-06
B O 0 1.9570313725125743e-07
at O 0 6.676622366086349e-09
a O 0 1.429234286476344e-09
maximum O 0 2.435288859459206e-09
likelihood O 0 2.3068684740223944e-09
value O 0 2.970778067989954e-10
of O 0 1.9957979713325358e-11
the O 0 2.3417029426653357e-10
recombinant O 0 3.6885385856777475e-09
fraction O 0 3.8787386635874554e-09
of O 0 8.937030004929625e-10
0 O 0 9.658248956156967e-08
. O 0 3.110888613377938e-08

04 O 0 0.005423173774033785
. O 0 1.9843319023493677e-05

18 O 0 3.8093312468845397e-06
families O 0 1.6695590687731965e-08
with O 0 5.641593414651425e-09
21 O 0 7.135523105716857e-08
informative O 0 4.001391573638102e-08
matings O 0 3.8338558283612656e-07
for O 0 2.2036572566719315e-09
both O 0 3.738864773339401e-09
properdin O 0 2.6738402993942145e-06
Factor O 0 4.097125483326636e-08
B O 0 2.0171545145331038e-07
allotype O 0 1.3644954606206738e-06
and O 0 2.7819895720426757e-08
HLA O 0 8.917862942325883e-06
- O 0 6.3480188146058936e-06
B O 0 6.61288765968493e-07
were O 0 5.624768206757835e-09
found O 0 1.2235904733870484e-08
. O 0 4.201748637910896e-08

Of O 0 1.6930817992033553e-07
72 O 0 1.6404715097451117e-06
informative O 0 8.377349445254367e-07
meioses O 0 1.0542122254264541e-05
, O 0 5.65777913408283e-09
three O 0 2.054246106553137e-09
recombinants O 0 1.5159647546170163e-06
were O 0 5.420647486431562e-09
found O 0 1.4051182439800414e-09
, O 0 7.681161262595992e-11
giving O 0 2.2193220872157582e-10
a O 0 5.413381409802298e-10
recombinant O 0 1.5392879859632558e-08
fraction O 0 3.553177974069399e-09
of O 0 2.108302643577531e-09
0 O 0 1.2487836897889792e-07
. O 0 5.961771165630125e-08

042 O 0 0.0037604658864438534
. O 0 1.730891744955443e-05

A O 0 1.1325720151944552e-05
lod O 0 0.000665831146761775
score O 0 2.0197087735596142e-07
of O 0 2.281724142960684e-09
16 O 0 1.9980673116037906e-08
between O 0 1.0331254962636649e-08
HLA O 0 4.75448496217723e-06
- O 0 1.6180707689272822e-06
B O 0 1.466566885710563e-07
and O 0 1.338938404593648e-09
Factor O 0 5.796292779081114e-09
B O 0 5.479601128399736e-08
allotypes O 0 2.5983135287788173e-07
was O 0 1.1385295373145254e-08
calculated O 0 1.4594825792357824e-08
at O 0 1.7563995813318911e-09
a O 0 7.209899344218229e-10
maximum O 0 1.65366453863669e-09
likelihood O 0 2.279892719059262e-09
value O 0 4.0294031999899005e-10
of O 0 4.6051270435887304e-11
the O 0 4.667169428707041e-10
recombinant O 0 1.0139587836022201e-08
fraction O 0 4.649100215914359e-09
of O 0 1.7470975777200692e-09
0 O 0 1.291396358737984e-07
. O 0 4.2998809846039876e-08

04 O 0 0.00604126276448369
. O 0 2.4344497433048673e-05

A O 0 1.018945113173686e-06
crossover O 0 2.442072570829623e-07
was O 0 8.539305440535827e-08
shown O 0 8.040005994303101e-09
to O 0 1.2258510873053297e-09
have O 0 2.956341560444997e-10
occurred O 0 3.949329752117592e-09
between O 0 3.604177789551244e-10
genes O 0 3.8970546789585114e-09
for O 0 4.611897808093346e-10
Factor O 0 6.461287949122152e-09
B O 0 3.636380085936253e-08
and O 0 5.129054070351913e-09
HLA O 0 3.2572982036072062e-06
- O 0 5.551501089939848e-06
D O 0 6.017606665409403e-06
, O 0 3.596589415177931e-10
in O 0 1.194662035963745e-09
which O 0 1.346190980910933e-08
HLA O 0 4.401339538162574e-06
- O 0 2.8635793114517583e-06
D O 0 8.790916581347119e-06
segregared O 0 1.4914530765963718e-06
with O 0 1.5254924434771056e-08
HLA O 0 4.280951543478295e-06
- O 0 2.6130544483748963e-07
A O 0 4.603325010066328e-08
and O 0 1.9776988935404916e-08
B O 0 7.006370310591592e-07
. O 0 5.9174080746515756e-08

These O 0 5.673905789649325e-08
studies O 0 1.5263189823144785e-08
suggest O 0 8.693866959674779e-09
that O 0 1.4823740845937294e-10
the O 0 3.4854288899488495e-10
genes O 0 6.3394098859248516e-09
for O 0 5.436424643789906e-10
Factor O 0 1.6565506300025845e-08
B O 0 8.043781235755887e-06
and O 0 0.007585414219647646
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.1238018293724394e-09
located O 0 7.754477948651584e-09
outside O 0 3.990703767442483e-09
those O 0 2.2862534088119446e-10
for O 0 5.345489051400421e-10
HLA O 0 9.006667767152976e-08
, O 0 8.321743988348729e-11
that O 0 3.421065167263926e-11
the O 0 3.3081304362525543e-10
order O 0 5.304901518066174e-10
of O 0 2.775954743849951e-10
genese O 0 6.350152830236766e-07
is O 0 3.944895521357239e-09
HLA O 0 4.370061219560739e-07
- O 0 8.123696915163237e-08
A O 0 3.094761424904391e-08
, O 0 2.8575812827114078e-09
- O 0 3.5853574331667915e-07
B O 0 1.1855990322828802e-07
, O 0 1.1005951705556072e-09
- O 0 1.8298618442713632e-07
D O 0 6.696942023154406e-07
, O 0 8.372663118372259e-10
Factor O 0 3.9584322486518886e-09
B O 0 1.3563617073941714e-07
allotype O 0 9.507234608463477e-06
, O 0 1.5321633327403106e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 4.0946057655588675e-10
that O 0 6.629144455594371e-11
the O 0 1.195840648726687e-09
genes O 0 1.3513262331343867e-07
coding O 0 2.1778101654490456e-05
for O 0 1.0939697858702857e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.7523046125234032e-08
Factor O 0 4.728426361566562e-08
B O 0 2.42299421415737e-07
allotypes O 0 2.530365463826456e-07
are O 0 1.75389799905723e-10
approximately O 0 9.917403565040672e-10
3 O 0 2.000675713986766e-08
- O 0 6.621419288421748e-07
- O 0 9.801008218346396e-07
5 O 0 2.1317321241554055e-08
centimorgans O 0 1.610016084896415e-07
from O 0 1.5479666437556716e-09
the O 0 6.274702535336019e-09
HLA O 0 5.786276346952945e-07
- O 0 3.557336825110724e-08
A O 0 1.3892309524976554e-08
and O 0 9.80295133956588e-09
HLA O 0 3.080814622080652e-06
- O 0 7.1227270836971e-07
B O 0 1.4919950785952096e-07
loci O 0 2.5430511030322123e-08
, O 0 2.257205533595652e-10
and O 0 8.687641578353222e-11
that O 0 2.3708146557055443e-11
the O 0 2.0067655870370515e-10
apparent O 0 4.8543866704164884e-09
lack O 0 9.481861962257199e-10
of O 0 7.48433190422837e-11
recombinants O 0 7.778151456250271e-08
between O 0 6.010381636833984e-10
the O 0 8.534217221800589e-10
Factor O 0 1.5136150111061397e-08
B O 0 1.97989635353224e-07
gene O 0 2.404588485660497e-06
and O 0 0.00041388170211575925
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.6426898810095736e-06
suggests O 0 1.2229278922859521e-08
that O 0 1.1267160121564146e-10
these O 0 6.468050400831871e-11
two O 0 1.1914619291175654e-10
genes O 0 7.778905519728596e-09
lie O 0 4.982584123069955e-09
in O 0 1.006804750680601e-09
close O 0 8.694281738996779e-09
proximity O 0 8.901343662159888e-09
to O 0 3.823764416210906e-09
one O 0 2.297199763745539e-09
another O 0 9.908653453294392e-09
. O 0 4.20578167847907e-08

Distribution O 0 8.518789513800584e-07
of O 0 2.232068219143457e-08
emerin O 0 5.159974080015672e-06
and O 0 1.634118973470322e-08
lamins O 0 3.4877448342740536e-06
in O 0 6.59504939548583e-09
the O 0 1.417458150854145e-08
heart O 0 8.062058896030067e-07
and O 0 1.8711687754802142e-09
implications O 0 1.4859226737939935e-08
for O 0 7.571869353739658e-09
Emery B-Disease 1 0.9991100430488586
- I-Disease 1 0.998698353767395
Dreifuss I-Disease 1 0.9999891519546509
muscular I-Disease 1 0.9999771118164062
dystrophy I-Disease 1 0.9999693632125854
. O 0 1.7912391285790363e-06

Emerin O 0 0.00015777559019625187
is O 0 4.00351360951845e-08
a O 0 1.2490738221515585e-08
nuclear O 0 9.401623657367963e-08
membrane O 0 1.331162735596081e-07
protein O 0 8.107814863933527e-08
which O 0 4.237779904769923e-09
is O 0 6.195153279264787e-10
missing O 0 4.52490711566611e-09
or O 0 7.63601715192408e-09
defective O 0 2.8841980110883014e-06
in O 0 7.988709427309004e-08
Emery B-Disease 1 0.9999459981918335
- I-Disease 1 0.999796450138092
Dreifuss I-Disease 1 0.9999988079071045
muscular I-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999998807907104
( O 0 3.615629339037696e-06
EDMD B-Disease 1 1.0
) O 0 3.70978170849412e-07
. O 0 1.1951655665143335e-07

It O 0 3.6070429132450954e-07
is O 0 2.224824324770225e-09
one O 0 3.560618744291588e-10
member O 0 2.561840461989817e-10
of O 0 2.6822252752189968e-11
a O 0 1.2194986132030294e-09
family O 0 8.041203258812857e-09
of O 0 1.0842639008856736e-09
lamina O 0 1.6134779798449017e-05
- O 0 2.8709896469081286e-06
associated O 0 9.180141091746918e-08
proteins O 0 1.3783647112575181e-08
which O 0 2.4322484026839675e-09
includes O 0 3.4828653294738388e-09
LAP1 O 0 1.069074301085493e-06
, O 0 2.373341745354196e-09
LAP2 O 0 2.8900210509164026e-06
and O 0 2.5673459802533216e-08
lamin O 0 3.5801127523882315e-05
B O 0 3.58677061740309e-06
receptor O 0 3.7364968648034846e-06
( O 0 3.664726193619572e-07
LBR O 0 2.0174376913928427e-05
) O 0 1.0662909488701189e-07
. O 0 1.4356588451391872e-07

A O 0 2.1060525341454195e-06
panel O 0 1.2813530929633998e-06
of O 0 6.1157678921119896e-09
16 O 0 7.817476443960913e-08
monoclonal O 0 9.117553645410226e-07
antibodies O 0 1.9323520064062905e-06
( O 0 9.595579086862926e-08
mAbs O 0 1.93309301721456e-06
) O 0 6.860501056138446e-09
has O 0 1.5621650639729978e-09
been O 0 1.16435527885983e-09
mapped O 0 3.5424140065742904e-08
to O 0 3.1704211478356115e-10
six O 0 2.6361135496699717e-10
specific O 0 1.7685677922152365e-10
sites O 0 1.470536026282332e-09
throughout O 0 2.5968993622171865e-09
the O 0 1.5279608689411361e-09
emerin O 0 2.0439023273866042e-07
molecule O 0 1.4617279830986263e-08
using O 0 1.6120340617931106e-08
phage O 0 2.3324784592659853e-07
- O 0 1.0435191910573849e-07
displayed O 0 3.201855136580889e-08
peptide O 0 3.7358297788614436e-08
libraries O 0 3.2999645238618314e-09
and O 0 4.140265352781114e-10
has O 0 2.588565473082838e-10
been O 0 2.0497829822385683e-10
used O 0 1.3428462786180262e-09
to O 0 1.5719657797674813e-09
localize O 0 1.7067269482140546e-06
emerin O 0 1.0616664667395526e-06
in O 0 6.001277697009755e-09
human O 0 7.972145610324333e-09
and O 0 1.6239463107581287e-08
rabbit O 0 0.00019555848848540336
heart O 0 4.080171129317023e-05
. O 0 3.8402666291403875e-07

Several O 0 2.960277242891607e-06
mAbs O 0 5.832485112478025e-05
against O 0 1.0897861102421302e-07
different O 0 2.6501565386638504e-08
emerin O 0 1.4838637071079575e-05
epitopes O 0 6.5397134676459245e-06
did O 0 2.5837692874119966e-07
not O 0 4.9072639285441255e-09
recognize O 0 2.5799668179615765e-08
intercalated O 0 3.99517688265405e-07
discs O 0 2.984616230605752e-06
in O 0 3.7010472464515942e-09
the O 0 5.78137626661146e-09
heart O 0 3.4462132703083626e-07
, O 0 2.7036656247148017e-10
though O 0 4.66510496899275e-10
they O 0 2.265953535918186e-10
recognized O 0 5.697085025957449e-10
cardiomyocyte O 0 2.1031149799455306e-07
nuclei O 0 5.6049795915669165e-08
strongly O 0 1.0031518726805189e-08
, O 0 1.7644437300123883e-10
both O 0 2.1557231000279842e-10
at O 0 9.764026032144102e-09
the O 0 4.022317590113289e-09
rim O 0 7.744976215917632e-08
and O 0 1.0164407093782302e-09
in O 0 2.186758552014112e-09
intranuclear O 0 1.048634430844686e-06
spots O 0 1.4944103554626054e-07
or O 0 2.0145680679206635e-08
channels O 0 3.4499487355788006e-07
. O 0 1.5838189426631288e-07

A O 0 1.3916655916546006e-05
polyclonal O 0 0.0008338259649462998
rabbit O 0 0.00028521945932880044
antiserum O 0 5.7040750107262284e-05
against O 0 3.178217298227537e-07
emerin O 0 1.7860425941762514e-05
did O 0 5.181228246442515e-08
recognize O 0 8.673296747474524e-09
both O 0 1.1947576261661652e-09
nuclear O 0 2.7204077213127675e-08
membrane O 0 2.8918185179804823e-08
and O 0 2.3976063356911936e-09
intercalated O 0 7.91745975448066e-08
discs O 0 7.680101816731622e-07
but O 0 6.609112146449547e-10
, O 0 3.427243558395965e-11
after O 0 3.142570648151377e-10
affinity O 0 1.4136127823860534e-09
purification O 0 1.2079284239518984e-09
against O 0 7.381580902077189e-10
a O 0 2.3029909090865885e-09
pure O 0 1.3026891565459664e-08
- O 0 1.67109999438253e-06
emerin O 0 8.965975553110184e-07
band O 0 4.6357058636203874e-08
on O 0 2.9450870631109183e-09
a O 0 1.1968194213451966e-09
western O 0 1.068711430463054e-08
blot O 0 4.857550447923131e-05
, O 0 1.916784730937593e-09
it O 0 1.8600417872605135e-09
stained O 0 1.1497743798827287e-05
only O 0 5.240938238948445e-10
the O 0 1.4754469868094588e-09
nuclear O 0 8.986197030935728e-08
membrane O 0 2.354209414079378e-07
. O 0 9.283765933787436e-08

These O 0 8.811548468656838e-08
results O 0 4.689007937486167e-08
would O 0 2.728533621265683e-09
not O 0 2.752640337888579e-10
be O 0 1.1126127796856622e-10
expected O 0 1.3130484477485993e-09
if O 0 6.969358423702943e-10
immunostaining O 0 1.606758104344408e-07
at O 0 2.5747068477244284e-08
intercalated O 0 4.239398876393352e-08
discs O 0 2.881649834307609e-07
were O 0 5.933959990045423e-10
due O 0 1.7406316388246523e-09
to O 0 3.451122720932176e-10
a O 0 1.1185925519185957e-09
product O 0 1.6939329938736591e-09
of O 0 6.857171080953961e-11
the O 0 9.898166730692992e-10
emerin O 0 2.1772670777409076e-07
gene O 0 4.664770969498022e-08
and O 0 1.2787403358416327e-09
, O 0 1.0757188195764655e-10
therefore O 0 3.610679810694961e-10
, O 0 8.244393362444313e-11
cast O 0 7.406514845875733e-10
some O 0 6.746574826577145e-11
doubt O 0 3.033916451400387e-10
upon O 0 7.754439451668205e-11
the O 0 3.5972619327750976e-10
hypothesis O 0 8.759982073058836e-09
that O 0 2.8872977342331296e-09
cardiac B-Disease 0 0.0007262808503583074
defects I-Disease 0 0.14354293048381805
in O 0 3.75892426518476e-07
EDMD B-Disease 1 1.0
are O 0 6.773748673083446e-09
caused O 0 3.4622818390062093e-08
by O 0 1.8539106916293235e-09
absence O 0 1.1356320328559377e-08
of O 0 1.1284650991427725e-09
emerin O 0 6.008603577356553e-06
from O 0 3.101013135164976e-08
intercalated O 0 2.9620762234117137e-06
discs O 0 3.5984932765131816e-05
. O 0 2.1693745111406315e-07

Although O 0 1.2404955214151414e-06
emerin O 0 8.053551937337033e-06
was O 0 2.733316684100373e-08
abundant O 0 5.137239078578659e-09
in O 0 1.8761290299096345e-09
the O 0 2.70065703134037e-09
membranes O 0 1.371256388438269e-07
of O 0 7.952883906980901e-10
cardiomyocyte O 0 1.6218032214965206e-06
nuclei O 0 1.8025096437668253e-07
, O 0 4.579098489276845e-10
it O 0 1.059870413655517e-09
was O 0 3.589890340549573e-08
absent O 0 6.151848364055468e-09
from O 0 4.880155723974156e-10
many O 0 1.8311650806790425e-10
non O 0 6.3870717603720095e-09
- O 0 7.270473929565924e-07
myocyte O 0 6.0544934967765585e-06
cells O 0 6.865870716410427e-08
in O 0 7.410248858974455e-09
the O 0 2.1686952678123816e-08
heart O 0 2.862006795112393e-06
. O 0 1.3045520574905822e-07

This O 0 3.716647256624128e-08
distribution O 0 2.176323832259186e-08
of O 0 9.584413263041824e-10
emerin O 0 1.9325750599819003e-06
was O 0 1.1917767217539676e-08
similar O 0 8.858150324364544e-10
to O 0 2.675079047165241e-10
that O 0 9.233106640360589e-11
of O 0 1.944215344273914e-10
lamin O 0 3.0036164844204905e-07
A O 0 5.524356083697057e-09
, O 0 1.6261764157476932e-10
a O 0 5.879252640283994e-10
candidate O 0 2.3836215223838053e-09
gene O 0 1.329761545321162e-08
for O 0 1.565370749689876e-10
an O 0 1.3548039357047514e-09
autosomal O 0 7.267684122780338e-05
form O 0 3.6601227293431293e-07
of O 0 2.0631691199923807e-07
EDMD B-Disease 1 1.0
. O 0 7.200333129731007e-07

In O 0 8.954643817560282e-07
contrast O 0 9.40857262321515e-07
, O 0 6.327694990204691e-08
lamin O 0 0.00020569532352965325
B1 O 0 0.00701098470017314
was O 0 5.608176252280828e-07
absent O 0 1.6545432401926519e-07
from O 0 8.626655834120811e-09
cardiomyocyte O 0 9.494535788689973e-07
nuclei O 0 1.0848875575675265e-07
, O 0 1.3984473579142787e-09
showing O 0 6.992252821191869e-08
that O 0 7.724805684006242e-09
lamin O 0 2.283775211253669e-05
B1 O 0 4.4913125748280436e-05
is O 0 1.2025400675241826e-09
not O 0 1.4767639888724204e-10
essential O 0 9.972710851569033e-11
for O 0 6.841859717665599e-11
localization O 0 1.1207329286833101e-08
of O 0 2.5063742747910567e-10
emerin O 0 4.1997100197477266e-07
to O 0 2.7297410998272653e-09
the O 0 9.928083244403751e-09
nuclear O 0 1.2316145330260042e-06
lamina O 0 1.7317037418251857e-05
. O 0 1.7734582513639907e-07

Lamin O 1 0.8118476271629333
B1 O 1 0.9904885292053223
is O 0 1.1359054497006582e-07
also O 0 1.5574029177400917e-08
almost O 0 4.815443155337107e-09
completely O 0 6.860948786879817e-08
absent O 0 1.283633821458352e-07
from O 0 2.0288355884190423e-08
skeletal O 0 0.003144594607874751
muscle O 0 0.0004391568654682487
nuclei O 0 1.7602053048904054e-05
. O 0 5.839094114890031e-07

In O 0 1.0547099918767344e-05
EDMD B-Disease 1 0.9999998807907104
, O 0 1.3739078319474629e-08
the O 0 1.9690336028332922e-09
additional O 0 1.4352277144524805e-09
absence O 0 8.46254444297756e-09
of O 0 4.2034620229003394e-09
lamin O 0 8.081035775830969e-05
B1 O 0 0.00048108483315445483
from O 0 1.1917181552689726e-07
heart O 0 0.00011769340926548466
and O 0 3.9071011315172655e-07
skeletal O 0 0.476736843585968
muscle O 0 0.0020860200747847557
nuclei O 0 1.7782726899895351e-06
which O 0 1.3993953551505456e-08
already O 0 9.78136061036139e-09
lack O 0 3.678695126296816e-09
emerin O 0 5.071853138360893e-06
may O 0 1.841225483190101e-08
offer O 0 3.9747033442338875e-10
an O 0 7.143643315776771e-11
alternative O 0 1.1976233338373277e-09
explanation O 0 7.140895097457189e-10
of O 0 1.2650962222249262e-10
why O 0 2.423963030295795e-09
these O 0 5.627522892126535e-10
tissues O 0 6.368303928638852e-08
are O 0 1.1122563287058185e-10
particularly O 0 1.8744050755969965e-09
affected O 0 8.085589087158951e-09
. O 0 2.476920224481205e-09
. O 0 4.088468230634135e-08

Genetic O 0 3.0720031645614654e-05
mapping O 0 4.896794052910991e-06
of O 0 1.9281822360994738e-08
the O 0 1.1882318773359657e-07
copper B-Disease 0 4.145429193158634e-05
toxicosis I-Disease 0 0.00025985180400311947
locus O 0 4.548871856968617e-06
in O 0 5.6253714575404956e-08
Bedlington O 0 0.0001649112527957186
terriers O 0 0.00020808733825106174
to O 0 9.154612001793794e-08
dog O 0 0.0001308542414335534
chromosome O 0 3.5576467780629173e-06
10 O 0 1.1025960588995076e-08
, O 0 1.356530582308224e-10
in O 0 4.19800361139977e-10
a O 0 5.0500745807369185e-09
region O 0 3.5076539006695384e-08
syntenic O 0 2.049849626928335e-06
to O 0 3.15325365818353e-09
human O 0 7.413896607744164e-09
chromosome O 0 2.210116917922278e-06
region O 0 2.2618068840074557e-07
2p13 O 0 1.3419679817161523e-05
- O 0 1.5042167433421127e-05
p16 O 0 3.250213558203541e-05
. O 0 6.048763907529064e-07

Abnormal O 1 0.9998511075973511
hepatic B-Disease 1 0.9999432563781738
copper I-Disease 0 0.3243500590324402
accumulation I-Disease 0 2.2822923710918985e-06
is O 0 2.2617145933878646e-09
recognized O 0 2.055370984521687e-09
as O 0 1.8542077873107132e-09
an O 0 1.9524173922036425e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 1.3355382577628916e-07
man O 0 3.3352282002852007e-07
, O 0 1.2250891412435294e-09
mouse O 0 3.1594461233908078e-06
, O 0 1.0726159516138978e-08
rat O 0 7.747509698674548e-06
and O 0 2.052993686163518e-08
dog O 0 9.988706733565778e-05
. O 0 1.9712032894858567e-07

The O 0 2.811279955494683e-07
major O 0 9.352510943472225e-08
cause O 0 2.0186574545277836e-07
of O 0 1.4757516986207975e-08
hepatic B-Disease 0 0.21894654631614685
copper I-Disease 0 0.04052700847387314
accumulation I-Disease 0 8.393423058805638e-07
in O 0 2.1857879062281427e-08
man O 0 1.0470181166510883e-07
is O 0 1.6431161986574239e-09
a O 0 1.0836814112735738e-08
dysfunctional O 0 8.015990715648513e-06
ATP7B O 0 1.226968288392527e-05
gene O 0 2.4050539195741294e-06
, O 0 1.2227412859999731e-08
causing O 0 1.7333693904220127e-05
Wilson B-Disease 0 0.003629674669355154
disease I-Disease 0 0.1839810311794281
( O 0 9.078206062440586e-07
WD B-Disease 0 0.002849623328074813
) O 0 3.3960284895329096e-07
. O 0 3.1063117944540863e-07

Mutations O 0 0.00024012189533095807
in O 0 1.0087663326885377e-07
the O 0 3.150567806642357e-08
ATP7B O 0 8.01476835476933e-06
genes O 0 9.45512397265702e-08
have O 0 1.7098158444639466e-09
also O 0 1.1047046610812572e-09
been O 0 7.138770685699569e-10
demonstrated O 0 2.626859396670511e-09
in O 0 3.362637945869551e-09
mouse O 0 5.901435542909894e-06
and O 0 2.424264700096046e-08
rat O 0 1.857364441093523e-05
. O 0 1.3225883321865695e-07

The O 0 1.3519235153580667e-06
ATP7B O 0 3.694295810419135e-05
gene O 0 2.8247757200006163e-06
has O 0 1.3009089805393614e-08
been O 0 1.1902087093673686e-09
excluded O 0 1.7032182331178092e-09
in O 0 2.1116901283146916e-10
the O 0 5.084120902054678e-10
much O 0 3.1476172779321132e-09
rarer O 0 2.4090107331176114e-07
human O 0 7.19059585208015e-08
copper B-Disease 1 0.7160715460777283
overload I-Disease 0 0.0010571625316515565
disease O 0 3.157931359965005e-06
non B-Disease 0 2.700318724180306e-08
- I-Disease 0 1.6416437347288593e-06
Indian I-Disease 0 3.787299718283066e-08
childhood I-Disease 0 5.316428359947167e-05
cirrhosis I-Disease 0 3.405601091799326e-05
, O 0 4.962779964756692e-09
indicating O 0 4.6398631070587726e-07
genetic O 0 3.079390126004e-06
heterogeneity O 0 2.014257916016504e-05
. O 0 7.849478151911171e-07

By O 0 2.3397548432058102e-07
investigating O 0 3.9065682244654454e-07
the O 0 6.112155404025543e-08
common O 0 2.910791181420791e-06
autosomal O 1 0.9999408721923828
recessive O 1 0.9999996423721313
copper B-Disease 1 0.9999765157699585
toxicosis I-Disease 1 0.9979888200759888
( O 0 1.4317336081148824e-06
CT B-Disease 1 0.9682281613349915
) O 0 3.067879816853747e-08
in O 0 1.2840788876644638e-08
Bedlington O 0 0.0003753080090973526
terriers O 0 0.0007043717196211219
, O 0 8.042445820422017e-09
we O 0 3.3968142187923434e-10
have O 0 1.0414458878615918e-10
identified O 0 6.208378255934122e-10
a O 0 3.9812439456277104e-10
new O 0 4.896904215456743e-09
locus O 0 7.09402527832026e-08
involved O 0 3.255055558426534e-09
in O 0 3.203379606020462e-07
progressive O 1 0.9999905824661255
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.2944482225284446e-06

We O 0 3.1943588396643463e-07
examined O 0 3.2736366506469494e-07
whether O 0 1.1215840700629087e-08
the O 0 1.8455359906965896e-08
WD B-Disease 0 0.0001516789779998362
gene O 0 3.4805345876520732e-06
ATP7B O 0 1.605205579835456e-05
was O 0 5.838871430796644e-08
also O 0 1.315532571766198e-09
causative O 0 1.9514693860855914e-08
for O 0 8.215373381581514e-10
CT B-Disease 0 0.0002162582823075354
by O 0 2.7406343861002824e-09
investigating O 0 2.0018209312411273e-08
the O 0 2.8324423695380574e-08
chromosomal O 0 0.0003357941750437021
co O 0 1.6261955124718952e-06
- O 0 7.577758651677868e-07
localization O 0 4.5014348870608956e-07
of O 0 2.648886665568284e-09
ATP7B O 0 5.549024081119569e-06
and O 0 2.8407294294652274e-09
C04107 O 0 3.860583674963891e-08
, O 0 1.5366315164744293e-10
using O 0 1.2175417340998251e-09
fluorescence O 0 4.184729007761234e-08
in O 0 3.92617405253759e-09
situ O 0 8.699178266624585e-08
hybridization O 0 5.4248079806029637e-08
( O 0 6.653282369484259e-09
FISH O 0 4.7768690336624786e-08
) O 0 1.6052288387413682e-08
. O 0 4.2727958060595483e-08

C04107 O 0 0.00011966702004428953
is O 0 6.377931782708401e-08
an O 0 5.402584157820911e-09
anonymous O 0 2.3108687230433134e-07
microsatellite O 0 8.356607395398896e-06
marker O 0 1.9802826045633992e-06
closely O 0 4.024461475182761e-07
linked O 0 5.759724444942549e-06
to O 0 2.087182480181582e-07
CT B-Disease 1 0.9988583326339722
. O 0 1.0097631957250996e-06

However O 0 1.1222665534660337e-06
, O 0 1.0623020330058353e-07
BAC O 0 3.416446634219028e-05
clones O 0 1.3269411738292547e-06
containing O 0 8.414840380055466e-08
ATP7B O 0 2.838242608049768e-06
and O 0 7.588365491528748e-09
C04107 O 0 3.8062557905504946e-07
mapped O 0 1.5678111253691895e-07
to O 0 3.704465623144415e-09
the O 0 1.325226683945857e-08
canine O 0 1.0349624062655494e-05
chromosome O 0 5.802008217870025e-06
regions O 0 8.176471766319082e-08
CFA22q11 O 0 1.526900814496912e-05
and O 0 1.3868429071806077e-08
CFA10q26 O 0 1.869206244009547e-06
, O 0 1.3230766482408285e-09
respectively O 0 3.895627820327263e-09
, O 0 2.0462986860536603e-10
demonstrating O 0 2.1625439217132225e-09
that O 0 1.7513415162540014e-09
WD B-Disease 0 1.275122122024186e-05
cannot O 0 1.327131382566904e-08
be O 0 1.6691094062437628e-09
homologous O 0 7.818878344778568e-08
to O 0 4.184856905453671e-08
CT B-Disease 1 0.8494386672973633
. O 0 6.385332085301343e-07

The O 0 4.97743826599617e-07
copper O 0 3.554445129339001e-06
transport O 0 1.1715651027088825e-07
genes O 0 2.392615101598494e-07
CTR1 O 0 3.174190169374924e-06
and O 0 1.0032628061651394e-08
CTR2 O 0 5.778562353953021e-06
were O 0 9.343646745207934e-09
also O 0 1.2516153669039909e-09
excluded O 0 3.1560274393882537e-09
as O 0 6.798052676337818e-10
candidate O 0 3.0806552864248715e-09
genes O 0 8.35132762944113e-09
for O 0 1.406110228252544e-09
CT B-Disease 1 0.9803932309150696
since O 0 1.442322883349334e-07
they O 0 7.22676474218531e-10
both O 0 6.80211220682736e-10
mapped O 0 1.228294479460601e-07
to O 0 5.671814573560141e-09
canine O 0 8.172469279088546e-06
chromosome O 0 6.670128186669899e-06
region O 0 3.29338973870108e-07
CFA11q22 O 0 6.581209891010076e-05
. O 0 5.590943601418985e-07

2 O 0 4.899813575320877e-05
- O 0 5.911274638492614e-05
22 O 0 1.5509012882830575e-06
. O 0 2.2023816370619897e-07

5 O 0 4.1471259464742616e-05
. O 0 3.1261745334631996e-06

A O 0 3.3471146707597654e-06
transcribed O 0 1.5700146832386963e-05
sequence O 0 7.092097007443954e-07
identified O 0 3.975283746626701e-08
from O 0 2.851461511355069e-09
the O 0 1.5925567531382967e-09
C04107 O 0 3.895013662713609e-07
- O 0 1.4483519805708056e-07
containing O 0 2.8606802260355835e-08
BAC O 0 5.916265581618063e-05
was O 0 3.668592896133305e-08
found O 0 8.866517520189632e-10
to O 0 2.4261681552673053e-10
be O 0 8.500340709094445e-11
homologous O 0 2.688548494944598e-09
to O 0 2.174073143734745e-10
a O 0 8.370012460900966e-10
gene O 0 2.9271344459402826e-08
expressed O 0 1.1209162487091362e-09
from O 0 1.3047674052302227e-09
human O 0 5.373644196282612e-09
chromosome O 0 1.246139504473831e-06
2p13 O 0 1.2378648079902632e-06
- O 0 4.814903604710707e-07
p16 O 0 4.923805363432621e-07
, O 0 6.694509946392202e-10
a O 0 1.6693959548064186e-09
region O 0 6.253173090442488e-09
devoid O 0 1.9229084102789784e-08
of O 0 2.0952088675141312e-10
any O 0 1.2444288932655923e-09
positional O 0 2.6824857286555925e-06
candidate O 0 2.320028471558544e-07
genes O 0 1.39776216201426e-06
. O 0 2.1111128489792463e-07

Molecular O 0 1.3689864317711908e-05
analysis O 0 1.0539265105080631e-07
of O 0 1.5220010807226458e-09
the O 0 7.614259445176685e-09
APC B-Disease 0 3.1951236678651185e-07
gene O 0 1.0611638856516947e-07
in O 0 3.8632776977465255e-09
205 O 0 4.6888199989325585e-08
families O 0 5.834415617300692e-09
: O 0 2.8914419747394504e-09
extended O 0 2.2099644070294744e-07
genotype O 0 5.5860360589576885e-05
- O 0 2.961383324873168e-05
phenotype O 0 1.2479051292757504e-05
correlations O 0 6.34496473139734e-07
in O 0 4.5998142184089374e-08
FAP B-Disease 0 3.1242592513081036e-07
and O 0 3.6502462164023086e-10
evidence O 0 2.171627877523008e-10
for O 0 3.446766136394608e-11
the O 0 1.41375758322404e-10
role O 0 5.859392970819499e-10
of O 0 1.633606305784241e-10
APC B-Disease 0 5.586323581496799e-08
amino O 0 3.46329223077646e-08
acid O 0 8.856671485091283e-08
changes O 0 5.585566213994753e-07
in O 1 0.9557868838310242
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.0018501352751627564
. O 0 6.59943111713801e-07

BACKGROUND O 0 0.00013723237498197705
/ O 0 2.1967605789541267e-05
AIMS O 0 2.2593147264160507e-07
The O 0 4.831247846226461e-09
development O 0 1.1623255247172892e-08
of O 0 1.458402266507619e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.9415269392197843e-08
a O 0 9.6933643334296e-09
variable O 0 1.635984716585881e-07
range O 0 3.5536746878506165e-08
of O 0 1.970213325819259e-09
extracolonic O 0 2.6928333682008088e-05
manifestations O 0 1.7837844552559545e-06
in O 0 5.177274942980148e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.00026020457153208554
FAP B-Disease 0 4.60793380625546e-05
) O 0 1.3042207314128973e-08
is O 0 4.243609630361078e-10
the O 0 3.5324110303491807e-10
result O 0 5.680461656609737e-10
of O 0 6.078038072843128e-11
the O 0 2.270445387253517e-09
dominant O 0 2.968880608023028e-06
inheritance O 0 1.389347062286106e-06
of O 0 2.9637698162332526e-07
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 1.0
( O 0 9.522660548100248e-06
APC B-Disease 0 1.3571715498983394e-05
) O 0 8.176223076361566e-08
gene O 0 8.058829735091422e-06
mutations O 0 2.8256728910491802e-05
. O 0 4.335722110226925e-07

In O 0 1.9117150884540024e-07
this O 0 4.556953037138101e-09
study O 0 1.2042340458151557e-09
, O 0 9.355816815714846e-11
direct O 0 2.0043413595516313e-09
mutation O 0 7.143448499391525e-08
analysis O 0 2.3612949373585934e-09
of O 0 1.5686076049181708e-10
the O 0 4.643995410447133e-09
APC B-Disease 0 1.9375028159629437e-07
gene O 0 6.977917621497909e-08
was O 0 5.786119583461868e-09
performed O 0 3.4408313975831106e-09
to O 0 9.591746286119474e-10
determine O 0 3.345482113559228e-08
genotype O 0 7.938544513308443e-06
- O 0 9.434131243324373e-06
phenotype O 0 4.831204478250584e-06
correlations O 0 2.2164820734360546e-07
for O 0 1.7069126112545518e-09
nine O 0 9.219547791872174e-09
extracolonic O 0 2.573151277829311e-06
manifestations O 0 6.481607783825893e-08
and O 0 1.1242135000699705e-09
to O 0 6.569673138834276e-10
investigate O 0 6.0857234807087934e-09
the O 0 6.591151180401766e-09
incidence O 0 5.393180799728725e-07
of O 0 1.1912353325982394e-09
APC B-Disease 0 5.048093498771777e-07
mutations O 0 5.294041329761967e-07
in O 0 5.569832595142543e-08
non O 0 2.3590833734488115e-05
- O 1 1.0
FAP O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.417582436464727e-06

METHODS O 0 2.2614474346482893e-06
The O 0 1.0871744393625704e-07
APC B-Disease 0 9.210365874423587e-07
gene O 0 4.940342819281796e-07
was O 0 2.0430482194910837e-08
analysed O 0 1.0906241243446857e-07
in O 0 6.73247946281208e-09
190 O 0 1.0339657308122696e-07
unrelated O 0 1.0339558542682425e-07
FAP B-Disease 0 6.436665103137784e-07
and O 0 8.379313243267461e-09
15 O 0 7.837527249421328e-08
non O 0 5.220508683123626e-06
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.1495813851070125e-05
using O 0 5.249907530924247e-07
denaturing O 0 0.0010823770426213741
gradient O 0 1.0564484000497032e-05
gel O 0 8.62343586049974e-06
electrophoresis O 0 3.470973695129942e-07
, O 0 9.645132470481599e-10
the O 0 1.0531238103794749e-09
protein O 0 4.3524423176677374e-08
truncation O 0 5.093774575470889e-07
test O 0 1.0404485806247976e-07
, O 0 7.746903674110683e-10
and O 0 4.299163247623028e-10
direct O 0 9.967472180960613e-09
sequencing O 0 9.147208857029909e-07
. O 0 1.3936157472471677e-07

RESULTS O 0 4.735439142677933e-05
Chain O 0 3.333134009153582e-05
terminating O 0 3.931192622985691e-06
signals O 0 4.666894255933585e-06
were O 0 3.3095330920218657e-09
only O 0 3.6324249164110256e-10
identified O 0 2.365848184027186e-09
in O 0 2.090866590975793e-09
patients O 0 5.031422833923216e-09
belonging O 0 8.469390522236608e-09
to O 0 2.9744764429295856e-09
the O 0 1.1039154479419722e-08
FAP B-Disease 0 4.0032165316006285e-07
group O 0 5.9738458624281066e-09
( O 0 4.560483102267199e-09
105 O 0 1.1647227182720599e-07
patients O 0 7.719859951293984e-08
) O 0 1.923209147491889e-08
. O 0 8.098494674868562e-08

Amino O 0 1.7683742044027895e-05
acid O 0 5.155094640940661e-06
changes O 0 9.371849785111408e-08
were O 0 3.138211468467489e-09
identified O 0 2.737813087350105e-09
in O 0 1.6055832219308286e-09
four O 0 2.2152253364993157e-09
patients O 0 2.9116862254596754e-09
, O 0 1.0807574973847878e-10
three O 0 1.0803658662128512e-10
of O 0 7.236678617461578e-11
whom O 0 7.569454507638795e-10
belonged O 0 5.062380292741864e-09
to O 0 3.7620326298615225e-10
the O 0 1.6224563914590817e-09
non O 0 1.043701836067612e-08
- O 0 9.671056204751949e-07
FAP O 0 8.927427757043915e-07
group O 0 8.298233922232612e-08
of O 0 5.759219220635714e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 4.186165097053163e-05
. O 0 5.213416329752363e-07

Genotype O 1 0.5691457986831665
- O 0 0.09687076508998871
phenotype O 0 0.00021726622071582824
correlations O 0 2.683396587599418e-06
identified O 0 6.726834556047834e-08
significant O 0 3.6659331126287498e-09
differences O 0 2.0951389956280764e-08
in O 0 4.6448280777156015e-09
the O 0 2.247514840902909e-09
nature O 0 8.206305635027888e-10
of O 0 1.5116026486072798e-10
certain O 0 6.775324745689204e-09
extracolonic O 0 2.6817033358383924e-06
manifestations O 0 2.0500790753885667e-07
in O 0 5.324349672264361e-08
FAP B-Disease 0 1.7489641095380648e-06
patients O 0 1.8418718994439587e-08
belonging O 0 1.3190407877061716e-08
to O 0 6.1877170054458475e-09
three O 0 1.0636539649055976e-08
mutation O 0 4.836833340959856e-06
subgroups O 0 8.946927323449927e-07
. O 0 2.2987796910456382e-07

CONCLUSIONS O 0 2.505381235096138e-05
Extended O 0 4.097265446034726e-06
genotype O 0 0.0001759649021551013
- O 0 5.4805426771054044e-05
phenotype O 0 1.2403000255289953e-05
correlations O 0 3.7099195537848573e-07
made O 0 7.187878292569394e-09
in O 0 1.0986110909882996e-09
this O 0 2.91830670740012e-10
study O 0 8.037058796261931e-10
may O 0 6.9135963620681196e-09
have O 0 4.354013677376756e-11
the O 0 1.3966580669766415e-10
potential O 0 1.0558465213250656e-10
to O 0 1.133099447603314e-10
determine O 0 3.5958760968846093e-10
the O 0 2.9646196608723585e-10
most O 0 1.554724127217355e-10
appropriate O 0 1.8242496402365305e-09
surveillance O 0 9.4113843829291e-08
and O 0 1.2254490755481129e-09
prophylactic O 0 1.949758399177881e-07
treatment O 0 2.4190178748995095e-08
regimens O 0 1.0511902104326509e-07
for O 0 4.3120482184910713e-10
those O 0 4.4795983589196453e-10
patients O 0 2.03522176889237e-09
with O 0 7.991948769436874e-10
mutations O 0 5.766763706560596e-07
associated O 0 1.1562558910327425e-08
with O 0 2.604796822680555e-09
life O 0 4.724333280137216e-08
threatening O 0 1.0267321158607956e-05
conditions O 0 1.6821840063130367e-06
. O 0 1.450389390811324e-07

This O 0 8.55453166082043e-08
study O 0 1.1431295909858363e-08
also O 0 5.165198824208517e-10
provided O 0 1.0444495962547151e-10
evidence O 0 6.038818056719464e-11
for O 0 2.737089548066063e-11
the O 0 3.4416436367479264e-10
pathological O 0 9.318391391843761e-09
nature O 0 9.294495173506334e-10
of O 0 2.795380038556061e-10
amino O 0 4.681099596837157e-08
acid O 0 5.4402782723173004e-08
changes O 0 1.2644967739561253e-08
in O 0 1.3921593655652487e-08
APC O 0 2.3147242700360948e-07
associated O 0 4.4659671516456e-09
with O 0 1.0313471188183598e-09
both O 0 6.838070110148919e-09
FAP B-Disease 0 8.303377967422421e-07
and O 0 9.220586072444803e-09
non O 0 1.0445578482176643e-05
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 6.262360693654045e-05
. O 0 4.5004473037124626e-08
. O 0 1.5084511062468664e-07

Inherited B-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999994039535522
and O 0 0.04620660841464996
cancer B-Disease 1 0.6497414708137512
risk O 0 5.408076049207011e-07
of O 0 1.910703595342511e-09
the O 0 5.087142795900945e-08
APC O 0 5.373951807996491e-06
I1307K O 0 8.246894140029326e-06
polymorphism O 0 1.776092904037796e-05
. O 0 3.215025117242476e-07

Germ O 0 0.08097417652606964
- O 0 0.19147390127182007
line O 0 2.8031732654199004e-05
and O 0 1.4925268132515157e-08
somatic O 0 6.640568130933389e-07
truncating O 0 3.3438191167078912e-06
mutations O 0 1.1412764706619782e-06
of O 0 9.197571593233533e-10
the O 0 3.8397698354231125e-09
APC B-Disease 0 2.404422616564261e-07
gene O 0 4.5837431628115155e-08
are O 0 2.5341104215037547e-10
thought O 0 1.3430254686142007e-09
to O 0 9.249896848473327e-09
initiate O 0 0.00014979098341427743
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.00024319086514879018
formation O 0 5.223317202762701e-06
in O 0 6.444847531383857e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.00017254949489142746
sporadic O 1 0.9999996423721313
colorectal O 1 1.0
carcinogenesis O 1 0.9984773993492126
, O 0 3.9372829974126944e-07
respectively O 0 6.591417900381202e-07
. O 0 2.5523914359837363e-07

Recently O 0 7.825180546205956e-06
, O 0 2.0896795405178636e-08
an O 0 1.6441799033373172e-08
isoleucine O 0 0.00042046510498039424
- O 0 3.1406823836732656e-05
- O 0 1.5404490113724023e-05
> O 0 3.559954620868666e-06
lysine O 0 4.728840940515511e-05
polymorphism O 0 1.4941046174499206e-05
at O 0 5.891101295674162e-07
codon O 0 2.5873352569760755e-05
1307 O 0 3.443996320129372e-05
( O 0 4.626598482104782e-08
I1307K O 0 3.507330177399126e-07
) O 0 1.295663465405994e-09
of O 0 1.2146161854076354e-10
the O 0 1.1941516664393248e-09
APC B-Disease 0 1.5585506218940282e-07
gene O 0 5.474900177659947e-08
has O 0 1.0969904984392542e-09
been O 0 2.1959904727975044e-10
identified O 0 4.602442593704126e-10
in O 0 3.5953276467104445e-10
6 O 0 7.779394906037851e-09
% O 0 5.894658094973693e-10
- O 0 4.1145032270151205e-08
7 O 0 1.2197643783906642e-08
% O 0 1.9617976687591465e-10
of O 0 4.689501564847376e-11
the O 0 2.3438488927496337e-09
Ashkenazi O 0 5.185039526622859e-07
Jewish O 0 4.668277853170366e-08
population O 0 2.73657168037289e-08
. O 0 1.0834069996690232e-07

To O 0 3.130421077912615e-07
assess O 0 4.4315285663287796e-07
the O 0 1.5326961033679254e-08
risk O 0 9.330734407342334e-09
of O 0 9.002996959051046e-11
this O 0 5.736097152819752e-10
common O 0 1.4816746052304097e-08
APC B-Disease 0 1.3402813010543468e-06
allelic O 0 8.08760250947671e-06
variant O 0 0.002417628187686205
in O 0 0.01762050949037075
colorectal O 1 1.0
carcinogenesis O 0 0.04773126542568207
, O 0 3.8916788014375925e-08
we O 0 7.384721167902342e-10
have O 0 1.5646484108344794e-10
analyzed O 0 3.699501593956711e-09
a O 0 9.012124380092246e-10
large O 0 1.413507533243319e-09
cohort O 0 4.428274991141734e-08
of O 0 1.0801521899139743e-09
unselected O 0 3.27025304613926e-06
Ashkenazi O 0 2.7272035367786884e-06
Jewish O 0 7.244948108109384e-08
subjects O 0 3.83818274940495e-08
with O 0 9.278239510024378e-09
adenomatous B-Disease 0 0.0006364592700265348
polyps I-Disease 0 0.00011287797678960487
and O 0 1.1792454124304186e-08
. O 0 1.146199721802077e-07
or O 1 0.9999995231628418
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.576096808619809e-09
for O 0 2.6675381348262306e-10
the O 0 7.513890842858473e-09
APC O 0 1.0300637995896977e-06
I1307K O 0 2.593575118225999e-06
polymorphism O 0 8.915822036215104e-06
. O 0 2.748992073975387e-07

The O 0 1.7514295223008958e-06
APC O 0 1.5296336641767994e-05
I1307K O 0 8.097373211057857e-06
allele O 0 4.201639058010187e-06
was O 0 7.122469725118208e-08
identified O 0 7.638449872615638e-09
in O 0 6.547134834278268e-09
48 O 0 3.275384941048287e-08
( O 0 1.9534645012697638e-09
10 O 0 8.566377052154905e-10
. O 0 2.6112076390027994e-10
1 O 0 2.0112500553892687e-09
% O 0 2.0006356293844618e-10
) O 0 2.970358958798158e-10
of O 0 4.6209935877783437e-10
476 O 0 8.489188303428818e-07
patients O 0 2.6553786369731824e-07
. O 0 1.6124869262057473e-07

Compared O 0 3.829160050372593e-06
with O 0 7.946732161201453e-09
the O 0 3.682900429069491e-09
frequency O 0 8.657513603793632e-07
in O 0 1.4091924294135083e-09
two O 0 9.535541106719947e-11
separate O 0 1.1535524757633198e-09
population O 0 1.9031191900165112e-10
control O 0 1.0283677909228572e-08
groups O 0 1.21886542525651e-10
, O 0 4.105607173676695e-11
the O 0 8.711540933070694e-10
APC O 0 1.1856577941671276e-07
I1307K O 0 2.2890489503879508e-07
allele O 0 1.637737625515001e-07
is O 0 5.864939089939014e-10
associated O 0 8.612413560094012e-10
with O 0 8.523882988331621e-11
an O 0 1.4306626716642512e-10
estimated O 0 9.269920386856256e-10
relative O 0 1.4026822370283298e-08
risk O 0 9.543666301681242e-09
of O 0 8.468724055354926e-10
1 O 0 1.2118640313474316e-07
. O 0 7.439311389134673e-08

5 O 0 6.1386963352561e-05
- O 0 5.1151593652321026e-05
1 O 0 1.8207279026682954e-06
. O 0 2.517987525152421e-07

7 O 0 0.00015895372780505568
for O 0 5.961025635770056e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9977832436561584
( O 0 1.5599364360241452e-06
both O 0 3.381565818472154e-07
P O 0 0.0590994656085968
= O 0 6.7125188252248336e-06
. O 0 4.481140791767757e-08
01 O 0 1.1694519344018772e-05
) O 0 5.2001183803440654e-08
. O 0 8.845732679674256e-08

Furthermore O 0 3.8807711462141015e-06
, O 0 2.386320474556669e-08
compared O 0 3.7490927695671417e-08
with O 0 3.752897104192243e-09
noncarriers O 0 4.1542020881024655e-06
, O 0 5.342474462821656e-09
APC O 0 2.180144775820736e-07
I1307K O 0 2.3013569716567872e-07
carriers O 0 1.3103096385691515e-08
had O 0 2.9566589176965863e-09
increased O 0 1.1566567703624742e-09
numbers O 0 1.4444386797762832e-09
of O 0 1.058373499951415e-09
adenomas B-Disease 0 9.16084463824518e-05
and O 0 0.014954844489693642
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9937605261802673
per O 0 2.0004390535177663e-06
patient O 0 9.239495557267219e-05
( O 0 3.1926958854455734e-07
P O 0 0.006427554879337549
= O 0 1.1105296380264917e-06
. O 0 5.968709082537771e-09
03 O 0 3.859244372961257e-07
) O 0 1.0350145185356041e-09
, O 0 1.3110681984507266e-10
as O 0 2.1293812546563373e-10
well O 0 1.4513419632766755e-10
as O 0 1.7024961995737442e-10
a O 0 2.9215996288911583e-09
younger O 0 3.9807467544505926e-08
age O 0 1.1183968418038148e-08
at O 0 1.1729222393341843e-07
diagnosis O 0 1.9796367269009352e-05
. O 0 1.9613997892520274e-07

We O 0 1.5445853307483048e-07
conclude O 0 1.2397605075875617e-07
that O 0 1.236533431203668e-09
the O 0 3.0227240710445358e-09
APC O 0 2.8931489737260563e-07
I1307K O 0 2.2862498383346974e-07
variant O 0 4.282725569737522e-07
leads O 0 1.178968833670524e-08
to O 0 6.305163058328844e-09
increased O 0 3.649199413757742e-07
adenoma B-Disease 1 0.9999998807907104
formation O 0 1.102996023405467e-07
and O 0 1.2172188812442641e-09
directly O 0 2.8231692539293363e-09
contributes O 0 3.1892124496835095e-09
to O 0 7.842170246519231e-10
3 O 0 6.020767884251654e-09
% O 0 8.891463676441447e-10
- O 0 2.479171357094856e-08
4 O 0 4.519765894883676e-09
% O 0 1.4933908276670849e-10
of O 0 9.201620021492829e-11
all O 0 4.772185313584032e-09
Ashkenazi O 0 0.018502095714211464
Jewish O 1 0.9989801049232483
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3156433169569937e-06

The O 0 4.6814747634016385e-08
estimated O 0 9.841770065577293e-09
relative O 0 2.0625074981239777e-08
risk O 0 9.819344448658285e-09
for O 0 5.920077206233998e-10
carriers O 0 1.900266610732615e-08
may O 0 2.825702694053689e-08
justify O 0 2.613945859764044e-08
specific O 0 2.3192212594835837e-09
clinical O 0 7.340027252666914e-09
screening O 0 1.7653544404083732e-08
for O 0 2.603444404503108e-10
the O 0 1.5525735141963537e-09
360 O 0 1.9594212474771666e-08
, O 0 3.3012154121436765e-10
000 O 0 6.742191249742291e-10
Americans O 0 2.1348425804923465e-10
expected O 0 1.0837386543727234e-09
to O 0 5.302787098315775e-10
harbor O 0 9.268404710383038e-09
this O 0 2.0360750585535214e-10
allele O 0 1.3114496155708366e-08
, O 0 8.562518055699186e-11
and O 0 1.004567679041557e-10
genetic O 0 3.843887874666052e-09
testing O 0 8.78333761278327e-09
in O 0 1.7598267287866065e-09
the O 0 6.250415185427016e-10
setting O 0 4.9936872414946265e-09
of O 0 1.9165280473742996e-10
long O 0 4.0527613265339824e-08
- O 0 8.258032835328777e-07
term O 0 4.865902525352794e-08
- O 0 3.7589739321219895e-08
outcome O 0 4.33431379676108e-09
studies O 0 2.4658239894392864e-09
may O 0 5.473488329243992e-09
impact O 0 2.4448029378731917e-08
significantly O 0 3.1476087315240875e-05
on O 1 0.9999996423721313
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 8.807110134512186e-07
in O 0 3.476096299692699e-09
this O 0 1.661714543743642e-09
population O 0 4.076466719737937e-09
. O 0 5.064701014134698e-08

Localization O 0 7.313014975807164e-06
of O 0 1.990528097906008e-08
human O 0 4.0170526460769906e-08
BRCA1 O 0 4.985741725249682e-06
and O 0 5.5596189874052016e-09
its O 0 3.569761730659593e-08
loss O 0 1.904216588854979e-07
in O 0 1.963169538043985e-08
high O 0 3.3292647003690945e-06
- O 0 7.139537501643645e-06
grade O 0 2.337221474135731e-07
, O 0 2.1449291232045198e-09
non B-Disease 0 3.4914913271677506e-07
- I-Disease 1 0.9951305389404297
inherited I-Disease 1 0.9999963045120239
breast I-Disease 1 0.9999963045120239
carcinomas I-Disease 1 1.0
. O 0 1.9122796857118374e-06

Although O 0 1.6542622915949323e-07
the O 0 7.03147673419835e-09
link O 0 1.3136556731296878e-07
between O 0 1.0539120687269588e-08
the O 0 1.3821905042732396e-07
BRCA1 O 0 0.1004132553935051
tumour B-Disease 1 0.9999998807907104
- O 0 7.261587143148063e-06
suppressor O 0 1.8100916349794716e-05
gene O 0 3.1148244943324244e-06
and O 0 1.981900510372725e-07
hereditary B-Disease 1 0.9999998807907104
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 6.654500506186878e-09
established O 0 2.9202402718198073e-09
, O 0 9.888122265433452e-11
the O 0 2.638870233440116e-10
role O 0 5.94433613443357e-10
, O 0 5.974488959115121e-11
if O 0 7.551237413139233e-11
any O 0 5.671322092504205e-11
, O 0 6.557026449582892e-11
of O 0 1.3345496929773049e-10
BRCA1 O 0 3.2028086138780054e-07
in O 0 5.3868616234353794e-09
non B-Disease 0 2.4387722419305646e-07
- I-Disease 1 0.7827775478363037
familial I-Disease 1 0.8267644643783569
cancers I-Disease 1 0.5376999974250793
is O 0 3.259169645275506e-08
unclear O 0 4.2713128323157434e-07
. O 0 2.784857429105614e-07

BRCA1 O 0 0.18143855035305023
mutations O 0 0.0002598936262074858
are O 0 1.3009510801964552e-08
rare O 0 3.8454150086408845e-08
in O 0 4.3479783329303245e-08
sporadic B-Disease 1 0.7301211357116699
cancers I-Disease 1 0.9962791800498962
, O 0 6.726164514248012e-09
but O 0 4.672694231544483e-09
loss O 0 2.625488271235099e-08
of O 0 6.6133615250763e-10
BRCA1 O 0 1.9585638710850617e-06
resulting O 0 2.0881333995248497e-08
from O 0 7.472499952143608e-09
reduced O 0 6.312156841659089e-08
expression O 0 3.783848256944111e-08
or O 0 1.79520096565966e-08
incorrect O 0 1.8156632108912163e-07
subcellular O 0 1.6791994994491688e-06
localization O 0 9.535078220324067e-07
is O 0 1.2913138336401175e-09
postulated O 0 9.081877472283395e-09
to O 0 3.866364450821891e-10
be O 0 8.610175072920612e-11
important O 0 6.067196745007664e-11
in O 0 9.013155777282122e-10
non B-Disease 0 4.702810230128307e-08
- I-Disease 0 0.028137922286987305
familial I-Disease 1 0.9997740387916565
breast I-Disease 1 1.0
and I-Disease 1 0.9999974966049194
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.8859301462725853e-06

Epigenetic O 0 0.0005140831344760954
loss O 0 0.00017920095706358552
, O 0 3.9970281306977995e-08
however O 0 5.070217135028088e-09
, O 0 6.620984871474889e-10
has O 0 3.9644973415242646e-10
not O 0 1.3025189260496006e-10
received O 0 1.5838770572873528e-10
general O 0 2.7351912401663014e-10
acceptance O 0 2.0109278686675225e-09
due O 0 1.0031346420191767e-08
to O 0 1.2037860708247194e-09
controversy O 0 3.763907852061266e-09
regarding O 0 5.276756254168902e-10
the O 0 9.297012049103159e-10
subcellular O 0 2.296115297895085e-07
localization O 0 8.340108337279162e-08
of O 0 1.0732027488913332e-09
BRCA1 O 0 5.59097031782585e-07
proteins O 0 8.268054685345305e-09
, O 0 1.7116652539783672e-10
reports O 0 2.406609356242484e-09
of O 0 8.500795206645151e-11
which O 0 9.8490515743066e-10
have O 0 1.9464824196901986e-10
ranged O 0 4.999967551100326e-09
from O 0 1.9348486701709078e-10
exclusively O 0 1.4167762518724203e-09
nuclear O 0 3.1231759400895953e-09
, O 0 5.976996675371993e-11
to O 0 1.511095276685026e-10
conditionally O 0 2.0599991046310606e-08
nuclear O 0 4.2099452812749405e-09
, O 0 7.619031794359188e-11
to O 0 2.570925417000325e-10
the O 0 1.1626026363842357e-08
ER O 0 7.21994138075388e-06
/ O 0 1.5994700106602977e-06
golgi O 0 2.4299463348143036e-06
, O 0 1.4650320956377527e-09
to O 0 2.248882857713852e-09
cytoplasmic O 0 1.8068227802814363e-07
invaginations O 0 2.3430594353612832e-07
into O 0 2.1550334849962383e-09
the O 0 6.1388143457463684e-09
nucleus O 0 1.3906392837270687e-07
. O 0 5.1080078833365405e-08

In O 0 1.914798701818654e-07
an O 0 2.8795650308666154e-09
attempt O 0 3.6694466132303205e-08
to O 0 5.557392768196223e-09
resolve O 0 3.374313450876798e-08
this O 0 1.1887817397138178e-09
issue O 0 4.4423837941565125e-09
, O 0 4.1374231818380736e-10
we O 0 3.7216021930852605e-10
have O 0 5.389695911794945e-10
comprehensively O 0 9.770381836915476e-08
characterized O 0 4.644821416377454e-08
19 O 0 1.3159541367713246e-07
anti O 0 7.703488336119335e-06
- O 0 0.00021184375509619713
BRCA1 O 0 9.83320496743545e-05
antibodies O 0 6.025300990586402e-06
. O 0 2.366883649074225e-07

These O 0 6.004571559969918e-07
reagents O 0 3.3071225971070817e-06
detect O 0 4.5182091525930446e-06
a O 0 4.416836674181468e-08
220 O 0 2.0465259353841248e-07
- O 0 1.694356114967377e-06
kD O 0 1.8110802102455636e-06
protein O 0 1.3670154430656112e-07
localized O 0 1.9329219469454983e-07
in O 0 6.057847556917295e-09
discrete O 0 2.5983576179555712e-08
nuclear O 0 6.195123347652043e-08
foci O 0 2.2315282421914162e-07
in O 0 1.8065421381052715e-09
all O 0 3.6914152290457025e-10
epithelial O 0 3.344888455103501e-08
cell O 0 4.27930416435629e-07
lines O 0 4.31787583465848e-07
, O 0 9.650225757384945e-11
including O 0 2.360581174976062e-11
those O 0 1.1150388945502243e-10
derived O 0 4.522887842028922e-09
from O 0 5.451714812920727e-08
breast B-Disease 0 0.0004302741726860404
malignancies I-Disease 0 1.796824471966829e-05
. O 0 3.139530804219248e-07

Immunohistochemical O 0 0.0018288263818249106
staining O 0 0.00016303210577461869
of O 0 7.346178421130389e-08
human O 0 1.5271932340965577e-07
breast O 0 5.40242726856377e-05
specimens O 0 1.2399520699091227e-07
also O 0 4.165537248468354e-08
revealed O 0 5.133030072101974e-07
BRCA1 O 0 6.08890059083933e-06
nuclear O 0 3.073379559737077e-07
foci O 0 9.396536370331887e-06
in O 0 4.727087059563928e-07
benign O 1 0.9998571872711182
breast O 1 0.904072642326355
, O 0 1.71023501138734e-07
invasive B-Disease 0 0.001246382249519229
lobular I-Disease 1 0.999868631362915
cancers I-Disease 1 0.9989601373672485
and O 0 2.402724703642889e-06
low B-Disease 1 0.9998339414596558
- I-Disease 1 0.9997894167900085
grade I-Disease 0 0.10969718545675278
ductal I-Disease 1 0.9988958835601807
carcinomas I-Disease 1 1.0
. O 0 9.433276318304706e-06

Conversely O 0 3.05548710457515e-05
, O 0 1.9656917515931127e-07
BRCA1 O 0 1.3209930330049247e-05
expression O 0 2.0893590146897623e-07
was O 0 1.2864181542227016e-07
reduced O 0 4.7927120050417216e-08
or O 0 1.3203294457753145e-08
undetectable O 0 2.0244141296643647e-07
in O 0 8.92568463584098e-10
the O 0 3.280808957839554e-10
majority O 0 4.4482145744595414e-10
of O 0 2.1424828577920607e-10
high O 0 1.0962380656565074e-06
- O 0 1.6281248463201337e-05
grade O 0 2.4349801606149413e-06
, O 0 3.9682689134679094e-08
ductal B-Disease 0 0.0028140200302004814
carcinomas I-Disease 1 1.0
, O 0 7.954223057993204e-09
suggesting O 0 5.738609587524479e-08
that O 0 9.015787005850484e-10
absence O 0 5.136553404838651e-09
of O 0 7.903435683687121e-10
BRCA1 O 0 4.237638677295763e-06
may O 0 3.488758082426102e-08
contribute O 0 3.32467775532308e-10
to O 0 2.958315814538537e-10
the O 0 1.1141465527941818e-09
pathogenesis O 0 2.4236360474105823e-08
of O 0 1.236752228406246e-10
a O 0 1.1450077552765947e-09
significant O 0 1.5897434479938966e-09
percentage O 0 1.6865575602764693e-08
of O 0 8.455860456280107e-10
sporadic B-Disease 1 0.975416898727417
breast I-Disease 1 0.9999905824661255
cancers I-Disease 0 0.002322572283446789
. O 0 3.7878994163520474e-08
. O 0 1.6391769008805568e-07

